nct_id|nlm_download_date_description|study_first_submitted_date|results_first_submitted_date|disposition_first_submitted_date|last_update_submitted_date|study_first_submitted_qc_date|study_first_posted_date|study_first_posted_date_type|results_first_submitted_qc_date|results_first_posted_date|results_first_posted_date_type|disposition_first_submitted_qc_date|disposition_first_posted_date|disposition_first_posted_date_type|last_update_submitted_qc_date|last_update_posted_date|last_update_posted_date_type|start_month_year|start_date_type|start_date|verification_month_year|verification_date|completion_month_year|completion_date_type|completion_date|primary_completion_month_year|primary_completion_date_type|primary_completion_date|target_duration|study_type|acronym|baseline_population|brief_title|official_title|overall_status|last_known_status|phase|enrollment|enrollment_type|source|limitations_and_caveats|number_of_arms|number_of_groups|why_stopped|has_expanded_access|expanded_access_type_individual|expanded_access_type_intermediate|expanded_access_type_treatment|has_dmc|is_fda_regulated_drug|is_fda_regulated_device|is_unapproved_device|is_ppsd|is_us_export|biospec_retention|biospec_description|ipd_time_frame|ipd_access_criteria|ipd_url|plan_to_share_ipd|plan_to_share_ipd_description|created_at|updated_at|source_class|delayed_posting|expanded_access_nctid|expanded_access_status_for_nctid|fdaaa801_violation|baseline_type_units_analyzed
NCT05665062||2022-12-08|||2023-02-08|2022-12-16|2022-12-27|Actual|||||||2023-02-08|2023-02-10|Actual|February 2023|Anticipated|2023-02-28|January 2023|2023-01-31|November 2026|Anticipated|2026-11-30|June 2024|Anticipated|2024-06-30||Interventional|||Autologous CD19 CAR-T Cell Therapy (SYNCAR-001) + Orthogonal IL-2 (STK-009) in Subjects With CD19+ Hematologic Malignancies|A Phase 1 Study to Evaluate the Safety and Tolerability of a Combination Autologous CD19 CAR T Cell Therapy (SYNCAR-001 + STK-009) in Subjects With Relapsed or Refractory CD19+ Hematologic Malignancies|Recruiting||Phase 1|36|Anticipated|Synthekine||1|||f||||f|t|f|||||||||No||2023-09-01 05:49:41.473704|2023-09-01 05:49:41.473704|INDUSTRY|||||
NCT05322330||2022-03-21|||2023-02-07|2022-04-03|2022-04-11|Actual|||||||2023-02-07|2023-02-09|Actual|February 10, 2022|Actual|2022-02-10|March 2022|2022-03-31|February 10, 2024|Anticipated|2024-02-10|February 10, 2024|Anticipated|2024-02-10||Interventional|||Clinical Study of XPO-1 Inhibitors Plus CAR-T Cells in Relapsed Refractory B-cell Non-Hodgkin's Lymphoma|Clinical Study of the Efficacy and Safety of XPO-1 Inhibitors in Combination With CAR-T Cells in Relapsed Refractory B-cell Non-Hodgkin's Lymphoma|Recruiting||Phase 2|20|Anticipated|The First Affiliated Hospital of Soochow University||1|||f||||f|f|f|||||||||||2023-09-01 05:50:08.068044|2023-09-01 05:50:08.068044|OTHER|||||
NCT05212584||2022-01-16|||2022-06-30|2022-01-16|2022-01-28|Actual|||||||2022-06-30|2022-07-06|Actual|July 1, 2022|Actual|2022-07-01|January 2022|2022-01-31|June 30, 2024|Anticipated|2024-06-30|June 30, 2024|Anticipated|2024-06-30||Interventional|||CD7 CAR-T Cell Treatment of Relapsed/Refractory CD7+ T -Acute Lymphoblastic Leukemia/ Lymphoma|CD7 CAR-T Cell Treatment of Relapsed/Refractory CD7+ T -Acute Lymphoblastic Leukemia/ Lymphoma|Recruiting||Phase 1|24|Anticipated|iCell Gene Therapeutics||1|||f|||||f|f|||||||||||2023-09-01 05:59:41.845638|2023-09-01 05:59:41.845638|INDUSTRY|||||
NCT03208556||2017-06-27|||2017-09-12|2017-07-03|2017-07-05|Actual|||||||2017-09-12|2017-09-14|Actual|June 21, 2017|Actual|2017-06-21|July 2017|2017-07-31|June 1, 2020|Anticipated|2020-06-01|June 1, 2019|Anticipated|2019-06-01||Interventional|||Safety and Efficacy of iPD1 CD19 eCAR T Cells in Relapsed or Refractory B-cell Lymphoma|Pilot Study of Autologous Anti-CD19 4-1BB CAR T Cells With Cell-intrinsic PD1 Inhibition in Relapsed or Refractory B-cell Lymphoma|Unknown status|Recruiting|Phase 1|20|Anticipated|Peking University||1|||f||||t|f|f|||||||||||2023-09-04 09:12:53.49732|2023-09-04 09:12:53.49732|OTHER|||||
NCT05170568||2021-12-24|||2022-10-31|2021-12-24|2021-12-28|Actual|||||||2022-10-31|2022-11-01|Actual|December 1, 2021|Actual|2021-12-01|October 2022|2022-10-31|December 1, 2024|Anticipated|2024-12-01|December 1, 2022|Anticipated|2022-12-01||Interventional|||PA3-17 Injection Treatment of Adult Patients With CD7-positive Relapsed/Refractory Lymphoid Hematologic Malignancies|A Phase I Open-label, Dose-escalation Trial of PA3-17 Injection in Adult Patients With CD7-positive Relapsed/Refractory Lymphoid Hematologic Malignancies|Recruiting||Phase 1|22|Anticipated|PersonGen BioTherapeutics (Suzhou) Co., Ltd.||1|||f|||||f|f|||||||||Undecided||2023-09-03 11:18:45.836795|2023-09-03 11:18:45.836795|INDUSTRY|||||
NCT02744287||2016-04-11|||2023-04-18|2016-04-15|2016-04-20|Estimate|||||||2023-04-18|2023-04-20|Actual|November 2016|Actual|2016-11-30|April 2023|2023-04-30|February 2026|Anticipated|2026-02-28|October 2025|Anticipated|2025-10-31||Interventional|||Safety and Activity Study of PSCA-Targeted CAR-T Cells (BPX-601) in Subjects With Selected Advanced Solid Tumors|A Phase 1/2 Feasibility, Safety, and Activity Study of PSCA-Specific Chimeric Antigen Receptor Engineered T Cells (BPX-601) in Subjects With Previously Treated Advanced Solid Tumors|Suspended||Phase 1/Phase 2|151|Anticipated|Bellicum Pharmaceuticals||2||Due to a Dose Limiting Toxicity.|f||||f|t|f|||||||||No||2023-08-31 13:01:10.917031|2023-08-31 13:01:10.917031|INDUSTRY|||||
NCT05341492||2022-04-18|||2023-02-26|2022-04-18|2022-04-22|Actual|||||||2023-02-26|2023-02-28|Actual|May 1, 2022|Actual|2022-05-01|February 2023|2023-02-28|May 1, 2025|Anticipated|2025-05-01|May 1, 2025|Anticipated|2025-05-01||Interventional|||EGFR/B7H3 CAR-T on Lung Cancer and Triple Negative Breast Cancer|A Single-arm, Open, Exploratory Clinical Study Evaluating the Safety and Efficacy of EGFR/B7H3 CAR-T in Patients With EGFR/ B7H3-positive Advanced Solid Tumors (Lung and Triple-negative Breast Cancer)|Recruiting||Early Phase 1|30|Anticipated|Second Affiliated Hospital of Guangzhou Medical University||1|||f|||||f|f|||||||||No||2023-08-31 08:01:02.025179|2023-08-31 08:01:02.025179|OTHER|||||
NCT03330834||2017-10-01|2020-04-15||2020-07-09|2017-10-30|2017-11-06|Actual|2020-07-09|2020-07-13|Actual||||2020-07-09|2020-07-13|Actual|November 20, 2017|Actual|2017-11-20|July 2020|2020-07-31|April 14, 2020|Actual|2020-04-14|April 14, 2020|Actual|2020-04-14||Interventional|||CAR-T Cell Immunotherapy for Advanced Lung Cancer|Safety and Toxicity of CAR-T Cell Immunotherapy in Patients With Advanced Lung Cancer After Standard Treatment Failure: A Single-Arm and Single-Center Phase I Clinical Study|Terminated||Phase 1|1|Actual|Sun Yat-sen University||1||Serious adverse events|f||||t|f|f|||||||||Undecided||2023-09-01 06:09:57.453436|2023-09-01 06:09:57.453436|OTHER|||||
NCT03310008||2017-08-02|||2020-06-15|2017-10-10|2017-10-16|Actual|||||||2020-06-15|2020-06-16|Actual|August 7, 2017|Actual|2017-08-07|June 2020|2020-06-30|May 2021|Anticipated|2021-05-31|May 2021|Anticipated|2021-05-31||Interventional|SHRINK||Dose Escalation and Dose Expansion Phase I Study to Assess the Safety and Clinical Activity of Multiple Doses of NKR-2 Administered Concurrently With FOLFOX in Colorectal Cancer With Potentially Resectable Liver Metastases|An Open-label, Phase I Study to Assess the Safety and Clinical Activity of Multiple Doses of NKR-2, Administered Concurrently With the Neoadjuvant FOLFOX Treatment in Patients With Potentially Resectable Liver Metastases From Colorectal Cancer|Unknown status|Active, not recruiting|Phase 1|36|Anticipated|Celyad Oncology SA||4|||f||||t|f|f|||||||||No||2023-08-31 08:01:09.735849|2023-08-31 08:01:09.735849|INDUSTRY|||||
NCT02303821||2014-11-20|||2023-03-07|2014-11-25|2014-12-01|Estimate|||||||2023-03-07|2023-03-09|Actual|February 16, 2015|Actual|2015-02-16|February 2023|2023-02-28|February 22, 2026|Anticipated|2026-02-22|February 22, 2024|Anticipated|2024-02-22||Interventional|||Study of Carfilzomib in Combination With Induction Chemotherapy in Children With Relapsed or Refractory Acute Lymphoblastic Leukemia|Phase 1b/2 Study of Carfilzomib in Combination With Induction Chemotherapy in Children With Relapsed or Refractory Acute Lymphoblastic Leukemia|Recruiting||Phase 1|118|Anticipated|Amgen||4|||f||||t|||||||||||||2023-09-04 09:14:46.671406|2023-09-04 09:14:46.671406|INDUSTRY|||||
NCT04037241||2019-07-26|||2022-03-30|2019-07-26|2019-07-30|Actual|||||||2022-03-30|2022-04-01|Actual|November 1, 2021|Anticipated|2021-11-01|March 2022|2022-03-31|January 1, 2022|Anticipated|2022-01-01|January 1, 2022|Anticipated|2022-01-01||Interventional|||Study of Anti-CEA CAR-T + Chemotherapy VS Chemotherapy Alone in Patients With CEA+Pancreatic Cancer & Liver Metastases|A Randomized Open-Label Phase 2b Study of Hepatic Infusions of Anti-CEA CAR-T Cells Alternating With Systemic Chemotherapy Versus Chemotherapy Alone In Patients With Liver Metastases Due To CEA-Expressing Pancreatic Adenocarcinoma|Withdrawn||Phase 2/Phase 3|0|Actual|Sorrento Therapeutics, Inc.||8||Sponsor terminated|f||||t|t|f|||||||||||2023-08-31 13:01:34.349333|2023-08-31 13:01:34.349333|INDUSTRY|||||
NCT03029338||2017-01-20|||2022-01-24|2017-01-20|2017-01-24|Estimate|||||||2022-01-24|2022-01-26|Actual|June 8, 2017|Actual|2017-06-08|January 2022|2022-01-31|June 22, 2021|Actual|2021-06-22|May 22, 2019|Actual|2019-05-22||Interventional|||CD19 CAR T Cells in Patients With Relapsed or Refractory CD19 Positive B-cell Lymphoma|CD19 CAR T Cells in Patients With Relapsed or Refractory CD19 Positive B-cell Lymphoma|Completed||Phase 1|20|Actual|Institute of Hematology & Blood Diseases Hospital||1|||f|||||f|f|||||||||Undecided||2023-08-31 08:07:29.966291|2023-08-31 08:07:29.966291|OTHER|||||
NCT05239702||2021-12-01|||2022-02-13|2022-02-13|2022-02-15|Actual|||||||2022-02-13|2022-02-15|Actual|February 28, 2022|Anticipated|2022-02-28|February 2022|2022-02-28|December 1, 2024|Anticipated|2024-12-01|December 1, 2024|Anticipated|2024-12-01||Interventional|||Clinical Study of Targeting CD7 CAR-T Cells in the Treatment of Autoimmune Diseases|A Clinical Study on the Safety and Effectiveness of Targeting CD7 Chimeric Antigen Receptor T Cells in the Treatment of Autoimmune Diseases|Recruiting||Early Phase 1|75|Anticipated|Zhejiang University||5|||f||||t|f|f|||||||||||2023-09-03 11:29:13.308468|2023-09-03 11:29:13.308468|OTHER|||||
NCT05620706||2022-11-11|||2022-11-17|2022-11-11|2022-11-17|Actual|||||||2022-11-17|2022-11-22|Actual|November 1, 2022|Actual|2022-11-01|November 2022|2022-11-30|October 31, 2028|Anticipated|2028-10-31|October 31, 2025|Anticipated|2025-10-31||Interventional|||Study of GPC-3 CAR-T Cells in Treating With Hepatocellular Carcinoma|Study of GPC-3 CAR-T Cells in Advanced Hepatocellular Carcinoma|Recruiting||Not Applicable|20|Anticipated|Shenzhen University General Hospital||1|||f|||||f|f|||||||||No||2023-09-03 11:36:37.686925|2023-09-03 11:36:37.686925|OTHER|||||
NCT02935257||2016-10-14|||2022-09-15|2016-10-14|2016-10-17|Estimate|||||||2022-09-15|2022-09-19|Actual|September 29, 2017|Actual|2017-09-29|September 2022|2022-09-30|December 2033|Anticipated|2033-12-31|December 2024|Anticipated|2024-12-31||Interventional|ALLCAR19||Immunotherapy for High Risk/Relapsed CD19+ Acute Lymphoblastic Leukaemia, B-cell Non-Hodgkin's Lymphoma (B-NHL) and Chronic Lymphocytic Leukaemia (CLL)/ Small Lymphocytic Lymphoma (SLL) Using CAR T-cells to Target CD19|Immunotherapy for High Risk/Relapsed CD19+ Acute Lymphoblastic Leukaemia, B-cell Non-Hodgkin's Lymphoma (B-NHL) and Chronic Lymphocytic Leukaemia (CLL)/ Small Lymphocytic Lymphoma (SLL) Using CAR T-cells to Target CD19|Recruiting||Phase 1|60|Anticipated|University College, London||1|||f||||t|f|f|||f||||||No||2023-08-31 08:11:45.369131|2023-08-31 08:11:45.369131|OTHER|||||
NCT05204160||2022-01-11|||2023-04-20|2022-01-11|2022-01-24|Actual|||||||2023-04-20|2023-04-24|Actual|April 11, 2022|Actual|2022-04-11|April 2023|2023-04-30|October 21, 2024|Anticipated|2024-10-21|October 21, 2024|Anticipated|2024-10-21||Interventional|||Pembrolizumab as Salvage Therapy for the Treatment of Multiple Myeloma in Patients Progressing on CAR-T Cell Therapy|Phase II Study of Pembrolizumab as Salvage Therapy Among Multiple Myeloma Patients Progressing on CAR-T Cell Therapy|Recruiting||Phase 2|30|Anticipated|Emory University||1|||f||||t|t|f|||f||||||||2023-08-31 08:15:04.917066|2023-08-31 08:15:04.917066|OTHER|||||
NCT03778346||2018-12-14|||2020-11-16|2018-12-17|2018-12-19|Actual|||||||2020-11-16|2020-11-18|Actual|November 15, 2018|Actual|2018-11-15|November 2020|2020-11-30|December 31, 2022|Anticipated|2022-12-31|June 30, 2022|Anticipated|2022-06-30||Interventional|||Integrin β7, BCMA, CS1, CD38 and CD138 as the Single or Compound Targets for the Fourth Genenation of CAR-T Cells|Integrin β7, BCMA, CS1, CD38 and CD138 as the Single or Compound Targets for the Fourth Genenation of CAR-T Cells|Unknown status|Recruiting|Phase 1|30|Anticipated|The Sixth Affiliated Hospital of Wenzhou Medical University||1|||f|||||f|f|||||||||Undecided||2023-09-03 11:40:32.780824|2023-09-03 11:40:32.780824|OTHER|||||
NCT05023707||2021-08-10|||2021-12-29|2021-08-23|2021-08-26|Actual|||||||2021-12-29|2021-12-30|Actual|December 31, 2021|Anticipated|2021-12-31|July 2021|2021-07-31|June 30, 2025|Anticipated|2025-06-30|June 30, 2023|Anticipated|2023-06-30||Interventional|||Anti-FLT3 CAR T-cell Therapy in FLT3 Positive Relapsed/Refractory Acute Myeloid Leukemia|Pilot Study of the Safety and Efficacy of Anti-FLT3 Chimeric Antigen Receptor Engineered T-Cells in the Treatment of Relapsed or Refractory Acute Myeloid Leukemia (AML)|Recruiting||Phase 1/Phase 2|5|Anticipated|The First Affiliated Hospital of Soochow University||1|||f|||||f|f|||||||||||2023-08-31 08:19:21.94645|2023-08-31 08:19:21.94645|OTHER|||||
NCT04148430||2019-10-30|||2023-02-23|2019-10-31|2019-11-01|Actual|||||||2023-02-23|2023-02-24|Actual|October 30, 2019|Actual|2019-10-30|February 2023|2023-02-28|October 2024|Anticipated|2024-10-31|October 2024|Anticipated|2024-10-31||Interventional|||A Study of Anakinra to Prevent or Treat Severe Side Effects for Patients Receiving CAR-T Cell Therapy|A Phase II Study of IL-1 Receptor Antagonist Anakinra to Prevent Severe Neurotoxicity and Cytokine Release Syndrome in Patients Receiving CD19-Specific Chimeric Antigen Receptor (CAR) T Cells|Active, not recruiting||Phase 2|62|Actual|Memorial Sloan Kettering Cancer Center||1|||f|||||t|f|||||||||Yes|• Memorial Sloan Kettering Cancer Center supports the international committee of medical journal editors (ICMJE) and the ethical obligation of responsible sharing of data from clinical trials. The protocol summary, a statistical summary, and informed consent form will be made available on clinicaltrials.gov when required as a condition of Federal awards, other agreements supporting the research and/or as otherwise required. Requests for deidentified individual participant data can be made beginning 12 months after publication and for up to 36 months post publication. Deidentified individual participant data reported in the manuscript will be shared under the terms of a Data Use Agreement and may only be used for approved proposals. Requests may be made to: crdatashare@mskcc.org.|2023-09-01 06:38:38.717925|2023-09-01 06:38:38.717925|OTHER|||||
NCT03467256||2018-03-09|||2023-02-22|2018-03-14|2018-03-15|Actual|||||||2023-02-22|2023-02-24|Actual|May 14, 2018|Actual|2018-05-14|February 2023|2023-02-28|October 15, 2025|Anticipated|2025-10-15|October 15, 2020|Actual|2020-10-15||Interventional|||CD19 T-CAR for Treatment of Children and Young Adults With r/r B-ALL|A Single-Arm Phase I/II Study Evaluating the Safety and Clinical Efficacy Of the 2-nd Generation CD19 Autologous CAR T Cells on the CliniMACS Prodigy Automated Manufacturing Platform in Treatment of Paediatric And Young Adult Patients With Relapsed/Refractory B-lineage Acute Lymphoblastic Leukemia|Active, not recruiting||Phase 1/Phase 2|18|Anticipated|Federal Research Institute of Pediatric Hematology, Oncology and Immunology||1|||f||||t|f|f|||||||||||2023-09-01 06:38:45.863589|2023-09-01 06:38:45.863589|OTHER|||||
NCT05194709||2022-01-04|||2022-01-18|2022-01-14|2022-01-18|Actual|||||||2022-01-18|2022-02-02|Actual|December 30, 2021|Actual|2021-12-30|January 2022|2022-01-31|December 30, 2022|Anticipated|2022-12-30|December 30, 2022|Anticipated|2022-12-30||Interventional|||Study of Anti-5T4 CAR-NK Cell Therapy in Advanced Solid Tumors|Clinical Trial of Anti-5T4 Oncofetal Trophoblast Glycoprotein (5T4) Conjugated Antibody Redirecting Natural Killer (CAR-NK) Cells in Advanced Solid Tumors|Recruiting||Early Phase 1|40|Anticipated|Wuxi People's Hospital||1|||f||||f|f|f|||||||||No||2023-09-04 09:18:31.425435|2023-09-04 09:18:31.425435|OTHER|||||
NCT05576220||2022-10-02|||2023-03-13|2022-10-08|2022-10-12|Actual|||||||2023-03-13|2023-03-14|Actual|April 30, 2023|Anticipated|2023-04-30|March 2023|2023-03-31|July 30, 2023|Anticipated|2023-07-30|April 30, 2023|Anticipated|2023-04-30||Interventional|||Remote Temperature Monitoring of Adult Subjects Undergoing Outpatient Stem Cell Transplant or CAR-T Cell Therapy|Remote Temperature Monitoring of Adult Subjects Undergoing Outpatient Stem Cell Transplant or CAR-T Cell Therapy at Risk for Developing Infections and/or Cytokine Release Syndrome|Not yet recruiting||Not Applicable|210|Anticipated|IDION Inc.||2|||f||||f|f|t|t||f||||||No||2023-09-01 06:48:33.683056|2023-09-01 06:48:33.683056|INDUSTRY|||||
NCT03291444||2017-09-20|||2021-08-01|2017-09-21|2017-09-25|Actual|||||||2021-08-01|2021-08-09|Actual|September 23, 2017|Actual|2017-09-23|August 2021|2021-08-31|June 1, 2025|Anticipated|2025-06-01|December 31, 2024|Anticipated|2024-12-31||Interventional|||CAR-T Cells Combined With Peptide Specific Dendritic Cell in Relapsed/Refractory Leukemia/MDS|A Clinical Study of Chimeric Antigen Receptor T Cells Combined With Eps8 Peptide Specific Dendritic Cell for Patients With Relapsed/Refractory Leukemia and Myelodysplastic Syndromes|Recruiting||Phase 1|30|Anticipated|Zhujiang Hospital||2|||f||||t|f|f|||||||||No||2023-08-31 08:29:09.373231|2023-08-31 08:29:09.373231|OTHER|||||
NCT05269914||2021-12-03|||2022-03-04|2022-03-04|2022-03-08|Actual|||||||2022-03-04|2022-03-08|Actual|April 2022|Anticipated|2022-04-30|March 2022|2022-03-31|June 30, 2023|Anticipated|2023-06-30|December 31, 2022|Anticipated|2022-12-31||Interventional|||Safety, Efficacy and Pharmacokinetics of XKDCT023 in DLBCL|Safety, Efficacy and Pharmacokinetics of XKDCT023 in Adult Patients With Recurrent or Refractory Diffuse Large B-cell Lymphoma|Not yet recruiting||Not Applicable|10|Anticipated|The Affiliated Hospital of Qingdao University||1|||f||||t|f|f|||||||||||2023-09-01 07:07:13.443663|2023-09-01 07:07:13.443663|OTHER|||||
NCT05262673||2022-02-21|||2022-03-07|2022-02-21|2022-03-02|Actual|||||||2022-03-07|2022-03-08|Actual|March 1, 2022|Anticipated|2022-03-01|March 2022|2022-03-31|December 31, 2025|Anticipated|2025-12-31|December 31, 2024|Anticipated|2024-12-31||Interventional|||NGS-MRD Assessment of Combination Immunotherapies Targeting B-ALL|NGS-MRD Evaluation of Antigen-specific T Cells and DC Vaccine Combination Targeting B-cell Acute Lymphoblastic Leukemia|Recruiting||Phase 1|10|Anticipated|Shenzhen Geno-Immune Medical Institute||1|||f||||f|f|f|||||||||||2023-09-01 07:07:20.74085|2023-09-01 07:07:20.74085|OTHER|||||
NCT05052528||2021-09-13|||2022-03-08|2021-09-13|2021-09-22|Actual|||||||2022-03-08|2022-03-10|Actual|September 17, 2021|Actual|2021-09-17|March 2022|2022-03-31|February 15, 2025|Anticipated|2025-02-15|August 15, 2024|Anticipated|2024-08-15||Interventional|||Fludarabine and Cyclophosphamide With or Without Rituximab Before CD19 Chimeric Antigen Receptor T Cells for the Treatment of Relapsed or Refractory Diffuse Large B-Cell Lymphoma|A Phase I Study to Evaluate the Safety of Escalating Doses of Lymphodepleting Conditioning Chemotherapy Prior to CD19 Chimeric Antigen Receptor T Cells in Subjects With Relapsed/Refractory Diffuse Large B-cell Lymphoma|Recruiting||Phase 1|36|Anticipated|University of California, Davis||6|||f||||t|t|f|||f||||||||2023-09-01 07:08:28.043923|2023-09-01 07:08:28.043923|OTHER|||||
NCT04260945||2020-02-06|||2022-03-06|2020-02-06|2020-02-07|Actual|||||||2022-03-06|2022-03-08|Actual|March 10, 2020|Actual|2020-03-10|August 2021|2021-08-31|February 10, 2022|Actual|2022-02-10|October 10, 2021|Actual|2021-10-10||Interventional|||CD19/CD20 Dual-CAR-T in B-cell Leukemia Patients|CD19/CD20 Dual-CAR-T for Patients With B-cell Leukemia|Completed||Phase 1|12|Actual|Hebei Yanda Ludaopei Hospital||1|||f||||t|f|f|||||||||||2023-09-01 07:10:59.113473|2023-09-01 07:10:59.113473|OTHER|||||
NCT04260932||2020-02-06|||2022-03-06|2020-02-06|2020-02-07|Actual|||||||2022-03-06|2022-03-08|Actual|March 1, 2020|Actual|2020-03-01|August 2021|2021-08-31|September 10, 2021|Actual|2021-09-10|May 10, 2021|Actual|2021-05-10||Interventional|||CD19/CD20 Dual-CAR-T in B-cell Lymphoma Patients|CD19/CD20 Dual-CAR-T for Patients With B-cell Lymphoma|Completed||Phase 1|12|Actual|Hebei Yanda Ludaopei Hospital||1|||f||||t|f|f|||||||||||2023-09-01 07:10:59.777953|2023-09-01 07:10:59.777953|OTHER|||||
NCT03373071||2017-12-06|||2022-03-09|2017-12-08|2017-12-14|Actual|||||||2022-03-09|2022-03-10|Actual|December 23, 2017|Actual|2017-12-23|March 2022|2022-03-31|April 8, 2036|Anticipated|2036-04-08|May 11, 2021|Actual|2021-05-11||Interventional|||Anti-CD19 CAR T Cells in Pediatric Patients Affected by Relapsed/Refractory CD19+ ALL and NHL|Phase I/II Study of Anti-CD19 Chimeric Antigen Receptor-Expressing T Cells in Pediatric Patients Affected by Relapsed/Refractory CD19+ Acute Lymphoblastic Leukemia and Non Hodgkin Lymphoma|Active, not recruiting||Phase 1/Phase 2|29|Actual|Bambino Gesù Hospital and Research Institute||1|||f||||t|f|f|||||||||Undecided||2023-09-01 07:13:08.7679|2023-09-01 07:13:08.7679|OTHER|||||
NCT04943016||2021-06-04|||2021-06-28|2021-06-28|2021-06-29|Actual|||||||2021-06-28|2021-06-29|Actual|July 1, 2021|Anticipated|2021-07-01|May 2021|2021-05-31|December 31, 2024|Anticipated|2024-12-31|December 31, 2024|Anticipated|2024-12-31||Interventional|||CD19 CAR T Cells in Children and Adults With Relapsed or Refractory CD19 Positive B Cell Malignancies|Phase I Clinical Trial of CD19 Chimeric Antigen Receptor (CAR) T Cells in Children and Adults With Relapsed or Refractory CD19 Positive B Cell Malignancies|Not yet recruiting||Phase 1|12|Anticipated|National Taiwan University Hospital||1|||f||||f|f|f|||||||||No||2023-08-31 12:56:46.26289|2023-08-31 12:56:46.26289|OTHER|||||
NCT05605197||2022-10-03|||2022-10-29|2022-10-29|2022-11-04|Actual|||||||2022-10-29|2022-11-04|Actual|October 19, 2022|Actual|2022-10-19|October 2022|2022-10-31|October 8, 2025|Anticipated|2025-10-08|October 8, 2023|Anticipated|2023-10-08||Interventional|||U87 CART in Treatment of Advanced Pancreatic Cancer|Clinical Study to Evaluate the Safety and Efficacy of U87 CART in Treatment of Advanced Pancreatic Cancer|Recruiting||Phase 1|12|Anticipated|Shanghai Unicar-Therapy Bio-medicine Technology Co.,Ltd||1|||f|||||f|f|||||||||No||2023-08-31 08:37:29.971982|2023-08-31 08:37:29.971982|INDUSTRY|||||
NCT02439788||2015-05-07|||2017-06-09|2015-05-07|2015-05-12|Estimate|||||||2017-06-09|2017-06-14|Actual|August 2017|Anticipated|2017-08-31|June 2017|2017-06-30|October 2030|Anticipated|2030-10-31|September 2019|Anticipated|2019-09-30||Interventional|GINAKIT||3RD GENERATION GD2 SPECIFIC CHIMERIC ANTIGEN RECEPTOR TRANSDUCED AUTOLOGOUS NATURAL KILLER T-CELLS FOR NEUROBLASTOMA|3RD GENERATION GD2 SPECIFIC CHIMERIC ANTIGEN RECEPTOR AND INDUCIBLE CASPASE 9 SAFETY SWITCH TRANSDUCED AUTOLOGOUS NATURAL KILLER T-CELLS TO TREAT CHILDREN WITH NEUROBLASTOMA (GINAKIT)|Withdrawn||Phase 1|0|Actual|Baylor College of Medicine||1||Based on newly available preclinical data we changed the CAR construct to a more effective version and will now study that product on a different protocol.|f||||t|t|f|||||||||||2023-09-04 09:21:25.338391|2023-09-04 09:21:25.338391|OTHER|||||
NCT03196830||2017-06-20|||2019-04-14|2017-06-21|2017-06-23|Actual|||||||2019-04-14|2019-04-16|Actual|June 1, 2017|Actual|2017-06-01|April 2019|2019-04-30|May 31, 2021|Anticipated|2021-05-31|May 31, 2021|Anticipated|2021-05-31||Interventional|||CAR-T for R/R B-NHL|Safety and Efficacy of Chimeric Antigen Receptor T Cell (CAR-T) Treating Relaspe/Refractory CD19/CD20/CD22/CD30 Postive Non-Hodgkin Lymphoma|Unknown status|Recruiting|Phase 2|10|Anticipated|The First Affiliated Hospital of Soochow University||1|||f||||f|f|f|||||||||No||2023-08-31 08:50:48.853964|2023-08-31 08:50:48.853964|OTHER|||||
NCT03182816||2017-06-05|||2017-06-07|2017-06-07|2017-06-09|Actual|||||||2017-06-07|2017-06-09|Actual|June 7, 2017|Anticipated|2017-06-07|June 2017|2017-06-30|April 20, 2019|Anticipated|2019-04-20|January 20, 2019|Anticipated|2019-01-20||Interventional|||CTLA-4 and PD-1 Antibodies Expressing EGFR-CAR-T Cells for EGFR Positive Advanced Solid Tumor|A Clinical Study of CTLA-4 and PD-1 Antibodies Expressing EGFR-CAR-T Cells for Patients With EGFR Positive Advanced Solid Tumors|Unknown status|Recruiting|Phase 1/Phase 2|40|Anticipated|Shanghai Cell Therapy Research Institute||1|||f||||f|f|f|||||||||No||2023-09-04 09:25:30.49962|2023-09-04 09:25:30.49962|OTHER|||||
NCT04877080||2021-04-13|||2023-02-08|2021-05-05|2021-05-07|Actual|||||||2023-02-08|2023-02-10|Actual|May 5, 2021|Anticipated|2021-05-05|February 2023|2023-02-28|December 31, 2023|Anticipated|2023-12-31|June 30, 2023|Anticipated|2023-06-30||Interventional|||CD19 and BCMA Targeted Fast Dual CAR-T for CD19+ Refractory/Relapsed B-NHL|Exploratory Study to Evaluate Efficacy and Safety of Fast Dual CAR-T Injection in CD19+ Refractory or Relapsed B Cell Non-Hodgkinlymphoma|Withdrawn||Phase 1|0|Actual|920th Hospital of Joint Logistics Support Force of People's Liberation Army of China||1||The PI decides to withdraw the research.|f||||f|f|f|||||||||||2023-08-31 08:56:59.372805|2023-08-31 08:56:59.372805|OTHER|||||
NCT05381662||2018-08-05|||2023-02-08|2022-05-18|2022-05-19|Actual|||||||2023-02-08|2023-02-10|Actual|August 2, 2018|Actual|2018-08-02|December 2022|2022-12-31|December 1, 2025|Anticipated|2025-12-01|August 2, 2024|Anticipated|2024-08-02||Interventional|||CD19 Chimeric Antigen Receptors and CD19 Positive Feeder T Cells as a Leukemia Consolidation Treatment|CD19 Chimeric Antigen Receptors and CD19 Positive Feeder T Cells as a Leukemia Consolidation Treatment|Recruiting||Phase 1/Phase 2|10|Anticipated|Shanghai Unicar-Therapy Bio-medicine Technology Co.,Ltd||2|||f|||||f|f|||||||||||2023-08-31 08:57:00.978635|2023-08-31 08:57:00.978635|INDUSTRY|||||
NCT03185468||2017-06-10|||2019-09-18|2017-06-10|2017-06-14|Actual|||||||2019-09-18|2019-09-19|Actual|May 15, 2017|Actual|2017-05-15|September 2019|2019-09-30|December 2020|Anticipated|2020-12-31|December 2019|Anticipated|2019-12-31||Interventional|||Intervention of Bladder Cancer by CAR-T|Intervention of Advanced or Metastatic Urothelial Bladder Cancer by 4SCAR-T Cell Therapies|Unknown status|Recruiting|Phase 1/Phase 2|20|Anticipated|Shenzhen Geno-Immune Medical Institute||2|||f||||f|f|f|||||||||No||2023-09-04 09:25:39.794908|2023-09-04 09:25:39.794908|OTHER|||||
NCT05418088||2022-05-16|||2022-11-04|2022-06-10|2022-06-14|Actual|||||||2022-11-04|2022-11-07|Actual|June 30, 2022|Actual|2022-06-30|November 2022|2022-11-30|December 31, 2024|Anticipated|2024-12-31|December 31, 2023|Anticipated|2023-12-31||Interventional|||Genetically Engineered Cells (Anti-CD19/CD20/CD22 CAR T-cells) for the Treatment of Relapsed or Refractory Lymphoid Malignancies|Phase I Clinical Trial of Anti-CD19/20/22 Chimeric Antigen Receptor T Cells for Treatment of Relapsed or Refractory Lymphoid Malignancies (Non-Hodgkin Lymphoma, Acute Lymphoblastic Leukemia, Chronic Lymphocytic Leukemia, B-Prolymphocytic Leukemia)|Recruiting||Phase 1|36|Anticipated|Ohio State University Comprehensive Cancer Center||2|||||||t|t|f|||||||||No||2023-09-01 07:49:37.029709|2023-09-01 07:49:37.029709|OTHER|||||
NCT03098355||2017-03-26|||2022-11-04|2017-03-26|2017-03-31|Actual|||||||2022-11-04|2022-11-07|Actual|December 30, 2017|Actual|2017-12-30|September 2022|2022-09-30|December 31, 2023|Anticipated|2023-12-31|December 15, 2022|Anticipated|2022-12-15||Interventional|||Interleukin-2 Following 4SCAR19/22 T Cells Targeting Refractory and/or Recurrent B Cell Malignancies|Anti-CD19/CD22 4th Generation CAR-T Cells (4SCAR19/22) Followed by Interleukin-2 Treating Pediatric Relapsed and Refractory B Cell Malignancies|Suspended||Phase 1/Phase 2|30|Anticipated|Zhujiang Hospital||1||Recruitment stopped due to the global outbreak of COVID 19|f||||t|f|f|||||||||No||2023-09-01 07:52:06.940644|2023-09-01 07:52:06.940644|OTHER|||||
NCT05359211||2022-04-28|||2023-05-04|2022-04-28|2022-05-03|Actual|||||||2023-05-04|2023-05-06|Actual|December 8, 2022|Actual|2022-12-08|May 2023|2023-05-31|December 31, 2024|Anticipated|2024-12-31|January 31, 2024|Anticipated|2024-01-31||Interventional|||NKTR-255 in Combination With CAR-T Cell Therapy for the Treatment of Relapsed or Refractory Large B-cell Lymphoma|A Phase Ib Open-Label Study Evaluating the Safety and Efficacy of NKTR-255 in Combination With CD19-Directed CAR-T Cell Therapy in Patients With Relapsed/Refractory (R/R) Large B-Cell Lymphoma (LBCL)|Recruiting||Phase 1|24|Anticipated|Fred Hutchinson Cancer Center||1|||||||t|t|f|||||||||No||2023-09-03 12:18:20.643022|2023-09-03 12:18:20.643022|OTHER|||||
NCT04889716||2021-05-07|||2023-05-03|2021-05-14|2021-05-17|Actual|||||||2023-05-03|2023-05-06|Actual|November 5, 2021|Actual|2021-11-05|May 2023|2023-05-31|December 31, 2025|Anticipated|2025-12-31|December 31, 2024|Anticipated|2024-12-31||Interventional|||CAR-T Followed by Bispecific Antibodies|Phase II Study of Dual Targeting of CD19 and CD20 Antigens Using Sequential CD19-directed 4-1BB-CD3ζ CAR-T Cells Followed by Mosunetuzumab or Glofitamab in Relapsed or Refractory Diffuse Large B-cell or Transformed Follicular Lymphomas|Recruiting||Phase 2|42|Anticipated|Abramson Cancer Center at Penn Medicine||2|||f||||f|t|f|||||||||||2023-09-03 12:21:03.585138|2023-09-03 12:21:03.585138|OTHER|||||
NCT04422912||2020-06-02|||2023-05-04|2020-06-05|2020-06-09|Actual|||||||2023-05-04|2023-05-06|Actual|September 29, 2020|Actual|2020-09-29|May 2023|2023-05-31|September 2026|Anticipated|2026-09-30|September 2026|Anticipated|2026-09-30||Interventional|||Open-label Study to Determine the Maximum Tolerated Dose of DSG3-CAART in Mucosal-dominant PV Patients (mPV)|A Phase 1, Open-label, Safety and Dosing Study of Autologous Desmoglein 3 Chimeric Autoantibody Receptor T Cells (DSG3-CAART) in Subjects With Active, Anti-DSG3, Mucosal-dominant Pemphigus Vulgaris|Recruiting||Phase 1|39|Anticipated|Cabaletta Bio||1|||f|||||t|f|||||||||||2023-09-03 12:23:24.551283|2023-09-03 12:23:24.551283|INDUSTRY|||||
NCT02706392||2016-03-01|2022-05-17||2022-08-11|2016-03-07|2016-03-11|Estimate|2022-08-11|2022-08-31|Actual||||2022-08-11|2022-08-31|Actual|March 16, 2016|Actual|2016-03-16|August 2022|2022-08-31|September 28, 2021|Actual|2021-09-28|May 17, 2021|Actual|2021-05-17||Interventional|||Genetically Modified T-Cell Therapy in Treating Patients With Advanced ROR1+ Malignancies|Phase I Study of Adoptive Immunotherapy for Advanced ROR1+ Malignancies With Defined Subsets of Autologous T Cells Engineered to Express a ROR1-Specific Chimeric Antigen Receptor|Terminated||Phase 1|21|Actual|Fred Hutchinson Cancer Center||1||Terminated due to slow accruals.|f||||t|t|f|||||||||No||2023-09-04 09:29:17.119391|2023-09-04 09:29:17.119391|OTHER|||||
NCT02416466||2015-03-30|||2019-03-25|2015-04-09|2015-04-15|Estimate|||||||2019-03-25|2019-03-26|Actual|April 2015||2015-04-30|March 2019|2019-03-31|June 2018|Actual|2018-06-30|November 21, 2016|Actual|2016-11-21||Interventional|HITM-SIR||CAR-T Hepatic Artery Infusions and Sir-Spheres for Liver Metastases|Phase Ib Trial of CAR-T Hepatic Artery Infusions Followed by Selective Internal Radiation Therapy (SIRT) With Yttrium-90 Sir-Spheres® for CEA-Expressing Liver Metastases|Completed||Phase 1|8|Actual|Roger Williams Medical Center||1|||f||||t|||||||||||No||2023-09-04 09:29:22.034671|2023-09-04 09:29:22.034671|OTHER|||||
NCT05248048||2022-02-08|||2022-02-09|2022-02-09|2022-02-21|Actual|||||||2022-02-09|2022-02-21|Actual|September 13, 2021|Actual|2021-09-13|February 2022|2022-02-28|October 2022|Anticipated|2022-10-31|October 2022|Anticipated|2022-10-31||Interventional|||NKG2D CAR-T Cells to Treat Patients With Previously Treated Liver Metastatic Colorectal Cancer|Hepatic Artery Transfusion of NKG2D CAR-T Cells to Treat Patients With Previously Treated Liver Metastatic Colorectal Cancer: a Prospective, Multicenter Clinical Trial|Recruiting||Early Phase 1|9|Anticipated|The Third Affiliated Hospital of Guangzhou Medical University||1|||f|||||f|f|||||||||||2023-08-31 09:10:17.355497|2023-08-31 09:10:17.355497|OTHER|||||
NCT04480788||2020-07-14|||2021-01-04|2020-07-17|2020-07-21|Actual|||||||2021-01-04|2021-01-06|Actual|November 24, 2020|Actual|2020-11-24|January 2021|2021-01-31|August 31, 2022|Anticipated|2022-08-31|August 1, 2022|Anticipated|2022-08-01||Interventional|||CD7-CART in the Treatment of r / r CD7 Positive Hemolymph System Malignancies on Increasing Dose and Open Label Study|Early Clinical Study on Increasing Dose and Open Label of T Cell Injection Targeting CD7 Autologous Chimeric Antigen Receptor in the Treatment of Relapsed / Refractory CD7 Positive Hemolymph System Malignancies|Unknown status|Recruiting|Phase 1|9|Anticipated|PersonGen BioTherapeutics (Suzhou) Co., Ltd.||1|||f||||f|f|f|||f||||||||2023-08-31 09:12:21.727193|2023-08-31 09:12:21.727193|INDUSTRY|||||
NCT03761056||2018-11-29|2022-05-16||2023-07-25|2018-11-29|2018-12-03|Actual|2022-07-04|2022-07-08|Actual||||2023-07-25|2023-07-27|Actual|January 29, 2019|Actual|2019-01-29|July 2023|2023-07-31|December 2023|Anticipated|2023-12-31|May 17, 2021|Actual|2021-05-17||Interventional|ZUMA-12|Safety Analysis Set included all participants treated with any dose of axicabtagene ciloleucel.|Study to Evaluate the Efficacy and Safety of Axicabtagene Ciloleucel as First-Line Therapy in Participants With High-Risk Large B-Cell Lymphoma|A Phase 2 Multicenter Study Evaluating the Efficacy and Safety of Axicabtagene Ciloleucel as First-Line Therapy in Subjects With High-Risk Large B-Cell Lymphoma (ZUMA-12)|Active, not recruiting||Phase 2|42|Actual|Gilead Sciences||1|||f||||t|t|f|||||||||No||2023-09-01 08:16:19.862193|2023-09-01 08:16:19.862193|INDUSTRY|||||
NCT03166878||2017-05-23|||2017-06-22|2017-05-23|2017-05-25|Actual|||||||2017-06-22|2017-06-23|Actual|June 2017|Anticipated|2017-06-30|June 2017|2017-06-30|May 2022|Anticipated|2022-05-31|May 2022|Anticipated|2022-05-31||Interventional|||A Study Evaluating UCART019 in Patients With Relapsed or Refractory CD19+ Leukemia and Lymphoma|Phase I/II Study to Determine the Safety, Tolerability, Biological Activity and Efficacy of Universal CRISPR-Cas9 Gene-Editing CAR-T Cells Targeting CD19(UCART019) in Patients With Relapsed or Refractory CD19+ Leukemia and Lymphoma|Unknown status|Recruiting|Phase 1/Phase 2|80|Anticipated|Chinese PLA General Hospital||1|||f||||f|f|f|||f||||||||2023-08-31 09:14:48.147272|2023-08-31 09:14:48.147272|OTHER|||||
NCT02535364||2015-08-24|2018-04-24||2020-04-30|2015-08-27|2015-08-28|Estimate|2018-06-22|2018-07-19|Actual||||2020-04-30|2020-05-04|Actual|August 21, 2015|Actual|2015-08-21|April 2020|2020-04-30|September 1, 2017|Actual|2017-09-01|April 24, 2017|Actual|2017-04-24||Interventional|ROCKET|Total number of subjects who received at least one infusion of JCAR015|Study Evaluating the Efficacy and Safety of JCAR015 in Adult B-cell Acute Lymphoblastic Leukemia (B-ALL)|A Phase 2, Single-arm, Multicenter Trial to Determine the Efficacy and Safety of JCAR015 in Adult Subjects With Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia|Terminated||Phase 2|82|Actual|Juno Therapeutics, a Subsidiary of Celgene||1||Safety reasons|f||||t|||||||||||||2023-09-04 09:41:45.026548|2023-09-04 09:41:45.026548|INDUSTRY|||||
NCT03070327||2017-02-28|||2023-03-08|2017-02-28|2017-03-03|Actual|||||||2023-03-08|2023-03-09|Actual|February 27, 2017|Actual|2017-02-27|March 2023|2023-03-31|February 2024|Anticipated|2024-02-29|February 2024|Anticipated|2024-02-29||Interventional|||BCMA Targeted CAR T Cells With or Without Lenalidomide for the Treatment of Multiple Myeloma|A Phase I Trial of B-cell Maturation Antigen (BCMA) Targeted EGFRt/BCMA-41BBz Chimeric Antigen Receptor (CAR) Modified T Cells With or Without Lenalidomide for the Treatment of Multiple Myeloma (MM)|Active, not recruiting||Phase 1|20|Actual|Memorial Sloan Kettering Cancer Center||1|||f|||||t|f|||||||||||2023-09-04 09:44:29.681188|2023-09-04 09:44:29.681188|OTHER|||||
NCT04977024||2021-06-11|||2023-06-13|2021-07-22|2021-07-26|Actual|||||||2023-06-13|2023-06-15|Actual|September 27, 2021|Actual|2021-09-27|June 2023|2023-06-30|January 31, 2025|Anticipated|2025-01-31|March 31, 2024|Anticipated|2024-03-31||Interventional|||SARS-CoV-2 Vaccine (COH04S1) Versus EUA SARS-COV-2 Vaccine for the Treatment of COVID-19 in Patients With Blood Cancer|A Multi-Center, Observer-Blinded, EUA Vaccine-Controlled, Randomized Phase II Study to Evaluate the Biological Activity of COH04S1 (SARS-CoV-2 Vaccine) Compared to EUA SARS-CoV-2 Vaccines in Hematology Patients Who Have Received Cellular Therapy (HCT or CAR-T)|Recruiting||Phase 2|240|Anticipated|GeoVax, Inc.||2|||||||t|t|f|||f||||||||2023-08-31 13:18:24.768303|2023-08-31 13:18:24.768303|INDUSTRY|||||
NCT03672305||2018-09-07|||2018-09-15|2018-09-12|2018-09-14|Actual|||||||2018-09-15|2018-09-18|Actual|October 1, 2018|Anticipated|2018-10-01|September 2018|2018-09-30|October 30, 2019|Anticipated|2019-10-30|October 30, 2019|Anticipated|2019-10-30||Interventional|||Clinical Study on the Efficacy and Safety of c-Met/PD-L1 CAR-T Cell Injection in the Treatment of HCC|Single-center, Open Clinical Study on the Efficacy and Safety of c-Met/PD-L1 Chimeric Antigen Receptor T Cell Injection in the Treatment of Primary Hepatocellular Carcinoma|Unknown status|Not yet recruiting|Early Phase 1|50|Anticipated|The Second Hospital of Nanjing Medical University||1|||f|||||f|f|||||||||||2023-09-04 10:02:48.33563|2023-09-04 10:02:48.33563|OTHER|||||
NCT03473457||2018-03-15|||2021-09-05|2018-03-21|2018-03-22|Actual|||||||2021-09-05|2021-09-13|Actual|April 1, 2018|Actual|2018-04-01|September 2021|2021-09-30|December 31, 2020|Actual|2020-12-31|December 31, 2020|Actual|2020-12-31||Interventional|AML||CAR-T Cells Therapy in Relapsed/Refractory Acute Myeloid Leukemia|The Prospective, Multi-center And Single-arm Clinical Study of Chimeric Antigen Receptor T(CAR-T) Cells Therapy in Relapsed/Refractory Acute Myeloid Leukemia|Terminated||Not Applicable|2|Actual|Zhujiang Hospital||1||The therapeutic effect was not as expected|f||||t|f|f|||||||||Undecided||2023-09-04 10:08:05.399388|2023-09-04 10:08:05.399388|OTHER|||||
NCT05155215||2021-11-30|||2021-11-30|2021-11-30|2021-12-13|Actual|||||||2021-11-30|2021-12-13|Actual|December 31, 2021|Anticipated|2021-12-31|November 2021|2021-11-30|February 28, 2023|Anticipated|2023-02-28|December 31, 2022|Anticipated|2022-12-31||Interventional|||Study to Evaluate the Safety and Efficacy of IM19 CAR-T Cells in Patients With Relapsed and Refractory (R/R) Mantle Cell Lymphoma|A Phase 1-2 Study to Evaluate the Safety and Efficacy of IM19 CAR-T Cells in Patients With Relapsed and Refractory (R/R) Mantle Cell Lymphoma|Not yet recruiting||Phase 1/Phase 2|68|Anticipated|Beijing Immunochina Medical Science & Technology Co., Ltd.||1|||f|||||f|f|||||||||||2023-09-04 10:08:51.169711|2023-09-04 10:08:51.169711|INDUSTRY|||||
NCT03672851||2018-09-13|||2019-09-03|2018-09-13|2018-09-17|Actual|||||||2019-09-03|2019-09-06|Actual|April 17, 2019|Actual|2019-04-17|May 2019|2019-05-31|July 31, 2019|Actual|2019-07-31|July 31, 2019|Actual|2019-07-31||Interventional|||Study Evaluating Safety and Efficacy of CAR-T Cells Targeting CD123 in Patients With Acute Leukemia|Study Evaluating Safety and Efficacy of CAR-T Cells Targeting CD123 in Patients With Acute Leukemia|Terminated||Phase 1|2|Actual|Second Affiliated Hospital of Xi'an Jiaotong University||1||adverse effect|f||||f|f|f|||||||||Undecided||2023-09-04 10:10:36.363372|2023-09-04 10:10:36.363372|OTHER|||||
NCT04268706||2020-02-11|||2023-04-04|2020-02-12|2020-02-13|Actual|||||||2023-04-04|2023-04-05|Actual|February 1, 2021|Actual|2021-02-01|April 2023|2023-04-30|March 2037|Anticipated|2037-03-31|May 2025|Anticipated|2025-05-31||Interventional|||Phase 2 Study Evaluating Autologous CD30.CAR-T Cells in Patients With Relapsed/Refractory Hodgkin Lymphoma (CHARIOT)|A Phase 2 Multi-Center Study Evaluating the Safety and Efficacy of CD30-Directed Genetically Modified Autologous T Cells (CD30.CAR-T) in Adult and Pediatric Patients With Relapsed or Refractory Classical Hodgkin Lymphoma|Active, not recruiting||Phase 2|97|Anticipated|Tessa Therapeutics||1|||||||t|t|f|||||||||No||2023-08-31 09:35:56.811638|2023-08-31 09:35:56.811638|INDUSTRY|||||
NCT04684563||2020-12-11|||2023-06-20|2020-12-21|2020-12-24|Actual|||||||2023-06-20|2023-06-22|Actual|May 6, 2021|Actual|2021-05-06|March 2023|2023-03-31|May 2036|Anticipated|2036-05-31|May 2036|Anticipated|2036-05-31||Interventional|||huCART19-IL18 in CD19+ Cancers|Phase I Trial of huCART19-IL18 Cells in Patients With Relapsed or Refractory CD19+ Cancers|Recruiting||Phase 1|72|Anticipated|University of Pennsylvania||17|||f||||t|t|f|||||||||No||2023-09-04 10:15:55.942478|2023-09-04 10:15:55.942478|OTHER|||||
NCT03664661||2018-09-06|||2018-09-07|2018-09-07|2018-09-10|Actual|||||||2018-09-07|2018-09-10|Actual|April 11, 2018|Actual|2018-04-11|September 2018|2018-09-30|April 30, 2020|Anticipated|2020-04-30|April 10, 2019|Anticipated|2019-04-10||Interventional|||BCMA-CAR-T in Relapsed/Refractory Multiple Myeloma|a Single-center, One Arm, Open Clinical Study of BCMA Nanobody CAR-T Cell in Refractory/Relapsed Myeloma|Unknown status|Recruiting|Phase 1|15|Anticipated|Henan Cancer Hospital||1|||f||||t|f|f|||||||||||2023-09-04 10:26:23.837918|2023-09-04 10:26:23.837918|OTHER_GOV|||||
NCT03658655||2018-08-30|||2020-02-27|2018-09-02|2018-09-05|Actual|||||||2020-02-27|2020-02-28|Actual|June 1, 2018|Actual|2018-06-01|October 2019|2019-10-31|November 30, 2019|Actual|2019-11-30|November 10, 2019|Actual|2019-11-10||Interventional|||Stem Cells From Human Exfoliated Teeth in Treatment of Type 2 Diabetes|Open, One-arm, Single-center Clinical Study to Evaluate the Efficacy and Safety of Stem Cells From Human Exfoliated Teeth in the Treatment of Type 2 Diabetes|Completed||Early Phase 1|24|Actual|CAR-T (Shanghai) Biotechnology Co., Ltd.||1|||f|||||f|f|||||||||No||2023-09-04 10:29:28.337899|2023-09-04 10:29:28.337899|INDUSTRY|||||
NCT03648697||2018-08-24|||2020-08-09|2018-08-24|2018-08-27|Actual|||||||2020-08-09|2020-08-11|Actual|October 10, 2018|Actual|2018-10-10|August 2020|2020-08-31|October 10, 2021|Anticipated|2021-10-10|October 8, 2021|Anticipated|2021-10-08||Interventional|||EBV-TCR-T（YT-E001）for Patients With EBV-positive Recurrent or Metastatic NPC|A Pilot Study of EBV-TCR-T(YT-E001) in NPC Patients|Unknown status|Recruiting|Phase 2|20|Anticipated|Fujian Cancer Hospital||1|||f||||t|f|f|||||||||No||2023-09-04 10:35:05.774321|2023-09-04 10:35:05.774321|OTHER_GOV|||||
NCT05239143||2022-02-03|||2023-05-04|2022-02-03|2022-02-14|Actual|||||||2023-05-04|2023-05-06|Actual|February 15, 2022|Actual|2022-02-15|May 2023|2023-05-31|April 2039|Anticipated|2039-04-30|April 2026|Anticipated|2026-04-30||Interventional|||P-MUC1C-ALLO1 Allogeneic CAR-T Cells in the Treatment of Subjects With Advanced or Metastatic Solid Tumors|A Phase 1 Dose Escalation and Expanded Cohort Study of P-MUC1C-ALLO1 in Adult Subjects With Advanced or Metastatic Solid Tumors|Recruiting||Phase 1|100|Anticipated|Poseida Therapeutics, Inc.||4|||f|||||t|f|||||||||||2023-09-01 09:30:00.373718|2023-09-01 09:30:00.373718|INDUSTRY|||||
NCT04205409||2019-12-17|||2023-04-28|2019-12-17|2019-12-19|Actual|||||||2023-04-28|2023-05-03|Actual|June 5, 2020|Actual|2020-06-05|February 2023|2023-02-28|August 1, 2028|Anticipated|2028-08-01|August 1, 2023|Anticipated|2023-08-01||Interventional|||Nivolumab for Relapsed, Refractory, or Detectable Disease Post Chimeric Antigen Receptor T-cell Treatment in Patients With Hematologic Malignancies|Nivolumab for Relapsed or Refractory Disease Post Chimeric Antigen Receptor T-Cell Treatment in Patients With Hematologic Malignancies|Active, not recruiting||Phase 2|20|Actual|University of Washington||1|||f||||t|t|f|||||||||No||2023-09-01 09:32:12.112881|2023-09-01 09:32:12.112881|OTHER|||||
NCT03468153||2018-03-11|||2018-03-16|2018-03-11|2018-03-16|Actual|||||||2018-03-16|2018-03-20|Actual|January 1, 2018|Actual|2018-01-01|March 2018|2018-03-31|January 1, 2020|Anticipated|2020-01-01|January 1, 2019|Anticipated|2019-01-01||Interventional|||Dual Specificity CD19 and CD22 CAR-T Cell Immunotherapy for CD19+CD22+ Relapsed and Refractory Lymphoma|The Safety and Efficacy of Dual Specificity CD19 and CD22 CAR-T Cell Immunotherapy for CD19+CD22+ Relapsed and Refractory Lymphoma|Unknown status|Recruiting|Phase 1/Phase 2|10|Anticipated|Ruijin Hospital||1|||f|||||f|f|||||||||Undecided||2023-09-04 10:41:19.12204|2023-09-04 10:41:19.12204|OTHER|||||
NCT02529813||2015-08-18|||2022-06-29|2015-08-18|2015-08-20|Estimate|||||||2022-06-29|2022-06-30|Actual|December 16, 2015|Actual|2015-12-16|June 2022|2022-06-30|November 8, 2021|Actual|2021-11-08|November 8, 2021|Actual|2021-11-08||Interventional|||CD19-Specific T-cells in Treating Patients With Advanced Lymphoid Malignancies|CD19+ Chimeric Antigen Receptor T Cells for Patients With Advanced Lymphoid Malignancies|Completed||Phase 1|26|Actual|M.D. Anderson Cancer Center||1|||f||||f|t|f|||||||||||2023-09-04 10:41:58.63878|2023-09-04 10:41:58.63878|OTHER|||||
NCT03649529||2018-08-23|||2019-12-05|2018-08-26|2018-08-28|Actual|||||||2019-12-05|2019-12-06|Actual|September 27, 2018|Actual|2018-09-27|December 2019|2019-12-31|January 1, 2022|Anticipated|2022-01-01|September 15, 2021|Anticipated|2021-09-15||Interventional|||Treatment of Malignant Melanoma With GPA-TriMAR-T Cell Therapy|Adoptive Immunotherapy for HLA_A2 Genotype gp100 Positive Malignant Melanoma With GPA-TriMAR-T Cell|Unknown status|Recruiting|Early Phase 1|6|Anticipated|Timmune Biotech Inc.||1|||f||||t|f|f|||||||||No||2023-09-04 10:48:23.565151|2023-09-04 10:48:23.565151|INDUSTRY|||||
NCT03615313||2018-06-28|||2018-07-30|2018-07-30|2018-08-03|Actual|||||||2018-07-30|2018-08-03|Actual|August 6, 2018|Anticipated|2018-08-06|July 2018|2018-07-31|December 3, 2020|Anticipated|2020-12-03|August 3, 2020|Anticipated|2020-08-03||Interventional|PAEMCMPAST||PD-1 Antibody Expressing mesoCAR-T Cells for Mesothelin Positive Advanced Solid Tumor|A Clinical Study of PD-1 Antibody Expressing mesoCAR-T Cells for Patients With Mesothelin Positive Advanced Solid Tumors|Unknown status|Recruiting|Phase 1/Phase 2|50|Anticipated|Shanghai Cell Therapy Research Institute||1|||f||||f|f|f|||||||||||2023-09-04 10:50:35.625658|2023-09-04 10:50:35.625658|OTHER|||||
NCT05568680||2022-09-28|||2023-04-03|2022-10-05|2022-10-06|Actual|||||||2023-04-03|2023-04-06|Actual|March 30, 2023|Actual|2023-03-30|April 2023|2023-04-30|March 30, 2026|Anticipated|2026-03-30|March 15, 2026|Anticipated|2026-03-15||Interventional|||SynKIR-110 for Mesothelin Expressing Ovarian Cancer, Cholangiocarcinoma or Mesothelioma|A Phase 1 Study of SynKIR-110, Autologous T Cells Transduced With Mesothelin KIR-CAR, in Subjects With Mesothelin-Expressing Advanced Ovarian Cancer, Cholangiocarcinoma, or Mesothelioma|Recruiting||Phase 1|42|Anticipated|Verismo Therapeutics||1|||f||||t|t|f|||f||||||No||2023-09-01 09:38:39.662281|2023-09-01 09:38:39.662281|INDUSTRY|||||
NCT03612739||2018-07-20|||2019-10-25|2018-07-27|2018-08-02|Actual|||||||2019-10-25|2019-10-29|Actual|December 2018|Anticipated|2018-12-31|November 2018|2018-11-30|August 2021|Anticipated|2021-08-31|May 2019|Anticipated|2019-05-31||Interventional|EPITHINK||EPITHINK: Epigenetic Drug Treatment and Therapeutic Immunotherapy With NKR-2|An Open-label, Phase I Study to Assess the Safety of NKR-2 Treatment Administered Concurrently With 5-azacytidine in Treatment-naïve Acute Myeloid Leukemia or Myelodysplastic Syndrome Patients Not Candidates for Intensive Therapy|Withdrawn||Phase 1|0|Actual|Celyad Oncology SA||3||Sponsor decision|f||||t|t|f|||||||||Undecided||2023-09-04 10:57:10.398327|2023-09-04 10:57:10.398327|INDUSTRY|||||
NCT03548207||2018-05-25|||2022-10-05|2018-05-25|2018-06-07|Actual|||||||2022-10-05|2022-10-06|Actual|June 29, 2018|Actual|2018-06-29|October 2022|2022-10-31|August 23, 2022|Actual|2022-08-23|August 23, 2022|Actual|2022-08-23||Interventional|CARTITUDE-1||A Study of JNJ-68284528, a Chimeric Antigen Receptor T Cell (CAR-T) Therapy Directed Against B-Cell Maturation Antigen (BCMA) in Participants With Relapsed or Refractory Multiple Myeloma|A Phase 1b-2, Open-Label Study of JNJ-68284528, A Chimeric Antigen Receptor T-Cell (CAR-T) Therapy Directed Against BCMA in Subjects With Relapsed or Refractory Multiple Myeloma|Completed||Phase 1/Phase 2|126|Actual|Janssen Research & Development, LLC||1|||t||||f|t|f|||||||||||2023-09-01 09:40:54.30287|2023-09-01 09:40:54.30287|INDUSTRY||NCT05346835|Available||
NCT03146234||2017-04-24|||2019-08-22|2017-05-05|2017-05-09|Actual|||||||2019-08-22|2019-08-28|Actual|March 17, 2017|Actual|2017-03-17|November 2018|2018-11-30|October 18, 2018|Actual|2018-10-18|October 18, 2018|Actual|2018-10-18||Interventional|||CAR-GPC3 T Cells in Patients With Refractory Hepatocellular Carcinoma|Clinical Study of Redirected Autologous T Cells With a GPC3-targeted Chimeric Antigen Receptor in Patients With Refractory Hepatocellular Carcinoma|Completed||Not Applicable|7|Actual|RenJi Hospital||1|||f||||t|f|f|||||||||Undecided||2023-09-04 10:59:46.138069|2023-09-04 10:59:46.138069|OTHER|||||
NCT05108805||2021-10-29|||2023-03-30|2021-10-29|2021-11-05|Actual|||||||2023-03-30|2023-03-31|Actual|December 2, 2021|Actual|2021-12-02|March 2023|2023-03-31|December 31, 2024|Anticipated|2024-12-31|December 31, 2023|Anticipated|2023-12-31||Interventional|||Chimeric Antigen Receptor (CAR) T Cell Therapy With YESCARTA in the Outpatient Setting|Safety and Feasibility Study of Chimeric Antigen Receptor (CAR) T Cell Therapy With YESCARTA in the Outpatient Setting|Recruiting||Not Applicable|20|Anticipated|Vanderbilt-Ingram Cancer Center||1|||f||||t|f|f|||f||||||Undecided||2023-08-31 10:03:38.61749|2023-08-31 10:03:38.61749|OTHER|||||
NCT03110640||2017-04-06|||2019-11-25|2017-04-11|2017-04-12|Actual|||||||2019-11-25|2019-11-27|Actual|October 1, 2016|Actual|2016-10-01|November 2019|2019-11-30|September 2021|Anticipated|2021-09-30|June 2020|Anticipated|2020-06-30||Interventional|||Anti-CD19 CAR T Infusion Combined With Allogeneic Stem Cell Transplantation for B-cell Leukemia/Lymphoma|A Phase I Study of Administrating CD19 Chimeric Antigen Receptor Expressing T Cells Followed by Allogeneic Stem Cell Transplantation in Patients With Refractory CD19+ B-linage Leukemia/Lymphoma|Unknown status|Recruiting|Phase 1|20|Anticipated|First Affiliated Hospital of Wenzhou Medical University||1|||f||||t|f|f|||||||||Undecided||2023-08-31 10:16:50.851124|2023-08-31 10:16:50.851124|OTHER|||||
NCT03398967||2018-01-08|||2018-01-08|2018-01-08|2018-01-16|Actual|||||||2018-01-08|2018-01-16|Actual|January 2, 2018|Actual|2018-01-02|January 2018|2018-01-31|May 20, 2022|Anticipated|2022-05-20|May 20, 2022|Anticipated|2022-05-20||Interventional|||A Feasibility and Safety Study of Universal Dual Specificity CD19 and CD20 or CD22 CAR-T Cell Immunotherapy for Relapsed or Refractory Leukemia and Lymphoma|Phase I/II Study to Evaluate Treatment of Relapsed or Refractory Leukemia and Lymphoma With Universal CRISPR-Cas9 Gene-Editing CAR-T Cells Targeting CD19 and CD20 or CD22|Unknown status|Recruiting|Phase 1/Phase 2|80|Anticipated|Chinese PLA General Hospital|||||f||||f|f|f|||||||||||2023-09-04 11:04:42.342153|2023-09-04 11:04:42.342153|OTHER|||||
NCT03125577||2017-04-19|||2019-09-18|2017-04-19|2017-04-24|Actual|||||||2019-09-18|2019-09-19|Actual|July 15, 2017|Actual|2017-07-15|September 2019|2019-09-30|December 2021|Anticipated|2021-12-31|July 31, 2019|Actual|2019-07-31||Interventional|||Combination CAR-T Cell Therapy Targeting Hematological Malignancies|Combination CAR-T Therapy of 4SCAR19 Plus 4SCAR20, 22, 38, 70 and 123 Targeting Hematological Malignancies|Unknown status|Recruiting|Phase 1/Phase 2|100|Anticipated|Shenzhen Geno-Immune Medical Institute||1|||f||||f|f|f|||||||||No||2023-09-04 11:04:44.975884|2023-09-04 11:04:44.975884|OTHER|||||
NCT03393936||2017-12-25|||2021-10-19|2018-01-03|2018-01-09|Actual|||||||2021-10-19|2021-10-21|Actual|March 26, 2018|Actual|2018-03-26|October 2021|2021-10-31|June 30, 2023|Anticipated|2023-06-30|June 30, 2022|Anticipated|2022-06-30||Interventional|||Safety and Efficacy of CCT301 CAR-T in Adult Subjects With Recurrent or Refractory Stage IV Renal Cell Carcinoma|A Dose Escalation and Dose Expansion Trial to Assess the Safety, Tolerability and Anti-tumor Activity of Autologous T Cell Modified Chimeric Antigen Receptor (CAR) CCT 301-38 or CCT 301-59 in Patients With Recurrent or Refractory Stage IV Renal Cell Carcinoma|Active, not recruiting||Phase 1/Phase 2|66|Anticipated|Shanghai PerHum Therapeutics Co., Ltd.||2|||f||||t|f|f|||||||||||2023-08-31 10:18:19.69256|2023-08-31 10:18:19.69256|INDUSTRY|||||
NCT05085444||2021-10-11|||2021-10-11|2021-10-11|2021-10-20|Actual|||||||2021-10-11|2021-10-20|Actual|October 8, 2021|Actual|2021-10-08|October 2021|2021-10-31|October 8, 2024|Anticipated|2024-10-08|October 8, 2024|Anticipated|2024-10-08||Interventional|||A Study of CD19/BCMA Chimeric Antigen Receptor T Cells Therapy for Patients With Refractory Scleroderma|A Study of CD19/BCMA Chimeric Antigen Receptor T Cells Therapy for Patients With Refractory Scleroderma|Recruiting||Early Phase 1|9|Anticipated|Zhejiang University||1|||f||||t|f|f|||||||||||2023-08-31 10:18:50.24048|2023-08-31 10:18:50.24048|OTHER|||||
NCT04287660||2020-02-19|||2021-10-22|2020-02-25|2020-02-27|Actual|||||||2021-10-22|2021-10-25|Actual|October 19, 2017|Actual|2017-10-19|February 2021|2021-02-28|January 31, 2025|Anticipated|2025-01-31|January 31, 2023|Anticipated|2023-01-31||Interventional|||Study of BiRd Regimen Combined With BCMA CAR T-cell Therapy in Newly Diagnosed Multiple Myeloma (MM) Patients|A Phase 3, Single Arm, Multi-Center Study to Assess the Efficacy and Safety of Clarithromycin(Biaxin)-Lenalidomide-Low-Dose-Dexamethasone (BiRd) Combined With B-cell Maturation Antigen (BCMA)-Directed Chimeric Antigen Receptor (CAR) T-cell Therapy in Patients With Newly Diagnosed Multiple Myeloma|Recruiting||Phase 3|20|Anticipated|The First Affiliated Hospital of Soochow University||1|||f|||||f|f|||||||||||2023-08-31 10:21:30.422938|2023-08-31 10:21:30.422938|OTHER|||||
NCT04270461||2020-02-10|||2020-10-18|2020-02-13|2020-02-17|Actual|||||||2020-10-18|2020-10-22|Actual|March 17, 2020|Actual|2020-03-17|October 2020|2020-10-31|October 17, 2020|Actual|2020-10-17|October 17, 2020|Actual|2020-10-17||Interventional|||NKG2D-based CAR T-cells Immunotherapy for Patient With r/r NKG2DL+ Solid Tumors|A Phase I Clinical Trial of NKG2D-based CAR T-cells Injection for Subjects With Relapsed/Refractory NKG2DL+ Solid Tumors|Withdrawn||Phase 1|0|Actual|Jiujiang University Affiliated Hospital||1||Study is withdrawn because of administrative reasons|f|||||f|f|||||||||No||2023-08-31 10:21:58.755109|2023-08-31 10:21:58.755109|OTHER_GOV|||||
NCT04088864||2019-09-11|||2022-09-08|2019-09-11|2019-09-13|Actual|||||||2022-09-08|2022-09-13|Actual|January 10, 2020|Actual|2020-01-10|September 2022|2022-09-30|August 2035|Anticipated|2035-08-31|August 2025|Anticipated|2025-08-31||Interventional|||CD22-CAR T Cells in Children and Young Adults With B Cell Malignancies|Phase Ib Clinical Trial of Autologous CD22 Chimeric Antigen Receptor (CAR) T Cells in Children and Young Adults With Recurrent or Refractory B Cell Malignancies|Suspended||Phase 1|52|Anticipated|Stanford University||2||Business decision|f||||t|t|f|||f||||||No||2023-08-31 10:24:11.532093|2023-08-31 10:24:11.532093|OTHER|||||
NCT04007029||2019-06-20|||2022-09-09|2019-07-01|2019-07-05|Actual|||||||2022-09-09|2022-09-13|Actual|October 4, 2019|Actual|2019-10-04|September 2022|2022-09-30|August 1, 2024|Anticipated|2024-08-01|August 1, 2023|Anticipated|2023-08-01||Interventional|||Modified Immune Cells (CD19/CD20 CAR-T Cells) in Treating Patients With Recurrent or Refractory B-Cell Lymphoma or Chronic Lymphocytic Leukemia|Study of CD19/CD20 Bispecific Chimeric Antigen Receptor (CAR)-T Cells for the Treatment of Relapsed or Refractory B-Cell Lymphomas and Chronic Lymphocytic Leukemia (CD20 - Cluster of Differentiation Antigen 20)|Recruiting||Phase 1|24|Anticipated|Jonsson Comprehensive Cancer Center||1|||f||||t|t|f|||f||||||||2023-08-31 10:25:16.917329|2023-08-31 10:25:16.917329|OTHER|||||
NCT04194931||2019-12-09|||2019-12-10|2019-12-10|2019-12-11|Actual|||||||2019-12-10|2019-12-11|Actual|December 1, 2019|Anticipated|2019-12-01|December 2019|2019-12-31|December 31, 2020|Anticipated|2020-12-31|December 31, 2020|Anticipated|2020-12-31||Interventional|||Humanized CAR-T Cells of Anti-BCAM and Anti-CD19 Against Relapsed and Refractory Multiple Myeloma|Study Evaluating the Safety and Efficacy With Sequential Infusion of Humanized CAR-T Cells of Anti-BCAM and Anti-CD19 Against Relapsed and Refractory Multiple Myeloma|Unknown status|Recruiting|Phase 1|20|Anticipated|The First Affiliated Hospital of Nanchang University||1|||f||||t|f|f|||f||||||||2023-08-31 10:28:13.673173|2023-08-31 10:28:13.673173|OTHER|||||
NCT03939026||2019-04-04|||2022-05-25|2019-05-03|2019-05-06|Actual|||||||2022-05-25|2022-05-26|Actual|May 1, 2019|Actual|2019-05-01|May 2022|2022-05-31|August 2026|Anticipated|2026-08-31|December 2022|Anticipated|2022-12-31||Interventional|ALPHA||Safety and Efficacy of ALLO-501 Anti-CD19 Allogeneic CAR T Cells in Adults With Relapsed/Refractory Large B Cell or Follicular Lymphoma|A Single-Arm, Open-Label, Phase 1 Study Evaluating the Safety, Efficacy, and Cellular Kinetics/Pharmacodynamics of ALLO-501, an Anti-CD19 Allogeneic CAR T Cell Therapy, And ALLO-647, An Anti-CD52 Monoclonal Antibody, in Patients With Relapsed/Refractory Large B-Cell Lymphoma or Follicular Lymphoma|Active, not recruiting||Phase 1|74|Anticipated|Allogene Therapeutics||1|||||||t|t|f|||||||||||2023-09-04 11:10:56.924494|2023-09-04 11:10:56.924494|INDUSTRY|||||
NCT05066022||2021-08-31|||2021-10-27|2021-09-23|2021-10-04|Actual|||||||2021-10-27|2021-11-04|Actual|October 28, 2021|Anticipated|2021-10-28|September 2021|2021-09-30|July 29, 2024|Anticipated|2024-07-29|August 30, 2022|Anticipated|2022-08-30||Interventional|||A Study to Access the Safety and Efficacy of CT0590 in Patients With Relapsed and/or Refractory Multiple Myeloma|Open Label, Single Arm Clinical Trial to Evaluate the Safety and Efficacy of CT0590 Chimeric Antigen Receptor T Cell （CAR T）in Patients With Relapsed and/or Refractory Multiple Myeloma|Recruiting||Not Applicable|24|Anticipated|The First Affiliated Hospital of Soochow University||1|||f|||||f|f|||||||||No||2023-08-31 10:48:52.955143|2023-08-31 10:48:52.955143|OTHER|||||
NCT04662294||2020-10-22|||2021-10-26|2020-12-05|2020-12-10|Actual|||||||2021-10-26|2021-11-04|Actual|November 18, 2021|Anticipated|2021-11-18|December 2020|2020-12-31|January 15, 2027|Anticipated|2027-01-15|January 15, 2024|Anticipated|2024-01-15||Interventional|||CD 70 CAR T for Patients With CD70 Positive Malignant Hematologic Diseases|Clinical Trial for the Safety and Efficacy of CD 70 CAR T for Patients With CD70 Positive Malignant Hematologic Diseases|Recruiting||Early Phase 1|108|Anticipated|Zhejiang University||3|||f||||t|f|f|||||||||No||2023-08-31 10:49:22.795932|2023-08-31 10:49:22.795932|OTHER|||||
NCT04014894||2019-07-02|||2021-11-11|2019-07-08|2019-07-10|Actual|||||||2021-11-11|2021-11-12|Actual|June 12, 2019|Actual|2019-06-12|November 2021|2021-11-30|July 1, 2022|Anticipated|2022-07-01|July 1, 2021|Actual|2021-07-01||Interventional|||ET019003-T Cells in Relapsed/Refractory CD19+ B-Cell Leukemia and Lymphoma|Safety and Efficiency Study of ET019003-T Cells in Relapsed/Refractory CD19+ B-Cell Leukemia and Lymphoma|Active, not recruiting||Phase 1|9|Anticipated|Wuhan Union Hospital, China||1|||f||||f|f|f|||||||||||2023-08-31 10:54:40.166211|2023-08-31 10:54:40.166211|OTHER|||||
NCT03155191||2017-04-14|||2022-06-15|2017-05-15|2017-05-16|Actual|||||||2022-06-15|2022-06-21|Actual|June 1, 2017|Actual|2017-06-01|June 2022|2022-06-30|March 31, 2035|Anticipated|2035-03-31|March 31, 2035|Anticipated|2035-03-31||Interventional|TBI-1501||Study of TBI-1501 for Relapsed or Refractory Acute Lymphoblastic Leukemia|A Multicenter Phase I/II Study for Relapsed or Refractory CD19+ B-acute Lymphoblastic Leukemia|Active, not recruiting||Phase 1/Phase 2|21|Anticipated|Takara Bio Inc.||1|||f||||t|f|f|||||||||No||2023-08-31 10:57:37.69129|2023-08-31 10:57:37.69129|INDUSTRY|||||
NCT05066646||2021-09-22|||2021-11-21|2021-09-23|2021-10-04|Actual|||||||2021-11-21|2021-11-23|Actual|April 1, 2020|Actual|2020-04-01|September 2021|2021-09-30|June 2024|Anticipated|2024-06-30|October 2022|Anticipated|2022-10-31||Interventional|FUMANBA-1||A Phase 1/2 Study of a Fully Human BCMA-targeting CAR (CT103A) in Patients With Relapsed/Refractory Multiple Myeloma (FUMANBA-1)|Phase 1/2 Clinical Study on Fully Human BCMA Chimeric Antigen Receptor Autologous T Cell Injection (CT103A) in the Treatment of Patients With Relapsed/Refractory Multiple Myeloma|Recruiting||Phase 1/Phase 2|132|Anticipated|Nanjing IASO Biotherapeutics Co.,Ltd||1|||f||||t|f|f|||||||||No||2023-08-31 11:10:08.417937|2023-08-31 11:10:08.417937|INDUSTRY|||||
NCT03585517||2018-07-01|||2023-01-18|2018-07-01|2018-07-13|Actual|||||||2023-01-18|2023-01-19|Actual|July 21, 2018|Actual|2018-07-21|July 2018|2018-07-31|October 1, 2020|Actual|2020-10-01|August 1, 2020|Actual|2020-08-01||Interventional|||Safety and Efficacy Evaluation of IM23 CAR-T Cells (IM23CAR-T)|Safety and Efficacy Evaluation of IM23 CAR-T Cells On CD123+ AML Patients|Completed||Phase 1|10|Actual|Beijing Immunochina Medical Science & Technology Co., Ltd.||1|||f|||||f|f|||||||||||2023-09-01 10:01:04.187224|2023-09-01 10:01:04.187224|INDUSTRY|||||
NCT05028933||2021-08-19|||2023-01-27|2021-08-25|2021-08-31|Actual|||||||2023-01-27|2023-01-30|Actual|September 30, 2021|Actual|2021-09-30|January 2023|2023-01-31|December 31, 2024|Anticipated|2024-12-31|December 30, 2023|Anticipated|2023-12-30||Interventional|||IMC001 for Clinical Research on Advanced Digestive System Malignancies|Autologous T Cells Modified by Chimeric Antigen Receptor Targeting EpCAM for Clinical Research on Advanced Digestive System Malignancies|Recruiting||Phase 1|48|Anticipated|Zhejiang University||1|||f||||t|f|f|||||||||No||2023-09-01 10:03:17.041301|2023-09-01 10:03:17.041301|OTHER|||||
NCT03975907||2019-05-30|||2023-01-26|2019-06-04|2019-06-05|Actual|||||||2023-01-26|2023-01-30|Actual|June 10, 2019|Actual|2019-06-10|January 2023|2023-01-31|December 31, 2025|Anticipated|2025-12-31|December 31, 2023|Anticipated|2023-12-31||Interventional|||Clinical Trial to Evaluate CT053 in Patients With Relapsed and/or Refractory Multiple Myeloma (LUMMICAR STUDY 1)|Open Label, Phase I/II Clinical Trial to Evaluate the Safety and Efficacy of Fully Human Anti-BCMA Chimeric Antibody Receptor Autologous T Cell （CAR T）in Patients With Relapsed and/or Refractory Multiple Myeloma (LUMMICAR STUDY 1)|Recruiting||Phase 1/Phase 2|114|Anticipated|CARsgen Therapeutics Co., Ltd.||1|||f||||t|f|f|||||||||No||2023-09-01 10:04:02.665636|2023-09-01 10:04:02.665636|INDUSTRY|||||
NCT03142646||2016-06-06|||2018-04-28|2017-05-04|2017-05-05|Actual|||||||2018-04-28|2018-05-01|Actual|August 30, 2016|Actual|2016-08-30|October 2017|2017-10-31|October 1, 2018|Anticipated|2018-10-01|June 1, 2018|Anticipated|2018-06-01||Interventional|IM19CAR-T||Safety and Efficacy Evaluation of IM19 CAR-T Cells|Safety and Efficacy Evaluation of IM19 CAR-T Cells on Refractory or Relapsed B-ALL Patients|Unknown status|Recruiting|Phase 1/Phase 2|60|Anticipated|Beijing Immunochina Medical Science & Technology Co., Ltd.||1|||f|||||||||||||||No||2023-09-04 11:12:16.630647|2023-09-04 11:12:16.630647|INDUSTRY|||||
NCT04488354||2020-07-20|||2023-06-27|2020-07-22|2020-07-28|Actual|||||||2023-06-27|2023-06-29|Actual|January 21, 2021|Actual|2021-01-21|June 2023|2023-06-30|August 2036|Anticipated|2036-08-31|August 2036|Anticipated|2036-08-31||Interventional|||Long-term Follow-up Study for Patients Treated With CLBR001 CAR-T|A Study to Evaluate the Long-Term Safety of CLBR001, A Lentiviral Based Chimeric Antigen Receptor, In Patients With B-Cell Malignancies Previously Administered CLBR001|Enrolling by invitation||Phase 1|36|Anticipated|Calibr, a division of Scripps Research||1|||f||||f|t|f|||||||||No||2023-08-31 11:21:37.293426|2023-08-31 11:21:37.293426|OTHER|||||
NCT05310591||2022-03-09|||2022-04-04|2022-04-04|2022-04-05|Actual|||||||2022-04-04|2022-04-05|Actual|April 2022|Anticipated|2022-04-30|February 2022|2022-02-28|April 2026|Anticipated|2026-04-30|July 2024|Anticipated|2024-07-31||Interventional|CAPTiRALL||Combination of an Anti-PD1 Antibody With Tisagenlecleucel Reinfusion in Children, Adolescents and Young Adults With Acute Lymphoblastic Leukemia After Loss of Persistence|Combination of an Anti-PD1 Antibody With Tisagenlecleucel Reinfusion in Children, Adolescents and Young Adults With Acute Lymphoblastic Leukemia After Loss of Persistence|Not yet recruiting||Phase 1/Phase 2|26|Anticipated|Assistance Publique - Hôpitaux de Paris||2|||f||||t|f|f|||||||||Undecided||2023-08-31 11:24:34.90003|2023-08-31 11:24:34.90003|OTHER|||||
NCT05063682||2021-06-10|||2021-09-30|2021-09-30|2021-10-01|Actual|||||||2021-09-30|2021-10-01|Actual|May 15, 2020|Actual|2020-05-15|September 2021|2021-09-30|October 2023|Anticipated|2023-10-31|October 2023|Anticipated|2023-10-31||Interventional|CARTREMENDOUS||The Efficacy and Safety of Brain-targeting Immune Cells (EGFRvIII-CAR T Cells) in Treating Patients With Leptomeningeal Disease From Glioblastoma. Administering Patients EGFRvIII -CAR T Cells May Help to Recognize and Destroy Brain Tumor Cells in Patients|A Phase 1 Study to Evaluate EGFRvIII -Targeted Chimeric Antigen Receptor (CAR) T Cells for Adult Patients With Leptomeningeal Glioblastoma|Active, not recruiting||Phase 1|10|Actual|Chembrain LTD||1|||f||||t|f|f|||||||||No||2023-08-31 11:31:02.291673|2023-08-31 11:31:02.291673|INDUSTRY|||||
NCT05060796||2021-09-19|||2023-02-26|2021-09-19|2021-09-29|Actual|||||||2023-02-26|2023-02-28|Actual|September 1, 2019|Actual|2019-09-01|February 2023|2023-02-28|November 1, 2034|Anticipated|2034-11-01|November 1, 2024|Anticipated|2024-11-01||Interventional|||Study of CXCR5 Modified EGFR Targeted CAR-T Cells for Advanced NSCLC|A Single-arm, Open-label, Phase I Study to Evaluate the Safety and Efficacy of CXCR5 Modified EGFR Chimeric Antigen Receptor Autologous T Cells in EGFR-positive Patients With Advanced Non-small Cell Lung Cancer|Recruiting||Early Phase 1|11|Anticipated|Second Affiliated Hospital of Guangzhou Medical University||1|||f|||||f|f|||||||||No||2023-08-31 11:32:13.214653|2023-08-31 11:32:13.214653|OTHER|||||
NCT05596266||2022-10-23|||2022-10-23|2022-10-23|2022-10-27|Actual|||||||2022-10-23|2022-10-27|Actual|October 25, 2022|Anticipated|2022-10-25|October 2022|2022-10-31|October 25, 2025|Anticipated|2025-10-25|December 31, 2024|Anticipated|2024-12-31||Interventional|||CD5 CAR-T Therapy for Refractory/Relapsed CD5+ T-cell Acute Lymphoblastic Leukemia|A Phase I Study of CD5 CAR-T for Refractory/Relapsed CD5+ T-ALL Patients|Recruiting||Phase 1|20|Anticipated|Xuanwu Hospital, Beijing||1|||f|||||f|f|||||||||||2023-09-01 10:43:19.883679|2023-09-01 10:43:19.883679|OTHER|||||
NCT03097770||2017-03-26|||2020-08-31|2017-03-26|2017-03-31|Actual|||||||2020-08-31|2020-09-02|Actual|April 1, 2017|Actual|2017-04-01|December 2019|2019-12-31|January 31, 2020|Actual|2020-01-31|May 10, 2019|Actual|2019-05-10||Interventional|||Treatment of Relapsed and/or Chemotherapy Refractory B-cell Malignancy by Tandem CAR T Cells Targeting CD19 and CD20|Clinical Study of CD19/CD20 tanCAR T Cells in Relapsed and/or Chemotherapy Refractory B-cell Leukemias and Lymphomas|Completed||Phase 1/Phase 2|100|Actual|Chinese PLA General Hospital||1|||f||||t|f|f|||||||||||2023-08-31 11:33:56.556296|2023-08-31 11:33:56.556296|OTHER|||||
NCT05137275||2021-11-11|||2022-10-25|2021-11-28|2021-11-30|Actual|||||||2022-10-25|2022-10-27|Actual|November 24, 2021|Actual|2021-11-24|October 2022|2022-10-31|May 2023|Anticipated|2023-05-31|April 2023|Anticipated|2023-04-30||Interventional|||Study of Anti-5T4 CAR-raNK Cell Therapy in Locally Advanced or Metastatic Solid Tumors|Dose Escalation and Extension Study to Evaluate the Safety, Tolerability, and Initial Efficacy of Anti-5T4 CAR-raNK Cell Therapy in Locally Advanced or Metastatic Solid Tumors|Recruiting||Early Phase 1|56|Anticipated|Shanghai East Hospital||1|||f||||f|f|f|||||||||No||2023-09-01 10:44:38.164293|2023-09-01 10:44:38.164293|OTHER|||||
NCT03599375||2018-07-15|||2019-02-24|2018-07-15|2018-07-26|Actual|||||||2019-02-24|2019-02-26|Actual|May 1, 2019|Anticipated|2019-05-01|February 2019|2019-02-28|December 30, 2021|Anticipated|2021-12-30|December 30, 2020|Anticipated|2020-12-30||Interventional|||Immunotherapy With CD19 CART-cells for B Cell Acute Lymphoblastic Leukemia|Safety and Clinical Activity of CD19 Chimeric Antigen Receptor T Cells in Treating Patients With Recurrent or Refractory CD19 Positive B Cell Acute Lymphoblastic Leukemia|Unknown status|Not yet recruiting|Phase 1|20|Anticipated|The First Hospital of Jilin University||1|||f||||f|f|f|||f||||||||2023-08-31 11:37:02.171491|2023-08-31 11:37:02.171491|OTHER|||||
NCT03407859||2017-04-09|||2021-08-09|2018-01-16|2018-01-23|Actual|||||||2021-08-09|2021-08-10|Actual|January 18, 2016|Actual|2016-01-18|July 2021|2021-07-31|March 31, 2022|Anticipated|2022-03-31|December 31, 2021|Anticipated|2021-12-31||Interventional|||Sequential Treatment With CD20/CD22/CD10-CART After CD19-CART Treatment Base on MRD in Relapsed/Refractory B-ALL|Sequential Treatment With CD20/CD22/CD10-CART After CD19-CART Treatment Base on MRD in Relapsed/Refractory B-ALL|Unknown status|Recruiting|Early Phase 1|30|Anticipated|Zhujiang Hospital||1|||f||||t|f|f|||f||||||Undecided||2023-08-31 11:38:09.638329|2023-08-31 11:38:09.638329|OTHER|||||
NCT04191941||2019-12-06|||2019-12-06|2019-12-06|2019-12-10|Actual|||||||2019-12-06|2019-12-10|Actual|September 1, 2019|Actual|2019-09-01|December 2019|2019-12-31|December 31, 2021|Anticipated|2021-12-31|August 31, 2021|Anticipated|2021-08-31||Interventional|||Treatment of Hematological Malignancy With Novel CAR-T Cells.|Adoptive Immunotherapy for Hematological Malignancy With Novel CAR-T Cells.|Unknown status|Recruiting|Early Phase 1|9|Anticipated|Timmune Biotech Inc.||1|||f||||t|f|f|||||||||No||2023-08-31 11:41:24.465521|2023-08-31 11:41:24.465521|INDUSTRY|||||
NCT04249947||2020-01-28|||2022-11-15|2020-01-29|2020-01-31|Actual|||||||2022-11-15|2022-11-17|Actual|February 28, 2020|Actual|2020-02-28|November 2022|2022-11-30|September 2036|Anticipated|2036-09-30|September 2023|Anticipated|2023-09-30||Interventional|||P-PSMA-101 CAR-T Cells in the Treatment of Subjects With Metastatic Castration-Resistant Prostate Cancer (mCRPC) and Advanced Salivary Gland Cancers (SGC)|A Phase 1 Dose Escalation and Expanded Cohort Study of P-PSMA-101 in Subjects With Metastatic Castration-Resistant Prostate Cancer (mCRPC) and Advanced Salivary Gland Cancers (SGC)|Active, not recruiting||Phase 1|60|Anticipated|Poseida Therapeutics, Inc.||4|||f||||t|t|f|||||||||No||2023-08-31 11:52:14.391326|2023-08-31 11:52:14.391326|INDUSTRY|||||
NCT05619861||2022-11-09|||2022-11-09|2022-11-09|2022-11-17|Actual|||||||2022-11-09|2022-11-17|Actual|April 27, 2020|Actual|2020-04-27|November 2022|2022-11-30|December 26, 2023|Anticipated|2023-12-26|January 26, 2023|Anticipated|2023-01-26||Interventional|||CAR-T Cells in the Treatment of Malignant Hematological Tumors|Clinical Study of CAR-T Technique in the Treatment of Recurrent and Refractory Hematopoietic and Lymphatic Tumor|Recruiting||Not Applicable|20|Anticipated|Hebei Senlang Biotechnology Inc., Ltd.||1|||f|||||f|f|||||||||||2023-08-31 11:52:31.315773|2023-08-31 11:52:31.315773|INDUSTRY|||||
NCT03154775||2017-05-13|||2017-05-13|2017-05-13|2017-05-16|Actual|||||||2017-05-13|2017-05-16|Actual|May 3, 2017|Actual|2017-05-03|May 2017|2017-05-31|December 31, 2018|Anticipated|2018-12-31|April 30, 2018|Anticipated|2018-04-30||Interventional|||Study of Safety and Efficacy of C-CAR011 in B-NHL Patients|Study of Safety and Efficacy of Anti-CD19 Chimeric Antigen Receptor T Cell(C-CAR011) Treatment in Subjects With Relapsed or Refractory B Cell Non-Hodgkin Lymphoma|Unknown status|Recruiting|Phase 1|15|Anticipated|Cellular Biomedicine Group Ltd.||1|||f||||t|f|f|||||||||Undecided||2023-08-31 11:58:36.740463|2023-08-31 11:58:36.740463|INDUSTRY|||||
NCT03018093||2017-01-10|||2017-01-18|2017-01-10|2017-01-11|Estimate|||||||2017-01-18|2017-01-20|Estimate|January 2017||2017-01-31|January 2017|2017-01-31|November 2018|Anticipated|2018-11-30|August 2018|Anticipated|2018-08-31||Interventional|||A Phase I Study Evaluating Safety and Efficacy of C-CAR011 Treatment in Adult Subjects With r/r CD19+B-ALL|A Phase I Study Evaluating Safety and Efficacy of CBM.CD19-targeted Chimeric Antigen Receptor T Cells (C-CAR011) Treatment in Adult Subjects With Relapsed/Refractory CD19+ B Cells Acute Lymphoblastic Leukemia(CALL-1)|Unknown status|Recruiting|Phase 1|20|Anticipated|Cellular Biomedicine Group Ltd.||1|||f||||t|||||||||||Undecided||2023-08-31 12:03:03.925912|2023-08-31 12:03:03.925912|INDUSTRY|||||
NCT04359784||2020-04-15|||2023-04-04|2020-04-22|2020-04-24|Actual|||||||2023-04-04|2023-04-06|Actual|December 27, 2021|Actual|2021-12-27|April 2023|2023-04-30|March 3, 2024|Anticipated|2024-03-03|March 3, 2024|Anticipated|2024-03-03||Interventional|||Anakinra for the Prevention of Cytokine Release Syndrome and Neurotoxicity in Patients With B-Cell Non-Hodgkin Lymphoma Receiving CD19-Targeted CAR-T Cell Therapy|Phase 2 Pilot Study to Evaluate Efficacy and Safety of Anakinra to Prevent CD19-Targeted CAR-T Cell-Related Cytokine Release Syndrome (CRS) and Neurotoxicity in Patients With B Cell Lymphoma|Suspended||Phase 2|25|Anticipated|Fred Hutchinson Cancer Center||1||Recruitment on hold while awaiting negotiation to increase accrual.|f||||t|t|f|||||||||No||2023-09-01 11:10:07.027712|2023-09-01 11:10:07.027712|OTHER|||||
NCT03373097||2017-12-06|||2022-03-09|2017-12-08|2017-12-14|Actual|||||||2022-03-09|2022-03-24|Actual|January 5, 2018|Actual|2018-01-05|March 2022|2022-03-31|December 2027|Anticipated|2027-12-31|December 2024|Anticipated|2024-12-31||Interventional|||Anti-GD2 CAR T Cells in Pediatric Patients Affected by High Risk and/or Relapsed/Refractory Neuroblastoma or Other GD2-positive Solid Tumors|Phase I/II Study of Anti-GD2 Chimeric Antigen Receptor-Expressing T Cells in Pediatric Patients Affected by High Risk and/or Relapsed/Refractory Neuroblastoma or Other GD2-positive Solid Tumors|Recruiting||Phase 1/Phase 2|42|Anticipated|Bambino Gesù Hospital and Research Institute||1|||f||||t|f|f|||||||||Undecided||2023-09-01 11:14:31.013018|2023-09-01 11:14:31.013018|OTHER|||||
NCT05437341||2022-06-21|||2022-06-25|2022-06-25|2022-06-29|Actual|||||||2022-06-25|2022-06-29|Actual|June 30, 2022|Anticipated|2022-06-30|June 2022|2022-06-30|June 30, 2026|Anticipated|2026-06-30|December 31, 2025|Anticipated|2025-12-31||Interventional|||PSMA/CD70 Bi-specific CAR-T Cell Therapy|PSMA/CD70 Bi-specific CAR-T Cells for Cancer Treatment|Recruiting||Phase 1/Phase 2|60|Anticipated|Shenzhen Geno-Immune Medical Institute||1|||f||||f|f|f|||||||||No||2023-09-01 11:15:14.370164|2023-09-01 11:15:14.370164|OTHER|||||
NCT05437328||2022-06-21|||2022-06-25|2022-06-25|2022-06-29|Actual|||||||2022-06-25|2022-06-29|Actual|June 30, 2022|Anticipated|2022-06-30|June 2022|2022-06-30|June 30, 2026|Anticipated|2026-06-30|December 31, 2025|Anticipated|2025-12-31||Interventional|||GD2/CD56 Bi-specific CAR-T Cell Therapy|GD2/CD56 Bi-specific CAR-T Cells for Cancer Treatment|Recruiting||Phase 1/Phase 2|60|Anticipated|Shenzhen Geno-Immune Medical Institute||1|||f||||f|f|f|||||||||No||2023-09-01 11:15:15.021118|2023-09-01 11:15:15.021118|OTHER|||||
NCT05437315||2022-06-21|||2022-06-25|2022-06-25|2022-06-29|Actual|||||||2022-06-25|2022-06-29|Actual|June 30, 2022|Anticipated|2022-06-30|June 2022|2022-06-30|June 30, 2026|Anticipated|2026-06-30|December 31, 2025|Anticipated|2025-12-31||Interventional|||GD2/PSMA Bi-specific CAR-T Cell Therapy|GD2/PSMA Bi-specific CAR-T Cells For the Treatment of GD2 and PSMA Positive Solid Tumors|Recruiting||Phase 1/Phase 2|60|Anticipated|Shenzhen Geno-Immune Medical Institute||1|||f||||f|f|f|||||||||No||2023-09-01 11:15:15.768781|2023-09-01 11:15:15.768781|OTHER|||||
NCT05436509||2022-06-22|||2022-06-28|2022-06-28|2022-06-29|Actual|||||||2022-06-28|2022-06-29|Actual|June 30, 2022|Anticipated|2022-06-30|June 2022|2022-06-30|June 30, 2026|Anticipated|2026-06-30|December 31, 2025|Anticipated|2025-12-31||Interventional|||CD19/79b Bi-specific CAR-T Cell Therapy|CD19/79b Bi-specific CAR-T Cells Targeting B Cell Malignancies|Recruiting||Phase 1/Phase 2|60|Anticipated|Shenzhen Geno-Immune Medical Institute||1|||f||||f|f|f|||||||||No||2023-09-01 11:15:29.251941|2023-09-01 11:15:29.251941|OTHER|||||
NCT05436496||2022-06-22|||2022-06-28|2022-06-28|2022-06-29|Actual|||||||2022-06-28|2022-06-29|Actual|June 30, 2022|Anticipated|2022-06-30|June 2022|2022-06-30|June 30, 2026|Anticipated|2026-06-30|December 31, 2025|Anticipated|2025-12-31||Interventional|||CD19/70 Bi-specific CAR-T Cell Therapy|CD19/70 Bi-specific CAR-T Cells Targeting B Cell Malignancies|Recruiting||Phase 1/Phase 2|30|Anticipated|Shenzhen Geno-Immune Medical Institute||1|||f||||f|f|f|||||||||No||2023-09-01 11:15:29.849081|2023-09-01 11:15:29.849081|OTHER|||||
NCT01735604||2012-11-23|||2015-09-27|2012-11-27|2012-11-28|Estimate|||||||2015-09-27|2015-09-29|Estimate|January 2013||2013-01-31|September 2015|2015-09-30|October 2018|Anticipated|2018-10-31|May 2017|Anticipated|2017-05-31||Interventional|||Genetically Engineered Lymphocyte Therapy in Treating Patients With Lymphoma That is Resistant or Refractory to Chemotherapy|Pilot Study of Redirected Autologous T Cells Transduced to Express A CD20-Specific Chimeric Immunoreceptor in Patient With Chemotherapy Resistant or Refractory CD20+ Leukemia and Lymphoma|Unknown status|Recruiting|Phase 1/Phase 2|50|Anticipated|Chinese PLA General Hospital||1|||f||||t|||||||||||||2023-09-01 11:43:05.847512|2023-09-01 11:43:05.847512|OTHER|||||
NCT05396300||2022-05-25|||2023-07-14|2022-05-25|2022-05-31|Actual|||||||2023-07-14|2023-07-17|Actual|May 25, 2022|Actual|2022-05-25|July 2023|2023-07-31|May 15, 2025|Anticipated|2025-05-15|May 15, 2024|Anticipated|2024-05-15||Interventional|||A Clinical Study of CEA-targeted CAR-T in the Treatment of CEA-positive Advanced Malignant Solid Tumors|A Phase I Clinical Study of Anti-CEA CAR-T Therapy in the Treatment of CEA-positive Advanced Malignant Solid Tumors|Recruiting||Phase 1|60|Anticipated|Zhejiang University||2|||f|||||f|f|||||||||||2023-09-04 11:19:55.275343|2023-09-04 11:19:55.275343|OTHER|||||
NCT05089266||2021-10-11|||2023-07-13|2021-10-11|2021-10-22|Actual|||||||2023-07-13|2023-07-17|Actual|November 30, 2021|Actual|2021-11-30|July 2023|2023-07-31|January 30, 2025|Anticipated|2025-01-30|July 30, 2024|Anticipated|2024-07-30||Interventional|||Study of αPD1-MSLN-CAR T Cells to Evaluate the Safety, Tolerability, and Effectiveness for Patients With MSLN-positive Advanced Solid Tumors|Study of αPD1-MSLN-CAR T Cells to Evaluate the Safety, Tolerability, and Effectiveness for Patients With MSLN-positive Advanced Solid Tumors.|Recruiting||Phase 1|30|Anticipated|Shanghai Cell Therapy Group Co.,Ltd||1|||f||||t|f|f|||||||||Yes||2023-09-04 11:20:27.936031|2023-09-04 11:20:27.936031|INDUSTRY|||||
NCT04768608||2021-02-18|||2023-07-14|2021-02-23|2021-02-24|Actual|||||||2023-07-14|2023-07-17|Actual|December 23, 2021|Actual|2021-12-23|July 2023|2023-07-31|May 30, 2023|Actual|2023-05-30|June 30, 2022|Actual|2022-06-30||Interventional|||PD1 Integrated Anti-PSMA CART in Treating Patients With Castrate-Resistant Prostate Cancer|Clinical Trial for the Safety and Efficacy of Non-viral PD1 Integrated Anti-PSMA Chimeric Antigen Receptor T Cells in the Treatment of Refractory Castrate-Resistant Prostate Cancer|Completed||Phase 1|3|Actual|Zhejiang University||1|||f||||f|f|f|||||||||||2023-09-04 11:20:51.416146|2023-09-04 11:20:51.416146|OTHER|||||
NCT04652219||2020-11-09|||2023-07-14|2020-12-02|2020-12-03|Actual|||||||2023-07-14|2023-07-17|Actual|October 10, 2020|Actual|2020-10-10|July 2023|2023-07-31|October 9, 2021|Actual|2021-10-09|October 9, 2021|Actual|2021-10-09||Interventional|CART||CART Therapy in GUCY2C-positive Digestive Tract Tumors|Clinical Study on the Safety and Efficacy of CART Cells in the Treatment of Advanced GUCY2C-positive Digestive Tract Tumors|Completed||Early Phase 1|1|Actual|Zhejiang University||1|||f||||f|f|f|||||||||No||2023-09-04 11:21:09.229946|2023-09-04 11:21:09.229946|OTHER|||||
NCT03618381||2018-07-16|||2023-07-13|2018-08-06|2018-08-07|Actual|||||||2023-07-13|2023-07-17|Actual|June 18, 2019|Actual|2019-06-18|July 2023|2023-07-31|June 2038|Anticipated|2038-06-30|June 2024|Anticipated|2024-06-30||Interventional|||EGFR806 CAR T Cell Immunotherapy for Recurrent/Refractory Solid Tumors in Children and Young Adults|Phase I Study of EGFR806 CAR T Cell Immunotherapy for Recurrent/Refractory Solid Tumors in Children and Young Adults|Recruiting||Phase 1|44|Anticipated|Seattle Children's Hospital||2|||f||||t|t|f|||||||||No||2023-09-04 11:22:17.780521|2023-09-04 11:22:17.780521|OTHER|||||
NCT04545762||2020-08-31|||2023-05-05|2020-09-10|2020-09-11|Actual|||||||2023-05-05|2023-05-09|Actual|September 11, 2020|Actual|2020-09-11|May 2023|2023-05-31|October 31, 2023|Anticipated|2023-10-31|October 31, 2023|Anticipated|2023-10-31||Interventional|||Anti-CD19 Chimeric Antigen Receptor T Cells for Treatment of Relapsed or Refractory Non-Hodgkin Lymphoma|A Phase 1 Clinical Trial of Anti-CD19 Chimeric Antigen Receptor T Cells for Treatment of Relapsed or Refractory Non-Hodgkin Lymphoma|Recruiting||Phase 1|36|Anticipated|University of California, San Francisco||1|||f||||t|t|f|||||||||No||2023-09-04 11:27:55.702989|2023-09-04 11:27:55.702989|OTHER|||||
NCT04419909||2020-05-28|||2023-06-21|2020-06-03|2020-06-09|Actual|||||||2023-06-21|2023-06-22|Actual|May 2024|Anticipated|2024-05-31|June 2023|2023-06-30|July 2027|Anticipated|2027-07-31|July 2027|Anticipated|2027-07-31||Interventional|||Retreatment With CTL019/CTL119|Retreatment With CTL019/CTL119 in Patients With Late Relapse of B-Cell Lymphomas|Not yet recruiting||Phase 1|12|Anticipated|University of Pennsylvania||1|||f||||t|t|f|||||||||No||2023-09-04 11:28:10.207368|2023-09-04 11:28:10.207368|OTHER|||||
NCT02850536||2016-07-14|||2021-10-20|2016-07-29|2016-08-01|Estimate|||||||2021-10-20|2021-10-21|Actual|February 1, 2017|Actual|2017-02-01|October 2021|2021-10-31|September 17, 2021|Actual|2021-09-17|December 31, 2018|Actual|2018-12-31||Interventional|HITM-SURE||CAR-T Hepatic Artery Infusions or Pancreatic Venous Infusions for CEA-Expressing Liver Metastases or Pancreas Cancer|Phase Ib Trial of CAR-T Hepatic Artery Infusions or Pancreatic Venous Infusions Delivered With the Surefire Infusion System (SIS) for CEA-Expressing Liver Metastases or Pancreas Cancer|Completed||Phase 1|5|Actual|Roger Williams Medical Center||1|||f||||t|t|f|||||||||||2023-09-04 11:33:58.553665|2023-09-04 11:33:58.553665|OTHER|||||
NCT01864889||2013-05-20|||2016-01-26|2013-05-26|2013-05-30|Estimate|||||||2016-01-26|2016-01-28|Estimate|April 2013||2013-04-30|January 2016|2016-01-31|April 2017|Anticipated|2017-04-30|April 2017|Anticipated|2017-04-30||Interventional|CART19||Treatment of Relapsed and/or Chemotherapy Refractory B-cell Malignancy by CART19|Clinical Study of Chimeric CD(Cluster of Differentiation)19 Antigen Receptor-modified T Cells in Relapsed and/or Chemotherapy Refractory B-cell Leukemias and Lymphomas|Unknown status|Recruiting|Not Applicable|12|Anticipated|Chinese PLA General Hospital||1|||f||||t|||||||||||||2023-09-01 12:56:58.786085|2023-09-01 12:56:58.786085|OTHER|||||
NCT01864902||2013-05-20|||2016-01-26|2013-05-26|2013-05-30|Estimate|||||||2016-01-26|2016-01-28|Estimate|April 2013||2013-04-30|January 2016|2016-01-31|April 2017|Anticipated|2017-04-30|April 2016|Anticipated|2016-04-30||Interventional|CART33||Treatment of Relapsed and/or Chemotherapy Refractory CD33 Positive Acute Myeloid Leukemia by CART-33|Clinical Study of Chimeric CD(Cluster of Differentiation)33 Antigen Receptor-modified T Cells in Relapsed and/or Chemotherapy Refractory Acute Myeloid Leukemias|Unknown status|Recruiting|Phase 1/Phase 2|10|Anticipated|Chinese PLA General Hospital||1|||f||||t|||||||||||||2023-09-01 12:56:59.43114|2023-09-01 12:56:59.43114|OTHER|||||
NCT05510596||2022-06-03|||2023-05-09|2022-08-19|2022-08-22|Actual|||||||2023-05-09|2023-05-11|Actual|September 22, 2022|Actual|2022-09-22|May 2023|2023-05-31|March 2025|Anticipated|2025-03-31|March 2025|Anticipated|2025-03-31||Interventional|MR-ICANS||Magnetic Resonance Imaging in Immune Effector Cell-Associated Neurotoxicity Syndrome|Contribution of Magnetic Resonance Imaging in Immune Effector Cell-Associated Neurotoxicity Syndrome|Recruiting||Not Applicable|20|Anticipated|University Hospital, Montpellier||1|||f||||t|f|f|||||||||||2023-09-01 13:06:14.290528|2023-09-01 13:06:14.290528|OTHER|||||
NCT05225363||2021-12-08|||2023-05-09|2022-01-26|2022-02-04|Actual|||||||2023-05-09|2023-05-11|Actual|May 5, 2022|Actual|2022-05-05|May 2023|2023-05-31|April 5, 2027|Anticipated|2027-04-05|April 5, 2026|Anticipated|2026-04-05||Interventional|||Modified Immune Cells (TAG72-CAR T Cells) for the Treatment of Patients With Platinum Resistant Epithelial Ovarian Cancer|A Phase 1 Study to Evaluate TAG72-Targeting Chimeric Antigen Receptor (CAR) T Cells in Patients With Advanced Epithelial Ovarian Cancer|Recruiting||Phase 1|33|Anticipated|City of Hope Medical Center||1|||f||||t|t|f|||f||||||||2023-09-01 13:07:18.147906|2023-09-01 13:07:18.147906|OTHER|||||
NCT05105867||2021-10-25|||2023-05-08|2021-10-25|2021-11-03|Actual|||||||2023-05-08|2023-05-10|Actual|September 29, 2021|Actual|2021-09-29|April 2023|2023-04-30|November 30, 2024|Anticipated|2024-11-30|August 31, 2024|Anticipated|2024-08-31||Interventional|||CD19 Targeted Universal Chimeric Antigen Receptor T Cells Injection for CD19+ Refractory/Relapsed B-cell Malignancies|A Single-Arm, Open-Label Study to Evaluate the Efficacy and Safety of Anti-CD19 Universal CAR-T Cells in the Treatment of CD19+ Relapsed/Refractory B-cell Acute Lymphoblastic Leukemia and Relapsed/Refractory B-cell Non-Hodgkin Lymphoma|Recruiting||Early Phase 1|15|Anticipated|920th Hospital of Joint Logistics Support Force of People's Liberation Army of China||1|||f||||f|f|f|||||||||||2023-08-31 12:13:11.032899|2023-08-31 12:13:11.032899|OTHER|||||
NCT04074330||2019-08-28|||2023-05-10|2019-08-28|2019-08-30|Actual|||||||2023-05-10|2023-05-11|Actual|October 15, 2019|Actual|2019-10-15|May 2023|2023-05-31|April 26, 2023|Actual|2023-04-26|April 26, 2023|Actual|2023-04-26||Interventional|||A Study of TAK-981 Given With Rituximab in Adults With Relapsed or Refractory CD20-Positive Non-Hodgkin Lymphoma|Phase 1/2 Study of TAK-981 in Combination With Rituximab in Patients With Relapsed/Refractory CD20-Positive Non-Hodgkin Lymphoma|Completed||Phase 1/Phase 2|39|Actual|Takeda||4|||f||||t|t|f|||||||IPD from eligible studies will be shared with qualified researchers according to the criteria and process described on https://vivli.org/ourmember/takeda/. For approved requests, the researchers will be provided access to anonymized data (to respect patient privacy in line with applicable laws and regulations) and with information necessary to address the research objectives under the terms of a data sharing agreement.|https://vivli.org/ourmember/takeda/|Yes|Takeda provides access to the de-identified individual participant data (IPD) for eligible studies to aid qualified researchers in addressing legitimate scientific objectives (Takeda's data sharing commitment is available on https://clinicaltrials.takeda.com/takedas-commitment?commitment=5). These IPDs will be provided in a secure research environment following approval of a data sharing request, and under the terms of a data sharing agreement.|2023-09-01 13:10:04.702634|2023-09-01 13:10:04.702634|INDUSTRY|||||
NCT01886976||2013-06-24|||2016-01-26|2013-06-24|2013-06-26|Estimate|||||||2016-01-26|2016-01-28|Estimate|June 2013||2013-06-30|January 2016|2016-01-31|June 2016|Anticipated|2016-06-30|June 2016|Anticipated|2016-06-30||Interventional|CART-138||Treatment of Chemotherapy Refractory Multiple Myeloma by CART-138|Clinical Study of Chimeric CD(Cluster of Differentiation)138 Antigen Receptor-modified T Cells in Relapsed and/or Chemotherapy Refractory Multiple Myelomas|Unknown status|Recruiting|Phase 1/Phase 2|10|Anticipated|Chinese PLA General Hospital||1|||f||||t|||||||||||||2023-09-01 13:22:29.016388|2023-09-01 13:22:29.016388|OTHER|||||
NCT05117138||2021-09-06|||2021-11-09|2021-11-09|2021-11-11|Actual|||||||2021-11-09|2021-11-11|Actual|January 1, 2022|Anticipated|2022-01-01|September 2021|2021-09-30|March 1, 2024|Anticipated|2024-03-01|December 1, 2023|Anticipated|2023-12-01||Interventional|||Safety and Efficacy of Chimeric Antigen Receptor T Lymphocytes for Patients With Intermediate and Advanced Tumors|Safety and Efficacy of Chimeric Antigen Receptor T Lymphocytes for Patients With Intermediate and Advanced Tumors|Not yet recruiting||Phase 1/Phase 2|39|Anticipated|Beijing Immunochina Medical Science & Technology Co., Ltd.||2|||f|||||f|f|||||||||No||2023-09-04 11:54:12.848536|2023-09-04 11:54:12.848536|INDUSTRY|||||
NCT03327285||2017-08-17|||2020-09-30|2017-10-29|2017-10-31|Actual|||||||2020-09-30|2020-10-01|Actual|March 1, 2018|Actual|2018-03-01|September 2020|2020-09-30|April 30, 2021|Anticipated|2021-04-30|February 28, 2021|Anticipated|2021-02-28||Interventional|||C-CAR011 Treatment in Subjects With ALL After HSCT|A Study Evaluating Safety and Efficacy of CBM.CD19-targeted Chimeric Antigen Receptor T Cells (C-CAR011) Treatment in Subjects With Acute Lymphoblastic Leukemia(ALL) After Hematopoietic Stem Cell Transplantation（HSCT）|Unknown status|Active, not recruiting|Not Applicable|40|Anticipated|Peking University People's Hospital||1|||f||||t|f|f|||||||||Undecided||2023-09-04 11:55:08.422615|2023-09-04 11:55:08.422615|OTHER|||||
NCT03321123||2017-09-20|||2017-10-22|2017-10-22|2017-10-25|Actual|||||||2017-10-22|2017-10-25|Actual|December 1, 2017|Anticipated|2017-12-01|October 2017|2017-10-31|December 31, 2019|Anticipated|2019-12-31|July 1, 2019|Anticipated|2019-07-01||Interventional|||MB-CART19.1 in Patients With R/R ALL|Adoptive Therapy With MB-CART19.1 in Patients With Relapsed/Refractory CD19-positive B Cell Acute Lymphoblastic Leukemia|Unknown status|Not yet recruiting|Phase 2|10|Anticipated|Shanghai Children's Medical Center||1|||f|||||f|f|||||||||Undecided||2023-09-04 11:59:13.340625|2023-09-04 11:59:13.340625|OTHER|||||
NCT02981628||2016-11-29|||2023-05-20|2016-11-30|2016-12-05|Estimate|||||||2023-05-20|2023-05-23|Actual|June 5, 2017|Actual|2017-06-05|March 2023|2023-03-31|December 31, 2024|Anticipated|2024-12-31|December 31, 2024|Anticipated|2024-12-31||Interventional|||Inotuzumab Ozogamicin in Treating Younger Patients With B-Lymphoblastic Lymphoma or Relapsed or Refractory CD22 Positive B Acute Lymphoblastic Leukemia|A Phase 2 Study of Inotuzumab Ozogamicin (NSC# 772518) in Children and Young Adults With Relapsed or Refractory CD22+ B-Acute Lymphoblastic Leukemia (B-ALL)|Recruiting||Phase 2|80|Anticipated|Children's Oncology Group||2|||||||f|t|f|||||||||||2023-09-04 12:10:53.114612|2023-09-04 12:10:53.114612|NETWORK|||||
NCT05334823||2022-03-16|||2022-05-19|2022-04-13|2022-04-19|Actual|||||||2022-05-19|2022-05-20|Actual|January 26, 2022|Actual|2022-01-26|April 2022|2022-04-30|July 1, 2025|Anticipated|2025-07-01|December 31, 2023|Anticipated|2023-12-31||Interventional|||A Study of pCAR-19B in the Treatment of CD19-positive Relapsed/Refractory B-ALL in Children and Adolescents|A Phase II Clinical Study of Anti-CD19 CAR-T Therapy (pCAR-19B) in the Treatment of CD19-positive Relapsed/Refractory B-ALL|Recruiting||Phase 2|100|Anticipated|Chongqing Precision Biotech Co., Ltd||1|||f|||||f|f|||||||||||2023-09-04 12:12:13.421651|2023-09-04 12:12:13.421651|INDUSTRY|||||
NCT03302403||2017-09-26|||2020-10-05|2017-09-30|2017-10-05|Actual|||||||2020-10-05|2020-10-08|Actual|December 29, 2017|Actual|2017-12-29|October 2020|2020-10-31|December 12, 2023|Anticipated|2023-12-12|December 12, 2020|Anticipated|2020-12-12||Interventional|||Clinical Study of Redirected Autologous T Cells With a Chimeric Antigen Receptor in Patients With Malignant Tumors|Clinical Study of Redirected Autologous T Cells With a Chimeric Antigen Receptor in Patients With Malignant Tumors|Active, not recruiting||Not Applicable|18|Actual|First Affiliated Hospital of Wenzhou Medical University||1|||f||||t|f|f|||||||||No||2023-09-04 12:22:40.492944|2023-09-04 12:22:40.492944|OTHER|||||
NCT03915184||2019-04-03|||2023-05-08|2019-04-12|2019-04-16|Actual|||||||2023-05-08|2023-05-10|Actual|September 25, 2019|Actual|2019-09-25|May 2023|2023-05-31|December 31, 2034|Anticipated|2034-12-31|December 31, 2024|Anticipated|2024-12-31||Interventional|||Clinical Trial to Evaluate Zevor-cel (CT053) in Patients With Relapsed and/or Refractory Multiple Myeloma (LUMMICAR STUDY 2)|Open Label, Multi-center, Phase 1b/2 Clinical Trial to Evaluate the Safety and Efficacy of Autologous CAR BCMA T Cells (CT053) in Patients With Relapsed and/or Refractory Multiple Myeloma (LUMMICAR STUDY 2)|Recruiting||Phase 1/Phase 2|105|Anticipated|CARsgen Therapeutics Co., Ltd.||1|||f||||t|t|f|||f||||||||2023-08-31 12:17:20.062558|2023-08-31 12:17:20.062558|INDUSTRY|||||
NCT04935580||2021-06-13|||2022-08-01|2021-06-14|2021-06-23|Actual|||||||2022-08-01|2022-08-03|Actual|June 28, 2021|Actual|2021-06-28|August 2022|2022-08-31|July 1, 2023|Anticipated|2023-07-01|July 1, 2023|Anticipated|2023-07-01||Interventional|||Study of FasT CAR-T GC012F Injection in High Risk TE NDMM Patients|Frontline Therapy of GC012F Injection in Transplant Eligible Newly Diagnosed Multiple Myeloma Patients With High-Risk Profile|Recruiting||Phase 1/Phase 2|20|Anticipated|Shanghai Changzheng Hospital||1|||f||||f|f|f|||||||||||2023-09-04 12:37:00.520132|2023-09-04 12:37:00.520132|OTHER|||||
NCT03818165||2019-01-23|||2023-01-12|2019-01-23|2019-01-28|Actual|||||||2023-01-12|2023-01-17|Actual|July 29, 2019|Actual|2019-07-29|January 2023|2023-01-31|May 21, 2021|Actual|2021-05-21|January 19, 2020|Actual|2020-01-19||Interventional|AntiCEA_CART||Phase 1b Study of CAR2Anti-CEA CAR-T Cell Hepatic Infusions for Pancreatic Carcinoma Patients With CEA+ Liver Metastases|Phase 1b Study of the Efficacy and Safety of CAR2 Anti-CEA CAR-T Cell Hepatic Infusions for Pancreatic Carcinoma Patients With CEA+ Liver Metastases Resistant to Standard Therapy Using the HITM Method and Pressure Enabled Delivery Device|Terminated||Phase 1|2|Actual|Sorrento Therapeutics, Inc.||1||Limited enrollment.|f||||t|t|f|||||||||||2023-08-31 12:33:59.816843|2023-08-31 12:33:59.816843|INDUSTRY|||||
NCT04916860||2021-06-01|||2023-03-30|2021-06-01|2021-06-08|Actual|||||||2023-03-30|2023-03-31|Actual|January 27, 2021|Actual|2021-01-27|March 2023|2023-03-31|March 31, 2023|Anticipated|2023-03-31|January 31, 2023|Actual|2023-01-31||Interventional|||Clinical Study of SenL-T7 CAR T Cells in the Treatment of Relapsed and Refractory CD7+ T-cell Lymphoblastic Leukemia or T-cell Lymphoblastic Lymphoma|Clinical Study of SenL-T7 CAR T Cells in the Treatment of Relapsed and Refractory CD7+ T-cell Lymphoblastic Leukemia or T-cell Lymphoblastic Lymphoma|Active, not recruiting||Not Applicable|100|Anticipated|Hebei Senlang Biotechnology Inc., Ltd.||1|||f|||||f|f|||||||||||2023-08-31 12:49:00.202765|2023-08-31 12:49:00.202765|INDUSTRY|||||
NCT05634785||2022-11-22|||2023-06-16|2022-11-22|2022-12-02|Actual|||||||2023-06-16|2023-06-18|Actual|December 9, 2022|Actual|2022-12-09|June 2023|2023-06-30|December 2026|Anticipated|2026-12-31|December 2026|Anticipated|2026-12-31||Interventional|||CD30 CAR for CD30+ NSGCT|Administration of T Lymphocytes Expressing the CD30 Chimeric Antigen Receptor (CAR) for Patients With CD30+ Nonseminomatous Germ Cell Tumors (NSGCT)|Recruiting||Phase 2|18|Anticipated|UNC Lineberger Comprehensive Cancer Center||1|||f||||t|t|f|||||||||No||2023-08-31 13:15:38.623603|2023-08-31 13:15:38.623603|OTHER|||||
NCT03277729||2017-09-07|||2023-05-04|2017-09-07|2017-09-11|Actual|||||||2023-05-04|2023-05-06|Actual|December 5, 2017|Actual|2017-12-05|May 2023|2023-05-31|November 16, 2037|Anticipated|2037-11-16|November 16, 2024|Anticipated|2024-11-16||Interventional|||A Phase I/II Study to Evaluate the Safety of Cellular Immunotherapy Using Autologous T Cells Engineered to Express a CD20-Specific Chimeric Antigen Receptor for Patients With Relapsed or Refractory B Cell Non-Hodgkin Lymphomas|A Phase I/II Study to Evaluate the Safety of Cellular Immunotherapy Using Autologous T Cells Engineered to Express a CD20-Specific Chimeric Antigen Receptor for Patients With Relapsed or Refractory B Cell Non-Hodgkin Lymphomas|Recruiting||Phase 1/Phase 2|50|Anticipated|Fred Hutchinson Cancer Center||1|||f||||t|t|f|||||||||No||2023-09-03 12:27:45.652764|2023-09-03 12:27:45.652764|OTHER|||||
NCT05352828||2022-04-08|||2023-03-31|2022-04-24|2022-04-29|Actual|||||||2023-03-31|2023-04-03|Actual|July 25, 2022|Actual|2022-07-25|March 2023|2023-03-31|December 15, 2037|Anticipated|2037-12-15|December 15, 2025|Anticipated|2025-12-15||Interventional|ACTION||Autologous CD30.CAR-T in Combination With Nivolumab in cHL Patients After Failure of Frontline Therapy|Phase 1b Study Evaluating the Safety and Efficacy of Autologous CD30.CAR-T in Combination With PD-1 Checkpoint Inhibitor (Nivolumab) in Relapsed or Refractory Classical Hodgkin Lymphoma Patients After Failure of Frontline Therapy (ACTION)|Active, not recruiting||Phase 1|15|Actual|Tessa Therapeutics||1|||f||||t|t|f|||||||||No||2023-09-03 12:34:11.445819|2023-09-03 12:34:11.445819|INDUSTRY|||||
NCT04817774||2021-03-09|||2023-03-31|2021-03-23|2021-03-26|Actual|||||||2023-03-31|2023-04-03|Actual|March 17, 2021|Actual|2021-03-17|March 2023|2023-03-31|March 4, 2026|Anticipated|2026-03-04|November 13, 2024|Anticipated|2024-11-13||Interventional|STeadfast||Safety & Tolerability Study of Chimeric Antigen Receptor T-Reg Cell Therapy in Living Donor Renal Transplant Recipients|Multicentre Open-Label Single Ascending Dose Dose-Ranging Phase I/IIa Study to Evaluate Safety and Tolerability of an Autologous Antigen-Specific Chimeric Antigen Receptor TRegulatory Cell Therapy in Living Donor Renal Transplant Recipients|Recruiting||Phase 1/Phase 2|42|Anticipated|Sangamo Therapeutics||2|||f||||t|f|f|||||||||No||2023-09-03 12:35:14.406802|2023-09-03 12:35:14.406802|INDUSTRY|||||
NCT04690595||2020-12-24|||2023-03-30|2020-12-29|2020-12-30|Actual|||||||2023-03-30|2023-04-03|Actual|May 18, 2021|Actual|2021-05-18|March 2023|2023-03-31|November 18, 2026|Anticipated|2026-11-18|November 18, 2025|Anticipated|2025-11-18||Interventional|||BAFFR Targeting CAR-T Cells for the Treatment of Relapsed or Refractory B-cell ALL|A Phase 1 Study Evaluating BAFFR-targeting CAR T Cells for Patients With Relapsed or Refractory B-cell Acute Lymphoblastic Leukemia|Recruiting||Phase 1|24|Anticipated|PeproMene Bio, Inc.||1|||f||||t|t|f|||||||||No||2023-09-03 12:35:37.79447|2023-09-03 12:35:37.79447|INDUSTRY|||||
NCT04163302||2019-11-12|||2019-11-14|2019-11-12|2019-11-14|Actual|||||||2019-11-14|2019-11-15|Actual|July 7, 2019|Actual|2019-07-07|November 2019|2019-11-30|July 1, 2022|Anticipated|2022-07-01|July 1, 2021|Anticipated|2021-07-01||Interventional|||Safety and Efficiency Study of CD19-PD1-CART Cell in Relapsed/Refractory B Cell Lymphoma|Safety and Efficiency Study of CD19-PD1-CART Cell in Relapsed/Refractory B Cell Lymphoma|Unknown status|Recruiting|Phase 2|30|Anticipated|Chinese PLA General Hospital||1|||f||||f|f|f|||f||||||No||2023-09-02 12:29:27.351076|2023-09-02 12:29:27.351076|OTHER|||||
NCT05632380||2022-11-08|||2022-11-21|2022-11-21|2022-11-30|Actual|||||||2022-11-21|2022-11-30|Actual|July 14, 2022|Actual|2022-07-14|November 2022|2022-11-30|June 30, 2025|Anticipated|2025-06-30|December 30, 2023|Anticipated|2023-12-30||Interventional|||ASCT in Combination With C-CAR088 for Treating Patients With Ultra High-risk Multiple Myeloma (MM)|The Safety and Efficacy of Autologous Hematopoietic Stem Cell Transplantation (ASCT) in Combination With C-CAR088, an Autologous BCMA CAR-T Cell Product, for Treating Patients With Ultra High-risk Multiple Myeloma|Recruiting||Phase 1/Phase 2|20|Anticipated|Institute of Hematology & Blood Diseases Hospital||1|||f|||||f|f|||||||||||2023-09-03 12:39:24.205133|2023-09-03 12:39:24.205133|OTHER|||||
NCT03912480||2019-04-10|||2019-04-18|2019-04-10|2019-04-11|Actual|||||||2019-04-18|2019-04-22|Actual|January 5, 2019|Actual|2019-01-05|April 2019|2019-04-30|March 31, 2021|Anticipated|2021-03-31|December 30, 2020|Anticipated|2020-12-30||Interventional|||Stem Cells From Human Exfoliated Teeth in Treatment of Diabetic Patients With Significantly Reduced Islet Function|Study on the Efficacy and Safety of Stem Cells From Human Exfoliated Teeth in Treating Diabetic Patients With Significantly Reduced Islet Function|Unknown status|Recruiting|Early Phase 1|24|Anticipated|CAR-T (Shanghai) Biotechnology Co., Ltd.||1|||f||||f|f|f|||||||||||2023-09-03 12:43:38.657017|2023-09-03 12:43:38.657017|INDUSTRY|||||
NCT03910842||2019-04-08|||2019-09-05|2019-04-08|2019-04-10|Actual|||||||2019-09-05|2019-09-06|Actual|March 21, 2019|Actual|2019-03-21|March 2019|2019-03-31|October 15, 2022|Anticipated|2022-10-15|April 15, 2022|Anticipated|2022-04-15||Interventional|||Treatment of Children CD19+ Leukemia and Non-Hodgkin Lymphoma With CD19-TriCAR-T/SILK Cell Therapy|Adoptive Immunotherapy for Children CD19+ Leukemia and Non-Hodgkin Lymphoma With CD19-TriCAR-T/SILK Cell|Unknown status|Recruiting|Early Phase 1|12|Anticipated|Timmune Biotech Inc.||1|||f||||t|f|f|||||||||No||2023-09-03 12:44:25.872021|2023-09-03 12:44:25.872021|INDUSTRY|||||
NCT03050190||2017-02-08|||2019-09-18|2017-02-09|2017-02-10|Actual|||||||2019-09-18|2019-09-19|Actual|July 2013||2013-07-31|September 2019|2019-09-30|December 2020|Anticipated|2020-12-31|July 2019|Actual|2019-07-31||Interventional|||A Phase I/II Multiple Center Trial of 4SCAR19 Cells in the Treatment of Relapsed and Refractory B Cell Malignancies|A Phase I/II Multiple Center Trial of 4SCAR19 Cells in the Treatment of Relapsed and Refractory B Cell Malignancies|Unknown status|Recruiting|Phase 1/Phase 2|200|Anticipated|Shenzhen Geno-Immune Medical Institute||1|||f||||t|f|f|||||||||Undecided||2023-08-31 13:28:25.546291|2023-08-31 13:28:25.546291|OTHER|||||
NCT05571540||2022-10-04|||2022-11-27|2022-10-05|2022-10-07|Actual|||||||2022-11-27|2022-11-30|Actual|October 1, 2022|Actual|2022-10-01|November 2022|2022-11-30|October 31, 2024|Anticipated|2024-10-31|January 31, 2024|Anticipated|2024-01-31||Interventional|||Anti-CD19 Universal CAR-T Cells for r/r CD19+ B-ALL|An Investigator-initiated Trial to Evaluate the Efficacy and Safety of Anti-CD19 Universal CAR-T Cells in the Treatment of Relapsed/Refractory(r/r) CD19+ B-cell Acute Lymphoblastic Leukemia(B-ALL)|Withdrawn||Phase 1/Phase 2|0|Actual|Kunming Hope of Health Hospital||1||The PI decides to stop.|f|||||f|f|||||||||||2023-09-03 12:44:54.578313|2023-09-03 12:44:54.578313|OTHER|||||
NCT03252171||2015-10-18|||2020-07-14|2017-08-14|2017-08-17|Actual|||||||2020-07-14|2020-07-16|Actual|October 15, 2015|Actual|2015-10-15|July 2020|2020-07-31|August 15, 2016|Actual|2016-08-15|August 15, 2016|Actual|2016-08-15||Interventional|||CAR-T Cell Immunotherapy for GD2 Positive Glioma Patients|Chimeric Antigen Receptor-Modified T Cells for GD2 Positive Recurrent and Metastatic Glioma|Withdrawn||Phase 1/Phase 2|0|Actual|Fuda Cancer Hospital, Guangzhou||2||Project terminated due to revision of local regulations|f||||t|||||||||||||2023-09-04 12:52:42.152864|2023-09-04 12:52:42.152864|OTHER|||||
NCT04289220||2020-02-26|||2021-05-12|2020-02-26|2020-02-28|Actual|||||||2021-05-12|2021-05-13|Actual|March 15, 2020|Actual|2020-03-15|May 2021|2021-05-31|September 15, 2023|Anticipated|2023-09-15|March 15, 2023|Anticipated|2023-03-15||Interventional|||Anti-CD19 CAR in PiggyBac Transposon-Engineered T Cells for Relapsed/Refractory B-cell Lymphoma or B-cell Acute Lymphoblastic Leukemia|A Phase I Clinical Trial of Anti-CD19 Chimeric Antigen Receptor in PiggyBac Transposon-Engineered T Cells for the Treatment of Patients With Relapsed/Refractory/High-risk B-cell Lymphoma or B-cell Acute Lymphoblastic Leukemia|Recruiting||Phase 1|10|Anticipated|Yan'an Affiliated Hospital of Kunming Medical University||1|||f||||t|f|f|||||||||||2023-09-02 12:30:24.872289|2023-09-02 12:30:24.872289|OTHER|||||
NCT04121273||2019-10-08|||2021-03-01|2019-10-08|2019-10-09|Actual|||||||2021-03-01|2021-03-03|Actual|October 5, 2019|Actual|2019-10-05|March 2021|2021-03-31|November 1, 2021|Anticipated|2021-11-01|October 1, 2021|Anticipated|2021-10-01||Interventional|||GPC3-targeted CAR-T Cell for Treating GPC3 Positive Advanced HCC|Clinical Study of GPC3-targeted Chimeric Antigen Receptor T Cells fo Treating Advanced Hepatocellular Carcinoma|Unknown status|Recruiting|Phase 1|20|Anticipated|The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School||1|||f|||||f|f|||||||||No||2023-08-31 13:33:52.337011|2023-08-31 13:33:52.337011|OTHER|||||
NCT02963038||2016-10-28|||2017-04-27|2016-11-09|2016-11-15|Estimate|||||||2017-04-27|2017-04-28|Actual|June 2016||2016-06-30|November 2016|2016-11-30|June 2021|Anticipated|2021-06-30|June 2017|Anticipated|2017-06-30||Interventional|||CAR T Cells for Refractory B Cell Malignancy|Autologous CD19-targeting CAR T Cells for Refractory B Cell Malignancy|Unknown status|Recruiting|Phase 1/Phase 2|10|Anticipated|Hebei Senlang Biotechnology Inc., Ltd.||1|||f||||f|||||||||||No||2023-09-01 18:46:04.791473|2023-09-01 18:46:04.791473|INDUSTRY|||||
NCT04884984||2021-05-10|||2021-05-10|2021-05-10|2021-05-13|Actual|||||||2021-05-10|2021-05-13|Actual|July 1, 2017|Actual|2017-07-01|May 2021|2021-05-31|December 31, 2024|Anticipated|2024-12-31|December 31, 2022|Anticipated|2022-12-31||Interventional|||Anti-CLL1 CAR T-cell Therapy in CLL1 Positive Relapsed/Refractory Acute Myeloid Leukemia (AML)|Pilot Study of the Safety and Efficacy of Anti-CLL1 Chimeric Antigen Receptor Engineered T-Cells in the Treatment of CLL1 Positive Relapsed or Refractory Acute Myeloid Leukemia (AML)|Recruiting||Phase 1/Phase 2|20|Anticipated|The First Affiliated Hospital of Soochow University||1|||f|||||f|f|||||||||||2023-08-31 13:35:24.825038|2023-08-31 13:35:24.825038|OTHER|||||
NCT03825731||2019-01-22|||2019-01-30|2019-01-30|2019-01-31|Actual|||||||2019-01-30|2019-01-31|Actual|January 17, 2019|Actual|2019-01-17|January 2019|2019-01-31|September 16, 2019|Anticipated|2019-09-16|September 16, 2019|Anticipated|2019-09-16||Interventional|||A Study of GC022 CAR-T Cell Immunotherapy for Relapsed or Refractory B- ALL|A Study of GC022 CAR-T Cell Immunotherapy for Relapsed or Refractory B- ALL|Unknown status|Recruiting|Early Phase 1|20|Anticipated|Hebei Yanda Ludaopei Hospital||1|||f|||||f|f|||||||||No||2023-08-31 13:35:43.755821|2023-08-31 13:35:43.755821|OTHER|||||
NCT04863066||2020-12-07|||2021-04-25|2021-04-25|2021-04-28|Actual|||||||2021-04-25|2021-04-28|Actual|May 1, 2021|Anticipated|2021-05-01|October 2020|2020-10-31|October 1, 2022|Anticipated|2022-10-01|June 15, 2022|Anticipated|2022-06-15||Interventional|TCTIWHI||Third-Generation CAR-T-cell Therapy in Individuals With HIV-1 Infection|A Phase I Trial Using Third-Generation CAR-T-cell Therapy in Individuals With HIV-1 Infection|Unknown status|Not yet recruiting|Phase 1|8|Anticipated|Beijing 302 Hospital||1|||f||||t|f|f|||f||||||No||2023-08-31 13:38:17.389565|2023-08-31 13:38:17.389565|OTHER|||||
NCT05354375||2022-04-26|||2022-04-26|2022-04-26|2022-04-29|Actual|||||||2022-04-26|2022-04-29|Actual|December 1, 2022|Anticipated|2022-12-01|November 2021|2021-11-30|November 30, 2026|Anticipated|2026-11-30|November 30, 2025|Anticipated|2025-11-30||Interventional|||Clinical Study of PSMA-targeted CAR-T Cells in the Treatment of Castration-resistant Prostate Cancer|Clinical Study of PSMA-targeted CAR-T Cells in the Treatment of Castration-resistant Prostate Cancer|Recruiting||Phase 1|20|Anticipated|The Affiliated Hospital of Xuzhou Medical University||1|||f||||t|f|f|||||||||No||2023-09-04 12:59:51.808472|2023-09-04 12:59:51.808472|OTHER|||||
NCT04822974||2021-03-24|||2021-03-26|2021-03-26|2021-03-30|Actual|||||||2021-03-26|2021-03-30|Actual|May 1, 2021|Anticipated|2021-05-01|March 2021|2021-03-31|September 1, 2022|Anticipated|2022-09-01|May 1, 2022|Anticipated|2022-05-01||Interventional|TTV-CART||TORQUETENOVIRUS IN CAR-T THERAPY: PREDICTION OF THE CRS|TORQUETENOVIRUS IN CAR-T THERAPY: PREDICTION OF THE RISK OF CYTOKINE RELEASE SYNDROME AND DIFFERENTIAL DIAGNOSIS WITH INFECTION|Unknown status|Not yet recruiting|Not Applicable|20|Anticipated|Institut Paoli-Calmettes||1|||f||||f|f|f|||||||||No||2023-08-31 13:52:55.727308|2023-08-31 13:52:55.727308|OTHER|||||
NCT04780529||2021-02-28|||2021-02-28|2021-02-28|2021-03-03|Actual|||||||2021-02-28|2021-03-03|Actual|March 2021|Anticipated|2021-03-31|February 2021|2021-02-28|March 2026|Anticipated|2026-03-31|April 2022|Anticipated|2022-04-30||Interventional|||CART Therapy in Digestive System Tumors|Chimeric Antigen Receptor T Cells (CART) Therapy in GUCY2C Positive Digestive System Tumors|Not yet recruiting||Not Applicable|20|Anticipated|Innovative Cellular Therapeutics Co., Ltd.||1|||f|||||f|f|||||||||||2023-08-31 13:56:46.62663|2023-08-31 13:56:46.62663|OTHER|||||
NCT04855253||2021-04-19|||2023-07-06|2021-04-19|2021-04-22|Actual|||||||2023-07-06|2023-07-07|Actual|June 9, 2021|Actual|2021-06-09|July 2023|2023-07-31|December 2024|Anticipated|2024-12-31|December 2024|Anticipated|2024-12-31||Interventional|||Study of E7777 Prior to Kymriah for R/R DLBCL|Phase I/II Trial Using E7777 to Enhance Regulatory T-Cell Depletion Prior to Tisagenlecleucel (Kymriah) Therapy for Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL)|Recruiting||Phase 1/Phase 2|30|Anticipated|Masonic Cancer Center, University of Minnesota||4|||f||||t|t|f|||||||||||2023-09-04 13:05:03.415077|2023-09-04 13:05:03.415077|OTHER|||||
NCT04715191||2021-01-15|||2023-07-06|2021-01-15|2021-01-20|Actual|||||||2023-07-06|2023-07-07|Actual|July 3, 2023|Anticipated|2023-07-03|July 2023|2023-07-31|July 3, 2041|Anticipated|2041-07-03|August 1, 2026|Anticipated|2026-08-01||Interventional|||Interleukin-15 and -21 Armored Glypican-3-specific Chimeric Antigen Receptor Expressed in T Cells for Pediatric Solid Tumors|Interleukin-15 and -21 Armored Glypican-3-specific Chimeric Antigen Receptor Expressing Autologous T Cells as an Immunotherapy for Children With Solid Tumors (CARE)|Not yet recruiting||Phase 1|24|Anticipated|Baylor College of Medicine||1|||f||||t|t|f|||||||||||2023-09-04 13:05:24.927192|2023-09-04 13:05:24.927192|OTHER|||||
NCT04377932||2020-05-04|||2023-07-06|2020-05-04|2020-05-07|Actual|||||||2023-07-06|2023-07-07|Actual|December 8, 2021|Actual|2021-12-08|July 2023|2023-07-31|February 1, 2040|Anticipated|2040-02-01|February 1, 2025|Anticipated|2025-02-01||Interventional|||Interleukin-15 Armored Glypican 3-specific Chimeric Antigen Receptor Expressed in T Cells for Pediatric Solid Tumors|Interleukin-15 Armored Glypican-3-specific Chimeric Antigen Receptor Expressing Autologous T Cells as Immunotherapy for Children With Solid Tumors|Recruiting||Phase 1|24|Anticipated|Baylor College of Medicine||1|||f||||t|t|f|||f||||||||2023-09-04 13:06:04.385104|2023-09-04 13:06:04.385104|OTHER|||||
NCT04240808||2020-01-22|||2023-07-06|2020-01-22|2020-01-27|Actual|||||||2023-07-06|2023-07-07|Actual|July 17, 2020|Actual|2020-07-17|July 2023|2023-07-31|December 2023|Anticipated|2023-12-31|December 2023|Anticipated|2023-12-31||Interventional|||Study of Feasibility and Safety of UCD19 Chimeric Antigen Receptor (CAR) T Cells in Adult Subjects With Relapsed/Refractory (R/R) B-Cell Non-Hodgkin's Lymphoma (B-NHL)|Phase I Study of Feasibility and Safety of UCD19 Chimeric Antigen Receptor (CAR) T Cells in Adult Subjects With Relapsed/Refractory (R/R) B-Cell Non-Hodgkin's Lymphoma (B-NHL)|Active, not recruiting||Phase 1|11|Actual|University of Colorado, Denver||1|||f|||||t|f|||||||||No||2023-09-04 13:06:17.649016|2023-09-04 13:06:17.649016|OTHER|||||
NCT04049383||2019-08-06|||2023-07-05|2019-08-06|2019-08-08|Actual|||||||2023-07-05|2023-07-07|Actual|October 16, 2020|Actual|2020-10-16|July 2023|2023-07-31|June 1, 2026|Anticipated|2026-06-01|June 1, 2025|Anticipated|2025-06-01||Interventional|CAR-20/19-T||CAR-20/19-T Cells in Patients With Relapsed/Refractory B Cell ALL|Phase 1 Study of Redirected Autologous T Cells Engineered to Contain an Anti-CD19 and Anti-CD20 scFv Coupled to CD3ζ and 4-1BB Signaling Domains in Patients With Relapsed/ Refractory CD19 or CD20 B-cell Acute Lymphoblastic Leukemia|Recruiting||Phase 1|24|Anticipated|Medical College of Wisconsin||4|||||||t|t|f|||||||||No||2023-09-04 13:06:34.060834|2023-09-04 13:06:34.060834|OTHER|||||
NCT04796688||2021-03-10|||2021-03-11|2021-03-11|2021-03-15|Actual|||||||2021-03-11|2021-03-15|Actual|March 10, 2021|Anticipated|2021-03-10|March 2021|2021-03-31|March 10, 2024|Anticipated|2024-03-10|March 10, 2023|Anticipated|2023-03-10||Interventional|||Universal Chimeric Antigen Receptor-modified AT19 Cells for CD19+ Relapsed/Refractory Hematological Malignancies|Safety and Efficacy of Universal Chimeric Antigen Receptor-modified AT19 Cells in Patients With CD19+ Relapsed/Refractory Hematological Malignancies: a Single-center, Open-label, Single-arm Clinical Study|Recruiting||Phase 1|27|Anticipated|Wuhan Union Hospital, China||1|||f|||||f|f|||||||||No||2023-08-31 14:01:07.701924|2023-08-31 14:01:07.701924|OTHER|||||
NCT03564977||2018-06-11|||2018-06-28|2018-06-11|2018-06-21|Actual|||||||2018-06-28|2018-07-02|Actual|July 15, 2018|Anticipated|2018-07-15|June 2018|2018-06-30|June 15, 2020|Anticipated|2020-06-15|June 15, 2020|Anticipated|2020-06-15||Interventional|||CD19-targeted CAR-T Cell Therapy for MRD+ B-cell Malignancies After Autologous Stem Cell Transplantation|CD19-targeted CAR-T Cell Therapy for Minimal Residual Disease in B-cell Malignancies After Autologous Stem Cell Transplantation|Unknown status|Recruiting|Not Applicable|20|Anticipated|Qingdao Central Hospital||1|||f|||||f|f|||||||||||2023-09-04 13:09:30.896977|2023-09-04 13:09:30.896977|OTHER|||||
NCT03545815||2018-05-23|||2020-08-06|2018-05-23|2018-06-04|Actual|||||||2020-08-06|2020-08-10|Actual|March 19, 2018|Actual|2018-03-19|August 2020|2020-08-31|December 30, 2020|Anticipated|2020-12-30|October 30, 2020|Anticipated|2020-10-30||Interventional|||Study of CRISPR-Cas9 Mediated PD-1 and TCR Gene-knocked Out Mesothelin-directed CAR-T Cells in Patients With Mesothelin Positive Multiple Solid Tumors.|Phase I Study to Evaluate Treatment of CRISPR-Cas9 Mediated PD-1 and TCR Gene-knocked Out Chimeric Antigen Receptor (CAR) T Cells in Patients With Mesothelin Positive Multiple Solid Tumors.|Unknown status|Recruiting|Phase 1|10|Anticipated|Chinese PLA General Hospital||1|||f|||||f|f|||||||||No||2023-09-04 13:12:47.721796|2023-09-04 13:12:47.721796|OTHER|||||
NCT02247609||2014-09-17|||2014-10-16|2014-09-21|2014-09-25|Estimate|||||||2014-10-16|2014-10-20|Estimate|January 2014||2014-01-31|January 2014|2014-01-31|October 2017|Anticipated|2017-10-31|October 2016|Anticipated|2016-10-31||Interventional|4SCAR19273||Evaluation of 4th Generation Safety-designed CAR T Cells Targeting High-risk and Refractory B Cell Lymphomas|Safety and Efficacy Evaluation of 4th Generation Safety-engineered CAR T Cells Targeting High-risk and Refractory B Cell Lymphomas|Unknown status|Recruiting|Phase 1/Phase 2|20|Anticipated|Peking University||1|||f||||t|||||||||||||2023-08-31 14:03:58.021953|2023-08-31 14:03:58.021953|OTHER|||||
NCT05613348||2022-10-13|||2022-11-04|2022-11-04|2022-11-14|Actual|||||||2022-11-04|2022-11-14|Actual|December 1, 2022|Anticipated|2022-12-01|October 2022|2022-10-31|December 1, 2028|Anticipated|2028-12-01|December 1, 2025|Anticipated|2025-12-01||Interventional|CAR19T2||CD19 CAR T-cell Target Relapsed/Refractory Acute B Cell Leukemia/Lymphoma|Humanized CAR19T2 T Cell in Children With Refractory/Relapsed B-cell Leukemia/Lymphoma|Not yet recruiting||Phase 1/Phase 2|70|Anticipated|Zhujiang Hospital||1|||f||||f|f|f|||||||||No||2023-08-31 14:06:25.417639|2023-08-31 14:06:25.417639|OTHER|||||
NCT01897415||2013-07-09|||2017-09-16|2013-07-09|2013-07-12|Estimate|||||||2017-09-16|2017-09-19|Actual|July 2013||2013-07-31|September 2017|2017-09-30|March 2017|Actual|2017-03-31|December 2015|Actual|2015-12-31||Interventional|||Autologous Redirected RNA Meso CAR T Cells for Pancreatic Cancer|Phase I Clinical Trial of Autologous Mesothelin Re-directed T Cells in Patients With Chemotherapy Refractory Metastatic Pancreatic Cancer|Completed||Phase 1|16|Actual|University of Pennsylvania||1|||f||||t|||||||||||||2023-08-31 14:13:41.552147|2023-08-31 14:13:41.552147|OTHER|||||
NCT04693676||2020-12-03|||2023-05-23|2020-12-31|2021-01-05|Actual|||||||2023-05-23|2023-05-25|Actual|August 3, 2020|Actual|2020-08-03|May 2023|2023-05-31|April 30, 2024|Anticipated|2024-04-30|December 31, 2023|Anticipated|2023-12-31||Interventional|||A Study of C-CARP039 Treatment in Subjects With r/r NHL SubjectsNon-Hodgkin's Lymphoma|A Phase 1 Study Evaluating Safety and Efficacy of C-CAR039 Treatment in Subjects With Relapsed and/or Refractory NHL|Active, not recruiting||Phase 1|17|Actual|First Affiliated Hospital of Zhejiang University||1|||f||||f|f|f|||||||||No||2023-09-01 14:11:21.982577|2023-09-01 14:11:21.982577|OTHER|||||
NCT05123001||2021-10-29|||2022-03-29|2021-11-12|2021-11-17|Actual|||||||2022-03-29|2022-04-07|Actual|July 15, 2021|Actual|2021-07-15|March 2022|2022-03-31|September 2022|Anticipated|2022-09-30|July 2022|Anticipated|2022-07-31||Interventional|||Wearable Sensors and Molecular Omics to Detect and Mitigate Cell Therapy Adverse Events|Wearable Sensors and Molecular Omics to Detect and Mitigate Cell Therapy Adverse Events|Recruiting||Not Applicable|15|Anticipated|Stanford University||3|||f||||t|f|f|||||||||No||2023-08-31 14:21:45.956868|2023-08-31 14:21:45.956868|OTHER|||||
NCT05577000||2022-10-08|||2023-01-06|2022-10-08|2022-10-13|Actual|||||||2023-01-06|2023-01-10|Actual|October 18, 2021|Actual|2021-10-18|January 2023|2023-01-31|October 1, 2039|Anticipated|2039-10-01|October 31, 2025|Anticipated|2025-10-31||Interventional|||Anti-BCMA Chimeric Antigen Receptor T Cells for Relapsed or Refractory Multiple Myeloma|A Phase 1b Clinical Trial of Anti-BCMA Chimeric Antigen Receptor T Cells for Treatment of Relapsed or Refractory Multiple Myeloma|Recruiting||Phase 1|24|Anticipated|University of California, San Francisco||4|||f||||t|t|f|||||||||||2023-08-31 14:23:20.750382|2023-08-31 14:23:20.750382|OTHER|||||
NCT03117751||2017-03-27|||2023-05-24|2017-04-12|2017-04-18|Actual|||||||2023-05-24|2023-05-25|Actual|March 29, 2017|Actual|2017-03-29|May 2023|2023-05-31|March 31, 2028|Anticipated|2028-03-31|September 30, 2026|Anticipated|2026-09-30||Interventional|||Total Therapy XVII for Newly Diagnosed Patients With Acute Lymphoblastic Leukemia and Lymphoma|Total Therapy XVII for Newly Diagnosed Patients With Acute Lymphoblastic Leukemia and Lymphoma|Active, not recruiting||Phase 2/Phase 3|793|Actual|St. Jude Children's Research Hospital||7|||||||t|t|f|||||||||||2023-09-01 14:12:57.166548|2023-09-01 14:12:57.166548|OTHER|||||
NCT04767308||2021-02-09|||2021-02-19|2021-02-19|2021-02-23|Actual|||||||2021-02-19|2021-02-23|Actual|March 2021|Anticipated|2021-03-31|February 2021|2021-02-28|December 2023|Anticipated|2023-12-31|September 2023|Anticipated|2023-09-30||Interventional|||Safety and Efficacy of CT125A Cells for Treatment of Relapsed/Refractory CD5+ Hematopoietic Malignancies|A Single-center, Single-arm Exploratory Clinical Trial to Evaluate the Safety and Efficacy of Fully Human Anti-CD5 Chimeric Antigen Receptor T Cells (CT125A Cells) for the Treatment of Relapsed/Refractory CD5+ Hematopoietic Malignancies|Not yet recruiting||Early Phase 1|18|Anticipated|Huazhong University of Science and Technology||1|||f||||f|f|f|||||||||Yes|Individual deidentified participant data that underlie the results published will be shared in the publication. Data will be available upon request and after the approval of data request proposal.|2023-08-31 14:25:31.27311|2023-08-31 14:25:31.27311|OTHER|||||
NCT01840566||2013-04-23|||2023-05-24|2013-04-23|2013-04-25|Estimate|||||||2023-05-24|2023-05-25|Actual|April 2013||2013-04-30|May 2023|2023-05-31|April 2024|Anticipated|2024-04-30|April 2024|Anticipated|2024-04-30||Interventional|||High Dose Therapy and Autologous Stem Cell Transplantation Followed by Infusion of Chimeric Antigen Receptor (CAR) Modified T-Cells Directed Against CD19+ B-Cells for Relapsed and Refractory Aggressive B Cell Non-Hodgkin Lymphoma|A Phase I Trial of High Dose Therapy and Autologous Stem Cell Transplantation Followed by Infusion of Chimeric Antigen Receptor (CAR) Modified T-Cells Directed Against CD19+ B-Cells for Relapsed and Refractory Aggressive B Cell Non-Hodgkin Lymphoma|Active, not recruiting||Phase 1|17|Actual|Memorial Sloan Kettering Cancer Center||1|||f|||||||||||||||||2023-09-01 14:13:56.255346|2023-09-01 14:13:56.255346|OTHER|||||
NCT05287165||2022-03-10|||2022-03-10|2022-03-10|2022-03-18|Actual|||||||2022-03-10|2022-03-18|Actual|March 10, 2022|Actual|2022-03-10|March 2022|2022-03-31|June 30, 2024|Anticipated|2024-06-30|April 30, 2024|Anticipated|2024-04-30||Interventional|||Clinical Trial to Evaluate the Safety and Efficacy of IM96 CAR-T Cells Therapy in Patients With Advanced Digestive System Neoplasms|Clinical Trial to Evaluate the Safety and Efficacy of IM96 CAR-T Cells Therapy in Patients With Advanced Digestive System Neoplasms|Recruiting||Early Phase 1|19|Anticipated|Beijing Immunochina Medical Science & Technology Co., Ltd.||1|||f|||||f|f|||||||||||2023-08-31 14:49:23.095909|2023-08-31 14:49:23.095909|INDUSTRY|||||
NCT03624036||2018-08-07|2022-02-14||2022-12-06|2018-08-07|2018-08-09|Actual|2022-05-06|2022-05-10|Actual||||2022-12-06|2022-12-08|Actual|November 15, 2018|Actual|2018-11-15|December 2022|2022-12-31|November 18, 2022|Actual|2022-11-18|February 12, 2021|Actual|2021-02-12||Interventional|ZUMA-8|Safety Analysis Set included all participants who were treated with any dose of brexucabtagene autoleucel.|Safety and Tolerability of Brexucabtagene Autoleucel (KTE-X19) in Adults With Relapsed/Refractory Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma|A Phase 1 Multicenter Study Evaluating the Safety and Tolerability of KTE-X19 in Adult Subjects With Relapsed/Refractory Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma|Terminated||Phase 1|16|Actual|Gilead Sciences||4||Development program terminated|f||||f|t|f|||||||||No||2023-09-02 12:42:15.455782|2023-09-02 12:42:15.455782|INDUSTRY|||||
NCT05210907||2022-01-14|||2023-02-03|2022-01-14|2022-01-27|Actual|||||||2023-02-03|2023-02-06|Actual|February 15, 2022|Actual|2022-02-15|January 2023|2023-01-31|August 31, 2026|Anticipated|2026-08-31|September 30, 2025|Anticipated|2025-09-30||Interventional|||Clinical Study of Hospital-manufactured CD19 CAR-T in Children and Adolescents With Acute Lymphoblastic Leukemia|A Phase Ib, Clinical Trial of Hospital-manufactured CD19 Chimeric Antigen Receptor T Cells (SNUH-CD19-CAR-T) in Children and Adolescents With Relapsed or Refractory CD19 Positive Acute Lymphoblastic Leukemia|Recruiting||Phase 1|5|Anticipated|Seoul National University Hospital||1|||f||||f|f|f|||||||||Undecided||2023-09-02 12:42:34.168646|2023-09-02 12:42:34.168646|OTHER|||||
NCT04318327||2020-03-20|||2023-08-30|2020-03-20|2020-03-23|Actual|||||||2023-08-30|2023-08-31|Estimate|July 23, 2020|Actual|2020-07-23|August 2023|2023-08-31|December 18, 2025|Anticipated|2025-12-18|December 18, 2025|Anticipated|2025-12-18||Interventional|||BCMA-directed CAR-T Cell Therapy in Adult Patients With Multiple Myeloma|Phase I, Open Label, Study of B-cell Maturation Antigen (BCMA)-Directed CAR-T Cells in Adult Patients With Multiple Myeloma|Recruiting||Phase 1|96|Anticipated|Novartis||2|||f||||f|t|f|||||||||No||2023-08-31 14:58:13.615851|2023-08-31 14:58:13.615851|INDUSTRY|||||
NCT03241940||2017-08-03|||2023-07-27|2017-08-03|2017-08-08|Actual|||||||2023-07-27|2023-07-28|Actual|October 20, 2017|Actual|2017-10-20|July 2023|2023-07-31|August 1, 2035|Anticipated|2035-08-01|August 1, 2025|Anticipated|2025-08-01||Interventional|||Phase I Dose Escalation Study of CD19/CD22 Chimeric Antigen Receptor (CAR) T Cells in Children and Young Adults With Recurrent or Refractory B Cell Malignancies|Phase I Dose Escalation Study of CD19/CD22 Chimeric Antigen Receptor (CAR) T Cells in Children and Young Adults With Recurrent or Refractory B Cell Malignancies|Recruiting||Phase 1|50|Anticipated|Stanford University||1|||f||||t|t|f|||||||||No||2023-08-31 14:59:34.550932|2023-08-31 14:59:34.550932|OTHER|||||
NCT03233854||2017-07-26|||2023-07-27|2017-07-26|2017-07-31|Actual|||||||2023-07-27|2023-07-28|Actual|September 1, 2017|Actual|2017-09-01|July 2023|2023-07-31|September 1, 2035|Anticipated|2035-09-01|September 1, 2025|Anticipated|2025-09-01||Interventional|||CD19/CD22 Chimeric Antigen Receptor (CAR) T Cells With or Without NKTR-255 in Adults With Recurrent or Refractory B Cell Malignancies|Phase 1 Dose Escalation Study of CD19/CD22 Chimeric Antigen Receptor (CAR) T Cells With or Without NKTR-255 in Adults With Recurrent or Refractory B Cell Malignancies|Recruiting||Phase 1|60|Anticipated|Stanford University||1|||f||||t|t|f|||||||||No||2023-08-31 14:59:35.5034|2023-08-31 14:59:35.5034|OTHER|||||
NCT00085930||2004-06-17|||2023-07-26|2004-06-18|2004-06-21|Estimate|||||||2023-07-26|2023-07-28|Actual|April 2003||2003-04-30|July 2023|2023-07-31|December 2023|Anticipated|2023-12-31|January 2010|Actual|2010-01-31||Interventional|NESTLES||Blood T-Cells and EBV Specific CTLs Expressing GD-2 Specific Chimeric T Cell Receptors to Neuroblastoma Patients|Administration of Peripheral Blood T-Cells and EBV Specific CTLs Transduced to Express GD-2 Specific Chimeric T Cell Receptors to Patients With Neuroblastoma|Active, not recruiting||Phase 1|19|Actual|Baylor College of Medicine||1|||f||||t|t|f|||||||||||2023-08-31 15:00:58.003606|2023-08-31 15:00:58.003606|OTHER|||||
NCT04766840||2021-01-27|||2021-02-19|2021-02-19|2021-02-23|Actual|||||||2021-02-19|2021-02-23|Actual|March 1, 2021|Anticipated|2021-03-01|January 2021|2021-01-31|December 1, 2023|Anticipated|2023-12-01|June 1, 2023|Anticipated|2023-06-01||Interventional|||Donor-derived CAR-T Cells in the Treatment of AML Patients|A Study to Evaluate the Safety and Efficacy of Donor-derived CAR-T Cells in the Treatment of Patients With Relapsed or Refractory Acute Myeloid Leukemia|Not yet recruiting||Phase 1|9|Anticipated|Beijing Immunochina Medical Science & Technology Co., Ltd.||1|||f||||f|f|f|||||||||No||2023-08-31 15:03:11.812814|2023-08-31 15:03:11.812814|INDUSTRY|||||
NCT03275493||2017-09-05|||2022-05-18|2017-09-06|2017-09-07|Actual|||||||2022-05-18|2022-05-19|Actual|July 1, 2017|Actual|2017-07-01|May 2022|2022-05-31|September 18, 2024|Anticipated|2024-09-18|September 18, 2023|Anticipated|2023-09-18||Interventional|||Humanized CD19 CAR-T Cells With CRS Suppression Technology for r/r CD19+ Acute Lymphoblastic Leukemia|Humanized Chimeric Antigen Receptor T Cells Against CD19 With Cytokine Release Syndrome (CRS) Suppression Technology for Refractory/Relapsed CD19+ Acute Lymphoblastic Leukemia|Recruiting||Phase 1/Phase 2|40|Anticipated|Shanghai Unicar-Therapy Bio-medicine Technology Co.,Ltd||2|||f|||||f|f|||||||||||2023-09-02 12:53:56.393182|2023-09-02 12:53:56.393182|INDUSTRY|||||
NCT03060356||2017-02-07|||2023-06-20|2017-02-17|2017-02-23|Actual|||||||2023-06-20|2023-06-22|Actual|December 21, 2016|Actual|2016-12-21|June 2023|2023-06-30|March 27, 2020|Actual|2020-03-27|March 27, 2020|Actual|2020-03-27||Interventional|||Autologous T Cells Expressing MET scFv CAR (RNA CART-cMET)|Clinical Trial of Autologous cMET Redirected T Cells Administered Intravenously in Patients With Melanoma & Breast Carcinoma|Terminated||Early Phase 1|77|Actual|University of Pennsylvania||2||Halt in funding||||||t|f|||||||||Undecided||2023-09-04 13:24:44.04201|2023-09-04 13:24:44.04201|OTHER|||||
NCT03086954||2017-03-13|||2017-03-21|2017-03-21|2017-03-22|Actual|||||||2017-03-21|2017-03-22|Actual|April 2017|Anticipated|2017-04-30|March 2017|2017-03-31|March 2021|Anticipated|2021-03-31|March 2021|Anticipated|2021-03-31||Interventional|EECPL||Study Evaluating the Efficacy and Safety With CAR-T Immunotherapy for CD19 Positive Lymphoma|Open, Single Arm,Multicenter Phase 2 Clinical Study to Evaluating the Efficacy and Safety of the Chimeric Antigen Receptor T Cell Immunotherapy (CAR-T) for CD19 Positive Lymphoma|Unknown status|Not yet recruiting|Phase 1|24|Anticipated|Sinobioway Cell Therapy Co., Ltd.||1|||f||||f|f|f|||||||||No||2023-08-31 15:30:15.588656|2023-08-31 15:30:15.588656|INDUSTRY|||||
NCT03084380||2017-03-05|||2017-03-17|2017-03-17|2017-03-20|Actual|||||||2017-03-17|2017-03-20|Actual|June 1, 2017|Anticipated|2017-06-01|March 2017|2017-03-31|May 31, 2020|Anticipated|2020-05-31|May 31, 2019|Anticipated|2019-05-31||Interventional|||Anti-GPC3 CAR-T for Treating GPC3-positive Advanced Hepatocellular Carcinoma (HCC)|Phase I Trial of Anti-GPC3 Chimeric T Cells for Subjects With GPC3-Positive Advanced Hepatocellular Carcinoma|Unknown status|Not yet recruiting|Phase 1/Phase 2|20|Anticipated|Xinqiao Hospital of Chongqing||1|||f||||t|f|f|||||||||Yes||2023-08-31 15:37:22.527095|2023-08-31 15:37:22.527095|OTHER|||||
NCT03559439||2018-05-30|||2020-11-03|2018-06-13|2018-06-18|Actual|||||||2020-11-03|2020-11-05|Actual|April 24, 2018|Actual|2018-04-24|November 2020|2020-11-30|December 31, 2021|Anticipated|2021-12-31|November 30, 2021|Anticipated|2021-11-30||Interventional|||CD19-targeting CAR T Cells in Relapsed or Refractory CD19 Positive B-cell Malignancies|CD19-targeting CAR T Cell Therapy in the Treatment of Relapsed or Refractory CD19 Positive B-cell Malignancies|Unknown status|Recruiting|Phase 1|9|Anticipated|Shanghai Tong Ren Hospital||1|||f||||f|f|f|||||||||No||2023-09-04 13:28:21.337072|2023-09-04 13:28:21.337072|OTHER|||||
NCT04934774||2021-02-27|||2021-06-19|2021-06-19|2021-06-22|Actual|||||||2021-06-19|2021-06-22|Actual|December 1, 2020|Actual|2020-12-01|June 2021|2021-06-30|June 1, 2023|Anticipated|2023-06-01|June 1, 2023|Anticipated|2023-06-01||Interventional|||Non-gene Edited Anti-CD7 CAR T Cells for Relapsed/Refractory T Cell Malignances|Non-gene Edited Anti-CD7 CAR T Cells for Relapsed/Refractory T Cell Malignances|Unknown status|Recruiting|Phase 1|20|Anticipated|iCell Gene Therapeutics||1|||f||||f|f|f|||||||||No||2023-09-04 13:30:09.770504|2023-09-04 13:30:09.770504|INDUSTRY|||||
NCT03765177||2018-12-04|||2022-03-26|2018-12-04|2018-12-05|Actual|||||||2022-03-26|2022-04-06|Actual|October 16, 2019|Actual|2019-10-16|March 2022|2022-03-31|October 31, 2022|Anticipated|2022-10-31|October 2022|Anticipated|2022-10-31||Interventional|CLIC-01||CLIC-1901 for the Treatment of Patients With Relapsed/Refractory CD19 Positive Hematologic Malignancies|Canadian-Led Immunotherapies in Cancer: CLIC-1901 for the Treatment of Patients With Relapsed/Refractory CD19 Positive Hematologic Malignancies|Recruiting||Phase 1/Phase 2|60|Anticipated|Ottawa Hospital Research Institute||1|||f||||t|f|f|||||||||Undecided||2023-09-01 15:49:39.835118|2023-09-01 15:49:39.835118|OTHER|||||
NCT03682744||2018-09-21|||2022-03-25|2018-09-21|2018-09-25|Actual|||||||2022-03-25|2022-04-06|Actual|September 13, 2018|Actual|2018-09-13|March 2022|2022-03-31|March 2021|Anticipated|2021-03-31|December 2020|Anticipated|2020-12-31||Interventional|||CAR-T Intraperitoneal Infusions for CEA-Expressing Adenocarcinoma Peritoneal Metastases or Malignant Ascites (IPC)|Immunotherapy for Peritoneal Carcinomatosis (IPC) - A Phase I Study of the Safety and Efficacy of Anti-CEA CAR-T Cell Intraperitoneal Infusions for Treatment of CEA-Expressing Adenocarcinoma Peritoneal Metastases or Malignant Ascites|Withdrawn||Phase 1|0|Actual|Sorrento Therapeutics, Inc.||1||Unable to enroll subjects|f||||t|t|f|||||||||||2023-09-01 15:55:25.80783|2023-09-01 15:55:25.80783|INDUSTRY|||||
NCT05370430||2022-05-06|||2022-10-18|2022-05-06|2022-05-11|Actual|||||||2022-10-18|2022-10-20|Actual|June 13, 2022|Actual|2022-06-13|October 2022|2022-10-31|June 13, 2026|Anticipated|2026-06-13|July 13, 2025|Anticipated|2025-07-13||Interventional|||BAFFR-targeting CAR T Cells for Patients With Relapsed or Refractory B-NHL|A Phase 1 Study Evaluating BAFFR-targeting CAR T Cells for Patients With Relapsed or Refractory B-cell Non-Hodgkin's Lymphoma (B-NHL)|Recruiting||Phase 1|18|Anticipated|PeproMene Bio, Inc.||1|||||||t|t|f|||||||||||2023-08-31 16:12:49.855405|2023-08-31 16:12:49.855405|INDUSTRY|||||
NCT04381741||2020-05-06|||2023-02-02|2020-05-06|2020-05-11|Actual|||||||2023-02-02|2023-02-06|Actual|June 18, 2020|Actual|2020-06-18|February 2023|2023-02-28|September 1, 2023|Anticipated|2023-09-01|September 1, 2023|Anticipated|2023-09-01||Interventional|CICPD||CD19 CAR-T Expressing IL7 and CCL19 Combined With PD1 mAb for Relapsed or Refractory Diffuse Large B Cell Lymphoma|CD19 CAR-T Expressing IL7 and CCL19 Combined With PD1 mAb for Relapsed or Refractory Diffuse Large B Cell Lymphoma|Enrolling by invitation||Phase 1|24|Anticipated|Second Affiliated Hospital, School of Medicine, Zhejiang University||1|||f||||f|f|f|||||||||No||2023-08-31 16:15:38.155967|2023-08-31 16:15:38.155967|OTHER|||||
NCT05638828||2022-11-28|||2022-11-28|2022-11-28|2022-12-06|Actual|||||||2022-11-28|2022-12-06|Actual|December 1, 2022|Anticipated|2022-12-01|September 2022|2022-09-30|December 1, 2024|Anticipated|2024-12-01|December 1, 2023|Anticipated|2023-12-01||Interventional|||A Study of RD14-01 in Patients With Advanced Solid Tumors|A Study of RD14-01 in Patients With Advanced Solid Tumors|Not yet recruiting||Early Phase 1|24|Anticipated|Peking University||1|||f||||t|f|f|||||||||||2023-09-01 15:58:18.869717|2023-09-01 15:58:18.869717|OTHER|||||
NCT05618041||2022-11-08|||2022-12-02|2022-11-08|2022-11-16|Actual|||||||2022-12-02|2022-12-06|Actual|September 7, 2022|Actual|2022-09-07|November 2022|2022-11-30|December 6, 2024|Anticipated|2024-12-06|September 6, 2024|Anticipated|2024-09-06||Interventional|||The Safety and Efficay Investigation of CAR-T Cell Therapy for Patients With Hematological Malignancies|The Safety and Efficay Investigation of CAR-T Cell Therapy for Patients With Hematological Malignancies|Recruiting||Not Applicable|50|Anticipated|Hebei Senlang Biotechnology Inc., Ltd.||1|||f|||||f|f|||||||||||2023-09-01 16:02:59.340868|2023-09-01 16:02:59.340868|INDUSTRY|||||
NCT05641428||2022-10-11|||2022-11-30|2022-11-30|2022-12-07|Actual|||||||2022-11-30|2022-12-07|Actual|October 18, 2022|Actual|2022-10-18|November 2022|2022-11-30|December 2027|Anticipated|2027-12-31|December 2025|Anticipated|2025-12-31||Interventional|HOVON161||Comparison of Point-of-care Produced CAR T-cell With Commercial CAR T-cells in Patients With R/R LBCL|A Phase II Non-inferiority Study Comparing Point-of-care Produced CAR T-cell to Commercial CAR T-cells in Patients With Relapsed/Refractory Non-Hodgkin Lymphoma|Recruiting||Phase 2|300|Anticipated|University Medical Center Groningen||2|||f||||t|f|f|||||||||No||2023-09-01 16:14:23.619783|2023-09-01 16:14:23.619783|OTHER|||||
NCT02980315||2016-11-30|||2016-11-30|2016-11-30|2016-12-02|Estimate|||||||2016-11-30|2016-12-02|Estimate|November 2016||2016-11-30|November 2016|2016-11-30|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Interventional|||A New EBV Related Technologies of T Cells in Treating Malignant Tumors and Clinical Application|A New Efficient EBV AssociatedTechnologies of T Cells in Treating Malignant Tumors and Clinical Application|Unknown status|Recruiting|Phase 1/Phase 2|20|Anticipated|The Second Hospital of Nanjing Medical University||2|||f|||||||||||||||||2023-08-31 16:43:32.92222|2023-08-31 16:43:32.92222|OTHER|||||
NCT02958397||2016-11-06|||2019-06-23|2016-11-06|2016-11-08|Estimate|||||||2019-06-23|2019-06-25|Actual|October 2016||2016-10-31|June 2019|2019-06-30|October 2020|Anticipated|2020-10-31|October 2019|Anticipated|2019-10-31||Interventional|||A Clinical Research of CD33-Targeted CAR-T in Myeloid Malignancies|A Clinical Research of CD33-Targeted CAR-T in Myeloid Malignancies|Unknown status|Recruiting|Phase 1/Phase 2|45|Anticipated|Southwest Hospital, China||1|||f||||f|||||||||||Undecided||2023-09-01 16:25:23.905488|2023-09-01 16:25:23.905488|OTHER|||||
NCT03030001||2017-01-20|||2017-01-20|2017-01-20|2017-01-24|Estimate|||||||2017-01-20|2017-01-24|Estimate|February 15, 2017|Anticipated|2017-02-15|January 2017|2017-01-31|February 1, 2019|Anticipated|2019-02-01|December 1, 2018|Anticipated|2018-12-01||Interventional|||PD-1 Antibody Expressing CAR T Cells for Mesothelin Positive Advanced Malignancies|PD-1 Antibody Expressing Chimeric Antigen Receptor T Cells for Mesothelin Positive Advanced Malignancies|Unknown status|Recruiting|Phase 1/Phase 2|40|Anticipated|Ningbo Cancer Hospital||1|||f||||t|f|f|||||||||Undecided||2023-08-31 16:48:23.605185|2023-08-31 16:48:23.605185|INDUSTRY|||||
NCT05583201||2022-10-13|||2023-02-06|2022-10-13|2022-10-17|Actual|||||||2023-02-06|2023-02-08|Actual|October 13, 2022|Actual|2022-10-13|February 2023|2023-02-28|June 1, 2026|Anticipated|2026-06-01|June 1, 2024|Anticipated|2024-06-01||Interventional|||NKG2D/CLDN18.2 CAR-T(KD-496) in the Treatment of Advanced NKG2DL+/CLDN18.2+ Solid Tumors|A Single-center, Open-label, Single-arm Clinical Study of the Safety and Efficacy of KD-496 CAR-T Therapy in Advanced NKG2DL+/CLDN18.2+ Solid Tumors|Recruiting||Early Phase 1|18|Anticipated|The Affiliated Hospital of the Chinese Academy of Military Medical Sciences||1|||f|||||f|f|||||||||No||2023-08-31 16:50:05.868858|2023-08-31 16:50:05.868858|OTHER|||||
NCT04155749||2019-10-17|||2023-07-10|2019-11-05|2019-11-07|Actual|||||||2023-07-10|2023-07-12|Actual|November 18, 2019|Actual|2019-11-18|July 2023|2023-07-31|November 1, 2035|Anticipated|2035-11-01|August 31, 2024|Anticipated|2024-08-31||Interventional|||Master Protocol for the Phase 1 Study of Cell Therapies in Multiple Myeloma|Master Protocol for the Phase 1 Study of Cell Therapies for the Treatment of Patients With Relapsed Refractory Multiple Myeloma, Including Long-term Safety Follow-up|Recruiting||Phase 1|65|Anticipated|Arcellx, Inc.||2|||f||||f|t|f|||||||||No||2023-09-03 12:54:22.633768|2023-09-03 12:54:22.633768|INDUSTRY|||||
NCT05241392||2022-01-13|||2023-07-25|2022-02-11|2022-02-15|Actual|||||||2023-07-25|2023-07-27|Actual|January 27, 2022|Actual|2022-01-27|July 2023|2023-07-31|December 31, 2024|Anticipated|2024-12-31|December 31, 2024|Anticipated|2024-12-31||Interventional|||Safety and Efficacy Study of Anti-B7-H3 CAR-T Cell Therapy for Recurrent Glioblastoma|An Open, Single-arm, Phase 1 Study to Evaluate the Safety/Preliminary Effectiveness and Determine the Maximal Tolerated Dose of B7-H3-targeting CAR-T Cell Therapy in Treating Recurrent Glioblastomas|Recruiting||Phase 1|30|Anticipated|Beijing Tiantan Hospital||1|||f|||||f|f|||||||||No||2023-08-31 16:56:54.733343|2023-08-31 16:56:54.733343|OTHER|||||
NCT05432401||2022-06-10|||2022-06-20|2022-06-20|2022-06-27|Actual|||||||2022-06-20|2022-06-27|Actual|June 9, 2022|Actual|2022-06-09|June 2022|2022-06-30|June 9, 2025|Anticipated|2025-06-09|June 9, 2023|Anticipated|2023-06-09||Interventional|||TAA05 Injection in the Treatment of Adult Patients With FLT3-positive Relapsed/Refractory Acute Myeloid Leukemia|Clinical Study of TAA05 Injection in the Treatment of Adult Patients With FLT3-positive Relapsed/Refractory Acute Myeloid Leukemia|Recruiting||Early Phase 1|18|Anticipated|PersonGen BioTherapeutics (Suzhou) Co., Ltd.||1|||f|||||f|f|||||||||||2023-09-01 16:50:34.361587|2023-09-01 16:50:34.361587|INDUSTRY|||||
NCT05576181||2022-09-23|||2022-10-08|2022-10-08|2022-10-12|Actual|||||||2022-10-08|2022-10-12|Actual|October 15, 2022|Anticipated|2022-10-15|September 2022|2022-09-30|July 22, 2025|Anticipated|2025-07-22|January 22, 2025|Anticipated|2025-01-22||Interventional|||Safety and Efficacy of ThisCART19A Bridging Hematopoietic Stem Cell Transplantation in Patients With Refractory or Relapsed B-cell Acute Lymphoblastic Leukemia|A Single Dose-escalation Study to Evaluate the Safety and Efficacy of Allogeneic CAR-T Targeting CD19 Bridging Hematopoietic Stem Cell Transplantation in Patients With Refractory or Relapsed B Cell Acute Lymphoblastic Leukemia|Not yet recruiting||Phase 1|19|Anticipated|Fundamenta Therapeutics, Ltd.||1|||f||||f|f|f|||||||||No||2023-09-01 16:57:33.622484|2023-09-01 16:57:33.622484|INDUSTRY|||||
NCT05640713||2022-11-28|||2022-11-28|2022-11-28|2022-12-07|Actual|||||||2022-11-28|2022-12-07|Actual|December 1, 2022|Anticipated|2022-12-01|November 2022|2022-11-30|August 1, 2025|Anticipated|2025-08-01|February 1, 2025|Anticipated|2025-02-01||Interventional|||Assessment of Safety and Efficacy of ThisCART19A in Adult Patients With B Cell Malignancies After Failure of Autologous Chimeric Antigen Receptor T- Cell(CAR-T) Therapy|A Single Dose-escalation Study to Evaluate the Safety and Efficacy of Allogeneic CAR-T Targeting CD19 (ThisCART19A) in Adult Patients With B Cell Malignancies After Failure of Autologous Chimeric Antigen Receptor T- Cell(CAR-T) Therapy|Not yet recruiting||Phase 1|12|Anticipated|Henan Cancer Hospital||1|||f|||||f|f|||||||||||2023-09-01 16:57:41.333852|2023-09-01 16:57:41.333852|OTHER_GOV|||||
NCT05509530||2022-08-02|||2022-08-19|2022-08-19|2022-08-22|Actual|||||||2022-08-19|2022-08-22|Actual|May 1, 2022|Actual|2022-05-01|August 2022|2022-08-31|May 1, 2025|Anticipated|2025-05-01|May 1, 2025|Anticipated|2025-05-01||Interventional|||Safety and Efficacy of Anti-BCMA/GPRC5D CAR-T Cell Therapy in Treating Relapsed and Refractory Multiple Myeloma(rr/MM)|Efficacy and Safety Study of Anti-BCMA/GPRC5D CAR-T Cells in Subjects With Relapsed and Refractory Multiple Myeloma|Recruiting||Phase 2|30|Anticipated|Xuzhou Medical University||1|||f||||t|f|f|||||||||||2023-08-31 17:20:59.179329|2023-08-31 17:20:59.179329|OTHER|||||
NCT04888442||2021-05-12|||2021-05-12|2021-05-12|2021-05-17|Actual|||||||2021-05-12|2021-05-17|Actual|October 26, 2020|Actual|2020-10-26|May 2021|2021-05-31|March 28, 2022|Anticipated|2022-03-28|January 30, 2022|Anticipated|2022-01-30||Interventional|||Phase I Study of pCAR-19B in the Treatment of Adult CD19-positive Relapsed/Refractory B-ALL|A Phase I Clinical Study of Anti-CD19 CAR-T Therapy (pCAR-19B) in the Treatment of Adult CD19-positive Relapsed/Refractory B-ALL|Unknown status|Recruiting|Phase 1|18|Anticipated|Chongqing Precision Biotech Co., Ltd||1|||f||||f|f|f|||||||||||2023-09-04 13:40:35.662073|2023-09-04 13:40:35.662073|INDUSTRY|||||
NCT03960060||2019-05-08|||2021-10-19|2019-05-21|2019-05-22|Actual|||||||2021-10-19|2021-10-21|Actual|May 16, 2019|Actual|2019-05-16|October 2021|2021-10-31|June 30, 2023|Anticipated|2023-06-30|June 30, 2022|Anticipated|2022-06-30||Interventional|CAR||A Study of CCT301-59 CAR T Therapy in Adult Subjects With Recurrent or Refractory Solid Tumors|Evaluation of CAR (Chimeric Antigen Receptor) Modified Autologous T Cell CCT301-59 in Patients With Recurrent or Refractory Solid Tumors on the Basis of Safety, Tolerability and Anti-tumor Activity Study.|Active, not recruiting||Phase 1|18|Anticipated|Shanghai PerHum Therapeutics Co., Ltd.||1|||f|||||f|f|||||||||||2023-09-01 17:07:46.881546|2023-09-01 17:07:46.881546|INDUSTRY|||||
NCT03690011||2018-09-20|||2023-04-26|2018-09-27|2018-10-01|Actual|||||||2023-04-26|2023-04-28|Actual|August 2, 2021|Actual|2021-08-02|April 2023|2023-04-30|May 1, 2039|Anticipated|2039-05-01|May 1, 2024|Anticipated|2024-05-01||Interventional|||Cell Therapy for High Risk T-Cell Malignancies Using CD7-Specific CAR Expressed On Autologous T Cells|Cell Therapy for High Risk T-cell Malignancies Using CD7-Specific CAR Expressed on Non-Edited T Cells (CRIMSON-NE)|Recruiting||Phase 1|21|Anticipated|Baylor College of Medicine||1|||f||||t|t|f|||||||||||2023-09-03 13:09:17.996055|2023-09-03 13:09:17.996055|OTHER|||||
NCT01818323||2013-03-19|||2022-03-28|2013-03-25|2013-03-26|Estimate|||||||2022-03-28|2022-04-06|Actual|June 2015||2015-06-30|March 2022|2022-03-31|December 2023|Anticipated|2023-12-31|December 2023|Anticipated|2023-12-31||Interventional|||Phase I Trial: T4 Immunotherapy of Head and Neck Cancer|Phase I Trial: T4 Immunotherapy of Head and Neck Cancer|Recruiting||Phase 1|30|Anticipated|King's College London||1|||f||||t|f|f|||||||||Yes||2023-09-01 17:22:59.162952|2023-09-01 17:22:59.162952|OTHER|||||
NCT04544592||2019-05-29|||2022-11-09|2020-09-03|2020-09-10|Actual|||||||2022-11-09|2022-11-14|Actual|February 24, 2021|Actual|2021-02-24|November 2022|2022-11-30|July 2026|Anticipated|2026-07-31|June 2026|Anticipated|2026-06-30||Interventional|||UCD19 CarT in Treatment of Pediatric B-ALL and B-NHL|Phase 1/2 Dose Escalation and Preliminary Efficacy of CD19 Directed Car T Cells Generated Using The Miltenyi Clinimacs Prodigy System (UCD19 CarT) in Pediatric Patients With Relapsed and/or Refractory B-Cell Acute Lymphoblastic Leukemia (B-ALL) and B-Cell Non-Hodgkins Lymphoma(B-NHL)|Recruiting||Phase 1/Phase 2|50|Anticipated|University of Colorado, Denver||1|||f||||t|t|f|||f||||||No||2023-08-31 17:32:06.787737|2023-08-31 17:32:06.787737|OTHER|||||
NCT02968472||2016-11-16|||2016-11-17|2016-11-17|2016-11-18|Estimate|||||||2016-11-17|2016-11-18|Estimate|March 2015||2015-03-31|November 2016|2016-11-30|May 2019|Anticipated|2019-05-31|May 2019|Anticipated|2019-05-31||Interventional|||A Phase I Trial of 4SCAR19 Cells in the Treatment of Relapsed and Refractory B Cell Leukemia|Single Center, Open, Phase I Clinical Trial of 4SCAR19 Cells in the Treatment of Relapsed and Refractory B Cell Leukemia|Unknown status|Recruiting|Phase 1|30|Anticipated|The First People's Hospital of Yunnan||1|||f||||t|||||||||||Undecided||2023-09-01 18:50:38.578503|2023-09-01 18:50:38.578503|OTHER|||||
NCT05020444||2021-08-18|||2023-03-13|2021-08-18|2021-08-25|Actual|||||||2023-03-13|2023-03-15|Actual|October 5, 2021|Actual|2021-10-05|March 2023|2023-03-31|January 1, 2025|Anticipated|2025-01-01|January 1, 2024|Anticipated|2024-01-01||Interventional|||TriPRIL CAR T Cells in Multiple Myeloma|A Phase I Clinical Trial With TriPRIL CAR T Cells for the Treatment of Patients With Relapsed or Refractory Multiple Myeloma|Recruiting||Phase 1|18|Anticipated|Massachusetts General Hospital||2|||f||||t|t|f||||||Data can be shared no earlier than 1 year following the date of publication|Contact the Partners Innovations team at http://www.partners.org/innovation||Yes|The Dana-Farber / Harvard Cancer Center encourages and supports the responsible and ethical sharing of data from clinical trials. De-identified participant data from the final research dataset used in the published manuscript may only be shared under the terms of a Data Use Agreement. Requests may be directed to: [contact information for Sponsor Investigator or designee]. The protocol and statistical analysis plan will be made available on Clinicaltrials.gov only as required by federal regulation or as a condition of awards and agreements supporting the research.|2023-09-01 17:44:35.749693|2023-09-01 17:44:35.749693|OTHER|||||
NCT04214392||2019-12-27|||2023-03-13|2019-12-27|2020-01-02|Actual|||||||2023-03-13|2023-03-15|Actual|February 26, 2020|Actual|2020-02-26|March 2023|2023-03-31|December 31, 2024|Anticipated|2024-12-31|January 2, 2024|Anticipated|2024-01-02||Interventional|||Chimeric Antigen Receptor (CAR) T Cells With a Chlorotoxin Tumor-Targeting Domain for the Treatment of MMP2+ Recurrent or Progressive Glioblastoma|A Phase 1 Study to Evaluate Chimeric Antigen Receptor (CAR) T Cells With a Chlorotoxin Tumor-Targeting Domain for Patients With MMP2+ Recurrent or Progressive Glioblastoma|Recruiting||Phase 1|36|Anticipated|City of Hope Medical Center||2|||||||t|t|f|||||||||||2023-09-01 17:46:16.670986|2023-09-01 17:46:16.670986|OTHER|||||
NCT05432882||2022-06-21|||2022-06-21|2022-06-21|2022-06-27|Actual|||||||2022-06-21|2022-06-27|Actual|June 30, 2022|Anticipated|2022-06-30|June 2022|2022-06-30|June 30, 2026|Anticipated|2026-06-30|December 31, 2025|Anticipated|2025-12-31||Interventional|||CD19/22 Bi-specific CAR-T Cell Therapy|CD19/22 Bi-specific CAR-T Cells Targeting B Cell Malignancies|Recruiting||Phase 1/Phase 2|60|Anticipated|Shenzhen Geno-Immune Medical Institute||1|||f||||f|f|f|||||||||No||2023-09-01 18:08:57.459432|2023-09-01 18:08:57.459432|OTHER|||||
NCT02958384||2016-11-06|||2018-01-20|2016-11-06|2016-11-08|Estimate|||||||2018-01-20|2018-01-23|Actual|October 2016||2016-10-31|January 2018|2018-01-31|October 2020|Anticipated|2020-10-31|October 2019|Anticipated|2019-10-31||Interventional|||A Clinical Research of LeY-Targeted CAR-T in Myeloid Malignancies|A Clinical Research of LeY-Targeted CAR-T in Myeloid Malignancies|Unknown status|Recruiting|Phase 1/Phase 2|45|Anticipated|Southwest Hospital, China||1|||f||||f|||||||||||Undecided||2023-09-01 18:09:23.924999|2023-09-01 18:09:23.924999|OTHER|||||
NCT04727008||2020-11-30|||2021-04-07|2021-01-25|2021-01-27|Actual|||||||2021-04-07|2021-04-08|Actual|June 3, 2021|Anticipated|2021-06-03|April 2021|2021-04-30|December 31, 2025|Anticipated|2025-12-31|December 31, 2022|Anticipated|2022-12-31||Interventional|||CXCR4 Modified Anti-BCMA CAR T Cells for Multiple Myeloma|Phase I Study of A CXCR4 Modified BCMA CAR-T in Patients With Refractory and/or Relapsed Multiple Myeloma|Not yet recruiting||Early Phase 1|12|Anticipated|Sichuan University||1|||f|||||f|f|||||||||No||2023-09-01 18:21:55.846431|2023-09-01 18:21:55.846431|OTHER|||||
NCT04394650||2020-05-14|||2023-02-28|2020-05-14|2020-05-19|Actual|||||||2023-02-28|2023-03-01|Actual|August 18, 2020|Actual|2020-08-18|February 2023|2023-02-28|June 23, 2025|Anticipated|2025-06-23|June 23, 2025|Anticipated|2025-06-23||Interventional|||A Study of CC-98633, BCMA-targeted Chimeric Antigen Receptor (CAR) T Cells, in Participants With Relapsed and/or Refractory Multiple Myeloma|A Phase I, Multi Center, Open Label Study of CC-98633, BCMA Targeted NEX-T Chimeric Antigen Receptor (CAR) T Cells, in Subjects With Relapsed and/or Refractory Multiple Myeloma|Active, not recruiting||Phase 1|150|Anticipated|Juno Therapeutics, a Subsidiary of Celgene||1|||f||||t|t|f||||||See Plan Description|See Plan Description|https://www.celgene.com/research-development/clinical-trials/clinical-trials-data-sharing/|Yes|"Information relating to our policy on data sharing and the process for requesting data can be found at the following link:~https://www.celgene.com/research-development/clinical-trials/clinical-trials-data-sharing/"|2023-08-31 17:51:04.018489|2023-08-31 17:51:04.018489|INDUSTRY|||||
NCT03081910||2017-03-08|||2023-02-28|2017-03-10|2017-03-16|Actual|||||||2023-02-28|2023-03-02|Actual|November 1, 2017|Actual|2017-11-01|February 2023|2023-02-28|September 1, 2039|Anticipated|2039-09-01|January 15, 2024|Anticipated|2024-01-15||Interventional|MAGENTA||Autologous T-Cells Expressing a Second Generation CAR for Treatment of T-Cell Malignancies Expressing CD5 Antigen|Phase 1 Therapy With Manufactured Autologous T-Cells Expressing a Second Generation Chimeric Antigen Receptor (CAR) for Treatment of T-Cell Malignancies Expressing CD5 Antigen|Recruiting||Phase 1|42|Anticipated|Baylor College of Medicine||2|||f||||t|t|f|||f||||||||2023-08-31 17:51:28.386941|2023-08-31 17:51:28.386941|OTHER|||||
NCT04605666||2020-10-25|||2023-03-16|2020-10-25|2020-10-28|Actual|||||||2023-03-16|2023-03-20|Actual|May 1, 2020|Actual|2020-05-01|March 2023|2023-03-31|December 31, 2023|Anticipated|2023-12-31|June 30, 2023|Anticipated|2023-06-30||Interventional|||CD19-CAR-T2 Cells for CD19 Positive Acute Lymphoblastic Leukemia|CD19-Chimeric Antigen Receptor-T2 Cells for CD19 Positive Acute Lymphoblastic Leukemia|Recruiting||Phase 2|60|Anticipated|Nanfang Hospital, Southern Medical University||1|||f||||t|f|f|||||||||Undecided||2023-08-31 18:01:15.026804|2023-08-31 18:01:15.026804|OTHER|||||
NCT04531046||2020-08-25|||2023-03-17|2020-08-25|2020-08-28|Actual|||||||2023-03-17|2023-03-20|Actual|March 10, 2021|Actual|2021-03-10|March 2023|2023-03-31|June 2025|Anticipated|2025-06-30|April 2023|Anticipated|2023-04-30||Interventional|||Axi-Cel as a 2nd Line Therapy in Patients With Relapsed/Refractory Aggressive B Lymphoma Ineligible to Autologous Stem Cell Transplantation|Phase 2, Open-Label Study Evaluating Axi-Cel as a 2nd Line Therapy in Patients With Relapsed/Refractory Aggressive B-Non Hodgkin Lymphoma (B-NHL) Who Are Ineligible to Autologous Stem Cell Transplantation|Active, not recruiting||Phase 2|60|Anticipated|The Lymphoma Academic Research Organisation||1|||f||||f|f|f|||||||||No||2023-08-31 18:01:17.457899|2023-08-31 18:01:17.457899|OTHER|||||
NCT02431988||2015-03-23|||2023-04-26|2015-04-27|2015-05-01|Estimate|||||||2023-04-26|2023-04-28|Actual|June 2016|Actual|2016-06-30|April 2023|2023-04-30|March 21, 2022|Actual|2022-03-21|February 2, 2020|Actual|2020-02-02||Interventional|COBALT||Evaluation of CAR19 T-cells as an Optimal Bridge to Allogeneic Transplantation|COBALT: Evaluation of CAR19 T-cells as an Optimal Bridge to Allogeneic Transplantation|Completed||Phase 1|10|Actual|University College, London||1|||f||||t|f|f|||||||||||2023-09-03 13:10:06.976947|2023-09-03 13:10:06.976947|OTHER|||||
NCT05621096||2022-10-27|||2023-06-10|2022-11-11|2022-11-17|Actual|||||||2023-06-10|2023-06-13|Actual|March 21, 2023|Actual|2023-03-21|June 2023|2023-06-30|July 2025|Anticipated|2025-07-31|July 2025|Anticipated|2025-07-31||Interventional|||Low Dose Radiation as Bridging Therapy in Relapsed B-Cell Non-Hodgkin Lymphoma|Feasibility of Low Dose Radiation as Bridging Therapy for Lisocabtagene Maraleucel in Relapsed B-Cell Non-Hodgkin Lymphoma|Recruiting||Phase 1|33|Anticipated|University of Nebraska||1|||f||||t|t|f|||t||||||||2023-08-31 18:27:05.498384|2023-08-31 18:27:05.498384|OTHER|||||
NCT02958410||2016-11-06|||2019-06-23|2016-11-06|2016-11-08|Estimate|||||||2019-06-23|2019-06-25|Actual|October 2016||2016-10-31|June 2019|2019-06-30|October 2020|Anticipated|2020-10-31|October 2019|Anticipated|2019-10-31||Interventional|||A Clinical Research of CD30-Targeted CAR-T in Lymphocyte Malignancies|A Clinical Research of CD30-Targeted CAR-T in Lymphocyte Malignancies|Unknown status|Recruiting|Phase 1/Phase 2|45|Anticipated|Southwest Hospital, China||1|||f||||f|||||||||||Undecided||2023-09-01 19:24:09.345724|2023-09-01 19:24:09.345724|OTHER|||||
NCT04717999||2021-01-16|||2021-01-16|2021-01-16|2021-01-22|Actual|||||||2021-01-16|2021-01-22|Actual|September 1, 2021|Anticipated|2021-09-01|January 2021|2021-01-31|December 31, 2023|Anticipated|2023-12-31|September 30, 2023|Anticipated|2023-09-30||Interventional|||Pilot Study of NKG2D CAR-T in Treating Patients With Recurrent Glioblastoma|Pilot Study of UWNKG2D CAR-T in Treating Patients With Recurrent Glioblastoma|Not yet recruiting||Not Applicable|20|Anticipated|UWELL Biopharma||1|||f||||t|f|f|||||||||||2023-09-01 19:25:07.722727|2023-09-01 19:25:07.722727|INDUSTRY|||||
NCT02965092||2016-11-13|||2019-05-08|2016-11-13|2016-11-16|Estimate|||||||2019-05-08|2019-05-10|Actual|December 2, 2015|Actual|2015-12-02|May 2019|2019-05-31|December 2021|Anticipated|2021-12-31|January 2021|Anticipated|2021-01-31||Interventional|||CD19 Chimeric Antigen Receptor (CAR)-Modified T Cell Therapy in Treating Patients With B-cell Malignancies|Treatment of Relapsed or Refractory B-cell Malignancies by CD19 Chimeric Antigen Receptor (CAR)-Modified T Cells|Unknown status|Recruiting|Phase 1/Phase 2|80|Anticipated|Wuhan Sian Medical Technology Co., Ltd||1|||f||||f|f|f|||||||||Undecided||2023-09-01 19:26:03.564637|2023-09-01 19:26:03.564637|INDUSTRY|||||
NCT05666700||2022-12-04|||2023-08-22|2022-12-18|2022-12-28|Actual|||||||2023-08-22|2023-08-23|Actual|December 2023|Anticipated|2023-12-31|August 2023|2023-08-31|August 2025|Anticipated|2025-08-31|August 2025|Anticipated|2025-08-31||Interventional|CARAMEL||CAR-T Cell Therapy in RelApsed/Refractory Myeloma With ExtrameduLlary Disease - an in Vivo Imaging and Molecular Monitoring Study|CAR-T Cell Therapy in RelApsed/Refractory Myeloma With ExtrameduLlary Disease - an in Vivo Imaging and Molecular Monitoring Study|Not yet recruiting||Phase 1|15|Anticipated|Peter MacCallum Cancer Centre, Australia||1|||f||||t|f|f|||||||||No||2023-09-03 13:15:15.876922|2023-09-03 13:15:15.876922|OTHER|||||
NCT03854994||2019-02-20|||2019-02-25|2019-02-25|2019-02-26|Actual|||||||2019-02-25|2019-02-26|Actual|August 1, 2018|Actual|2018-08-01|February 2019|2019-02-28|August 1, 2022|Anticipated|2022-08-01|August 1, 2021|Anticipated|2021-08-01||Interventional|||CD19 CAR-T Cell Therapy for Relapsed/Refractory B-cell Lymphoma and B-cell Acute Lymphoblastic Leukemia|A Phase I Clinical Trial of Anti-CD19 Chimeric Antigen Receptor With Synthetic Biology Optimizing Nano-vector T Cells Injection for Subjects With Relapsed/Refractory/High-risk B-cell Lymphoma and B-cell Acute Lymphoblastic Leukemia|Unknown status|Recruiting|Phase 1|10|Anticipated|Yan'an Affiliated Hospital of Kunming Medical University||1|||f||||t|f|f|||||||||Undecided||2023-09-03 13:17:37.718138|2023-09-03 13:17:37.718138|OTHER|||||
NCT05518253||2022-08-24|||2023-08-16|2022-08-24|2022-08-26|Actual|||||||2023-08-16|2023-08-21|Actual|May 30, 2022|Actual|2022-05-30|August 2023|2023-08-31|May 30, 2025|Anticipated|2025-05-30|May 30, 2024|Anticipated|2024-05-30||Interventional|||A Clinical Study of CD70-targeted CAR-T in the Treatment of CD70-positive Advanced/Metastatic Solid Tumors|A Phase I Clinical Study of CD70-targeting CAR-T Therapy in the Treatment of CD70-positive Advanced/Metastatic Solid Tumors|Recruiting||Phase 1|36|Anticipated|Zhejiang University||2|||f||||f|f|f|||||||||No||2023-09-01 19:44:41.241496|2023-09-01 19:44:41.241496|OTHER|||||
NCT05489991||2022-07-22|||2023-08-15|2022-08-03|2022-08-05|Actual|||||||2023-08-15|2023-08-18|Actual|September 6, 2022|Actual|2022-09-06|August 2023|2023-08-31|May 3, 2023|Actual|2023-05-03|May 3, 2023|Actual|2023-05-03||Interventional|||A Study of TmPSMA-02 Chimeric Antigen Receptor (CAR) T-cells in Patients With Metastatic Castration Resistant Prostate Cancer (mCRPC)|A Phase 1/2, Open-label, Multi-Center Study of Dually Armored Chimeric Antigen Receptor (CAR) T-cells (TmPSMA-02) in Patients With Metastatic Castration Resistant Prostate Cancer (mCRPC)|Terminated||Phase 1/Phase 2|1|Actual|Tceleron Therapeutics, Inc.||1||Study was stopped Sponsor discretion. No patients were dosed.|f||||t|t|f|||||||||||2023-09-01 19:45:01.810622|2023-09-01 19:45:01.810622|INDUSTRY|||||
NCT05468190||2022-07-19|||2023-08-16|2022-07-19|2022-07-21|Actual|||||||2023-08-16|2023-08-18|Actual|July 17, 2022|Actual|2022-07-17|August 2023|2023-08-31|July 17, 2025|Anticipated|2025-07-17|July 17, 2024|Anticipated|2024-07-17||Interventional|||A Clinical Research About CD70-positive Advanced/Metastatic Solid Tumors Treated by CD70-targeted CAR-T|A Phase I Clinical Study to Assess the Safety and Tolerability of CD70-targeting CAR-T in the Treatment of CD70-positive Advanced/Metastatic Solid Tumors|Recruiting||Phase 1|48|Anticipated|Chongqing Precision Biotech Co., Ltd||2|||f|||||f|f|||||||||||2023-09-01 19:45:19.835786|2023-09-01 19:45:19.835786|INDUSTRY|||||
NCT05442515||2022-07-01|||2023-08-16|2022-07-01|2022-07-05|Actual|||||||2023-08-16|2023-08-18|Actual|December 28, 2022|Actual|2022-12-28|August 15, 2023|2023-08-15|July 1, 2029|Anticipated|2029-07-01|July 1, 2027|Anticipated|2027-07-01||Interventional|||CD19/CD22 Bicistronic Chimeric Antigen Receptor (CAR) T Cells in Children and Young Adults With Recurrent or Refractory CD19/CD22-expressing B Cell Malignancies|Phase 1/2 Dose Escalation Study of CD19/CD22 Bicistronic Chimeric Antigen Receptor (CAR) T Cells in Children and Young Adults With Recurrent or Refractory CD19/CD22-expressing B Cell Malignancies|Recruiting||Phase 1/Phase 2|146|Anticipated|National Institutes of Health Clinical Center (CC)||4|||f|||||t|f||||||Clinical data available during the study and indefinitely.|Clinical data will be made available via subscription to BTRIS and with the permission of the study PI.||Yes|.All IPD recorded in the medical record will be shared with intramural investigators upon request.|2023-09-01 19:45:37.21046|2023-09-01 19:45:37.21046|NIH|||||
NCT05420545||2022-06-12|||2023-08-16|2022-06-12|2022-06-15|Actual|||||||2023-08-16|2023-08-18|Actual|December 31, 2021|Actual|2021-12-31|August 2023|2023-08-31|December 31, 2024|Anticipated|2024-12-31|December 31, 2023|Anticipated|2023-12-31||Interventional|||A Clinical Study of CD70-targeted CAR-T in the Treatment of CD70-positive Advanced/Metastatic Solid Tumors|A Phase I Clinical Study of CD70-targeting CAR-T Therapy in the Treatment of CD70-positive Advanced/Metastatic Solid Tumors|Recruiting||Phase 1|36|Anticipated|Chongqing Precision Biotech Co., Ltd||2|||f|||||f|f|||||||||||2023-09-01 19:45:52.815879|2023-09-01 19:45:52.815879|INDUSTRY|||||
NCT05420519||2022-06-12|||2023-08-16|2022-06-12|2022-06-15|Actual|||||||2023-08-16|2023-08-18|Actual|December 31, 2021|Actual|2021-12-31|August 2023|2023-08-31|December 31, 2024|Anticipated|2024-12-31|December 31, 2023|Anticipated|2023-12-31||Interventional|||Clinical Study of CD70-targeted CAR-T Therapy for Advanced/Advanced Renal Cancer|A Phase I Clinical Study of CD70-targeted CAR-T Therapy for Advanced/Advanced Renal Cancer|Recruiting||Phase 1|24|Anticipated|Chongqing Precision Biotech Co., Ltd||1|||f|||||f|f|||||||||||2023-09-01 19:45:53.585203|2023-09-01 19:45:53.585203|INDUSTRY|||||
NCT05400109||2022-05-27|||2023-08-16|2022-05-27|2022-06-01|Actual|||||||2023-08-16|2023-08-21|Actual|April 26, 2023|Actual|2023-04-26|August 2023|2023-08-31|December 2024|Anticipated|2024-12-31|June 2024|Anticipated|2024-06-30||Interventional|||Evaluate the Safety of UF-KURE19 Cells in Non-Hodgkin Lymphomas|A Phase 1 Single Arm, Open Label Study to Evaluate the Safety of UF-KURE19 Cells in Patients With Relapsed or Refractory B Cell Non-Hodgkin Lymphomas|Recruiting||Phase 1|10|Anticipated|Case Comprehensive Cancer Center||1||||||||t|f|||f||||||No||2023-09-01 19:46:10.906566|2023-09-01 19:46:10.906566|OTHER|||||
NCT05035407||2021-09-03|||2023-08-31|2021-09-03|2021-09-05|Actual|||||||2023-08-31|2023-09-01|Estimate|March 8, 2022|Actual|2022-03-08|August 30, 2023|2023-08-30|April 5, 2026|Anticipated|2026-04-05|April 7, 2025|Anticipated|2025-04-07||Interventional|||T Cell Receptor Gene Therapy Targeting KK-LC-1 for Gastric, Breast, Cervical, Lung and Other KK-LC-1 Positive Epithelial Cancers|A Phase I Trial of T Cell Receptor Gene Therapy Targeting KK-LC-1 for Gastric, Breast, Cervical, Lung and Other KK-LC-1 Positive Epithelial Cancers|Recruiting||Phase 1|100|Anticipated|National Institutes of Health Clinical Center (CC)||1|||f|||||t|f||||||Clinical data available during the study and indefinitely.|Clinical data will be made available via subscription to BTRIS and with the permission of the study PI.||Yes|.IPD recorded in the medical record will be shared with intramural investigators upon request.|2023-09-01 19:49:32.884195|2023-09-01 19:49:32.884195|NIH|||||
NCT05003895||2021-08-12|||2023-08-16|2021-08-12|2021-08-13|Actual|||||||2023-08-16|2023-08-18|Actual|December 8, 2021|Actual|2021-12-08|August 14, 2023|2023-08-14|December 31, 2025|Anticipated|2025-12-31|December 31, 2024|Anticipated|2024-12-31||Interventional|||GPC3 Targeted CAR-T Cell Therapy in Advanced GPC3 Expressing Hepatocellular Carcinoma (HCC)|Phase I Study of GPC3 Targeted CAR-T Cell Therapy in Advanced GPC3 Expressing Hepatocellular Carcinoma (HCC)|Recruiting||Phase 1|38|Anticipated|National Institutes of Health Clinical Center (CC)||2|||f|||||t|f||||||Clinical data available during the study and indefinitely.@@@@@@Genomic data are available once genomic data are uploaded per protocol GDS plan for as long as database is active.|Clinical data will be made available via subscription to BTRIS and with the permission of the study PI. @@@@@@Genomic data are made available via dbGaP through requests to the data custodians.||Yes|.All IPD recorded in the medical record will be shared with intramural investigators upon request.@@@@@@In addition, all large scale genomic sequencing data will be shared with subscribers to dbGaP|2023-09-01 19:49:52.409389|2023-09-01 19:49:52.409389|NIH|||||
NCT04420754||2020-06-03|||2023-08-16|2020-06-03|2020-06-09|Actual|||||||2023-08-16|2023-08-21|Actual|September 28, 2020|Actual|2020-09-28|August 2023|2023-08-31|December 2024|Anticipated|2024-12-31|September 28, 2023|Anticipated|2023-09-28||Interventional|||Study of AIC100 CAR T Cells in Relapsed/Refractory Thyroid Cancer|A Multicenter Phase I Study of AIC100 CAR T Cells in Relapsed and/or Refractory Advanced Thyroid Cancer or Anaplastic Thyroid Cancer|Recruiting||Phase 1|30|Anticipated|AffyImmune Therapeutics, Inc.||6|||f||||t|t|f|||||||||No||2023-09-01 19:54:19.751|2023-09-01 19:54:19.751|INDUSTRY|||||
NCT04416984||2020-05-29|||2023-08-17|2020-06-02|2020-06-04|Actual|||||||2023-08-17|2023-08-21|Actual|May 21, 2020|Actual|2020-05-21|August 2023|2023-08-31|May 2029|Anticipated|2029-05-31|January 2025|Anticipated|2025-01-31||Interventional|ALPHA2||Safety and Efficacy of ALLO-501A Anti-CD19 Allogeneic CAR T Cells in Adults With Relapsed/Refractory Large B Cell Lymphoma (ALPHA2)|A Single-Arm, Open-Label, Phase 1/2 Study Evaluating the Safety, Efficacy, and Cellular Kinetics/Pharmacodynamics of ALLO-501A, an Anti-CD19 Allogeneic CAR T Cell Therapy, and ALLO-647, an Anti-CD52 Monoclonal Antibody, in Subjects With Relapsed/Refractory Large B-Cell Lymphoma (LBCL)|Recruiting||Phase 1/Phase 2|160|Anticipated|Allogene Therapeutics||1|||f||||t|t|f|||f||||||||2023-09-01 19:54:21.242565|2023-09-01 19:54:21.242565|INDUSTRY|||||
NCT04227275||2019-12-12|||2023-08-16|2020-01-09|2020-01-13|Actual|||||||2023-08-16|2023-08-21|Actual|November 22, 2019|Actual|2019-11-22|August 2023|2023-08-31|November 7, 2022|Actual|2022-11-07|November 7, 2022|Actual|2022-11-07||Interventional|||A Study of CART-PSMA-TGFβRDN in Patients With Metastatic Castration Resistant Prostate Cancer|A Phase 1 Open-Label, Multi-Center Study of PSMA Targeted Genetically Modified Chimeric Antigen Receptor T Cells in Patients With Metastatic Castration Resistant Prostate Cancer|Terminated||Phase 1|16|Actual|Tceleron Therapeutics, Inc.||1||Based on the safety events and evidence of biologic activity without sustained clinical responses the Sponsor finds the risk/benefit analysis unfavorable for patients and has terminated the study.|f||||t|t|f|||||||||No||2023-09-01 19:55:15.927686|2023-09-01 19:55:15.927686|INDUSTRY|||||
NCT04029038||2019-07-19|||2023-08-16|2019-07-19|2019-07-23|Actual|||||||2023-08-16|2023-08-21|Actual|May 15, 2019|Actual|2019-05-15|August 2023|2023-08-31|November 16, 2022|Actual|2022-11-16|November 16, 2022|Actual|2022-11-16||Interventional|||Modified Immune Cells (CD19-CD22 CAR T Cells) in Treating Patients With Recurrent or Refractory CD19 Positive, CD22 Positive Leukemia or Lymphoma|Phase I/II Study of Dual CD19-CD22 Chimeric Antigen Receptor (CAR) T Cells in Patients With Advanced CD19+ CD22+ Lymphoid Malignancies|Withdrawn||Phase 1/Phase 2|0|Actual|M.D. Anderson Cancer Center||1||0 participant accrual|||||f|t|f|||||||||||2023-09-01 19:56:31.729643|2023-09-01 19:56:31.729643|OTHER|||||
NCT02315612||2014-12-11|||2023-08-16|2014-12-11|2014-12-12|Estimate|||||||2023-08-16|2023-08-18|Actual|December 12, 2014|Actual|2014-12-12|August 15, 2023|2023-08-15|June 1, 2040|Anticipated|2040-06-01|April 3, 2019|Actual|2019-04-03||Interventional|||Anti-CD22 Chimeric Receptor T Cells in Pediatric and Young Adults With Recurrent or Refractory CD22-expressing B Cell Malignancies|Phase I Dose Escalation Study of Anti-CD22 Chimeric Receptor T Cells in Pediatric and Young Adults With Recurrent or Refractory CD22-expressing B Cell Malignancies|Recruiting||Phase 1|208|Anticipated|National Institutes of Health Clinical Center (CC)||2|||f|||||t|f||||||Clinical data available during the study and indefinitely.|Clinical data will be made available via subscription to BTRIS and with the permission of the study PI.||Yes|.All IPD recorded in the medical record will be shared with intramural investigators upon request.|2023-09-01 20:02:21.024643|2023-09-01 20:02:21.024643|NIH|||||
NCT03631576||2018-08-13|||2019-12-29|2018-08-13|2018-08-15|Actual|||||||2019-12-29|2020-01-02|Actual|August 10, 2018|Actual|2018-08-10|December 2019|2019-12-31|August 10, 2021|Anticipated|2021-08-10|August 10, 2021|Anticipated|2021-08-10||Interventional|||CD123/CLL1 CAR-T Cells for R/R AML (STPHI_0001)|CD123/CLL1 CAR-T Cell Therapy for Relapsed and Refractory Acute Myeloid Leukemia|Unknown status|Recruiting|Phase 2/Phase 3|20|Anticipated|Fujian Medical University||1|||f|||||f|f|||||||||||2023-09-03 13:21:49.333876|2023-09-03 13:21:49.333876|OTHER|||||
NCT05539430||2022-09-01|||2023-04-24|2022-09-09|2022-09-14|Actual|||||||2023-04-24|2023-04-26|Actual|April 18, 2023|Actual|2023-04-18|April 2023|2023-04-30|December 2025|Anticipated|2025-12-31|July 2025|Anticipated|2025-07-31||Interventional|||Claudin 18.2-Targeted Chimeric Antigen Receptor T-cells in Subjects With Unresectable, Locally Advanced, or Metastatic Gastric, Gastroesophageal Junction (GEJ), Esophageal, or Pancreatic Adenocarcinoma|A Phase 1, Open-Label, Dose Escalation and Expansion, Multicenter Study of Claudin 18.2-Targeted Chimeric Antigen Receptor T-cells in Subjects With Unresectable, Locally Advanced, or Metastatic Gastric, Gastroesophageal Junction (GEJ), Esophageal, or Pancreatic Adenocarcinoma|Recruiting||Phase 1|56|Anticipated|Legend Biotech USA Inc||1|||f|||||t|f|||||||||No||2023-09-01 20:15:53.140646|2023-09-01 20:15:53.140646|INDUSTRY|||||
NCT01853631||2013-05-01|||2023-04-24|2013-05-09|2013-05-15|Estimate|||||||2023-04-24|2023-04-26|Actual|February 2014||2014-02-28|April 2023|2023-04-30|February 2036|Anticipated|2036-02-29|December 2024|Anticipated|2024-12-31||Interventional|SAGAN||Activated T-Cells Expressing 2nd or 3rd Generation CD19-Specific CAR, Advanced B-Cell NHL, ALL, and CLL (SAGAN)|Phase I Study of Activated T-Cells Expressing Second or Third Generation CD19-Specific Chimeric Antigen Receptors for Advanced B-Cell Non-Hodgkin's Lymphoma, Acute Lymphocytic Leukemia and Chronic Lymphocytic Leukemia (SAGAN)|Recruiting||Phase 1|64|Anticipated|Baylor College of Medicine||4|||f||||t|t|f|||||||||No||2023-09-01 20:20:50.138361|2023-09-01 20:20:50.138361|OTHER|||||
NCT05070156||2021-09-10|||2022-07-27|2021-09-27|2021-10-07|Actual|||||||2022-07-27|2022-07-28|Actual|October 29, 2021|Actual|2021-10-29|July 2022|2022-07-31|September 30, 2022|Anticipated|2022-09-30|August 31, 2022|Anticipated|2022-08-31||Interventional|||B010-A Injection for Treating Patients With GPC3 Positive Advanced Hepatocellular Carcinoma|A Phase 1 Open-label, Single Arm Study Targeting Glypican-3 (GPC3) Chimeric Antigen Receptor Modified T Cells (CAR-T) for Treatment of Advanced Hepatocellular Carcinoma|Recruiting||Early Phase 1|3|Anticipated|Tongji University||1|||f||||t|f|f|||||||||||2023-08-31 18:39:37.443804|2023-08-31 18:39:37.443804|OTHER|||||
NCT05013372||2021-08-16|||2022-08-01|2021-08-18|2021-08-19|Actual|||||||2022-08-01|2022-08-02|Actual|January 2023|Anticipated|2023-01-31|August 2022|2022-08-31|January 1, 2025|Anticipated|2025-01-01|January 1, 2024|Anticipated|2024-01-01||Interventional|||CD147-CAR T Cells for Relapsed/Refractory T Cell Non-Hodgkin's Lymphoma|A Pioneering Study on the Safety and Efficacy of CD147-Chimeric Antigen Receptor (CAR) T Cells in Patients With Relapsed or Refractory T-cell Non-Hodgkin's Lymphoma|Not yet recruiting||Early Phase 1|12|Anticipated|Peking University People's Hospital||1|||f|||||f|f|||||||||No||2023-08-31 18:39:46.233653|2023-08-31 18:39:46.233653|OTHER|||||
NCT04214886||2019-12-16|||2022-08-11|2019-12-30|2020-01-02|Actual|||||||2022-08-11|2022-08-15|Actual|December 31, 2019|Actual|2019-12-31|August 2022|2022-08-31|December 31, 2034|Anticipated|2034-12-31|August 11, 2022|Actual|2022-08-11||Interventional|||CD19 Chimeric Antigen Receptor (CAR) T Cells for Adults With Recurrent or Refractory B Cell Malignancies|Dose Escalation Study of CD19 Chimeric Antigen Receptor (CAR) T Cells With a CD34 Selection Marker in Adults With Recurrent or Refractory B Cell Malignancies|Active, not recruiting||Phase 1|24|Anticipated|Loyola University||4|||f||||t|t|f|||||||||No||2023-08-31 18:39:51.8662|2023-08-31 18:39:51.8662|OTHER|||||
NCT04601831||2020-10-09|||2023-07-17|2020-10-19|2020-10-26|Actual|||||||2023-07-17|2023-07-19|Actual|December 23, 2020|Actual|2020-12-23|July 2023|2023-07-31|December 2024|Anticipated|2024-12-31|December 2024|Anticipated|2024-12-31||Interventional|||'Re-Priming' RT After Incomplete Response to CAR-T in R/R NHL|A Phase I/II Trial of 'Re-Priming' Radiation Therapy for Relapsed/Refractory Non-Hodgkin Lymphoma Patients in Incomplete Response After Chimeric Antigen Receptor T-cell (CAR-T) Therapy|Recruiting||Phase 1/Phase 2|20|Anticipated|University of Texas Southwestern Medical Center||1|||f||||t|f|f|||||||||||2023-09-01 20:26:35.912046|2023-09-01 20:26:35.912046|OTHER|||||
NCT05621486||2022-11-03|||2022-11-17|2022-11-17|2022-11-18|Actual|||||||2022-11-17|2022-11-18|Actual|September 14, 2022|Actual|2022-09-14|November 2022|2022-11-30|December 31, 2026|Anticipated|2026-12-31|December 31, 2024|Anticipated|2024-12-31||Interventional|||A Clinical Study to Evaluate B4T2-001 CAR T Cells in the Treatment of Advanced Solid Tumors|A FIH, Single Arm, Open Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Antitumor Activity of Autologous CAR T Cells Targeting BT-001 in Patients With Advanced Solid Tumors|Recruiting||Phase 1|36|Anticipated|Shanghai East Hospital||1|||f||||f|f|f|||||||||No||2023-08-31 18:40:08.177432|2023-08-31 18:40:08.177432|OTHER|||||
NCT04316624||2020-03-15|||2023-07-17|2020-03-18|2020-03-20|Actual|||||||2023-07-17|2023-07-19|Actual|September 29, 2019|Actual|2019-09-29|March 2020|2020-03-31|February 8, 2023|Actual|2023-02-08|February 8, 2023|Actual|2023-02-08||Interventional|||A Study of C-CAR066 in Subjects With r/r Diffuse Large B Cell Lymphoma Who Received CD19 CAR-T Therapy|A Study Evaluating Safety and Efficacy of CBM.CD20 CAR-T(C-CAR066) in Subjects With r/r Diffuse Large B Cell Lymphoma Who Received CD19 CAR-T Therapy|Completed||Phase 1|7|Actual|Institute of Hematology & Blood Diseases Hospital||1|||f||||f|f|f|||||||||No||2023-09-01 20:27:03.155611|2023-09-01 20:27:03.155611|OTHER|||||
NCT04036019||2019-07-08|||2023-07-17|2019-07-25|2019-07-29|Actual|||||||2023-07-17|2023-07-19|Actual|May 28, 2019|Actual|2019-05-28|July 2019|2019-07-31|June 20, 2022|Actual|2022-06-20|June 20, 2022|Actual|2022-06-20||Interventional|||A Study of C-CAR066 in Subjects With r/r B Cell Lymphoma Who Received CD19 CAR-T Therapy|A Study Evaluating Safety and Efficacy of CBM.CD20 CAR-T(C-CAR066) in Subjects With r/r B Cell Lymphoma Who Received CD19 CAR-T Therapy|Completed||Phase 1|14|Actual|Shanghai Tongji Hospital, Tongji University School of Medicine||1|||f|||||f|f|||||||||||2023-09-01 20:27:35.245091|2023-09-01 20:27:35.245091|OTHER|||||
NCT05404048||2022-05-05|||2022-07-15|2022-05-31|2022-06-03|Actual|||||||2022-07-15|2022-07-18|Actual|May 18, 2022|Actual|2022-05-18|July 2022|2022-07-31|May 2025|Anticipated|2025-05-31|May 2024|Anticipated|2024-05-31||Interventional|||PD-L1 PET-imaging During CAR T-cell Therapy|Programmed Death Ligand 1 (PD-L1)-PET Imaging in Patients With (Diffuse) Large B-cell Lymphoma Who Are Treated With CD19-directed CAR T-cell Therapy: a Pilot Study|Recruiting||Phase 2|20|Anticipated|University Medical Center Groningen||1|||f||||t|f|f|||||||||No||2023-09-03 13:32:54.10881|2023-09-03 13:32:54.10881|OTHER|||||
NCT04412174||2020-05-21|||2020-06-01|2020-06-01|2020-06-02|Actual|||||||2020-06-01|2020-06-02|Actual|June 2020|Anticipated|2020-06-30|May 2020|2020-05-31|December 2022|Anticipated|2022-12-31|December 2022|Anticipated|2022-12-31||Interventional|||A Study of GC022F CAR-T Cell Immunotherapy for Relapsed or Refractory B- NHL|A Study of GC022F CAR-T Cell Immunotherapy for Relapsed or Refractory B- NHL|Unknown status|Not yet recruiting|Early Phase 1|18|Anticipated|Hebei Yanda Ludaopei Hospital||1|||f||||f|f|f|||||||||||2023-09-04 14:00:30.915631|2023-09-04 14:00:30.915631|OTHER|||||
NCT05373147||2022-05-10|||2022-10-24|2022-05-10|2022-05-13|Actual|||||||2022-10-24|2022-10-26|Actual|October 30, 2020|Actual|2020-10-30|October 2022|2022-10-31|August 2023|Anticipated|2023-08-31|February 2023|Anticipated|2023-02-28||Interventional|||αPD1-MSLN-CAR T Cells for the Treatment of MSLN-positive Advanced Solid Tumors|An Exploratory Study of αPD1-MSLN-CAR T Cells Secreting PD-1 Nanobodies for the Treatment of MSLN-positive Advanced Solid Tumors|Recruiting||Early Phase 1|21|Anticipated|Shanghai Mengchao Cancer Hospital||1|||f||||f|f|f|||||||||||2023-09-01 21:01:22.54881|2023-09-01 21:01:22.54881|OTHER|||||
NCT02876978||2016-08-09|||2016-08-23|2016-08-23|2016-08-24|Estimate|||||||2016-08-23|2016-08-24|Estimate|March 2016||2016-03-31|August 2016|2016-08-31|April 2019|Anticipated|2019-04-30|October 2017|Anticipated|2017-10-31||Interventional|||Anti-GPC3 CAR T for Recurrent or Refractory Lung Squamous Cell Carcinoma|Preliminary Clinical Study of Autologous T Cells Modified Chimeric Antigen Receptor (CAR) Targeting GPC3 for the Treatment of Recurrent or Refractory Lung Squamous Cell Carcinoma|Unknown status|Recruiting|Phase 1|20|Anticipated|CARsgen Therapeutics Co., Ltd.||1|||f||||f|||||||||||No||2023-09-02 13:31:28.403463|2023-09-02 13:31:28.403463|INDUSTRY|||||
NCT04303520||2020-03-09|||2020-03-09|2020-03-09|2020-03-11|Actual|||||||2020-03-09|2020-03-11|Actual|May 3, 2018|Actual|2018-05-03|March 2020|2020-03-31|February 2021|Anticipated|2021-02-28|September 2020|Anticipated|2020-09-30||Interventional|||Anti-CD19/CD22 Bispecific CAR-T Cell Therapy for CD19-positive ALL|A Phase I Clinical Trial of T-Cells Targeting CD19 and CD22 for Subjects With CD19-positive Acute Lymphoblastic Leukemia|Unknown status|Recruiting|Phase 1|20|Anticipated|The Second Affiliated Hospital of Henan University of Traditional Chinese Medicine||1|||f||||t|f|f|||||||||Yes||2023-09-02 13:31:53.256825|2023-09-02 13:31:53.256825|OTHER|||||
NCT03085173||2017-03-15|||2023-04-06|2017-03-20|2017-03-21|Actual|||||||2023-04-06|2023-04-07|Actual|March 15, 2017|Actual|2017-03-15|April 2023|2023-04-30|March 2024|Anticipated|2024-03-31|March 2024|Anticipated|2024-03-31||Interventional|||"A Trial of Armored CAR T Cells Targeting CD19 For Patients With Relapsed CD19+ Hematologic Malignancies"|"A Phase I Trial of CD19-Targeted EGFRt/19-28z/4-1BBL Armored Chimeric Antigen Receptor (CAR) Modified T Cells in Patients With Relapsed or Refractory CD19+ Hematologic Malignancies"|Active, not recruiting||Phase 1|39|Actual|Memorial Sloan Kettering Cancer Center||1|||f|||||t|f|||||||||||2023-09-01 21:15:56.151707|2023-09-01 21:15:56.151707|OTHER|||||
NCT04514029||2020-08-12|||2022-11-02|2020-08-12|2020-08-14|Actual|||||||2022-11-02|2022-11-03|Actual|August 6, 2020|Actual|2020-08-06|November 2022|2022-11-30|December 2023|Anticipated|2023-12-31|December 2023|Anticipated|2023-12-31||Interventional|||Neurotoxicity Prophylaxis With Intrathecal Dexamethasone and Simvastatin Post Axi-Cel|Neurotoxicity Prophylaxis With Intrathecal Dexamethasone and Simvastatin in Adults Receiving Axicabtagene Ciloleucel (Axi-Cel) Treatment|Recruiting||Early Phase 1|20|Anticipated|Masonic Cancer Center, University of Minnesota||1|||f||||t|t|f|||||||||||2023-09-01 21:25:03.967938|2023-09-01 21:25:03.967938|OTHER|||||
NCT03754764||2018-11-24|||2018-12-05|2018-11-24|2018-11-27|Actual|||||||2018-12-05|2018-12-07|Actual|November 23, 2018|Actual|2018-11-23|December 2018|2018-12-31|November 23, 2022|Anticipated|2022-11-23|November 23, 2022|Anticipated|2022-11-23||Interventional|||A Feasibility and Safety Study of CD38 CAR-T Cell Immunotherapy for Relapsed B-cell Acute Lymphoblastic Leukemia After CD19 CAR-T Adoptive Cellular Immunotherapy|Phase I/II Study to Evaluate Treatment of Relapsed B-cell Acute Lymphoblastic Leukemia After CD19 CAR-T Adoptive Cellular Immunotherapy With CAR-T Cells Targeting CD38|Unknown status|Recruiting|Phase 1/Phase 2|80|Anticipated|Chinese PLA General Hospital|||||f||||f|f|f|||||||||Undecided||2023-09-03 13:45:46.296184|2023-09-03 13:45:46.296184|OTHER|||||
NCT05431608||2022-06-20|||2023-07-13|2022-06-20|2022-06-24|Actual|||||||2023-07-13|2023-07-14|Actual|June 20, 2022|Actual|2022-06-20|July 2023|2023-07-31|June 20, 2024|Anticipated|2024-06-20|June 20, 2024|Anticipated|2024-06-20||Interventional|||A Study of MCARH109 and MCARH125 in People With Multiple Myeloma|Phase I Trial of Concurrent Administration of GPRC5D-Targeted CAR T Cell MCARH109 and BCMA-Targeted CAR T Cell MCARH125 in Patients With Relapsed or Refractory Multiple Myeloma|Recruiting||Phase 1|24|Anticipated|Memorial Sloan Kettering Cancer Center||5||||||||t|f|||||||||Yes|Memorial Sloan Kettering Cancer Center supports the international committee of medical journal editors (ICMJE) and the ethical obligation of responsible sharing of data from clinical trials. The protocol summary, a statistical summary, and informed consent form will be made available on clinicaltrials.gov when required as a condition of Federal awards, other agreements supporting the research and/or as otherwise required. Requests for deidentified individual participant data can be made beginning 12 months after publication and for up to 36 months post publication. Deidentified individual participant data reported in the manuscript will be shared under the terms of a Data Use Agreement and may only be used for approved proposals. Requests may be made to: crdatashare@mskcc.org.|2023-08-31 19:12:47.158273|2023-08-31 19:12:47.158273|OTHER|||||
NCT05397496||2022-05-25|||2023-07-13|2022-05-25|2022-05-31|Actual|||||||2023-07-13|2023-07-14|Actual|October 3, 2022|Actual|2022-10-03|July 2023|2023-07-31|February 27, 2026|Anticipated|2026-02-27|February 28, 2025|Anticipated|2025-02-28||Interventional|||Study of PIT565 in Relapsed and/or Refractory B-cell Malignancies|A Phase I, Open-label, Multi-center Study of PIT565 in Patients With Relapsed and/or Refractory B-cell Malignancies|Recruiting||Phase 1|140|Anticipated|Novartis||5|||f||||f|t|f|||||||||No||2023-08-31 19:12:57.160049|2023-08-31 19:12:57.160049|INDUSTRY|||||
NCT04691284||2020-12-19|||2021-03-02|2020-12-30|2020-12-31|Actual|||||||2021-03-02|2021-03-03|Actual|March 1, 2021|Actual|2021-03-01|March 2021|2021-03-31|December 2024|Anticipated|2024-12-31|December 2023|Anticipated|2023-12-31||Interventional|SCTMICROBIOM||Microbiome in Cancer Patients With High Dose Chemotherapy With Stem Cell Transplantation|Microbiome in Cancer Patients Undergoing High Dose Chemotherapy With Stem Cell Transplantation|Recruiting||Not Applicable|100|Anticipated|National Cancer Institute, Slovakia||1|||f||||f|f|f|||||||||No||2023-09-01 21:52:52.528787|2023-09-01 21:52:52.528787|OTHER_GOV|||||
NCT04691713||2020-12-07|||2020-12-28|2020-12-28|2020-12-31|Actual|||||||2020-12-28|2020-12-31|Actual|September 1, 2019|Actual|2019-09-01|December 2020|2020-12-31|December 1, 2021|Anticipated|2021-12-01|February 26, 2021|Anticipated|2021-02-26||Interventional|||CD276 CAR-T for Patients With Advanced CD276+ Solid Tumors|CD276 CAR-T for Patients With Advanced CD276+ Solid Tumors|Unknown status|Recruiting|Not Applicable|5|Anticipated|PersonGen BioTherapeutics (Suzhou) Co., Ltd.||1|||f||||f|f|f|||||||||||2023-09-01 21:53:02.1855|2023-09-01 21:53:02.1855|INDUSTRY|||||
NCT05667506||2022-12-05|||2023-03-24|2022-12-19|2022-12-28|Actual|||||||2023-03-24|2023-03-27|Actual|February 7, 2023|Actual|2023-02-07|March 2023|2023-03-31|December 30, 2025|Anticipated|2025-12-30|June 30, 2024|Anticipated|2024-06-30||Interventional|||A Study of CNCT19 Treatment in Children and Adolescent r/r ALL Patients(Pediatric)|A Phase Ib/II, Single Arm, Multi-center Study Evaluating the Safety and Efficacy of CNCT19 in Children and Adolescent(Pediatric) Patients With Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia (r/r B-ALL)|Recruiting||Phase 1/Phase 2|47|Anticipated|Juventas Cell Therapy Ltd.||1|||f||||t|f|f|||||||||No|Currently the investigators have no plan of interim anaylsis, the investigators don't plan to share individual participant data(IPD) during the trial on-going.|2023-09-01 21:59:31.771397|2023-09-01 21:59:31.771397|INDUSTRY|||||
NCT05266950||2021-12-29|||2023-03-23|2022-02-23|2022-03-04|Actual|||||||2023-03-23|2023-03-27|Actual|December 14, 2021|Actual|2021-12-14|March 2023|2023-03-31|December 1, 2025|Anticipated|2025-12-01|December 1, 2024|Anticipated|2024-12-01||Interventional|||Safety and Efficacy Study of CI-135 CAR-T Cells in Subjects With Relapsed or Refractory Acute Myeloid Leukemia|First-in-Human (FIH), Open-Label, Non-Randomized, Single-Arm Phase 1 Study to Evaluate the Safety and Efficacy of CI-135 CAR-T Cells in Subjects With Relapsed or Refractory Acute Myeloid Leukemia|Recruiting||Phase 1|7|Anticipated|Beijing Boren Hospital||1|||f|||||f|f|||||||||No||2023-09-01 22:00:22.004424|2023-09-01 22:00:22.004424|OTHER|||||
NCT05098613||2021-10-06|||2023-03-24|2021-10-18|2021-10-28|Actual|||||||2023-03-24|2023-03-27|Actual|December 21, 2021|Actual|2021-12-21|March 2023|2023-03-31|December 2025|Anticipated|2025-12-31|December 2024|Anticipated|2024-12-31||Interventional|||Preliminary Safety and Tolerability of CD19x22 CAR T Cells in Adolescent and Adult R/R B-NHL Patients|Phase 1/1b Study of Bispecific CD19 and CD22 Chimeric Antigen Receptor Co-Expressing T Cells (CD19x22 CAR T) in Adolescent and Adult Patients With Relapsed and/or Refractory B-Non-Hodgkin's Lymphoma (B-NHL)|Recruiting||Phase 1|20|Anticipated|University of Colorado, Denver||1|||f||||t|t|f|||||||||Undecided||2023-09-01 22:00:43.146143|2023-09-01 22:00:43.146143|OTHER|||||
NCT04723914||2021-01-21|||2021-01-23|2021-01-23|2021-01-26|Actual|||||||2021-01-23|2021-01-26|Actual|October 20, 2020|Actual|2020-10-20|October 2020|2020-10-31|December 31, 2022|Anticipated|2022-12-31|December 31, 2022|Anticipated|2022-12-31||Interventional|CAR-T||Dual Target CAR-T Cells in B-cell Lymphoma|Clinical Trial of CD19/CD20 Dual Target CAR-T Cells in the Treatment of Relapsed/Refractory B-cell Lymphoma|Unknown status|Recruiting|Phase 1/Phase 2|20|Anticipated|Shenzhen University General Hospital||1|||f||||f|f|f|||||||||No|No plan|2023-09-01 22:06:17.786477|2023-09-01 22:06:17.786477|OTHER|||||
NCT02937844||2016-07-22|||2016-10-17|2016-10-17|2016-10-19|Estimate|||||||2016-10-17|2016-10-19|Estimate|July 2016||2016-07-31|October 2016|2016-10-31|July 2019|Anticipated|2019-07-31|July 2018|Anticipated|2018-07-31||Interventional|||Pilot Study of Autologous Chimeric Switch Receptor Modified T Cells in Recurrent Glioblastoma Multiforme|A Safety and Efficacy Study of Autologous Chimeric Switch Receptor Engineered T Cells Redirected to PD-L1 in Patients With Recurrent Glioblastoma Multiforme|Unknown status|Recruiting|Phase 1|20|Anticipated|Beijing Sanbo Brain Hospital||1|||f||||f|||||||||||Undecided||2023-09-01 22:08:41.652382|2023-09-01 22:08:41.652382|OTHER|||||
NCT02937103||2016-10-14|||2019-06-23|2016-10-14|2016-10-18|Estimate|||||||2019-06-23|2019-06-25|Actual|October 2016||2016-10-31|June 2019|2019-06-30|October 2020|Anticipated|2020-10-31|October 2019|Anticipated|2019-10-31||Interventional|||A Clinical Research of CD123-Targeted CAR-T in Myeloid Malignancies|A Clinical Research of CD123-Targeted CAR-T in Myeloid Malignancies|Unknown status|Recruiting|Phase 1/Phase 2|45|Anticipated|Southwest Hospital, China||1|||f||||f|||||||||||Undecided||2023-09-01 22:08:55.051532|2023-09-01 22:08:55.051532|OTHER|||||
NCT02935153||2016-10-14|||2019-06-23|2016-10-14|2016-10-17|Estimate|||||||2019-06-23|2019-06-25|Actual|October 2016||2016-10-31|June 2019|2019-06-30|October 2020|Anticipated|2020-10-31|October 2019|Anticipated|2019-10-31||Interventional|||A Clinical Research of CD22-Targeted CAR-T in B Cell Malignancies|A Clinical Research of CD22-Targeted CAR-T in B Cell Malignancies|Unknown status|Recruiting|Phase 1/Phase 2|45|Anticipated|Southwest Hospital, China||1|||f||||f|||||||||||Undecided||2023-09-01 22:09:34.100657|2023-09-01 22:09:34.100657|OTHER|||||
NCT02919046||2016-09-26|||2017-03-13|2016-09-27|2016-09-29|Estimate|||||||2017-03-13|2017-03-14|Actual|September 2016||2016-09-30|March 2017|2017-03-31|September 2020|Anticipated|2020-09-30|September 2020|Anticipated|2020-09-30||Interventional|||Study Evaluating the Efficacy and Safety With CAR-T for Relapsed or Refractory Neuroblastoma in Children|Single Arm and Multicenter Clinical Trial to Evaluating the Efficacy and Safety of the Chimeric Antigen Receptor T Cell Immunotherapy (CAR-T) for Relapsed or Refractory Neuroblastoma in Children|Unknown status|Recruiting|Not Applicable|22|Anticipated|Sinobioway Cell Therapy Co., Ltd.||1|||f||||f|||||||||||No||2023-09-01 22:13:28.781593|2023-09-01 22:13:28.781593|INDUSTRY|||||
NCT05415475||2022-06-09|||2022-07-19|2022-06-09|2022-06-13|Actual|||||||2022-07-19|2022-07-22|Actual|September 10, 2021|Actual|2021-09-10|June 2022|2022-06-30|September 15, 2024|Anticipated|2024-09-15|September 15, 2023|Anticipated|2023-09-15||Interventional|||Clinical Study of CEA-targeted CAR-T Therapy for CEA-positive Advanced Malignant Solid Tumors|A Safety and Efficacy Clinical Study of CEA-targeted CAR-T Therapy for CEA-positive Advanced Malignant Solid Tumors|Recruiting||Phase 1|36|Anticipated|Chongqing Precision Biotech Co., Ltd||2|||f|||||f|f|||||||||||2023-09-01 22:28:02.104731|2023-09-01 22:28:02.104731|INDUSTRY|||||
NCT02706405||2016-02-24|2022-05-06||2022-08-01|2016-03-07|2016-03-11|Estimate|2022-08-01|2022-08-24|Actual||||2022-08-01|2022-08-24|Actual|November 15, 2016|Actual|2016-11-15|August 2022|2022-08-31|May 28, 2021|Actual|2021-05-28|May 28, 2021|Actual|2021-05-28||Interventional|||JCAR014 and Durvalumab in Treating Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma|A Phase 1b Study of JCAR014, Autologous T Cells Engineered to Express a CD19-Specific Chimeric Antigen Receptor, in Combination With Durvalumab (MEDI4736) for Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma|Terminated||Phase 1|30|Actual|Fred Hutchinson Cancer Center||8||Terminated due to slow accrual.|f||||t|t|f|||||||||||2023-09-04 14:11:51.027842|2023-09-04 14:11:51.027842|OTHER|||||
NCT05075603||2021-09-13|||2023-04-07|2021-10-09|2021-10-13|Actual|||||||2023-04-07|2023-04-11|Actual|August 6, 2021|Actual|2021-08-06|April 2023|2023-04-30|February 2026|Anticipated|2026-02-28|November 2024|Anticipated|2024-11-30||Interventional|||Relapsed/Refractory Large B-cell Lymphoma With NT-I7 Post-CD19 CAR T-cell Therapy|A Phase 1b Study Evaluating the Safety, Tolerability and Preliminary Anti-tumor Activity of NT-I7 (Efineptakin Alfa) a Long-acting Human IL-7, Post-Kymriah® (Tisagenlecleucel), Post-Yescarta® (Axicabtagene Ciloleucel), or Post-Breyanzi® (Lisocabtagene Maraleucel) in Subjects With Relapsed/Refractory Large B-cell Lymphoma|Recruiting||Phase 1|57|Anticipated|NeoImmuneTech||1|||f||||t|t|f|||||||||||2023-09-01 22:30:41.917292|2023-09-01 22:30:41.917292|INDUSTRY|||||
NCT02873390||2016-08-15|||2016-10-06|2016-08-16|2016-08-19|Estimate|||||||2016-10-06|2016-10-07|Estimate|August 2016||2016-08-31|August 2016|2016-08-31|July 2018|Anticipated|2018-07-31|March 2018|Anticipated|2018-03-31||Interventional|||PD-1 Antibody Expressing CAR-T Cells for EGFR Family Member Positive Advanced Solid Tumor|A Clinical Study of PD-1 Antibody Expressing CAR-T Cells for EGFR Family Member Positive Advanced Solid Tumor|Unknown status|Recruiting|Phase 1/Phase 2|20|Anticipated|Ningbo Cancer Hospital||1|||f||||f|||||||||||No||2023-09-02 13:54:30.587688|2023-09-02 13:54:30.587688|INDUSTRY|||||
NCT02663297||2016-01-17|||2023-01-04|2016-01-21|2016-01-26|Estimate|||||||2023-01-04|2023-01-05|Actual|July 15, 2016|Actual|2016-07-15|January 2023|2023-01-31|January 2037|Anticipated|2037-01-31|January 15, 2021|Actual|2021-01-15||Interventional|||Administration of T Lymphocytes for Prevention of Relapse of Lymphomas|Phase I Study of the Administration of T Lymphocytes Expressing the CD30 Chimeric Antigen Receptor (CAR) for Prevention of Relapse of CD30+ Lymphomas After High Dose Therapy and Autologous Stem Transplantation (ATLAS)|Active, not recruiting||Phase 1|18|Actual|UNC Lineberger Comprehensive Cancer Center||1|||f||||t|t|f|||||||||No||2023-08-31 19:31:37.009672|2023-08-31 19:31:37.009672|OTHER|||||
NCT02159495||2014-06-06|||2023-01-04|2014-06-06|2014-06-10|Estimate|||||||2023-01-04|2023-01-05|Actual|December 15, 2015|Actual|2015-12-15|January 2023|2023-01-31|June 15, 2023|Anticipated|2023-06-15|June 15, 2023|Anticipated|2023-06-15||Interventional|||Genetically Modified T-cell Immunotherapy in Treating Patients With Relapsed/Refractory Acute Myeloid Leukemia and Persistent/Recurrent Blastic Plasmacytoid Dendritic Cell Neoplasm|Phase I Study of Cellular Immunotherapy Using T Cells Lentivirally Transduced to Express a CD123-Specific, Hinge-Optimized, CD28-Costimulatory Chimeric Antigen Receptor and a Truncated EGFR for Patients With CD123+ Relapsed/Refractory Acute Myeloid Leukemia and Persistent/Recurrent Blastic Plasmacytoid Dendritic Cell Neoplasm|Active, not recruiting||Phase 1|31|Actual|City of Hope Medical Center||1|||f||||t|||||||||||||2023-08-31 19:31:55.038323|2023-08-31 19:31:55.038323|OTHER|||||
NCT03179007||2017-06-05|||2017-06-05|2017-06-05|2017-06-07|Actual|||||||2017-06-05|2017-06-07|Actual|June 7, 2017|Anticipated|2017-06-07|June 2017|2017-06-30|April 20, 2019|Anticipated|2019-04-20|January 20, 2019|Anticipated|2019-01-20||Interventional|||CTLA-4 and PD-1 Antibodies Expressing MUC1-CAR-T Cells for MUC1 Positive Advanced Solid Tumor|A Clinical Study of CTLA-4 and PD-1 Antibodies Expressing MUC1-CAR-T Cells for Patients With MUC1 Positive Advanced Solid Tumors|Unknown status|Recruiting|Phase 1/Phase 2|40|Anticipated|Shanghai Cell Therapy Research Institute||1|||f||||f|f|f|||||||||No||2023-09-04 14:13:05.320949|2023-09-04 14:13:05.320949|OTHER|||||
NCT02761915||2016-02-24|2021-06-15||2021-07-23|2016-05-03|2016-05-04|Estimate|2021-07-23|2021-08-17|Actual||||2021-07-23|2021-08-17|Actual|February 29, 2016|Actual|2016-02-29|July 2021|2021-07-31|December 16, 2020|Actual|2020-12-16|December 16, 2020|Actual|2020-12-16||Interventional|||A Phase I Trial of Anti-GD2 T-cells (1RG-CART)|A Cancer Research UK Phase I Trial of Anti-GD2 Chimeric Antigen Receptor (CAR) Transduced T-cells (1RG-CART) in Patients With Relapsed or Refractory Neuroblastoma|Completed||Phase 1|17|Actual|Cancer Research UK||6|||f||||f|f|f|||||||||No||2023-09-04 14:13:17.298284|2023-09-04 14:13:17.298284|OTHER|||||
NCT03768310||2018-11-20|||2022-07-19|2018-12-05|2018-12-07|Actual|||||||2022-07-19|2022-07-21|Actual|June 2022|Anticipated|2022-06-30|July 2022|2022-07-31|August 2040|Anticipated|2040-08-31|August 2025|Anticipated|2025-08-31||Interventional|||CD19.CAR-multiVSTs for Patients With CD19+ B-ALL or NHL Undergoing Related Allogeneic HSCT (CARMA)|Phase I Study of the Administration of CD19 Chimeric Antigen Receptor Multivirus-Specific Cytotoxic T Lymphocytes for Prophylaxis or Therapy of Relapse of CD19 Positive Malignancies After Allogeneic Hematopoietic Stem Cell Transplantation|Withdrawn||Phase 1|0|Actual|Baylor College of Medicine||2||We decided to move on to another product and as a result will not be moving forward with this study.|f||||t|t|f|||||||||||2023-09-01 22:36:26.754833|2023-09-01 22:36:26.754833|OTHER|||||
NCT05022849||2021-08-20|||2023-08-15|2021-08-20|2021-08-26|Actual|||||||2023-08-15|2023-08-16|Actual|September 28, 2021|Actual|2021-09-28|August 2023|2023-08-31|June 30, 2037|Anticipated|2037-06-30|July 3, 2024|Anticipated|2024-07-03||Interventional|||A Study of JNJ-75229414 for Metastatic Castration-resistant Prostate Cancer Participants|A Phase 1, Dose Escalation Study of JNJ-75229414, a Chimeric Antigen Receptor T Cell (CAR-T) Therapy Directed Against KLK2 for Metastatic Castration-Resistant Prostate Cancer|Active, not recruiting||Phase 1|15|Actual|Janssen Research & Development, LLC||2|||f||||f|t|f||||||||https://www.janssen.com/clinical-trials/transparency|Yes|The data sharing policy of the Janssen Pharmaceutical Companies of Johnson & Johnson is available at www.janssen.com/clinical-trials/transparency. As noted on this site, requests for access to the study data can be submitted through Yale Open Data Access (YODA) Project site at yoda.yale.edu|2023-09-01 22:46:07.882638|2023-09-01 22:46:07.882638|INDUSTRY|||||
NCT04923893||2021-06-10|||2023-08-15|2021-06-10|2021-06-11|Actual|||||||2023-08-15|2023-08-16|Actual|August 19, 2021|Actual|2021-08-19|August 2023|2023-08-31|January 16, 2034|Anticipated|2034-01-16|June 11, 2026|Anticipated|2026-06-11||Interventional|CARTITUDE-5||A Study of Bortezomib, Lenalidomide and Dexamethasone (VRd) Followed by Cilta-cel, a CAR-T Therapy Directed Against BCMA Versus VRd Followed by Lenalidomide and Dexamethasone (Rd) Therapy in Participants With Newly Diagnosed Multiple Myeloma for Whom ASCT is Not Planned as Initial Therapy|A Phase 3 Randomized Study Comparing Bortezomib, Lenalidomide and Dexamethasone (VRd) Followed by Ciltacabtagene Autoleucel, a Chimeric Antigen Receptor T Cell (CAR-T) Therapy Directed Against BCMA Versus Bortezomib, Lenalidomide, and Dexamethasone (VRd) Followed by Lenalidomide and Dexamethasone (Rd) Therapy in Participants With Newly Diagnosed Multiple Myeloma for Whom Hematopoietic Stem Cell Transplant is Not Planned as Initial Therapy|Recruiting||Phase 3|650|Anticipated|Janssen Research & Development, LLC||2|||t||||t|t|f||||||||https://www.janssen.com/clinical-trials/transparency|Yes|The data sharing policy of the Janssen Pharmaceutical Companies of Johnson & Johnson is available at www.janssen.com/clinical-trials/transparency. As noted on this site, requests for access to the study data can be submitted through Yale Open Data Access (YODA) Project site at yoda.yale.edu|2023-09-01 22:46:30.85002|2023-09-01 22:46:30.85002|INDUSTRY||NCT05346835|Available||
NCT04662099||2020-12-03|||2023-08-15|2020-12-03|2020-12-10|Actual|||||||2023-08-15|2023-08-16|Actual|March 25, 2020|Actual|2020-03-25|August 2023|2023-08-31|December 30, 2023|Anticipated|2023-12-30|December 30, 2023|Anticipated|2023-12-30||Interventional|||T Cells Expressing a Bispecific CAR Targeting CS1 and BCMA in Relapsed/Refractory Multiple Myeloma|Safety and Efficacy of the Bispecific CAR T Therapy Targeting CS1 and BCMA in Patients With Relapsed/ Refractory Multiple Myeloma: a Single-center, Open-label, Single-arm Clinical Study|Recruiting||Phase 1|24|Anticipated|Wuhan Union Hospital, China||1|||f|||||f|f|||f||||||No||2023-09-01 22:47:25.953626|2023-09-01 22:47:25.953626|OTHER|||||
NCT03013712||2017-01-03|||2017-01-04|2017-01-04|2017-01-06|Estimate|||||||2017-01-04|2017-01-06|Estimate|January 2017||2017-01-31|January 2017|2017-01-31|December 2020|Anticipated|2020-12-31|December 2018|Anticipated|2018-12-31||Interventional|CARTEPC||A Clinical Research of CAR T Cells Targeting EpCAM Positive Cancer|A Clinical Research of CAR T Cells Targeting EpCAM Positive Cancer|Unknown status|Recruiting|Phase 1/Phase 2|60|Anticipated|First Affiliated Hospital of Chengdu Medical College||1|||f||||t|||||||||||No||2023-08-31 19:43:40.774763|2023-08-31 19:43:40.774763|OTHER|||||
NCT04181827||2019-11-27|||2023-08-15|2019-11-27|2019-12-02|Actual|||||||2023-08-15|2023-08-16|Actual|June 12, 2020|Actual|2020-06-12|August 2023|2023-08-31|June 30, 2027|Anticipated|2027-06-30|April 10, 2026|Anticipated|2026-04-10||Interventional|CARTITUDE-4||A Study Comparing JNJ-68284528, a CAR-T Therapy Directed Against B-cell Maturation Antigen (BCMA), Versus Pomalidomide, Bortezomib and Dexamethasone (PVd) or Daratumumab, Pomalidomide and Dexamethasone (DPd) in Participants With Relapsed and Lenalidomide-Refractory Multiple Myeloma|A Phase 3 Randomized Study Comparing JNJ-68284528, a Chimeric Antigen Receptor T Cell (CAR-T) Therapy Directed Against BCMA, Versus Pomalidomide, Bortezomib and Dexamethasone (PVd) or Daratumumab, Pomalidomide and Dexamethasone (DPd) in Subjects With Relapsed and Lenalidomide-Refractory Multiple Myeloma|Active, not recruiting||Phase 3|419|Actual|Janssen Research & Development, LLC||2|||t||||t|t|f||||||||https://www.janssen.com/clinical-trials/transparency|Yes|The data sharing policy of the Janssen Pharmaceutical Companies of Johnson & Johnson is available at www.janssen.com/clinical-trials/transparency. As noted on this site, requests for access to the study data can be submitted through Yale open Data Access (YODA) Project site at yoda.yale.edu|2023-09-01 22:49:21.135366|2023-09-01 22:49:21.135366|INDUSTRY||NCT05346835|Available||
NCT04133636||2019-10-18|||2023-08-15|2019-10-18|2019-10-21|Actual|||||||2023-08-15|2023-08-16|Actual|November 7, 2019|Actual|2019-11-07|August 2023|2023-08-31|May 30, 2025|Anticipated|2025-05-30|May 30, 2025|Anticipated|2025-05-30||Interventional|CARTITUDE-2||A Study of JNJ-68284528, a Chimeric Antigen Receptor T Cell (CAR-T) Therapy Directed Against B-cell Maturation Antigen (BCMA) in Participants With Multiple Myeloma|A Phase 2, Multicohort Open-Label Study of JNJ-68284528, a Chimeric Antigen Receptor T Cell (CAR-T) Therapy Directed Against BCMA in Subjects With Multiple Myeloma|Active, not recruiting||Phase 2|169|Actual|Janssen Research & Development, LLC||1|||t||||t|t|f||||||||https://www.janssen.com/clinical-trials/transparency|Yes|"The data sharing policy of the Janssen Pharmaceutical Companies of Johnson & Johnson is available at www.janssen.com/clinical-trials/transparency.~As noted on this site, requests for access to the study data can be submitted through Yale Open Data Access (YODA) Project site at yoda.yale.edu"|2023-09-01 22:49:29.502615|2023-09-01 22:49:29.502615|INDUSTRY||NCT05346835|Available||
NCT01430390||2011-09-06|||2023-08-15|2011-09-07|2011-09-08|Estimate|||||||2023-08-15|2023-08-16|Actual|September 2011||2011-09-30|August 2023|2023-08-31|September 2026|Anticipated|2026-09-30|September 2026|Anticipated|2026-09-30||Interventional|||In Vitro Expanded Allogeneic Epstein-Barr Virus Specific Cytotoxic T-Lymphocytes (EBV-CTLs) Genetically Targeted to the CD19 Antigen in B-cell Malignancies|A Phase I Trial Using In Vitro Expanded Allogeneic Epstein-Barr Virus Specific Cytotoxic T-Lymphocytes (EBV-CTLs) Genetically Targeted to the CD19 Antigen in B-cell Malignancies|Active, not recruiting||Phase 1|19|Actual|Memorial Sloan Kettering Cancer Center||1|||f|||||||||||||||||2023-09-01 22:53:04.565953|2023-09-01 22:53:04.565953|OTHER|||||
NCT02729493||2016-03-23|||2017-03-13|2016-03-31|2016-04-06|Estimate|||||||2017-03-13|2017-03-15|Actual|November 14, 2015|Actual|2015-11-14|March 2017|2017-03-31|November 2019|Anticipated|2019-11-30|November 2019|Anticipated|2019-11-30||Interventional|EECLC||Study Evaluating the Efficacy and Safety With CAR-T for Liver Cancer|Single Arm,Two Phase,Multicenter Trial to Evaluating the Efficacy and Safety of the CAR-T for Liver Cancer|Unknown status|Recruiting|Not Applicable|25|Anticipated|Sinobioway Cell Therapy Co., Ltd.||1|||f||||t|||||||||||No|No plans to share data.|2023-09-02 14:04:03.976771|2023-09-02 14:04:03.976771|INDUSTRY|||||
NCT04723901||2021-01-21|||2021-01-23|2021-01-23|2021-01-26|Actual|||||||2021-01-23|2021-01-26|Actual|October 20, 2020|Actual|2020-10-20|January 2021|2021-01-31|December 31, 2022|Anticipated|2022-12-31|December 31, 2022|Anticipated|2022-12-31||Interventional|CAR-T||Dual Target CAR-T Cells in B-cell Acute Lymphoblastic Leukemia|Clinical Trial of CD19/CD22 Dual Target CAR-T Cells in the Treatment of Relapsed/Refractory B-cell Acute Lymphoblastic Leukemia|Unknown status|Recruiting|Phase 1/Phase 2|20|Anticipated|Shenzhen University General Hospital||1|||f||||f|f|f|||||||||No|no intention|2023-09-01 22:59:30.988353|2023-09-01 22:59:30.988353|OTHER|||||
NCT02725125||2016-03-25|||2017-03-21|2016-03-30|2016-03-31|Estimate|||||||2017-03-21|2017-03-23|Actual|November 2015||2015-11-30|March 2017|2017-03-31|November 2019|Anticipated|2019-11-30|November 2019|Anticipated|2019-11-30||Interventional|EECSC||Study Evaluating the Efficacy and Safety With CAR-T for Stomach Cancer|Single-arm,Two Phase,Multicenter Trial to Evaluating the Efficacy and Safety of the CAR-T for Stomach Cancer|Unknown status|Recruiting|Not Applicable|19|Anticipated|Sinobioway Cell Therapy Co., Ltd.||1|||f||||t|||||||||||No|No plans to share data.|2023-09-02 14:06:17.828038|2023-09-02 14:06:17.828038|INDUSTRY|||||
NCT05544526||2022-09-13|||2023-05-12|2022-09-15|2022-09-16|Actual|||||||2023-05-12|2023-05-15|Actual|May 30, 2023|Anticipated|2023-05-30|May 2023|2023-05-31|December 2039|Anticipated|2039-12-31|December 2025|Anticipated|2025-12-31||Interventional|CARMIGO||CAR T Cells to Target GD2 for DMG|Chimeric Antigen Receptor (CAR)-T Cells to Target GD2 for Diffuse Midline Glioma|Not yet recruiting||Phase 1|12|Anticipated|University College, London||1|||f||||t|f|f|||||||||No||2023-08-31 19:54:10.512577|2023-08-31 19:54:10.512577|OTHER|||||
NCT04655677||2020-09-25|||2020-11-30|2020-11-30|2020-12-07|Actual|||||||2020-11-30|2020-12-07|Actual|August 25, 2020|Actual|2020-08-25|July 2020|2020-07-31|October 2022|Anticipated|2022-10-31|July 2022|Anticipated|2022-07-31||Interventional|||A Study of EXP039 Treatment in Subjects With r/r NHL Subjects|A Phase 1 Study Evaluating Safety and Efficacy of EXP039 Treatment in Subjects With Relapsed and/or Refractory NHL|Unknown status|Recruiting|Phase 1|10|Anticipated|Peking Union Medical College Hospital||1|||f||||f|f|f|||||||||No||2023-09-01 23:08:24.726157|2023-09-01 23:08:24.726157|OTHER|||||
NCT04653649||2020-11-18|||2020-11-30|2020-11-30|2020-12-04|Actual|||||||2020-11-30|2020-12-04|Actual|September 29, 2020|Actual|2020-09-29|November 2020|2020-11-30|December 30, 2023|Anticipated|2023-12-30|December 30, 2023|Anticipated|2023-12-30||Interventional|||CAR T-cells Against CD30 (HSP-CAR30) for Relapsed/ Refractory Hodgkin and T-cell Lymphoma.|Immunotherapy With Autologous CAR30 T Cells for Patients With Classic Hodgkin Lymphoma and Non-Hodgkin T-cell Lymphoma With CD30 Expression.|Recruiting||Phase 1/Phase 2|30|Anticipated|Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau||1|||f||||t|f|f|||||||||No||2023-09-01 23:08:58.176493|2023-09-01 23:08:58.176493|OTHER|||||
NCT04653493||2020-11-22|||2021-03-17|2020-11-28|2020-12-04|Actual|||||||2021-03-17|2021-03-19|Actual|August 2021|Anticipated|2021-08-31|March 2021|2021-03-31|August 2024|Anticipated|2024-08-31|August 2024|Anticipated|2024-08-31||Interventional|||CD19 Targeted CAR T Cell Therapy in Patients With Relapsed/ Refractory B Cell Acute Lymphoblastic Leukaemia (ALL)|Phase I Clinical Trial Evaluating Safety of CD19 CAR-T Cells in Patients With Relapsed or Refractory Acute B-cell Lymphoblastic Leukemia (R/R B-ALL)|Not yet recruiting||Phase 1|22|Anticipated|Sabz Biomedicals||1|||f||||t|f|f|||||||||Undecided||2023-09-01 23:08:59.879888|2023-09-01 23:08:59.879888|INDUSTRY|||||
NCT04650724||2020-11-25|||2020-11-25|2020-11-25|2020-12-03|Actual|||||||2020-11-25|2020-12-03|Actual|October 11, 2018|Actual|2018-10-11|November 2020|2020-11-30|October 1, 2020|Actual|2020-10-01|December 20, 2018|Actual|2018-12-20||Interventional|||Clinical Study of T Cell Infusion Targeting BCMA Chimeric Antigen Receptor|Single Arm, Single Center, Open Label Clinical Trial of BCMA Autologous Chimeric Antigen Receptor T Cell Infusion in Patients With BCMA Positive Recurrent or Refractory Multiple Myeloma|Completed||Early Phase 1|3|Actual|PersonGen BioTherapeutics (Suzhou) Co., Ltd.||1|||f||||f|f|f|||||||||Undecided||2023-09-01 23:09:37.202847|2023-09-01 23:09:37.202847|INDUSTRY|||||
NCT02710149||2015-11-08|||2019-06-24|2016-03-11|2016-03-16|Estimate|||||||2019-06-24|2019-06-25|Actual|March 2016||2016-03-31|June 2019|2019-06-30|March 2021|Anticipated|2021-03-31|March 2020|Anticipated|2020-03-31||Interventional|||A Clinical Research of CD20-Targeted CAR-T in B Cell Malignancies|A Clinical Research of CD20-Targeted CAR-T in B Cell Malignancies|Unknown status|Recruiting|Phase 1/Phase 2|45|Anticipated|Southwest Hospital, China||1|||f||||f|||||||||||Undecided||2023-09-02 14:10:43.012395|2023-09-02 14:10:43.012395|OTHER|||||
NCT04637503||2020-10-16|||2020-11-18|2020-11-18|2020-11-19|Actual|||||||2020-11-18|2020-11-19|Actual|November 18, 2020|Anticipated|2020-11-18|November 2020|2020-11-30|December 31, 2023|Anticipated|2023-12-31|November 19, 2020|Actual|2020-11-19||Interventional|||4SCAR-T Therapy Targeting GD2, PSMA and CD276 for Treating Neuroblastoma|Multi-center Phase I/II Clinical Trial of 4SCAR-T Therapy Targeting GD2, PSMA and CD276 for Treating Neuroblastoma|Recruiting||Phase 1/Phase 2|100|Anticipated|Shenzhen Geno-Immune Medical Institute||1|||f||||f|f|f|||||||||No||2023-09-01 23:10:17.241588|2023-09-01 23:10:17.241588|OTHER|||||
NCT04637269||2020-11-12|||2020-11-14|2020-11-14|2020-11-19|Actual|||||||2020-11-14|2020-11-19|Actual|November 17, 2020|Anticipated|2020-11-17|November 2020|2020-11-30|November 1, 2023|Anticipated|2023-11-01|November 1, 2021|Anticipated|2021-11-01||Interventional|||Anti-BCMA CAR-T Cell Therapy for the R/R Multiple Myeloma|Anti-BCMA CAR-T Cell Therapy for the Relapsed or Refractory Multiple Myeloma: a Multi-center, Uncontrolled Trial.|Recruiting||Early Phase 1|16|Anticipated|Xinqiao Hospital of Chongqing||1|||f||||t|f|f|||||||||||2023-09-01 23:10:27.590181|2023-09-01 23:10:27.590181|OTHER|||||
NCT03602612||2018-07-26|2023-03-29||2023-04-24|2018-07-26|2018-07-27|Actual|2023-04-24|2023-05-15|Actual||||2023-04-24|2023-05-15|Actual|September 14, 2018|Actual|2018-09-14|April 2023|2023-04-30|January 1, 2024|Anticipated|2024-01-01|January 1, 2023|Actual|2023-01-01||Interventional||Baseline data collected for two participants enrolled but not treated is reported here.|T Cells Expressing a Novel Fully-Human Anti-BCMA CAR for Treating Multiple Myeloma|A Phase I Clinical Trial of T Cells Expressing a Novel Fully-human Anti-BCMA CAR for Treating Multiple Myeloma|Active, not recruiting||Phase 1|35|Actual|National Institutes of Health Clinical Center (CC)||2|||f||||f|t|f||||||Clinical data will be available during the study and indefinitely.|Clinical data will be made available via subscription to Biomedical Translational Research Information System (BTRIS) and with the permission of the study principal investigator (PI).||Yes|All individual participant data (IPD) recorded in the medical record will be shared with intramural investigators upon request.|2023-08-31 19:57:12.946289|2023-08-31 19:57:12.946289|NIH|||||
NCT03500991||2018-03-21|||2022-12-14|2018-04-09|2018-04-18|Actual|||||||2022-12-14|2022-12-19|Actual|July 26, 2018|Actual|2018-07-26|December 2022|2022-12-31|July 26, 2039|Anticipated|2039-07-26|July 26, 2024|Anticipated|2024-07-26||Interventional|||HER2-specific CAR T Cell Locoregional Immunotherapy for HER2-positive Recurrent/Refractory Pediatric CNS Tumors|Phase 1 Study of HER2-Specific CAR T Cell Locoregional Immunotherapy for HER2 Positive Recurrent/Refractory Pediatric Central Nervous System Tumors|Recruiting||Phase 1|48|Anticipated|Seattle Children's Hospital||2|||f||||t|t|f|||||||||No||2023-09-02 14:13:29.807119|2023-09-02 14:13:29.807119|OTHER|||||
NCT04107142||2019-09-21|||2019-09-26|2019-09-26|2019-09-27|Actual|||||||2019-09-26|2019-09-27|Actual|December 1, 2019|Anticipated|2019-12-01|September 2019|2019-09-30|March 1, 2021|Anticipated|2021-03-01|September 1, 2020|Anticipated|2020-09-01||Interventional|||Haplo / Allogeneic NKG2DL-targeting Chimeric Antigen Receptor-grafted γδ T Cells for Relapsed or Refractory Solid Tumour|A Phase I Dose-escalation Trial to Evaluate Haploidentical / Allogeneic Natural Killer Group 2D Ligand (NKG2DL)-Targeting Chimeric Antigen Receptor-grafted Gamma Delta (γδ) T Cells (CTM-N2D) in Subjects With Relapsed or Refractory Solid Tumour|Unknown status|Not yet recruiting|Phase 1|10|Anticipated|CytoMed Therapeutics Pte Ltd||1|||f||||f|f|f|||||||||No||2023-09-02 14:19:23.198382|2023-09-02 14:19:23.198382|INDUSTRY|||||
NCT02050347||2014-01-29|||2023-02-14|2014-01-29|2014-01-30|Estimate|||||||2023-02-14|2023-02-16|Actual|April 2014||2014-04-30|February 2023|2023-02-28|February 2024|Anticipated|2024-02-29|December 2023|Anticipated|2023-12-31||Interventional|CARPASCIO||Activated T Lymphocytes Expressing CARs, Relapsed CD19+ Malignancies Post-Allo HSCT(CARPASCIO)|Phase I Study of Activated T Lymphocytes Expressing Chimeric Antigen Receptors for Therapy of Relapsed CD19-Positive Malignancies Post-Allogeneic Hematopoietic Stem Cell Transplantation Infused Only After Engraftment (CARPASCIO)|Recruiting||Phase 1|40|Anticipated|Baylor College of Medicine||4|||f||||t|||||||||||||2023-08-31 20:10:12.232164|2023-08-31 20:10:12.232164|OTHER|||||
NCT03287817||2017-09-11|||2022-10-19|2017-09-18|2017-09-19|Actual|||||||2022-10-19|2022-10-20|Actual|September 5, 2017|Actual|2017-09-05|October 2022|2022-10-31|November 2024|Anticipated|2024-11-30|November 2024|Anticipated|2024-11-30||Interventional|ALEXANDER||CD19/22 CAR T Cells (AUTO3) for the Treatment of Diffuse Large B Cell Lymphoma|A Single Arm, Open-label, Multi-centre, Phase I/II Study Evaluating the Safety and Clinical Activity of AUTO3, a CAR T Cell Treatment Targeting CD19 and CD22 With Anti PD1 Antibody in Patients With Relapsed or Refractory Diffuse Large B Cell Lymphoma|Active, not recruiting||Phase 1/Phase 2|73|Actual|Autolus Limited||1|||f||||t|t|f|||||||||||2023-08-31 20:13:01.037993|2023-08-31 20:13:01.037993|INDUSTRY|||||
NCT02917083||2016-09-23|||2023-03-06|2016-09-26|2016-09-28|Estimate|||||||2023-03-06|2023-03-08|Actual|May 8, 2017|Actual|2017-05-08|March 2023|2023-03-31|February 2040|Anticipated|2040-02-29|April 2026|Anticipated|2026-04-30||Interventional|RELY-30||CD30 CAR T Cells, Relapsed CD30 Expressing Lymphoma (RELY-30)|Phase I Study of Relapsed CD30 Expressing Lymphoma Treated With CD30 CAR T Cells (RELY-30)|Recruiting||Phase 1|60|Anticipated|Baylor College of Medicine||1|||f||||t|t|f|||||||||||2023-09-02 14:23:46.121108|2023-09-02 14:23:46.121108|OTHER|||||
NCT05445765||2022-06-30|||2022-06-30|2022-06-30|2022-07-06|Actual|||||||2022-06-30|2022-07-06|Actual|July 1, 2022|Anticipated|2022-07-01|June 2022|2022-06-30|June 30, 2024|Anticipated|2024-06-30|June 30, 2024|Anticipated|2024-06-30||Interventional|||Anti-CD33 CAR-T Cells for the Treatment of Relapsed/Refractory CD33+ Acute Myeloid Leukemia|Anti-CD33 CAR-T Cells for the Treatment of Relapsed/Refractory CD33+ Acute Myeloid Leukemia|Not yet recruiting||Phase 1|10|Anticipated|iCell Gene Therapeutics||1|||f|||||f|f|||||||||||2023-08-31 20:15:12.497066|2023-08-31 20:15:12.497066|INDUSTRY|||||
NCT04303247||2020-03-05|||2020-03-08|2020-03-08|2020-03-11|Actual|||||||2020-03-08|2020-03-11|Actual|May 1, 2020|Anticipated|2020-05-01|March 2020|2020-03-31|May 1, 2023|Anticipated|2023-05-01|May 1, 2021|Anticipated|2021-05-01||Interventional|||CD19 and CD22 Dual-targeted CAR-T Cells for Relapsed or Refractory B-NHL|CD19 and CD22 Dual-targeted CAR-T Cells for Relapsed or Refractory B-NHL: a Multi-center, Uncontrolled Trial.|Unknown status|Not yet recruiting|Early Phase 1|30|Anticipated|Xinqiao Hospital of Chongqing||1|||f||||f|f|f|||||||||||2023-09-02 14:26:22.613326|2023-09-02 14:26:22.613326|OTHER|||||
NCT04666168||2020-11-11|||2020-12-07|2020-12-07|2020-12-14|Actual|||||||2020-12-07|2020-12-14|Actual|October 22, 2020|Actual|2020-10-22|November 2020|2020-11-30|October 21, 2025|Anticipated|2025-10-21|October 21, 2023|Anticipated|2023-10-21||Interventional|||A Multicenter Clinical Study on the Safety and Efficacy of CAR-T in the Treatment of Relapsed / Refractory Non Hodgkin's Lymphoma|A Multicenter Clinical Study on the Safety and Efficacy of CAR-T in the Treatment of Relapsed / Refractory Non Hodgkin's Lymphoma|Recruiting||Not Applicable|200|Anticipated|Hebei Senlang Biotechnology Inc., Ltd.||1|||f|||||f|f|||||||||||2023-09-01 23:42:14.855045|2023-09-01 23:42:14.855045|INDUSTRY|||||
NCT04665076||2020-12-07|||2020-12-07|2020-12-07|2020-12-11|Actual|||||||2020-12-07|2020-12-11|Actual|October 22, 2020|Actual|2020-10-22|October 2020|2020-10-31|October 21, 2025|Anticipated|2025-10-21|October 21, 2023|Anticipated|2023-10-21||Interventional|||Multicenter Clinical Study on the Safety and Effectiveness of CAR-T in the Treatment of Relapsed/Refractory Plasma Cell Tumors|Multicenter Clinical Study on the Safety and Effectiveness of CAR-T in the Treatment of Relapsed/Refractory Plasma Cell Tumors|Recruiting||Not Applicable|60|Anticipated|Hebei Senlang Biotechnology Inc., Ltd.||1|||f|||||f|f|||||||||||2023-09-01 23:42:34.838814|2023-09-01 23:42:34.838814|INDUSTRY|||||
NCT04661020||2020-12-03|||2020-12-03|2020-12-03|2020-12-09|Actual|||||||2020-12-03|2020-12-09|Actual|December 20, 2020|Anticipated|2020-12-20|December 2020|2020-12-31|December 20, 2026|Anticipated|2026-12-20|December 20, 2023|Anticipated|2023-12-20||Interventional|||CD19 CAR-T Therapy for Elderly Patients With B-cell Non-Hodgkin's Lymphoma|Clinical Trial for the Safety and Efficacy of CD19 CAR-T Therapy for Elderly Patients With B-cell Non-Hodgkin's Lymphoma|Not yet recruiting||Early Phase 1|36|Anticipated|Zhejiang University||1|||f||||t|f|f|||||||||No||2023-09-01 23:43:37.234193|2023-09-01 23:43:37.234193|OTHER|||||
NCT04288726||2020-02-26|||2023-03-08|2020-02-26|2020-02-28|Actual|||||||2023-03-08|2023-03-09|Actual|September 16, 2020|Actual|2020-09-16|March 2023|2023-03-31|June 1, 2037|Anticipated|2037-06-01|June 1, 2025|Anticipated|2025-06-01||Interventional|||Allogeneic CD30.CAR-EBVSTs in Patients With Relapsed or Refractory CD30-Positive Lymphomas|A Phase 1 Study Evaluating the Safety and Activity of Allogeneic CD30 Chimeric Antigen Receptor Epstein-Barr Virus-Specific T Lymphocytes (CD30.CAR-EBVSTs) in Patients With Relapsed or Refractory CD30-Positive Lymphomas|Recruiting||Phase 1|18|Anticipated|Baylor College of Medicine||1|||f||||t|t|f|||||||||||2023-09-03 14:12:50.409164|2023-09-03 14:12:50.409164|OTHER|||||
NCT04626739||2020-11-06|||2020-11-11|2020-11-11|2020-11-13|Actual|||||||2020-11-11|2020-11-13|Actual|April 1, 2020|Actual|2020-04-01|November 2020|2020-11-30|March 30, 2023|Anticipated|2023-03-30|March 30, 2023|Anticipated|2023-03-30||Interventional|||CAR-T Cells in Treating Patients With Relapsed or Refractory NHL|An Open, Uncontrolled, Multicenter Clinical Trial to Explore the Safety, Efficacy, and Remission Phase of Chimeric Antigen Receptor T Cell (CAR-T) in the Treatment of Relapsed Refractory (R/R) Non-Hodgkin Lymphoma (NHL)|Unknown status|Recruiting|Early Phase 1|100|Anticipated|Hebei Senlang Biotechnology Inc., Ltd.||1|||f|||||f|f|||||||||No||2023-09-01 23:47:24.128425|2023-09-01 23:47:24.128425|INDUSTRY|||||
NCT04610125||2020-10-26|||2020-10-29|2020-10-29|2020-10-30|Actual|||||||2020-10-29|2020-10-30|Actual|June 23, 2020|Actual|2020-06-23|August 2020|2020-08-31|June 22, 2025|Anticipated|2025-06-22|June 22, 2023|Anticipated|2023-06-22||Interventional|||Clinical Trial of CAR-T in the Treatment of Relapsed and Refractory Hematopoietic and Lymphoid Tissue Tumors in Children|Clinical Trial of CAR-T in the Treatment of Relapsed and Refractory Hematopoietic and Lymphoid Tissue Tumors in Children|Recruiting||Not Applicable|30|Anticipated|Hebei Senlang Biotechnology Inc., Ltd.||1|||f|||||f|f|||||||||||2023-09-01 23:52:45.638316|2023-09-01 23:52:45.638316|INDUSTRY|||||
NCT03685786||2018-09-24|||2018-12-05|2018-09-25|2018-09-26|Actual|||||||2018-12-05|2018-12-07|Actual|June 1, 2018|Actual|2018-06-01|December 2018|2018-12-31|September 2, 2021|Anticipated|2021-09-02|June 2, 2021|Anticipated|2021-06-02||Interventional|||CART19 Cells Treatment of MRD of B Cell Malignancies and Then Auto-HSCT|The Study of Autologous T Cells Expressing CD19 Chimeric Antigen Receptors Treatment of Minimal Residual Disease(MRD) of B Cell Malignancies and Then Autologous Hematopoietic Stem Cell Transplantation(Auto-HSCT)|Unknown status|Recruiting|Phase 1|20|Anticipated|Shenzhen Second People's Hospital||1|||f|||||f|f|||||||||||2023-09-03 14:15:48.330194|2023-09-03 14:15:48.330194|OTHER|||||
NCT04594135||2020-10-14|||2021-02-27|2020-10-14|2020-10-20|Actual|||||||2021-02-27|2021-03-02|Actual|December 1, 2020|Actual|2020-12-01|February 2021|2021-02-28|November 30, 2023|Anticipated|2023-11-30|November 30, 2023|Anticipated|2023-11-30||Interventional|CD5CAR-T||Anti-CD5 CAR T Cells for Relapsed/Refractory T Cell Malignancies|Anti-CD5 CAR T Cells for Relapsed/Refractory T Cell Malignancies|Recruiting||Phase 1|20|Anticipated|iCell Gene Therapeutics||1|||f||||f|f|f|||||||||No||2023-09-01 23:57:07.34631|2023-09-01 23:57:07.34631|INDUSTRY|||||
NCT04213469||2019-12-26|||2022-09-28|2019-12-26|2019-12-30|Actual|||||||2022-09-28|2022-09-30|Actual|March 13, 2020|Actual|2020-03-13|September 2022|2022-09-30|April 1, 2023|Anticipated|2023-04-01|November 1, 2021|Actual|2021-11-01||Interventional|||PD1-CD19-CART in Patients With r/r B-cell Lymphoma|a Safety and Efficacy Evaluation of PD1-CD19-CART in Patients With Relapse/Refractory B-cell Lymphoma|Active, not recruiting||Not Applicable|20|Anticipated|Bioray Laboratories||1|||f|||||f|f|||||||||No||2023-09-01 23:58:34.313967|2023-09-01 23:58:34.313967|INDUSTRY|||||
NCT04295018||2020-03-02|||2020-03-02|2020-03-02|2020-03-04|Actual|||||||2020-03-02|2020-03-04|Actual|October 23, 2019|Actual|2019-10-23|October 2019|2019-10-31|December 2021|Anticipated|2021-12-31|September 2021|Anticipated|2021-09-30||Interventional|||A Study of BCMA-directed CAR-T Cells Treatment in Subjects With r/r Multiple Myeloma|A Phase # Study Evaluating Safety and Efficacy of C-CAR088 Treatment in Subjects With Relapsed or Refractory Multiple Myeloma|Unknown status|Recruiting|Phase 1|10|Anticipated|Peking Union Medical College Hospital||1|||f||||f|f|f|||||||||No||2023-09-02 14:34:44.37015|2023-09-02 14:34:44.37015|OTHER|||||
NCT04295096||2020-03-02|||2021-06-07|2020-03-02|2020-03-04|Actual|||||||2021-06-07|2021-06-09|Actual|April 1, 2020|Actual|2020-04-01|June 2021|2021-06-30|March 2024|Anticipated|2024-03-31|February 2024|Anticipated|2024-02-29||Interventional|||Collection of PBMCs From Healthy Subjects for the Development of Cellular Immunotherapy Product|Collection of Peripheral Blood Mononuclear Cells From Healthy Subjects for the Development of Cellular Immunotherapy Product|Recruiting||Not Applicable|172|Anticipated|Zhaxin Hospital of Integrated Traditional Chinese and Western Medicine, Shanghai||1|||f||||f|f|f|||||||||No||2023-09-02 14:34:45.015942|2023-09-02 14:34:45.015942|OTHER|||||
NCT02575261||2015-09-29|||2020-07-14|2015-10-13|2015-10-14|Estimate|||||||2020-07-14|2020-07-16|Actual|September 2015|Actual|2015-09-30|July 2020|2020-07-31|August 15, 2016|Actual|2016-08-15|August 15, 2016|Actual|2016-08-15||Interventional|||CAR-T Cell Immunotherapy for EphA2 Positive Malignant Glioma Patients|Chimeric Antigen Receptor-Modified T Cells for EphA2 Positive Recurrent and Metastatic Malignant Glioma|Withdrawn||Phase 1/Phase 2|0|Actual|Fuda Cancer Hospital, Guangzhou||2|||f||||t|||||||||||||2023-09-02 14:36:10.347585|2023-09-02 14:36:10.347585|OTHER|||||
NCT03483103||2018-03-23|2022-09-23||2023-01-11|2018-03-23|2018-03-30|Actual|2022-12-09|2022-12-29|Actual||||2023-01-11|2023-01-13|Actual|July 26, 2018|Actual|2018-07-26|January 2023|2023-01-31|December 1, 2022|Actual|2022-12-01|September 24, 2021|Actual|2021-09-24||Interventional||74 participants were leukapheresed.|Lisocabtagene Maraleucel (JCAR017) as Second-Line Therapy (TRANSCEND-PILOT-017006)|A Phase 2 Study of Lisocabtagene Maraleucel (JCAR017) as Second-Line Therapy in Adult Patients With Aggressive B-cell NHL (017006)|Completed||Phase 2|74|Actual|Juno Therapeutics, a Subsidiary of Celgene||1|||f||||t|t|f|||||||||||2023-09-02 14:42:09.645174|2023-09-02 14:42:09.645174|INDUSTRY|||||
NCT05141253||2021-11-09|||2022-04-26|2021-11-18|2021-12-02|Actual|||||||2022-04-26|2022-04-27|Actual|January 12, 2022|Actual|2022-01-12|April 2022|2022-04-30|November 1, 2036|Anticipated|2036-11-01|November 1, 2023|Anticipated|2023-11-01||Interventional|||Safety and Efficacy of RD133 in Subjects With Relapsed or Refractory MSLN-Positive Solid Tumors|A Single-Center Exploratory Clinical Study to Evaluate the Safety and Efficacy of RD133 in Subjects With Relapsed or Refractory MSLN-Positive Solid Tumors|Recruiting||Early Phase 1|24|Anticipated|Tongji Hospital||1|||f|||||f|f|||||||||Undecided||2023-08-31 20:24:47.630722|2023-08-31 20:24:47.630722|OTHER|||||
NCT04093648||2019-09-16|||2020-05-19|2019-09-16|2019-09-18|Actual|||||||2020-05-19|2020-05-20|Actual|January 2020|Anticipated|2020-01-31|May 2020|2020-05-31|January 2038|Anticipated|2038-01-31|February 2023|Anticipated|2023-02-28||Interventional|||T Cells co- Expressing a Second Generation Glypican 3-specific Chimeric Antigen Receptor With Cytokines Interleukin-21 and 15 as Immunotherapy for Patients With Liver Cancer (TEGAR)|T Cells co- Expressing a Second Generation Glypican 3-specific Chimeric Antigen Receptor With Cytokines Interleukin-21 and 15 as Immunotherapy for Patients With Liver Cancer|Withdrawn||Phase 1|0|Actual|Baylor College of Medicine||1||The key elements of this study were incorporated into another study.|||||t|t|f|||||||||||2023-09-02 14:44:42.166299|2023-09-02 14:44:42.166299|OTHER|||||
NCT04546906||2020-09-04|||2020-09-04|2020-09-04|2020-09-14|Actual|||||||2020-09-04|2020-09-14|Actual|September 1, 2020|Actual|2020-09-01|September 2020|2020-09-30|December 1, 2022|Anticipated|2022-12-01|September 1, 2022|Anticipated|2022-09-01||Interventional|||Safety and Efficacy Study of CD22 CAR-T Cells for Relapsed or Refractory Acute Lymphoblastic Leukemia|Safety and Efficacy Study of CD22 CAR-T Cells for Relapsed or Refractory Acute Lymphoblastic Leukemia|Unknown status|Recruiting|Not Applicable|20|Anticipated|Hebei Senlang Biotechnology Inc., Ltd.||1|||f|||||f|f|||||||||||2023-09-02 00:19:32.89639|2023-09-02 00:19:32.89639|INDUSTRY|||||
NCT04541368||2020-08-19|||2020-12-09|2020-09-01|2020-09-09|Actual|||||||2020-12-09|2020-12-10|Actual|December 31, 2020|Anticipated|2020-12-31|December 2020|2020-12-31|December 31, 2026|Anticipated|2026-12-31|December 31, 2023|Anticipated|2023-12-31||Interventional|||A Study of CS1-targeted CAR-T Cells Therapy for Relapsed Multiple Myeloma After BCMA CAR-T Cells Therapy|Clinical Trial for the Safety and Efficacy of CS1-targeted CAR-T Cells Therapy for Relapsed Multiple Myeloma After BCMA CAR-T Cells Therapy|Not yet recruiting||Early Phase 1|50|Anticipated|Zhejiang University||1|||f||||t|f|f|||||||||No||2023-09-02 00:20:06.663177|2023-09-02 00:20:06.663177|OTHER|||||
NCT05626322||2022-11-15|||2023-08-21|2022-11-15|2022-11-23|Actual|||||||2023-08-21|2023-08-24|Actual|August 4, 2023|Actual|2023-08-04|August 2023|2023-08-31|July 5, 2026|Anticipated|2026-07-05|January 1, 2026|Anticipated|2026-01-01||Interventional|||Effects of Maplirpacept (PF-07901801),Tafasitamab, and Lenalidomide in People With Relapsed or Refractory Diffuse Large B-cell Lymphoma|A PHASE 1b/2 STUDY OF PF-07901801, A CD47 BLOCKING AGENT, WITH TAFASITAMAB AND LENALIDOMIDE FOR PARTICIPANTS WITH RELAPSED/REFRACTORY DIFFUSE LARGE B CELL LYMPHOMA NOT ELIGIBLE FOR STEM CELL TRANSPLANTATION|Recruiting||Phase 1/Phase 2|70|Anticipated|Pfizer||2|||f|||||t|f||||||||https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests|Yes|Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.|2023-09-04 14:28:37.834778|2023-09-04 14:28:37.834778|INDUSTRY|||||
NCT04532281||2020-08-20|||2020-10-22|2020-08-25|2020-08-31|Actual|||||||2020-10-22|2020-10-26|Actual|November 1, 2020|Anticipated|2020-11-01|October 2020|2020-10-31|November 1, 2026|Anticipated|2026-11-01|November 1, 2023|Anticipated|2023-11-01||Interventional|||A Study of Murine CD19 CAR-T Therapy for Patients With Relapsed or Refractory CD19+ B-cell Hematological Malignancies|Clinical Trial for the Safety and Efficacy of Murine CD19 CAR-T Cells Therapy for Patients With Relapsed and/or Refractory B-cell Acute Lymphoblastic Leukemia and B-cell Non-Hodgkin's Lymphoma|Recruiting||Early Phase 1|120|Anticipated|Zhejiang University||1|||f||||t|f|f|||||||||No||2023-09-02 00:30:42.720424|2023-09-02 00:30:42.720424|OTHER|||||
NCT04532203||2020-08-20|||2020-10-22|2020-08-25|2020-08-31|Actual|||||||2020-10-22|2020-10-26|Actual|November 1, 2020|Anticipated|2020-11-01|October 2020|2020-10-31|November 1, 2026|Anticipated|2026-11-01|November 1, 2023|Anticipated|2023-11-01||Interventional|||A Study of CAR-T Cells Therapy for Patients With Relapsed and/or Refractory Central Nervous System Hematological Malignancies|Clinical Trial for the Safety and Efficacy of CAR-T Cells Therapy for Patients With the Central Nervous System Involvement of Relapsed and/or Refractory B-cell Acute Lymphoblastic Leukemia or B-cell Non-Hodgkin's Lymphoma|Recruiting||Early Phase 1|72|Anticipated|Zhejiang University||1|||f||||t|f|f|||||||||No||2023-09-02 00:30:44.822393|2023-09-02 00:30:44.822393|OTHER|||||
NCT04718883||2021-01-14|||2021-03-17|2021-01-17|2021-01-22|Actual|||||||2021-03-17|2021-03-18|Actual|January 13, 2021|Actual|2021-01-13|March 2021|2021-03-31|June 30, 2025|Anticipated|2025-06-30|June 30, 2023|Anticipated|2023-06-30||Interventional|||CD19-targeted CAR T Cells for Relapsed and Refractory (R/R) Mantle Cell Lymphoma|A Phase II Open-Label, Single-Arm, Multicenter Study of JWCAR029, CD19-targeted Chimeric Antigen Receptor (CAR) T Cells for Relapsed and Refractory (R/R) Mantle Cell Lymphoma|Recruiting||Phase 2|59|Anticipated|Shanghai Ming Ju Biotechnology Co., Ltd.||1|||f||||f|f|f|||||||||No||2023-09-02 00:36:30.574907|2023-09-02 00:36:30.574907|INDUSTRY|||||
NCT05396885||2022-05-12|||2023-08-22|2022-05-25|2022-05-31|Actual|||||||2023-08-22|2023-08-24|Actual|August 9, 2022|Actual|2022-08-09|August 2023|2023-08-31|May 31, 2025|Anticipated|2025-05-31|May 31, 2024|Anticipated|2024-05-31||Interventional|||Study of CART-ddBMCA in Relapsed or Refractory Multiple Myeloma (iMMagine-1)|A Phase II Study of CART-ddBCMA for the Treatment of Patients With Relapsed or Refractory Multiple Myeloma|Recruiting||Phase 2|110|Anticipated|Arcellx, Inc.||1|||f||||t|t|f|||||||||No||2023-09-04 14:29:25.575949|2023-09-04 14:29:25.575949|INDUSTRY|||||
NCT03029273||2017-01-20|||2019-01-16|2017-01-20|2017-01-24|Estimate|||||||2019-01-16|2019-01-17|Actual|March 21, 2017|Actual|2017-03-21|January 2019|2019-01-31|March 2019|Anticipated|2019-03-31|March 2019|Anticipated|2019-03-31||Interventional|||NY-ESO-1 TCR （TAEST16001）for Patients With Advanced NSCLC|Pilot Study of Affinity-enhanced Anti-NY-ESO-1 TCR Engineered Autologous T Cells in NSCLC Patients|Unknown status|Recruiting|Phase 1|20|Anticipated|Guangzhou Institute of Respiratory Disease||1|||f|||||f|f|||||||||Undecided||2023-08-31 20:38:50.030442|2023-08-31 20:38:50.030442|OTHER|||||
NCT04499573||2020-07-31|||2023-02-21|2020-07-31|2020-08-05|Actual|||||||2023-02-21|2023-02-22|Actual|July 27, 2020|Actual|2020-07-27|February 2023|2023-02-28|March 13, 2027|Anticipated|2027-03-13|March 13, 2022|Actual|2022-03-13||Interventional|||Bispecific CD19/CD22 CAR-T for Treatment of Children and Young Adults With r/r B-ALL|Safety and Efficiency of Anti-CD19/CD22 Tandem Fully Human Chimeric Antigen Receptor (CAR)-Transduced T-cell Therapy for Pediatric and Young Adult Patients With Relapsed/Refractory B-cell Acute Lymphoblastic Leukemia: a Single Centre, Non-randomised, Open Label Phase I-II Clinical Trial of Automatically Produced Cell Therapy Product MB-CAR-T19-22 Using CliniMACS Prodigy|Active, not recruiting||Phase 1/Phase 2|50|Anticipated|Federal Research Institute of Pediatric Hematology, Oncology and Immunology||1|||f|||||f|f|||||||||Undecided||2023-08-31 20:44:04.379656|2023-08-31 20:44:04.379656|OTHER|||||
NCT05451212||2022-06-30|||2023-08-01|2022-07-05|2022-07-11|Actual|||||||2023-08-01|2023-08-02|Actual|November 23, 2022|Actual|2022-11-23|August 2023|2023-08-31|October 2028|Anticipated|2028-10-31|October 2028|Anticipated|2028-10-31||Interventional|||Open-label Study to Evaluate the Safety of Various Dosing Regimens of MuSK-CAART for MuSK Myasthenia Gravis|A Phase 1, Open-label, Safety and Dose-finding Study of Autologous Muscle-specific Tyrosine Kinase Chimeric Autoantibody Receptor T Cells (MuSK-CAART) in Subjects With Anti-MuSK-antibody-positive Myasthenia Gravis|Recruiting||Phase 1|24|Anticipated|Cabaletta Bio||1|||f||||f|t|f|||||||||||2023-09-02 15:01:54.372425|2023-09-02 15:01:54.372425|INDUSTRY|||||
NCT04351022||2020-04-15|||2020-04-21|2020-04-15|2020-04-17|Actual|||||||2020-04-21|2020-04-24|Actual|July 1, 2017|Actual|2017-07-01|April 2020|2020-04-30|December 31, 2023|Anticipated|2023-12-31|December 31, 2021|Anticipated|2021-12-31||Interventional|||CD38-targeted Chimeric Antigen Receptor T Cell (CART) in Relapesd or Refractory Acute Myeloid Leukemia|Pilot Study of the Efficacy and Safety of CD38 Targeted Chimeric Antigen Receptor Engineered T-Cells in the Treatment of CD38 Positive Relapsed or Refractory Acute Myeloid Leukemia (AML)|Recruiting||Phase 1/Phase 2|20|Anticipated|The First Affiliated Hospital of Soochow University||1|||f|||||f|f|||||||||No||2023-08-31 20:51:35.389223|2023-08-31 20:51:35.389223|OTHER|||||
NCT04835519||2021-04-05|||2023-02-06|2021-04-05|2021-04-08|Actual|||||||2023-02-06|2023-02-08|Actual|April 8, 2021|Actual|2021-04-08|February 2023|2023-02-28|September 8, 2024|Anticipated|2024-09-08|September 8, 2024|Anticipated|2024-09-08||Interventional|||Phase I/II Study of Enhanced CD33 CAR T Cells in Subjects With Relapsed or Refractory Acute Myeloid Leukemia|Open-Label, Nonramdominzed, Single-Arm Phase I/II Study to Evaluate the Safety and Tolerability of Functionally Enhanced CD33 CAR T Cells in Subjects With Relapsed or Refractory Acute Myeloid Leukemia|Recruiting||Phase 1/Phase 2|25|Anticipated|Beijing Boren Hospital||1|||f|||||f|f|||||||||No||2023-08-31 20:52:50.177528|2023-08-31 20:52:50.177528|OTHER|||||
NCT05077527||2021-10-01|||2023-07-31|2021-10-01|2021-10-14|Actual|||||||2023-07-31|2023-08-02|Actual|January 15, 2024|Anticipated|2024-01-15|July 2023|2023-07-31|January 31, 2027|Anticipated|2027-01-31|January 31, 2026|Anticipated|2026-01-31||Interventional|||Immune Cell Therapy (CAR-T) for the Treatment of Patients With HIV and B-Cell Non-Hodgkin Lymphoma|Axicabtagene Ciloleucel in Relapsed or Refractory HIV-Associated Aggressive B-Cell Non-Hodgkin Lymphoma|Not yet recruiting||Phase 1|20|Anticipated|AIDS Malignancy Consortium||1|||f||||f|t|f|||t||||||||2023-09-02 15:03:12.749566|2023-09-02 15:03:12.749566|NETWORK|||||
NCT02107963||2014-04-05|||2023-08-23|2014-04-05|2014-04-09|Estimate|||||||2023-08-23|2023-08-24|Actual|February 28, 2014|Actual|2014-02-28|August 22, 2023|2023-08-22|January 31, 2017|Actual|2017-01-31|August 15, 2016|Actual|2016-08-15||Interventional|||A Phase I Trial of T Cells Expressing an Anti-GD2 Chimeric Antigen Receptor in Children and Young Adults With GD2+ Solid Tumors|A Phase I Trial of T Cells Expressing an Anti-GD2 Chimeric Antigen Receptor in Children and Young Adults With GD2+ Solid Tumors|Completed||Phase 1|15|Actual|National Institutes of Health Clinical Center (CC)||2|||f|||||t|f||||||Clinical data available during the study and indefinitely.|Clinical data will be made available via subscription to BTRIS and with the permission of the study PI.||Yes|.All IPD recorded in the medical record will be shared with intramural investigators upon request|2023-09-04 14:34:35.539016|2023-09-04 14:34:35.539016|NIH|||||
NCT04340154||2020-04-08|||2023-08-01|2020-04-08|2020-04-09|Actual|||||||2023-08-01|2023-08-02|Actual|May 1, 2020|Actual|2020-05-01|August 2023|2023-08-31|November 1, 2024|Anticipated|2024-11-01|May 1, 2024|Anticipated|2024-05-01||Interventional|||Study of Sequential CAR-T Cell Treating Leukemia Children|Phase II Study of Sequential Chimeric Antigen Receptor T Cell Targeting at Different B-cell Antigens Treating Refractory or Relapsed B-cell Acute Lymphoblastic Leukemia Children|Active, not recruiting||Phase 2|100|Anticipated|Beijing Boren Hospital||1|||f|||||f|f|||||||||No||2023-09-02 15:05:37.460223|2023-09-02 15:05:37.460223|OTHER|||||
NCT03635632||2018-08-13|||2023-08-01|2018-08-15|2018-08-17|Actual|||||||2023-08-01|2023-08-02|Actual|April 23, 2019|Actual|2019-04-23|August 2023|2023-08-31|December 2039|Anticipated|2039-12-31|June 2024|Anticipated|2024-06-30||Interventional|||C7R-GD2.CART Cells for Patients With Relapsed or Refractory Neuroblastoma and Other GD2 Positive Cancers (GAIL-N)|Phase I Study of Autologous T Lymphocytes Expressing GD2-specific Chimeric Antigen and Constitutively Active IL-7 Receptors for the Treatment of Patients With Relapsed or Refractory Neuroblastoma and Other GD2 Positive Solid Cancers(GAIL-N)|Recruiting||Phase 1|94|Anticipated|Baylor College of Medicine||2|||f||||t|t|f|||||||||||2023-09-02 15:07:10.735333|2023-09-02 15:07:10.735333|OTHER|||||
NCT04283006||2020-02-20|||2020-08-20|2020-02-21|2020-02-25|Actual|||||||2020-08-20|2020-08-21|Actual|May 23, 2018|Actual|2018-05-23|August 2020|2020-08-31|May 23, 2028|Anticipated|2028-05-23|May 23, 2023|Anticipated|2023-05-23||Interventional|||A Study of CD20/CD22 Targeted CAR T-cell Therapy for Relapsed or Refractory Lymphoid Malignancies|A Study of CD20/CD22 Targeted CAR T-cell Therapy for Relapsed or Refractory Lymphoid Malignancies|Recruiting||Early Phase 1|100|Anticipated|Zhejiang University||1|||f||||t|f|f|||||||||No||2023-09-02 15:12:29.54189|2023-09-02 15:12:29.54189|OTHER|||||
NCT04715217||2021-01-07|||2021-01-17|2021-01-17|2021-01-20|Actual|||||||2021-01-17|2021-01-20|Actual|January 19, 2021|Anticipated|2021-01-19|January 2021|2021-01-31|December 31, 2023|Anticipated|2023-12-31|December 31, 2021|Anticipated|2021-12-31||Interventional|||Targeting CD19 and CD22 CAR-T Cells Immunotherapy in Patients With Relapsed or Refractory B Cell Lymphoma|A Clinical Study to Evaluate the Safety and Effectiveness of CD19-CD22 CAR-T Cells Immunotherapy in Patients With Relapsed or Refractory B Cell Lymphoma|Recruiting||Phase 1/Phase 2|24|Anticipated|Shanxi Province Cancer Hospital||4|||f||||f|f|f||||||Within six months after the study completed|Research site||Yes|Plan to Share Clinical Study Report within six months after the study completed|2023-09-02 01:27:34.402744|2023-09-02 01:27:34.402744|OTHER|||||
NCT05318963||2022-03-15|||2023-08-01|2022-04-01|2022-04-08|Actual|||||||2023-08-01|2023-08-03|Actual|March 14, 2022|Actual|2022-03-14|August 2023|2023-08-31|June 30, 2026|Anticipated|2026-06-30|June 30, 2024|Anticipated|2024-06-30||Interventional|||Targeting CD19/CD20/CD22 Triple-targeted Cell in Patients With Relapsed/Refractory B-cell Lymphoma|A Phase I, Open-label Clinical Study to Evaluate the Safety, Tolerability, and Efficacy of LCAR-AIO, a Triple-targeted Cell Preparation Targeting CD19/CD20/CD22, in Patients With Relapsed/Refractory B-cell Lymphoma|Recruiting||Phase 1|34|Anticipated|Institute of Hematology & Blood Diseases Hospital||1|||f||||f|f|f|||||||||No||2023-09-03 14:29:15.439475|2023-09-03 14:29:15.439475|OTHER|||||
NCT04714827||2021-01-07|||2021-01-17|2021-01-15|2021-01-19|Actual|||||||2021-01-17|2021-01-22|Actual|January 31, 2021|Anticipated|2021-01-31|January 2021|2021-01-31|December 31, 2023|Anticipated|2023-12-31|January 31, 2022|Anticipated|2022-01-31||Interventional|||Targeting CD19 and BCMA CAR-T Cells Immunotherapy in Patients With Relapsed or Refractory Multiple Myeloma|A Clinical Study to Evaluate the Safety and Effectiveness of CD19- BCMA CAR - T Cells Immunotherapy in Patients With Relapsed or Refractory Multiple Myeloma|Recruiting||Phase 1/Phase 2|24|Anticipated|Shanxi Province Cancer Hospital||4|||f||||f|f|f||||||Within six months after the study completed|Research site||Yes|Plan to Share Clinical Study Report within six months after the study completed|2023-09-02 01:31:26.698202|2023-09-02 01:31:26.698202|OTHER|||||
NCT04714593||2021-01-07|||2021-01-17|2021-01-15|2021-01-19|Actual|||||||2021-01-17|2021-01-22|Actual|January 15, 2021|Anticipated|2021-01-15|January 2021|2021-01-31|December 31, 2023|Anticipated|2023-12-31|December 31, 2021|Anticipated|2021-12-31||Interventional|||Targeting CD19 and CD22 CAR-T Cells Immunotherapy in Patients With Relapsed or Refractory Acute B Lymphocytic Leukemia|A Clinical Study to Evaluate the Safety and Effectiveness of CD19- BCMA CAR - T Cells Immunotherapy in Patients With Relapsed or Refractory Acute B Lymphocytic Leukemia|Recruiting||Phase 1/Phase 2|24|Anticipated|Shanxi Province Cancer Hospital||4|||f||||f|f|f||||||Within six months after the study completed|Research site||Yes|Plan to Share Clinical Study Report within six months after the study completed|2023-09-02 01:35:11.338224|2023-09-02 01:35:11.338224|OTHER|||||
NCT02959151||2016-11-06|||2016-11-07|2016-11-07|2016-11-08|Estimate|||||||2016-11-07|2016-11-08|Estimate|July 2016||2016-07-31|November 2016|2016-11-30|July 2018|Anticipated|2018-07-31|January 2018|Anticipated|2018-01-31||Interventional|||A Study of Chimeric Antigen Receptor T Cells Combined With Interventional Therapy in Advanced Liver Malignancy|A Single-arm Pilot Clinical Study of Chimeric Antigen Receptor T Cells Combined With Interventional Therapy in Advanced Liver Malignancy|Unknown status|Recruiting|Phase 1/Phase 2|20|Anticipated|Shanghai GeneChem Co., Ltd.||1|||f||||f|||||||||||Undecided||2023-08-31 21:09:58.912194|2023-08-31 21:09:58.912194|INDUSTRY|||||
NCT05362331||2022-05-02|||2023-02-06|2022-05-02|2022-05-05|Actual|||||||2023-02-06|2023-02-09|Actual|January 1, 2023|Anticipated|2023-01-01|January 2023|2023-01-31|June 30, 2025|Anticipated|2025-06-30|June 30, 2025|Anticipated|2025-06-30||Interventional|||Companion for CAR-T Web App During Chimeric Antigen Receptor T-cell Therapy|"Feasibility of a Companion for CAR-T Web App During Chimeric Antigen Receptor T-cell Therapy"|Withdrawn||Not Applicable|0|Actual|University of California, San Francisco||1||Contract issues|f||||f|f|f|||||||||No||2023-08-31 21:11:23.44087|2023-08-31 21:11:23.44087|OTHER|||||
NCT03271515||2017-08-31|||2021-01-19|2017-08-31|2017-09-05|Actual|||||||2021-01-19|2021-01-20|Actual|March 1, 2021|Anticipated|2021-03-01|January 2021|2021-01-31|March 1, 2023|Anticipated|2023-03-01|March 1, 2022|Anticipated|2022-03-01||Interventional|||Immunotherapy With Bispecific CAR-T Cells for B-Cell Lymphoma, ALL and CLL|Phase I Study of T Cells Expressing an Anti-CD19 and Anti-CD20 Bispecific Chimeric Receptor in Patients With B Cell Malignancies|Unknown status|Not yet recruiting|Phase 1|20|Anticipated|Beijing Doing Biomedical Co., Ltd.||2|||f||||f|f|f|||||||||No||2023-09-02 01:55:58.874826|2023-09-02 01:55:58.874826|INDUSTRY|||||
NCT03271632||2017-08-27|||2019-09-18|2017-08-31|2017-09-05|Actual|||||||2019-09-18|2019-09-19|Actual|July 15, 2017|Actual|2017-07-15|September 2019|2019-09-30|December 31, 2020|Anticipated|2020-12-31|December 31, 2019|Anticipated|2019-12-31||Interventional|||Multi-CAR T Cell Therapy in the Treatment of Multiple Myeloma|Multiple Antigen-specific CAR T Cells For the Treatment of Multiple Myeloma|Unknown status|Recruiting|Phase 1/Phase 2|20|Anticipated|Shenzhen Geno-Immune Medical Institute||1|||f||||f|f|f|||||||||No||2023-09-02 01:57:01.17683|2023-09-02 01:57:01.17683|OTHER|||||
NCT04702841||2021-01-07|||2021-03-04|2021-01-07|2021-01-11|Actual|||||||2021-03-04|2021-03-08|Actual|June 3, 2020|Actual|2020-06-03|March 2021|2021-03-31|December 2022|Anticipated|2022-12-31|June 2022|Anticipated|2022-06-30||Interventional|||CAR - γ δ T Cells in the Treatment of Relapsed and Refractory CD7 Positive T Cell-derived Malignant Tumors|Clinical Application of Chimeric Antigen Receptor Modified γδ T Cells（CAR - γ δ T Cells） in Relapsed and Refractory CD7 Positive T Cell-derived Malignant Tumors|Unknown status|Recruiting|Early Phase 1|8|Anticipated|PersonGen BioTherapeutics (Suzhou) Co., Ltd.||1|||f||||f|f|f|||||||||||2023-09-02 02:00:40.355777|2023-09-02 02:00:40.355777|INDUSTRY|||||
NCT04827745||2021-03-25|||2023-04-06|2021-03-29|2021-04-01|Actual|||||||2023-04-06|2023-04-10|Actual|June 11, 2021|Actual|2021-06-11|April 2023|2023-04-30|November 1, 2025|Anticipated|2025-11-01|November 1, 2023|Anticipated|2023-11-01||Interventional|||Blinatumomab for Treatment of R/R or MRD-positive CD19-Positive MPAL|A Multicenter Phase II Study of Blinatumomab for Treatment of Adult Patients With Morphologic Relapsed/Refractory or Measurable Residual Disease (MRD) CD19-Positive Mixed Phenotype Acute Leukemia (MPAL)|Active, not recruiting||Phase 2|2|Actual|University of Maryland, Baltimore||2|||||||t|t|f|||||||||||2023-08-31 21:18:34.214277|2023-08-31 21:18:34.214277|OTHER|||||
NCT04700319||2021-01-05|||2021-03-04|2021-01-05|2021-01-07|Actual|||||||2021-03-04|2021-03-08|Actual|April 19, 2019|Actual|2019-04-19|March 2021|2021-03-31|June 1, 2021|Anticipated|2021-06-01|May 1, 2021|Anticipated|2021-05-01||Interventional|||CAR-T CD19/CD20 for Patients With Advanced CD19/CD20+ B Cell Line Recurrent or Refractory Hematological Malignancies|CAR-T CD19/CD20 for Patients With Advanced CD19/CD20+ B Cell Line Recurrent or Refractory Hematological Malignancies|Unknown status|Recruiting|Early Phase 1|30|Anticipated|PersonGen BioTherapeutics (Suzhou) Co., Ltd.||1|||f||||f|f|f|||||||||||2023-09-02 02:10:28.060432|2023-09-02 02:10:28.060432|INDUSTRY|||||
NCT02445222||2015-05-01|||2023-04-06|2015-05-12|2015-05-15|Estimate|||||||2023-04-06|2023-04-10|Actual|November 2, 2015|Actual|2015-11-02|April 2023|2023-04-30|February 22, 2036|Anticipated|2036-02-22|February 22, 2036|Anticipated|2036-02-22||Interventional|PAVO||CAR-T Long Term Follow Up (LTFU) Study|Long Term Follow-Up of Patients Exposed to Lentiviral-Based CAR T-Cell Therapy|Recruiting||Not Applicable|1400|Anticipated|Novartis||1|||f||||f|t|f|||||||||||2023-08-31 21:20:19.142399|2023-08-31 21:20:19.142399|INDUSTRY|||||
NCT02976857||2016-11-21|||2019-01-16|2016-11-28|2016-11-29|Estimate|||||||2019-01-16|2019-01-17|Actual|December 2016||2016-12-31|November 2016|2016-11-30|January 9, 2019|Actual|2019-01-09|September 11, 2018|Actual|2018-09-11||Interventional|C-CAR011||A Phase 1 Study Evaluating Safety and Efficacy of C-CAR011 Treatment in DLBCL Subjects|A Phase 1 Single Center, Non-randomized Study Evaluating Safety and Efficacy of Anti-CD19 Chimeric Antigen Receptor T-cell (C-CAR011) Treatment in Subjects With Refractory Diffuse Large B-cell Lymphoma|Completed||Phase 1|15|Anticipated|Cellular Biomedicine Group Ltd.||1|||f||||t|||||||||||Undecided||2023-08-31 21:20:55.058112|2023-08-31 21:20:55.058112|INDUSTRY|||||
NCT03907527||2019-04-05|||2023-01-05|2019-04-05|2019-04-09|Actual|||||||2023-01-05|2023-01-09|Actual|April 30, 2019|Actual|2019-04-30|January 2023|2023-01-31|November 15, 2028|Anticipated|2028-11-15|December 15, 2023|Anticipated|2023-12-15||Interventional|||Modified Immune Cells (Autologous CAR T Cells) in Treating Patients With Advanced, Recurrent Platinum Resistant Ovarian, Fallopian Tube or Primary Peritoneal Cancer|Phase I/Ib Study Evaluating Safety and Efficacy of PRGN-3005 UltraCAR-T® (Autologous CAR T Cells) in Advanced Stage Platinum Resistant Ovarian Cancer Patients|Recruiting||Phase 1|71|Anticipated|Precigen, Inc||2|||f||||t|t|f|||f||||||No||2023-09-03 15:08:13.097429|2023-09-03 15:08:13.097429|INDUSTRY|||||
NCT02893189||2016-05-17|||2023-06-21|2016-09-01|2016-09-08|Estimate|||||||2023-06-21|2023-06-22|Actual|April 27, 2017|Actual|2017-04-27|June 2023|2023-06-30|December 31, 2022|Actual|2022-12-31|December 31, 2019|Actual|2019-12-31||Interventional|CARD||CAR19 Donor Lymphocytes for Relapsed CD19+ Malignancies Following Allogeneic Transplantation|Chimeric Antigen Receptor (CAR)19 Donor Lymphocytes for Relapsed Cluster of Differentiation (CD)19+ Malignancies Following Allogeneic Transplantation (CARD)|Completed||Phase 1|17|Actual|University College, London||1|||f||||t|f|f|||||||||Undecided||2023-09-02 02:16:48.822525|2023-09-02 02:16:48.822525|OTHER|||||
NCT04003649||2018-11-23|||2023-02-07|2019-06-28|2019-07-01|Actual|||||||2023-02-07|2023-02-09|Actual|December 2, 2019|Actual|2019-12-02|February 2023|2023-02-28|December 31, 2024|Anticipated|2024-12-31|December 31, 2023|Anticipated|2023-12-31||Interventional|||IL13Ra2-CAR T Cells With or Without Nivolumab and Ipilimumab in Treating Patients With GBM|A Phase 1 Study to Evaluate IL13Rα2-Targeted Chimeric Antigen Receptor (CAR) T Cells Combined With Checkpoint Inhibition for Patients With Resectable Recurrent Glioblastoma|Recruiting||Phase 1|60|Anticipated|City of Hope Medical Center||3|||||||t|t|f|||||||||||2023-08-31 21:22:00.669351|2023-08-31 21:22:00.669351|OTHER|||||
NCT03744676||2018-11-07|||2023-03-01|2018-11-15|2018-11-16|Actual|||||||2023-03-01|2023-03-03|Actual|November 29, 2018|Actual|2018-11-29|March 2023|2023-03-31|September 27, 2023|Anticipated|2023-09-27|September 27, 2023|Anticipated|2023-09-27||Interventional|||A Safety Trial of Lisocabtagene Maraleucel (JCAR017) for Relapsed and Refractory (R/R) B-cell Non-Hodgkin Lymphoma (NHL) in the Outpatient Setting (TRANSCEND-OUTREACH-007)|A Safety Trial of Lisocabtagene Maraleucel (JCAR017) for Relapsed and Refractory (R/R) B-cell Non-Hodgkin Lymphoma (NHL) in the Outpatient Setting|Active, not recruiting||Phase 2|41|Actual|Juno Therapeutics, a Subsidiary of Celgene||1|||f||||f|t|f||||||See Plan Description|See Plan Description|https://www.bms.com/researchers-and-partners/clinical-trials-and-research/disclosure-commitment.html|Yes|"Information relating to our policy on data sharing and the process for requesting data can be found at the following link:~https://www.celgene.com/research-development/clinical-trials/clinical-trials-data-sharing/"|2023-09-02 15:40:01.014776|2023-09-02 15:40:01.014776|INDUSTRY|||||
NCT04162353||2019-11-11|||2021-05-17|2019-11-11|2019-11-14|Actual|||||||2021-05-17|2021-05-19|Actual|May 2021|Anticipated|2021-05-31|May 2021|2021-05-31|September 2021|Anticipated|2021-09-30|September 2021|Anticipated|2021-09-30||Interventional|||BCMA-CD19 cCAR in Multiple Myeloma and Plasmacytoid Lymphoma|BCMA-CD19 cCAR in Relapsed and /or Refractory Multiple Myeloma and Plasmacytoid Lymphoma|Unknown status|Recruiting|Phase 1|12|Anticipated|iCell Gene Therapeutics||1|||f||||f|f|f|||||||||No||2023-09-02 15:41:23.109711|2023-09-02 15:41:23.109711|INDUSTRY|||||
NCT04162119||2019-11-11|||2019-11-14|2019-11-11|2019-11-14|Actual|||||||2019-11-14|2019-11-18|Actual|July 7, 2019|Actual|2019-07-07|November 2019|2019-11-30|October 10, 2022|Anticipated|2022-10-10|October 10, 2021|Anticipated|2021-10-10||Interventional|||Safety and Efficiency Study of BCMA-PD1-CART Cells in Relapsed/Refractory Multiple Myeloma|Safety and Efficiency Study of BCMA-PD1-CART Cells in Relapsed/Refractory Multiple Myeloma|Unknown status|Recruiting|Phase 2|30|Anticipated|Chinese PLA General Hospital||1|||f|||||f|f|||||||||No||2023-09-02 15:41:41.285384|2023-09-02 15:41:41.285384|OTHER|||||
NCT04156269||2019-11-06|||2019-11-08|2019-11-06|2019-11-07|Actual|||||||2019-11-08|2019-11-12|Actual|August 31, 2018|Actual|2018-08-31|January 2019|2019-01-31|September 1, 2021|Anticipated|2021-09-01|September 1, 2021|Anticipated|2021-09-01||Interventional|||BCMA-CS1 Compound CAR (cCAR) T Cells for Relapsed/Refractory Multiple Myeloma|Phase I, Interventional, Single Arm, Open Label, Treatment Study to Evaluate the Safety and Tolerability of BCMA-CS1 cCAR in Patients With Relapsed and/or Refractory Multiple Myeloma|Unknown status|Recruiting|Early Phase 1|12|Anticipated|iCell Gene Therapeutics||1|||f||||t|f|f|||||||||No||2023-09-02 15:44:13.186136|2023-09-02 15:44:13.186136|INDUSTRY|||||
NCT02975687||2016-11-23|||2019-07-07|2016-11-23|2016-11-29|Estimate|||||||2019-07-07|2019-07-09|Actual|November 2016||2016-11-30|July 2019|2019-07-31|December 31, 2018|Actual|2018-12-31|December 2018|Actual|2018-12-31||Interventional|||CD19 CAR T Cells in Patients With Resistant or Refractory CD19+ Acute Lymphoblastic Leukemia|CD19 CAR T Cells in Patients With Resistant or Refractory CD19+ Acute Lymphoblastic Leukemia|Completed||Phase 1|20|Actual|Institute of Hematology & Blood Diseases Hospital||1|||f|||||||||||||||||2023-08-31 21:23:12.184662|2023-08-31 21:23:12.184662|OTHER|||||
NCT04516551||2020-08-13|||2020-11-12|2020-08-15|2020-08-18|Actual|||||||2020-11-12|2020-11-17|Actual|November 20, 2020|Anticipated|2020-11-20|November 2020|2020-11-30|December 1, 2022|Anticipated|2022-12-01|December 1, 2021|Anticipated|2021-12-01||Interventional|||Anti-CD19 Allo-CAR-T Cells for Relapsed B Cell Malignancies After HSCT|Anti-CD19 Donor-derived CAR-T Cells for Patients With Relapsed B Cell Malignancies After Hematopoietic Stem Cell Transplantation: a Multi-center, Uncontrolled Trial.|Unknown status|Recruiting|Phase 1|18|Anticipated|Xinqiao Hospital of Chongqing||1|||f||||f|f|f|||||||||No||2023-09-02 02:32:48.631898|2023-09-02 02:32:48.631898|OTHER|||||
NCT04324996||2020-03-25|||2020-11-16|2020-03-25|2020-03-27|Actual|||||||2020-11-16|2020-11-17|Actual|February 21, 2020|Actual|2020-02-21|November 2020|2020-11-30|August 31, 2022|Anticipated|2022-08-31|February 20, 2022|Anticipated|2022-02-20||Interventional|||A Phase I/II Study of Universal Off-the-shelf NKG2D-ACE2 CAR-NK Cells for Therapy of COVID-19|A Phase I/II Study of Universal Off-the-shelf NKG2D-ACE2 CAR-NK Cells Secreting IL15 Superagonist and GM-CSF-neutralizing scFv for Therapy of COVID-19|Unknown status|Recruiting|Phase 1/Phase 2|90|Anticipated|Chongqing Public Health Medical Center||5|||f|||||f|f|||||||||No||2023-09-02 02:33:16.350703|2023-09-02 02:33:16.350703|OTHER|||||
NCT04513431||2020-07-31|||2020-08-11|2020-08-11|2020-08-14|Actual|||||||2020-08-11|2020-08-14|Actual|August 30, 2020|Anticipated|2020-08-30|August 2020|2020-08-31|August 30, 2023|Anticipated|2023-08-30|March 30, 2021|Anticipated|2021-03-30||Interventional|CRC||A Clinical Research of CAR T Cells Targeting CEA Positive Colorectal Cancer (CRC)|A Study Evaluating the Safety and Preliminary Efficacy of Anti-CEA CAR-T Cells for the Prevention of Postoperative Recurrence and Metastasis of Stage III Colorectal Cancer or Liver Metastasis of Colorectal Cancer|Unknown status|Not yet recruiting|Early Phase 1|18|Anticipated|Ruijin Hospital||1|||f||||f|f|f|||||||||No||2023-09-02 02:35:34.071442|2023-09-02 02:35:34.071442|OTHER|||||
NCT03741127||2018-11-07|||2023-04-25|2018-11-09|2018-11-14|Actual|||||||2023-04-25|2023-04-27|Actual|October 29, 2018|Actual|2018-10-29|April 2023|2023-04-30|November 2032|Anticipated|2032-11-30|August 2032|Anticipated|2032-08-31||Interventional|||Long-Term Follow-Up Study for Subjects Treated With P-BCMA-101|Open Label, Multicenter, Long-Term Follow-Up Study for Subjects Treated With P-BCMA-101|Active, not recruiting||Phase 1|100|Anticipated|Poseida Therapeutics, Inc.||1|||f||||t|t|f|||||||||||2023-09-02 15:59:03.506537|2023-09-02 15:59:03.506537|INDUSTRY|||||
NCT03601078||2018-07-17|||2023-04-25|2018-07-17|2018-07-26|Actual|||||||2023-04-25|2023-04-27|Actual|December 13, 2018|Actual|2018-12-13|April 2023|2023-04-30|December 30, 2030|Anticipated|2030-12-30|December 18, 2023|Anticipated|2023-12-18||Interventional|KarMMa-2||An Efficacy and Safety Study of bb2121 in Subjects With Relapsed and Refractory Multiple Myeloma and in Subjects With High-Risk Multiple Myeloma|A Phase 2, Multi-cohort, Open-label, Multicenter Study to Evaluate the Efficacy and Safety of bb2121 in Subjects With Relapsed and Refractory Multiple Myeloma and in Subjects With Clinical High-Risk Multiple Myeloma (KarMMa-2)|Recruiting||Phase 2|235|Anticipated|Celgene||3|||f||||t|t|f|||||||||||2023-09-02 15:59:12.470376|2023-09-02 15:59:12.470376|INDUSTRY|||||
NCT05639179||2022-11-25|||2022-12-07|2022-11-25|2022-12-06|Actual|||||||2022-12-07|2022-12-08|Actual|December 5, 2022|Actual|2022-12-05|December 2022|2022-12-31|December 31, 2025|Anticipated|2025-12-31|December 31, 2024|Anticipated|2024-12-31||Interventional|||Novel Anti-CD19 Universal CAR-T Cells for r/r CD19+ B-ALL|An Investigator-initiated Trial to Evaluate the Efficacy and Safety of Anti-CD19 Universal CAR-T Cells in the Treatment of Relapsed/Refractory(r/r) CD19+ B-cell Acute Lymphoblastic Leukemia(B-ALL)|Recruiting||Phase 1/Phase 2|30|Anticipated|920th Hospital of Joint Logistics Support Force of People's Liberation Army of China||1|||f||||f|f|f|||||||||||2023-09-02 02:38:22.105857|2023-09-02 02:38:22.105857|OTHER|||||
NCT05286164||2022-02-24|||2022-04-14|2022-03-17|2022-03-18|Actual|||||||2022-04-14|2022-04-15|Actual|April 2022|Anticipated|2022-04-30|March 2022|2022-03-31|April 2024|Anticipated|2024-04-30|April 2023|Anticipated|2023-04-30||Interventional|||Eltrombopag Treatment in Patients With Prolonged BM Toxicity After CART|Eltrombopag Treatment and Analysis of Bone Marrow Environment in Patients With Prolonged Bone Marrow Toxicity After CART Treatment|Recruiting||Phase 2|30|Anticipated|Tel-Aviv Sourasky Medical Center||1|||f||||f|f|f|||||||||||2023-09-02 16:04:14.535568|2023-09-02 16:04:14.535568|OTHER_GOV|||||
NCT02954445||2016-11-02|||2019-06-23|2016-11-02|2016-11-03|Estimate|||||||2019-06-23|2019-06-25|Actual|October 2016||2016-10-31|June 2019|2019-06-30|October 2020|Anticipated|2020-10-31|October 2019|Anticipated|2019-10-31||Interventional|||A Clinical Research of BCMA-Targeted CAR-T in B Cell Malignancies|A Clinical Research of BCMA-Targeted CAR-T in B Cell Malignancies|Unknown status|Recruiting|Phase 1/Phase 2|45|Anticipated|Southwest Hospital, China||1|||f||||f|||||||||||Undecided||2023-09-02 02:44:58.744017|2023-09-02 02:44:58.744017|OTHER|||||
NCT03614858||2018-07-28|||2022-05-18|2018-07-28|2018-08-03|Actual|||||||2022-05-18|2022-05-19|Actual|September 1, 2017|Actual|2017-09-01|May 2022|2022-05-31|January 1, 2024|Anticipated|2024-01-01|December 1, 2023|Anticipated|2023-12-01||Interventional|||CD19/CD22-targeted Chimeric Antigen Receptor Engineered T Cell (CART) in B-Cell Acute Lymphoblastic Leukemia.|Pilot Study of the Efficacy and Safety of Cluster of Differentiation Antigen 19 (CD19) /Cluster of Differentiation Antigen 22 (CD22) CART in the Treatment of Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia.|Recruiting||Phase 1/Phase 2|20|Anticipated|Shanghai Unicar-Therapy Bio-medicine Technology Co.,Ltd||1|||f|||||f|f|||||||||||2023-09-02 16:12:48.356041|2023-09-02 16:12:48.356041|INDUSTRY|||||
NCT05064787||2021-09-08|||2022-04-12|2021-09-22|2021-10-01|Actual|||||||2022-04-12|2022-04-13|Actual|March 11, 2022|Actual|2022-03-11|April 2022|2022-04-30|March 2023|Anticipated|2023-03-31|December 2022|Anticipated|2022-12-31||Interventional|||Evaluating the Feasibility of a Digital Health Coaching Program for Individuals Following CAR T Therapy|Evaluating the Feasibility of a Digital Health Coaching Program for Individuals Following CAR T Therapy|Recruiting||Not Applicable|50|Anticipated|Pack Health||1|||f||||f|f|f|||||||||No||2023-09-02 16:13:21.363086|2023-09-02 16:13:21.363086|INDUSTRY|||||
NCT02274584||2014-10-22|||2014-10-22|2014-10-22|2014-10-24|Estimate|||||||2014-10-22|2014-10-24|Estimate|March 2014||2014-03-31|October 2014|2014-10-31|October 2017|Anticipated|2017-10-31|October 2016|Anticipated|2016-10-31||Interventional|||CAR T Cells Targeting CD30 Positive Lymphomas (4SCAR30273)|Safety and Efficacy Evaluation of 4th Generation Safety-engineered CAR T Cells Targeting Relapsed and Refractory CD30 Positive Lymphomas|Unknown status|Recruiting|Phase 1/Phase 2|20|Anticipated|Peking University||1|||f||||t|||||||||||||2023-09-02 02:46:03.100757|2023-09-02 02:46:03.100757|OTHER|||||
NCT02203825||2014-07-25|||2018-05-30|2014-07-29|2014-07-30|Estimate|||||||2018-05-30|2018-06-01|Actual|March 2015||2015-03-31|May 2018|2018-05-31|March 2018|Actual|2018-03-31|March 2018|Actual|2018-03-31||Interventional|||Safety Study of Chimeric Antigen Receptor Modified T-cells Targeting NKG2D-Ligands|A Phase 1 Study of Chimeric Antigen Receptor Modified T-cells Targeting NKG2D-Ligands in Patients With Acute Myeloid Leukemia (AML)/Advanced Myelodysplastic Syndrome (MDS-RAEB) and Multiple Myeloma.|Completed||Phase 1|12|Actual|Celyad Oncology SA||1|||f||||t|||||||||||||2023-09-04 14:53:48.295866|2023-09-04 14:53:48.295866|INDUSTRY|||||
NCT04712864||2020-12-01|||2022-02-15|2021-01-14|2021-01-15|Actual|||||||2022-02-15|2022-02-16|Actual|September 13, 2021|Actual|2021-09-13|February 2022|2022-02-28|December 2025|Anticipated|2025-12-31|December 2023|Anticipated|2023-12-31||Interventional|||Study of CD4-Targeted Chimeric Antigen Receptor T-Cells (CD4- CAR-T) in Subjects With Relapsed or Refractory T-Cell Lymphoma|A Phase 1, First-In-Human, Open-Label, Multicenter, Multicohort Study of CD4-Targeted Chimeric Antigen Receptor T-Cells (CD4- CAR-T) in Subjects With Relapsed or Refractory T-Cell Lymphoma|Active, not recruiting||Phase 1|50|Anticipated|Legend Biotech USA Inc||1|||f||||f|t|f|||f||||||No||2023-09-02 16:18:03.597131|2023-09-02 16:18:03.597131|INDUSTRY|||||
NCT05143151||2021-11-22|||2021-12-02|2021-12-02|2021-12-03|Actual|||||||2021-12-02|2021-12-03|Actual|July 1, 2021|Actual|2021-07-01|July 2021|2021-07-31|July 2024|Anticipated|2024-07-31|June 2024|Anticipated|2024-06-30||Interventional|CAR-T||CD276-targeted Chimeric Antigen Receptor T Cells in Treatment With Advanced Pancreatic Cancer|Study on the Efficacy and Safety of CD276-targeted Chimeric Antigen Receptor T Cells (CD276 CAR-T) in Refractory Pancreatic Cancer|Recruiting||Phase 1/Phase 2|10|Anticipated|Shenzhen University General Hospital||1|||f||||f|f|f|||||||||No||2023-09-02 02:56:29.187831|2023-09-02 02:56:29.187831|OTHER|||||
NCT05143112||2021-11-22|||2021-11-22|2021-11-22|2021-12-03|Actual|||||||2021-11-22|2021-12-03|Actual|February 5, 2021|Actual|2021-02-05|February 2021|2021-02-28|February 2024|Anticipated|2024-02-29|February 2024|Anticipated|2024-02-29||Interventional|CAR-T||Allogeneic CD19 CAR-T Cells for the Treatment of Relapsed/Refractory B-cell Lymphoma|Allogeneic CD19 CAR-T Cells for the Treatment of Relapsed/Refractory B-cell Lymphoma|Recruiting||Phase 1/Phase 2|20|Anticipated|Shenzhen University General Hospital||1|||f||||f|f|f|||||||||||2023-09-02 02:56:31.192|2023-09-02 02:56:31.192|OTHER|||||
NCT05149391||2021-11-09|||2021-11-24|2021-11-24|2021-12-08|Actual|||||||2021-11-24|2021-12-08|Actual|July 20, 2021|Actual|2021-07-20|November 2021|2021-11-30|October 2024|Anticipated|2024-10-31|July 2024|Anticipated|2024-07-31||Interventional|||A Study of C-CAR039 in Subjects With Relapsed and/or Refractory B Cell Non-Hodgkin's Lymphoma|A Phase 1 Study of CD19 and CD20 Targeted Chimeric Antigen Receptor T Cells Therapy (C-CAR039) in Subjects With Relapsed and/or Refractory B Cell Non-Hodgkin's Lymphoma|Recruiting||Phase 1|18|Anticipated|Peking University||1|||f||||f|f|f|||||||||No||2023-09-02 02:58:22.871044|2023-09-02 02:58:22.871044|OTHER|||||
NCT04692948||2020-12-28|||2021-03-04|2020-12-31|2021-01-05|Actual|||||||2021-03-04|2021-03-08|Actual|December 9, 2019|Actual|2019-12-09|March 2021|2021-03-31|December 2023|Anticipated|2023-12-31|December 2021|Anticipated|2021-12-31||Interventional|||TAA6 Cell Injection In The Treatment of Patients With Relapsed / Refractory Acute Myeloid Leukemia|TAA6 Cell Injection In The Treatment of Patients With Relapsed / Refractory Acute Myeloid Leukemia|Recruiting||Not Applicable|5|Anticipated|PersonGen BioTherapeutics (Suzhou) Co., Ltd.||1|||f||||f|f|f|||||||||||2023-09-02 02:59:27.419547|2023-09-02 02:59:27.419547|INDUSTRY|||||
NCT03617198||2018-07-09|||2022-10-11|2018-08-02|2018-08-06|Actual|||||||2022-10-11|2022-10-14|Actual|July 31, 2019|Actual|2019-07-31|October 2022|2022-10-31|December 2027|Anticipated|2027-12-31|December 2026|Anticipated|2026-12-31||Interventional|||CD4 CAR+ ZFN-modified T Cells in HIV Therapy|A Pilot Study of T Cells Genetically Modified by Zinc Finger Nucleases SB-728mR and CD4 Chimeric Antigen Receptor in HIV-infected Subjects|Active, not recruiting||Phase 1|12|Actual|University of Pennsylvania||2|||f||||t|t|f|||||||||||2023-09-02 16:28:17.454489|2023-09-02 16:28:17.454489|OTHER|||||
NCT02844062||2016-07-22|||2016-07-22|2016-07-22|2016-07-26|Estimate|||||||2016-07-22|2016-07-26|Estimate|July 2016||2016-07-31|July 2016|2016-07-31|July 2019|Anticipated|2019-07-31|July 2018|Anticipated|2018-07-31||Interventional|||Pilot Study of Autologous Anti-EGFRvIII CAR T Cells in Recurrent Glioblastoma Multiforme|A Safety and Efficacy Study of Autologous Chimeric Antigen Receptor Engineered T Cells Redirected to EGFRvIII in Patients With Recurrent Glioblastoma Multiforme|Unknown status|Recruiting|Phase 1|20|Anticipated|Beijing Sanbo Brain Hospital||1|||f||||t|||||||||||Yes||2023-09-02 16:28:33.323499|2023-09-02 16:28:33.323499|OTHER|||||
NCT04691349||2020-12-28|||2021-01-08|2020-12-28|2020-12-31|Actual|||||||2021-01-08|2021-01-11|Actual|September 27, 2020|Actual|2020-09-27|January 2021|2021-01-31|September 26, 2021|Anticipated|2021-09-26|January 26, 2021|Anticipated|2021-01-26||Interventional|||CAR-T for r/r Malignant Tumors in Children|Chimeric Antigen Receptor T Cells Therapy for r/r Malignant Tumors in Children|Unknown status|Recruiting|Early Phase 1|10|Anticipated|PersonGen BioTherapeutics (Suzhou) Co., Ltd.||1|||f|||||f|f|||||||||||2023-09-02 03:02:48.305698|2023-09-02 03:02:48.305698|INDUSTRY|||||
NCT03430011||2018-02-06|||2023-02-28|2018-02-09|2018-02-12|Actual|||||||2023-02-28|2023-03-01|Actual|February 1, 2018|Actual|2018-02-01|February 2023|2023-02-28|April 7, 2023|Anticipated|2023-04-07|April 7, 2023|Anticipated|2023-04-07||Interventional|EVOLVE||Study Evaluating the Safety and Efficacy of JCARH125 in Subjects With Relapsed and/or Refractory Multiple Myeloma|Protocol H125001: An Open-Label Phase 1/2 Study of JCARH125, BCMA-targeted Chimeric Antigen Receptor (CAR) T Cells, in Subjects With Relapsed or Refractory Multiple Myeloma|Active, not recruiting||Phase 1/Phase 2|169|Actual|Juno Therapeutics, a Subsidiary of Celgene||2|||f||||t|t|f|||||||||Undecided||2023-08-31 21:30:06.977108|2023-08-31 21:30:06.977108|INDUSTRY|||||
NCT04237428||2020-01-13|||2020-01-17|2020-01-17|2020-01-23|Actual|||||||2020-01-17|2020-01-23|Actual|May 31, 2019|Actual|2019-05-31|January 2020|2020-01-31|May 31, 2021|Anticipated|2021-05-31|June 15, 2019|Actual|2019-06-15||Interventional|||CD19-CART in the Treatment of R/R CD19 Positive Non-Hodgkin's Lymphoma|Clinical Study on the Treatment of Relapsed or Refractory CD19 Positive Non-Hodgkin's Lymphoma Patients With Target CD19 Chimeric Antigen Receptor T Cell Infusion|Unknown status|Recruiting|Not Applicable|20|Anticipated|PersonGen BioTherapeutics (Suzhou) Co., Ltd.||1|||f|||||f|f|||||||||Undecided||2023-09-02 16:36:38.46508|2023-09-02 16:36:38.46508|INDUSTRY|||||
NCT05627323||2022-11-16|||2023-08-04|2022-11-16|2022-11-25|Actual|||||||2023-08-04|2023-08-07|Actual|June 6, 2023|Actual|2023-06-06|August 2023|2023-08-31|January 2041|Anticipated|2041-01-31|October 2024|Anticipated|2024-10-31||Interventional|||CAR T Cells in Patients With MMP2+ Recurrent or Progressive Glioblastoma|A Phase 1b Study to Evaluate CHM-1101, a CAR T-Cell Therapy With a Chlorotoxin Tumor-Targeting Domain for Patients With Matrix Metallopeptidase 2 Positive (MMP2+) Recurrent or Progressive Glioblastoma Multiforme|Recruiting||Phase 1|42|Anticipated|Chimeric Therapeutics||2|||f||||t|t|f|||||||||No||2023-09-02 16:42:44.445194|2023-09-02 16:42:44.445194|INDUSTRY|||||
NCT05117008||2021-11-02|||2023-08-03|2021-11-02|2021-11-11|Actual|||||||2023-08-03|2023-08-07|Actual|July 19, 2022|Actual|2022-07-19|August 2023|2023-08-31|January 2032|Anticipated|2032-01-31|January 2027|Anticipated|2027-01-31||Interventional|EMBRACE||Maintenance Belantamab Mafodotin (Blenrep®) After B-cell Maturation Antigen-Directed Chimeric Antigen Receptor T-cell Therapy in Patients With Relapsed and/or Refractory Multiple Myeloma|A Multicenter Phase II Study of Maintenance Belantamab Mafodotin (Blenrep®) After BCMA-Directed Chimeric Antigen Receptor T-cell Therapy in Patients With Relapsed and/or Refractory Multiple Myeloma|Recruiting||Phase 2|45|Anticipated|Medical College of Wisconsin||1|||||||t|t|f|||||||||No||2023-09-02 16:44:19.065858|2023-09-02 16:44:19.065858|OTHER|||||
NCT04984356||2021-07-29|||2023-08-02|2021-07-29|2021-07-30|Actual|||||||2023-08-02|2023-08-07|Actual|January 14, 2022|Actual|2022-01-14|August 2023|2023-08-31|August 2026|Anticipated|2026-08-31|May 2026|Anticipated|2026-05-31||Interventional|||A Phase 1/2 Study of the Safety and Efficacy of Anti-CD7 Allogeneic CAR-T Cells (WU-CART-007) in Patients With Relapsed or Refractory T-ALL/LBL|A Phase 1/2 Dose-Escalation and Dose-Expansion Study of the Safety and Efficacy of Anti-CD7 Allogeneic CAR-T Cells (WU-CART-007) in Patients With Relapsed or Refractory T-cell Acute Lymphoblastic Leukemia (T-ALL)/Lymphoblastic Lymphoma (LBL)|Recruiting||Phase 1/Phase 2|44|Anticipated|Wugen, Inc.||1|||f||||t|t|f|||||||||||2023-09-02 16:44:40.052692|2023-09-02 16:44:40.052692|INDUSTRY|||||
NCT05594797||2022-10-18|||2022-12-07|2022-10-21|2022-10-26|Actual|||||||2022-12-07|2022-12-09|Actual|July 12, 2022|Actual|2022-07-12|October 2022|2022-10-31|July 31, 2027|Anticipated|2027-07-31|July 31, 2025|Anticipated|2025-07-31||Interventional|||Human BCMA Targeted T Cells Injection（BCMA CAR-T）for Subjects With R/R MM|A Phase Ⅱ Clinical Study Evaluating the Efficacy and Safety of Human BCMA Targeted T Cells Injection Therapy for Relapsed/Refractory Multiple Myeloma|Recruiting||Phase 2|100|Anticipated|Hrain Biotechnology Co., Ltd.||1|||f||||f|f|f|||||||||No||2023-09-02 03:23:28.41855|2023-09-02 03:23:28.41855|INDUSTRY|||||
NCT02933775||2016-10-13|||2016-10-13|2016-10-13|2016-10-14|Estimate|||||||2016-10-13|2016-10-14|Estimate|October 2016||2016-10-31|October 2016|2016-10-31|January 2020|Anticipated|2020-01-31|April 2018|Anticipated|2018-04-30||Interventional|||CD19-redirected Autologous Cells (CAR-CD19 T Cells)|Autologous T Cells With a Chimeric Antigen Receptor in Patients With CD19-positive Malignant B Cell Leukemia and Lymphoma|Unknown status|Not yet recruiting|Phase 1|45|Anticipated|RenJi Hospital||1|||f||||t|||||||||||||2023-09-02 03:23:42.797719|2023-09-02 03:23:42.797719|OTHER|||||
NCT05467254||2022-07-01|||2022-07-19|2022-07-19|2022-07-20|Actual|||||||2022-07-19|2022-07-20|Actual|August 2, 2022|Anticipated|2022-08-02|July 2022|2022-07-31|August 2, 2025|Anticipated|2025-08-02|August 2, 2024|Anticipated|2024-08-02||Interventional|||Evaluate the Safety and Efficacy of CLL1+CD33 CAR-T in Patients With R/R AML|To Evaluate the Safety and Efficacy of CLL1+CD33 CAR-T in Patients With Relapsed and Refractory Acute Myeloid Leukemia|Not yet recruiting||Phase 1|20|Anticipated|Zhejiang University||1|||f||||f|f|f|||||||||||2023-09-02 03:24:36.523855|2023-09-02 03:24:36.523855|OTHER|||||
NCT05168748||2021-11-03|||2022-12-20|2021-12-09|2021-12-23|Actual|||||||2022-12-20|2022-12-21|Actual|January 24, 2023|Anticipated|2023-01-24|September 2022|2022-09-30|August 13, 2026|Anticipated|2026-08-13|August 13, 2026|Anticipated|2026-08-13||Interventional|||CD19- and CD22-directed CAR-T Cell Therapy in Patients With Acute Lymphoblastic Leukemia|Phase I, Open Label, Multicenter, Dose Escalation and Expansion Study of IMJ995 in Acute Lymphoblastic Leukemia|Withdrawn||Phase 1|0|Actual|Novartis||1||Sponsor's decision|f||||f|t|f|||||||||No||2023-09-02 16:57:48.330097|2023-09-02 16:57:48.330097|INDUSTRY|||||
NCT05467202||2022-07-01|||2022-07-17|2022-07-17|2022-07-20|Actual|||||||2022-07-17|2022-07-20|Actual|August 1, 2022|Anticipated|2022-08-01|July 2022|2022-07-31|August 2, 2025|Anticipated|2025-08-02|August 2, 2024|Anticipated|2024-08-02||Interventional|||Evaluate the Safety and Efficacy of CLL1 CAR-T in Patients With R/R AML|To Evaluate the Safety and Efficacy of CLL1 CAR-T in Patients With Relapsed and Refractory Acute Myeloid Leukemia|Not yet recruiting||Phase 1|20|Anticipated|Zhejiang University||1|||f||||f|f|f|||||||||||2023-09-02 03:27:32.798353|2023-09-02 03:27:32.798353|OTHER|||||
NCT02772198||2016-05-09|||2020-11-01|2016-05-12|2016-05-13|Estimate|||||||2020-11-01|2020-11-03|Actual|November 2016|Actual|2016-11-30|October 2020|2020-10-31|November 2022|Anticipated|2022-11-30|July 2022|Anticipated|2022-07-31||Interventional|||T-cells Expressing Anti-CD19 CAR in Pediatric and Young Adults With B-cell Malignancies|A Phase 1 / 2 Single Arm Study of T-cells Expressing Anti-CD19 Chimeric Antigen Receptor in Pediatric and Young Adult Patients With B-cell Malignancies|Unknown status|Recruiting|Phase 1/Phase 2|300|Anticipated|Sheba Medical Center||1|||f||||f|||||||||||Undecided||2023-09-02 17:03:17.000644|2023-09-02 17:03:17.000644|OTHER_GOV|||||
NCT04206943||2019-12-16|||2020-01-23|2019-12-19|2019-12-20|Actual|||||||2020-01-23|2020-01-27|Actual|October 12, 2019|Actual|2019-10-12|September 2019|2019-09-30|January 1, 2021|Anticipated|2021-01-01|January 1, 2021|Anticipated|2021-01-01||Interventional|ISIKOK-19||Study of CD19 Specific Chimeric Antigen Receptor Positive T Cells (CAR-T) in ALL and NHL|Phase I/ II Study of Cluster of Differentiation 19 (CD19) Specific CAR-T Cells (ISIKOK 19) in Relapsed/Refractory Acute Lymphoblastic Leukemia (ALL) and Non Hodgkin Lymphoma (NHL)|Unknown status|Recruiting|Phase 1/Phase 2|24|Anticipated|Acibadem University||2|||f||||f|f|f|||||||||||2023-09-02 03:35:09.791316|2023-09-02 03:35:09.791316|OTHER|||||
NCT05562024||2022-09-23|||2023-02-23|2022-09-27|2022-09-30|Actual|||||||2023-02-23|2023-02-27|Actual|December 30, 2022|Actual|2022-12-30|February 2023|2023-02-28|February 18, 2039|Anticipated|2039-02-18|December 18, 2025|Anticipated|2025-12-18||Interventional|||TAA06 Injection in the Treatment of Patients With B7-H3-positive Relapsed/ Refractory Neuroblastoma|An Open-label, Dose-escalation, and Dose-expansion Phase I Trial of TAA06 Injection in Patients With Relapsed/Refractory Neuroblastoma|Recruiting||Phase 1|24|Anticipated|PersonGen BioTherapeutics (Suzhou) Co., Ltd.||1|||f|||||f|f|||||||||||2023-09-02 03:37:01.936126|2023-09-02 03:37:01.936126|INDUSTRY|||||
NCT05659628||2022-11-26|||2022-12-12|2022-12-12|2022-12-21|Actual|||||||2022-12-12|2022-12-21|Actual|December 2022|Anticipated|2022-12-31|December 2022|2022-12-31|December 2026|Anticipated|2026-12-31|December 2024|Anticipated|2024-12-31||Interventional|||CD19 CAR-T Expressing IL-7 and CCL19 Combined With Anti-PD1 in RR-DLBCL|Phase Ib Clinical Study of CD19 CAR-T Expressing IL-7 and CCL19 Combined With Tislelizumab in the Treatment of Relapsed/Refractory Diffuse Large B-cell Lymphoma|Recruiting||Phase 1|24|Anticipated|Ningbo No. 1 Hospital||1|||f|||||f|f|||||||||No||2023-09-02 17:18:36.542647|2023-09-02 17:18:36.542647|OTHER|||||
NCT02537977||2015-08-26|||2018-11-29|2015-08-28|2015-09-02|Estimate|||||||2018-11-29|2018-12-03|Actual|July 2015|Actual|2015-07-31|November 2018|2018-11-30|June 2020|Anticipated|2020-06-30|June 2020|Anticipated|2020-06-30||Interventional|||CD19-directed CAR T Cells Therapy in Relapsed/Refractory B Cell Malignancy|CD19-directed Chimeric Antigen Receptor T Cells Therapy in Relapsed/Refractory B Cell Malignancy|Unknown status|Recruiting|Phase 1/Phase 2|60|Anticipated|Shanghai Tongji Hospital, Tongji University School of Medicine||1|||f||||t|||||||||||No||2023-09-02 17:18:59.270054|2023-09-02 17:18:59.270054|OTHER|||||
NCT05379569||2022-05-03|||2022-05-13|2022-05-13|2022-05-18|Actual|||||||2022-05-13|2022-05-18|Actual|May 15, 2022|Anticipated|2022-05-15|May 2022|2022-05-31|December 30, 2025|Anticipated|2025-12-30|November 30, 2023|Anticipated|2023-11-30||Interventional|||Comparative Study of BFC and BuCy Conditioning Regimen for Allo-PBSCT in Acute B-cell ALL|Shanghai General Hospital, Shanghai, Jiao Tong University School of Medicine|Recruiting||Phase 4|142|Anticipated|Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine||2|||f|||||f|f|||f||||||No||2023-09-02 17:19:47.339734|2023-09-02 17:19:47.339734|OTHER|||||
NCT05382377||2022-05-16|||2022-05-16|2022-05-16|2022-05-19|Actual|||||||2022-05-16|2022-05-19|Actual|May 17, 2022|Anticipated|2022-05-17|May 2022|2022-05-31|May 17, 2026|Anticipated|2026-05-17|May 17, 2024|Anticipated|2024-05-17||Interventional|||NKG2D CAR-T(KD-025) in the Treatment of Advanced NKG2DL+ Solid Tumors|A Single-center, Open-label, Single-arm Clinical Study of the Safety and Efficacy of KD-025 CAR-T Therapy in Advanced NKG2DL+ Solid Tumors|Recruiting||Early Phase 1|18|Anticipated|The Affiliated Hospital of the Chinese Academy of Military Medical Sciences||1|||f||||f|f|f|||||||||No||2023-09-02 17:23:07.723476|2023-09-02 17:23:07.723476|OTHER|||||
NCT05639972||2022-11-28|||2023-03-24|2022-11-28|2022-12-07|Actual|||||||2023-03-24|2023-03-28|Actual|April 2023|Anticipated|2023-04-30|March 2023|2023-03-31|October 1, 2026|Anticipated|2026-10-01|October 1, 2026|Anticipated|2026-10-01||Interventional|||E7 T-cell Receptor (TCR) -T Cell Induction Therapy for Locoregionally Advanced HPV-associated Cancers|A Feasibility Study of E7 TCR-T Cell Induction Therapy for Locoregionally Advanced HPV-Associated Cancers|Suspended||Phase 1/Phase 2|15|Anticipated|Rutgers, The State University of New Jersey||1||Protocol Amendment|f||||t|t|f|||t||||||No||2023-09-02 17:25:27.354204|2023-09-02 17:25:27.354204|OTHER|||||
NCT05588440||2022-09-23|||2023-06-13|2022-10-18|2022-10-20|Actual|||||||2023-06-13|2023-06-15|Actual|May 9, 2023|Actual|2023-05-09|June 2023|2023-06-30|December 2037|Anticipated|2037-12-31|December 2026|Anticipated|2026-12-31||Interventional|||A Clinical Study of ONCT-808 in Subjects With Relapsed or Refractory B-Cell Malignancies|Phase 1/2 Multi-Center Study to Evaluate the Safety and Efficacy of ONCT-808 in Adult Subjects With Relapsed or Refractory Aggressive B-Cell Malignancies|Recruiting||Phase 1/Phase 2|57|Anticipated|Oncternal Therapeutics, Inc||2||||||||t|f|||||||||Undecided||2023-09-02 17:36:04.150824|2023-09-02 17:36:04.150824|INDUSTRY|||||
NCT04740203||2021-01-31|||2021-02-04|2021-02-04|2021-02-05|Actual|||||||2021-02-04|2021-02-05|Actual|January 31, 2021|Anticipated|2021-01-31|February 2021|2021-02-28|January 31, 2025|Anticipated|2025-01-31|January 31, 2024|Anticipated|2024-01-31||Interventional|||Sequential CD19 and CD22 CAR-T Therapy for Newly Diagnosed Ph- B-ALL|Clinical Trial for the Safety and Efficacy of Sequential CD19 and CD22 CAR-T Therapy for Adult Patients With Newly Diagnosed Ph Chromosome Negative B-cell Acute Lymphoblastic Leukemia|Recruiting||Phase 1/Phase 2|50|Anticipated|Zhejiang University||1|||f||||t|f|f|||||||||No||2023-08-31 21:47:36.290218|2023-08-31 21:47:36.290218|OTHER|||||
NCT04473937||2020-07-13|||2021-01-19|2020-07-13|2020-07-16|Actual|||||||2021-01-19|2021-01-20|Actual|July 2021|Anticipated|2021-07-31|January 2021|2021-01-31|May 1, 2024|Anticipated|2024-05-01|May 1, 2022|Anticipated|2022-05-01||Interventional|||Radiation Post-CAR T in Refractory Lymphoma|Radiation Therapy To Enhance CAR T Efficacy Early in Post-CAR T Cell Therapy Refractory Lymphoma: A Pilot Study|Not yet recruiting||Not Applicable|20|Anticipated|Massachusetts General Hospital||1|||f||||t|f|t||||||Data can be shared no earlier than 1 year following the date of publication|Contact the Partners Innovations team at http://www.partners.org/innovation||Yes|The Dana-Farber / Harvard Cancer Center encourages and supports the responsible and ethical sharing of data from clinical trials. De-identified participant data from the final research dataset used in the published manuscript may only be shared under the terms of a Data Use Agreement. Requests may be directed to: [contact information for Sponsor Investigator or designee]. The protocol and statistical analysis plan will be made available on Clinicaltrials.gov only as required by federal regulation or as a condition of awards and agreements supporting the research.|2023-09-04 15:16:12.289028|2023-09-04 15:16:12.289028|OTHER|||||
NCT05172596||2021-12-22|||2023-08-21|2021-12-22|2021-12-29|Actual|||||||2023-08-21|2023-08-22|Actual|March 7, 2022|Actual|2022-03-07|August 2023|2023-08-31|December 16, 2025|Anticipated|2025-12-16|December 16, 2025|Anticipated|2025-12-16||Interventional|||PHE885 CAR-T Therapy in Adult Participants With Relapsed and Refractory Multiple Myeloma|A Phase 2 Study of PHE885, B-cell Maturation Antigen (BCMA)- Directed CAR-T Cells in Adult Participants With Relapsed and Refractory Multiple Myeloma.|Recruiting||Phase 2|136|Anticipated|Novartis||1|||f||||t|t|f||||||||https://www.clinicalstudydatarequest.com|Yes|"Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations.~The Trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com"|2023-09-02 17:54:35.373155|2023-09-02 17:54:35.373155|INDUSTRY|||||
NCT03932565||2019-04-27|||2020-11-16|2019-04-27|2019-04-30|Actual|||||||2020-11-16|2020-11-18|Actual|February 13, 2019|Actual|2019-02-13|November 2020|2020-11-30|December 31, 2021|Anticipated|2021-12-31|June 30, 2021|Anticipated|2021-06-30||Interventional|||Interventional Therapy Sequential With the Fourth-generation CAR-T Targeting Nectin4/FAP for Malignant Solid Tumors|Clinical Trial Study of Interventional Therapy Sequential With the Fourth-generation CAR-T Cells (IL7 and CCL19 or / and IL12) Targeting Nectin4/FAP in the Treatment of Advanced Malignant Solid Tumors With Nectin4-positive|Unknown status|Recruiting|Phase 1|30|Anticipated|The Sixth Affiliated Hospital of Wenzhou Medical University||1|||f|||||f|f|||||||||Undecided||2023-09-03 14:46:37.838196|2023-09-03 14:46:37.838196|OTHER|||||
NCT04923919||2021-05-08|||2023-07-12|2021-06-07|2021-06-11|Actual|||||||2023-07-12|2023-07-13|Actual|September 14, 2021|Actual|2021-09-14|July 2023|2023-07-31|December 5, 2024|Anticipated|2024-12-05|December 5, 2024|Anticipated|2024-12-05||Interventional|||Clinical Study of Chimeric Antigen Receptor T Lymphocytes (CAR-T) in the Treatment of Myeloid Leukemia|Clinical Study of Chimeric Antigen Receptor T Lymphocytes (CAR-T) in the Treatment of Myeloid Leukemia|Recruiting||Early Phase 1|100|Anticipated|920th Hospital of Joint Logistics Support Force of People's Liberation Army of China||1|||f||||f|f|f|||f||||||No||2023-09-04 15:19:10.127558|2023-09-04 15:19:10.127558|OTHER|||||
NCT03666000||2018-08-20|||2022-04-18|2018-09-07|2018-09-11|Actual|||||||2022-04-18|2022-04-25|Actual|March 11, 2019|Actual|2019-03-11|April 2022|2022-04-30|June 2024|Anticipated|2024-06-30|December 2023|Anticipated|2023-12-31||Interventional|||Dose-escalation, Dose-expansion Study of Safety of PBCAR0191 in Patients With r/r NHL and r/r B-cell ALL|Phase 1/2a, Open-label, Dose-escalation, Dose-expansion, Parallel Assignment Study to Evaluate Safety and Clinical Activity of PBCAR0191 in Subjects With Relapsed/Refractory (r/r) Non-Hodgkin Lymphoma (NHL) and r/r B-cell Acute Lymphoblastic Leukemia (B-ALL)|Recruiting||Phase 1/Phase 2|120|Anticipated|Precision BioSciences, Inc.||5|||f||||f|t|f|||||||||No||2023-09-02 18:18:01.639761|2023-09-02 18:18:01.639761|INDUSTRY|||||
NCT05664217||2022-12-01|||2023-08-30|2022-12-16|2022-12-23|Actual|||||||2023-08-30|2023-09-01|Estimate|December 23, 2022|Actual|2022-12-23|August 2023|2023-08-31|January 2029|Anticipated|2029-01-31|January 2027|Anticipated|2027-01-31||Interventional|||NKTR-255 vs Placebo Following CD19-directed CAR-T Therapy in Patients With Relapsed/Refractory Large B-cell Lymphoma|A Phase 2/3, Randomized, Double Blind, Placebo-controlled, Multicenter Study of NKTR-255 vs Placebo Following CD19-directed CAR-T Cell Therapy in Patients With Relapsed/Refractory Large B-cell Lymphoma|Recruiting||Phase 2/Phase 3|400|Anticipated|Nektar Therapeutics||4|||f||||t|t|f|||||||||||2023-09-02 04:17:16.820959|2023-09-02 04:17:16.820959|INDUSTRY|||||
NCT03642496||2018-08-13|||2018-08-22|2018-08-20|2018-08-22|Actual|||||||2018-08-22|2018-08-23|Actual|August 19, 2018|Anticipated|2018-08-19|July 2018|2018-07-31|September 20, 2020|Anticipated|2020-09-20|August 19, 2020|Anticipated|2020-08-19||Interventional|||Clinical Study of ET019002-T Cell Therapy for Refractory/Relapsed B-Cell Malignancies|The Clinical Study of Structurally Optimized ET019002-T Cell Therapy for Refractory/Relapsed B-Cell Malignancies|Unknown status|Not yet recruiting|Early Phase 1|18|Anticipated|First Affiliated Hospital Xi'an Jiaotong University||3|||||||t|t|f|||||||||No||2023-09-03 14:51:17.546009|2023-09-03 14:51:17.546009|OTHER|||||
NCT05621291||2022-11-16|||2023-08-31|2022-11-17|2022-11-18|Actual|||||||2023-08-31|2023-09-01|Estimate|September 6, 2023|Anticipated|2023-09-06|August 9, 2023|2023-08-09|December 31, 2025|Anticipated|2025-12-31|December 31, 2024|Anticipated|2024-12-31||Interventional|||A Study to Evaluate Next-Generation Sequencing (NGS) Testing and Monitoring of B-cell Recovery to Guide Management Following Chimeric Antigen Receptor T-cell (CART) Induced Remission in Children and Young Adults With B Lineage Acute Lymphoblastic Leu...|A Multicenter Study to Evaluate Next-Generation Sequencing (NGS) Testing and Monitoring of B-Cell Recovery to Guide Management Following Chimeric Antigen Receptor T-cell (CART) Induced Remission in Children and Young Adults With B Lineage Acute Lymphoblastic Leukemia|Not yet recruiting||Not Applicable|60|Anticipated|National Institutes of Health Clinical Center (CC)||1|||f|||||f|f||||||Clinical data will be made available within 10 years after completion of the primary endpoint. Genomic data are available once genomic data are uploaded per protocol GDS plan for as long as database is active.|Clinical data will be made available upon request and with the permission of the study PI. Genomic data are made available via dbGaP through requests to the data custodians.||Yes|.All IPD recorded in the medical record will be shared with intramural investigators upon request. In addition, all large scale genomic sequencing will be shared with subscribers to dbGaP.|2023-09-02 04:17:36.42546|2023-09-02 04:17:36.42546|NIH|||||
NCT04185038||2019-11-26|||2022-12-14|2019-12-02|2019-12-04|Actual|||||||2022-12-14|2022-12-19|Actual|December 11, 2019|Actual|2019-12-11|December 2022|2022-12-31|May 2041|Anticipated|2041-05-31|May 2026|Anticipated|2026-05-31||Interventional|||Study of B7-H3-Specific CAR T Cell Locoregional Immunotherapy for Diffuse Intrinsic Pontine Glioma/Diffuse Midline Glioma and Recurrent or Refractory Pediatric Central Nervous System Tumors|Phase 1 Study of B7-H3-Specific CAR T Cell Locoregional Immunotherapy for Diffuse Intrinsic Pontine Glioma/Diffuse Midline Glioma and Recurrent or Refractory Pediatric Central Nervous System Tumors|Recruiting||Phase 1|90|Anticipated|Seattle Children's Hospital||3|||f||||t|t|f|||||||||No||2023-09-02 18:26:27.945441|2023-09-02 18:26:27.945441|OTHER|||||
NCT04960579||2021-06-24|||2023-08-30|2021-07-09|2021-07-14|Actual|||||||2023-08-30|2023-09-01|Estimate|May 5, 2022|Actual|2022-05-05|August 2023|2023-08-31|March 2040|Anticipated|2040-03-31|June 2025|Anticipated|2025-06-30||Interventional|MM||P-BCMA-ALLO1 Allogeneic CAR-T Cells in the Treatment of Subjects With Multiple Myeloma|Open-Label, Multicenter, Phase 1 Study to Assess the Safety of P-BCMA-ALLO1 in Subjects With Relapsed / Refractory Multiple Myeloma (MM)|Recruiting||Phase 1|135|Anticipated|Poseida Therapeutics, Inc.||10|||f||||t|t|f|||||||||No||2023-09-02 04:21:08.638715|2023-09-02 04:21:08.638715|INDUSTRY|||||
NCT02723942||2016-03-20|||2020-07-14|2016-03-24|2016-03-31|Estimate|||||||2020-07-14|2020-07-16|Actual|June 2015|Actual|2015-06-30|July 2020|2020-07-31|August 15, 2016|Actual|2016-08-15|August 15, 2016|Actual|2016-08-15||Interventional|||CAR-T Cell Immunotherapy for HCC Targeting GPC3|Chimeric Antigen Receptor-Modified T Cell (CAR-T) Immunotherapy for Hepatocellular Carcinoma (HCC) Targeting Glypican-3 (GPC3)|Withdrawn||Phase 1/Phase 2|0|Actual|Fuda Cancer Hospital, Guangzhou||2||Project terminated due to revision of local regulations|f||||t|||||||||||||2023-09-02 18:28:29.919497|2023-09-02 18:28:29.919497|OTHER|||||
NCT05015972||2021-04-21|||2022-11-23|2021-08-15|2021-08-23|Actual|||||||2022-11-23|2022-11-29|Actual|August 20, 2021|Anticipated|2021-08-20|November 2022|2022-11-30|December 31, 2023|Anticipated|2023-12-31|June 30, 2023|Anticipated|2023-06-30||Interventional|||UCAR-T for CD19+ Refractory/Relapsed B Hematologic Malignancies|A Study of CTA30X UCAR-T Cell Injection in the Treatment of Patients With r/r CD19+ B Hematologic Malignancies|Withdrawn||Early Phase 1|0|Actual|920th Hospital of Joint Logistics Support Force of People's Liberation Army of China||1||No proper participant is found.|f||||f|f|f|||||||||||2023-09-02 18:28:31.833754|2023-09-02 18:28:31.833754|OTHER|||||
NCT02715362||2016-03-11|||2016-03-16|2016-03-16|2016-03-22|Estimate|||||||2016-03-16|2016-03-22|Estimate|March 2016||2016-03-31|March 2016|2016-03-31|March 2019|Anticipated|2019-03-31|July 2018|Anticipated|2018-07-31||Interventional|GPC3-CART||A Study of GPC3 Redirected Autologous T Cells for Advanced HCC|An Open-label, Uncontrolled, Single-arm Pilot Study to Evaluate Vascular Interventional Therapy Mediated GPC3-targeted Chimeric Antigen Receptor T Cells in Advanced Hepatocellular Carcinoma|Unknown status|Recruiting|Phase 1/Phase 2|30|Anticipated|Shanghai GeneChem Co., Ltd.||1|||f||||f|||||||||||Undecided||2023-09-02 18:28:42.62344|2023-09-02 18:28:42.62344|INDUSTRY|||||
NCT00586391||2007-12-21|||2023-02-14|2007-12-21|2008-01-04|Estimate|||||||2023-02-14|2023-02-16|Actual|February 2009||2009-02-28|February 2023|2023-02-28|July 2029|Anticipated|2029-07-31|July 2014|Actual|2014-07-31||Interventional|CRETI-NH||CD19 Chimeric Receptor Expressing T Lymphocytes In B-Cell Non Hodgkin's Lymphoma, ALL & CLL|Phase I Study Of CD19 Chimeric Receptor Expressing T Lymphocytes In B-Cell Non Hodgkin's Lymphoma, Acute Lymphocytic Leukemia, and Chronic Lymphocytic Leukemia|Active, not recruiting||Phase 1|14|Actual|Baylor College of Medicine||1|||f||||t|||||||||||||2023-08-31 21:48:59.690369|2023-08-31 21:48:59.690369|OTHER|||||
NCT04637763||2020-11-16|||2023-08-31|2020-11-16|2020-11-20|Actual|||||||2023-08-31|2023-09-01|Estimate|May 26, 2021|Actual|2021-05-26|March 2023|2023-03-31|September 2025|Anticipated|2025-09-30|August 2025|Anticipated|2025-08-31||Interventional|||CRISPR-Edited Allogeneic Anti-CD19 CAR-T Cell Therapy for Relapsed/Refractory B Cell Non-Hodgkin Lymphoma|A Phase 1, Multicenter, Open-Label Study of CB-010, a CRISPR-Edited Allogeneic Anti-CD19 CAR-T Cell Therapy in Patients With Relapsed/Refractory B Cell Non-Hodgkin Lymphoma (ANTLER)|Recruiting||Phase 1|72|Anticipated|Caribou Biosciences, Inc.||2|||f||||f|t|f|||||||||Undecided||2023-09-02 04:22:18.179868|2023-09-02 04:22:18.179868|INDUSTRY|||||
NCT02706782||2016-03-08|||2016-03-08|2016-03-08|2016-03-11|Estimate|||||||2016-03-08|2016-03-11|Estimate|March 2016||2016-03-31|March 2016|2016-03-31|September 2018|Anticipated|2018-09-30|February 2018|Anticipated|2018-02-28||Interventional|meso-CART||A Study of Mesothelin Redirected Autologous T Cells for Advanced Pancreatic Carcinoma|An Open-label, Uncontrolled, Single-arm Pilot Study to Evaluate Vascular Interventional Therapy Mediated Mesothelin-targeted Chimeric Antigen Receptor T Cells in Advanced Pancreatic Carcinoma|Unknown status|Recruiting|Phase 1|30|Anticipated|Shanghai GeneChem Co., Ltd.||1|||f||||f|||||||||||Undecided||2023-09-02 18:32:27.679292|2023-09-02 18:32:27.679292|INDUSTRY|||||
NCT04530565||2020-08-27|||2023-08-31|2020-08-27|2020-08-28|Actual|||||||2023-08-31|2023-09-01|Estimate|October 14, 2020|Actual|2020-10-14|March 2023|2023-03-31|July 1, 2028|Anticipated|2028-07-01|July 1, 2028|Anticipated|2028-07-01||Interventional|||Testing the Use of Steroids and Tyrosine Kinase Inhibitors With Blinatumomab or Chemotherapy for Newly Diagnosed BCR-ABL-Positive Acute Lymphoblastic Leukemia in Adults|A Phase III Randomized Trial of Steroids + Tyrosine Kinase Inhibitor (TKI) Induction With Chemotherapy or Blinatumomab for Newly Diagnosed BCR-ABL-Positive Acute Lymphoblastic Leukemia (ALL) in Adults|Recruiting||Phase 3|348|Anticipated|National Cancer Institute (NCI)||5|||f||||f|t|f||||||||https://grants.nih.gov/policy/sharing.htm|Yes|NCI is committed to sharing data in accordance with NIH policy. For more details on how clinical trial data is shared, access the link to the NIH data sharing policy page|2023-09-02 04:22:41.583765|2023-09-02 04:22:41.583765|NIH|||||
NCT04154709||2019-11-04|||2020-01-09|2019-11-04|2019-11-06|Actual|||||||2020-01-09|2020-01-14|Actual|December 10, 2019|Actual|2019-12-10|January 2020|2020-01-31|June 2022|Anticipated|2022-06-30|November 2021|Anticipated|2021-11-30||Interventional|||CTA101 UCAR-T Cell Injection for Treatment of Relapsed or Refractory CD19+ B-cell Acute Lymphoblastic Leukemia|CTA101 UCAR-T Cell Injection for Treatment of Relapsed or Refractory CD19+ B-cell Acute Lymphoblastic Leukemia|Unknown status|Recruiting|Phase 1|15|Anticipated|Xuzhou Medical University||1|||f||||t|f|f|||||||||No||2023-09-02 18:35:12.380534|2023-09-02 18:35:12.380534|OTHER|||||
NCT04099797||2019-09-20|||2023-08-30|2019-09-20|2019-09-23|Actual|||||||2023-08-30|2023-09-01|Estimate|February 3, 2020|Actual|2020-02-03|August 2023|2023-08-31|February 2039|Anticipated|2039-02-28|February 2025|Anticipated|2025-02-28||Interventional|||C7R-GD2.CAR T Cells for Patients With GD2-expressing Brain Tumors (GAIL-B)|Phase I Study of Autologous T Lymphocytes Expressing GD2-specific Chimeric Antigen and Constitutively Active IL-7 Receptors for the Treatment of Patients With GD2-expressing Brain Tumors (GAIL-B)|Recruiting||Phase 1|34|Anticipated|Baylor College of Medicine||1|||f||||t|t|f|||||||||||2023-09-02 04:24:42.164678|2023-09-02 04:24:42.164678|OTHER|||||
NCT04013802||2019-07-08|||2023-08-30|2019-07-08|2019-07-10|Actual|||||||2023-08-30|2023-09-01|Estimate|March 8, 2021|Actual|2021-03-08|August 2023|2023-08-31|May 1, 2024|Anticipated|2024-05-01|May 1, 2024|Anticipated|2024-05-01||Interventional|TETRAVI||TETRAVI Multivirus CTL for Treatment of EBV, CMV, Adenovirus, and BK Infections Post Allogeneic SCT.|Administration of Most Closely HLA-matched Multivirus-specific Cytotoxic T-Lymphocytes for the Treatment of EBV, CMV, Adenovirus, and BK Virus Infections Post Allogeneic Stem Cell Transplant|Recruiting||Phase 1|47|Anticipated|Baylor College of Medicine||1|||f||||t|t|f|||f||||||No||2023-09-02 04:24:58.623986|2023-09-02 04:24:58.623986|OTHER|||||
NCT01953900||2013-09-26|||2023-03-28|2013-09-26|2013-10-01|Estimate|||||||2023-03-28|2023-03-30|Actual|April 2014||2014-04-30|March 2023|2023-03-31|October 31, 2034|Anticipated|2034-10-31|October 31, 2019|Actual|2019-10-31||Interventional|VEGAS||iC9-GD2-CAR-VZV-CTLs/Refractory or Metastatic GD2-positive Sarcoma and Neuroblastoma|Vaccination to Enhance the Anti-Tumor Activity of GD2 Chimeric Antigen Receptor-Expressing, VZV-Specific T Cells in Subjects With Advanced Sarcomas and Neuroblastoma (VEGAS)|Active, not recruiting||Phase 1|26|Anticipated|Baylor College of Medicine||1|||f||||t|||||||||||||2023-09-04 15:41:14.245462|2023-09-04 15:41:14.245462|OTHER|||||
NCT05344664||2022-04-19|||2022-04-22|2022-04-22|2022-04-25|Actual|||||||2022-04-22|2022-04-25|Actual|April 14, 2022|Anticipated|2022-04-14|April 2022|2022-04-30|February 1, 2025|Anticipated|2025-02-01|October 14, 2024|Anticipated|2024-10-14||Interventional|||Novel GPC3 CAR-T Cell Therapy for Hepatocellular Carcinoma|Safety and Efficacy of Novel GPC3 CAR-T Cells in the Treatment of Hepatocellular Carcinoma Exploratory Clinical Studies|Not yet recruiting||Phase 1|12|Anticipated|Peking University|||||f||||t|f|f|||||||||||2023-09-02 18:36:42.984306|2023-09-02 18:36:42.984306|OTHER|||||
NCT03528421||2018-05-07|||2018-07-13|2018-05-07|2018-05-17|Actual|||||||2018-07-13|2018-07-16|Actual|May 22, 2018|Actual|2018-05-22|May 2018|2018-05-31|May 2020|Anticipated|2020-05-31|April 2020|Anticipated|2020-04-30||Interventional|||Assessment of Safety and Efficacy of IM19 for Relapsed or Refractory NHL Patients|Clinical Study to Evaluate the Safety and Efficacy of IM19 CAR-T Cell Therapy in Patients With Relapsed or Refractory CD19-positive Non-Hodgkin's Lymphoma|Unknown status|Recruiting|Phase 1|30|Anticipated|Beijing Immunochina Medical Science & Technology Co., Ltd.||1|||f|||||f|f|||||||||No||2023-09-04 15:41:43.095443|2023-09-04 15:41:43.095443|INDUSTRY|||||
NCT02830724||2016-07-12|||2023-08-31|2016-07-12|2016-07-13|Estimate|||||||2023-08-31|2023-09-01|Estimate|April 6, 2017|Actual|2017-04-06|August 30, 2023|2023-08-30|January 1, 2028|Anticipated|2028-01-01|January 1, 2027|Anticipated|2027-01-01||Interventional|||Administering Peripheral Blood Lymphocytes Transduced With a CD70-Binding Chimeric Antigen Receptor to People With CD70 Expressing Cancers|A Phase I/II Study Administering Peripheral Blood Lymphocytes Transduced With a CD70-Binding Chimeric Antigen Receptor to Patients With CD70-Expressing Cancers|Recruiting||Phase 1/Phase 2|124|Anticipated|National Institutes of Health Clinical Center (CC)||2|||f|||||t|f|||||||||||2023-09-02 04:27:01.143547|2023-09-02 04:27:01.143547|NIH|||||
NCT03927261||2019-04-23|||2023-06-21|2019-04-23|2019-04-25|Actual|||||||2023-06-21|2023-06-23|Actual|May 20, 2019|Actual|2019-05-20|June 2023|2023-06-30|August 1, 2025|Anticipated|2025-08-01|August 1, 2024|Anticipated|2024-08-01||Interventional|||PRGN-3006 Adoptive Cellular Therapy for CD33-Positive Relapsed or Refractory AML, MRD Positive AML or Higher Risk MDS|A Phase 1/1b Safety Study of PRGN-3006 Adoptive Cellular Therapy in Patients With CD33-Positive Relapsed or Refractory Acute Myeloid Leukemia, Minimal Residual Disease Positive Acute Myeloid Leukemia, and Higher Risk Myelodysplastic Syndrome|Recruiting||Phase 1|88|Anticipated|Precigen, Inc||1|||||||f|t|f|||||||||Undecided||2023-09-04 15:44:40.600728|2023-09-04 15:44:40.600728|INDUSTRY|||||
NCT04033302||2019-07-24|||2019-09-18|2019-07-24|2019-07-26|Actual|||||||2019-09-18|2019-09-19|Actual|September 1, 2019|Actual|2019-09-01|September 2019|2019-09-30|December 31, 2023|Anticipated|2023-12-31|July 31, 2021|Anticipated|2021-07-31||Interventional|||Multi-CAR T Cell Therapy Targeting CD7-positive Malignancies|A Multi-Center Study of Multiple CAR T Cell Therapy for CD7-positive Hematological Malignancies|Recruiting||Phase 1/Phase 2|30|Anticipated|Shenzhen Geno-Immune Medical Institute||1|||f||||f|f|f|||||||||||2023-09-02 18:51:28.624944|2023-09-02 18:51:28.624944|OTHER|||||
NCT04639739||2020-11-12|||2020-11-19|2020-11-19|2020-11-20|Actual|||||||2020-11-19|2020-11-20|Actual|December 17, 2020|Anticipated|2020-12-17|November 2020|2020-11-30|December 1, 2023|Anticipated|2023-12-01|December 1, 2021|Anticipated|2021-12-01||Interventional|||Anti-CD19 CAR NK Cell Therapy for R/R Non-Hodgkin Lymphoma.|Anti-CD19 CAR NK Cell Therapy for Relapsed or Refractory B Cell Non-Hodgkin Lymphoma: a Multi-center, Uncontrolled Trial.|Not yet recruiting||Early Phase 1|9|Anticipated|Xinqiao Hospital of Chongqing||1|||f||||f|f|f|||||||||||2023-09-02 05:34:21.545527|2023-09-02 05:34:21.545527|OTHER|||||
NCT04169022||2019-05-16|||2021-01-29|2019-11-18|2019-11-19|Actual|||||||2021-01-29|2021-02-01|Actual|July 10, 2019|Actual|2019-07-10|December 2020|2020-12-31|June 1, 2023|Anticipated|2023-06-01|June 1, 2021|Anticipated|2021-06-01||Interventional|CAR-LAM||AML Cell Immunotherapy Using Chimeric Antigen Receptor T-cells|Targeting Interleukin 1 Receptor Accessory Protein (IL1RAP) Expressing Acute Myeloid Leukemic (AML) Cells by Chimeric Antigen Receptor (CAR) Engineered T-cells|Unknown status|Recruiting|Not Applicable|50|Anticipated|Centre Hospitalier Universitaire de Besancon||2|||f||||f|f|f|||||||||||2023-09-02 18:58:46.850657|2023-09-02 18:58:46.850657|OTHER|||||
NCT04186052||2019-11-05|||2019-12-02|2019-12-02|2019-12-04|Actual|||||||2019-12-02|2019-12-04|Actual|March 8, 2019|Actual|2019-03-08|December 2019|2019-12-31|March 1, 2021|Anticipated|2021-03-01|March 1, 2021|Anticipated|2021-03-01||Interventional|||Clinical Trial of BCMA CAR T Cell Infusion in Patients With BCMA-positive r/r Multiple Myeloma|Clinical Study Protocol for Targeting BCMA Autochimeric Antigen Receptor T Cell Infusion One-arm, Single-center, Open-label Clinical Trial of BCMA Autologous Chimeric Antigen Receptor T Cell Infusion in Patients With BCMA-positive Relapsed/Refractory Multiple Myeloma|Unknown status|Recruiting|Early Phase 1|10|Anticipated|PersonGen BioTherapeutics (Suzhou) Co., Ltd.||1|||f|||||f|f|||||||||Undecided||2023-09-02 18:58:53.658355|2023-09-02 18:58:53.658355|INDUSTRY|||||
NCT04581473||2020-09-24|||2022-02-13|2020-10-05|2020-10-09|Actual|||||||2022-02-13|2022-03-02|Actual|October 23, 2020|Actual|2020-10-23|February 2022|2022-02-28|June 30, 2038|Anticipated|2038-06-30|June 30, 2024|Anticipated|2024-06-30||Interventional|||Study to Evaluate the Efficacy, Safety and Pharmacokinetics of CT041 Autologous CAR T-cell Injection|An Open, Multicenter, Phase Ib/II Study to Evaluate the Efficacy, Safety and Pharmacokinetics of CT041 Autologous CAR T-cell Injection in Patients With Advanced Gastric/ Gastroesophageal Junction Adenocarcinoma and Pancreatic Cancer|Recruiting||Phase 1/Phase 2|192|Anticipated|CARsgen Therapeutics Co., Ltd.||2|||f||||t|f|f|||||||||No||2023-09-04 15:50:15.146661|2023-09-04 15:50:15.146661|INDUSTRY|||||
NCT03574168||2018-06-11|||2018-06-20|2018-06-20|2018-06-29|Actual|||||||2018-06-20|2018-06-29|Actual|July 20, 2018|Anticipated|2018-07-20|June 2018|2018-06-30|December 31, 2019|Anticipated|2019-12-31|December 31, 2019|Anticipated|2019-12-31||Interventional|||CD19-CAR-T Cells in Patients With R/R B-ALL|Phase I Study of the Safety and Efficacy of CD19-CAR-T Cells in Patients With Relapsed or Refractory Acute B-cell Lymphoblastic Leukemia (R/R B-ALL)|Unknown status|Recruiting|Phase 1|40|Anticipated|Bioceltech Therapeutics, Ltd.||1|||f|||||f|f|||||||||Undecided||2023-09-03 15:03:04.169275|2023-09-03 15:03:04.169275|INDUSTRY|||||
NCT04184414||2019-11-04|||2019-12-01|2019-12-01|2019-12-03|Actual|||||||2019-12-01|2019-12-03|Actual|January 9, 2018|Actual|2018-01-09|December 2019|2019-12-31|January 1, 2020|Anticipated|2020-01-01|January 1, 2020|Anticipated|2020-01-01||Interventional|||The Clinical Application of Chimeric Antigen Receptor T Cells in the Treatment of CD19 Positive Recurrent Refractory B Cell-derived Hematological Malignancies|CD19-CART Cells in the Treatment of CD19+ r/r B Cell-derived Hematological Malignancies|Unknown status|Recruiting|Early Phase 1|10|Anticipated|PersonGen BioTherapeutics (Suzhou) Co., Ltd.||1|||f|||||f|f|||f||||||No||2023-09-02 19:05:08.185615|2023-09-02 19:05:08.185615|INDUSTRY|||||
NCT02813837||2016-06-19|||2016-06-26|2016-06-24|2016-06-27|Estimate|||||||2016-06-26|2016-06-28|Estimate|June 2015||2015-06-30|June 2016|2016-06-30|July 2021|Anticipated|2021-07-31|January 2021|Anticipated|2021-01-31||Interventional|||Chimeric Antigen Receptor T Cells (CART) Therapy in Refractory/Relapsed B Cell Hematologic Malignancies|A Multicenter Efficacy and Safety Study of Cluster of Differentiation 19 (CD19)-Targeted CART (CD19CART) Therapy for CD19 Positive Relapsed or Refractory B-cell Hematologic Malignancies (SCT019-01）|Unknown status|Recruiting|Not Applicable|30|Anticipated|Innovative Cellular Therapeutics Co., Ltd.||1|||f||||t|||||||||||Undecided||2023-09-02 19:05:45.660731|2023-09-02 19:05:45.660731|OTHER|||||
NCT05652920||2022-11-27|||2022-12-21|2022-12-07|2022-12-15|Actual|||||||2022-12-21|2022-12-23|Actual|December 15, 2022|Actual|2022-12-15|December 2022|2022-12-31|December 2026|Anticipated|2026-12-31|December 2026|Anticipated|2026-12-31||Interventional|||Ori-C101Chimeric Antigen Receptor (CAR) Modified T Cells for the Treatment of HCC|A Phase Ib/II, Open-Label, Multi-Center Study to Investigate the Safety, PK, and Efficacy of Ori-C101 in Advanced Hepatocellular Carcinoma (HCC) Patients (BEACON)|Recruiting||Phase 1/Phase 2|105|Anticipated|OriCell Therapeutics Co., Ltd.||1|||f|||||f|f|||f||||||No||2023-09-02 19:09:59.828034|2023-09-02 19:09:59.828034|INDUSTRY|||||
NCT04236011||2020-01-15|||2021-06-13|2020-01-18|2020-01-22|Actual|||||||2021-06-13|2021-06-15|Actual|January 16, 2020|Actual|2020-01-16|June 2021|2021-06-30|December 31, 2022|Anticipated|2022-12-31|July 31, 2022|Anticipated|2022-07-31||Interventional|||BCMA and CD19 Targeted Fast Dual CAR-T for BCMA+ Refractory/Relapsed Multiple Myeloma|Exploratory Study to Evaluate Efficacy and Safety of GC012F Injection in BCMA+ Refractory/Relapsed Multiple Myeloma|Unknown status|Recruiting|Early Phase 1|15|Anticipated|Shanghai Changzheng Hospital||1|||f|||||f|f|||||||||Undecided||2023-09-02 19:10:10.84962|2023-09-02 19:10:10.84962|OTHER|||||
NCT02794961||2016-06-06|||2016-06-06|2016-06-06|2016-06-09|Estimate|||||||2016-06-06|2016-06-09|Estimate|June 2016||2016-06-30|June 2016|2016-06-30|June 2019|Anticipated|2019-06-30|June 2018|Anticipated|2018-06-30||Interventional|||CD22 Targeting CAR-T Therapy Against B Cell Hematological Malignancies|Application of Humanized Anti-CD22 Antibody in CAR-T Therapy of B Cell Hematological Malignancies|Unknown status|Recruiting|Phase 1/Phase 2|10|Anticipated|Xuzhou Medical University||1|||f||||f|||||||||||Yes||2023-09-02 19:12:11.443499|2023-09-02 19:12:11.443499|OTHER|||||
NCT05445011||2022-06-23|||2022-06-29|2022-06-29|2022-07-06|Actual|||||||2022-06-29|2022-07-06|Actual|June 14, 2022|Actual|2022-06-14|June 2022|2022-06-30|June 14, 2027|Anticipated|2027-06-14|June 14, 2025|Anticipated|2025-06-14||Interventional|||Anti-FLT3 CAR-T Cell (TAA05 Cell Injection) in the Treatment of Relapsed / Refractory Acute Myeloid Leukemia|Safety and Efficacy of Anti-FLT3 CAR- T Cell (TAA05 Cell Injection) in the Treatment of Relapsed/ Refractory Acute Myeloid Leukemia|Recruiting||Phase 1|12|Anticipated|Wuhan Union Hospital, China||1|||f|||||f|f|||||||||No||2023-08-31 21:51:35.579907|2023-08-31 21:51:35.579907|OTHER|||||
NCT02930993||2016-10-10|||2016-10-11|2016-10-11|2016-10-12|Estimate|||||||2016-10-11|2016-10-12|Estimate|August 2016||2016-08-31|October 2016|2016-10-31|August 2019|Anticipated|2019-08-31|August 2018|Anticipated|2018-08-31||Interventional|||Anti-mesothelin CAR T Cells for Patients With Recurrent or Metastatic Malignant Tumors|A Safety and Efficacy Study of Autologous T Cells Engineered to Express Chimeric Antigen Receptor Targeting Mesothelin in Patients With Recurred or Metastatic Malignant Tumors|Unknown status|Recruiting|Phase 1|20|Anticipated|China Meitan General Hospital||1|||f||||f|||||||||||Undecided||2023-09-02 05:42:43.889499|2023-09-02 05:42:43.889499|OTHER|||||
NCT03893019||2019-03-06|||2021-09-20|2019-03-25|2019-03-27|Actual|||||||2021-09-20|2021-09-21|Actual|March 8, 2019|Actual|2019-03-08|September 2021|2021-09-30|July 2022|Anticipated|2022-07-31|July 2022|Anticipated|2022-07-31||Interventional|||MB-CART20.1 Melanoma|Multicenter Phase I Trial of MB-CART20.1 for the Treatment of Patients With Metastatic Melanoma|Recruiting||Early Phase 1|15|Anticipated|Miltenyi Biomedicine GmbH||3|||f||||t|f|f|||||||||No||2023-09-03 15:10:51.491328|2023-09-03 15:10:51.491328|INDUSTRY|||||
NCT02721407||2016-03-23|||2017-03-08|2016-03-23|2016-03-29|Estimate|||||||2017-03-08|2017-03-10|Actual|March 2016||2016-03-31|March 2017|2017-03-31|December 2019|Anticipated|2019-12-31|December 2018|Anticipated|2018-12-31||Interventional|MendCART||Anti-CD22 CAR-T Therapy for CD19-refractory or Resistant Lymphoma Patients|A Phase I Study of Anti-CD22:TCRz:4-1BB T-cells in Patient With CD22-Positive Recurrent Lymphoma That is Resistant or Refractory to Prior Anti-CD22:TCRz:CD28 Immunotherapy|Unknown status|Recruiting|Phase 1|20|Anticipated|Xinqiao Hospital of Chongqing||1|||f||||t|||||||||||Yes||2023-09-02 19:52:09.423189|2023-09-02 19:52:09.423189|OTHER|||||
NCT02765243||2016-05-03|||2021-08-02|2016-05-04|2016-05-06|Estimate|||||||2021-08-02|2021-08-03|Actual|January 1, 2016|Actual|2016-01-01|August 2021|2021-08-31|December 30, 2022|Anticipated|2022-12-30|January 12, 2019|Actual|2019-01-12||Interventional|4SCAR-GD2||Anti-GD2 4th Generation CART Cells Targeting Refractory and/or Recurrent Neuroblastoma|Anti-GD2 4th Generation Chimeric Antigen Receptor-modified T Cells (4SCAR-GD2) Targeting Refractory and/or Recurrent Neuroblastoma|Suspended||Phase 1|20|Anticipated|Zhujiang Hospital||1|||f||||t|||||||||||Undecided||2023-09-02 19:30:41.035102|2023-09-02 19:30:41.035102|OTHER|||||
NCT05326243||2022-03-25|||2023-02-21|2022-04-05|2022-04-13|Actual|||||||2023-02-21|2023-02-22|Actual|May 31, 2022|Actual|2022-05-31|October 2022|2022-10-31|September 24, 2024|Anticipated|2024-09-24|August 7, 2024|Anticipated|2024-08-07||Interventional|||Phase 1/2 Study of CD19 Chimeric Antigen Receptor T-cell (CD19 CAR-T) for Relapsed or Refractory B-cell Lymphoma|A Phase 1/2 Multicenter, Open-label, Single-arm Study to Evaluate the Safety and Efficacy of CD19-targeted Chimeric Antigen Receptor T-cell (CD19 CAR-T) Therapy in Patients With Relapsed or Refractory B-cell Lymphoma|Recruiting||Phase 1/Phase 2|49|Anticipated|Pell Bio-Med Technology Co., Ltd.||1|||f||||t|f|f|||||||||No||2023-08-31 21:57:10.00848|2023-08-31 21:57:10.00848|INDUSTRY|||||
NCT04670055||2020-12-09|||2020-12-09|2020-12-09|2020-12-17|Actual|||||||2020-12-09|2020-12-17|Actual|January 1, 2021|Anticipated|2021-01-01|December 2020|2020-12-31|January 1, 2027|Anticipated|2027-01-01|January 1, 2024|Anticipated|2024-01-01||Interventional|||A Study of Humanized BCMA-targeted CAR-T Cells Therapy for Refractory/Relapsed Multiple Myeloma|Clinical Trial for the Safety and Efficacy of Humanized BCMA-targeted CAR-T Cells Therapy for Refractory/Relapsed Multiple Myeloma|Not yet recruiting||Early Phase 1|50|Anticipated|Zhejiang University||1|||f||||t|f|f|||||||||No||2023-09-02 05:52:50.133747|2023-09-02 05:52:50.133747|OTHER|||||
NCT04657965||2020-10-22|||2020-12-05|2020-12-05|2020-12-08|Actual|||||||2020-12-05|2020-12-08|Actual|January 15, 2021|Anticipated|2021-01-15|December 2020|2020-12-31|January 15, 2027|Anticipated|2027-01-15|January 15, 2024|Anticipated|2024-01-15||Interventional|||LMP1 CAR-T for Patients With LMP1 Positive Infectious Diseases and Hematological Malignancies|Clinical Trial for the Safety and Efficacy of Sequential of LMP1 CAR-T for Patients With LMP1 Positive Infectious Diseases and Hematological Malignancies|Not yet recruiting||Early Phase 1|144|Anticipated|Zhejiang University||1|||f||||t|f|f|||||||||No||2023-09-02 05:53:56.093422|2023-09-02 05:53:56.093422|OTHER|||||
NCT04658004||2020-10-22|||2020-12-05|2020-12-05|2020-12-08|Actual|||||||2020-12-05|2020-12-08|Actual|January 15, 2021|Anticipated|2021-01-15|December 2020|2020-12-31|January 15, 2027|Anticipated|2027-01-15|January 15, 2024|Anticipated|2024-01-15||Interventional|||NKG2D CAR-T Cell Therapy for Patients With Relapsed and/or Refractory Acute Myeloid Leukemia|Clinical Trial for the Safety and Efficacy of NKG2D CAR-T Cell Therapy for Patients With Relapsed and/or Refractory Acute Myeloid Leukemia|Not yet recruiting||Early Phase 1|36|Anticipated|Zhejiang University||1|||f||||t|f|f|||||||||No||2023-09-02 05:53:57.311051|2023-09-02 05:53:57.311051|OTHER|||||
NCT02735291||2016-03-29|||2020-07-13|2016-04-11|2016-04-12|Estimate|||||||2020-07-13|2020-07-15|Actual|November 2015|Actual|2015-11-30|July 2020|2020-07-31|December 2025|Anticipated|2025-12-31|December 2019|Actual|2019-12-31||Interventional|EECNTL||Study Evaluating the Efficacy and Safety With CAR-T for Recurrent or Refractory Acute Non T Lymphocyte Leukemia|Single Arm, Two Phase, Multicenter Trial to Evaluating the Efficacy and Safety of the CAR-T for Recurrent or Refractory Acute Non T Lymphocyte Leukemia|Active, not recruiting||Not Applicable|72|Actual|Sinobioway Cell Therapy Co., Ltd.||1|||f||||t|||||||||||No||2023-09-02 19:45:50.754905|2023-09-02 19:45:50.754905|INDUSTRY|||||
NCT04665063||2020-12-07|||2020-12-24|2020-12-07|2020-12-11|Actual|||||||2020-12-24|2020-12-29|Actual|October 22, 2020|Actual|2020-10-22|October 2020|2020-10-31|October 21, 2025|Anticipated|2025-10-21|October 21, 2023|Anticipated|2023-10-21||Interventional|||A Multicenter Clinical Study on the Safety and Effectiveness of CAR-T in the Treatment of Relapsed/Refractory Hodgkin's Lymphoma|A Multicenter Clinical Study on the Safety and Effectiveness of CAR-T in the Treatment of Relapsed/Refractory Hodgkin's Lymphoma|Recruiting||Not Applicable|20|Anticipated|Hebei Senlang Biotechnology Inc., Ltd.||1|||f|||||f|f|||||||||||2023-09-02 05:55:22.077341|2023-09-02 05:55:22.077341|INDUSTRY|||||
NCT03497533||2018-02-11|||2019-09-05|2018-04-10|2018-04-13|Actual|||||||2019-09-05|2019-09-06|Actual|August 3, 2018|Actual|2018-08-03|September 2019|2019-09-30|December 31, 2020|Anticipated|2020-12-31|December 31, 2020|Anticipated|2020-12-31||Interventional|Trident19-H||Treatment of Refractory/Relapsed Non-Hodgkin Lymphoma With TriCAR-T_CD19|TriCAR-T-CD19 Adoptive Immunotherapy for CD19-positive Refractory/Relapsed Non-Hodgkin Lymphoma|Unknown status|Recruiting|Phase 1/Phase 2|6|Anticipated|Timmune Biotech Inc.||1|||f||||t|f|f|||||||||Undecided||2023-09-04 16:00:52.519993|2023-09-04 16:00:52.519993|INDUSTRY|||||
NCT02737085||2016-04-08|||2016-09-06|2016-04-08|2016-04-13|Estimate|||||||2016-09-06|2016-09-07|Estimate|March 2016||2016-03-31|March 2016|2016-03-31|December 2019|Anticipated|2019-12-31|December 2019|Anticipated|2019-12-31||Interventional|||the Sequential Therapy of CD19-targeted and CD20-targeted CAR-T Cell Therapy for Diffuse Large B Cell Lymphoma(DLBCL)|the Sequential Therapy of CD19-targeted and CD20-targeted CAR-T Cell Therapy for Diffuse Large B Cell Lymphoma(DLBCL)|Unknown status|Active, not recruiting|Phase 1/Phase 2|40|Anticipated|Southwest Hospital, China||1|||f||||t|||||||||||Undecided||2023-09-02 19:47:34.80605|2023-09-02 19:47:34.80605|OTHER|||||
NCT03019055||2017-01-05|2021-04-12||2023-07-24|2017-01-10|2017-01-12|Estimate|2021-05-06|2021-05-07|Actual||||2023-07-24|2023-07-27|Actual|October 16, 2017|Actual|2017-10-16|July 2023|2023-07-31|August 24, 2021|Actual|2021-08-24|October 1, 2019|Actual|2019-10-01||Interventional||Due to a lack of dose limiting toxicities at higher dosages, no subjects were enrolled in the 1.0x10^5 cell/kg dosage level.|Study of CAR-20/19-T Cells in Patients With Relapsed Refractory B Cell|Phase 1/1b Study of Redirected Autologous T Cells Engineered to Contain an Anti CD19 and Anti CD20 scFv Coupled to CD3ζ and 4-1BB Signaling Domains in Patients With Relapsed and/or Refractory CD19 or CD20 Positive B Cell Malignancies|Completed||Phase 1|26|Actual|Medical College of Wisconsin||4|||f||||t|t|f|||||||||No||2023-08-31 22:05:56.661832|2023-08-31 22:05:56.661832|OTHER|||||
NCT05260957||2022-02-15|||2023-01-03|2022-02-28|2022-03-02|Actual|||||||2023-01-03|2023-01-04|Actual|December 14, 2022|Actual|2022-12-14|January 2023|2023-01-31|December 2027|Anticipated|2027-12-31|December 2025|Anticipated|2025-12-31||Interventional|||CAR-T Cell Therapy, Mosunetuzumab and Polatuzumab for Treatment of Refractory/Relapsed Aggressive Non-Hodgkin's Lymphoma (NHL).|ML43165 - Single Arm Phase 2 Trial of an FDA Approved Anti-CD19 CAR-T Therapy Followed by Mosunetuzumab and Polatuzumab Consolidation for the Treatment of Refractory/Relapsed Aggressive NHL.|Recruiting||Phase 2|40|Anticipated|University of Miami||1|||f||||t|t|f|||||||||No||2023-09-02 19:56:40.163056|2023-09-02 19:56:40.163056|OTHER|||||
NCT04638270||2020-11-13|||2020-11-19|2020-11-19|2020-11-20|Actual|||||||2020-11-19|2020-11-20|Actual|November 21, 2020|Anticipated|2020-11-21|November 2020|2020-11-30|November 1, 2023|Anticipated|2023-11-01|November 1, 2021|Anticipated|2021-11-01||Interventional|||Anti-CD19 FasT CAR-T Cell Therapy for B Cell NHL|Anti-CD19 FasT CAR-T Cell Therapy for Patients With B Cell NHL: a Multi-center, Uncontrolled Trial.|Not yet recruiting||Early Phase 1|16|Anticipated|Xinqiao Hospital of Chongqing||1|||f||||f|f|f|||||||||||2023-09-02 06:06:06.53722|2023-09-02 06:06:06.53722|OTHER|||||
NCT03338972||2017-11-07|2022-04-26||2022-08-03|2017-11-07|2017-11-09|Actual|2022-08-03|2022-08-05|Actual||||2022-08-03|2022-08-05|Actual|November 29, 2017|Actual|2017-11-29|August 2022|2022-08-31|March 22, 2022|Actual|2022-03-22|May 3, 2021|Actual|2021-05-03||Interventional|||Immunotherapy With BCMA CAR-T Cells in Treating Patients With BCMA Positive Relapsed or Refractory Multiple Myeloma|A Phase I Study of Adoptive Immunotherapy for Advanced B-Cell Maturation Antigen (BCMA)+ Multiple Myeloma With Autologous CD4+ and CD8+ T Cells Engineered to Express a BCMA-Specific Chimeric Antigen Receptor|Completed||Phase 1|28|Actual|Fred Hutchinson Cancer Center||4|||f||||t|t|f|||||||||||2023-09-03 15:12:47.590553|2023-09-03 15:12:47.590553|OTHER|||||
NCT04162340||2019-11-11|||2021-05-17|2019-11-11|2019-11-14|Actual|||||||2021-05-17|2021-05-19|Actual|July 11, 2019|Actual|2019-07-11|May 2021|2021-05-31|October 2021|Anticipated|2021-10-31|October 2021|Anticipated|2021-10-31||Interventional|||CD4-specific CAR T Cells (CD4 CAR T Cells) for Relapsed/Refractory T Cell Malignancies|CD4-specific CAR T Cells (CD4 CAR T Cells) for Relapsed/Refractory T Cell Malignancies|Unknown status|Recruiting|Phase 1|12|Anticipated|iCell Gene Therapeutics||1|||f||||f|f|f|||||||||No||2023-09-02 20:00:06.168731|2023-09-02 20:00:06.168731|INDUSTRY|||||
NCT03455972||2018-02-19|||2021-05-17|2018-03-05|2018-03-07|Actual|||||||2021-05-17|2021-05-19|Actual|February 20, 2018|Actual|2018-02-20|December 2020|2020-12-31|December 2023|Anticipated|2023-12-31|December 2021|Anticipated|2021-12-31||Interventional|||Study of T Cells Targeting CD19/BCMA (CART-19/BCMA) for High Risk Multiple Myeloma Followed With Auto-HSCT|Study of T Cells Targeting CD19/BCMA (CART-19/BCMA) for High Risk Multiple Myeloma Followed With Auto-HSCT|Recruiting||Phase 1/Phase 2|15|Anticipated|The First Affiliated Hospital of Soochow University||1|||f|||||f|f|||||||||||2023-09-02 06:08:21.450285|2023-09-02 06:08:21.450285|OTHER|||||
NCT03999697||2019-06-25|||2019-06-25|2019-06-25|2019-06-27|Actual|||||||2019-06-25|2019-06-27|Actual|December 1, 2018|Actual|2018-12-01|June 2019|2019-06-30|December 1, 2020|Anticipated|2020-12-01|December 1, 2020|Anticipated|2020-12-01||Interventional|||A Clinical Research of CD22-Targeted CAR-T in B Cell Malignancies|Clinical Study of CD22 CAR T Cells in the Treatment of Patients With Relapsed or Refractory CD22 Positive B Cells With Acute Lymphoblastic Leukemia|Unknown status|Recruiting|Phase 1|10|Anticipated|PersonGen BioTherapeutics (Suzhou) Co., Ltd.||1|||f|||||f|f|||||||||||2023-09-02 20:01:43.628212|2023-09-02 20:01:43.628212|INDUSTRY|||||
NCT05263817||2021-12-01|||2022-02-21|2022-02-21|2022-03-03|Actual|||||||2022-02-21|2022-03-03|Actual|October 8, 2021|Actual|2021-10-08|February 2022|2022-02-28|October 1, 2024|Anticipated|2024-10-01|October 1, 2024|Anticipated|2024-10-01||Interventional|||A Clinical Study of CD19/BCMA CAR-T Cells in the Treatment of Refractory POEMS Syndrome, Amyloidosis, Autoimmune Hemolytic Anemia, and Vasculitis|A Clinical Study on the Safety and Effectiveness of CD19/BCMA Chimeric Antigen Receptor T Cells in the Treatment of Refractory POEMS Syndrome, Amyloidosis, Autoimmune Hemolytic Anemia, and Vasculitis|Recruiting||Early Phase 1|75|Anticipated|Zhejiang University||4|||f||||t|f|f|||||||||||2023-09-02 20:03:05.06985|2023-09-02 20:03:05.06985|OTHER|||||
NCT04627740||2020-11-05|||2020-11-11|2020-11-11|2020-11-13|Actual|||||||2020-11-11|2020-11-13|Actual|December 1, 2020|Anticipated|2020-12-01|November 2020|2020-11-30|December 31, 2023|Anticipated|2023-12-31|December 31, 2022|Anticipated|2022-12-31||Interventional|||Anti-ALPP CAR-T Cells Immunotherapy for Ovarian and Endometrial Cancer|A Single-Arm, Single-Center, Open-Label Pilot Study of Anti-ALPP CART-cells in Patient With Alkaline Phosphatase, Placental (ALPP)-Positive Metastatic Ovarian and Endometrial Cancer.|Not yet recruiting||Phase 1/Phase 2|20|Anticipated|Xinqiao Hospital of Chongqing||1|||f||||f|f|f|||||||||No||2023-09-02 06:11:52.43532|2023-09-02 06:11:52.43532|OTHER|||||
NCT04626765||2020-11-06|||2020-11-11|2020-11-11|2020-11-13|Actual|||||||2020-11-11|2020-11-13|Actual|April 1, 2020|Actual|2020-04-01|November 2020|2020-11-30|May 30, 2023|Anticipated|2023-05-30|March 30, 2023|Anticipated|2023-03-30||Interventional|||CAR-T for Children With Relapsed and Refractory Acute Lymphoblastic Leukemia|An Open, Uncontrolled, Multicenter Clinical Trial to Explore the Safety, Efficacy, and Remission Phase of Chimeric Antigen Receptor T Cell (CAR-T) in the Treatment of Children With Relapsed and Refractory Acute Lymphoblastic Leukemia|Unknown status|Recruiting|Early Phase 1|50|Anticipated|Hebei Senlang Biotechnology Inc., Ltd.||1|||f||||f|f|f|||||||||No||2023-09-02 06:12:19.662201|2023-09-02 06:12:19.662201|INDUSTRY|||||
NCT04626726||2020-11-06|||2020-11-11|2020-11-11|2020-11-13|Actual|||||||2020-11-11|2020-11-13|Actual|April 1, 2020|Actual|2020-04-01|November 2020|2020-11-30|May 30, 2023|Anticipated|2023-05-30|May 30, 2023|Anticipated|2023-05-30||Interventional|||Adult B-ALL Treated by CART Cell Bridging Allogeneic Hematopoietic Stem Cell Transplantation|A Clinical Trial to Explore the Safety, Efficacy, and Remission Phase of CAR-T Cell in the Treatment of Adult Relapsed Refractory (R/R) Acute Lymphoblastic Leukemia Bridging Allogeneic Hematopoietic Stem Cell Transplantation|Unknown status|Recruiting|Early Phase 1|50|Anticipated|Hebei Senlang Biotechnology Inc., Ltd.||1|||f|||||f|f|||||||||No||2023-09-02 06:12:24.928684|2023-09-02 06:12:24.928684|INDUSTRY|||||
NCT03884751||2019-02-25|||2022-02-08|2019-03-19|2019-03-21|Actual|||||||2022-02-08|2022-02-24|Actual|August 15, 2019|Actual|2019-08-15|February 2022|2022-02-28|December 3, 2021|Actual|2021-12-03|May 28, 2021|Actual|2021-05-28||Interventional|||Chimeric Antigen Receptor T Cells Targeting Glypican-3|A Phase I Clinical Study of Chimeric Antigen Receptor T Cells Targeting Glypican-3 (CAR-GPC3 T Cells) in Patients With Advanced Hepatocellular Carcinoma|Completed||Phase 1|9|Actual|CARsgen Therapeutics Co., Ltd.||1|||f||||t|f|f|||||||||No||2023-09-03 15:14:13.100229|2023-09-03 15:14:13.100229|INDUSTRY|||||
NCT02903810||2016-09-13|||2016-10-11|2016-09-15|2016-09-16|Estimate|||||||2016-10-11|2016-10-12|Estimate|September 2016||2016-09-30|October 2016|2016-10-31|December 2019|Anticipated|2019-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Combination Transfer of αCD19-TCRz-41BB and αCD22-TCRz-41BB CAR-T Cells for B-cell Hematologic Malignancy|A Phase I/II Study of Combination Transfer of αCD19-TCRz-41BB and αCD22-TCRz-41BB Chimeric Antigen Receptor T-Cells in Patients With Refractory or Recurrent CD19/22+ B-lineage Leukemia/Lymphoma|Unknown status|Recruiting|Phase 1/Phase 2|20|Anticipated|Xuzhou Medical University||1|||f||||f|||||||||||||2023-09-02 06:13:56.557704|2023-09-02 06:13:56.557704|OTHER|||||
NCT02617134||2015-11-26|||2016-12-04|2015-11-26|2015-11-30|Estimate|||||||2016-12-04|2016-12-06|Estimate|November 2015||2015-11-30|July 2016|2016-07-31|November 2018|Anticipated|2018-11-30|November 2017|Anticipated|2017-11-30||Interventional|||CAR-T Cell Immunotherapy in MUC1 Positive Solid Tumor|Immunotherapy With Chimeric Antigen Receptor-Modified T Cells for MUC1 Positive Advanced Refractory Solid Tumor|Unknown status|Recruiting|Phase 1/Phase 2|20|Anticipated|PersonGen BioTherapeutics (Suzhou) Co., Ltd.||1|||f||||t|||||||||||||2023-09-02 20:11:33.0312|2023-09-02 20:11:33.0312|INDUSTRY|||||
NCT04890236||2021-05-13|||2022-06-15|2021-05-13|2021-05-18|Actual|||||||2022-06-15|2022-06-21|Actual|January 13, 2022|Actual|2022-01-13|June 2022|2022-06-30|August 27, 2025|Anticipated|2025-08-27|August 27, 2024|Anticipated|2024-08-27||Interventional|||Duvelisib Exposure to Enhance Immune Profiles of T Cells in Patients With Recurrent or Refractory Diffuse Large B-Cell Lymphoma, DEEP T CELLS Study|Duvelisib Exposure to Enhance Immune Profiles of T Cells in Patients With Diffuse Large B Cell Lymphoma (DEEP T CELLS)|Recruiting||Early Phase 1|20|Anticipated|Emory University||1|||f||||t|t|f|||||||||||2023-09-02 06:18:39.296799|2023-09-02 06:18:39.296799|OTHER|||||
NCT02443831||2015-04-29|||2022-07-18|2015-05-13|2015-05-14|Estimate|||||||2022-07-18|2022-07-21|Actual|April 2016|Actual|2016-04-30|July 2022|2022-07-31|January 2032|Anticipated|2032-01-31|January 2, 2024|Anticipated|2024-01-02||Interventional|||CARPALL: Immunotherapy With CD19/22 CAR T-cells for CD19+ Haematological Malignancies|Immunotherapy With CD19/22 CAR Redirected T-cells for High Risk, Relapsed Paediatric CD19+ and/or CD22+ Acute Lymphoblastic Leukaemia and Other Haematological Malignancies|Active, not recruiting||Phase 1|33|Anticipated|University College, London||1|||f||||t|f|f|||||||||||2023-09-04 16:14:05.901817|2023-09-04 16:14:05.901817|OTHER|||||
NCT05202782||2022-01-04|||2022-08-01|2022-01-18|2022-01-24|Actual|||||||2022-08-01|2022-08-03|Actual|March 21, 2022|Actual|2022-03-21|August 2022|2022-08-31|October 9, 2029|Anticipated|2029-10-09|October 9, 2026|Anticipated|2026-10-09||Interventional|||Zanubrutinib and CAR T-cell Therapy for the Treatment of Recurrent or Refractory Aggressive B-cell Non-Hodgkin's Lymphoma or Transformed Indolent B-cell Lymphoma|Phase II, Single-Arm, Open-label, Multicenter Study Evaluating the Efficacy of Adjunctive Zanubrutinib and CAR T-Cell Therapy in Aggressive B-Cell Non-Hodgkin's Lymphoma|Recruiting||Phase 2|24|Anticipated|Northwestern University||1|||||||t|t|f|||f||||||||2023-09-04 16:14:42.415824|2023-09-04 16:14:42.415824|OTHER|||||
NCT05191472||2022-01-02|||2022-08-09|2022-01-02|2022-01-13|Actual|||||||2022-08-09|2022-08-11|Actual|May 3, 2022|Actual|2022-05-03|August 2022|2022-08-31|April 30, 2027|Anticipated|2027-04-30|August 31, 2025|Anticipated|2025-08-31||Interventional|||Pembrolizumab for the Treatment of Relapsed or Refractory Multiple Myeloma After Anti-BCMA CAR-T Therapies|Phase II Study of Pembrolizumab in Multiple Myeloma Patients Relapsing After or Refractory to Anti-BCMA CAR-T Therapies|Recruiting||Phase 2|25|Anticipated|University of California, San Francisco||1|||f||||t|t|f|||||||||No||2023-09-04 16:15:42.091619|2023-09-04 16:15:42.091619|OTHER|||||
NCT04601181||2020-10-16|||2020-11-27|2020-10-22|2020-10-23|Actual|||||||2020-11-27|2020-12-01|Actual|October 23, 2020|Actual|2020-10-23|October 2020|2020-10-31|October 15, 2023|Anticipated|2023-10-15|October 15, 2022|Anticipated|2022-10-15||Interventional|||Safety and Efficacy of ThisCART22 in Patients With Refractory or Relapsed B Cell Malignancies|A Study to Evaluate the Safety and Clinical Activity of Allogeneic CAR-T Targeting CD22 in Patients With Refractory or Relapsed B Cell Malignancies|Recruiting||Phase 1|20|Anticipated|Fundamenta Therapeutics, Ltd.||1|||f||||f|f|f|||||||||No||2023-09-02 06:22:47.433534|2023-09-02 06:22:47.433534|INDUSTRY|||||
NCT04599543||2020-10-21|||2020-10-22|2020-10-21|2020-10-22|Actual|||||||2020-10-22|2020-10-27|Actual|November 15, 2020|Anticipated|2020-11-15|October 2020|2020-10-31|November 15, 2026|Anticipated|2026-11-15|November 15, 2023|Anticipated|2023-11-15||Interventional|||IL3 CAR-T Cell Therapy for Patients With CD123 Positive Relapsed and/or Refractory Acute Myeloid Leukemia|Clinical Trial for the Safety and Efficacy of IL3 CAR-T Cell Therapy for Patients With CD123 Positive Relapsed and/or Refractory Acute Myeloid Leukemia|Not yet recruiting||Early Phase 1|36|Anticipated|Zhejiang University||1|||f||||t|f|f|||||||||No||2023-09-02 06:23:38.382676|2023-09-02 06:23:38.382676|OTHER|||||
NCT04219163||2020-01-03|||2022-11-21|2020-01-03|2020-01-06|Actual|||||||2022-11-21|2022-11-25|Actual|July 9, 2020|Actual|2020-07-09|November 2022|2022-11-30|July 31, 2038|Anticipated|2038-07-31|July 31, 2024|Anticipated|2024-07-31||Interventional|||Chimeric Antigen Receptor T-cells for The Treatment of AML Expressing CLL-1 Antigen|Chimeric Antigen Receptor T-cells for The Treatment of Acute Myeloid Leukemia Expressing CLL-1 Antigen|Recruiting||Phase 1|18|Anticipated|Baylor College of Medicine||1|||f||||t|t|f|||||||||No||2023-09-04 16:22:15.735153|2023-09-04 16:22:15.735153|OTHER|||||
NCT04603872||2020-10-21|||2020-10-27|2020-10-21|2020-10-27|Actual|||||||2020-10-27|2020-10-28|Actual|November 1, 2020|Anticipated|2020-11-01|October 2020|2020-10-31|November 1, 2026|Anticipated|2026-11-01|November 1, 2023|Anticipated|2023-11-01||Interventional|||CAR-T Cells Combined With Dasatinib for Patients With Relapsed and/or Refractory B-cell Hematological Malignancies|Clinical Trial for the Safety and Efficacy of CD19/BCMA-targeted CAR-T Cells Combined With Dasatinib for Patients With Relapsed and/or Refractory B-cell Acute Lymphoblastic Leukemia, B-cell Non-Hodgkin's Lymphoma and Multiple Myeloma|Recruiting||Early Phase 1|120|Anticipated|Zhejiang University||2|||f||||t|f|f|||||||||||2023-09-02 06:28:21.605553|2023-09-02 06:28:21.605553|OTHER|||||
NCT04626908||2020-11-03|||2020-11-07|2020-11-07|2020-11-13|Actual|||||||2020-11-07|2020-11-13|Actual|November 20, 2020|Anticipated|2020-11-20|November 2020|2020-11-30|June 30, 2023|Anticipated|2023-06-30|June 30, 2022|Anticipated|2022-06-30||Interventional|||Clinical Study of Targeting CD19 and CD22 Chimeric Antigen Receptor T Lymphocytes in the Treatment of Recurrent or Refractory B Cell Non-Hodgkin Lymphoma|Clinical Study of Targeting CD19 and CD22 Chimeric Antigen Receptor T Lymphocytes in the Treatment of Recurrent or Refractory B Cell Non-Hodgkin Lymphoma|Unknown status|Not yet recruiting|Phase 1/Phase 2|18|Anticipated|Zhejiang University||1|||f||||t|f|f|||||||||No||2023-09-02 06:28:34.079858|2023-09-02 06:28:34.079858|OTHER|||||
NCT04626752||2020-11-06|||2020-11-11|2020-11-11|2020-11-13|Actual|||||||2020-11-11|2020-11-13|Actual|April 1, 2020|Actual|2020-04-01|November 2020|2020-11-30|March 30, 2023|Anticipated|2023-03-30|March 30, 2023|Anticipated|2023-03-30||Interventional|||CAR-T Cells in Treating Patients With Relapsed or Refractory Multiple Myeloma|An Open, Uncontrolled, Multicenter Clinical Trial to Explore the Safety, Efficacy, and Remission Phase of Chimeric Antigen Receptor T Cell (CAR-T) in the Treatment of Relapsed Refractory (R/R) Multiple Myeloma (MM)|Unknown status|Recruiting|Early Phase 1|50|Anticipated|Hebei Senlang Biotechnology Inc., Ltd.||1|||f|||||f|f|||||||||No||2023-09-02 06:28:38.106409|2023-09-02 06:28:38.106409|INDUSTRY|||||
NCT04156178||2019-11-06|||2019-11-08|2019-11-06|2019-11-07|Actual|||||||2019-11-08|2019-11-12|Actual|August 1, 2018|Actual|2018-08-01|January 2019|2019-01-31|September 30, 2020|Anticipated|2020-09-30|September 30, 2020|Anticipated|2020-09-30||Interventional|||CD20-CD19 Compound CAR (cCAR) T Cells for Patients With Relapsed /Refractory B Cell Malignancies|Phase I, Interventional, Single Arm, Open Label, Treatment Study to Evaluate the Safety and Tolerability of CD20-CD19 cCAR in Patients With Relapsed and/or Refractory B Cell Malignancies|Unknown status|Recruiting|Early Phase 1|12|Anticipated|iCell Gene Therapeutics||1|||f||||t|f|f|||||||||No||2023-09-02 20:15:14.693686|2023-09-02 20:15:14.693686|INDUSTRY|||||
NCT03563326||2018-05-05|||2018-09-14|2018-06-08|2018-06-20|Actual|||||||2018-09-14|2018-09-17|Actual|August 30, 2018|Actual|2018-08-30|September 2018|2018-09-30|December 31, 2022|Anticipated|2022-12-31|December 31, 2019|Anticipated|2019-12-31||Interventional|||Intraperitoneal Infusion of EpCAM CAR-T Cell in Advanced Gastric Cancer With Peritoneal Metastasis (WCH-GC-CART)|Clinical Trial of Intraperitoneal CAR-T Cells Infusion for the Treatment of Advanced Gastric Cancer With Peritoneal Metastasis|Unknown status|Recruiting|Phase 1|40|Anticipated|West China Hospital||2|||f|||||f|f|||||||||Undecided|pending|2023-09-03 15:19:54.703619|2023-09-03 15:19:54.703619|OTHER|||||
NCT05206357||2022-01-21|||2023-08-07|2022-01-21|2022-01-25|Actual|||||||2023-08-07|2023-08-09|Actual|October 4, 2022|Actual|2022-10-04|July 2023|2023-07-31|June 18, 2027|Anticipated|2027-06-18|June 18, 2027|Anticipated|2027-06-18||Interventional|||Study of the Adverse Events and Change in Disease State of Pediatric Participants (and Young Adults Between the Ages of 18-25) With Relapsed/Refractory Aggressive Mature B-cell Neoplasms Receiving Subcutaneous (SC) Injections of Epcoritamab|A Single Arm, Open-Label, Phase 1b Trial of Epcoritamab in Pediatric Patients With Relapsed/Refractory Aggressive Mature B-cell Neoplasms|Recruiting||Phase 1|15|Anticipated|AbbVie||1|||f||||f|t|f|||f||||||No||2023-09-04 16:27:29.719571|2023-09-04 16:27:29.719571|INDUSTRY|||||
NCT04577326||2020-09-30|||2023-08-08|2020-09-30|2020-10-06|Actual|||||||2023-08-08|2023-08-09|Actual|September 30, 2020|Actual|2020-09-30|August 2023|2023-08-31|September 2024|Anticipated|2024-09-30|September 2024|Anticipated|2024-09-30||Interventional|||Mesothelin-targeted CAR T-cell Therapy in Patients With Mesothelioma|A Single-Arm, Open-Label, Phase I Trial to Assess the Safety of Genetically Engineered Autologous T Cells Targeting the Cell Surface Antigen Mesothelin With Cell-Intrinsic Checkpoint Inhibition in Patients With Mesothelioma|Recruiting||Phase 1|30|Anticipated|Memorial Sloan Kettering Cancer Center||1||||||||t|f|||||||||Yes|Memorial Sloan Kettering Cancer Center supports the international committee of medical journal editors (ICMJE) and the ethical obligation of responsible sharing of data from clinical trials. The protocol summary, a statistical summary, and informed consent form will be made available on clinicaltrials.gov when required as a condition of Federal awards, other agreements supporting the research and/or as otherwise required. Requests for deidentified individual participant data can be made beginning 12 months after publication and for up to 36 months post publication. Deidentified individual participant data reported in the manuscript will be shared under the terms of a Data Use Agreement and may only be used for approved proposals. Requests may be made to: crdatashare@mskcc.org.|2023-09-04 16:29:04.201455|2023-09-04 16:29:04.201455|OTHER|||||
NCT03593109||2018-07-07|||2021-10-28|2018-07-18|2018-07-19|Actual|||||||2021-10-28|2021-11-01|Actual|May 30, 2019|Actual|2019-05-30|November 2020|2020-11-30|May 1, 2021|Actual|2021-05-01|May 1, 2021|Actual|2021-05-01||Interventional|||A Single-center Clinical Study to Evaluate the Safety, Tolerability, and Efficacy of LCAR-L10D Cell Formulations Targeting CD19 and CD22 in Patients With CD19- and/or CD22-Positive Relapsed/Refractory B-cell Lymphoma|A Single-center Clinical Study to Evaluate the Safety, Tolerability, and Efficacy of LCAR-L10D Cell Formulations Targeting CD19 and CD22 in Patients With CD19- and/or CD22-Positive Relapsed/Refractory B-cell Lymphoma|Terminated||Phase 1|1|Actual|Second Affiliated Hospital of Xi'an Jiaotong University||1||Suitable patients were not recruited|f||||f|f|f|||||||||Undecided||2023-09-04 17:32:12.597703|2023-09-04 17:32:12.597703|OTHER|||||
NCT03792633||2019-01-02|||2023-08-07|2019-01-02|2019-01-03|Actual|||||||2023-08-07|2023-08-09|Actual|January 18, 2019|Actual|2019-01-18|August 2023|2023-08-31|August 2024|Anticipated|2024-08-31|August 2024|Anticipated|2024-08-31||Interventional|||Study of huCART19 for Very High-Risk (VHR) Subsets of Pediatric B-ALL|Phase 2 Study of Humanized CD19-directed Chimeric Antigen Receptor-modified T Cells (huCART19) for Very High-Risk Subsets of B Cell Acute Lymphoblastic Leukemia (B-ALL)|Active, not recruiting||Phase 2|100|Anticipated|University of Pennsylvania||2|||||||t|t|f|||||||||||2023-09-04 16:30:47.922383|2023-09-04 16:30:47.922383|OTHER|||||
NCT04617704||2020-08-20|||2021-09-21|2020-10-30|2020-11-05|Actual|||||||2021-09-21|2021-09-22|Actual|December 1, 2021|Anticipated|2021-12-01|October 2020|2020-10-31|February 1, 2022|Anticipated|2022-02-01|December 31, 2021|Anticipated|2021-12-31||Interventional|||BCMA and CD19 Targeted Fast Dual CART for Chromosomal Abnomalities High-risk BCMA+ Multiple Myeloma|Exploratory Study to Evaluate Efficacy and Safety of GC012F Injection in Chromosomal Abnomalities High-risk BCMA+ Multiple Myeloma|Unknown status|Not yet recruiting|Early Phase 1|15|Anticipated|Shanghai Changzheng Hospital||1|||f|||||f|f|||||||||Undecided||2023-09-02 06:33:19.195569|2023-09-02 06:33:19.195569|OTHER|||||
NCT05620342||2022-11-09|||2023-08-14|2022-11-09|2022-11-17|Actual|||||||2023-08-14|2023-08-15|Actual|June 21, 2023|Actual|2023-06-21|July 2023|2023-07-31|February 15, 2027|Anticipated|2027-02-15|February 15, 2025|Anticipated|2025-02-15||Interventional|||Autologous CAR T-Cells Targeting the GD2 Antigen for Lung Cancer|Administration of T Cells Expressing a 2nd Generation GD2 Chimeric Antigen Receptor, IL-15, and iCaspase9 Safety Switch in Subjects With Lung Cancer|Recruiting||Early Phase 1|24|Anticipated|UNC Lineberger Comprehensive Cancer Center||1|||||||t|t|f|||||||||No||2023-08-31 22:24:57.856127|2023-08-31 22:24:57.856127|OTHER|||||
NCT04595162||2020-10-14|||2020-10-14|2020-10-14|2020-10-20|Actual|||||||2020-10-14|2020-10-20|Actual|March 15, 2021|Anticipated|2021-03-15|November 2019|2019-11-30|December 15, 2035|Anticipated|2035-12-15|December 15, 2023|Anticipated|2023-12-15||Interventional|||A Study of GC019F CAR-T Cell Immunotherapy for Relapsed or Refractory B- ALL|A Study of GC019F CAR-T Cell Immunotherapy for Relapsed or Refractory B-cell Acute Lymphoblastic Leukemia|Not yet recruiting||Phase 1|12|Anticipated|Peking University Third Hospital||1|||f|||||f|f|||||||||||2023-09-02 06:38:07.218979|2023-09-02 06:38:07.218979|OTHER|||||
NCT04151186||2019-10-29|||2019-11-01|2019-11-01|2019-11-05|Actual|||||||2019-11-01|2019-11-05|Actual|November 20, 2019|Anticipated|2019-11-20|November 2019|2019-11-30|November 20, 2021|Anticipated|2021-11-20|May 20, 2021|Anticipated|2021-05-20||Interventional|||A Clinical Study on the Safety and Efficacy of CAR-T Therapy for the TM4SF1- and EpCAM-positive Solid Tumors|A Clinical Study on the Safety and Efficacy of Chimeric Antigen Receptor T-cell Therapy for the TM4SF1- and EpCAM-positive Recurrent/Refractory Solid Tumors|Unknown status|Not yet recruiting|Not Applicable|72|Anticipated|Tang-Du Hospital||1|||f||||t|f|f|||||||||No||2023-09-02 20:21:45.965508|2023-09-02 20:21:45.965508|OTHER|||||
NCT02624258||2015-12-01|||2020-05-19|2015-12-07|2015-12-08|Estimate|||||||2020-05-19|2020-05-21|Actual|November 2015||2015-11-30|May 2020|2020-05-31|December 6, 2019|Actual|2019-12-06|June 5, 2019|Actual|2019-06-05||Interventional|||Pilot Study of Non-Viral, RNA-Redirected Autologous T Cells in Patients With Refractory or Relapsed Hodgkin Lymphoma|Pilot Study of Non-Viral, RNA-Redirected Autologous T Cells Engineered to Contain Anti-CD19 Linked to TCR and 4-1BB Signaling Domains in Patients With Refractory or Relapsed Hodgkin Lymphoma|Terminated||Early Phase 1|2|Actual|University of Pennsylvania||1||Principal Investigator decision to stop trial|f||||t|||||||||||||2023-09-02 20:28:37.947061|2023-09-02 20:28:37.947061|OTHER|||||
NCT04182581||2019-11-27|||2019-11-27|2019-11-27|2019-12-02|Actual|||||||2019-11-27|2019-12-02|Actual|October 15, 2019|Actual|2019-10-15|October 2019|2019-10-31|May 2021|Anticipated|2021-05-31|September 2020|Anticipated|2020-09-30||Interventional|||A Study of BCMA/CD19 Dual-Target CAR-T Cell Immunotherapy for Relapsed or Refractory Multiple Myeloma|A Study of B-cell Maturation Antigen/Cluster of Differentiation Antigen 19 Dual-Target Chimeric Antigen Receptor T Cell Immunotherapy for Relapsed or Refractory Multiple Myeloma|Unknown status|Recruiting|Early Phase 1|18|Anticipated|Xijing Hospital||1|||f|||||f|f|||||||||||2023-09-02 20:35:46.491576|2023-09-02 20:35:46.491576|OTHER|||||
NCT05257083||2022-02-16|||2023-08-14|2022-02-16|2022-02-25|Actual|||||||2023-08-14|2023-08-15|Actual|October 2023|Anticipated|2023-10-31|August 2023|2023-08-31|August 2040|Anticipated|2040-08-31|June 2033|Anticipated|2033-06-30||Interventional|CARTITUDE-6||A Study of Daratumumab, Bortezomib, Lenalidomide and Dexamethasone (DVRd) Followed by Ciltacabtagene Autoleucel Versus Daratumumab, Bortezomib, Lenalidomide and Dexamethasone (DVRd) Followed by Autologous Stem Cell Transplant (ASCT) in Participants With Newly Diagnosed Multiple Myeloma|A Phase 3 Randomized Study Comparing Daratumumab, Bortezomib, Lenalidomide and Dexamethasone (DVRd) Followed by Ciltacabtagene Autoleucel Versus Daratumumab, Bortezomib, Lenalidomide and Dexamethasone (DVRd) Followed by Autologous Stem Cell Transplant (ASCT) in Participants With Newly Diagnosed Multiple Myeloma Who Are Transplant Eligible|Not yet recruiting||Phase 3|750|Anticipated|European Myeloma Network||2|||f||||t|t|f|||t||||||Yes|The data sharing policy of the Janssen Pharmaceutical Companies of Johnson & Johnson is available at www.janssen.com/clinical-trials/transparency.|2023-08-31 22:29:05.14682|2023-08-31 22:29:05.14682|NETWORK|||||
NCT04609241||2020-10-23|||2020-10-23|2020-10-23|2020-10-30|Actual|||||||2020-10-23|2020-10-30|Actual|November 15, 2020|Anticipated|2020-11-15|October 2020|2020-10-31|November 15, 2026|Anticipated|2026-11-15|November 15, 2023|Anticipated|2023-11-15||Interventional|||CD79b CAR-T Cell Therapy for Patients With Relapsed and/or Refractory Acute Lymphoblastic Leukemia and B-cell Non-Hodgkin's Lymphoma|Clinical Trial for the Safety and Efficacy of Murine CD79b CAR-T Therapy for Patients With Relapsed and/or Refractory B-cell Acute Lymphoblastic Leukemia and B-cell Non-Hodgkin's Lymphoma|Not yet recruiting||Early Phase 1|72|Anticipated|Zhejiang University||1|||f||||t|f|f|||||||||||2023-09-02 06:48:31.793878|2023-09-02 06:48:31.793878|OTHER|||||
NCT02672501||2016-01-25|||2016-02-01|2016-02-01|2016-02-03|Estimate|||||||2016-02-01|2016-02-03|Estimate|January 2016||2016-01-31|February 2016|2016-02-29|December 2019|Anticipated|2019-12-31|June 2018|Anticipated|2018-06-30||Interventional|||A Study to Assess CD19-targeted Immunotherapy T Cells in Patients With Relapsed or Refractory CD19+ B Cell Leukemia|Open-labeled, Uncontrolled, Single-arm Pilot Study to Evaluate Cellular Immunotherapy Using CD19-targeted Chimeric Antigen Receptor Engineered T Cells in Patients With Relapsed or Refractory CD19+ B Cell Leukemia|Unknown status|Recruiting|Phase 1/Phase 2|30|Anticipated|Shanghai GeneChem Co., Ltd.||1|||f||||f|||||||||||Undecided||2023-09-02 20:38:59.129879|2023-09-02 20:38:59.129879|INDUSTRY|||||
NCT02644655||2015-12-12|||2015-12-31|2015-12-31|2016-01-01|Estimate|||||||2015-12-31|2016-01-01|Estimate|September 2015||2015-09-30|September 2015|2015-09-30|September 2017|Anticipated|2017-09-30|March 2017|Anticipated|2017-03-31||Interventional|||Immunotherapy Using Autologous T Cell-Engineered With CD19-specific Chimeric Antigen Receptor for the Treatment of Recurrent /Refractory B Cell Leukemia|A Clinical Study Using Autologous T Cell Engineered With Chimeric Antigen Receptor Targeting to CD19（Cluster of Differentiation Antigen 19) in Treating Patients With Recurrent /Refractory B Cell Leukemia|Unknown status|Recruiting|Phase 1/Phase 2|20|Anticipated|Second Military Medical University||1|||f|||||||||||||||||2023-09-02 20:45:40.67353|2023-09-02 20:45:40.67353|OTHER|||||
NCT04160195||2019-11-08|2021-12-16||2022-01-26|2019-11-08|2019-11-12|Actual|2022-01-26|2022-02-15|Actual||||2022-01-26|2022-02-15|Actual|December 20, 2019|Actual|2019-12-20|January 2022|2022-01-31|June 11, 2021|Actual|2021-06-11|June 11, 2021|Actual|2021-06-11||Interventional||No participants were enrolled on group 2 because the study was stopped. The chimeric antigen receptor (CAR) gene used in this study is prone to recombination events and is therefore not stable.|T Cells Expressing Fully-human Anti-CD19 and Anti-CD20 Chimeric Antigen Receptors for Treating B-cell Malignancies and Hodgkin Lymphoma|T Cells Expressing Fully-human Anti-CD19 and Anti-CD20 Chimeric Antigen Receptors for Treating B-cell Malignancies and Hodgkin Lymphoma|Terminated||Phase 1|2|Actual|National Institutes of Health Clinical Center (CC)||2||The original principal investigator left the National Institutes of Health (NCI) and the decision was made to close the study to enrollment.|f||||f|t|f||||||Data will be shared before publication and at the time of publication or shortly thereafter indefinitely.|Data will be shared through ClinicalTrials.gov, BTRIS, approved outside collaborators under appropriate individual agreements, and publication and/or public presentations.||Yes|Human data will be shared as follows: Coded, linked data in a National Institutes of Health-funded or approved repository. Coded, linked data in the Biomedical Translational Research Information System (BTRIS). And coded, linked or identified data with approved outside collaborators under appropriate agreements.|2023-09-02 20:50:07.686118|2023-09-02 20:50:07.686118|NIH|||||
NCT05103631||2021-10-21|||2023-08-21|2021-10-21|2021-11-02|Actual|||||||2023-08-21|2023-08-23|Actual|June 17, 2021|Actual|2021-06-17|August 2023|2023-08-31|December 2039|Anticipated|2039-12-31|January 2025|Anticipated|2025-01-31||Interventional|||Interleukin-15 Armored Glypican 3-specific Chimeric Antigen Receptor Expressed in Autologous T Cells for Solid Tumors|Interleukin-15 Armored Glypican-3-specific Chimeric Antigen Receptor Expressing Autologous T Cells as Immunotherapy for Patients With SOLID TUMORS (CATCH)|Recruiting||Phase 1|27|Anticipated|Baylor College of Medicine||1|||f||||t|t|f|||f||||||||2023-09-03 15:33:25.655755|2023-09-03 15:33:25.655755|OTHER|||||
NCT05094206||2021-10-17|||2023-08-21|2021-10-17|2021-10-26|Actual|||||||2023-08-21|2023-08-23|Actual|June 30, 2022|Actual|2022-06-30|August 2023|2023-08-31|February 2026|Anticipated|2026-02-28|February 2025|Anticipated|2025-02-28||Interventional|||CAR20.19.22 T-cells in Relapsed, Refractory B-cell Malignancies|Phase I Trial of Anti-CD20, Anti-CD19, Anti-CD22 CAR (CAR20.19.22) T-cells for Relapsed, Refractory B-cell Malignancies|Active, not recruiting||Phase 1|48|Anticipated|Medical College of Wisconsin||10|||f||||t|t|f|||f||||||No||2023-09-03 15:33:26.378981|2023-09-03 15:33:26.378981|OTHER|||||
NCT05096234||2021-10-14|||2023-05-15|2021-10-14|2021-10-27|Actual|||||||2023-05-15|2023-05-17|Actual|September 28, 2021|Actual|2021-09-28|May 2023|2023-05-31|June 2024|Anticipated|2024-06-30|June 2024|Anticipated|2024-06-30||Interventional|||18F-F-AraG PET Imaging to Evaluate Immunological Response to CAR T Cell Therapy in Lymphoma|Pilot Study of [18F]F-AraG PET Imaging to Evaluate Immunological Response to Chimeric Antigen Receptor (CAR) T Cell Therapy in Lymphoma|Recruiting||Phase 2|6|Anticipated|Stanford University||1|||f||||t|t|f|||||||||No||2023-09-02 20:54:41.144277|2023-09-02 20:54:41.144277|OTHER|||||
NCT05032820||2021-07-08|||2023-08-10|2021-09-01|2021-09-02|Actual|||||||2023-08-10|2023-08-14|Actual|January 5, 2022|Actual|2022-01-05|August 2023|2023-08-31|April 2025|Anticipated|2025-04-30|April 2024|Anticipated|2024-04-30||Interventional|||MM CAR-T to Upgrade Response BMTCTN1902|Phase II Multicenter Trial of Anti-BCMA CAR T-Cell Therapy for MM Patients With Sub-Optimal Response After Auto HCT and Maintenance Len. BMTCTN1902|Recruiting||Phase 2|40|Anticipated|Medical College of Wisconsin||1|||f||||t|t|f||||||Within 6 months of official study closure at participating sites|Available to public|https://biolincc.nhlbi.nih.gov/home|Yes|Results will be published in a manuscript and supporting information submitted to NIH BioLINCC (including data dictionaries, case report forms, data submission documentation, documentation for outcomes dataset, etc., where indicated).|2023-08-31 22:31:43.908415|2023-08-31 22:31:43.908415|OTHER|||||
NCT04633148||2020-11-11|||2023-08-22|2020-11-11|2020-11-18|Actual|||||||2023-08-22|2023-08-23|Actual|November 23, 2020|Actual|2020-11-23|August 2023|2023-08-31|July 2025|Anticipated|2025-07-31|December 2024|Anticipated|2024-12-31||Interventional|||Dose-escalating Trial With UniCAR02-T Cells and PSMA Target Module (TMpPSMA) in Patients With Progressive Disease After Standard Systemic Therapy in Cancers With Positive PSMA Marker|Multicenter, Open-label, Adaptive Design Phase I Trial With Genetically Modified T-cells Carrying Universal Chimeric Antigen Receptors (UniCAR02-T) in Combination With PSMA Peptide Target Module (TMpPSMA) for the Treatment of Patients With Progressive Disease After Standard Systemic Therapy in Cancers With Positive PSMA Marker|Recruiting||Phase 1|51|Anticipated|AvenCell Europe GmbH||1|||f||||t|f|f|||||||||No||2023-09-03 15:34:50.177193|2023-09-03 15:34:50.177193|INDUSTRY|||||
NCT05000450||2021-08-04|||2023-08-09|2021-08-04|2021-08-11|Actual|||||||2023-08-09|2023-08-14|Actual|June 6, 2021|Actual|2021-06-06|August 2023|2023-08-31|July 2025|Anticipated|2025-07-31|July 2025|Anticipated|2025-07-31||Interventional|||Safety and Efficacy of ALLO-605 an Anti-BCMA Allogeneic CAR T Cell Therapy in Patients With Relapsed/Refractory Multiple Myeloma|A Single-Arm, Open-Label, Phase 1/2 Study Evaluating the Safety, Efficacy, and Cellular Kinetics/Pharmacodynamics of ALLO-647 and ALLO-605, an Anti- BCMA Allogeneic CAR T Cell Therapy in Patients With Relapsed/Refractory Multiple Myeloma|Active, not recruiting||Phase 1/Phase 2|136|Anticipated|Allogene Therapeutics||1|||f|||||t|f|||||||||||2023-08-31 22:32:11.43012|2023-08-31 22:32:11.43012|INDUSTRY|||||
NCT04572308||2020-09-27|||2021-06-23|2020-09-30|2020-10-01|Actual|||||||2021-06-23|2021-06-29|Actual|October 1, 2020|Actual|2020-10-01|June 2021|2021-06-30|May 30, 2021|Actual|2021-05-30|May 30, 2021|Actual|2021-05-30||Interventional|||Cell Therapy for CD7 Positive T-cell Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma Using CD7-Specific CAR-T Cells|Cell Therapy for CD7 Positive T-cell Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma Using CD7-Specific CAR-T Cells|Completed||Phase 1|20|Actual|Hebei Senlang Biotechnology Inc., Ltd.||1|||f|||||f|f|||||||||||2023-09-02 06:56:53.0411|2023-09-02 06:56:53.0411|INDUSTRY|||||
NCT04464200||2020-07-06|||2023-08-22|2020-07-06|2020-07-09|Actual|||||||2023-08-22|2023-08-23|Actual|July 6, 2020|Actual|2020-07-06|August 2023|2023-08-31|July 2026|Anticipated|2026-07-31|July 2026|Anticipated|2026-07-31||Interventional|||19(T2)28z1xx Chimeric Antigen Receptor (CAR) T Cells in People With B-Cell Cancers|A Phase I Study of CD19-Targeted 19(T2)28z1xx Chimeric Antigen Receptor (CAR) Modified T Cells in Adult Patients With Relapsed or Refractory B-cell Malignancies|Active, not recruiting||Phase 1|30|Actual|Memorial Sloan Kettering Cancer Center||1||||||||t|f|||||||||Yes|Memorial Sloan Kettering Cancer Center supports the international committee of medical journal editors (ICMJE) and the ethical obligation of responsible sharing of data from clinical trials. The protocol summary, a statistical summary, and informed consent form will be made available on clinicaltrials.gov when required as a condition of Federal awards, other agreements supporting the research and/or as otherwise required. Requests for deidentified individual participant data can be made beginning 12 months after publication and for up to 36 months post publication. Deidentified individual participant data reported in the manuscript will be shared under the terms of a Data Use Agreement and may only be used for approved proposals. Requests may be made to: crdatashare@mskcc.org.|2023-09-03 15:35:29.080608|2023-09-03 15:35:29.080608|OTHER|||||
NCT04442022||2020-06-10|||2023-08-22|2020-06-18|2020-06-22|Actual|||||||2023-08-22|2023-08-23|Actual|September 3, 2020|Actual|2020-09-03|August 2023|2023-08-31|December 2025|Anticipated|2025-12-31|December 2024|Anticipated|2024-12-31||Interventional|||A Study of Rituximab-Gemcitabine-Dexamethasone-Platinum (R-GDP) With or Without Selinexor in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma|A Phase 2/3, Multicenter Randomized Study of Rituximab-Gemcitabine-Dexamethasone-Platinum (R-GDP) With or Without Selinexor in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma (RR DLBCL)|Recruiting||Phase 2/Phase 3|501|Anticipated|Karyopharm Therapeutics Inc||6|||f||||t|t|f|||||||||Undecided||2023-09-03 15:35:30.833962|2023-09-03 15:35:30.833962|INDUSTRY|||||
NCT04196491||2019-12-10|||2023-08-21|2019-12-10|2019-12-12|Actual|||||||2023-08-21|2023-08-23|Actual|May 27, 2020|Actual|2020-05-27|August 2023|2023-08-31|June 7, 2023|Actual|2023-06-07|June 7, 2023|Actual|2023-06-07||Interventional|KarMMa-4||A Study to Evaluate the Safety of bb2121 in Subjects With High Risk, Newly Diagnosed Multiple Myeloma (NDMM)|A Phase 1, Open-label, Multicenter Study to Evaluate the Safety of bb2121 in Subjects With High Risk, Newly Diagnosed Multiple Myeloma (KarMMa-4)|Completed||Phase 1|13|Actual|Celgene||1|||f||||t|t|f||||||See Plan Description|See Plan Description|https://www.celgene.com/research-development/clinical-trials/clinical-trials-data-sharing/|Yes|"Information relating to our policy on data sharing and the process for requesting data can be found at the following link:~https://www.celgene.com/research-development/clinical-trials/clinical-trials-data-sharing/"|2023-09-03 15:36:00.884807|2023-09-03 15:36:00.884807|INDUSTRY|||||
NCT04855136||2021-04-19|||2023-08-09|2021-04-19|2021-04-22|Actual|||||||2023-08-09|2023-08-14|Actual|June 1, 2021|Actual|2021-06-01|August 2023|2023-08-31|December 6, 2026|Anticipated|2026-12-06|December 23, 2024|Anticipated|2024-12-23||Interventional|KarMMa-7||Safety and Efficacy of bb2121 (Ide-cel) Combinations in Multiple Myeloma|An Exploratory Phase 1/2 Trial to Determine Recommended Phase 2 Dose (RP2D), Safety and Preliminary Efficacy of bb2121 (Ide-cel) Combinations in Subjects With Relapsed/Refractory Multiple Myeloma (KarMMa-7)|Active, not recruiting||Phase 1/Phase 2|312|Anticipated|Celgene||2|||f||||t|t|f||||||See Plan Description|See Plan Description|https://www.bms.com/researchers-and-partners/clinical-trials-and-research/disclosure-commitment.html|Yes|"BMS will provide access to individual anonymized participant data upon request from qualified researchers, and subject to certain criteria.~Additional information regarding Bristol Myer Squibb's data sharing policy and process can be found at: https://www.bms.com/researchers-and-partners/clinical-trials-and-research/disclosurecommitment.html"|2023-08-31 22:33:23.505517|2023-08-31 22:33:23.505517|INDUSTRY|||||
NCT04792489||2021-02-25|||2023-08-08|2021-03-09|2021-03-11|Actual|||||||2023-08-08|2023-08-14|Actual|May 25, 2021|Actual|2021-05-25|August 2023|2023-08-31|December 31, 2026|Anticipated|2026-12-31|December 31, 2024|Anticipated|2024-12-31||Interventional|||DALY 2.0 USA/ MB-CART2019.1 for DLBCL|A Multi-center Single Arm Phase II Study to Evaluate the Safety and Efficacy of Genetically Engineered Autologous Cells Expressing Anti-CD20 and Anti-CD19 Specific Chimeric Antigen Receptor in Subjects With Relapsed and/or Refractory Diffuse Large B Cell Lymphoma|Recruiting||Phase 2|110|Anticipated|Miltenyi Biomedicine GmbH||1|||f||||t|t|f|||||||||No||2023-08-31 22:33:44.046835|2023-08-31 22:33:44.046835|INDUSTRY|||||
NCT04153799||2019-10-09|||2020-05-09|2019-11-05|2019-11-06|Actual|||||||2020-05-09|2020-05-12|Actual|November 1, 2019|Actual|2019-11-01|May 2020|2020-05-31|December 2022|Anticipated|2022-12-31|December 2021|Anticipated|2021-12-31||Interventional|||Study of CXCR5 Modified EGFE Chimeric Antigen Receptor Autologous T Cells in EGFR- Positive Patients With Advanced Non-small Cell Lung Cancer|A Single-arm, Open-label, Phase I Study to Evaluate the Safety and Efficacy of CXCR5 Modified EGFR Chimeric Antigen Receptor Autologous T Cells in EGFR-positive Patients With Advanced Non-small Cell Lung Cancer|Unknown status|Recruiting|Phase 1|11|Anticipated|Sun Yat-sen University||1|||f|||||f|f|||||||||||2023-09-02 21:00:45.698813|2023-09-02 21:00:45.698813|OTHER|||||
NCT03448393||2018-02-27|||2023-08-22|2018-02-27|2018-02-28|Actual|||||||2023-08-22|2023-08-23|Actual|March 26, 2018|Actual|2018-03-26|August 18, 2023|2023-08-18|December 31, 2040|Anticipated|2040-12-31|December 1, 2025|Anticipated|2025-12-01||Interventional|||CD19/CD22 Chimeric Antigen Receptor (CAR) T Cells in Children and Young Adults With Recurrent or Refractory CD19/CD22-expressing B Cell Malignancies|Phase 1 Dose Escalation Study of CD19/CD22 Chimeric Antigen Receptor (CAR) T Cells in Children and Young Adults With Recurrent or Refractory CD19/CD22-expressing B Cell Malignancies|Recruiting||Phase 1|140|Anticipated|National Institutes of Health Clinical Center (CC)||2|||f|||||t|f||||||Clinical data available during the study and indefinitely.|Clinical data will be made available via subscription to BTRIS and with the permission of the study PI.||Yes|.All IPD recorded in the medical record will be shared with intramural investigators upon request.|2023-09-03 15:37:09.698997|2023-09-03 15:37:09.698997|NIH|||||
NCT04991948||2021-07-28|||2022-02-22|2021-07-28|2021-08-05|Actual|||||||2022-02-22|2022-03-09|Actual|November 22, 2021|Actual|2021-11-22|February 2022|2022-02-28|May 25, 2038|Anticipated|2038-05-25|August 21, 2023|Anticipated|2023-08-21||Interventional|||Study of Pembrolizumab Treatment After CYAD-101 With FOLFOX Preconditioning in Metastatic Colorectal Cancer|An Open-label, Phase Ib Study to Assess the Safety and Clinical Activity of CYAD-101 Administered Concurrently With FOLFOX Chemotherapy, Followed by Pembrolizumab Treatment, in Patients With Metastatic Colorectal Cancer|Recruiting||Phase 1|34|Anticipated|Celyad Oncology SA||1|||f||||t|t|f|||||||||No||2023-09-02 07:02:37.545631|2023-09-02 07:02:37.545631|INDUSTRY|||||
NCT04467853||2020-07-01|||2023-08-11|2020-07-10|2020-07-13|Actual|||||||2023-08-11|2023-08-15|Actual|September 21, 2020|Actual|2020-09-21|August 2023|2023-08-31|July 17, 2023|Actual|2023-07-17|July 17, 2023|Actual|2023-07-17||Interventional|||A Clinical Study to Evaluate CAR-T Cell-based Medicinal Product in the Treatment of Advanced Solid Tumors|A Phase 1, Open-Label Study Evaluating the Safety, Tolerability and Efficacy of LCAR-C18S, an CAR-T Cell Therapy Targeting Claudin18.2 in Patients With Advanced Solid Tumors|Terminated||Phase 1|34|Actual|Shanghai East Hospital||1||Both the sponsors and collaborator are considering terminating the study|f||||f|f|f|||||||||No||2023-08-31 22:36:22.770408|2023-08-31 22:36:22.770408|OTHER|||||
NCT05574114||2022-10-06|||2023-07-21|2022-10-06|2022-10-10|Actual|||||||2023-07-21|2023-07-24|Actual|October 5, 2022|Actual|2022-10-05|July 2023|2023-07-31|October 2025|Anticipated|2025-10-31|October 2025|Anticipated|2025-10-31||Interventional|||A Study of Radiation Therapy Before CAR T Cell Therapy for People With B Cell Lymphoma|A Phase I Study Of Split-Course Bridging Radiotherapy (SC-BRT) Prior To Commercial CD19 CAR T-Cell Therapies For Patients With Relapsed or Refractory B-Cell Lymphomas|Recruiting||Phase 1|20|Anticipated|Memorial Sloan Kettering Cancer Center||1|||f|||||t|f|||f||||||Yes|Memorial Sloan Kettering Cancer Center supports the international committee of medical journal editors (ICMJE) and the ethical obligation of responsible sharing of data from clinical trials. The protocol summary, a statistical summary, and informed consent form will be made available on clinicaltrials.gov when required as a condition of Federal awards, other agreements supporting the research and/or as otherwise required. Requests for deidentified individual participant data can be made beginning 12 months after publication and for up to 36 months post publication. Deidentified individual participant data reported in the manuscript will be shared under the terms of a Data Use Agreement and may only be used for approved proposals. Requests may be made to: crdatashare@mskcc.org|2023-09-02 21:06:21.424554|2023-09-02 21:06:21.424554|OTHER|||||
NCT05535855||2022-09-06|||2023-07-21|2022-09-06|2022-09-10|Actual|||||||2023-07-21|2023-07-24|Actual|August 2023|Anticipated|2023-08-31|July 2023|2023-07-31|July 2027|Anticipated|2027-07-31|July 1, 2025|Anticipated|2025-07-01||Interventional|||UCD19 CAR T Therapy in Adults With B-ALL and MRD Positivity in CR1|Phase I Safety and Tolerability Trial of CD19 Directed CAR T Cells in Adult Patients With B-Cell Acute Lymphoblastic Leukemia (B-ALL) With Minimal Residual Disease (MRD) Positivity at First Complete Remission|Recruiting||Phase 1|14|Anticipated|University of Colorado, Denver||1|||f||||t|t|f|||||||||No||2023-09-02 21:06:25.205166|2023-09-02 21:06:25.205166|OTHER|||||
NCT05010564||2021-08-11|||2023-07-21|2021-08-11|2021-08-18|Actual|||||||2023-07-21|2023-07-24|Actual|July 18, 2023|Actual|2023-07-18|July 2023|2023-07-31|March 29, 2040|Anticipated|2040-03-29|July 17, 2026|Anticipated|2026-07-17||Interventional|TRICAR-ALL||Trivalent CAR-T Cell in Acute B-Lineage Leukemia (TRICAR-ALL)|(H-49235) Trivalent Autologous T-Lymphocytes Co-Expressing Three Chimeric Antigen Receptors Targeting CD19, CD20 AND CD22 in Acute B-lineage Leukemia (TRICAR-ALL)|Recruiting||Phase 1|38|Anticipated|Baylor College of Medicine||1|||f||||t|t|f|||f||||||||2023-09-02 21:07:32.451287|2023-09-02 21:07:32.451287|OTHER|||||
NCT04555551||2020-09-08|||2023-07-21|2020-09-14|2020-09-18|Actual|||||||2023-07-21|2023-07-24|Actual|September 8, 2020|Actual|2020-09-08|July 2023|2023-07-31|August 2024|Anticipated|2024-08-31|August 2024|Anticipated|2024-08-31||Interventional|||MCARH109 Chimeric Antigen Receptor (CAR) Modified T Cells for the Treatment of Multiple Myeloma|Phase I Trial of G Protein-coupled Receptor Class C Group 5 Member D (GPRC5D) Targeted MCARH109 Chimeric Antigen Receptor (CAR) Modified T Cells for the Treatment of Multiple Myeloma|Active, not recruiting||Phase 1|17|Actual|Memorial Sloan Kettering Cancer Center||1||||||||t|f|||||||||Yes|Memorial Sloan Kettering Cancer Center supports the international committee of medical journal editors (ICMJE) and the ethical obligation of responsible sharing of data from clinical trials. The protocol summary, a statistical summary, and informed consent form will be made available on clinicaltrials.gov when required as a condition of Federal awards, other agreements supporting the research and/or as otherwise required. Requests for deidentified individual participant data can be made beginning 12 months after publication and for up to 36 months post publication. Deidentified individual participant data reported in the manuscript will be shared under the terms of a Data Use Agreement and may only be used for approved proposals. Requests may be made to: crdatashare@mskcc.org.|2023-09-02 21:08:18.422836|2023-09-02 21:08:18.422836|OTHER|||||
NCT04546893||2020-09-04|||2020-09-04|2020-09-04|2020-09-14|Actual|||||||2020-09-04|2020-09-14|Actual|September 1, 2020|Actual|2020-09-01|September 2020|2020-09-30|December 1, 2022|Anticipated|2022-12-01|September 1, 2022|Anticipated|2022-09-01||Interventional|||Safety and Efficacy Study of SL1904B CAR-T Cells for Relapsed or Refractory B-Cell Acute Lymphocyte Leukemia|Safety and Efficacy Study of SL1904B CAR-T Cells for Relapsed or Refractory B-Cell Acute Lymphocyte Leukemia|Unknown status|Recruiting|Not Applicable|20|Anticipated|Hebei Senlang Biotechnology Inc., Ltd.||1|||f|||||f|f|||||||||||2023-09-02 07:05:32.833932|2023-09-02 07:05:32.833932|INDUSTRY|||||
NCT04539444||2020-08-31|||2021-07-30|2020-08-31|2020-09-07|Actual|||||||2021-07-30|2021-08-02|Actual|August 1, 2020|Actual|2020-08-01|August 2020|2020-08-31|February 1, 2023|Anticipated|2023-02-01|February 1, 2022|Anticipated|2022-02-01||Interventional|||A Study of CD19/22 CART Cells Combined With PD-1 Inhibitor in Relapsed/Refractory B-cell Lymphoma|A Study Evaluated Efficacy and Safety of CD19/22 Chimeric Antigen Receptor T Cells Combined With PD-1 Inhibitor in Relapsed/Refractory B-cell Non-Hodgkin's Lymphoma|Unknown status|Recruiting|Phase 2|10|Anticipated|The First Affiliated Hospital of Soochow University||1|||f||||f|f|f|||||||||||2023-09-02 07:06:26.791709|2023-09-02 07:06:26.791709|OTHER|||||
NCT04093596||2019-09-16|||2023-08-09|2019-09-16|2019-09-18|Actual|||||||2023-08-09|2023-08-14|Actual|September 23, 2019|Actual|2019-09-23|August 2023|2023-08-31|September 2027|Anticipated|2027-09-30|September 2027|Anticipated|2027-09-30||Interventional|UNIVERSAL||Safety and Efficacy of ALLO-715 BCMA Allogenic CAR T Cells in in Adults With Relapsed or Refractory Multiple Myeloma (UNIVERSAL)|A Single-Arm, Open-Label, Phase 1 Study of the Safety, Efficacy, and Cellular Kinetics/Pharmacodynamics of ALLO-715 to Evaluate an Anti-BCMA Allogeneic CAR T Cell Therapy With or Without Nirogacestat in Subjects With Relapsed/Refractory Multiple Myeloma|Active, not recruiting||Phase 1|132|Anticipated|Allogene Therapeutics||1|||||||f|t|f|||||||||||2023-08-31 22:38:20.852162|2023-08-31 22:38:20.852162|INDUSTRY|||||
NCT04532268||2020-08-20|||2020-08-25|2020-08-25|2020-08-31|Actual|||||||2020-08-25|2020-08-31|Actual|August 23, 2020|Anticipated|2020-08-23|August 2020|2020-08-31|August 23, 2026|Anticipated|2026-08-23|August 23, 2023|Anticipated|2023-08-23||Interventional|||A Study of Humanized CD19 CAR-T Cells Therapy for Patients With Relapsed and/or Refractory B-cell ALL and B-cell NHL|Clinical Trial for the Safety and Efficacy of Humanized CD19 CAR-T Cells Therapy for Patients With Relapsed and/or Refractory B-cell Acute Lymphoblastic Leukemia and B-cell Non-Hodgkin's Lymphoma|Recruiting||Early Phase 1|72|Anticipated|Zhejiang University||1|||f||||t|f|f|||||||||No||2023-09-02 07:09:54.310064|2023-09-02 07:09:54.310064|OTHER|||||
NCT05298995||2022-03-18|||2022-03-18|2022-03-18|2022-03-28|Actual|||||||2022-03-18|2022-03-28|Actual|May 2022|Anticipated|2022-05-31|March 2022|2022-03-31|May 2037|Anticipated|2037-05-31|May 2026|Anticipated|2026-05-31||Interventional|||GD2-CAR T Cells for Pediatric Brain Tumours|Phase I Study of Anti-GD2 Chimeric Antigen Receptor-Expressing T Cells in Pediatric and Young Adult Patients Affected by Relapsed/Refractory Central Nervous System Tumors|Not yet recruiting||Phase 1|54|Anticipated|Bambino Gesù Hospital and Research Institute||3|||f|||||f|f|||||||||No||2023-09-02 21:18:58.728563|2023-09-02 21:18:58.728563|OTHER|||||
NCT02690545||2016-02-10|||2023-08-14|2016-02-19|2016-02-24|Estimate|||||||2023-08-14|2023-08-15|Actual|August 26, 2016|Actual|2016-08-26|August 2023|2023-08-31|August 26, 2040|Anticipated|2040-08-26|August 26, 2025|Anticipated|2025-08-26||Interventional|||Study of CD30 CAR for Relapsed/Refractory CD30+ HL and CD30+ NHL|Phase Ib/II Study of the Administration of T Lymphocytes Expressing the CD30 Chimeric Antigen Receptor (CAR) for Relapsed/Refractory CD30+ Hodgkin's Lymphoma and CD30+ Non-Hodgkin's Lymphoma|Recruiting||Phase 1/Phase 2|40|Anticipated|UNC Lineberger Comprehensive Cancer Center||1|||f||||t|t|f|||||||||No||2023-08-31 22:43:53.383085|2023-08-31 22:43:53.383085|OTHER|||||
NCT04553393||2020-09-10|||2020-12-03|2020-09-16|2020-09-17|Actual|||||||2020-12-03|2020-12-04|Actual|September 9, 2020|Actual|2020-09-09|December 2020|2020-12-31|September 8, 2022|Anticipated|2022-09-08|September 8, 2021|Anticipated|2021-09-08||Interventional|||Decitabine-primed Tandem CD19/CD20 CAR T Cells Plus Epigenetic Agents in Aggressive r/r B-NHL With Huge Tumor Burden|Treatment of Decitabine-primed Tandem Targeting CD19 and CD20 Chimeric Antigen Receptor T Cells Plus Epigenetic Agents in Aggressive Relapsed and/or Refractory Non-Hodgkin's Lymphoma Patients With Huge Tumor Burden|Unknown status|Recruiting|Phase 1/Phase 2|80|Anticipated|Chinese PLA General Hospital||4|||f|||||f|f|||||||||||2023-09-02 07:12:35.00802|2023-09-02 07:12:35.00802|OTHER|||||
NCT03287804||2017-09-11|2020-09-04||2020-09-30|2017-09-17|2017-09-19|Actual|2020-09-30|2020-10-23|Actual||||2020-09-30|2020-10-23|Actual|May 5, 2017|Actual|2017-05-05|September 2020|2020-09-30|September 5, 2019|Actual|2019-09-05|September 5, 2019|Actual|2019-09-05||Interventional|APRIL||APRIL CAR T Cells (AUTO2) Targeting BCMA and TACI for the Treatment of Multiple Myeloma|A Single-Arm, Open-Label, Multi-Centre, Phase I/II Study Evaluating the Safety and Clinical Activity of AUTO2, a CAR T Cell Treatment Targeting BCMA and TACI, in Patients With Relapsed or Refractory Multiple Myeloma|Terminated||Phase 1/Phase 2|12|Actual|Autolus Limited||1||Preliminary efficacy seen to date following treatment with AUTO2 has been determined not sufficient to warrant further development|f||||t|t|f|||||||||||2023-09-03 15:47:30.982145|2023-09-03 15:47:30.982145|INDUSTRY|||||
NCT04550663||2020-09-08|||2020-09-20|2020-09-14|2020-09-16|Actual|||||||2020-09-20|2020-09-23|Actual|September 25, 2020|Anticipated|2020-09-25|September 2020|2020-09-30|March 25, 2023|Anticipated|2023-03-25|September 25, 2022|Anticipated|2022-09-25||Interventional|||NKG2D CAR-T(KD-025) in the Treatment of Relapsed or Refractory NKG2DL+ Tumors|One-center, Open-label, Single-arm Clinical Study of the Safety and Effectiveness of NKG2D CAR-T Cells Infusion in the Treatment of Relapsed/ Refractory NKG2DL+ Tumors|Unknown status|Not yet recruiting|Phase 1|10|Anticipated|The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School||1|||f||||f|f|f|||||||||No||2023-09-02 07:14:29.562794|2023-09-02 07:14:29.562794|OTHER|||||
NCT05577091||2022-10-01|||2023-02-07|2022-10-10|2022-10-13|Actual|||||||2023-02-07|2023-02-08|Actual|May 1, 2023|Anticipated|2023-05-01|February 2023|2023-02-28|November 1, 2032|Anticipated|2032-11-01|November 1, 2024|Anticipated|2024-11-01||Interventional|||Tris-CAR-T Cell Therapy for Recurrent Glioblastoma|Phase 1 Study of Autologous Tris-CAR-T Cell Locoregional Immunotherapy for Recurrent Glioblastoma|Not yet recruiting||Phase 1|10|Anticipated|Beijing Tiantan Hospital||1|||f||||t|f|f|||||||||No||2023-08-31 22:50:38.043824|2023-08-31 22:50:38.043824|OTHER|||||
NCT03323944||2017-10-19|||2023-06-20|2017-10-26|2017-10-27|Actual|||||||2023-06-20|2023-06-22|Actual|September 15, 2017|Actual|2017-09-15|June 2023|2023-06-30|September 2024|Anticipated|2024-09-30|September 2024|Anticipated|2024-09-30||Interventional|||CAR T Cell Immunotherapy for Pancreatic Cancer|Phase I Study of Human Chimeric Antigen Receptor Modified T Cells (CAR T Cells) in Patients With Pancreatic Cancer|Recruiting||Phase 1|18|Anticipated|University of Pennsylvania||5|||f||||t|t|f|||||||||||2023-09-04 16:53:34.858707|2023-09-04 16:53:34.858707|OTHER|||||
NCT04537442||2020-08-28|||2020-08-28|2020-08-28|2020-09-03|Actual|||||||2020-08-28|2020-09-03|Actual|September 3, 2020|Anticipated|2020-09-03|August 2020|2020-08-31|March 2, 2023|Anticipated|2023-03-02|December 30, 2022|Anticipated|2022-12-30||Interventional|||Clinical Study to Evaluate the Safety and Efficacy of IM21 CAR-T Cells in the Treatment of Elderly Patients With Relapsed or Refractory Multiple Myeloma|Clinical Study to Evaluate the Safety and Efficacy of IM21 CAR-T Cells in the Treatment of Elderly Patients With Relapsed or Refractory Multiple Myeloma|Unknown status|Recruiting|Phase 1|10|Anticipated|Beijing Immunochina Medical Science & Technology Co., Ltd.||1|||f|||||f|f|||||||||No||2023-09-02 07:20:40.361521|2023-09-02 07:20:40.361521|INDUSTRY|||||
NCT04795882||2021-03-02|||2022-09-15|2021-03-09|2021-03-12|Actual|||||||2022-09-15|2022-09-19|Actual|April 22, 2022|Actual|2022-04-22|June 2022|2022-06-30|December 31, 2035|Anticipated|2035-12-31|December 31, 2025|Anticipated|2025-12-31||Interventional|MCARTY||A New Study Evaluating the Activity of Modular CAR T for mYeloma|An Open Label, Phase 1 Study Evaluating the Activity of Modular CAR T for mYeloma|Enrolling by invitation||Phase 1|24|Anticipated|University College, London||2|||f||||t|f|f|||||||||No||2023-09-04 16:55:09.214228|2023-09-04 16:55:09.214228|OTHER|||||
NCT04534634||2020-08-25|||2020-08-28|2020-08-28|2020-09-01|Actual|||||||2020-08-28|2020-09-01|Actual|April 1, 2019|Actual|2019-04-01|August 2020|2020-08-31|July 31, 2025|Anticipated|2025-07-31|July 31, 2023|Anticipated|2023-07-31||Interventional|||Study of IFN-α Combined With CAR-T Cell Therapy in Relapsed and Refractory Acute Lymphoblastic Leukemia（R/R-ALL）|An Open-label, Phase 2, Single-Center Study to Assess the Efficacy and Safety of Interferon-α Combined With Chimeric Antigen Receptor (CAR) T-cell Therapy in Patients With Relapsed and Refractory Acute Lymphoblastic Leukemia（R/R-ALL)|Recruiting||Phase 2|60|Anticipated|The First Affiliated Hospital of Soochow University||2|||f||||t|f|f|||||||||||2023-09-02 07:23:08.67557|2023-09-02 07:23:08.67557|OTHER|||||
NCT05312411||2019-03-20|||2023-06-27|2022-03-28|2022-04-05|Actual|||||||2023-06-27|2023-06-29|Actual|May 20, 2022|Actual|2022-05-20|June 2023|2023-06-30|April 30, 2040|Anticipated|2040-04-30|April 30, 2025|Anticipated|2025-04-30||Interventional|||A Phase I Feasibility And Safety Study of Fluorescein-Specific (FITC-E2) CAR T Cells In Combination With Parenterally Administered Folate-Fluorescein (UB-TT170) For Osteogenic Sarcoma|A Phase I Feasibility And Safety Study of Fluorescein-Specific (FITC-Ew) CAR T Cells In Combination With Parenterally Administered Folate-Fluorescein (UB-TT170) For Osteogenic Sarcoma|Recruiting||Phase 1|21|Anticipated|Seattle Children's Hospital||1|||f||||t|t|f|||||||||No||2023-08-31 23:01:54.364084|2023-08-31 23:01:54.364084|OTHER|||||
NCT03767751||2018-12-05|||2018-12-05|2018-12-05|2018-12-07|Actual|||||||2018-12-05|2018-12-07|Actual|December 5, 2018|Actual|2018-12-05|December 2018|2018-12-31|December 5, 2022|Anticipated|2022-12-05|December 5, 2022|Anticipated|2022-12-05||Interventional|||A Feasibility and Safety Study of Dual Specificity CD38 and BCMA CAR-T Cell Immunotherapy for Relapsed or Refractory Multiple Myeloma|Phase I/II Study to Evaluate Treatment of Relapsed or Refractory Multiple Myeloma With Dual CAR-T Cells Targeting CD38 and BCMA|Unknown status|Recruiting|Phase 1/Phase 2|80|Anticipated|Chinese PLA General Hospital|||||f||||f|f|f|||||||||||2023-09-03 16:01:17.947796|2023-09-03 16:01:17.947796|OTHER|||||
NCT05105152||2021-10-07|||2023-06-27|2021-10-25|2021-11-03|Actual|||||||2023-06-27|2023-06-29|Actual|November 29, 2021|Actual|2021-11-29|June 2023|2023-06-30|January 31, 2039|Anticipated|2039-01-31|February 29, 2024|Anticipated|2024-02-29||Interventional|||PLAT-08: A Study Of SC-DARIC33 CAR T Cells In Pediatric And Young Adults With Relapsed Or Refractory CD33+ AML|Pediatric And Young Adult Leukemia Adoptive Therapy (PLAT)-08: A Phase 1 Study Of SC-DARIC33 In Pediatric And Young Adults With Relapsed Or Refractory CD33+ AML|Recruiting||Phase 1|18|Anticipated|Seattle Children's Hospital||1|||f||||t|t|f|||||||||||2023-08-31 23:02:48.779113|2023-08-31 23:02:48.779113|OTHER|||||
NCT04094766||2019-09-17|||2020-11-03|2019-09-17|2019-09-19|Actual|||||||2020-11-03|2020-11-05|Actual|August 1, 2017|Actual|2017-08-01|November 2020|2020-11-30|August 30, 2020|Anticipated|2020-08-30|August 30, 2020|Anticipated|2020-08-30||Interventional|||Safety and Efficacy of Dual Specificity CD19 and CD22 CAR-T Cell Immunotherapy in R/R Acute B Lymphoblastic Leukemia|A Phase I Clinical Study of Dual Specificity CD19 and CD22 Chimeric Antigen Receptor T Cell Therapy in Relapsed or Refractory Acute B Lymphoblastic Leukemia|Withdrawn||Phase 1|0|Actual|Second Affiliated Hospital of Xi'an Jiaotong University||1||Production plan adjustment|f||||f|f|f|||||||||Undecided||2023-09-02 21:56:09.86897|2023-09-02 21:56:09.86897|OTHER|||||
NCT03751293||2018-11-15|||2019-05-13|2018-11-20|2018-11-23|Actual|||||||2019-05-13|2019-05-15|Actual|January 8, 2019|Actual|2019-01-08|May 2019|2019-05-31|October 30, 2020|Anticipated|2020-10-30|October 30, 2019|Anticipated|2019-10-30||Interventional|||A Study of BCMA-directed CAR-T Cells Treatment in Subjects With r/r Multiple Myeloma|A Phase Ⅰ Study Evaluating Safety and Efficacy of C-CAR088 Treatment in Subjects With Relapsed or Refractory Multiple Myeloma|Unknown status|Recruiting|Phase 1|10|Anticipated|Hebei Yanda Ludaopei Hospital||1|||f||||t|f|f|||||||||||2023-09-03 16:06:16.032925|2023-09-03 16:06:16.032925|OTHER|||||
NCT04571138||2020-09-02|||2023-06-27|2020-09-25|2020-09-30|Actual|||||||2023-06-27|2023-06-29|Actual|September 25, 2020|Actual|2020-09-25|June 2023|2023-06-30|February 2039|Anticipated|2039-02-28|June 2024|Anticipated|2024-06-30||Interventional|||A Pediatric and Young Adult Trial of Genetically Modified T Cells Directed Against CD22 for Relapsed/Refractory Leukemia or Lymphoma|Pediatric and Young Adult Leukemia Adoptive Therapy (PLAT)-07: A Phase 1/2 Study of CD22-Specific CAR T Cells for CD22+ Leukemia or Lymphoma|Recruiting||Phase 1/Phase 2|42|Anticipated|Seattle Children's Hospital||1|||||||t|t|f|||||||||||2023-08-31 23:05:10.302993|2023-08-31 23:05:10.302993|OTHER|||||
NCT04450069||2020-06-23|||2023-06-27|2020-06-25|2020-06-29|Actual|||||||2023-06-27|2023-06-29|Actual|August 14, 2020|Actual|2020-08-14|June 2023|2023-06-30|June 2024|Anticipated|2024-06-30|August 2023|Anticipated|2023-08-31||Interventional|||CLBR001 and SWI019 in Patients With Relapsed / Refractory B-cell Malignancies|A Phase 1, Open-label, Dose Escalating Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Clinical Activity of the Combination of CLBR001 and SWI019 in Patients With Relapsed/Refractory B-cell Malignancies|Active, not recruiting||Phase 1|36|Anticipated|Calibr, a division of Scripps Research||1|||||||t|t|f|||||||||No||2023-08-31 23:05:55.095856|2023-08-31 23:05:55.095856|OTHER|||||
NCT03684889||2018-09-17|||2023-06-27|2018-09-24|2018-09-26|Actual|||||||2023-06-27|2023-06-29|Actual|November 28, 2018|Actual|2018-11-28|June 2023|2023-06-30|December 2036|Anticipated|2036-12-31|February 8, 2021|Actual|2021-02-08||Interventional|||CD19-specific CAR T Cells With a Fully Human Binding Domain for CD19+ Leukemia or Lymphoma|Pediatric and Young Adult Leukemia Adoptive Therapy (PLAT)-06: A Phase 1/2 Study of CD19-specific CAR T Cells With a Fully Human Binding Domain for CD19+ Leukemia or Lymphoma|Active, not recruiting||Phase 1|16|Actual|Seattle Children's Hospital||2|||f||||t|t|f|||||||||No||2023-08-31 23:08:33.477978|2023-08-31 23:08:33.477978|OTHER|||||
NCT03853616||2019-02-19|||2021-11-30|2019-02-22|2019-02-25|Actual|||||||2021-11-30|2021-12-01|Actual|November 26, 2018|Actual|2018-11-26|November 2021|2021-11-30|December 2022|Anticipated|2022-12-31|August 2022|Anticipated|2022-08-31||Interventional|||MB-CART19.1 r/r CD19+ B-cell Malignancies (BCM)|A Phase I/II Safety, Dose Finding and Feasibility Trial of MB-CART19.1 in Patients With Relapsed or Refractory CD19 Positive B Cell Malignancies|Recruiting||Phase 1/Phase 2|48|Anticipated|Miltenyi Biomedicine GmbH||5|||f||||t|f|f|||||||||No||2023-09-02 07:34:03.323302|2023-09-02 07:34:03.323302|INDUSTRY|||||
NCT03330691||2017-10-31|||2023-06-27|2017-11-01|2017-11-06|Actual|||||||2023-06-27|2023-06-29|Actual|November 3, 2017|Actual|2017-11-03|June 2023|2023-06-30|March 3, 2035|Anticipated|2035-03-03|September 15, 2023|Anticipated|2023-09-15||Interventional|||A Feasibility and Safety Study of Dual Specificity CD19 and CD22 CAR-T Cell Immunotherapy for CD19+CD22+ Leukemia|Pediatric and Young Adult Leukemia Adoptive Therapy (PLAT)-05: A Phase 1 Feasibility and Safety Study of Dual Specificity CD19 and CD22 CAR-T Cell Immunotherapy for CD19+CD22+ Leukemia|Recruiting||Phase 1|80|Anticipated|Seattle Children's Hospital||2|||f||||t|t|f|||||||||No||2023-08-31 23:09:45.592116|2023-08-31 23:09:45.592116|OTHER|||||
NCT04077866||2019-08-26|||2022-12-25|2019-09-03|2019-09-04|Actual|||||||2022-12-25|2022-12-28|Actual|June 1, 2023|Anticipated|2023-06-01|December 2022|2022-12-31|August 1, 2025|Anticipated|2025-08-01|June 1, 2025|Anticipated|2025-06-01||Interventional|||B7-H3 CAR-T for Recurrent or Refractory Glioblastoma|B7-H3-Targeted Chimeric Antigen Receptor (CAR) T Cells in Treating Patients With Recurrent or Refractory Glioblastoma|Recruiting||Phase 1/Phase 2|40|Anticipated|Second Affiliated Hospital, School of Medicine, Zhejiang University||2|||f||||f|f|f|||||||||No||2023-09-03 16:13:22.656773|2023-09-03 16:13:22.656773|OTHER|||||
NCT03244306||2017-08-03|||2023-06-27|2017-08-08|2017-08-09|Actual|||||||2023-06-27|2023-06-29|Actual|July 27, 2017|Actual|2017-07-27|June 2023|2023-06-30|July 2035|Anticipated|2035-07-31|November 14, 2018|Actual|2018-11-14||Interventional|PLAT-04||A Phase 1 Study of CD22-CAR TCell Immunotherapy for CD22+ Leukemia and Lymphoma|Pediatric and Young Adult Leukemia Adoptive Therapy (PLAT)-04: A Phase 1 Feasibility and Safety Study of CD22-CAR T Cell Immunotherapy for CD22+ Leukemia and Lymphoma|Active, not recruiting||Phase 1|4|Actual|Seattle Children's Hospital||1|||||||t|t|f|||||||||||2023-08-31 23:10:04.202789|2023-08-31 23:10:04.202789|OTHER|||||
NCT03186118||2017-06-12|||2023-06-27|2017-06-12|2017-06-14|Actual|||||||2023-06-27|2023-06-29|Actual|August 4, 2017|Actual|2017-08-04|June 2023|2023-06-30|July 2033|Anticipated|2033-07-31|September 13, 2021|Actual|2021-09-13||Interventional|||Pilot Study of T-APCs Following CAR T Cell Immunotherapy for CD19+ Leukemia|Pediatric and Young Adult Leukemia Adoptive Therapy (PLAT)-03: A Pilot Feasibility and Safety Study of CD19t T-Antigen Presenting Cells (T-APCs) Following CAR T Cell Immunotherapy for CD19+ Leukemia|Active, not recruiting||Phase 1|30|Anticipated|Seattle Children's Hospital||4|||f||||t|t|f|||||||||||2023-08-31 23:10:14.618731|2023-08-31 23:10:14.618731|OTHER|||||
NCT05325801||2022-03-15|||2022-04-05|2022-04-05|2022-04-13|Actual|||||||2022-04-05|2022-04-13|Actual|April 2022|Anticipated|2022-04-30|April 2022|2022-04-30|March 2025|Anticipated|2025-03-31|March 2024|Anticipated|2024-03-31||Interventional|||A Study of CAR-T Cells Targeting Both BCMA and GPRC5D in Treatment of Relapsed or Refractory Multiple Myeloma|An Open-Label, Dose Finding Study to Investigate the Safety, Pharmacokinetics, and Preliminary Efficacy of BMCA and GPRC5D Dual Target CAR-T Cells Therapy in Patients With Relapsed or Refractory Multiple Myeloma|Not yet recruiting||Phase 1|9|Anticipated|Zhejiang University||1|||f|||||f|f|||||||||||2023-09-02 22:11:12.049424|2023-09-02 22:11:12.049424|OTHER|||||
NCT02028455||2014-01-03|2022-08-09||2023-06-27|2014-01-03|2014-01-07|Estimate|2023-02-16|2023-03-14|Actual||||2023-06-27|2023-06-28|Actual|February 11, 2014|Actual|2014-02-11|June 2023|2023-06-30|July 2036|Anticipated|2036-07-31|August 10, 2021|Actual|2021-08-10||Interventional|||A Pediatric and Young Adult Trial of Genetically Modified T Cells Directed Against CD19 for Relapsed/Refractory CD19+ Leukemia|Pediatric and Young Adult Leukemia Adoptive Therapy (PLAT)-02: A Phase 1/2 Feasibility and Safety Study of CD19-CAR T Cell Immunotherapy for CD19+ Leukemia|Active, not recruiting||Phase 1/Phase 2|167|Actual|Seattle Children's Hospital||7|||f||||t|t|f|||||||||||2023-08-31 23:11:52.601762|2023-08-31 23:11:52.601762|OTHER|||||
NCT02587689||2015-10-25|||2016-12-01|2015-10-25|2015-10-27|Estimate|||||||2016-12-01|2016-12-05|Estimate|October 2015||2015-10-31|December 2016|2016-12-31|October 2018|Anticipated|2018-10-31|October 2017|Anticipated|2017-10-31||Interventional|||Phase I/II Study of Anti-Mucin1 (MUC1) CAR T Cells for Patients With MUC1+ Advanced Refractory Solid Tumor|Phase I/II Study of Anti-MUC1 CAR T Cells for Patients With MUC1+ Advanced Refractory Solid Tumor|Unknown status|Recruiting|Phase 1/Phase 2|20|Anticipated|PersonGen BioTherapeutics (Suzhou) Co., Ltd.||1|||f||||t|||||||||||||2023-09-02 22:13:52.835836|2023-09-02 22:13:52.835836|INDUSTRY|||||
NCT01683279||2012-09-07|||2023-06-27|2012-09-07|2012-09-11|Estimate|||||||2023-06-27|2023-06-29|Actual|March 25, 2012|Actual|2012-03-25|June 2023|2023-06-30|January 7, 2030|Anticipated|2030-01-07|January 7, 2015|Actual|2015-01-07||Interventional|||A Pediatric Trial of Genetically Modified Autologous T Cells Directed Against CD19 for Relapsed CD19+ Acute Lymphoblastic Leukemia|Pediatric Leukemia Adoptive Therapy (PLAT)-01: A Phase 1 Feasibility and Safety Study of Cellular Immunotherapy for Relapsed Pediatric CD19+ Acute Lymphoblastic Leukemia Using Autologous T-cells Lentivirally Transduced To Express a CD19-Specific Chimeric Antigen Receptor|Active, not recruiting||Phase 1|6|Actual|Seattle Children's Hospital||1|||f||||t|t|f|||||||||||2023-08-31 23:12:24.7241|2023-08-31 23:12:24.7241|OTHER|||||
NCT03994705||2019-06-19|||2023-02-06|2019-06-19|2019-06-21|Actual|||||||2023-02-06|2023-02-08|Actual|August 6, 2019|Actual|2019-08-06|February 2023|2023-02-28|February 6, 2024|Anticipated|2024-02-06|February 6, 2024|Anticipated|2024-02-06||Interventional|||Descartes-11 in Multiple Myeloma|Phase I Safety Study of Descartes-11 in Patients With Relapsed/Refractory Multiple Myeloma|Active, not recruiting||Phase 1/Phase 2|25|Actual|Cartesian Therapeutics||1|||f||||f|t|f|||||||||No||2023-08-31 23:13:57.738599|2023-08-31 23:13:57.738599|INDUSTRY|||||
NCT02580747||2015-10-19|||2015-10-19|2015-10-19|2015-10-20|Estimate|||||||2015-10-19|2015-10-20|Estimate|October 2015||2015-10-31|October 2015|2015-10-31|November 2018|Anticipated|2018-11-30|November 2017|Anticipated|2017-11-30||Interventional|||Treatment of Relapsed and/or Chemotherapy Refractory Advanced Malignancies by CART-meso|Clinical Study of Chimeric Mesothelin Antigen Receptor-modified T Cells in Relapsed and/or Chemotherapy Refractory Malignancies|Unknown status|Recruiting|Phase 1|20|Anticipated|Chinese PLA General Hospital||1|||f||||t|||||||||||||2023-09-02 22:19:37.576849|2023-09-02 22:19:37.576849|OTHER|||||
NCT05268172||2021-12-06|||2023-01-30|2022-02-24|2022-03-07|Actual|||||||2023-01-30|2023-02-01|Actual|December 20, 2022|Actual|2022-12-20|October 2022|2022-10-31|December 30, 2023|Anticipated|2023-12-30|December 30, 2023|Anticipated|2023-12-30||Interventional|||IFN-γ Combined With T Cells in the Treatment of Refractory Malignant Pleural Effusion and Ascites|Single-arm Open Multicenter Study of IFN-γ Combined With T Cells in the Treatment of Refractory Malignant Pleural Effusion Tumors|Recruiting||Phase 1|40|Anticipated|Affiliated Hospital of Jiangnan University||1|||f|||||f|f|||||||||No|The associated efficacy is uncertain|2023-09-03 16:21:38.416305|2023-09-03 16:21:38.416305|OTHER|||||
NCT05651100||2022-11-26|||2022-12-06|2022-12-06|2022-12-14|Actual|||||||2022-12-06|2022-12-14|Actual|December 10, 2022|Anticipated|2022-12-10|December 2022|2022-12-31|December 10, 2025|Anticipated|2025-12-10|December 10, 2024|Anticipated|2024-12-10||Interventional|||Safety and Efficacy of Sequential CD19 and CD22 Targeted CAR-T Therapy for Relapsed/Refractory B Cell Lymphoma|Phase 1/Phase 2 Study of Sequential Chimeric Antigen Receptor T Cell Targeting at CD19 and CD22 B-cell Antigens Treating Refractory or Relapsed B-cell Lymphoma Patients|Not yet recruiting||Phase 1/Phase 2|50|Anticipated|Kecellitics Biotech Company Ltd||1|||f||||f|f|f|||||||||||2023-08-31 23:16:36.390074|2023-08-31 23:16:36.390074|INDUSTRY|||||
NCT05416554||2022-05-20|||2023-05-23|2022-06-08|2022-06-13|Actual|||||||2023-05-23|2023-05-25|Actual|July 2023|Anticipated|2023-07-31|May 2023|2023-05-31|December 2023|Anticipated|2023-12-31|December 2023|Anticipated|2023-12-31||Interventional|||Long-term Cognitive, Neuropsychiatric and Functional Outcomes in Adults Who Have Received Chimeric Antigen-Receptor T-Cell (CAR-T) Therapy for Aggressive Lymphoma at Stanford|Long-term Cognitive, Neuropsychiatric and Functional Outcomes in Adults Who Have Received Chimeric Antigen-Receptor T-Cell (CAR-T) Therapy for Aggressive Lymphoma at Stanford - A Pilot Study|Not yet recruiting||Not Applicable|20|Anticipated|Stanford University||1|||f|||||f|f|||||||||||2023-08-31 23:19:52.237192|2023-08-31 23:19:52.237192|OTHER|||||
NCT03497819||2017-10-27|||2018-04-12|2018-04-12|2018-04-13|Actual|||||||2018-04-12|2018-04-13|Actual|October 1, 2017|Actual|2017-10-01|April 2018|2018-04-30|October 31, 2020|Anticipated|2020-10-31|October 31, 2019|Anticipated|2019-10-31||Interventional|||Autologous CARTmeso/19 Against Pancreatic Cancer|Pilot Study of Autologous Chimeric Antigen Receptor Cells Against Mesothelin and CD19 in Patients With Pancreatic Cancer|Unknown status|Active, not recruiting|Early Phase 1|10|Anticipated|First Affiliated Hospital of Wenzhou Medical University||1|||f||||t|f|f|||||||||No||2023-09-04 17:11:59.152675|2023-09-04 17:11:59.152675|OTHER|||||
NCT05616468||2022-10-30|||2022-12-14|2022-11-07|2022-11-15|Actual|||||||2022-12-14|2022-12-15|Actual|December 30, 2022|Anticipated|2022-12-30|December 2022|2022-12-31|December 31, 2025|Anticipated|2025-12-31|December 1, 2024|Anticipated|2024-12-01||Interventional|||BGT007 Cell Treatment of Nasopharyngeal Carcinoma|Clinical Study of the Safety and Initial Efficacy of BGT007 Cells in the Treatment of Patients With Relapsed /Metastatic Nasopharyngeal Carcinoma|Recruiting||Early Phase 1|23|Anticipated|The Affiliated Hospital of Xuzhou Medical University||1|||f||||f|f|f|||||||||||2023-08-31 23:29:05.369166|2023-08-31 23:29:05.369166|OTHER|||||
NCT05366179||2022-05-04|||2023-06-16|2022-05-04|2022-05-09|Actual|||||||2023-06-16|2023-06-18|Actual|September 2, 2022|Actual|2022-09-02|June 2023|2023-06-30|May 2030|Anticipated|2030-05-31|October 31, 2024|Anticipated|2024-10-31||Interventional|||Autologous CAR-T Cells Targeting B7-H3 in Recurrent or Refractory GBM CAR.B7-H3Tc|Phase I Study of Intraventricular Infusion of T Cells Expressing B7-H3 Specific Chimeric Antigen Receptors (CAR) in Subjects With Recurrent or Refractory Glioblastoma|Recruiting||Phase 1|36|Anticipated|UNC Lineberger Comprehensive Cancer Center||1|||f||||t|t|f|||||||||||2023-08-31 13:16:45.835932|2023-08-31 13:16:45.835932|OTHER|||||
NCT01865617||2013-05-28|2022-03-21||2022-05-02|2013-05-30|2013-05-31|Estimate|2022-05-02|2022-05-25|Actual||||2022-05-02|2022-05-25|Actual|May 22, 2013|Actual|2013-05-22|May 2022|2022-05-31|March 26, 2021|Actual|2021-03-26|March 26, 2021|Actual|2021-03-26||Interventional|||Laboratory Treated T Cells in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia, Non-Hodgkin Lymphoma, or Acute Lymphoblastic Leukemia|Phase I/II Study of Immunotherapy for Advanced CD19+ Chronic Lymphocytic Leukemia, Acute Lymphoblastic Leukemia/Lymphoma and Non-Hodgkin Lymphoma With Defined Subsets of Autologous T Cells Engineered to Express a CD19-Specific Chimeric Antigen Receptor|Completed||Phase 1/Phase 2|204|Actual|Fred Hutchinson Cancer Center||13|||f||||t|t|f|||||||||No||2023-09-04 17:25:13.130845|2023-09-04 17:25:13.130845|OTHER|||||
NCT05320081||2021-11-24|||2022-04-08|2022-04-08|2022-04-11|Actual|||||||2022-04-08|2022-04-11|Actual|November 30, 2021|Actual|2021-11-30|April 2022|2022-04-30|June 30, 2024|Anticipated|2024-06-30|December 31, 2023|Anticipated|2023-12-31||Interventional|||Camrelizumab Combined With CD30 CAR-T in the Treatment of Relapsed/Refractory CD30+ Lymphoma|Camrelizumab Combined With CD30 CAR-T in the Treatment of Relapsed/Refractory CD30+ Lymphoma: a Single-arm, Open-label Clinical Study|Recruiting||Phase 2|30|Anticipated|Huazhong University of Science and Technology||1|||f||||f|f|f|||||||||No||2023-09-04 17:28:56.850608|2023-09-04 17:28:56.850608|OTHER|||||
NCT03740256||2018-11-09|||2023-03-02|2018-11-09|2018-11-14|Actual|||||||2023-03-02|2023-03-06|Actual|December 14, 2020|Actual|2020-12-14|March 2023|2023-03-31|December 30, 2038|Anticipated|2038-12-30|December 30, 2024|Anticipated|2024-12-30||Interventional|VISTA||Binary Oncolytic Adenovirus in Combination With HER2-Specific Autologous CAR VST, Advanced HER2 Positive Solid Tumors|A First in Human Phase I Trial of Binary Oncolytic Adenovirus in Combination With HER2-Specific Autologous CAR T Cells in Patients With Advanced HER2 Positive Solid Tumors|Recruiting||Phase 1|45|Anticipated|Baylor College of Medicine||1|||f||||t|t|f|||f||||||||2023-09-02 22:41:04.340955|2023-09-02 22:41:04.340955|OTHER|||||
NCT04938115||2021-06-16|||2022-05-24|2021-06-16|2021-06-24|Actual|||||||2022-05-24|2022-05-31|Actual|May 10, 2021|Actual|2021-05-10|June 2021|2021-06-30|June 30, 2023|Anticipated|2023-06-30|May 31, 2023|Anticipated|2023-05-31||Interventional|||Cell Therapy for CD7 Positive Acute Leukemia or Mixed Lineage Leukemia Except Those Who Are Diagnosed With T-ALL/T-LBL Using CD7-Specific CAR-T Cells|Cell Therapy for CD7 Positive Acute Leukemia or Mixed Lineage Leukemia Except Those Who Are Diagnosed With T-ALL/T-LBL Using CD7-Specific CAR-T Cells|Unknown status|Recruiting|Not Applicable|50|Anticipated|Hebei Senlang Biotechnology Inc., Ltd.||1|||f|||||f|f|||||||||||2023-09-04 17:29:43.014695|2023-09-04 17:29:43.014695|INDUSTRY|||||
NCT02186860||2014-07-08|||2021-02-06|2014-07-09|2014-07-10|Estimate|||||||2021-02-06|2021-02-10|Actual|July 2016|Actual|2016-07-31|February 2021|2021-02-28|December 2021|Anticipated|2021-12-31|October 2021|Anticipated|2021-10-31||Interventional|||Chimeric Antigen Receptor (CAR)-Modified T Cell Therapy in Treating Patients With Acute Lymphoblastic Leukemia|Treatment of Chemotherapy Resistant or Refractory Acute Lymphoblastic Leukemia by Chimeric Antigen Receptor (CAR)-Modified T Cells|Unknown status|Recruiting|Phase 1|5|Anticipated|Affiliated Hospital to Academy of Military Medical Sciences||1|||f||||t|||||||||||||2023-09-03 16:43:41.85262|2023-09-03 16:43:41.85262|OTHER|||||
NCT04322292||2020-03-24|||2020-03-24|2020-03-24|2020-03-26|Actual|||||||2020-03-24|2020-03-26|Actual|September 12, 2019|Actual|2019-09-12|March 2020|2020-03-31|November 2021|Anticipated|2021-11-30|August 2021|Anticipated|2021-08-31||Interventional|||A Study of BCMA-directed CAR-T Cells Treatment in Subjects With r/r Multiple Myeloma|A Phase Ⅰ Study Evaluating Safety and Efficacy of C-CAR088 Treatment in Subjects With Relapsed or Refractory Multiple Myeloma|Unknown status|Recruiting|Phase 1|10|Anticipated|Institute of Hematology & Blood Diseases Hospital||1|||f||||f|f|f|||||||||No||2023-09-02 08:19:15.302673|2023-09-02 08:19:15.302673|OTHER|||||
NCT02650999||2016-01-07|2020-04-28||2021-07-20|2016-01-07|2016-01-08|Estimate|2020-05-11|2020-05-12|Actual||||2021-07-20|2021-07-22|Actual|January 2016||2016-01-31|July 2021|2021-07-31|June 12, 2020|Actual|2020-06-12|February 25, 2019|Actual|2019-02-25||Interventional|||Pembrolizumab in Patients Failing to Respond to or Relapsing After CAR T Cell Therapy for Relapsed or Refractory Lymphomas|Phase I/II Study of Pembrolizumab in Patients Failing to Respond to or Relapsing After Anti-CD19 Chimeric Antigen Receptor Modified T Cell Therapy for Relapsed or Refractory CD19+ Lymphomas|Completed||Phase 1/Phase 2|12|Actual|Abramson Cancer Center at Penn Medicine||1|||f||||t|||||||||||||2023-08-31 23:53:35.485096|2023-08-31 23:53:35.485096|OTHER|||||
NCT02631044||2015-12-11|||2023-03-01|2015-12-11|2015-12-15|Estimate|||||||2023-03-01|2023-03-03|Actual|January 6, 2016|Actual|2016-01-06|March 2023|2023-03-31|May 10, 2024|Anticipated|2024-05-10|May 10, 2024|Anticipated|2024-05-10||Interventional|||Study Evaluating the Safety and Pharmacokinetics of JCAR017 in B-cell Non-Hodgkin Lymphoma (TRANSCEND-NHL-001)|A Phase 1, Multicenter, Open-Label Study of JCAR017, CD19-targeted Chimeric Antigen Receptor (CAR) T Cells, for Relapsed and Refractory (R/R) B-cell Non-Hodgkin Lymphoma (NHL)|Active, not recruiting||Phase 1|385|Actual|Juno Therapeutics, a Subsidiary of Celgene||2|||f||||t|t|f|||||||||||2023-09-02 22:59:29.493574|2023-09-02 22:59:29.493574|INDUSTRY|||||
NCT02259556||2014-10-05|||2016-01-26|2014-10-07|2014-10-08|Estimate|||||||2016-01-26|2016-01-28|Estimate|October 2014||2014-10-31|January 2016|2016-01-31|October 2029|Anticipated|2029-10-31|October 2018|Anticipated|2018-10-31||Interventional|CART30||CD30-directed Chimeric Antigen Receptor T (CART30) Therapy in Relapsed and Refractory CD30 Positive Lymphomas|CD30-directed Chimeric Antigen Receptor T (CART30) Therapy in Relapsed and Refractory CD30 Positive Lymphomas|Recruiting||Phase 1/Phase 2|30|Anticipated|Chinese PLA General Hospital||1|||f||||t|||||||||||||2023-09-03 16:52:20.925221|2023-09-03 16:52:20.925221|OTHER|||||
NCT05436223||2022-06-23|||2022-06-29|2022-06-27|2022-06-29|Actual|||||||2022-06-29|2022-07-05|Actual|August 9, 2021|Actual|2021-08-09|June 2022|2022-06-30|August 9, 2026|Anticipated|2026-08-09|August 9, 2024|Anticipated|2024-08-09||Interventional|||Human CD19 Targeted T Cells Injection(CD19 CAR-T) Therapy for Relapsed and Refractory B-cell Non-Hodgkin's Lymphoma|A Phase Ⅱ Clinical Study Evaluating the Efficacy and Safety of Human CD19 Targeted T Cells Injection (CD19 CAR-T) Therapy for Relapsed and Refractory B-cell Non-Hodgkin's Lymphoma|Recruiting||Phase 2|100|Anticipated|Hrain Biotechnology Co., Ltd.||1|||f||||f|f|f|||||||||No||2023-08-31 23:56:21.069714|2023-08-31 23:56:21.069714|INDUSTRY|||||
NCT01218867||2010-10-08|2016-04-15||2019-11-18|2010-10-08|2010-10-11|Estimate|2016-06-09|2016-07-22|Estimate||||2019-11-18|2019-12-10|Actual|November 10, 2010|Actual|2010-11-10|November 2019|2019-11-30|December 15, 2015|Actual|2015-12-15|September 3, 2014|Actual|2014-09-03||Interventional|||CAR T Cell Receptor Immunotherapy Targeting VEGFR2 for Patients With Metastatic Cancer|Phase I/II Study of Metastatic Cancer Using Lymphodepleting Conditioning Followed by Infusion of Anti-VEGFR2 Gene Engineered CD8+ Lymphocytes|Terminated||Phase 1/Phase 2|24|Actual|National Institutes of Health Clinical Center (CC)||11||No objective responses were observed.|f||||t|t|f|||||||||No||2023-09-02 08:24:15.86555|2023-09-02 08:24:15.86555|NIH|||||
NCT04928105||2021-06-09|||2022-05-24|2021-06-09|2021-06-16|Actual|||||||2022-05-24|2022-05-31|Actual|January 27, 2021|Actual|2021-01-27|June 2021|2021-06-30|March 31, 2023|Anticipated|2023-03-31|January 31, 2023|Anticipated|2023-01-31||Interventional|||Senl-T7 CAR-T Cells for Treatment of Relapsed or Refractory CD7+ Lymphoma|Clinical Study of Senl-T7 CAR-T Cells in the Treatment of Relapsed or Refractory CD7+ Lymphoma|Unknown status|Recruiting|Not Applicable|100|Anticipated|Hebei Senlang Biotechnology Inc., Ltd.||1|||f|||||f|f|||||||||||2023-09-04 17:35:35.843306|2023-09-04 17:35:35.843306|INDUSTRY|||||
NCT04317885||2020-03-20|||2023-05-24|2020-03-20|2020-03-23|Actual|||||||2023-05-24|2023-05-26|Actual|November 5, 2019|Actual|2019-11-05|May 2023|2023-05-31|December 30, 2023|Anticipated|2023-12-30|June 30, 2023|Anticipated|2023-06-30||Interventional|||A Study Evaluating Safety and Efficacy of C-CAR039 Treatment in NHL Subjects|A Study Evaluating Safety and Efficacy of C-CAR039 Treatment in Relapsed or Refractory NHL Subjects|Active, not recruiting||Phase 1|25|Actual|Shanghai Tongji Hospital, Tongji University School of Medicine||1|||f||||f|f|f|||||||||||2023-09-02 08:28:23.337839|2023-09-02 08:28:23.337839|OTHER|||||
NCT04186520||2019-12-02|||2023-06-07|2019-12-02|2019-12-04|Actual|||||||2023-06-07|2023-06-08|Actual|May 18, 2020|Actual|2020-05-18|June 2023|2023-06-30|December 31, 2025|Anticipated|2025-12-31|December 31, 2025|Anticipated|2025-12-31||Interventional|||CAR-20/19-T Cells in Patients With Relapsed Refractory B Cell Malignancies|Phase I/II Study of Tandem, Bispecific Anti-CD19 Anti-CD20 CAR-T Cells for Patients With Relapsed and/or Refractory B Cell Malignancies|Recruiting||Phase 1/Phase 2|100|Anticipated|Medical College of Wisconsin||6|||f||||t|t|f|||||||||No||2023-09-01 00:01:23.128175|2023-09-01 00:01:23.128175|OTHER|||||
NCT04067414||2019-01-07|||2020-03-15|2019-08-22|2019-08-26|Actual|||||||2020-03-15|2020-03-17|Actual|June 14, 2018|Actual|2018-06-14|March 2020|2020-03-31|December 31, 2020|Anticipated|2020-12-31|July 31, 2020|Anticipated|2020-07-31||Interventional|||Exploratory Study of CD19-targeted Chimeric Antigen Receptor T Cells(BZ019) for Relapsed and Refractory B-cell Lymphoma|A Single Cohort, Open-label, Multicenter, Dose-escalation Study of Safety and Efficacy of BZ019 for Adult CD19 Positive Relapsed and Refractory B-cell Non-Hodgkin Lymphoma|Unknown status|Active, not recruiting|Phase 1|12|Actual|Institute of Hematology & Blood Diseases Hospital||1|||f||||t|f|f|||||||||No||2023-09-02 23:09:58.968153|2023-09-02 23:09:58.968153|OTHER|||||
NCT05239676||2021-12-01|||2022-02-13|2022-02-13|2022-02-15|Actual|||||||2022-02-13|2022-02-15|Actual|February 28, 2022|Anticipated|2022-02-28|February 2022|2022-02-28|December 1, 2024|Anticipated|2024-12-01|December 1, 2024|Anticipated|2024-12-01||Interventional|||Autologous Hematopoietic Stem Cell Transplantation Combined With CAR-T Cells in the Treatment of Refractory and Relapsed Malignant Lymphoma|Clinical Study on the Safety and Effectiveness of Autologous Hematopoietic Stem Cell Transplantation Combined With CAR-T Cells in the Treatment of Refractory and Relapsed Malignant Lymphoma|Recruiting||Early Phase 1|50|Anticipated|Zhejiang University||1|||f||||t|f|f|||||||||||2023-09-03 16:58:33.868922|2023-09-03 16:58:33.868922|OTHER|||||
NCT05349266||2022-04-08|||2022-04-21|2022-04-21|2022-04-27|Actual|||||||2022-04-21|2022-04-27|Actual|March 18, 2022|Actual|2022-03-18|April 2022|2022-04-30|April 30, 2024|Anticipated|2024-04-30|March 30, 2024|Anticipated|2024-03-30||Interventional|||Assessment of Safety and Efficacy of ThisCART19A in Adult Patients With B-NHL After Failure of Autologous Chimeric Antigen Receptor T- Cell(CAR-T) Therapy|Assessment of Safety and Efficacy of ThisCART19A in Adult Patients With B Cells Non-Hodgkin's Lymphoma(B-NHL) After Failure of Autologous CAR-T Therapy|Recruiting||Phase 1|16|Anticipated|Zhejiang University||3|||f||||f|f|f|||||||||||2023-09-01 00:03:50.499288|2023-09-01 00:03:50.499288|OTHER|||||
NCT05336383||2022-04-13|||2022-07-09|2022-04-13|2022-04-20|Actual|||||||2022-07-09|2022-07-12|Actual|May 31, 2022|Actual|2022-05-31|July 2022|2022-07-31|December 7, 2023|Anticipated|2023-12-07|December 7, 2023|Anticipated|2023-12-07||Interventional|||Phase II Study of Salvage Radiation Treatment After B-cell Maturation Antigen Chimeric Antigen Receptor T-cell Therapy for Relapsed Refractory Multiple Myeloma|Phase II Study of Salvage Radiation Treatment After B-cell Maturation Antigen Chimeric Antigen Receptor T-cell Therapy for Relapsed Refractory Multiple Myeloma|Recruiting||Phase 2|30|Anticipated|M.D. Anderson Cancer Center||1|||f||||t|t|f|||f||||||||2023-09-01 00:04:00.537321|2023-09-01 00:04:00.537321|OTHER|||||
NCT04337606||2020-04-04|||2020-04-04|2020-04-04|2020-04-07|Actual|||||||2020-04-04|2020-04-07|Actual|April 4, 2020|Anticipated|2020-04-04|April 2020|2020-04-30|April 4, 2026|Anticipated|2026-04-04|April 4, 2024|Anticipated|2024-04-04||Interventional|||Chidamide in Combination With Decitabine in Non-Hodgkin's Lymphoma Relapsed After Chimeric Antigen Receptor|Chidamide in Combination With Decitabine in Non-Hodgkin's Lymphoma Relapsed After Chimeric Antigen Receptor : An Open-label Phase I/II Trial|Recruiting||Phase 1/Phase 2|100|Anticipated|Chinese PLA General Hospital||2|||f||||t|f|f|||||||||||2023-09-01 00:05:01.292011|2023-09-01 00:05:01.292011|OTHER|||||
NCT02862028||2016-08-07|||2016-08-23|2016-08-07|2016-08-10|Estimate|||||||2016-08-23|2016-08-25|Estimate|August 2016||2016-08-31|August 2016|2016-08-31|July 2018|Anticipated|2018-07-31|March 2018|Anticipated|2018-03-31||Interventional|||PD-1 Antibody Expressing CAR-T Cells for EGFR Family Member Positive Advanced Solid Tumor (Lung, Liver and Stomach)|A Clinical Study of PD-1 Antibody Expressing CAR-T Cells for EGFR Family Member Positive Advanced Solid Tumor (Lung, Liver and Stomach)|Unknown status|Recruiting|Phase 1/Phase 2|20|Anticipated|Shanghai International Medical Center||1|||f|||||||||||||||||2023-09-02 09:36:57.520913|2023-09-02 09:36:57.520913|INDUSTRY|||||
NCT04336501||2020-04-03|||2020-12-15|2020-04-06|2020-04-07|Actual|||||||2020-12-15|2020-12-17|Actual|January 1, 2019|Actual|2019-01-01|December 2020|2020-12-31|December 1, 2021|Anticipated|2021-12-01|December 1, 2021|Anticipated|2021-12-01||Interventional|||Efficacy and Safety Evaluation of IM19 CAR-T Cell Therapy for MRD+ After Transplantation|Efficacy Study About Donor Derived CD19-target T Cell to Treat B-ALL Post Hematopoietic Stem Cell Transplantation|Unknown status|Recruiting|Not Applicable|20|Anticipated|Beijing Immunochina Medical Science & Technology Co., Ltd.||1|||f||||f|f|f|||||||||No||2023-09-01 00:07:21.232091|2023-09-01 00:07:21.232091|INDUSTRY|||||
NCT04561557||2020-09-10|||2023-04-10|2020-09-18|2020-09-23|Actual|||||||2023-04-10|2023-04-12|Actual|September 22, 2020|Actual|2020-09-22|April 2023|2023-04-30|May 31, 2024|Anticipated|2024-05-31|February 22, 2024|Anticipated|2024-02-22||Interventional|CARTinNS||Safety and Efficacy of CT103A Cells for Relapsed/Refractory Antibody-associated Idiopathic Inflammatory Diseases of the Nervous System|An Open Label Clinical Trial to Evaluate the Safety and Efficacy of CT103A Cells for the Treatment of Relapsed/Refractory Antibody-associated Idiopathic Inflammatory Diseases of the Nervous System|Recruiting||Early Phase 1|18|Anticipated|Tongji Hospital||3|||f||||f|f|f|||||||||No||2023-09-02 23:17:29.780302|2023-09-02 23:17:29.780302|OTHER|||||
NCT01109095||2010-04-13|||2019-04-24|2010-04-21|2010-04-22|Estimate|||||||2019-04-24|2019-04-25|Actual|October 2010||2010-10-31|April 2019|2019-04-30|March 7, 2018|Actual|2018-03-07|June 2014|Actual|2014-06-30||Interventional|HERT-GBM||CMV-specific Cytotoxic T Lymphocytes Expressing CAR Targeting HER2 in Patients With GBM|Administration of HER2 Chimeric Antigen Receptor Expressing CMV-Specific Cytotoxic T Cells Ins Patients With Glioblastoma Multiforme (HERT-GBM)|Completed||Phase 1|16|Actual|Baylor College of Medicine||1|||f||||t|||||||||||||2023-09-03 17:11:09.445926|2023-09-03 17:11:09.445926|OTHER|||||
NCT02792114||2016-06-02|||2023-06-29|2016-06-06|2016-06-07|Estimate|||||||2023-06-29|2023-07-03|Actual|June 2016|Actual|2016-06-30|June 2023|2023-06-30|June 2024|Anticipated|2024-06-30|June 2024|Anticipated|2024-06-30||Interventional|||T-Cell Therapy for Advanced Breast Cancer|A Phase I Clinical Trial to Evaluate the Safety and Tolerability of Mesothelin-Specific Chimeric Antigen Receptor-Positive T Cells in Patients With Metastatic Mesothelin-Expressing Breast Cancer|Active, not recruiting||Phase 1|186|Actual|Memorial Sloan Kettering Cancer Center||1|||f|||||||||||||||||2023-09-02 08:37:29.269638|2023-09-02 08:37:29.269638|OTHER|||||
NCT05371093||2022-05-09|||2023-08-07|2022-05-09|2022-05-12|Actual|||||||2023-08-07|2023-08-08|Actual|September 12, 2022|Actual|2022-09-12|August 2023|2023-08-31|July 2029|Anticipated|2029-07-31|July 2029|Anticipated|2029-07-31||Interventional|ZUMA-22||Study of Axicabtagene Ciloleucel Versus Standard of Care Therapy in Participants With Relapsed/Refractory Follicular Lymphoma|A Phase 3 Randomized, Open-Label, Multicenter Study Evaluating the Efficacy of Axicabtagene Ciloleucel Versus Standard of Care Therapy in Subjects With Relapsed/Refractory Follicular Lymphoma|Recruiting||Phase 3|230|Anticipated|Gilead Sciences||2|||f||||t|t|f|||||||||No||2023-09-03 17:17:49.71437|2023-09-03 17:17:49.71437|INDUSTRY|||||
NCT05364424||2022-05-03|||2023-08-07|2022-05-03|2022-05-06|Actual|||||||2023-08-07|2023-08-08|Actual|November 4, 2022|Actual|2022-11-04|August 2023|2023-08-31|June 24, 2024|Anticipated|2024-06-24|June 24, 2024|Anticipated|2024-06-24||Interventional|||A Study Evaluating the Efficacy, Safety, and Pharmacokinetics of Glofitamab in Combination With Rituximab Plus Ifosfamide, Carboplatin Etoposide Phosphate in Participants With Relapsed/Refractory Transplant or CAR-T Therapy Eligible Diffuse B-Cell Lymphoma|A Phase IB, Open-Label, Multicenter, Single Arm Study Evaluating the Preliminary Efficacy, Safety, and Pharmacokinetics of Glofitamab in Combination With Rituximab Plus Ifosfamide, Carboplatin Etoposide Phosphate in Patients With Relapsed/Refractory Transplant or CAR-T Therapy Eligible Diffuse B-Cell Lymphoma|Recruiting||Phase 1|40|Anticipated|Hoffmann-La Roche||1|||f||||t|t|f|||||||||Yes|Qualified researchers may request access to individual patient level data through the clinical study data request platform (www.vivli.org). Further details on Roche's criteria for eligible studies are available here (https://vivli.org/ourmember/roche/). For further details on Roche's Global Policy on the Sharing of Clinical Information and how to request access to related clinical study documents, see here (https://www.roche.com/research_and_development/who_we_are_how_we_work/clinical_trials/our_commitment_to_data_sharing.htm).|2023-09-03 17:17:51.479115|2023-09-03 17:17:51.479115|INDUSTRY|||||
NCT04989803||2021-07-26|||2023-08-04|2021-07-26|2021-08-04|Actual|||||||2023-08-04|2023-08-08|Actual|October 27, 2021|Actual|2021-10-27|August 2023|2023-08-31|January 2041|Anticipated|2041-01-31|April 2024|Anticipated|2024-04-30||Interventional|||Study of KITE-363 or KITE-753 in Participants With Relapsed and/or Refractory B-cell Lymphoma|A Phase 1 Open-label, Multicenter Study Evaluating the Safety and Efficacy of KITE-363 or KITE-753, Autologous Anti-CD19/CD20 CAR T-cell Therapies, in Subjects With Relapsed and/or Refractory B-cell Lymphoma|Recruiting||Phase 1|114|Anticipated|Gilead Sciences||2|||f||||t|t|f|||t||||||No||2023-09-03 17:19:11.382195|2023-09-03 17:19:11.382195|INDUSTRY|||||
NCT04897321||2021-05-11|||2023-08-07|2021-05-18|2021-05-21|Actual|||||||2023-08-07|2023-08-08|Actual|July 6, 2022|Actual|2022-07-06|August 2023|2023-08-31|March 1, 2027|Anticipated|2027-03-01|March 1, 2026|Anticipated|2026-03-01||Interventional|||B7-H3-Specific Chimeric Antigen Receptor Autologous T-Cell Therapy for Pediatric Patients With Solid Tumors (3CAR)|B7-H3-Specific Chimeric Antigen Receptor Autologous T-Cell Therapy for Pediatric Patients With Solid Tumors (3CAR)|Recruiting||Phase 1|32|Anticipated|St. Jude Children's Research Hospital||1|||||||f|t|f|||t||||||||2023-09-03 17:19:29.886087|2023-09-03 17:19:29.886087|OTHER|||||
NCT04196413||2019-12-10|||2023-08-04|2019-12-10|2019-12-12|Actual|||||||2023-08-04|2023-08-08|Actual|June 4, 2020|Actual|2020-06-04|August 2023|2023-08-31|July 31, 2043|Anticipated|2043-07-31|July 31, 2028|Anticipated|2028-07-31||Interventional|||GD2 CAR T Cells in Diffuse Intrinsic Pontine Gliomas(DIPG) & Spinal Diffuse Midline Glioma(DMG)|Phase 1 Clinical Trial of Autologous GD2 Chimeric Antigen Receptor (CAR) T Cells (GD2CART) for Diffuse Intrinsic Pontine Gliomas (DIPG) and Spinal Diffuse Midline Glioma (DMG)|Recruiting||Phase 1|54|Anticipated|Stanford University||1|||f||||t|t|f|||f||||||No||2023-09-03 17:21:09.559428|2023-09-03 17:21:09.559428|OTHER|||||
NCT04264039||2020-02-07|||2020-02-07|2020-02-07|2020-02-11|Actual|||||||2020-02-07|2020-02-11|Actual|April 1, 2020|Anticipated|2020-04-01|February 2020|2020-02-29|April 1, 2022|Anticipated|2022-04-01|April 1, 2021|Anticipated|2021-04-01||Interventional|||Anti-CD19 U-CAR-T Cell Therapy for B Cell Hematologic Malignancies|Anti-CD19 Universal CAR-T Cells for CD19+ B Cell Hematologic Malignancies: a Multi-center, Uncontrolled Trial|Unknown status|Not yet recruiting|Early Phase 1|30|Anticipated|Xinqiao Hospital of Chongqing||1|||f||||f|f|f|||||||||||2023-09-02 08:53:31.984463|2023-09-02 08:53:31.984463|OTHER|||||
NCT04816526||2021-03-23|||2022-04-04|2021-03-23|2021-03-25|Actual|||||||2022-04-04|2022-04-06|Actual|December 1, 2021|Actual|2021-12-01|April 2022|2022-04-30|March 15, 2025|Anticipated|2025-03-15|February 25, 2023|Anticipated|2023-02-25||Interventional|||Descartes-08 Consolidation Treatment in Patients With High-Risk Multiple Myeloma Who Have Residual Disease After Induction Therapy|Phase 2 Study of Descartes-08 Consolidation Treatment in Patients With High-Risk Multiple Myeloma Who Have Residual Disease After Induction Therapy|Recruiting||Phase 2|30|Anticipated|Cartesian Therapeutics||1|||f||||f|t|f|||||||||||2023-09-01 00:48:54.329143|2023-09-01 00:48:54.329143|INDUSTRY|||||
NCT05531708||2022-08-22|||2023-02-27|2022-09-07|2022-09-08|Actual|||||||2023-02-27|2023-03-01|Actual|April 2, 2021|Actual|2021-04-02|February 2023|2023-02-28|April 30, 2026|Anticipated|2026-04-30|April 30, 2025|Anticipated|2025-04-30||Interventional|||Exploratory Study of Novel MSLN CAR-T Cell Therapy in Patients With MSLN-positive Advanced Refractory Solid Tumors|Safety and Efficacy Study of Novel Mesothelin CAR-T Cell Therapy in Patients With Mesothelin-positive Advanced Refractory Solid Tumors|Withdrawn||Phase 1|0|Actual|Shanghai Pudong Hospital||1||The study is not initiated and we want it to be withdrawn.|f||||f|f|f|||||||||No||2023-09-01 00:55:39.856663|2023-09-01 00:55:39.856663|OTHER|||||
NCT05513612||2022-08-22|||2023-02-27|2022-08-22|2022-08-24|Actual|||||||2023-02-27|2023-03-01|Actual|August 1, 2020|Actual|2020-08-01|February 2023|2023-02-28|December 31, 2026|Anticipated|2026-12-31|December 31, 2025|Anticipated|2025-12-31||Interventional|||Novel CAR-T Cell Therapy in the Treatment of Hematopoietic and Lymphoid Malignancies|Safety and Efficacy Study of Novel CAR-T Cell Therapy in the Treatment of Hematopoietic and Lymphoid Malignancies|Withdrawn||Phase 1|0|Actual|Shanghai Pudong Hospital||1||The study is not initiated and we want it to be withdrawn.|f||||f|f|f|||||||||No||2023-09-01 00:55:53.914652|2023-09-01 00:55:53.914652|OTHER|||||
NCT00889954||2009-04-24|||2018-09-15|2009-04-28|2009-04-29|Estimate|||||||2018-09-15|2018-09-18|Actual|May 2009||2009-05-31|September 2018|2018-09-30|January 21, 2018|Actual|2018-01-21|July 2015|Actual|2015-07-31||Interventional|HERCREEM||Her2 and TGFBeta Cytotoxic T Cells in Treatment of Her2 Positive Malignancy|Administration of Her2 Chimeric Receptor and TGFbeta Dominant Negative Receptor (DNR) Expressing EBV Specific Lymphocytes for Subjects With Advanced Her2 Positive Malignancy (HERCREEM)|Completed||Phase 1|20|Actual|Baylor College of Medicine||1|||f||||t|t|f|||||||||||2023-09-02 23:43:34.461772|2023-09-02 23:43:34.461772|OTHER|||||
NCT04037566||2019-07-11|||2019-07-27|2019-07-27|2019-07-30|Actual|||||||2019-07-27|2019-07-30|Actual|August 2019|Anticipated|2019-08-31|July 2019|2019-07-31|August 2024|Anticipated|2024-08-31|August 2021|Anticipated|2021-08-31||Interventional|||CRISPR (HPK1) Edited CD19-specific CAR-T Cells (XYF19 CAR-T Cells) for CD19+ Leukemia or Lymphoma.|A Safety Study of Autologous T Cells Engineered to Target CD19 and CRISPR Gene Edited to Eliminate Endogenous HPK1 (XYF19 CAR-T Cells) for Relapsed or Refractory Haematopoietic Malignancies.|Recruiting||Phase 1|40|Anticipated|Xijing Hospital||1|||f||||f|f|f|||||||||No||2023-09-02 23:44:42.134297|2023-09-02 23:44:42.134297|OTHER|||||
NCT02541370||2015-09-02|||2019-12-15|2015-09-02|2015-09-04|Estimate|||||||2019-12-15|2019-12-17|Actual|June 2015||2015-06-30|June 2015|2015-06-30|June 2019|Actual|2019-06-30|June 2019|Actual|2019-06-30||Interventional|||Treatment of Relapsed and/or Chemotherapy Refractory Advanced Malignancies by CART133|Clinical Study of Chimeric CD(Cluster of Differentiation)133 Antigen Receptor-modified T Cells in Relapsed and/or Chemotherapy Refractory Malignancies|Completed||Phase 1/Phase 2|20|Anticipated|Chinese PLA General Hospital||1|||f||||t|||||||||||||2023-09-02 23:44:53.258504|2023-09-02 23:44:53.258504|OTHER|||||
NCT04844866||2021-03-30|||2023-07-07|2021-04-12|2021-04-14|Actual|||||||2023-07-07|2023-07-10|Actual|August 18, 2021|Actual|2021-08-18|July 2023|2023-07-31|December 31, 2024|Anticipated|2024-12-31|December 31, 2023|Anticipated|2023-12-31||Interventional|DALY 2-EU||Efficacy and Safety of MB-CART2019.1 vs. SoC in Lymphoma Patients|A Pivotal Phase II Randomised, Multi-centre, Open-label Study to Evaluate the Efficacy and Safety of MB-CART2019.1 Compared to SoC Therapy in Participants With r/r DLBCL, Who Are Not Eligible for HDC and ASCT|Recruiting||Phase 2|168|Anticipated|Miltenyi Biomedicine GmbH||2|||f|||||f|f|||||||||No||2023-09-02 08:58:13.145094|2023-09-02 08:58:13.145094|INDUSTRY|||||
NCT04815356||2021-03-24|||2023-07-07|2021-03-24|2021-03-25|Actual|||||||2023-07-07|2023-07-10|Actual|May 23, 2022|Actual|2022-05-23|July 6, 2023|2023-07-06|December 1, 2036|Anticipated|2036-12-01|December 1, 2036|Anticipated|2036-12-01||Interventional|||Phase I Study of Anti-CD22 Chimeric Receptor T Cells in Patients With Relapsed/Refractory Hairy Cell Leukemia and Variant|Phase I Study of Anti-CD22 Chimeric Receptor T Cells in Patients With Relapsed/Refractory Hairy Cell Leukemia and Variant|Recruiting||Phase 1|27|Anticipated|National Institutes of Health Clinical Center (CC)||2|||f|||||t|f||||||Clinical data available during the study and indefinitely.|Clinical data will be made available via subscription to BTRIS and with the permission of the study PI.||Yes|.All IPD recorded in the medical record will be shared with intramural investigators upon request.|2023-09-02 08:58:16.016264|2023-09-02 08:58:16.016264|NIH|||||
NCT04257175||2020-01-20|||2022-10-30|2020-02-04|2020-02-05|Actual|||||||2022-10-30|2022-11-01|Actual|February 18, 2020|Actual|2020-02-18|October 2022|2022-10-31|December 1, 2023|Anticipated|2023-12-01|March 1, 2023|Anticipated|2023-03-01||Interventional|||CAR-T CD19 for Acute Myelogenous Leukemia With t 8:21 and CD19 Expression|Giving CAR-T CD19 Transgenic T Cells for Acute Myeloid Leukemia Patients (AML) With t 8:21 and CD19 Expression|Recruiting||Phase 2/Phase 3|10|Anticipated|Sheba Medical Center||1|||f|||||f|f|||||||||||2023-09-03 18:48:22.731477|2023-09-03 18:48:22.731477|OTHER_GOV|||||
NCT04483778||2020-07-14|||2023-07-06|2020-07-20|2020-07-23|Actual|||||||2023-07-06|2023-07-10|Actual|July 13, 2020|Actual|2020-07-13|July 2023|2023-07-31|December 2040|Anticipated|2040-12-31|December 2025|Anticipated|2025-12-31||Interventional|||B7H3 CAR T Cell Immunotherapy for Recurrent/Refractory Solid Tumors in Children and Young Adults|Phase I Study of B7H3 CAR T Cell Immunotherapy for Recurrent/Refractory Solid Tumors in Children and Young Adults|Active, not recruiting||Phase 1|68|Anticipated|Seattle Children's Hospital||3|||f||||t|t|f|||||||||No||2023-09-02 08:58:42.264715|2023-09-02 08:58:42.264715|OTHER|||||
NCT05199961||2022-01-06|||2023-05-11|2022-01-19|2022-01-20|Actual|||||||2023-05-11|2023-05-12|Actual|January 25, 2022|Actual|2022-01-25|May 2023|2023-05-31|September 13, 2022|Actual|2022-09-13|September 13, 2022|Actual|2022-09-13||Interventional|||Quality of Life of Adults With Diffuse Large B-cell Lymphoma Treated With Tisagenlecleucel|Quality of Life of Adults With Diffuse Large B-cell Lymphoma Treated With Tisagenlecleucel|Terminated||Not Applicable|4|Actual|Pack Health||1||Sponsor requested early termination|f||||f|f|f|||||||||No||2023-09-02 09:40:04.322994|2023-09-02 09:40:04.322994|INDUSTRY|||||
NCT03874897||2019-03-11|||2022-02-25|2019-03-12|2019-03-14|Actual|||||||2022-02-25|2022-03-14|Actual|March 26, 2019|Actual|2019-03-26|October 2021|2021-10-31|March 20, 2024|Anticipated|2024-03-20|March 20, 2021|Actual|2021-03-20||Interventional|||Chimeric Antigen Receptor T Cells Targeting claudin18.2 in Solid Tumors.|An Open Label, Single/Multiple Dose Exploratory Clinical Study to Evaluate the Safety, Efficacy, and Cytokinetics of Autologous Humanized Anti-claudin18.2 Chimeric Antigen Receptor T Cell in Advanced Solid Tumor Subjects|Recruiting||Phase 1|123|Anticipated|Peking University||1|||f||||t|f|f|||||||||Yes||2023-09-03 17:44:10.547327|2023-09-03 17:44:10.547327|OTHER|||||
NCT03929107||2019-04-22|||2019-04-25|2019-04-25|2019-04-26|Actual|||||||2019-04-25|2019-04-26|Actual|March 28, 2019|Actual|2019-03-28|April 2019|2019-04-30|April 30, 2022|Anticipated|2022-04-30|January 31, 2022|Anticipated|2022-01-31||Interventional|||Interleukin-7 and Chemokine (C-C Motif) Ligand 19-expressing CD19-CAR-T for Refractory/Relapsed B Cell Lymphoma.|Interleukin-7 and Chemokine (C-C Motif) -Ligand 19-expressing CD19-CAR-T for Refractory/Relapsed B Cell Lymphoma|Unknown status|Recruiting|Phase 2|80|Anticipated|First Affiliated Hospital of Zhejiang University||1|||f|||||f|f|||||||||||2023-09-03 17:45:29.603824|2023-09-03 17:45:29.603824|OTHER|||||
NCT05625594||2022-11-15|||2023-07-07|2022-11-15|2022-11-23|Actual|||||||2023-07-07|2023-07-11|Actual|June 29, 2023|Actual|2023-06-29|July 2023|2023-07-31|July 29, 2027|Anticipated|2027-07-29|July 29, 2026|Anticipated|2026-07-29||Interventional|||Intracerebroventricular Administration of CD19-CAR T Cells (CD19CAR-CD28-CD3zeta-EGFRt-expressing Tcm-enriched T-lymphocytes) for the Treatment of Primary Central Nervous System Lymphoma|A Phase 1 Study to Evaluate Intracerebroventricular (ICV) Administration of CD19-Targeting Chimeric Antigen Receptor (CAR) T Cells in Patients With Primary CNS Lymphoma|Recruiting||Phase 1|20|Anticipated|City of Hope Medical Center||1|||||||t|t|f|||||||||||2023-09-02 09:04:57.594121|2023-09-02 09:04:57.594121|OTHER|||||
NCT05352542||2022-04-01|||2023-07-10|2022-04-23|2022-04-29|Actual|||||||2023-07-10|2023-07-11|Actual|May 19, 2022|Actual|2022-05-19|July 2023|2023-07-31|October 2026|Anticipated|2026-10-31|July 2024|Anticipated|2024-07-31||Interventional|||GPC3-targeting LCAR-H93T Cell in Treatment of Advanced Hepatocellular Carcinoma|A Phase I Clinical Trial for Evaluating the Safety, Tolerance and Efficacy of GPC3-targeting LCAR-H93T Cell in Treatment of Advanced Hepatocellular Carcinoma|Recruiting||Phase 1|34|Anticipated|The Affiliated Hospital of the Chinese Academy of Military Medical Sciences||1|||f||||f|f|f|||||||||No||2023-09-02 09:05:44.753108|2023-09-02 09:05:44.753108|OTHER|||||
NCT05350852||2022-04-09|||2022-04-26|2022-04-26|2022-04-28|Actual|||||||2022-04-26|2022-04-28|Actual|March 18, 2022|Actual|2022-03-18|April 2022|2022-04-30|April 30, 2024|Anticipated|2024-04-30|March 30, 2024|Anticipated|2024-03-30||Interventional|||Evaluate the Safety, Efficacy and Pharmacokinetics of ThisCART19A in Patients With MRD+ B-ALL|To Evaluate the Safety, Efficacy and Pharmacokinetics of ThisCART19A in Patients With MRD Positive Acute B-cell Leukemia|Recruiting||Phase 1|16|Anticipated|Zhejiang University||3|||f||||f|f|f|||||||||||2023-09-03 00:14:08.008852|2023-09-03 00:14:08.008852|OTHER|||||
NCT03825718||2019-01-22|||2022-04-21|2019-01-30|2019-01-31|Actual|||||||2022-04-21|2022-04-28|Actual|January 17, 2019|Actual|2019-01-17|January 2019|2019-01-31|December 1, 2020|Actual|2020-12-01|September 1, 2020|Actual|2020-09-01||Interventional|||A Study of GC007F CAR-T Cell Immunotherapy for Relapsed or Refractory B- ALL|A Study of GC007F CAR-T Cell Immunotherapy for Relapsed or Refractory B- ALL|Completed||Early Phase 1|29|Actual|Hebei Yanda Ludaopei Hospital||1|||f|||||f|f|||||||||||2023-09-03 00:15:14.666313|2023-09-03 00:15:14.666313|OTHER|||||
NCT00840853||2009-02-09|||2023-07-07|2009-02-09|2009-02-10|Estimate|||||||2023-07-07|2023-07-11|Actual|April 2009||2009-04-30|July 2023|2023-07-31|April 2031|Anticipated|2031-04-30|April 2016|Actual|2016-04-30||Interventional|MULTIPRAT||Multi-virus CTLs Expressing CD19 Chimeric Receptors, CD19 Positive Malignancies Post SCT, MULTIPRAT|Phase I Study of the Administration of Multi-Virus-Specific Cytotoxic T Lymphocytes Expressing CD19 Chimeric Receptors for Prophylaxis or Therapy of Relapse of CD19 Positive Malignancies Post Hematopoietic Stem Cell Transplantation|Active, not recruiting||Phase 1|68|Anticipated|Baylor College of Medicine||4|||f||||t|||||||||||||2023-09-02 09:10:25.807304|2023-09-02 09:10:25.807304|OTHER|||||
NCT05654077||2022-12-07|||2022-12-15|2022-12-07|2022-12-16|Actual|||||||2022-12-15|2022-12-19|Actual|January 18, 2022|Actual|2022-01-18|December 2022|2022-12-31|December 30, 2025|Anticipated|2025-12-30|December 30, 2022|Anticipated|2022-12-30||Interventional|||EBV CAR-T Cells for Nasopharyngeal Carcinoma|To Investigate the Safety and Preliminary Efficacy of EBV CAR-T Cells in the Treatment of Relapsed/Refractory EBV-positive Nasopharyngeal Carcinoma|Recruiting||Early Phase 1|24|Anticipated|The Affiliated Hospital of Xuzhou Medical University||1|||f||||f|f|f|||||||||||2023-09-02 09:42:16.898763|2023-09-02 09:42:16.898763|OTHER|||||
NCT05155189||2021-12-07|||2022-03-13|2021-12-07|2021-12-13|Actual|||||||2022-03-13|2022-03-15|Actual|December 9, 2021|Actual|2021-12-09|December 2021|2021-12-31|May 2024|Anticipated|2024-05-31|April 2024|Anticipated|2024-04-30||Interventional|||A Study to Evaluate Safety and Efficacy of Armored CAR-T Cell Injection C-CAR031 in Advanced Hepatocellular Carcinoma|A Clinical Study to Evaluate Safety and Efficacy of C-CAR031 Armored CAR-T Cell Injection in Treatment of Advanced Hepatocellular Carcinoma|Recruiting||Phase 1|20|Anticipated|Zhejiang University||1|||f|||||f|f|||||||||No||2023-09-03 17:59:32.210305|2023-09-03 17:59:32.210305|OTHER|||||
NCT00924326||2009-06-17|2019-01-04||2021-12-29|2009-06-17|2009-06-18|Estimate|2019-03-20|2019-03-21|Actual||||2021-12-29|2022-01-12|Actual|February 17, 2009|Actual|2009-02-17|December 2021|2021-12-31|November 17, 2021|Actual|2021-11-17|September 30, 2015|Actual|2015-09-30||Interventional|||CAR T Cell Receptor Immunotherapy for Patients With B-cell Lymphoma|An Assessment of the Safety and Feasibility of Administering T-Cells Expressing an Anti-CD19 Chimeric Antigen Receptor to Patients With B-Cell Lymphoma|Completed||Phase 1/Phase 2|43|Actual|National Institutes of Health Clinical Center (CC)||10|||f||||f|t|f|||||||||No||2023-09-03 18:01:19.563836|2023-09-03 18:01:19.563836|NIH|||||
NCT05201781||2022-01-10|||2023-07-19|2022-01-10|2022-01-21|Actual|||||||2023-07-19|2023-07-20|Actual|March 9, 2022|Actual|2022-03-09|July 2023|2023-07-31|July 29, 2037|Anticipated|2037-07-29|July 29, 2037|Anticipated|2037-07-29||Interventional|||A Long-term Study for Participants Previously Treated With Ciltacabtagene Autoleucel|Long-term Follow-up Study for Participants Previously Treated With Ciltacabtagene Autoleucel|Recruiting||Phase 4|228|Anticipated|Janssen Research & Development, LLC||1|||t||||f|t|f||||||||https://www.janssen.com/clinical-trials/transparency|Yes|The data sharing policy of the Janssen Pharmaceutical Companies of Johnson & Johnson is available at www.janssen.com/clinical-trials/transparency. As noted on this site, requests for access to the study data can be submitted through Yale Open Data Access (YODA) Project site at yoda.yale.edu|2023-09-03 00:25:48.237226|2023-09-03 00:25:48.237226|INDUSTRY||NCT05346835|Available||
NCT03483688||2018-03-14|||2020-03-03|2018-03-23|2018-03-30|Actual|||||||2020-03-03|2020-03-05|Actual|March 6, 2018|Actual|2018-03-06|March 2018|2018-03-31|January 10, 2020|Actual|2020-01-10|December 10, 2019|Actual|2019-12-10||Interventional|||A PhaseⅠb Study Evaluating Safety and Efficacy of C-CAR011 Treatment in B- NHL Subjects|A Phase Ⅰb Study Evaluating Safety and Efficacy of Anti-CD19 Chimeric Antigen Receptor T-cell (C-CAR011) Treatment in Subjects With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma|Completed||Phase 1|6|Actual|Peking Union Medical College Hospital||1|||f||||t|f|f|||||||||||2023-09-03 18:08:00.416028|2023-09-03 18:08:00.416028|OTHER|||||
NCT04008394||2019-07-02|||2019-08-05|2019-07-02|2019-07-05|Actual|||||||2019-08-05|2019-08-07|Actual|July 3, 2019|Actual|2019-07-03|August 2019|2019-08-31|January 1, 2023|Anticipated|2023-01-01|July 1, 2022|Anticipated|2022-07-01||Interventional|||Anti-CD30 CAR-T Therapy in Patients With Refractory/Relapsed Lymphocyte Malignancies|Efficacy and Safety of Anti-CD30 CAR-T Therapy in Patients With Refractory/Relapsed Lymphocyte Malignancies：a Single-center, Open, Single-arm Clinical Study.|Unknown status|Recruiting|Phase 1|50|Anticipated|Wuhan Union Hospital, China||1|||f|||||f|f|||f||||||No||2023-09-03 00:36:49.379695|2023-09-03 00:36:49.379695|OTHER|||||
NCT03716856||2018-09-27|||2020-10-06|2018-10-22|2018-10-23|Actual|||||||2020-10-06|2020-10-08|Actual|March 23, 2018|Actual|2018-03-23|September 2020|2020-09-30|June 23, 2023|Anticipated|2023-06-23|June 23, 2020|Actual|2020-06-23||Interventional|||Clinical Study of CAR-BCMA T in Patients With Refractory or Relapsed Multiple Myeloma|Clinical Study of Redirected Autologous T Cells With a BCMA-targeted Chimeric Antigen Receptor in Patients With Refractory or Relapsed Multiple Myeloma|Unknown status|Active, not recruiting|Phase 1|11|Actual|First Affiliated Hospital of Zhejiang University||1|||f||||f|f|f|||||||||No||2023-09-03 18:13:33.115119|2023-09-03 18:13:33.115119|OTHER|||||
NCT03902197||2019-04-01|||2019-04-04|2019-04-01|2019-04-03|Actual|||||||2019-04-04|2019-04-08|Actual|April 22, 2019|Anticipated|2019-04-22|March 2019|2019-03-31|December 21, 2023|Anticipated|2023-12-21|December 31, 2021|Anticipated|2021-12-31||Interventional|||CD19 hsCAR-T for Refractory/Relapsed CD19+ B-ALL Patients|A Phase II Study of CD19 hsCAR-T for Refractory/Relapsed CD19+ B-ALL Patients Previously Treated With Cell Therapy|Recruiting||Phase 2|50|Anticipated|Xuanwu Hospital, Beijing||1|||f|||||f|f|||||||||||2023-09-03 18:13:57.545872|2023-09-03 18:13:57.545872|OTHER|||||
NCT05277987||2022-03-03|||2022-03-03|2022-03-03|2022-03-14|Actual|||||||2022-03-03|2022-03-14|Actual|March 2022|Anticipated|2022-03-31|March 2022|2022-03-31|March 2025|Anticipated|2025-03-31|March 2025|Anticipated|2025-03-31||Interventional|||An Evaluation Trial About Anti-claudin18.2 the Specificity of Chimeric Antigen Receptor T Cells in the Advanced Gastric / Esophagogastric Junction Adenocarcinoma and Pancreatic Cancer Subjects|A Single Arm, Open Lable and Single Site Early Phase I Clinical Trial to Evaluate the Safety, Cell Kinetics and Initial Efficacy About Anti-claudin18.2 the Specificity of Chimeric Antigen Receptor T Cells in the Advanced Gastric / Esophagogastric Junction Adenocarcinoma and Pancreatic Cancer Subjects|Recruiting||Early Phase 1|18|Anticipated|Shenzhen Fifth People's Hospital||1|||f||||t|f|f|||||||||Undecided||2023-09-03 00:38:57.079501|2023-09-03 00:38:57.079501|OTHER|||||
NCT04048434||2019-08-06|||2021-03-26|2019-08-06|2019-08-07|Actual|||||||2021-03-26|2021-04-01|Actual|June 2021|Anticipated|2021-06-30|March 2021|2021-03-31|September 2024|Anticipated|2024-09-30|September 2023|Anticipated|2023-09-30||Interventional|CYTORELEASE||Extracorporeal Cytokine Adsorption as Additive Treatment of CAR-T Associated Cytokine Release Syndrome (CRS)|Effectivity of Extracorporeal Cytokine Adsorption (Cytosorb) as Additive Treatment of CAR-T Cell Associated Cytokine Release (CRS) Syndrome and Encephalopathy Syndrome (CRES)|Recruiting||Not Applicable|34|Anticipated|Hannover Medical School||2|||f||||f|f|f|||t||||||No||2023-09-03 00:41:02.406655|2023-09-03 00:41:02.406655|OTHER|||||
NCT03881761||2019-03-16|||2019-03-19|2019-03-16|2019-03-19|Actual|||||||2019-03-19|2019-03-21|Actual|February 1, 2019|Actual|2019-02-01|January 2019|2019-01-31|January 31, 2022|Anticipated|2022-01-31|January 31, 2021|Anticipated|2021-01-31||Interventional|||CD19/20 Bispecific Nanobody-derived CAR-T Cells in B Cell Lymphoma|Clinical Study of CD19/CD20 Bispecific Nanobody-derived CAR-T Cells in Refractroy/Relasped B Cell Lymphoma|Unknown status|Recruiting|Phase 1|50|Anticipated|Henan Cancer Hospital||1|||f|||||f|f|||||||||||2023-09-03 18:18:24.583488|2023-09-03 18:18:24.583488|OTHER_GOV|||||
NCT05306080||2022-03-09|||2023-02-02|2022-03-30|2022-03-31|Actual|||||||2023-02-02|2023-02-03|Actual|April 17, 2022|Actual|2022-04-17|February 2023|2023-02-28|April 2025|Anticipated|2025-04-30|January 2025|Anticipated|2025-01-31||Interventional|||Tadekinig Alfa (IL-18BP) Rescue Therapy for CAR T Cell Related Cytokine Release Syndrome (CRS) and HLH-like Syndrome|Pilot, Open-Label Study Evaluating the Safety and Feasibility of Using Rescue Therapies for CAR T Cell Related Cytokine Release Syndrome (CRS) and HLH-like Syndrome|Recruiting||Early Phase 1|10|Anticipated|University of Pennsylvania||1|||f|||||t|f|||||||||Undecided||2023-09-03 00:45:03.363408|2023-09-03 00:45:03.363408|OTHER|||||
NCT04412889||2020-05-21|||2020-06-01|2020-06-01|2020-06-02|Actual|||||||2020-06-01|2020-06-02|Actual|June 2020|Anticipated|2020-06-30|May 2020|2020-05-31|December 2022|Anticipated|2022-12-31|December 2022|Anticipated|2022-12-31||Interventional|||A Study of BCMA/CD19 Dual-Target CAR-T Cell Immunotherapy for Relapsed or Refractory MM|A Study of B-Cell Maturation Antigen/Cluster of Differentiation 19 Dual-Target Chimeric Antigen Receptor T Cell Immunotherapy for Relapsed or Refractory Multiple Myeloma|Unknown status|Not yet recruiting|Early Phase 1|18|Anticipated|Hebei Yanda Ludaopei Hospital||1|||f||||f|f|f|||||||||||2023-09-04 17:49:20.650778|2023-09-04 17:49:20.650778|OTHER|||||
NCT03711864||2018-10-17|||2020-09-28|2018-10-17|2018-10-19|Actual|||||||2020-09-28|2020-09-30|Actual|February 25, 2019|Actual|2019-02-25|September 2020|2020-09-30|December 20, 2021|Anticipated|2021-12-20|October 10, 2021|Anticipated|2021-10-10||Interventional|||Safety and Efficacy of IM21 Car-t Cells in Patients With Recurrent or Refractory BCMA Positive Multiple Myeloma|Safety and Efficacy of IM21 Car-t Cells in Patients With Recurrent or Refractory BCMA Positive Multiple Myeloma|Unknown status|Recruiting|Phase 1|15|Anticipated|Peking Union Medical College Hospital||1|||f||||f|f|f|||||||||||2023-09-03 18:29:02.733143|2023-09-03 18:29:02.733143|OTHER|||||
NCT03904069||2019-03-21|||2023-06-09|2019-04-03|2019-04-04|Actual|||||||2023-06-09|2023-06-12|Actual|March 13, 2023|Anticipated|2023-03-13|June 2023|2023-06-30|August 7, 2030|Anticipated|2030-08-07|August 7, 2030|Anticipated|2030-08-07||Interventional|||Study Evaluating the Safety, Tolerability, and Efficacy of FLT3 CAR-T AMG 553 in FLT3-positive Relapsed/Refractory AML|A Phase 1 Study Evaluating the Safety, Tolerability, and Efficacy of FLT3 Chimeric Antigen Receptor T-cell (CAR-T) AMG 553 in Subjects With FLT3-positive Relapsed/Refractory Acute Myeloid Leukemia.|Withdrawn||Phase 1|0|Actual|Amgen||1||Following a recent cellular therapy strategy assessment, Amgen has decided to cancel study 20180091.|f||||f|t|f||||||Data sharing requests relating to this study will be considered beginning 18 months after the study has ended and either 1) the product and indication have been granted marketing authorization in both the US and Europe or 2) clinical development for the product and/or indication discontinues and the data will not be submitted to regulatory authorities. There is no end date for eligibility to submit a data sharing request for this study.|Qualified researchers may submit a request containing the research objectives, the Amgen product(s) and Amgen study/studies in scope, endpoints/outcomes of interest, statistical analysis plan, data requirements, publication plan, and qualifications of the researcher(s). In general, Amgen does not grant external requests for individual patient data for the purpose of re-evaluating safety and efficacy issues already addressed in the product labelling. Requests are reviewed by a committee of internal advisors. If not approved, a Data Sharing Independent Review Panel will arbitrate and make the final decision. Upon approval, information necessary to address the research question will be provided under the terms of a data sharing agreement. This may include anonymized individual patient data and/or available supporting documents, containing fragments of analysis code where provided in analysis specifications. Further details are available at the link below.|https://www.amgen.com/datasharing|Yes|De-identified individual patient data for variables necessary to address the specific research question in an approved data sharing request.|2023-09-04 17:53:51.147191|2023-09-04 17:53:51.147191|INDUSTRY|||||
NCT04447573||2020-06-22|||2020-09-25|2020-06-22|2020-06-25|Actual|||||||2020-09-25|2020-09-29|Actual|June 30, 2020|Actual|2020-06-30|August 2020|2020-08-31|December 30, 2022|Anticipated|2022-12-30|August 30, 2022|Anticipated|2022-08-30||Interventional|||Immunotherapy With BCMA CAR-T Cells in Treating Patients With Relapsed or Refractory Multiple Myeloma|Immunotherapy With BCMA CAR-T Cells in Treating Patients With Relapsed or Refractory Multiple Myeloma|Unknown status|Recruiting|Not Applicable|20|Anticipated|Hebei Senlang Biotechnology Inc., Ltd.||1|||f|||||f|f|||||||||||2023-09-04 17:49:49.745412|2023-09-04 17:49:49.745412|INDUSTRY|||||
NCT05190653||2021-12-07|||2023-02-28|2021-12-29|2022-01-13|Actual|||||||2023-02-28|2023-03-02|Actual|April 8, 2022|Actual|2022-04-08|February 2023|2023-02-28|December 2024|Anticipated|2024-12-31|April 8, 2024|Anticipated|2024-04-08||Interventional|PALS_CT||Early Integration of Palliative and Supportive Care in Cellular Therapy|Early Integration of Palliative and Supportive Care for Patients and Family Caregivers Undergoing Hematopoietic Stem Cell Transplantation or Chimeric Antigen Receptor T-Cell Therapy: A Prospective Pragmatic Randomized Clinical Trial|Recruiting||Not Applicable|152|Anticipated|Alberta Health Services, Calgary||2|||f||||t|f|f|||||||||No||2023-09-01 01:41:45.359995|2023-09-01 01:41:45.359995|OTHER|||||
NCT04003168||2019-06-24|||2021-02-25|2019-06-28|2019-07-01|Actual|||||||2021-02-25|2021-03-01|Actual|July 1, 2019|Actual|2019-07-01|February 2021|2021-02-28|July 2024|Anticipated|2024-07-31|July 2022|Anticipated|2022-07-31||Interventional|||Human BCMA Targeted T Cells Injection Therapy for BCMA-positive Relapsed/Refractory Multiple Myeloma|A Phase I Clinical Trial to Evaluate the Safety and Efficacy of Human BCMA Targeted T Cells Injection for Subjects With BCMA-positive Relapsed/Refractory Multiple Myeloma|Recruiting||Phase 1|18|Anticipated|Hrain Biotechnology Co., Ltd.||1|||f||||t|f|f|||||||||||2023-09-03 01:09:04.44306|2023-09-03 01:09:04.44306|INDUSTRY|||||
NCT05470777||2022-07-20|||2022-10-30|2022-07-20|2022-07-22|Actual|||||||2022-10-30|2022-11-01|Actual|January 19, 2020|Actual|2020-01-19|October 2022|2022-10-31|December 31, 2024|Anticipated|2024-12-31|May 1, 2024|Anticipated|2024-05-01||Interventional|||CD22/CD19 CAR-T and Auto-HSCT Sandwich Strategy as Consolidation Therapy for B-ALL|Safety and Efficacy of CD22/CD19 CAR T-cells and Autologous HSCT Sandwich Strategy as Consolidation Therapy for B-cell Acute Lymphoblastic Leukemia|Recruiting||Phase 1/Phase 2|35|Anticipated|The First Affiliated Hospital of Soochow University||1|||f|||||f|f|||||||||||2023-09-03 18:44:32.167469|2023-09-03 18:44:32.167469|OTHER|||||
NCT03931421||2019-04-25|||2019-06-01|2019-04-25|2019-04-30|Actual|||||||2019-06-01|2019-06-04|Actual|July 31, 2019|Anticipated|2019-07-31|June 2019|2019-06-30|December 31, 2022|Anticipated|2022-12-31|November 30, 2022|Anticipated|2022-11-30||Interventional|||B Cell Maturation Antigen（BMCA）-Targeted CAR-T for Refractory/Relapsed Multiple Myeloma|B Cell Maturation Antigen（BMCA）-Targeted CAR-T for Refractory/Relapsed Multiple Myeloma|Unknown status|Recruiting|Phase 2|30|Anticipated|First Affiliated Hospital of Zhejiang University||1|||f||||f|f|f|||||||||Yes|All the data would be available on the website of the affiliated hospital after the trial is completed|2023-09-03 18:49:50.79453|2023-09-03 18:49:50.79453|OTHER|||||
NCT04823091||2021-03-29|||2022-03-01|2021-03-29|2021-03-30|Actual|||||||2022-03-01|2022-03-16|Actual|April 15, 2021|Actual|2021-04-15|March 2022|2022-03-31|April 7, 2024|Anticipated|2024-04-07|April 7, 2023|Anticipated|2023-04-07||Interventional|||Anti-CD7 CAR-Engineered T Cells for T Lymphoid Malignancies Malignancies|Safety and Efficacy of Anti-CD7 CAR-Engineered T Cells for Relapsed/Refractory T Lymphoid Malignancies: a Single-center, Open-label, Non-randomized, Single-arm Clinical Study|Recruiting||Phase 1|24|Anticipated|Wuhan Union Hospital, China||1|||f|||||f|f|||||||||No||2023-09-03 18:50:17.630359|2023-09-03 18:50:17.630359|OTHER|||||
NCT03573700||2018-06-20|||2023-08-22|2018-06-20|2018-06-29|Actual|||||||2023-08-22|2023-08-23|Actual|July 24, 2018|Actual|2018-07-24|August 2023|2023-08-31|July 1, 2024|Anticipated|2024-07-01|July 1, 2023|Actual|2023-07-01||Interventional|||Evaluation of CD19-Specific CAR Engineered Autologous T-Cells for Treatment of Relapsed/Refractory CD19+ Acute Lymphoblastic Leukemia|SJCAR19: A Phase I/II Study Evaluating SJCAR19 (CD19-Specific CAR Engineered Autologous T-Cells) in Pediatric and Young Adult Patients ≤ 21 Years of Age With Relapsed or Refractory CD19+ Acute Lymphoblastic Leukemia|Active, not recruiting||Phase 1/Phase 2|26|Actual|St. Jude Children's Research Hospital||1|||||||f|t|t|t||||||||||2023-09-03 01:22:41.206326|2023-09-03 01:22:41.206326|OTHER|||||
NCT04506983||2020-08-06|||2022-01-29|2020-08-07|2020-08-10|Actual|||||||2022-01-29|2022-02-14|Actual|June 10, 2022|Anticipated|2022-06-10|January 2022|2022-01-31|October 10, 2023|Anticipated|2023-10-10|June 10, 2023|Anticipated|2023-06-10||Interventional|||GPC3-CAR-T Cells for the Hepatocellular Carcinoma|The Phase I Efficacy and Safety Clinical Study of GPC3-CAR-T Cells in Hepatocellular Carcinoma Patients|Suspended||Phase 1|12|Anticipated|Beijing Tsinghua Chang Gung Hospital||1||Adjust the plan|f|||||f|f|||||||||||2023-09-04 17:54:35.460964|2023-09-04 17:54:35.460964|OTHER|||||
NCT03814447||2019-01-18|||2021-08-09|2019-01-18|2019-01-24|Actual|||||||2021-08-09|2021-08-10|Actual|August 16, 2019|Actual|2019-08-16|August 2021|2021-08-31|January 2023|Anticipated|2023-01-31|January 2023|Anticipated|2023-01-31||Interventional|||The Fourth Generation CART-cell Therapy for Refractory-Relapsed Ovarian Cancer|The Clinical Research of Fourth Generation CART-cell Therapy in Refractory-Relapsed Ovarian Cancer|Unknown status|Recruiting|Early Phase 1|10|Anticipated|Shanghai 6th People's Hospital||1|||f||||t|f|f|||||||||No||2023-09-03 18:55:41.45312|2023-09-03 18:55:41.45312|OTHER|||||
NCT05164042||2021-11-22|||2021-12-07|2021-12-07|2021-12-20|Actual|||||||2021-12-07|2021-12-20|Actual|February 5, 2021|Actual|2021-02-05|February 2021|2021-02-28|February 2024|Anticipated|2024-02-29|February 2024|Anticipated|2024-02-29||Interventional|CAR-T||Allogeneic CD19 CAR-T Cells for the Treatment of Relapsed/Refractory B-cell Acute Lymphoblastic Leukemia|Allogeneic CD19 CAR-T Cells for the Treatment of Relapsed/Refractory B-cell Acute Lymphoblastic Leukemia|Recruiting||Phase 1/Phase 2|20|Anticipated|Shenzhen University General Hospital||1|||f||||f|f|f|||||||||No||2023-09-03 18:56:00.085165|2023-09-03 18:56:00.085165|OTHER|||||
NCT03815383||2019-01-22|||2019-07-01|2019-01-22|2019-01-24|Actual|||||||2019-07-01|2019-07-05|Actual|April 11, 2019|Actual|2019-04-11|December 2018|2018-12-31|April 2021|Anticipated|2021-04-30|January 2021|Anticipated|2021-01-31||Interventional|||A Study of BCMA-directed CAR-T Cells Treatment in Subjects With r/r Multiple Myeloma|A Phase Ⅰ Study Evaluating Safety and Efficacy of C-CAR088 Treatment in Subjects With Relapsed or Refractory Multiple Myeloma|Unknown status|Recruiting|Phase 1|12|Anticipated|The First Affiliated Hospital with Nanjing Medical University||1|||f|||||f|f|||||||||||2023-09-03 18:58:05.920066|2023-09-03 18:58:05.920066|OTHER|||||
NCT02782351||2016-05-17|||2017-08-03|2016-05-22|2016-05-25|Estimate|||||||2017-08-03|2017-08-04|Actual|May 2016||2016-05-31|August 2017|2017-08-31|December 2018|Anticipated|2018-12-31|June 2018|Anticipated|2018-06-30||Interventional|||Humanized CAR-T Therapy for Treatment of B Cell Malignancy|Humanized CAR-T Therapy for Treatment of Recurrent or Refractory B Cell Malignancy by Targeting CD19|Unknown status|Recruiting|Phase 1/Phase 2|50|Anticipated|Xuzhou Medical University||1|||f||||f|||||||||||Yes||2023-09-02 09:50:45.751673|2023-09-02 09:50:45.751673|OTHER|||||
NCT02547948||2015-09-04|||2020-07-14|2015-09-10|2015-09-14|Estimate|||||||2020-07-14|2020-07-16|Actual|September 2015|Actual|2015-09-30|July 2020|2020-07-31|August 15, 2016|Actual|2016-08-15|August 15, 2016|Actual|2016-08-15||Interventional|||CD19-targeting CAR T Cells for B Cell Lymphoma|CD19-targeting CAR T Cells for Refractory B Cell Lymphoma|Withdrawn||Phase 1/Phase 2|0|Actual|Fuda Cancer Hospital, Guangzhou||2|||f||||t|||||||||||||2023-09-03 01:33:08.263775|2023-09-03 01:33:08.263775|OTHER|||||
NCT04010877||2019-07-04|||2019-09-18|2019-07-04|2019-07-08|Actual|||||||2019-09-18|2019-09-19|Actual|August 1, 2019|Actual|2019-08-01|September 2019|2019-09-30|December 31, 2023|Anticipated|2023-12-31|July 31, 2021|Anticipated|2021-07-31||Interventional|||Multiple CAR-T Cell Therapy Targeting AML|Multi-center Phase I/II Clinical Trial of Multiple CAR T Cells for Treating Acute Myeloid Leukemia|Recruiting||Phase 1/Phase 2|10|Anticipated|Shenzhen Geno-Immune Medical Institute||1|||f||||f|f|f|||||||||||2023-09-03 01:33:18.932772|2023-09-03 01:33:18.932772|OTHER|||||
NCT05340829||2022-04-09|||2022-04-17|2022-04-17|2022-04-22|Actual|||||||2022-04-17|2022-04-22|Actual|March 18, 2022|Actual|2022-03-18|April 2022|2022-04-30|April 30, 2024|Anticipated|2024-04-30|March 30, 2024|Anticipated|2024-03-30||Interventional|||Evaluate the Safety and Effect of ThisCART19A in Patients With AIDS Related B Cell Lymphoma/Lympholeukemia|To Evaluate the Safety, Efficacy, Pharmacokinetics of ThisCART19A in Patients With AIDS Related B Cell Lymphoma/Lympholeukemia|Recruiting||Phase 1|18|Anticipated|Zhejiang University||3|||f||||f|f|f|||||||||||2023-09-02 09:51:25.28308|2023-09-02 09:51:25.28308|OTHER|||||
NCT04975555||2021-07-05|||2022-12-16|2021-07-14|2021-07-23|Actual|||||||2022-12-16|2022-12-20|Actual|November 15, 2021|Actual|2021-11-15|December 2022|2022-12-31|December 31, 2025|Anticipated|2025-12-31|December 31, 2024|Anticipated|2024-12-31||Interventional|||Study to Evaluate the Role of Siltuximab in Treatment of Cytokine Release Syndrome (CRS) and Immune Effector Cell Associated Neurotoxicity (ICANS) Related to CAR-T Cell Therapy|A Phase II Pilot Study to Evaluate the Role of Siltuximab in Treatment of Cytokine Release Syndrome (CRS) and Immune Effector Cell Associated Neurotoxicity (ICANS) Related to Chimeric Antigen Receptor T-Cell Therapy (CAR-T) in Hematological Malignancies|Recruiting||Phase 2|30|Anticipated|University of Alabama at Birmingham||1|||f||||t|t|f|||||||||No|To Be determined|2023-09-02 09:52:15.648866|2023-09-02 09:52:15.648866|OTHER|||||
NCT04119024||2019-09-25|||2023-01-05|2019-10-04|2019-10-08|Actual|||||||2023-01-05|2023-01-06|Actual|November 27, 2019|Actual|2019-11-27|January 2023|2023-01-31|October 1, 2025|Anticipated|2025-10-01|October 1, 2024|Anticipated|2024-10-01||Interventional|||Gene Modified Immune Cells (IL13Ralpha2 CAR T Cells) After Conditioning Regimen for the Treatment of Stage IIIC or IV Melanoma|Phase 1 Dose Escalation Study of Systemically Administered IL13Ra2 Chimeric Antigen Receptor (CAR) T Cells After a Nonmyeloablative Conditioning Regimen in Patients With Metastatic Melanoma|Recruiting||Phase 1|24|Anticipated|Jonsson Comprehensive Cancer Center||1|||f||||t|t|f|||f||||||||2023-09-03 01:37:30.699057|2023-09-03 01:37:30.699057|OTHER|||||
NCT04226989||2020-01-08|||2020-02-19|2020-01-09|2020-01-13|Actual|||||||2020-02-19|2020-02-21|Actual|February 5, 2020|Actual|2020-02-05|February 2020|2020-02-29|May 31, 2024|Anticipated|2024-05-31|February 5, 2022|Anticipated|2022-02-05||Interventional|||A Study of CT-RD06 Cell Injection in Patients With Relapsed or Refractory CD19+ B-cell Hematological Malignancy|A Study of CT-RD06 Cell Injection in Patients With Relapsed or Refractory CD19+ B-cell Hematological Malignancy|Recruiting||Early Phase 1|72|Anticipated|Zhejiang University||1|||f||||t|f|f|||||||||||2023-09-02 09:52:46.383939|2023-09-02 09:52:46.383939|OTHER|||||
NCT04089215||2019-09-10|||2021-01-17|2019-09-11|2019-09-13|Actual|||||||2021-01-17|2021-01-22|Actual|June 11, 2019|Actual|2019-06-11|January 2021|2021-01-31|September 30, 2024|Anticipated|2024-09-30|December 31, 2022|Anticipated|2022-12-31||Interventional|||CD19-targeted CAR T Cells for Relapsed and Refractory (R/R) Non-Hodgkins Lymphoma|A Phase II Open-Label, Single-Arm, Multicenter Study of JWCAR029, CD19-targeted Chimeric Antigen Receptor (CAR) T Cells for Relapsed and Refractory (R/R) Non-Hodgkins Lymphoma|Recruiting||Phase 2|82|Anticipated|Shanghai Ming Ju Biotechnology Co., Ltd.||1|||f|||||f|f|||||||||No||2023-09-03 01:41:45.974703|2023-09-03 01:41:45.974703|INDUSTRY|||||
NCT03380039||2017-12-11|||2020-10-08|2017-12-15|2017-12-20|Actual|||||||2020-10-08|2020-10-12|Actual|October 13, 2017|Actual|2017-10-13|September 2020|2020-09-30|July 2, 2023|Anticipated|2023-07-02|July 2, 2020|Actual|2020-07-02||Interventional|||Clinical Study of CAR-BCMA T Cells in Patients With Refractory or Relapsed Multiple Myeloma|Clinical Study of Redirected Autologous T Cells With a BCMA-targeted Chimeric Antigen Receptor in Patients With Refractory or Relapsed Multiple Myeloma|Unknown status|Active, not recruiting|Not Applicable|6|Actual|Xinhua Hospital, Shanghai Jiao Tong University School of Medicine||1|||f||||t|f|f|||||||||No||2023-09-04 17:55:54.57887|2023-09-04 17:55:54.57887|OTHER|||||
NCT04608487||2020-10-19|||2023-06-07|2020-10-28|2020-10-29|Actual|||||||2023-06-07|2023-06-08|Actual|December 4, 2020|Actual|2020-12-04|June 2023|2023-06-30|June 1, 2025|Anticipated|2025-06-01|June 1, 2024|Anticipated|2024-06-01||Interventional|||Axi-cel in CNS Lymphoma|A Phase I Study of Anti-CD19 CAR T-cell Therapy With Axicabtagene Ciloleucel (Axi-cel) in Patients With Relapsed/Refractory Primary and Secondary Central Nervous System (CNS) Lymphoma|Active, not recruiting||Phase 1|18|Actual|Dana-Farber Cancer Institute||1|||f||||t|t|f||||||Data can be shared no earlier than 1 year following the date of publication|Contact the Belfer Office for Dana-Farber Innovations (BODFI) at innovation@dfci.harvard.edu||Yes|The Dana-Farber / Harvard Cancer Center encourages and supports the responsible and ethical sharing of data from clinical trials. De-identified participant data from the final research dataset used in the published manuscript may only be shared under the terms of a Data Use Agreement. Requests may be directed to: [contact information for Sponsor Investigator or designee]. The protocol and statistical analysis plan will be made available on Clinicaltrials.gov only as required by federal regulation or as a condition of awards and agreements supporting the research.|2023-09-01 01:53:17.74521|2023-09-01 01:53:17.74521|OTHER|||||
NCT03676504||2018-09-07|||2023-06-06|2018-09-16|2018-09-18|Actual|||||||2023-06-06|2023-06-08|Actual|September 7, 2018|Actual|2018-09-07|June 2023|2023-06-30|April 1, 2024|Anticipated|2024-04-01|January 1, 2024|Anticipated|2024-01-01||Interventional|||Treatment of Patients With Relapsed or Refractory CD19+ Lymphoid Disease With T Cells Expressing a Third-generation CAR|Treatment of Patients With Relapsed or Refractory CD19+ Lymphoid Disease With T Lymphocytes Transduced by RV-SFG.CD19.CD28.4-1BBzeta Retroviral Vector - a Unicenter Phase I/II Clinical Trial|Recruiting||Phase 1/Phase 2|68|Anticipated|University Hospital Heidelberg||3|||f|||||f|f|||||||||||2023-09-01 01:54:30.066998|2023-09-01 01:54:30.066998|OTHER|||||
NCT05176275||2021-12-03|||2021-12-16|2021-12-16|2022-01-04|Actual|||||||2021-12-16|2022-01-04|Actual|January 1, 2022|Anticipated|2022-01-01|December 2021|2021-12-31|December 1, 2022|Anticipated|2022-12-01|December 1, 2022|Anticipated|2022-12-01||Interventional|||PET / CT Imaging and Safety in Patients With Lymphoma Treated With CD19 Car-t Cells|PET / CT Imaging and Safety of the 68Ga-NOTA-RP25 Molecular Probe in Patients With Lymphoma Who Have Received Prior Therapy Containing CD19 CAR-T Cells|Not yet recruiting||Not Applicable|10|Anticipated|The First Affiliated Hospital of Soochow University||1|||f|||||f|f|||||||||||2023-09-03 19:08:02.286819|2023-09-03 19:08:02.286819|OTHER|||||
NCT03790891||2018-12-28|||2020-03-11|2018-12-28|2019-01-02|Actual|||||||2020-03-11|2020-03-13|Actual|January 5, 2019|Actual|2019-01-05|March 2020|2020-03-31|January 1, 2022|Anticipated|2022-01-01|June 1, 2021|Anticipated|2021-06-01||Interventional|||Treatment of Non-Hodgkin Lymphoma With CD19-TriCAR-T/SILK Cell Therapy|Adoptive Immunotherapy for Non-Hodgkin Lymphoma With CD19-TriCAR-T/SILK Cell|Unknown status|Recruiting|Early Phase 1|12|Anticipated|Timmune Biotech Inc.||1|||f||||t|f|f|||||||||No||2023-09-03 19:09:45.127078|2023-09-03 19:09:45.127078|INDUSTRY|||||
NCT05438368||2022-06-21|||2022-06-25|2022-06-25|2022-06-30|Actual|||||||2022-06-25|2022-06-30|Actual|June 30, 2022|Anticipated|2022-06-30|June 2022|2022-06-30|June 30, 2026|Anticipated|2026-06-30|December 31, 2025|Anticipated|2025-12-31||Interventional|||GD2/CD70 Bi-specific CAR-T Cell Therapy|GD2/CD70 Bi-specific CAR-T Cells for Cancer Treatment|Recruiting||Phase 1/Phase 2|30|Anticipated|Shenzhen Geno-Immune Medical Institute||1|||f||||f|f|f|||||||||No||2023-09-03 19:12:35.539496|2023-09-03 19:12:35.539496|OTHER|||||
NCT05234190||2022-02-01|||2022-12-22|2022-02-01|2022-02-10|Actual|||||||2022-12-22|2022-12-27|Actual|January 21, 2022|Actual|2022-01-21|December 2022|2022-12-31|March 2039|Anticipated|2039-03-31|June 2025|Anticipated|2025-06-30||Interventional|LIBERATE||Safety and Clinical Activity of QEL-001 in A2-mismatch Liver Transplant Patients|A Single-arm, Open-label, Multi-center, Phase I/II Study Evaluating the Safety and Clinical Activity of QEL-001, an Autologous CAR T Regulatory Cell Treatment Targeting HLA-A2, in HLA-A2/ A28neg Patients That Have Received an HLA-A2pos Liver Transplant.|Recruiting||Phase 1/Phase 2|33|Anticipated|Quell Therapeutics Limited||1|||f||||t|f|f|||||||||No||2023-09-03 19:12:55.351105|2023-09-03 19:12:55.351105|INDUSTRY|||||
NCT04085159||2019-09-09|||2020-06-10|2019-09-09|2019-09-11|Actual|||||||2020-06-10|2020-06-12|Actual|September 1, 2019|Actual|2019-09-01|June 2020|2020-06-30|December 31, 2022|Anticipated|2022-12-31|January 31, 2021|Anticipated|2021-01-31||Interventional|||Immunotherapy Based on Antigen-specific Immune Effector Cells Targeting Neurofibromatosis or Schwannomatosis|Immunotherapy Targeting Neurofibromatosis or Schwannomatosis|Unknown status|Recruiting|Phase 1/Phase 2|100|Anticipated|Shenzhen Geno-Immune Medical Institute||1|||f||||f|f|f|||||||||No||2023-09-03 02:03:35.275701|2023-09-03 02:03:35.275701|OTHER|||||
NCT04696731||2021-01-04|||2022-03-25|2021-01-04|2021-01-06|Actual|||||||2022-03-25|2022-03-29|Actual|February 24, 2021|Actual|2021-02-24|March 2022|2022-03-31|October 2025|Anticipated|2025-10-31|December 2022|Anticipated|2022-12-31||Interventional|TRAVERSE||Safety and Efficacy of ALLO-316 in Subjects With Advanced or Metastatic Clear Cell Renal Cell Carcinoma|A Phase 1 Multicenter Study Evaluating the Safety and Efficacy of ALLO-316 Following ALLO-647 Containing Conditioning Regimen in Subjects With Advanced or Metastatic Clear Cell Renal Cell Carcinoma|Recruiting||Phase 1|120|Anticipated|Allogene Therapeutics||1|||f||||f|t|f|||||||||||2023-09-03 02:04:05.560422|2023-09-03 02:04:05.560422|INDUSTRY|||||
NCT03706326||2018-10-11|||2018-10-11|2018-10-11|2018-10-16|Actual|||||||2018-10-11|2018-10-16|Actual|September 28, 2018|Actual|2018-09-28|October 2018|2018-10-31|September 28, 2021|Anticipated|2021-09-28|September 28, 2021|Anticipated|2021-09-28||Interventional|||CAR T and PD-1 Knockout Engineered T Cells for Esophageal Cancer|Combination Therapy of Anti-MUC1 CAR T Cells and PD-1 Knockout Engineered T Cells for Advanced Esophageal Cancer|Unknown status|Recruiting|Phase 1/Phase 2|20|Anticipated|The First Affiliated Hospital of Guangdong Pharmaceutical University||3|||f||||f|f|f|||||||||||2023-09-03 19:16:21.276212|2023-09-03 19:16:21.276212|OTHER|||||
NCT04004637||2019-06-28|||2020-09-25|2019-06-28|2019-07-02|Actual|||||||2020-09-25|2020-09-28|Actual|August 25, 2019|Actual|2019-08-25|September 2020|2020-09-30|June 1, 2021|Anticipated|2021-06-01|June 1, 2021|Anticipated|2021-06-01||Interventional|||CD7 CAR-T Cells for Patients With R/R CD7+ NK/T Cell Lymphoma,T-lymphoblastic Lymphoma and Acute Lymphocytic Leukemia|CD7 CAR-T Cells for Patients With Relapse/Refractory CD7+ NK/T Cell Lymphoma ,T-lymphoblastic Lymphoma and Acute Lymphocytic Leukemia|Unknown status|Recruiting|Phase 1|10|Anticipated|PersonGen BioTherapeutics (Suzhou) Co., Ltd.||1|||f||||f|f|f|||||||||Undecided||2023-09-03 02:07:08.883975|2023-09-03 02:07:08.883975|INDUSTRY|||||
NCT05277753||2022-02-21|||2022-03-14|2022-03-11|2022-03-14|Actual|||||||2022-03-14|2022-03-15|Actual|March 15, 2022|Anticipated|2022-03-15|March 2022|2022-03-31|December 31, 2025|Anticipated|2025-12-31|December 31, 2024|Anticipated|2024-12-31||Interventional|||NGS-MRD Assessment of Combination Immunotherapies Targeting T-ALL|NGS-MRD Evaluation of Antigen-specific T Cells and DC Vaccine Combination Targeting T-cell Acute Lymphoblastic Leukemia|Recruiting||Phase 1|10|Anticipated|Shenzhen Geno-Immune Medical Institute||1|||f||||f|f|f|||||||||||2023-09-03 02:08:00.156909|2023-09-03 02:08:00.156909|OTHER|||||
NCT05590221||2022-10-12|||2022-10-19|2022-10-19|2022-10-21|Actual|||||||2022-10-19|2022-10-21|Actual|December 10, 2022|Anticipated|2022-12-10|October 2022|2022-10-31|December 10, 2024|Anticipated|2024-12-10|February 10, 2024|Anticipated|2024-02-10||Interventional|||Relmacabtagene Autoleucel as First-Line Therapy for High-Risk Large B-Cell Lymphoma|Study to Evaluate the Efficacy and Safety of Relmacabtagene Autoleucel (Relma-cel) as First-Line Therapy in Adult Participants With High-Risk Large B-Cell Lymphoma|Not yet recruiting||Phase 2|20|Anticipated|Peking University Cancer Hospital & Institute||1|||f||||t|f|f|||f||||||No||2023-09-03 02:09:16.955338|2023-09-03 02:09:16.955338|OTHER|||||
NCT03064269||2017-02-18|||2023-01-11|2017-02-21|2017-02-27|Actual|||||||2023-01-11|2023-01-12|Actual|March 1, 2017|Actual|2017-03-01|February 2022|2022-02-28|February 18, 2024|Anticipated|2024-02-18|August 1, 2023|Anticipated|2023-08-01||Interventional|||CAR-T Therapy for Central Nervous System B-cell Acute Lymphocytic Leukemia|CAR-T Therapy for Central Nervous System B-cell Acute Lymphocytic Leukemia|Recruiting||Phase 1|10|Anticipated|Shanghai Unicar-Therapy Bio-medicine Technology Co.,Ltd||1|||f||||t|f|f|||||||||No||2023-09-03 19:19:28.872979|2023-09-03 19:19:28.872979|INDUSTRY|||||
NCT03502577||2018-04-11|||2023-07-10|2018-04-11|2018-04-18|Actual|||||||2023-07-10|2023-07-12|Actual|May 23, 2018|Actual|2018-05-23|July 2023|2023-07-31|September 1, 2026|Anticipated|2026-09-01|September 1, 2025|Anticipated|2025-09-01||Interventional|||BCMA-Specific CAR T-Cells Combined With a Gamma Secretase Inhibitor (JSMD194) to Treat Relapsed or Persistent Multiple Myeloma|A Phase I Study of B-Cell Maturation Antigen (BCMA)-Specific Chimeric Antigen Receptor T Cells in Combination With JSMD194, a Small Molecule Inhibitor of Gamma Secretase, in Patients With Relapsed or Persistent Multiple Myeloma|Suspended||Phase 1|18|Anticipated|Fred Hutchinson Cancer Center||1||Waiting on confirmation of additional funding|f||||t|t|f|||||||||No||2023-09-03 06:22:20.569951|2023-09-03 06:22:20.569951|OTHER|||||
NCT04860817||2021-04-22|||2022-11-23|2021-04-25|2021-04-27|Actual|||||||2022-11-23|2022-11-29|Actual|December 1, 2021|Anticipated|2021-12-01|November 2022|2022-11-30|November 1, 2023|Anticipated|2023-11-01|April 30, 2023|Anticipated|2023-04-30||Interventional|||A Study of Anti-CD7 CAR-T Cells in Pediatric and Young Adult Patients With Relapse and Refractory T-ALL/ T-LBL|Investigating the Safety and Efficacy of Anti-CD7 CAR-T Cell Immunotherapy in Patients With Relapse and Refractory T-cell Acute Lymphoblastic Leukemia or T Lymphoblastic Lymphoma|Withdrawn||Early Phase 1|0|Actual|920th Hospital of Joint Logistics Support Force of People's Liberation Army of China||1||No proper participant is found.|f||||f|f|f|||||||||No||2023-09-02 10:07:11.326169|2023-09-02 10:07:11.326169|OTHER|||||
NCT03383965||2017-12-06|||2017-12-19|2017-12-19|2017-12-27|Actual|||||||2017-12-19|2017-12-27|Actual|March 1, 2017|Actual|2017-03-01|March 2017|2017-03-31|December 31, 2025|Anticipated|2025-12-31|December 31, 2020|Anticipated|2020-12-31||Interventional|||CD30 Targeted CAR-T in Treating CD30-Expressing Lymphomas|A Clinical Study of CD30 Targeted CAR-T in Treating CD30-Expressing Lymphomas|Recruiting||Phase 1|20|Anticipated|Immune Cell, Inc.||1|||f|||||f|f|||||||||No||2023-09-04 17:58:53.985679|2023-09-04 17:58:53.985679|INDUSTRY|||||
NCT05546723||2022-09-15|||2023-01-11|2022-09-15|2022-09-21|Actual|||||||2023-01-11|2023-01-13|Actual|February 1, 2023|Anticipated|2023-02-01|January 2023|2023-01-31|December 31, 2024|Anticipated|2024-12-31|October 31, 2024|Anticipated|2024-10-31||Interventional|LMY-920-002||LMY-920 for Treatment of Relapsed or Refractory Myeloma|LUMT1A22, Phase 1 Study of BAFF CAR T Cells (LMY-920) for Treatment of Relapsed or Refractory Myeloma (LMY-920-002)|Not yet recruiting||Phase 1|30|Anticipated|Luminary Therapeutics||1|||f||||t|t|f|||||||||No||2023-09-03 02:20:14.652488|2023-09-03 02:20:14.652488|INDUSTRY|||||
NCT04903080||2021-05-21|||2023-01-11|2021-05-21|2021-05-26|Actual|||||||2023-01-11|2023-01-12|Actual|July 27, 2022|Actual|2022-07-27|January 2023|2023-01-31|February 28, 2043|Anticipated|2043-02-28|February 28, 2028|Anticipated|2028-02-28||Interventional|||HER2-specific Chimeric Antigen Receptor (CAR) T Cells for Children With Ependymoma|Phase 1 Trial of Autologous HER2-specific CAR T Cells in Pediatric Patients With Refractory or Recurrent Ependymoma|Active, not recruiting||Phase 1|50|Anticipated|Pediatric Brain Tumor Consortium||2|||f||||t|t|f|||||||||No||2023-09-03 19:26:52.774988|2023-09-03 19:26:52.774988|NETWORK|||||
NCT05388695||2022-05-19|||2023-01-11|2022-05-19|2022-05-24|Actual|||||||2023-01-11|2023-01-13|Actual|April 8, 2022|Actual|2022-04-08|January 2023|2023-01-31|May 1, 2025|Anticipated|2025-05-01|March 30, 2025|Anticipated|2025-03-30||Interventional|||To Observe the Dual-target Chimeric Antigen Receptor T Cells in the Treatment of B Cell Hematologic Tumors|To Observe the Long-term Efficacy and Safety of Dual-target Chimeric Antigen Receptor T Cells in the Treatment of Refractory Relapsed B Cell Hematologic Tumors|Recruiting||Phase 1|100|Anticipated|Hebei Senlang Biotechnology Inc., Ltd.||1|||f|||||f|f|||||||||No||2023-09-03 02:21:15.980359|2023-09-03 02:21:15.980359|INDUSTRY|||||
NCT05312801||2022-03-24|||2023-01-11|2022-04-01|2022-04-06|Actual|||||||2023-01-11|2023-01-13|Actual|January 23, 2023|Anticipated|2023-01-23|January 2023|2023-01-31|September 2, 2024|Anticipated|2024-09-02|June 1, 2024|Anticipated|2024-06-01||Interventional|||Phase 1 Study of BAFF CAR-T Cells (LMY-920) for Non-Hodgkin Lymphoma|LMY-920 for Treatment of Relapsed or Refractory Non-Hodgkin Lymphoma|Recruiting||Phase 1|20|Anticipated|Luminary Therapeutics||1|||f||||t|t|f|||||||||No||2023-09-03 02:21:39.83764|2023-09-03 02:21:39.83764|INDUSTRY|||||
NCT03767725||2018-12-05|||2018-12-07|2018-12-05|2018-12-07|Actual|||||||2018-12-07|2018-12-10|Actual|June 2, 2018|Actual|2018-06-02|December 2018|2018-12-31|September 1, 2021|Anticipated|2021-09-01|June 1, 2021|Anticipated|2021-06-01||Interventional|||Anti-BCMA or/and Anti-CD19 CART Cells Treatment of Relapsed Multiple Myeloma|Phase I Trial Study of Anti-BCMA (B-cell Maturation Antigen) or/and Anti-CD19 Chimeric Antigen Receptor T Cells (CART Cell) Treatment for the Patient of Relapsed Multiple Myeloma|Unknown status|Recruiting|Phase 1|10|Anticipated|Shenzhen Second People's Hospital||1|||f||||f|f|f|||||||||||2023-09-03 19:28:49.156893|2023-09-03 19:28:49.156893|OTHER|||||
NCT03916679||2019-04-12|||2019-04-12|2019-04-12|2019-04-16|Actual|||||||2019-04-12|2019-04-16|Actual|April 20, 2019|Anticipated|2019-04-20|April 2019|2019-04-30|April 20, 2023|Anticipated|2023-04-20|April 20, 2022|Anticipated|2022-04-20||Interventional|||MESO-CAR T Cells Therapy for Relapsed and Refractory Epithelial Ovarian Cancer|Safety and Effectiveness of MESO-CAR T Cells Therapy for Relapsed and Refractory Epithelial Ovarian Cancer|Unknown status|Recruiting|Phase 1/Phase 2|20|Anticipated|Second Affiliated Hospital, School of Medicine, Zhejiang University||1|||f|||||f|f|||||||||Undecided||2023-09-03 19:29:45.770096|2023-09-03 19:29:45.770096|OTHER|||||
NCT04697290||2021-01-05|||2022-01-29|2021-01-05|2021-01-06|Actual|||||||2022-01-29|2022-02-14|Actual|March 10, 2022|Anticipated|2022-03-10|January 2022|2022-01-31|June 10, 2023|Anticipated|2023-06-10|March 10, 2023|Anticipated|2023-03-10||Interventional|||CD19/CD20 Dual-CAR-T in B-cell Non-Hodgkin's Lymphoma Patients.|A Study of CD19/CD20 Dual CAR-T Cells in the Treatment of Relapsed or Refractory B-cell Non-Hodgkin's Lymphoma(B-NHL)|Suspended||Early Phase 1|12|Anticipated|Beijing Tsinghua Chang Gung Hospital||1||Plan adjustment|f|||||f|f|||||||||||2023-09-03 19:35:38.432365|2023-09-03 19:35:38.432365|OTHER|||||
NCT03289455||2017-09-11|2020-11-18||2021-01-11|2017-09-18|2017-09-21|Actual|2021-01-11|2021-02-01|Actual||||2021-01-11|2021-02-01|Actual|June 26, 2017|Actual|2017-06-26|January 2021|2021-01-31|May 18, 2020|Actual|2020-05-18|May 18, 2020|Actual|2020-05-18||Interventional|AMELIA|Patients infused with AUTO3|CD19 /22 CAR T Cells (AUTO3) for the Treatment of B Cell Acute Lymphoblastic Leukemia (ALL)|A Single-Arm, Open-Label, Multi-Centre, Phase I/II Study Evaluating the Safety and Clinical Activity Of AUTO3, a CAR T Cell Treatment Targeting CD19 And CD22 in Paediatric And Young Adult Patients With Relapsed or Refractory B Cell Acute Lymphoblastic Leukaemia|Completed||Phase 1/Phase 2|23|Actual|Autolus Limited||1|||f||||t|f|f|||||||||||2023-09-03 19:39:52.829733|2023-09-03 19:39:52.829733|INDUSTRY|||||
NCT05275062||2022-02-25|||2022-03-10|2022-03-10|2022-03-11|Actual|||||||2022-03-10|2022-03-11|Actual|February 15, 2022|Actual|2022-02-15|February 2022|2022-02-28|May 1, 2024|Anticipated|2024-05-01|March 1, 2024|Anticipated|2024-03-01||Interventional|||Clinical Trial to Evaluate the Safety and Efficacy of IM92 CAR-T Cells Therapy in Patients With Advanced Gastric or Pancreatic Adenocarcinoma|Clinical Trial to Evaluate the Safety and Efficacy of IM92 CAR-T Cells Therapy in Patients With Advanced Gastric or Pancreatic Adenocarcinoma|Recruiting||Early Phase 1|6|Anticipated|Beijing Immunochina Medical Science & Technology Co., Ltd.||1|||f|||||f|f|||||||||||2023-09-03 19:42:59.385655|2023-09-03 19:42:59.385655|INDUSTRY|||||
NCT02664363||2016-01-22|2020-07-08||2023-02-15|2016-01-26|2016-01-27|Estimate|2020-07-08|2020-07-24|Actual||||2023-02-15|2023-02-17|Actual|February 1, 2017|Actual|2017-02-01|February 2023|2023-02-28|September 12, 2019|Actual|2019-09-12|September 25, 2018|Actual|2018-09-25||Interventional|ExCeL||EGFRvIII CAR T Cells for Newly-Diagnosed WHO Grade IV Malignant Glioma|EGFRvIII Chimeric Antigen Receptor (CAR) Gene-modified T Cells for Patients With Newly-Diagnosed GBM During Lymphopenia|Terminated||Phase 1|3|Actual|Duke University||1||Study funding ended|f||||f|t|f|||||||||No||2023-09-03 02:36:41.367822|2023-09-03 02:36:41.367822|OTHER|||||
NCT05127135||2021-11-09|||2021-11-09|2021-11-09|2021-11-19|Actual|||||||2021-11-09|2021-11-19|Actual|January 22, 2020|Actual|2020-01-22|November 2021|2021-11-30|December 24, 2023|Anticipated|2023-12-24|January 24, 2023|Anticipated|2023-01-24||Interventional|||Safety and Efficacy of ThisCART7 in Patients With Refractory or Relapsed T Cell Malignancies|A Study to Evaluate the Safety and Clinical Activity of Allogeneic CAR-T Targeting CD7 in Patients With Refractory or Relapsed T Cell Malignancies|Recruiting||Phase 1|30|Anticipated|Fundamenta Therapeutics, Ltd.||1|||f||||f|f|f|||||||||No||2023-09-04 18:02:41.143811|2023-09-04 18:02:41.143811|INDUSTRY|||||
NCT05323201||2022-02-13|||2022-04-05|2022-04-05|2022-04-12|Actual|||||||2022-04-05|2022-04-12|Actual|February 10, 2022|Actual|2022-02-10|February 2022|2022-02-28|February 10, 2027|Anticipated|2027-02-10|February 10, 2024|Anticipated|2024-02-10||Interventional|||Study Of B7H3 CAR-T Cells in Treating Advanced Liver Cancer|A Single-Arm, Open-Label Study to Evaluate Safety and Efficacy of B7H3 or HBsAg Targeting CAR-T in Treating Advanced Hepatocellular Carcinoma|Recruiting||Phase 1/Phase 2|15|Anticipated|The Affiliated Hospital of Xuzhou Medical University||1|||f||||f|f|f|||||||||No||2023-09-02 10:16:32.429308|2023-09-02 10:16:32.429308|OTHER|||||
NCT03706547||2018-10-11|||2018-10-11|2018-10-11|2018-10-16|Actual|||||||2018-10-11|2018-10-16|Actual|October 30, 2018|Anticipated|2018-10-30|October 2018|2018-10-31|December 2021|Anticipated|2021-12-31|July 2020|Anticipated|2020-07-31||Interventional|||Anti-CD19/BCMA Bispecific CAR-T Cell Therapy for R/R MM|Clinical Study of Anti-CD19/BCMA Bispecific Chimeric Antigen Receptors (CARs) T Cell Therapy for Relapsed and Refractory Multiple Myeloma|Unknown status|Not yet recruiting|Phase 1|20|Anticipated|Shanghai Zhongshan Hospital||1|||f||||f|f|f|||||||||Undecided||2023-09-03 23:06:04.891651|2023-09-03 23:06:04.891651|OTHER|||||
NCT03958656||2019-05-21|2021-06-22||2021-08-19|2019-05-21|2019-05-22|Actual|2021-08-19|2021-09-09|Actual||||2021-08-19|2021-09-09|Actual|June 13, 2019|Actual|2019-06-13|August 2021|2021-08-31|January 19, 2021|Actual|2021-01-19|October 13, 2020|Actual|2020-10-13||Interventional||3/13 participants not treated in Level 2 (n=1) and Level 5 (n=2) collected baseline data is reported in the table.|T-cells Expressing an Anti-SLAMF7 CAR for Treating Multiple Myeloma|A Phase I Clinical Trial of T-cells Expressing an Anti-SLAMF7 CAR for Treating Multiple Myeloma|Completed||Phase 1|13|Actual|National Institutes of Health Clinical Center (CC)||2|||f||||f|t|f|||||||||No||2023-09-03 02:40:13.438577|2023-09-03 02:40:13.438577|NIH|||||
NCT04562298||2020-09-19|||2022-08-15|2020-09-19|2020-09-24|Actual|||||||2022-08-15|2022-08-18|Actual|October 21, 2020|Actual|2020-10-21|October 2021|2021-10-31|June 7, 2022|Actual|2022-06-07|June 7, 2022|Actual|2022-06-07||Interventional|||A Phase I Clinical Study to Evaluate the Safety, Tolerability, and Efficacy of LCAR-M23, a CAR-T Cell Therapy Targeting MSLN in Patients With Relapsed and Refractory Epithelial Ovarian Cancer|A Phase I Clinical Study to Evaluate the Safety, Tolerability, and Efficacy of LCAR-M23, a CAR-T Cell Therapy Targeting MSLN in Patients With Relapsed and Refractory Epithelial Ovarian Cancer|Terminated||Phase 1|15|Actual|Shanghai East Hospital||1||Both the sponsors and collaborator are considering terminating the study.|f||||f|f|f|||||||||||2023-09-01 02:04:34.77017|2023-09-01 02:04:34.77017|OTHER|||||
NCT03349255||2017-10-24|||2019-06-27|2017-11-16|2017-11-21|Actual|||||||2019-06-27|2019-07-01|Actual|October 6, 2017|Actual|2017-10-06|June 2019|2019-06-30|January 10, 2019|Actual|2019-01-10|January 10, 2019|Actual|2019-01-10||Interventional|||Clinical Study of ET1402L1-CAR T Cells in AFP Expressing Hepatocellular Carcinoma|Phase 1, Open-label, Two Routes IV and Intra-hepatic Artery Dose-escalation Clinical Study to Evaluate the Safety and Efficacy of ET1402L1-CAR T- Cells in AFP Expressing Hepatocellular Carcinoma (HCC)|Terminated||Phase 1|3|Actual|Aeon Therapeutics (Shanghai) Co., Ltd.||2||Will study new T-cell construct for the same indication|f||||t|t|f|||t||||||Undecided||2023-09-04 18:05:15.588996|2023-09-04 18:05:15.588996|INDUSTRY|||||
NCT05181501||2021-11-21|||2022-01-03|2022-01-03|2022-01-06|Actual|||||||2022-01-03|2022-01-06|Actual|April 2022|Anticipated|2022-04-30|January 2022|2022-01-31|April 2039|Anticipated|2039-04-30|April 2024|Anticipated|2024-04-30||Interventional|||A Study of Fully Human BCMA CAR-T (CT103A) in Patients With Newly Diagnosed High-risk Multiple Myeloma (FUMANBA-2)|A Multi-center Clinical Study of Fully Human BCMA Chimeric Antigen Receptor Autologous T (CAR-T) Cell Injection (CT103A) in the Treatment of Newly Diagnosed Subjects With High-risk Multiple Myeloma (FUMANBA-2)|Not yet recruiting||Phase 1|20|Anticipated|Nanjing IASO Biotherapeutics Co.,Ltd||1|||f|||||f|f|||f||||||||2023-09-03 20:02:32.106757|2023-09-03 20:02:32.106757|INDUSTRY|||||
NCT03851146||2019-02-12|||2022-05-01|2019-02-20|2019-02-22|Actual|||||||2022-05-01|2022-05-03|Actual|November 24, 2016|Actual|2016-11-24|May 2022|2022-05-31|April 1, 2022|Actual|2022-04-01|April 1, 2022|Actual|2022-04-01||Interventional|LeY-CAR-T||A Study of Anti-Lewis Y Chimeric Antigen Receptor-T Cells (LeY-CAR-T) in Patients With Solid Tumours|A Phase I Investigation of the Safety, Tolerability and Immunological Effects of T Lymphocytes Transduced With an Anti-Lewis Y (LeY) Chimeric Antigen Receptor Gene (LeY-CAR-T) in Patients With LeY Antigen Expressing Advanced Solid Tumours|Completed||Phase 1|20|Actual|Peter MacCallum Cancer Centre, Australia||1|||f||||t|f|f|||||||||No||2023-09-03 03:01:14.520817|2023-09-03 03:01:14.520817|OTHER|||||
NCT04264078||2020-02-07|||2021-06-21|2020-02-07|2020-02-11|Actual|||||||2021-06-21|2021-06-28|Actual|March 1, 2021|Actual|2021-03-01|June 2021|2021-06-30|June 1, 2023|Anticipated|2023-06-01|June 1, 2022|Anticipated|2022-06-01||Interventional|||Anti-CD7 U-CAR-T Cell Therapy for T/NK Cell Hematologic Malignancies|Anti-CD7 Universal CAR-T Cells for CD7+ T/NK Cell Hematologic Malignancies: a Multi-center, Uncontrolled Trial|Unknown status|Recruiting|Early Phase 1|30|Anticipated|Xinqiao Hospital of Chongqing||1|||f||||f|f|f|||||||||||2023-09-02 10:25:14.124209|2023-09-02 10:25:14.124209|OTHER|||||
NCT04082910||2019-09-04|||2022-04-08|2019-09-05|2019-09-10|Actual|||||||2022-04-08|2022-04-13|Actual|September 15, 2019|Actual|2019-09-15|April 2022|2022-04-30|December 30, 2023|Anticipated|2023-12-30|December 30, 2022|Anticipated|2022-12-30||Interventional|||Metoprolol Treatment for Cytokine Release Syndrome in Patients Treated With Chimeric Antigen Receptor T Cells|Metoprolol for the Treatment of Cytokine Release Syndrome in Patients Treated With Chimeric Antigen Receptor T Cells|Recruiting||Phase 1/Phase 2|30|Anticipated|Chinese PLA General Hospital||2|||f||||t|f|f|||||||||No||2023-09-03 03:16:15.545852|2023-09-03 03:16:15.545852|OTHER|||||
NCT03370198||2017-11-08|||2020-06-18|2017-12-06|2017-12-12|Actual|||||||2020-06-18|2020-06-18|Actual|October 11, 2017|Actual|2017-10-11|June 2020|2020-06-30|December 15, 2020|Anticipated|2020-12-15|January 15, 2019|Actual|2019-01-15||Interventional|LINK||Hepatic Transarterial Administrations of NKR-2 in Patients With Unresectable Liver Metastases From Colorectal Cancer|An Open-label Dose Escalation Phase I Study to Assess the Safety and Clinical Activity of Multiple Hepatic Transarterial Administrations of NKR-2 in Patients With Unresectable Liver Metastases From Colorectal Cancer|Unknown status|Active, not recruiting|Phase 1|1|Actual|Celyad Oncology SA||3|||f||||t|f|f|||||||||No||2023-09-03 20:14:55.827609|2023-09-03 20:14:55.827609|INDUSTRY|||||
NCT01593696||2012-05-05|2020-06-11||2020-08-14|2012-05-05|2012-05-08|Estimate|2020-08-14|2020-08-31|Actual||||2020-08-14|2020-08-31|Actual|June 29, 2012|Actual|2012-06-29|August 2020|2020-08-31|October 2, 2017|Actual|2017-10-02|November 11, 2016|Actual|2016-11-11||Interventional|||Anti-CD19 White Blood Cells for Children and Young Adults With B Cell Leukemia or Lymphoma|Phase I Study of T Cells Expressing an Anti-CD19 Chimeric Receptor in Children and Young Adults With B Cell Malignancies|Completed||Phase 1|53|Actual|National Institutes of Health Clinical Center (CC)||2|||f||||f|t|f|||||||||No||2023-09-01 02:09:13.939495|2023-09-01 02:09:13.939495|NIH|||||
NCT03356782||2017-11-24|||2020-06-10|2017-11-24|2017-11-29|Actual|||||||2020-06-10|2020-06-11|Actual|December 1, 2017|Actual|2017-12-01|June 2020|2020-06-30|December 31, 2023|Anticipated|2023-12-31|November 30, 2023|Anticipated|2023-11-30||Interventional|||Safety and Efficacy Evaluation of 4th Generation Safety-engineered CAR T Cells Targeting Sarcomas|Safety and Efficacy Evaluation of 4th Generation Safety-engineered CAR T Cells Targeting Sarcomas|Recruiting||Phase 1/Phase 2|20|Anticipated|Shenzhen Geno-Immune Medical Institute||1|||f||||f|f|f|||||||||No||2023-09-03 20:17:43.809217|2023-09-03 20:17:43.809217|OTHER|||||
NCT05239689||2021-12-01|||2022-02-13|2022-02-13|2022-02-15|Actual|||||||2022-02-13|2022-02-15|Actual|February 28, 2022|Anticipated|2022-02-28|February 2022|2022-02-28|December 5, 2024|Anticipated|2024-12-05|December 5, 2024|Anticipated|2024-12-05||Interventional|||Clinical Study of CD38 CAR-T Cells in the Treatment of Hematological Malignancies|Clinical Study on the Safety and Effectiveness of CD38 CAR-T Cells in the Treatment of CD38-positive Hematological Malignancies|Recruiting||Early Phase 1|36|Anticipated|Zhejiang University||1|||f||||t|f|f|||||||||||2023-09-03 20:18:36.426567|2023-09-03 20:18:36.426567|OTHER|||||
NCT04503538||2020-08-04|||2020-10-21|2020-08-04|2020-08-07|Actual|||||||2020-10-21|2020-10-23|Actual|December 2020|Anticipated|2020-12-31|October 2020|2020-10-31|November 2023|Anticipated|2023-11-30|September 2023|Anticipated|2023-09-30||Interventional|||Telemedicine for Early Detection of Cytokine Release Syndrome and Neurotoxicity|Telemedicine for Early Detection of Cytokine Release Syndrome and Neurotoxicity Following CAR-T Infusion on an Outpatient Basis|Withdrawn||Not Applicable|0|Actual|Wake Forest University Health Sciences||1||Principal investigator decided not to pursue trial|f||||t|f|f|||||||||No||2023-09-03 20:21:09.861414|2023-09-03 20:21:09.861414|OTHER|||||
NCT05430945||2022-06-18|||2022-06-18|2022-06-18|2022-06-24|Actual|||||||2022-06-18|2022-06-24|Actual|June 20, 2022|Anticipated|2022-06-20|June 2022|2022-06-30|June 20, 2025|Anticipated|2025-06-20|June 20, 2025|Anticipated|2025-06-20||Interventional|||A Study of BCMA-targeted CAR-T Cells Therapy for Refractory/Relapsed Multiple Myeloma|Clinical Trial for the Safety and Efficacy of BCMA-targeted CAR-T Cells Therapy for Refractory/Relapsed Multiple Myeloma|Recruiting||Early Phase 1|100|Anticipated|Zhejiang University||1|||f||||t|f|f|||||||||No||2023-09-04 18:11:02.291164|2023-09-04 18:11:02.291164|OTHER|||||
NCT04007978||2019-06-28|||2019-08-05|2019-07-02|2019-07-05|Actual|||||||2019-08-05|2019-08-07|Actual|August 5, 2019|Actual|2019-08-05|August 2019|2019-08-31|December 30, 2022|Anticipated|2022-12-30|June 30, 2022|Anticipated|2022-06-30||Interventional|||Anti-CD22 Chimeric Antigen Receptor (CAR)-Modified T Cell Therapy for Relapsed Refractory B-cell Malignancies|Efficacy and Safety of Anti-CD22 CAR-T Therapy in Patients With Relapsed/Refractory B-cell Malignancies: a Single-center, Open-label, Single-arm Clinical Study|Unknown status|Recruiting|Phase 1|50|Anticipated|Wuhan Union Hospital, China||1|||f|||||f|f|||||||||No||2023-09-03 03:34:55.701403|2023-09-03 03:34:55.701403|OTHER|||||
NCT03840317||2019-01-27|||2021-01-18|2019-02-12|2019-02-15|Actual|||||||2021-01-18|2021-01-20|Actual|January 2, 2019|Actual|2019-01-02|January 2021|2021-01-31|January 31, 2022|Anticipated|2022-01-31|September 1, 2021|Anticipated|2021-09-01||Interventional|||Senl_1904A and Senl_1904B Chimeric Antigen Receptor （CAR） T-Cell in the Treatment of r/ r Acute B Lymphocytic Leukemia|Randomized, Parallel-arm, Controlled Trial of Senl_1904A and Senl_1904B Autologous CAR-T Cell Injections in the Treatment of Relapsed and Refractory Acute B Lymphocytic Leukemia(r/r B-ALL)|Unknown status|Active, not recruiting|Phase 1|20|Anticipated|Hebei Senlang Biotechnology Inc., Ltd.||2|||f|||||f|f|||||||||||2023-09-03 20:35:22.143319|2023-09-03 20:35:22.143319|INDUSTRY|||||
NCT03811457||2019-01-17|||2019-01-17|2019-01-17|2019-01-22|Actual|||||||2019-01-17|2019-01-22|Actual|June 1, 2017|Actual|2017-06-01|January 2019|2019-01-31|December 31, 2018|Actual|2018-12-31|December 31, 2018|Actual|2018-12-31||Interventional|||Immunotherapy With CD19 CAR T-cells in Patients With Relapsed or Refractory CD19+ Leukemia and Lymphoma|Immunotherapy With CD19 CAR T-cells in Patients With Relapsed or Refractory CD19+ Leukemia and Lymphoma|Completed||Not Applicable|9|Actual|UWELL Biopharma||1|||f||||t|f|f|||||||||||2023-09-03 20:49:37.276952|2023-09-03 20:49:37.276952|INDUSTRY|||||
NCT04205838||2019-10-02|||2023-06-15|2019-12-17|2019-12-20|Actual|||||||2023-06-15|2023-06-18|Actual|March 4, 2020|Actual|2020-03-04|February 2023|2023-02-28|June 2025|Anticipated|2025-06-30|June 1, 2024|Anticipated|2024-06-01||Interventional|||Anakinra in Preventing Severe Chimeric Antigen Receptor T-Cell Related Encephalopathy Syndrome in Patients With Recurrent or Refractory Large B-cell Lymphoma|IL-1 Receptor Antagonist to Prevent Severe Chimeric Antigen Receptor T-Cell Related Encephalopathy Syndrome|Recruiting||Phase 2|36|Anticipated|Jonsson Comprehensive Cancer Center||1|||||||t|t|f|||t||||||||2023-09-02 10:34:47.131425|2023-09-02 10:34:47.131425|OTHER|||||
NCT05463640||2022-07-01|||2022-07-17|2022-07-17|2022-07-19|Actual|||||||2022-07-17|2022-07-19|Actual|August 2, 2022|Anticipated|2022-08-02|July 2022|2022-07-31|August 2, 2025|Anticipated|2025-08-02|August 2, 2024|Anticipated|2024-08-02||Interventional|||Evaluate the Safety and Efficacy of ADGRE2 CAR-T in Patients With R/R AML|To Evaluate the Safety and Efficacy of ADGRE2 CAR-T in Patients With Relapsed and Refractory Acute Myeloid Leukemia|Not yet recruiting||Phase 1|20|Anticipated|Zhejiang University||1|||f|||||f|f|||||||||||2023-09-03 20:52:37.708757|2023-09-03 20:52:37.708757|OTHER|||||
NCT03798509||2019-01-03|||2021-08-29|2019-01-08|2019-01-10|Actual|||||||2021-08-29|2021-08-31|Actual|March 13, 2019|Actual|2019-03-13|August 2021|2021-08-31|January 2024|Anticipated|2024-01-31|January 2022|Anticipated|2022-01-31||Interventional|||Human CD19 Targeted T Cells Injection Therapy for Relapsed and Refractory CD19-positive Leukemia|A Phase I Clinical Trial to Evaluate the Safety and Tolerability of Human CD19 Targeted T Cells Injection for Subjects With Relapsed and Refractory CD19-positive B-cell Acute Lymphoblastic Leukemia|Recruiting||Phase 1|18|Anticipated|Hrain Biotechnology Co., Ltd.||1|||f||||t|f|f|||||||||No||2023-09-03 20:53:34.108549|2023-09-03 20:53:34.108549|INDUSTRY|||||
NCT03799913||2019-01-08|||2019-04-09|2019-01-08|2019-01-10|Actual|||||||2019-04-09|2019-04-10|Actual|April 10, 2019|Anticipated|2019-04-10|April 2019|2019-04-30|April 2022|Anticipated|2022-04-30|October 2021|Anticipated|2021-10-31||Interventional|||MESO-CAR T Cells Therapy for Relapsed and Refractory Ovarian Cancer|A Clinical Trial of MESO-CAR T Cells Therapy for Relapsed and Refractory Ovarian Cancer|Unknown status|Recruiting|Early Phase 1|20|Anticipated|Zhejiang University||1|||f||||t|f|f|||||||||No||2023-09-03 20:54:53.807739|2023-09-03 20:54:53.807739|OTHER|||||
NCT03322735||2017-10-19|||2017-12-28|2017-10-23|2017-10-26|Actual|||||||2017-12-28|2017-12-29|Actual|December 8, 2017|Actual|2017-12-08|October 2017|2017-10-31|December 2019|Anticipated|2019-12-31|October 2018|Anticipated|2018-10-31||Interventional|||Study of BCMA CAR-T in Multiple Myeloma|A Study of BCMA CAR-T Cells for Patients With Relapse and Refractory Multiple Myeloma|Unknown status|Recruiting|Phase 1/Phase 2|10|Anticipated|Henan Cancer Hospital||1|||f||||t|f|f|||||||||||2023-09-04 18:17:34.724762|2023-09-04 18:17:34.724762|OTHER_GOV|||||
NCT03720457||2018-10-24|||2021-08-29|2018-10-24|2018-10-25|Actual|||||||2021-08-29|2021-08-31|Actual|November 13, 2018|Actual|2018-11-13|August 2021|2021-08-31|October 2023|Anticipated|2023-10-31|October 2021|Anticipated|2021-10-31||Interventional|||Human CD19 Targeted T Cells Injection(CD19 CAR-T) Therapy for Relapsed and Refractory CD19-positive Lymphoma.|A Phase I Clinical Trial of Human CD19 Targeted T Cells Injection for Subjects With Relapsed and Refractory CD19-positive Diffuse Large B-cell Lymphoma and Follicular Lymphoma|Recruiting||Phase 1|18|Anticipated|Hrain Biotechnology Co., Ltd.||1|||f||||t|f|f|||||||||No||2023-09-03 20:59:19.393155|2023-09-03 20:59:19.393155|INDUSTRY|||||
NCT04045847||2019-08-04|||2020-05-06|2019-08-04|2019-08-06|Actual|||||||2020-05-06|2020-05-07|Actual|May 30, 2019|Actual|2019-05-30|May 2019|2019-05-31|May 30, 2022|Anticipated|2022-05-30|October 30, 2020|Anticipated|2020-10-30||Interventional|||CD147-CART Cells in Patients With Recurrent Malignant Glioma.|A Clinical Study to Investigate the Safety, Tolerance and Efficacy Evaluation of Single-centre, Open-label of Local Treatment of CD147-CART in Recurrent Glioblastoma.|Unknown status|Recruiting|Early Phase 1|31|Anticipated|Xijing Hospital||1|||f||||t|f|f|||||||||||2023-09-03 03:58:53.976602|2023-09-03 03:58:53.976602|OTHER|||||
NCT03628612||2018-07-07|||2023-02-03|2018-08-09|2018-08-14|Actual|||||||2023-02-03|2023-02-06|Actual|August 3, 2018|Actual|2018-08-03|February 2023|2023-02-28|December 2043|Anticipated|2043-12-31|July 2043|Anticipated|2043-07-31||Interventional|||Long-term Follow-up of Patients Treated With Autologous T Cells Genetically Modified|Long-term Follow-up of Patients Previously Treated With Autologous T Cells Genetically Modified With Viral Vectors|Enrolling by invitation||Phase 2|500|Anticipated|Autolus Limited||1|||f||||f|f|f|||||||||No||2023-09-03 21:10:51.759587|2023-09-03 21:10:51.759587|INDUSTRY|||||
NCT04844086||2021-04-06|||2022-05-11|2021-04-08|2021-04-14|Actual|||||||2022-05-11|2022-05-18|Actual|March 2, 2021|Actual|2021-03-02|May 2022|2022-05-31|May 12, 2022|Actual|2022-05-12|May 12, 2022|Actual|2022-05-12||Interventional|||RPM CD19-mbIL15-CAR-T Cells in Patient With Advanced Lymphoid Malignancies|Infusion of CD19-Specific Chimeric Antigen Receptor T-cells Produced by Rapid Personalized Manufacture for Patients With Advanced Lymphoid Malignancies|Terminated||Phase 1|2|Actual|Eden BioCell Ltd.||1||CAR-T manufacturing technology can not meet the dose requirement for clinical patients.|f||||f|f|f|||||||||No||2023-09-02 10:42:54.665766|2023-09-02 10:42:54.665766|INDUSTRY|||||
NCT03198052||2017-06-22|||2023-02-11|2017-06-22|2017-06-23|Actual|||||||2023-02-11|2023-02-14|Actual|July 1, 2017|Actual|2017-07-01|February 2023|2023-02-28|August 1, 2026|Anticipated|2026-08-01|August 1, 2024|Anticipated|2024-08-01||Interventional|||GPC3/Mesothelin/Claudin18.2/GUCY2C/B7-H3/PSCA/PSMA/MUC1/TGFβ/HER2/Lewis-Y/AXL/EGFR-CAR-T Cells Against Cancers|CAR-T Targeting GPC3, Mesothelin, Claudin18.2, GUCY2C, B7-H3, PSCA, PSMA, MUC1, TGFβ, HER2, Lewis-Y, AXL, or EGFR for Immunotherapy of Lung Cancer: Phase I Clinical Trial|Recruiting||Phase 1|30|Anticipated|Second Affiliated Hospital of Guangzhou Medical University||1|||f||||f|f|f|||||||||No||2023-09-03 21:21:38.45174|2023-09-03 21:21:38.45174|OTHER|||||
NCT03298828||2017-07-24|||2017-09-26|2017-09-26|2017-10-02|Actual|||||||2017-09-26|2017-10-02|Actual|November 2017|Anticipated|2017-11-30|September 2017|2017-09-30|October 2022|Anticipated|2022-10-31|October 2020|Anticipated|2020-10-31||Interventional|||CD19 CAR and PD-1 Knockout Engineered T Cells for CD19 Positive Malignant B-cell Derived Leukemia and Lymphoma|CD19 Chimeric Antigen Receptor (CAR) and PD-1 Knockout Engineered T Cells for CD19 Positive Malignant B-cell Derived Leukemia and Lymphoma|Unknown status|Not yet recruiting|Phase 1|30|Anticipated|Third Military Medical University||2|||f||||f|f|f|||||||||Undecided||2023-09-03 21:23:31.155451|2023-09-03 21:23:31.155451|OTHER|||||
NCT02456350||2015-05-12|||2016-08-01|2015-05-27|2015-05-28|Estimate|||||||2016-08-01|2016-08-03|Estimate|April 2015||2015-04-30|August 2016|2016-08-31|December 2019|Anticipated|2019-12-31|December 2019|Anticipated|2019-12-31||Interventional|||Anti-CD19 Chimeric Antigen Receptor (CAR)-Transduced T Cell Therapy for Patients With B Cell Malignancies|Genetically Engineered T Cells Expressing an Anti-CD19 Chimeric Antigen Receptor for Treatment of Patients With B Cell Malignancies|Unknown status|Recruiting|Phase 1|36|Anticipated|Shenzhen Second People's Hospital||1|||f||||f|||||||||||||2023-09-03 21:31:21.755676|2023-09-03 21:31:21.755676|OTHER|||||
NCT03312205||2017-10-12|||2019-01-08|2017-10-12|2017-10-17|Actual|||||||2019-01-08|2019-01-09|Actual|August 29, 2017|Actual|2017-08-29|January 2019|2019-01-31|August 29, 2023|Anticipated|2023-08-29|August 29, 2019|Anticipated|2019-08-29||Interventional|||CAR-T Cells for Relapsed or Refractory Haematopoietic and Lymphoid Malignancies|CAR-T Cells for Relapsed or Refractory Haematopoietic and Lymphoid Malignancies|Unknown status|Recruiting|Phase 1/Phase 2|50|Anticipated|Hebei Senlang Biotechnology Inc., Ltd.||1|||f|||||f|f|||||||||Undecided||2023-09-04 18:25:45.301273|2023-09-04 18:25:45.301273|INDUSTRY|||||
NCT04129099||2019-10-15|||2020-05-26|2019-10-15|2019-10-16|Actual|||||||2020-05-26|2020-05-28|Actual|October 22, 2019|Actual|2019-10-22|May 2020|2020-05-31|June 2022|Anticipated|2022-06-30|September 2020|Anticipated|2020-09-30||Interventional|||A Study of GC022F CAR-T Cell Immunotherapy for Relapsed or Refractory B- ALL|A Study of GC022F CAR-T Cell Immunotherapy for Relapsed or Refractory B- ALL|Unknown status|Recruiting|Early Phase 1|18|Anticipated|Hebei Yanda Ludaopei Hospital||1|||f|||||f|f|||||||||||2023-08-31 12:38:21.748899|2023-08-31 12:38:21.748899|OTHER|||||
NCT03207178||2017-06-23|||2017-06-29|2017-06-29|2017-07-02|Actual|||||||2017-06-29|2017-07-02|Actual|March 1, 2017|Actual|2017-03-01|June 2017|2017-06-30|February 28, 2020|Anticipated|2020-02-28|February 28, 2019|Anticipated|2019-02-28||Interventional|||Sequential Infusion of Anti-CD19 and Anti-CD20 CAR-T Cells Against Relapsed and Refractory B-cell Lymphoma|Sequential Infusion of Anti-CD19 and Anti-CD20 Chimeric Antigen Receptor(CAR) T Cells Against Relapsed and Refractory B-cell Lymphoma|Unknown status|Recruiting|Phase 1/Phase 2|20|Anticipated|Shanghai Longyao Biotechnology Inc., Ltd.||1|||f||||t|f|f|||||||||No||2023-09-03 21:41:20.482065|2023-09-03 21:41:20.482065|OTHER|||||
NCT05044039||2021-09-03|||2023-02-12|2021-09-03|2021-09-14|Actual|||||||2023-02-12|2023-02-14|Actual|February 28, 2022|Actual|2022-02-28|February 2023|2023-02-28|October 31, 2029|Anticipated|2029-10-31|May 31, 2025|Anticipated|2025-05-31||Interventional|||Duvelisib Following Chimeric Antigen Receptor T-Cell Therapy|Phase I Dose Escalation and Dose Expansion Study of Duvelisib Following Chimeric Antigen Receptor T-Cell Therapy|Recruiting||Phase 1|43|Anticipated|Washington University School of Medicine||3|||f||||t|t|f|||f||||||No||2023-09-04 18:27:28.968967|2023-09-04 18:27:28.968967|OTHER|||||
NCT03118180||2017-04-11|||2017-04-14|2017-04-14|2017-04-18|Actual|||||||2017-04-14|2017-04-18|Actual|April 5, 2017|Actual|2017-04-05|April 2017|2017-04-30|December 31, 2020|Anticipated|2020-12-31|December 31, 2018|Anticipated|2018-12-31||Interventional|||CD19 Targeted Chimeric Antigen Receptor T Cells for B Cell Lymphoma|The Safety and Efficacy Evaluation of CD19 Targeted Chimeric Antigen Receptor T Cells for B Cell Lymphoma|Unknown status|Recruiting|Phase 1/Phase 2|50|Anticipated|Zhejiang University||1|||f||||t|f|f|||||||||Undecided||2023-09-03 21:45:59.373078|2023-09-03 21:45:59.373078|OTHER|||||
NCT04406610||2019-09-10|||2020-07-14|2020-05-24|2020-05-28|Actual|||||||2020-07-14|2020-07-16|Actual|September 1, 2015|Actual|2015-09-01|July 2020|2020-07-31|October 15, 2016|Actual|2016-10-15|August 15, 2016|Actual|2016-08-15||Interventional|||CAR-T Cell Immunotherapy for GD2 Positive Glioma Patients|Chimeric Antigen Receptor-Modified T Cells for GD2 Positive Recurrent and Metastatic Glioma|Withdrawn||Phase 1/Phase 2|0|Actual|Fuda Cancer Hospital, Guangzhou||2||Project terminated due to revision of local regulations|f||||t|||||||||||||2023-09-01 02:22:50.140808|2023-09-01 02:22:50.140808|OTHER|||||
NCT05252572||2021-12-01|||2022-02-13|2022-02-13|2022-02-23|Actual|||||||2022-02-13|2022-02-23|Actual|February 28, 2022|Anticipated|2022-02-28|February 2022|2022-02-28|November 30, 2024|Anticipated|2024-11-30|November 30, 2024|Anticipated|2024-11-30||Interventional|||Clinical Study of CLL1 CAR-T Cells in the Treatment of Hematological Malignancies|Clinical Study on the Safety and Effectiveness of CLL1 CAR-T Cells in the Treatment of CLL1-positive Hematological Malignancies|Recruiting||Early Phase 1|36|Anticipated|Zhejiang University||1|||f||||t|f|f|||||||||||2023-09-02 10:49:56.550986|2023-09-02 10:49:56.550986|OTHER|||||
NCT03185494||2017-06-10|||2019-04-16|2017-06-10|2017-06-14|Actual|||||||2019-04-16|2019-04-17|Actual|August 1, 2017|Actual|2017-08-01|July 2018|2018-07-31|August 1, 2020|Anticipated|2020-08-01|August 1, 2019|Anticipated|2019-08-01||Interventional|||Treatment of Relapsed and/or Chemotherapy Refractory B-cell Malignancy by Tandem CAR T Cells Targeting CD19 and CD22|Clinical Study of CD19/CD22 Tan CAR T Cells in Relapsed and/or Chemotherapy Refractory B-cell Leukemias and Lymphomas|Unknown status|Active, not recruiting|Phase 1/Phase 2|30|Anticipated|Chinese PLA General Hospital||1|||f||||t|f|f|||||||||Yes||2023-09-03 21:49:47.011739|2023-09-03 21:49:47.011739|OTHER|||||
NCT05008575||2021-08-14|||2021-12-22|2021-08-16|2021-08-17|Actual|||||||2021-12-22|2022-01-12|Actual|December 23, 2021|Actual|2021-12-23|December 2021|2021-12-31|December 1, 2023|Anticipated|2023-12-01|December 1, 2022|Anticipated|2022-12-01||Interventional|||Anti-CD33 CAR NK Cells in the Treatment of Relapsed/Refractory Acute Myeloid Leukemia|Phase I Study to Evaluate the Safety and Effectiveness of Anti-CD33 CAR NK Cell Therapy in Relapsed/Refractory Acute Myeloid Leukemia|Recruiting||Phase 1|27|Anticipated|Xinqiao Hospital of Chongqing||1|||f||||f|f|f|||||||||No||2023-09-03 21:57:31.612802|2023-09-03 21:57:31.612802|OTHER|||||
NCT03361748||2017-11-29|||2023-03-08|2017-11-29|2017-12-05|Actual|||||||2023-03-08|2023-03-09|Actual|December 13, 2017|Actual|2017-12-13|March 2023|2023-03-31|November 28, 2024|Anticipated|2024-11-28|November 28, 2024|Anticipated|2024-11-28||Interventional|KarMMa||Efficacy and Safety Study of bb2121 in Subjects With Relapsed and Refractory Multiple Myeloma|A Phase 2, Multicenter Study to Determine the Efficacy and Safety of bb2121 in Subjects With Relapsed and Refractory Multiple Myeloma|Active, not recruiting||Phase 2|149|Actual|Celgene||1|||f||||t|t|f|||||||||||2023-09-03 22:01:43.366208|2023-09-03 22:01:43.366208|INDUSTRY|||||
NCT03281551||2017-09-09|||2017-09-14|2017-09-11|2017-09-13|Actual|||||||2017-09-14|2017-09-15|Actual|October 1, 2017|Anticipated|2017-10-01|September 2017|2017-09-30|November 1, 2020|Anticipated|2020-11-01|September 1, 2020|Anticipated|2020-09-01||Interventional|||Efficacy and Safety of PZ01 Treatment in Patients With r/r CD19+ B-cell Acute Lymphoblastic Leukemia/B Cell Lymphoma|Study of Anti-CD19 Chimeric Antigen Receptor T Cells（PZ01） for Relapsed/ Refractory B-cell Acute Lymphoblastic Leukemia/B Cell Lymphoma|Unknown status|Recruiting|Phase 1|50|Anticipated|Pinze Lifetechnology Co. Ltd.||1|||f|||||f|f|||||||||No||2023-09-04 18:32:25.652775|2023-09-04 18:32:25.652775|INDUSTRY|||||
NCT05225831||2022-01-11|||2022-01-25|2022-01-25|2022-02-07|Actual|||||||2022-01-25|2022-02-07|Actual|August 15, 2021|Actual|2021-08-15|January 2022|2022-01-31|November 2023|Anticipated|2023-11-30|August 2023|Anticipated|2023-08-31||Interventional|||Safety and Efficacy of CD19/CD22 Dual Targeted CAR-T Cell Therapy in R/R B-Cell Acute Lymphoblastic Leukemia|Safety and Efficacy of CD19/CD22 Dual Targeted CAR-T Cell Therapy in Patients With R/R B-Cell Acute Lymphoblastic Leukemia|Recruiting||Early Phase 1|100|Anticipated|Hebei Senlang Biotechnology Inc., Ltd.||1|||f|||||f|f|||||||||||2023-09-03 05:47:45.276946|2023-09-03 05:47:45.276946|INDUSTRY|||||
NCT03356795||2017-11-24|||2019-09-18|2017-11-24|2017-11-29|Actual|||||||2019-09-18|2019-09-19|Actual|November 15, 2017|Actual|2017-11-15|September 2019|2019-09-30|December 2020|Anticipated|2020-12-31|January 31, 2019|Actual|2019-01-31||Interventional|||Intervention of CAR-T Against Cervical Cancer|Multicenter Trial of Chimeric Antigen Receptor-Modified T Cells (CAR-T Cells) in the Treatment of Cervical Cancer|Unknown status|Recruiting|Phase 1/Phase 2|20|Anticipated|Shenzhen Geno-Immune Medical Institute||1|||f||||f|f|f|||||||||No||2023-09-04 18:33:58.972641|2023-09-04 18:33:58.972641|OTHER|||||
NCT02846584||2016-07-25|||2016-09-06|2016-07-25|2016-07-27|Estimate|||||||2016-09-06|2016-09-07|Estimate|July 2016||2016-07-31|July 2016|2016-07-31|December 2019|Anticipated|2019-12-31|December 2019|Anticipated|2019-12-31||Interventional|||a Clinical Research of Sequential CAR-T Bridging HSCT in the Treatment of Relapse/Refractory B-cell Malignancies|a Clinical Research of Sequential CAR-T Bridging Hematopoietic Stem Cell Transplantation in the Treatment of Relapse/Refractory B-cell Malignancies|Unknown status|Active, not recruiting|Phase 2|100|Anticipated|Southwest Hospital, China||1|||f||||t|||||||||||No||2023-09-02 10:58:22.137712|2023-09-02 10:58:22.137712|OTHER|||||
NCT00902044||2009-05-13|||2022-11-21|2009-05-13|2009-05-14|Estimate|||||||2022-11-21|2022-11-22|Actual|February 11, 2010||2010-02-11|November 2022|2022-11-30|July 2032|Anticipated|2032-07-31|December 6, 2019|Actual|2019-12-06||Interventional|||Her2 Chimeric Antigen Receptor Expressing T Cells in Advanced Sarcoma|Administration of Her2 Chimeric Antigen Receptor Expressing T Cells for Subjects With Advanced Sarcoma (HEROS)|Active, not recruiting||Phase 1|36|Anticipated|Baylor College of Medicine||4|||f||||t|||||||||||||2023-09-02 10:59:32.284126|2023-09-02 10:59:32.284126|OTHER|||||
NCT02842138||2016-07-13|||2019-02-21|2016-07-19|2016-07-22|Estimate|||||||2019-02-21|2019-02-25|Actual|June 2016||2016-06-30|February 2019|2019-02-28|August 2019|Anticipated|2019-08-31|February 28, 2018|Actual|2018-02-28||Interventional|||Autologous CD19 CAR T Cells in Relapsed or Refractory B-cell Lymphoma|A Safety and Efficacy Study of Autologous T Cells Engineered to Express Chimeric Antigen Receptor Targeting CD19 in Patients With Relapsed or Refractory B-cell Lymphoma|Unknown status|Active, not recruiting|Phase 1|25|Anticipated|Peking University||1|||f||||t|||||||||||Yes||2023-09-02 11:01:11.340631|2023-09-02 11:01:11.340631|OTHER|||||
NCT04014881||2019-07-02|||2019-08-05|2019-07-08|2019-07-10|Actual|||||||2019-08-05|2019-08-07|Actual|July 6, 2019|Actual|2019-07-06|August 2019|2019-08-31|July 1, 2022|Anticipated|2022-07-01|July 1, 2021|Anticipated|2021-07-01||Interventional|||Safety and Efficacy of Anti-CD123 CAR-T Therapy in Patients With Refractory/ Relapsed CD123+ Acute Myeloid Leukemia.|Single-center, Open-label, Single-arm Clinical Study of Efficacy and Safety of Anti-CD123 CAR-T Therapy in Patients With Refractory/Relapsed CD123+ Acute Myeloid Leukemia.|Unknown status|Recruiting|Phase 1|50|Anticipated|Wuhan Union Hospital, China||1|||f||||f|f|f|||||||||||2023-09-03 06:27:53.512512|2023-09-03 06:27:53.512512|OTHER|||||
NCT04156243||2019-11-06|||2019-11-08|2019-11-06|2019-11-07|Actual|||||||2019-11-08|2019-11-12|Actual|February 1, 2018|Actual|2018-02-01|January 2019|2019-01-31|February 28, 2020|Anticipated|2020-02-28|February 28, 2020|Anticipated|2020-02-28||Interventional|||CD19 CARvac T Cells for Patients With Relapsed / Refractory B Cell Malignancies|Phase I, Interventional, Single Arm, Open Label, Treatment Study to Evaluate the Safety and Tolerability of CD19 CARvac in Patients With Relapsed and/or Refractory B Cell Malignancies|Unknown status|Recruiting|Early Phase 1|20|Anticipated|iCell Gene Therapeutics||1|||f||||t|f|f|||||||||No||2023-09-02 11:04:58.071066|2023-09-02 11:04:58.071066|INDUSTRY|||||
NCT03114670||2017-03-21|||2017-06-13|2017-04-10|2017-04-14|Actual|||||||2017-06-13|2017-06-14|Actual|March 25, 2017|Actual|2017-03-25|June 2017|2017-06-30|March 18, 2021|Anticipated|2021-03-18|March 18, 2019|Anticipated|2019-03-18||Interventional|||Donor-derived Anti-CD123-CART Cells for Recurred AML After Allo-HSCT|Donor-derived Anti-CD123 Chimeric Antigen Receptors Modified T Cells for Recurred Acute Myeloid Leukaemia After Allogeneic Hematopoietic Stem Cell Transplantation|Unknown status|Recruiting|Phase 1|20|Anticipated|Affiliated Hospital to Academy of Military Medical Sciences||1|||f||||t|f|f|||f||||||Undecided||2023-09-03 22:18:49.811759|2023-09-03 22:18:49.811759|OTHER|||||
NCT04440436||2020-06-18|||2020-12-04|2020-06-18|2020-06-19|Actual|||||||2020-12-04|2020-12-08|Actual|June 4, 2020|Actual|2020-06-04|December 2020|2020-12-31|June 4, 2035|Anticipated|2035-06-04|June 4, 2022|Anticipated|2022-06-04||Interventional|||Assessment of Safety and Efficacy of IM19 for Recurrent or Refractory (R/R) Non-Hodgkin's Lymphoma(NHL) Patients|Phase I/II Clinical Study to Evaluate the Safety and Efficacy of IM19 Chimeric Antigen Receptor T Cells(CAR-T) in the Treatment of Recurrent or Refractory (R/R) CD19 Positive Aggressive Non-Hodgkin's Lymphoma|Recruiting||Phase 1/Phase 2|52|Anticipated|Beijing Immunochina Medical Science & Technology Co., Ltd.||1|||f||||t|f|f|||||||||No||2023-09-03 22:19:08.435026|2023-09-03 22:19:08.435026|INDUSTRY|||||
NCT04500431||2020-08-02|||2020-08-02|2020-08-02|2020-08-05|Actual|||||||2020-08-02|2020-08-05|Actual|July 1, 2018|Actual|2018-07-01|August 2020|2020-08-31|December 1, 2022|Anticipated|2022-12-01|July 1, 2022|Anticipated|2022-07-01||Interventional|||Clinical Study to Evaluate the Safety and Feasibility of spCART-269 Injection in the Treatment of MM|Clinical Study to Evaluate the Safety and Feasibility of Targeting CD269 Chimeric Antigen Receptor Engineered T Cell (spCART-269) Injection in the Treatment of CD269-positive Multiple Myeloma|Unknown status|Recruiting|Phase 1|10|Anticipated|Shanghai Tongji Hospital, Tongji University School of Medicine||1|||f||||f|f|f|||||||||Yes|The data sets generated and analysed during the current study are available from the corresponding author on reasonable request.|2023-09-04 18:39:59.004199|2023-09-04 18:39:59.004199|OTHER|||||
NCT03121625||2017-04-17|||2017-04-23|2017-04-19|2017-04-20|Actual|||||||2017-04-23|2017-04-25|Actual|December 26, 2016|Actual|2016-12-26|April 2017|2017-04-30|December 2021|Anticipated|2021-12-31|December 2018|Anticipated|2018-12-31||Interventional|||CAR-T Therapy in Relapsed or Refractory Haematopoietic and Lymphoid Malignancies|CAR-T Therapy in Relapsed or Refractory Haematopoietic and Lymphoid Malignancies|Unknown status|Recruiting|Phase 1|30|Anticipated|Hebei Senlang Biotechnology Inc., Ltd.||1|||f||||f|f|f|||||||||Undecided||2023-09-04 18:40:44.677941|2023-09-04 18:40:44.677941|INDUSTRY|||||
NCT05016778||2021-06-06|||2022-10-30|2021-08-20|2021-08-23|Actual|||||||2022-10-30|2022-11-01|Actual|June 8, 2021|Actual|2021-06-08|October 2022|2022-10-31|June 30, 2025|Anticipated|2025-06-30|June 30, 2024|Anticipated|2024-06-30||Interventional|||A Study of CAR-T Cells Targeting GPRC5D in the Treatment of r/r Multiple Myeloma|A Single Arm, Open Label Clinical Study of CAR-T Cells Targeting GPRC5D in the Treatment of Relapsed / Refractory Multiple Myeloma(POLARIS)|Active, not recruiting||Early Phase 1|15|Anticipated|Zhejiang University||1|||f|||||f|f|||||||||||2023-09-02 11:08:08.412996|2023-09-02 11:08:08.412996|OTHER|||||
NCT05393986||2022-05-13|||2023-05-30|2022-05-24|2022-05-27|Actual|||||||2023-05-30|2023-05-31|Actual|August 4, 2022|Actual|2022-08-04|May 2023|2023-05-31|December 30, 2024|Anticipated|2024-12-30|June 30, 2023|Anticipated|2023-06-30||Interventional|||Claudin18.2-redirected Chimeric Antigen Receptor T Cells With Co-expression of Cytokines in Solid Tumors|An Open-Label, Single-Arm, Dose-Exploration Study to Evaluate the Safety, Tolerability, Preliminary Efficacy and Pharmacokinetics of CT048 in Subjects With Advanced Solid Tumors|Recruiting||Phase 1|63|Anticipated|Peking University||1|||f||||f|f|f|||||||||No||2023-09-03 05:56:08.58991|2023-09-03 05:56:08.58991|OTHER|||||
NCT03344705||2017-11-14|||2017-11-16|2017-11-14|2017-11-17|Actual|||||||2017-11-16|2017-11-17|Actual|August 21, 2017|Actual|2017-08-21|November 2017|2017-11-30|December 1, 2020|Anticipated|2020-12-01|October 1, 2020|Anticipated|2020-10-01||Interventional|||Safety and Efficacy Evaluation of IM19 Cells|Safety and Efficacy Evaluation of IM19 Chimeric Antigen Receptor-modified T Cells (IM19CAR-T) In CD19+ B Cell Malignancies|Unknown status|Recruiting|Phase 1|20|Anticipated|Beijing Immunochina Medical Science & Technology Co., Ltd.||1|||f||||f|f|f|||||||||||2023-09-04 18:42:51.71995|2023-09-04 18:42:51.71995|INDUSTRY|||||
NCT05458297||2022-07-11|||2023-08-25|2022-07-11|2022-07-14|Actual|||||||2023-08-25|2023-08-28|Actual|July 21, 2022|Actual|2022-07-21|August 2023|2023-08-31|April 26, 2027|Anticipated|2027-04-26|March 13, 2027|Anticipated|2027-03-13||Interventional|||A Study of Zilovertamab Vedotin (MK-2140) as Monotherapy and in Combination in Participants With Aggressive and Indolent B-cell Malignancies (MK-2140-006)|A Multicenter, Open-label, Phase 2 Basket Study to Evaluate the Safety and Efficacy of MK-2140 as a Monotherapy and in Combination in Participants With Aggressive and Indolent B-cell Malignancies|Recruiting||Phase 2|275|Anticipated|Merck Sharp & Dohme LLC||6|||f||||f|t|f||||||||http://engagezone.msd.com/ds_documentation.php|Yes|http://engagezone.msd.com/doc/ProcedureAccessClinicalTrialData.pdf|2023-09-03 06:00:12.906883|2023-09-03 06:00:12.906883|INDUSTRY|||||
NCT05377827||2022-05-11|||2023-08-24|2022-05-11|2022-05-17|Actual|||||||2023-08-24|2023-08-28|Actual|October 31, 2023|Anticipated|2023-10-31|August 2023|2023-08-31|April 30, 2026|Anticipated|2026-04-30|April 30, 2026|Anticipated|2026-04-30||Interventional|||Dose-Escalation and Dose-Expansion Study to Evaluate the Safety and Tolerability of Anti-CD7 Allogeneic CAR T-Cells (WU-CART-007) in Patients With CD7+ Hematologic Malignancies|Phase 1 Dose-Escalation and Dose-Expansion Study to Evaluate the Safety and Tolerability of Anti-CD7 Allogeneic CAR T-Cells (WU-CART-007) in Patients With CD7+ Hematologic Malignancies|Not yet recruiting||Phase 1|54|Anticipated|Washington University School of Medicine||4|||f||||t|t|f|||f||||||No||2023-09-03 06:00:27.789961|2023-09-03 06:00:27.789961|OTHER|||||
NCT05353530||2022-04-25|||2023-08-24|2022-04-25|2022-04-29|Actual|||||||2023-08-24|2023-08-28|Actual|July 25, 2023|Actual|2023-07-25|August 2023|2023-08-31|December 2042|Anticipated|2042-12-31|December 2027|Anticipated|2027-12-31||Interventional|IMPACT||Phase I Study of IL-8 Receptor-modified CD70 CAR T Cell Therapy in CD70+ and MGMT-unmethylated Adult Glioblastoma (IMPACT)|Phase I Study -To Assess Safety and Feasibility of IL-8 Receptor Modified Patient-derived Activated CD70 CAR T Cell Therapy in CD70+ and MGMT-unmethylated Adult GBM|Recruiting||Phase 1|18|Anticipated|University of Florida||1|||f||||t|t|f|||||||||No||2023-09-03 06:00:33.465381|2023-09-03 06:00:33.465381|OTHER|||||
NCT02822326||2016-06-28|||2017-09-08|2016-07-01|2016-07-04|Estimate|||||||2017-09-08|2017-09-11|Actual|January 2016||2016-01-31|September 2017|2017-09-30|September 2019|Anticipated|2019-09-30|September 2019|Anticipated|2019-09-30||Interventional|||Phase I Study of CD19-CAR-T2 Cells for Patients With Chemotherapy Resistant or Refractory CD19+ Acute Leukemia|CD19-CAR-T2 Cells for Relapse/Refractory CD19 Positive Acute Leukemia-a Phase I Trial|Unknown status|Recruiting|Phase 1|30|Anticipated|Guangdong Provincial People's Hospital||1|||f||||t|||||||||||No||2023-09-02 11:12:15.79245|2023-09-02 11:12:15.79245|OTHER|||||
NCT05081479||2021-10-05|||2023-08-25|2021-10-05|2021-10-18|Actual|||||||2023-08-25|2023-08-28|Actual|December 8, 2021|Actual|2021-12-08|August 2023|2023-08-31|October 21, 2024|Anticipated|2024-10-21|October 21, 2024|Anticipated|2024-10-21||Interventional|||A Study of N-Acetylcysteine (N-AC)in People Receiving CAR T-cell Therapy for Lymphoma|Phase I Study of N-Acetylcysteine to Optimize Metabolic Tumor Microenvironment in CD19 CAR T-cell Therapy in Lymphoma|Recruiting||Phase 1|32|Anticipated|Memorial Sloan Kettering Cancer Center||3|||f|||||t|f|||||||||Yes|Memorial Sloan Kettering Cancer Center supports the international committee of medical journal editors (ICMJE) and the ethical obligation of responsible sharing of data from clinical trials. The protocol summary, a statistical summary, and informed consent form will be made available on clinicaltrials.gov when required as a condition of Federal awards, other agreements supporting the research and/or as otherwise required. Requests for deidentified individual participant data can be made beginning 12 months after publication and for up to 36 months post publication. Deidentified individual participant data reported in the manuscript will be shared under the terms of a Data Use Agreement and may only be used for approved proposals. Requests may be made to: crdatashare@mskcc.org.|2023-09-03 06:01:26.887852|2023-09-03 06:01:26.887852|OTHER|||||
NCT04778579||2021-02-26|||2023-08-25|2021-03-02|2021-03-03|Actual|||||||2023-08-25|2023-08-28|Actual|May 11, 2021|Actual|2021-05-11|August 2023|2023-08-31|December 31, 2025|Anticipated|2025-12-31|December 31, 2023|Anticipated|2023-12-31||Interventional|CART19-BE-02||Study of the Infusion of ARI-0001 Cells in Patients With CD19 + Acute Lymphoid Leukemia Resistant or Refractory to Therapy|Phase 2 Study of the Infusion of Differentiated Autologous T-cells From Peripheral Blood, Expanded and Transduced With a Lentivirus to Express a Chimeric Antigen Receptor With Anti-CD19 Specificity (A3B1) Conjugated With the Co-stimulatory Regions 4-1BB and CD3z (ARI-0001 Cells) in Patients With CD19+ Acute Lymphoid Leukemia Resistant or Refractory to Therapy|Active, not recruiting||Phase 2|50|Actual|Institut d'Investigacions Biomèdiques August Pi i Sunyer||1|||f||||t|f|f|||||||||No||2023-09-03 06:02:05.750989|2023-09-03 06:02:05.750989|OTHER|||||
NCT05016063||2021-08-14|||2021-08-20|2021-08-20|2021-08-23|Actual|||||||2021-08-20|2021-08-23|Actual|September 1, 2021|Anticipated|2021-09-01|August 2021|2021-08-31|September 1, 2023|Anticipated|2023-09-01|September 1, 2022|Anticipated|2022-09-01||Interventional|||Dual CD33-CLL1-CAR-T Cells in the Treatment of Relapsed/Refractory Acute Myeloid Leukemia|Phase I Study to Evaluate the Safety and Effectiveness of Dual CD33-CLL1 CAR-T Therapy in Relapsed/Refractory Acute Myeloid Leukemia|Not yet recruiting||Early Phase 1|32|Anticipated|Xinqiao Hospital of Chongqing||1|||f||||f|f|f|||||||||No||2023-09-04 18:49:44.76307|2023-09-04 18:49:44.76307|OTHER|||||
NCT04404660||2020-05-12|||2023-08-24|2020-05-25|2020-05-27|Actual|||||||2023-08-24|2023-08-28|Actual|March 4, 2020|Actual|2020-03-04|August 2023|2023-08-31|May 2025|Anticipated|2025-05-31|May 2025|Anticipated|2025-05-31||Interventional|||A Study of CD19 Targeted CAR T Cell Therapy in Adult Patients With Relapsed or Refractory B Cell Acute Lymphoblastic Leukaemia (ALL)|An Open-Label, Multi-Centre, Phase Ib/II Study Evaluating the Safety and Efficacy of AUTO1, a CAR T Cell Treatment Targeting CD19, in Adult Patients With Relapsed or Refractory B Cell Acute Lymphoblastic Leukaemia|Active, not recruiting||Phase 1/Phase 2|153|Actual|Autolus Limited||1|||f||||t|t|f|||||||||||2023-09-03 06:03:03.594582|2023-09-03 06:03:03.594582|INDUSTRY|||||
NCT03144583||2017-04-26|||2023-08-25|2017-05-04|2017-05-09|Actual|||||||2023-08-25|2023-08-28|Actual|June 15, 2017|Actual|2017-06-15|August 2023|2023-08-31|September 13, 2022|Actual|2022-09-13|September 13, 2022|Actual|2022-09-13||Interventional|CART19-BE-01||Pilot Study on the Infusion of ARI-0001 Cells in Patients With CD19+ Leukemia or Lymphoma Refractory to Therapy|Pilot Study on the Infusion of Differentiated Autologous T-cells From Peripheral Blood, Expanded and Transduced With a Lentivirus to Express a Chimeric Antigen Receptor With Anti-CD19 Specificity Conjugated With the Co-stimulatory Regions 4-1BB and CD3z in Patients With CD19+ Leukemia or Lymphoma Refractory to Therapy|Completed||Phase 1|50|Actual|Institut d'Investigacions Biomèdiques August Pi i Sunyer||1|||f||||t|f|f|||||||||No||2023-09-03 06:04:58.159629|2023-09-03 06:04:58.159629|OTHER|||||
NCT03726515||2018-10-26|||2023-06-20|2018-10-30|2018-10-31|Actual|||||||2023-06-20|2023-06-22|Actual|March 11, 2019|Actual|2019-03-11|March 2021|2021-03-31|February 27, 2021|Actual|2021-02-27|February 27, 2021|Actual|2021-02-27||Interventional|||CART-EGFRvIII + Pembrolizumab in GBM|Phase 1 Study of EGFRvIII-Directed CAR T Cells Combined With PD-1 Inhibition in Patients With Newly Diagnosed, MGMT-Unmethylated Glioblastoma|Completed||Phase 1|7|Actual|University of Pennsylvania||1|||f||||t|t|f|||||||||||2023-09-03 22:41:44.752691|2023-09-03 22:41:44.752691|OTHER|||||
NCT03076437||2017-03-07|||2021-03-16|2017-03-07|2017-03-10|Actual|||||||2021-03-16|2021-03-19|Actual|January 15, 2016|Actual|2016-01-15|March 2021|2021-03-31|December 31, 2019|Actual|2019-12-31|May 26, 2019|Actual|2019-05-26||Interventional|||Anti-CD19 Chimeric Antigen Receptor (CAR)-Transduced T Cell Therapy for Patients With B Cell Malignancies|Anti-CD19 Chimeric Antigen Receptor (CAR)-Transduced T Cell Therapy for Patients With B Cell Malignancies|Completed||Phase 1/Phase 2|28|Actual|Shenzhen Institute for Innovation and Translational Medicine||1|||f||||t|f|f|||||||||No||2023-09-04 18:54:35.018414|2023-09-04 18:54:35.018414|OTHER|||||
NCT04696432||2020-11-30|||2023-05-28|2021-01-05|2021-01-06|Actual|||||||2023-05-28|2023-05-31|Actual|November 27, 2020|Actual|2020-11-27|May 2023|2023-05-31|December 30, 2023|Anticipated|2023-12-30|July 31, 2023|Anticipated|2023-07-31||Interventional|||A Study of C-CAR039 Treatment in Subjects With r/r NHL SubjectsNon-Hodgkin's Lymphoma|A Phase 1 Study Evaluating Safety and Efficacy of C-CAR039 Treatment in Subjects With Relapsed and/or Refractory NHL|Active, not recruiting||Phase 1|7|Actual|Tianjin Medical University Cancer Institute and Hospital||1|||f||||f|f|f|||||||||No||2023-09-03 06:08:46.648118|2023-09-03 06:08:46.648118|OTHER|||||
NCT04648046||2020-11-23|||2023-05-26|2020-11-23|2020-12-01|Actual|||||||2023-05-26|2023-05-30|Actual|March 1, 2021|Actual|2021-03-01|May 2023|2023-05-31|December 31, 2027|Anticipated|2027-12-31|December 31, 2026|Anticipated|2026-12-31||Interventional|||CAR-T Cells for HIV Infection|Safety and Anti-HIV Activity of Autologous CD4+ and CD8+ T Cells Transduced With a Lentiviral Vector Encoding Bi-specific Anti-gp120 CAR Molecules (LVgp120duoCAR-T) in Anti-retroviral Drug-treated HIV-1 Infection|Recruiting||Phase 1/Phase 2|18|Anticipated|University of California, San Francisco||3|||f||||t|t|f|||||||||No||2023-09-03 06:08:52.234317|2023-09-03 06:08:52.234317|OTHER|||||
NCT04557436||2020-09-15|||2023-05-30|2020-09-15|2020-09-21|Actual|||||||2023-05-30|2023-05-31|Actual|August 12, 2020|Actual|2020-08-12|May 2023|2023-05-31|December 31, 2023|Anticipated|2023-12-31|December 31, 2023|Anticipated|2023-12-31||Interventional|PBLTT52CAR19||TT52CAR19 Therapy for B-cell Acute Lymphoblastic Leukaemia (B-ALL)|Phase 1, Open Label Study of CRISPR-CAR Genome Edited T Cells (PBLTT52CAR19) in Relapsed /Refractory B Cell Acute Lymphoblastic Leukaemia|Active, not recruiting||Phase 1|10|Anticipated|Great Ormond Street Hospital for Children NHS Foundation Trust||1|||f||||t|f|f|||||||||No||2023-09-03 06:09:16.374172|2023-09-03 06:09:16.374172|OTHER|||||
NCT04510051||2020-08-10|||2023-05-26|2020-08-10|2020-08-12|Actual|||||||2023-05-26|2023-05-31|Actual|December 4, 2020|Actual|2020-12-04|May 2023|2023-05-31|September 18, 2023|Anticipated|2023-09-18|September 18, 2023|Anticipated|2023-09-18||Interventional|||CAR T Cells After Lymphodepletion for the Treatment of IL13Rα2 Positive Recurrent or Refractory Brain Tumors in Children|Phase I Study of Cellular Immunotherapy Using Memory Enriched T Cells Lentivirally Transduced to Express an IL13Rα2-Targeting, Hinge-Optimized, 41BB-Costimulatory Chimeric Receptor and a Truncated CD19 for Children With Recurrent/Refractory Malignant Brain Tumors|Recruiting||Phase 1|18|Anticipated|City of Hope Medical Center||1|||||||t|t|f|||||||||||2023-09-03 06:09:26.112741|2023-09-03 06:09:26.112741|OTHER|||||
NCT04097301||2019-08-05|2021-10-04||2021-12-20|2019-09-19|2019-09-20|Actual|2021-12-20|2022-01-19|Actual||||2021-12-20|2022-01-19|Actual|August 27, 2019|Actual|2019-08-27|December 2021|2021-12-31|June 18, 2021|Actual|2021-06-18|June 18, 2021|Actual|2021-06-18||Interventional||"Overall, 8 patients were enrolled in the study and underwent the screening phase to evaluate the compliance to the clinical inclusion / exclusion criteria as well as the CD44v6 expression by tumor cells (Table 10).~Of the 8 enrolled patients, 2 were treated with MLM-CAR44.1 T-cell at the first dose level. Five patients were screening failures and 1 patient dropped-out before lymphocyte apheresis for fulminant disease progression."|Study of CAR T-cell Therapy in Acute Myeloid Leukemia and Multiple Myeloma|A Phase I-IIa Trial to Assess the Safety and Antitumor Activity of Autologous CD44v6 CAR T-cells in Acute Myeloid Leukemia and Multiple Myeloma Expressing CD44v6|Terminated||Phase 1/Phase 2|8|Actual|AGC Biologics S.p.A.||1||Inability to close the study in a clinically relevant time frame|f||||t|f|f|||||||||||2023-09-03 22:53:47.976265|2023-09-03 22:53:47.976265|INDUSTRY|||||
NCT03696030||2018-06-27|||2022-09-14|2018-10-03|2018-10-04|Actual|||||||2022-09-14|2022-09-16|Actual|August 31, 2018|Actual|2018-08-31|September 2022|2022-09-30|August 31, 2023|Anticipated|2023-08-31|August 31, 2023|Anticipated|2023-08-31||Interventional|||HER2-CAR T Cells in Treating Patients With Recurrent Brain or Leptomeningeal Metastases|A Phase 1 Cellular Immunotherapy Study of Intraventricularly Administered Autologous HER2-Targeted Chimeric Antigen Receptor (HER2-CAR) T Cells in Patients With Brain and/or Leptomeningeal Metastases From HER2 Positive Cancers|Recruiting||Phase 1|39|Anticipated|City of Hope Medical Center||1|||||||t|t|f|||f||||||||2023-09-01 02:30:24.955789|2023-09-01 02:30:24.955789|OTHER|||||
NCT04385173||2020-02-04|||2022-12-25|2020-05-11|2020-05-12|Actual|||||||2022-12-25|2022-12-28|Actual|December 1, 2022|Actual|2022-12-01|December 2022|2022-12-31|May 1, 2024|Anticipated|2024-05-01|March 1, 2024|Anticipated|2024-03-01||Interventional|||Pilot Study of B7-H3 CAR-T in Treating Patients With Recurrent and Refractory Glioblastoma|A Pilot Study of Chimeric Antigen Receptor (CAR) T Cells Targeting B7-H3 Antigen in Treating Patients With Recurrent and Refractory Glioblastoma|Recruiting||Phase 1|12|Anticipated|Second Affiliated Hospital, School of Medicine, Zhejiang University||1|||f||||f|f|f|||||||||Undecided||2023-09-03 23:02:55.819804|2023-09-03 23:02:55.819804|OTHER|||||
NCT05309213||2022-03-25|||2022-03-25|2022-03-25|2022-04-04|Actual|||||||2022-03-25|2022-04-04|Actual|April 1, 2022|Anticipated|2022-04-01|March 2022|2022-03-31|June 1, 2025|Anticipated|2025-06-01|April 1, 2025|Anticipated|2025-04-01||Interventional|||Clinical Trial to Evaluate the Safety and Efficacy of IM19 CAR-T Cells in Patients With Relapsed and Refractory (R/R) B-cell Acute Lymphoblastic Leukemia|A Phase 1-2 Study to Evaluate the Safety and Efficacy of IM19 CAR-T Cells in Patients With Relapsed and Refractory (R/R) B-cell Acute Lymphoblastic Leukemia|Not yet recruiting||Phase 1/Phase 2|58|Anticipated|Beijing Immunochina Medical Science & Technology Co., Ltd.||1|||f|||||f|f|||||||||||2023-09-03 23:09:54.915208|2023-09-03 23:09:54.915208|INDUSTRY|||||
NCT04640909||2020-11-09|||2022-01-03|2020-11-18|2020-11-23|Actual|||||||2022-01-03|2022-01-04|Actual|October 1, 2021|Actual|2021-10-01|October 2021|2021-10-31|October 2024|Anticipated|2024-10-31|October 2024|Anticipated|2024-10-31||Interventional|||Impact of Treatment With Targeted Therapies on the Generation of CAR T Cells in CLL Patients|Impact of Treatment With Targeted Therapies on the Generation of Effective CAR T Cells in Patients With Chronic Lymphocytic Leukemia|Recruiting||Not Applicable|23|Anticipated|Gruppo Italiano Malattie EMatologiche dell'Adulto||1|||f|||||f|f|||||||||||2023-09-03 23:10:30.314352|2023-09-03 23:10:30.314352|OTHER|||||
NCT03774654||2018-12-11|||2023-05-10|2018-12-11|2018-12-13|Actual|||||||2023-05-10|2023-05-11|Actual|June 22, 2020|Actual|2020-06-22|May 2023|2023-05-31|March 2035|Anticipated|2035-03-31|April 2024|Anticipated|2024-04-30||Interventional|||CD19.CAR Allogeneic NKT for Patients With Relapsed or Refractory B-Cell Malignancies (ANCHOR)|Allogeneic Natural Killer T-Cells Expressing CD19 Specific Chimeric Antigen Receptor and Interleukin-15 in Relapsed or Refractory B-Cell Malignancies|Recruiting||Phase 1|48|Anticipated|Baylor College of Medicine||2|||f||||t|t|f|||f||||||||2023-09-01 02:32:06.064942|2023-09-01 02:32:06.064942|OTHER|||||
NCT01192464||2010-08-16|||2023-01-18|2010-08-31|2010-09-01|Estimate|||||||2023-01-18|2023-01-20|Actual|May 10, 2011|Actual|2011-05-10|January 2023|2023-01-31|October 2033|Anticipated|2033-10-31|May 29, 2012|Actual|2012-05-29||Interventional|CARCD30||EBV CTLs Expressing CD30 Chimeric Receptors For CD 30+ Lymphoma|Phase I Study of the Administration of EBV CTLs Expressing CD30 Chimeric Receptors for Relapsed CD30+ Hodgkin's Lymphoma and CD30+ Non-Hodgkin's Lymphoma (CAR CD 30)|Active, not recruiting||Phase 1|18|Anticipated|Baylor College of Medicine||1|||f||||t|t|f|||||||||||2023-09-03 23:12:17.578416|2023-09-03 23:12:17.578416|OTHER|||||
NCT03879382||2019-03-15|||2021-08-05|2019-03-15|2019-03-18|Actual|||||||2021-08-05|2021-08-06|Actual|February 27, 2019|Actual|2019-02-27|August 2021|2021-08-31|May 30, 2022|Anticipated|2022-05-30|August 30, 2020|Actual|2020-08-30||Interventional|||Anti-CD19/BCMA Bispecific CAR-T Cell Therapy for R/R POMES|A Phase I Clinical Trial of Human CD19/BCMA Bispecific CAR-T Cell Therapy for Subjects With Relapsed and Refractory POMES Syndrome.|Unknown status|Active, not recruiting|Phase 1|10|Anticipated|Hrain Biotechnology Co., Ltd.||1|||f||||t|f|f|||||||||No||2023-09-03 08:52:33.524214|2023-09-03 08:52:33.524214|INDUSTRY|||||
NCT03671460||2018-09-11|||2018-09-13|2018-09-13|2018-09-14|Actual|||||||2018-09-13|2018-09-14|Actual|September 7, 2018|Anticipated|2018-09-07|September 2018|2018-09-30|January 1, 2021|Anticipated|2021-01-01|January 1, 2020|Anticipated|2020-01-01||Interventional|||CD19 CAR-T Cells for Patients With Relapse and Refractory CD19+ B-ALL.|Phase I Study of the Safety and Efficacy of CD19 CAR-T Cells in Patients With Relapsed or Refractory Acute B-cell Lymphoblastic Leukemia (R/R B-ALL)|Unknown status|Recruiting|Phase 1|18|Anticipated|Tianjin Mycure Medical Technology Co., Ltd||1|||f||||f|f|f|||||||||Undecided|We don't decide when to share IPD and what will be shared.|2023-09-03 23:26:42.423397|2023-09-03 23:26:42.423397|INDUSTRY|||||
NCT05179603||2021-12-16|||2023-02-20|2021-12-16|2022-01-05|Actual|||||||2023-02-20|2023-02-21|Actual|December 7, 2021|Actual|2021-12-07|February 2023|2023-02-28|September 15, 2024|Anticipated|2024-09-15|September 14, 2023|Anticipated|2023-09-14||Interventional|||A Study of SAR444245 With or Without Other Anticancer Therapies for the Treatment of Adults and Adolescents With Relapsed or Refractory B Cell Lymphoma (Master Protocol) [Pegathor Lymphoma 205]|Phase 2 Non-randomized, Open-label, Multi-cohort, Multicenter Study Assessing the Clinical Benefit of SAR444245 (THOR-707) With or Without Other Anticancer Therapies for the Treatment of Adults and Adolescents With Relapsed or Refractory B Cell Lymphoma|Active, not recruiting||Phase 2|50|Anticipated|Sanofi||2|||f||||t|t|f|||t||||||Yes|Qualified researchers may request access to patient level data and related study documents including the clinical study report, study protocol with any amendments, blank case report form, statistical analysis plan, and dataset specifications. Patient level data will be anonymized and study documents will be redacted to protect the privacy of trial participants. Further details on Sanofi's data sharing criteria, eligible studies, and process for requesting access can be found at: https://vivli.org|2023-09-04 19:12:54.13853|2023-09-04 19:12:54.13853|INDUSTRY|||||
NCT03283631||2017-09-13|||2021-04-01|2017-09-13|2017-09-14|Actual|||||||2021-04-01|2021-04-05|Actual|May 30, 2018|Actual|2018-05-30|April 2021|2021-04-30|June 30, 2020|Actual|2020-06-30|September 19, 2019|Actual|2019-09-19||Interventional|INTERCEPT||Intracerebral EGFR-vIII CAR-T Cells for Recurrent GBM|INTERCEPT: INTracerebral EGFR-vIII Chimeric Antigen Receptor Gene-Modified T CElls for PaTients With Recurrent GBM|Terminated||Phase 1|2|Actual|Duke University||1||We are halting enrollment of this study.|f||||f|t|f|||||||||||2023-09-04 19:13:12.259693|2023-09-04 19:13:12.259693|OTHER|||||
NCT03464916||2018-02-14|||2022-03-14|2018-03-07|2018-03-14|Actual|||||||2022-03-14|2022-03-16|Actual|October 15, 2018|Actual|2018-10-15|March 2022|2022-03-31|February 28, 2022|Actual|2022-02-28|August 23, 2020|Actual|2020-08-23||Interventional|||Study to Evaluate the Safety and Efficacy of Anti-CD38 CAR-T in Relapsed or Refractory Multiple Myeloma Patients|A Phase 1, Open-Label, Dose-Escalation, Pharmacokinetic, and Pharmacodynamic Study of the Safety and Efficacy of CAR2 Anti-CD38 A2 CAR-T Cells in Patients With Relapsed or Refractory Multiple Myeloma|Completed||Phase 1|10|Actual|Sorrento Therapeutics, Inc.||1|||f|||||t|f|||||||||No||2023-09-03 23:31:24.295342|2023-09-03 23:31:24.295342|INDUSTRY|||||
NCT03661554||2018-09-03|||2018-09-06|2018-09-06|2018-09-07|Actual|||||||2018-09-06|2018-09-10|Actual|April 10, 2018|Actual|2018-04-10|September 2018|2018-09-30|November 30, 2018|Anticipated|2018-11-30|October 30, 2018|Anticipated|2018-10-30||Interventional|BCMA CAR-T||BCMA Nano Antibody CAR-T Cells for Patients With Refractory and Relapsed Multiple Myeloma|BCMA Nano Antibody CAR-T Cells for the Treatment of Refractory Relapsed Multiple ,Single Center, Single Arm and Open Clinical Study of Myeloma|Unknown status|Recruiting|Early Phase 1|15|Anticipated|The Pregene (ShenZhen) Biotechnology Company, Ltd.||1|||f||||f|f|f|||||||||Undecided||2023-09-03 23:33:25.553068|2023-09-03 23:33:25.553068|INDUSTRY|||||
NCT03267173||2017-08-27|||2017-08-27|2017-08-27|2017-08-30|Actual|||||||2017-08-27|2017-08-30|Actual|June 15, 2017|Actual|2017-06-15|August 2017|2017-08-31|June 2019|Anticipated|2019-06-30|June 2019|Anticipated|2019-06-30||Interventional|||Evaluate the Safety and Efficacy of CAR-T in the Treatment of Pancreatic Cancer.|Evaluate the Safety and Efficacy of Chimeric Antigen Receptor Engineered T Cell Immunotherapy (CAR-T) in the Treatment of Pancreatic Cancer in a Single Center, Non Controlled Clinical Study.|Unknown status|Recruiting|Early Phase 1|10|Anticipated|First Affiliated Hospital of Harbin Medical University||1|||f||||t|f|f|||||||||No||2023-09-04 19:14:48.463441|2023-09-04 19:14:48.463441|OTHER|||||
NCT03758417||2018-11-27|||2022-12-27|2018-11-27|2018-11-29|Actual|||||||2022-12-27|2022-12-28|Actual|January 23, 2019|Actual|2019-01-23|December 2022|2022-12-31|February 16, 2026|Anticipated|2026-02-16|February 16, 2026|Anticipated|2026-02-16||Interventional|CARTIFAN-1||A Study of LCAR-B38M CAR-T Cells, a Chimeric Antigen Receptor T-cell (CAR-T) Therapy Directed Against B-cell Maturation Antigen (BCMA) in Chinese Participants With Relapsed or Refractory Multiple Myeloma|A Phase 2, Open-Label Study of LCAR-B38M CAR-T Cells, a Chimeric Antigen Receptor T-cell (CAR-T) Therapy Directed Against BCMA in Chinese Subjects With Relapsed or Refractory Multiple Myeloma|Recruiting||Phase 2|130|Anticipated|Nanjing Legend Biotech Co.||1|||f||||f|t|f|||t||||||||2023-09-03 23:38:33.905781|2023-09-03 23:38:33.905781|INDUSTRY|||||
NCT03318861||2017-10-13|2020-05-06||2022-10-04|2017-10-20|2017-10-24|Actual|2020-05-06|2020-05-26|Actual||||2022-10-04|2022-10-28|Actual|October 20, 2017|Actual|2017-10-20|October 2022|2022-10-31|September 16, 2022|Actual|2022-09-16|May 19, 2019|Actual|2019-05-19||Interventional||The Full Analysis Set included all participants who were enrolled in the study.|Study to Evaluate the Safety and Efficacy of KITE-585 in Participants With Relapsed/Refractory Multiple Myeloma|A Phase 1 Multicenter Study of KITE-585, an Autologous Anti-BCMA CAR T-Cell Therapy, in Subjects With Relapsed/Refractory Multiple Myeloma|Terminated||Phase 1|17|Actual|Gilead Sciences||5||The study was terminated due to lack of efficacy|f||||f|t|f|||||||||No||2023-09-03 23:40:15.678503|2023-09-03 23:40:15.678503|INDUSTRY|||||
NCT05420493||2022-06-12|||2022-06-14|2022-06-12|2022-06-15|Actual|||||||2022-06-14|2022-06-16|Actual|September 6, 2021|Actual|2021-09-06|June 2022|2022-06-30|September 30, 2024|Anticipated|2024-09-30|September 30, 2023|Anticipated|2023-09-30||Interventional|||Clinical Study of Chimeric Antigen Receptor T Lymphocytes (CAR-T) in the Treatment of Relapsed/Refractory Non-Hodgkin Lymphoma|This is a Phase I Clinical Study to Evaluate the Safety and Efficacy of CAR-T Infusion Preparation in the Treatment of CD19-positive Relapsed/Refractory Non-Hodgkin Lymphoma.|Recruiting||Phase 1|54|Anticipated|Chongqing Precision Biotech Co., Ltd||1|||f|||||f|f|||||||||||2023-09-03 23:41:20.899115|2023-09-03 23:41:20.899115|INDUSTRY|||||
NCT03258047||2017-08-20|||2019-02-13|2017-08-21|2017-08-22|Actual|||||||2019-02-13|2019-02-15|Actual|September 15, 2017|Actual|2017-09-15|February 2019|2019-02-28|July 30, 2019|Anticipated|2019-07-30|January 13, 2019|Actual|2019-01-13||Interventional|||Novel Autologou CAR-T Therapy for Relapsed/Refractory B Cell Lymphoma|Novel Autologou CAR-T Therapy for Relapsed/Refractory B Cell Lymphoma|Unknown status|Active, not recruiting|Phase 2|60|Anticipated|First Affiliated Hospital of Zhejiang University||1|||f|||||f|f|||||||||Yes|All the data would be available on the corresponding website of the leading research center.|2023-09-04 19:15:46.422544|2023-09-04 19:15:46.422544|OTHER|||||
NCT03984968||2019-06-11|||2023-04-03|2019-06-11|2019-06-13|Actual|||||||2023-04-03|2023-04-04|Actual|January 1, 2018|Actual|2018-01-01|April 2023|2023-04-30|June 30, 2024|Anticipated|2024-06-30|December 31, 2023|Anticipated|2023-12-31||Interventional|||CD19 CAR-T Consolidation Therapy for Acute Lymphoblastic Leukemia|Evaluation of Safety and Efficacy of CD19 CAR-T Consolidation Therapy for Acute Lymphoblastic Leukemia Concomitant With Infusion of CD19+T Cells as Feeding Cells|Recruiting||Phase 1/Phase 2|27|Anticipated|The First Affiliated Hospital of Soochow University||1|||f|||||f|f|||||||||No||2023-09-03 23:44:28.985879|2023-09-03 23:44:28.985879|OTHER|||||
NCT05350787||2022-04-09|||2022-04-26|2022-04-26|2022-04-28|Actual|||||||2022-04-26|2022-04-28|Actual|March 18, 2022|Actual|2022-03-18|April 2022|2022-04-30|April 30, 2024|Anticipated|2024-04-30|March 30, 2024|Anticipated|2024-03-30||Interventional|||Evaluate the Safety, Efficacy and Pharmacokinetics of ThisCART19A in Patients With R/R B-ALL|To Evaluate the Safety, Efficacy and Pharmacokinetics of ThisCART19A in Patients With Relapsed and Refractory Acute B-cell Leukemia|Recruiting||Phase 1|16|Anticipated|Zhejiang University||3|||f|||||f|f|||||||||||2023-09-03 06:46:27.895626|2023-09-03 06:46:27.895626|OTHER|||||
NCT04966143||2021-07-12|||2021-07-15|2021-07-15|2021-07-19|Actual|||||||2021-07-15|2021-07-19|Actual|August 1, 2021|Anticipated|2021-08-01|July 2021|2021-07-31|August 1, 2024|Anticipated|2024-08-01|August 1, 2023|Anticipated|2023-08-01||Interventional|||Clinical Study of LY011 in the Treatment of Advanced Pancreatic Cancer|A Study of CLDN18.2 Chimeric Antigen Receptor T Cells in the Treatment of Advanced Pancreatic Cancer|Recruiting||Early Phase 1|30|Anticipated|Shanghai Longyao Biotechnology Inc., Ltd.||1|||f|||||f|f|||||||||||2023-09-04 19:17:25.754125|2023-09-04 19:17:25.754125|OTHER|||||
NCT04384393||2020-05-06|||2021-12-20|2020-05-08|2020-05-12|Actual|||||||2021-12-20|2022-01-11|Actual|May 9, 2020|Actual|2020-05-09|December 2021|2021-12-31|October 24, 2023|Anticipated|2023-10-24|November 10, 2022|Anticipated|2022-11-10||Interventional|||Safety and Efficacy of ThisCART19 in Patients With Refractory or Relapsed B Cell Malignancies|A Study to Evaluate the Safety and Clinical Activity of Allogeneic Chimeric Antigen Receptor T Cells Targeting CD19 in Patients With Refractory or Relapsed B Cell Malignancies.|Recruiting||Phase 1|30|Anticipated|Fundamenta Therapeutics, Ltd.||1|||f||||f|f|f|||||||||No||2023-09-03 23:57:49.605753|2023-09-03 23:57:49.605753|INDUSTRY|||||
NCT04008251||2019-07-01|||2019-08-05|2019-07-02|2019-07-05|Actual|||||||2019-08-05|2019-08-07|Actual|May 27, 2019|Actual|2019-05-27|July 2019|2019-07-31|December 31, 2022|Anticipated|2022-12-31|July 1, 2022|Anticipated|2022-07-01||Interventional|||Humanized CD19 Chimeric Antigen Receptor (CAR)-Modified T Cell Therapy in Treating Patients With B-cell Malignancies|Treatment of Relapsed or Refractory B-cell Malignancies by Humanized CD19 Chimeric Antigen Receptor (CAR)-Modified T Cells|Unknown status|Recruiting|Phase 1|10|Anticipated|Wuhan Sian Medical Technology Co., Ltd||1|||f||||f|f|f|||||||||No||2023-09-03 06:50:48.17743|2023-09-03 06:50:48.17743|INDUSTRY|||||
NCT04176913||2019-11-18|||2021-12-17|2019-11-22|2019-11-25|Actual|||||||2021-12-17|2022-01-10|Actual|December 1, 2020|Actual|2020-12-01|December 2021|2021-12-31|December 9, 2021|Actual|2021-12-09|December 9, 2021|Actual|2021-12-09||Interventional|||Study of LUCAR-20S in Patients With R/R NHL|A Study Evaluating the Safety, Tolerability, and Pharmacokinetics of LUCAR-20S in Patients With Relapsed/Refractory Diffuse Large B-Cell, Follicular, Mantle Cell or Small Lymphocytic Lymphoma|Terminated||Phase 1|7|Actual|The First Affiliated Hospital with Nanjing Medical University||1||Both the sponsors and collaborator are considering terminating the study|f|||||f|f|||||||||||2023-09-04 00:00:22.068969|2023-09-04 00:00:22.068969|OTHER|||||
NCT04011293||2019-07-03|||2019-07-04|2019-07-04|2019-07-08|Actual|||||||2019-07-04|2019-07-08|Actual|July 2019|Anticipated|2019-07-31|July 2019|2019-07-31|April 2022|Anticipated|2022-04-30|July 2020|Anticipated|2020-07-31||Interventional|||A Clinical Study of Anti-CD19 Chimeric Antigen Receptor T-Cell Injection (CNCT19) in the Treatment of Cluster of Differentiation 19 (CD19) Positive Relapsed or Refractory B Cell Malignancies|A Clinical Study of CNCT19 Cells in the Treatment of CD19 Positive Relapsed or Refractory B Cell Malignancies|Unknown status|Recruiting|Early Phase 1|20|Anticipated|Shandong University||1|||f|||||f|f|||||||||||2023-09-03 06:51:24.099407|2023-09-03 06:51:24.099407|OTHER|||||
NCT01355965||2011-05-17|||2017-09-16|2011-05-18|2011-05-19|Estimate|||||||2017-09-16|2017-09-19|Actual|May 2011||2011-05-31|September 2017|2017-09-30|October 2015|Actual|2015-10-31|July 2015|Actual|2015-07-31||Interventional|||Autologous Redirected RNA Meso-CIR T Cells|Phase 1 Clinical Trial of Autologous Mesothelin Re-Directed T Cells Administered Intravenously in Patients With Progressive Malignant Pleural Mesothelioma|Completed||Phase 1|18|Actual|University of Pennsylvania||2|||f||||t|||||||||||||2023-09-04 00:15:40.556889|2023-09-04 00:15:40.556889|OTHER|||||
NCT03952923||2019-02-25|||2022-01-28|2019-05-15|2019-05-16|Actual|||||||2022-01-28|2022-02-01|Actual|August 1, 2019|Actual|2019-08-01|August 2020|2020-08-31|March 31, 2021|Actual|2021-03-31|January 1, 2021|Actual|2021-01-01||Interventional|||CD19-CAR-T in B-cell Malignancies Patients|CD19-CAR-T for Patients With B Cell Malignancies|Completed||Phase 1|11|Actual|Hebei Yanda Ludaopei Hospital||1|||f||||t|f|f|||||||||||2023-09-04 00:26:35.884425|2023-09-04 00:26:35.884425|OTHER|||||
NCT04430595||2020-06-09|||2020-06-10|2020-06-10|2020-06-12|Actual|||||||2020-06-10|2020-06-12|Actual|June 1, 2020|Anticipated|2020-06-01|June 2020|2020-06-30|December 31, 2023|Anticipated|2023-12-31|May 31, 2023|Anticipated|2023-05-31||Interventional|||Multi-4SCAR-T Therapy Targeting Breast Cancer|Multiple 4SCAR-T Cell Therapy Targeting Breast Cancer|Recruiting||Phase 1/Phase 2|100|Anticipated|Shenzhen Geno-Immune Medical Institute||1|||f||||f|f|f|||||||||No||2023-09-04 19:25:44.05347|2023-09-04 19:25:44.05347|OTHER|||||
NCT05665725||2022-12-16|||2023-03-08|2022-12-16|2022-12-27|Actual|||||||2023-03-08|2023-03-09|Actual|January 31, 2023|Actual|2023-01-31|March 2023|2023-03-31|December 31, 2025|Anticipated|2025-12-31|December 31, 2024|Anticipated|2024-12-31||Interventional|||Siltuximab for the Prevention of CAR T Cell Related Cytokine Release Syndrome in Patients With CD19 Positive Non-Hodgkin Lymphoma|Phase I Study of Cytokine Release Syndrome Prophylaxis and Treatment With Siltuximab|Recruiting||Phase 1|10|Anticipated|Ohio State University Comprehensive Cancer Center||1|||||||t|t|f|||||||||No||2023-09-04 00:29:49.420705|2023-09-04 00:29:49.420705|OTHER|||||
NCT05648019||2022-08-01|||2023-03-07|2022-12-04|2022-12-13|Actual|||||||2023-03-07|2023-03-09|Actual|March 15, 2022|Actual|2022-03-15|March 2023|2023-03-31|December 2026|Anticipated|2026-12-31|December 2025|Anticipated|2025-12-31||Interventional|||CD19-Directed Chimeric Antigen Receptor (CAR) T-Cell Therapy for Relapsed/Refractory B-Lineage Leukaemia / Lymphoma - A Feasibility Protocol|CD19-Directed Chimeric Antigen Receptor (CAR) T-Cell Therapy for Relapsed/Refractory B-Lineage Leukaemia / Lymphoma - A Feasibility Protocol|Recruiting||Phase 2|40|Anticipated|KK Women's and Children's Hospital||1|||f||||f|f|f|||||||||Undecided||2023-09-04 00:30:52.592284|2023-09-04 00:30:52.592284|OTHER_GOV|||||
NCT04657861||2020-10-22|||2022-05-03|2020-12-05|2020-12-08|Actual|||||||2022-05-03|2022-05-09|Actual|May 3, 2022|Actual|2022-05-03|March 2022|2022-03-31|August 20, 2027|Anticipated|2027-08-20|August 20, 2024|Anticipated|2024-08-20||Interventional|||APRIL CAR-T Cell Therapy for Patients With BCMA/TACI Positive Relapsed and/or Refractory Multiple Myeloma|Clinical Trial for the Safety and Efficacy of APRIL CAR-T Cells Therapy for Patients With BCMA/TACI Positive Relapsed and/or Refractory Multiple Myeloma|Recruiting||Early Phase 1|36|Anticipated|Zhejiang University||1|||f||||t|f|f|||||||||No||2023-09-04 00:35:32.711198|2023-09-04 00:35:32.711198|OTHER|||||
NCT03605238||2018-06-29|||2019-09-17|2018-07-21|2018-07-30|Actual|||||||2019-09-17|2019-09-19|Actual|August 15, 2018|Anticipated|2018-08-15|August 2019|2019-08-31|August 15, 2020|Anticipated|2020-08-15|August 15, 2019|Anticipated|2019-08-15||Interventional|||Treatment of Relapsed and/or Refractory AQP4-IgG Seropositive NMOSD by Tandem CAR T Cells Targeting CD19 and CD20|Clinical Study of CD19/CD20 tanCAR T Cells in Relapsed and/or Refractory AQP4-IgG Seropositive Neuromyelitis Optica Spectrum Disorders (NMOSD)|Withdrawn||Phase 1|0|Actual|Chinese PLA General Hospital||1||It was hard to recruit patients|f||||f|f|f|||||||||No||2023-09-04 00:38:24.215322|2023-09-04 00:38:24.215322|OTHER|||||
NCT04204161||2019-12-13|||2021-02-03|2019-12-17|2019-12-18|Actual|||||||2021-02-03|2021-02-04|Actual|October 8, 2019|Actual|2019-10-08|February 2021|2021-02-28|October 8, 2024|Anticipated|2024-10-08|October 30, 2021|Anticipated|2021-10-30||Interventional|||A Clinical Study of CAR-T Cells Treatment for Children With CD19+/CD22+ R/R ALL and Lymphoma|A Clinical Study Evaluating the Safety and Efficacy of CAR-T19/CAR-T22 Treatment for Children With CD19 Positive Relapse or Refractory Childhood Acute Lymphoblastic Leukemia and Lymphoma|Recruiting||Phase 1|30|Anticipated|Shenzhen BinDeBio Ltd.||1|||f||||t|f|f|||||||||No||2023-09-02 11:39:12.132405|2023-09-02 11:39:12.132405|INDUSTRY|||||
NCT04864821||2021-04-25|||2021-04-30|2021-04-25|2021-04-29|Actual|||||||2021-04-30|2021-05-06|Actual|May 14, 2021|Anticipated|2021-05-14|April 2021|2021-04-30|May 14, 2023|Anticipated|2023-05-14|May 14, 2022|Anticipated|2022-05-14||Interventional|||Clinical Study of CD276 Targeted Autologous Chimeric Antigen Receptor T Cell Infusion in Patients With CD276 Positive Advanced Solid Tumor|Clinical Study of CD276 Targeted Autologous Chimeric Antigen Receptor T Cell Infusion in Patients With CD276 Positive Advanced Solid Tumor|Unknown status|Not yet recruiting|Early Phase 1|24|Anticipated|PersonGen BioTherapeutics (Suzhou) Co., Ltd.||1|||f||||f|f|f|||f||||||No||2023-09-04 19:28:17.153065|2023-09-04 19:28:17.153065|INDUSTRY|||||
NCT04083495||2019-09-05|||2023-04-11|2019-09-05|2019-09-10|Actual|||||||2023-04-11|2023-04-13|Actual|September 17, 2019|Actual|2019-09-17|April 2023|2023-04-30|August 2038|Anticipated|2038-08-31|February 23, 2028|Anticipated|2028-02-23||Interventional|||CD30 CAR for Relapsed/Refractory CD30+ T Cell Lymphoma|Phase II Study of the Administration of T Lymphocytes Expressing the CD30 Chimeric Antigen Receptor (CAR) for Relapsed/Refractory CD30+ Peripheral T Cell Lymphoma|Recruiting||Phase 2|20|Anticipated|UNC Lineberger Comprehensive Cancer Center||1|||f||||t|t|f|||||||||No||2023-09-04 00:46:52.740855|2023-09-04 00:46:52.740855|OTHER|||||
NCT03873805||2019-03-11|||2023-08-03|2019-03-12|2019-03-13|Actual|||||||2023-08-03|2023-08-04|Actual|August 20, 2019|Actual|2019-08-20|August 2023|2023-08-31|December 31, 2023|Anticipated|2023-12-31|August 19, 2022|Actual|2022-08-19||Interventional|||PSCA-CAR T Cells in Treating Patients With PSCA+ Metastatic Castration Resistant Prostate Cancer|A Phase I Study to Evaluate PSCA-Targeting Chimeric Antigen Receptor (CAR)-T Cells for Patients With PSCA+ Metastatic Castration Resistant Prostate Cancer|Active, not recruiting||Phase 1|15|Actual|City of Hope Medical Center||1|||||||t|t|f|||f||||||||2023-09-04 00:47:20.109044|2023-09-04 00:47:20.109044|OTHER|||||
NCT03648372||2018-08-24|||2023-04-12|2018-08-24|2018-08-27|Actual|||||||2023-04-12|2023-04-13|Actual|October 1, 2018|Actual|2018-10-01|April 2023|2023-04-30|October 2, 2024|Anticipated|2024-10-02|April 4, 2024|Anticipated|2024-04-04||Interventional|||A Study of TAK-981 in People With Advanced Solid Tumors or Cancers in the Immune System|An Open Label, Dose-Escalation, Phase 1/2 Study to Evaluate the Safety, Tolerability, Preliminary Efficacy and Pharmacokinetics of TAK-981 in Adult Patients With Advanced or Metastatic Solid Tumors or Relapsed/Refractory Hematologic Malignancies|Active, not recruiting||Phase 1/Phase 2|202|Anticipated|Takeda||7|||f||||t|t|f|||||||IPD from eligible studies will be shared with qualified researchers according to the criteria and process described on https://vivli.org/ourmember/takeda/. For approved requests, the researchers will be provided access to anonymized data (to respect patient privacy in line with applicable laws and regulations) and with information necessary to address the research objectives under the terms of a data sharing agreement.|https://vivli.org/ourmember/takeda/|Yes|Takeda provides access to the de-identified individual participant data (IPD) for eligible studies to aid qualified researchers in addressing legitimate scientific objectives (Takeda's data sharing commitment is available on https://clinicaltrials.takeda.com/takedas-commitment?commitment=5). These IPDs will be provided in a secure research environment following approval of a data sharing request, and under the terms of a data sharing agreement.|2023-09-04 00:47:36.284632|2023-09-04 00:47:36.284632|INDUSTRY|||||
NCT02132624||2014-05-05|||2017-10-27|2014-05-05|2014-05-07|Estimate|||||||2017-10-27|2017-10-30|Actual|April 2014||2014-04-30|October 2017|2017-10-31|May 31, 2017|Actual|2017-05-31|May 31, 2017|Actual|2017-05-31||Interventional|||CD19-targeting 3rd Generation CAR T Cells for Refractory B Cell Malignancy - a Phase I/IIa Trial.|CD19-targeting 3rd Generation CAR T Cells for Refractory B Cell Malignancy - a Phase I/IIa Trial.|Completed||Phase 1/Phase 2|15|Actual|Uppsala University||1|||f||||t|||||||||||||2023-09-04 00:50:17.833186|2023-09-04 00:50:17.833186|OTHER|||||
NCT05370547||2022-05-07|||2022-06-09|2022-05-07|2022-05-11|Actual|||||||2022-06-09|2022-06-13|Actual|May 25, 2022|Actual|2022-05-25|June 2022|2022-06-30|June 30, 2025|Anticipated|2025-06-30|June 30, 2024|Anticipated|2024-06-30||Interventional|||Chidamide Bridging for CAR-T Therapy|A Multiple Center Study on NOXA Expression-guided Randomized Chidamide Bridging Intervention in CAR-T Treated NHL Patients|Recruiting||Phase 1/Phase 2|120|Anticipated|Chinese PLA General Hospital||3|||f||||t|f|f|||f||||||No||2023-09-04 00:50:42.076519|2023-09-04 00:50:42.076519|OTHER|||||
NCT02134262||2014-04-16|||2014-11-04|2014-05-07|2014-05-09|Estimate|||||||2014-11-04|2014-11-06|Estimate|May 2014||2014-05-31|November 2014|2014-11-30|March 2017|Anticipated|2017-03-31|March 2017|Anticipated|2017-03-31||Interventional|||Gene Therapy for B-Cell Non-Hodgkin Lymphoma Using CD19 CAR Gene Transduced T Lymphocytes|Clinical Research of Gene Therapy for Refractory B-Cell Non-Hodgkin Lymphoma Using Autologous T Cells Expressing a Chimeric Antigen Receptor Specific to the CD19 Antigen|Unknown status|Recruiting|Phase 1/Phase 2|18|Anticipated|Jichi Medical University||4|||f||||t|||||||||||||2023-09-04 00:51:51.944379|2023-09-04 00:51:51.944379|OTHER|||||
NCT03579888||2018-06-25|||2021-05-28|2018-07-05|2018-07-09|Actual|||||||2021-05-28|2021-06-02|Actual|June 26, 2020|Actual|2020-06-26|May 2021|2021-05-31|May 27, 2021|Actual|2021-05-27|May 27, 2021|Actual|2021-05-27||Interventional|||CD19-Specific T Cells Post AlloSCT|Donor-Derived Very-Rapid Manufactured CD19-Specific T Cells for Lymphoid Malignancies After Allogeneic Hematopoietic Stem-Cell Transplantation|Terminated||Phase 1|4|Actual|M.D. Anderson Cancer Center||1||Study halted prematurely|||||t|t|f|||||||||||2023-09-04 00:54:59.958453|2023-09-04 00:54:59.958453|OTHER|||||
NCT05190185||2021-12-29|||2021-12-29|2021-12-29|2022-01-13|Actual|||||||2021-12-29|2022-01-13|Actual|June 1, 2021|Actual|2021-06-01|December 2021|2021-12-31|December 1, 2023|Anticipated|2023-12-01|December 1, 2023|Anticipated|2023-12-01||Interventional|||A Clinical Trial of TAA06 Injection in Advanced Solid Tumors|A Clinical Trial of TAA06 Injection in Advanced Solid Tumors|Recruiting||Phase 1|18|Anticipated|PersonGen BioTherapeutics (Suzhou) Co., Ltd.||1|||f|||||f|f|||||||||||2023-09-04 01:00:14.037881|2023-09-04 01:00:14.037881|INDUSTRY|||||
NCT03181126||2017-06-05|||2021-10-07|2017-06-07|2017-06-08|Actual|||||||2021-10-07|2021-10-14|Actual|November 27, 2017|Actual|2017-11-27|October 2021|2021-10-31|November 14, 2020|Actual|2020-11-14|November 11, 2020|Actual|2020-11-11||Interventional|||A Study of Venetoclax in Combination With Navitoclax and Chemotherapy in Subjects With Relapsed/Refractory Acute Lymphoblastic Leukemia or Relapsed/Refractory Lymphoblastic Lymphoma|A Phase 1 Dose Escalation, Open-Label Study of Venetoclax in Combination With Navitoclax and Chemotherapy in Subjects With Relapsed/Refractory Acute Lymphoblastic Leukemia or Relapsed/Refractory Lymphoblastic Lymphoma|Completed||Phase 1|69|Actual|AbbVie||1|||t||||f|t|f|||f||||||Undecided||2023-09-04 01:06:10.632607|2023-09-04 01:06:10.632607|INDUSTRY||NCT03123029|Available||
NCT05391490||2022-05-16|||2022-05-20|2022-05-20|2022-05-26|Actual|||||||2022-05-20|2022-05-26|Actual|October 2022|Anticipated|2022-10-31|May 2022|2022-05-31|November 2034|Anticipated|2034-11-30|November 2024|Anticipated|2024-11-30||Interventional|KCAT19||Allogeneic T Cells Expressing T Cell Receptor-KDEL and the Chimeric Antigen Receptor CAT19 for the Treatment of Advanced CD19+ Malignancies|Allogeneic T Cells Expressing T Cell Receptor-KDEL and the Chimeric Antigen Receptor CAT19 for the Treatment of Advanced CD19+ Malignancies|Not yet recruiting||Phase 1|12|Anticipated|University College, London||1|||f||||t|f|f|||||||||No||2023-09-04 01:08:29.419128|2023-09-04 01:08:29.419128|OTHER|||||
NCT05085418||2021-10-11|||2021-10-11|2021-10-11|2021-10-20|Actual|||||||2021-10-11|2021-10-20|Actual|November 5, 2021|Anticipated|2021-11-05|October 2021|2021-10-31|November 5, 2024|Anticipated|2024-11-05|November 5, 2024|Anticipated|2024-11-05||Interventional|||A Study of CD19/BCMA Chimeric Antigen Receptor T Cells Therapy for Patients With Refractory Immune Nephritis|A Study of CD19/BCMA Chimeric Antigen Receptor T Cells Therapy for Patients With Refractory Immune Nephritis|Recruiting||Early Phase 1|9|Anticipated|Zhejiang University||1|||f||||t|f|f|||||||||||2023-09-04 01:09:18.48813|2023-09-04 01:09:18.48813|OTHER|||||
NCT03068416||2017-02-21|||2021-10-14|2017-02-24|2017-03-01|Actual|||||||2021-10-14|2021-10-20|Actual|September 18, 2017|Actual|2017-09-18|October 2021|2021-10-31|August 19, 2021|Actual|2021-08-19|August 19, 2021|Actual|2021-08-19||Interventional|||CD19-targeting, 3rd Generation CAR T Cells for Refractory B Cells Malignancy|CD19-targeting, 3rd Generation CAR T Cells for Refractory B Cells Malignancy - a Phase II Trial.|Completed||Phase 2|24|Actual|Uppsala University||1|||f||||f|f|f|||||||||||2023-09-04 01:09:45.108211|2023-09-04 01:09:45.108211|OTHER|||||
NCT04853277||2021-04-13|||2021-04-16|2021-04-16|2021-04-21|Actual|||||||2021-04-16|2021-04-21|Actual|February 7, 2021|Actual|2021-02-07|April 2021|2021-04-30|February 2023|Anticipated|2023-02-28|February 2023|Anticipated|2023-02-28||Interventional|||Patient Reported Outcomes and Patient Education in Cellular Therapy Patients|Effect of Patient Education Regarding Emotional Stressors on Patient Reported Outcomes in Patients Undergoing Cellular Therapy (HSCT or CAR-T)|Unknown status|Recruiting|Not Applicable|30|Anticipated|Dartmouth-Hitchcock Medical Center||1|||f||||f|f|f|||||||||No|At this time there are no plans to share IPD.|2023-09-04 19:35:49.196461|2023-09-04 19:35:49.196461|OTHER|||||
NCT04443829||2020-06-18|||2023-06-21|2020-06-19|2020-06-23|Actual|||||||2023-06-21|2023-06-22|Actual|March 23, 2021|Actual|2021-03-23|June 2023|2023-06-30|December 2032|Anticipated|2032-12-31|December 2024|Anticipated|2024-12-31||Interventional|CAROUSEL||Immunotherapy Using CAR T-cells to Target CD19 for Relapsed/Refractory CD19+ Primary CNS Lymphoma|Immunotherapy Using CAR T-cells to Target CD19 for Relapsed/Refractory CD19+ Primary Central Nervous System (CNS) Lymphoma|Active, not recruiting||Phase 1|12|Anticipated|University College, London||1|||f||||t|f|f|||||||||No||2023-09-04 01:14:30.908282|2023-09-04 01:14:30.908282|OTHER|||||
NCT02728882||2016-03-29|||2017-03-21|2016-04-04|2016-04-05|Estimate|||||||2017-03-21|2017-03-23|Actual|July 2, 2015|Actual|2015-07-02|March 2017|2017-03-31|July 2019|Anticipated|2019-07-31|July 2019|Anticipated|2019-07-31||Interventional|EECBL||Study Evaluating the Efficacy and Safety With CAR-T for Recurrent or Refractory Diffuse Large B Cell Lymphoma|Single Arm, Two Phase, Multicenter Clinical Trial to Evaluating the Efficacy and Safety of the CAR-T for Recurrent or Refractory Diffuse Large B Cell Lymphoma|Unknown status|Recruiting|Not Applicable|24|Anticipated|Sinobioway Cell Therapy Co., Ltd.||1|||f||||f|f|f|||||||||No|No plans to share data.|2023-09-02 11:46:16.634079|2023-09-02 11:46:16.634079|INDUSTRY|||||
NCT05020392||2021-08-19|||2023-07-23|2021-08-19|2021-08-25|Actual|||||||2023-07-23|2023-07-25|Actual|September 14, 2021|Actual|2021-09-14|July 2023|2023-07-31|October 13, 2024|Anticipated|2024-10-13|October 13, 2023|Anticipated|2023-10-13||Interventional|||Autologous Cells Derived Anti-CD19 CAR-Engineered T Cells With Concurrent BTK Inhibitor for B Cell Lymphoma|Efficacy and Safety of Autologous Cells Derived Anti-CD19 CAR-Engineered T Cells With Concurrent BTK Inhibitor for B Cell Lymphoma：a Single-center, Open-label, Pragmatic Clinical Trial|Recruiting||Phase 3|24|Anticipated|Wuhan Union Hospital, China||2|||f|||||t|f|||t||||||No||2023-09-04 01:26:12.037405|2023-09-04 01:26:12.037405|OTHER|||||
NCT04881240||2021-04-27|||2023-07-23|2021-05-05|2021-05-11|Actual|||||||2023-07-23|2023-07-25|Actual|August 2023|Anticipated|2023-08-31|July 2023|2023-07-31|January 2026|Anticipated|2026-01-31|January 2025|Anticipated|2025-01-31||Interventional|||Study of CD19-directed Allogeneic Memory T-cell Therapy for Relapsed/Refractory CD19+ Leukemia|A Phase I Study Evaluating Allogeneic Memory T Cells Engineered to Express Chimeric Antigen Receptors Specific for CD19 for the Treatment of Pediatric and Young Adult Patients ≤ 21 Years of Age With Relapsed or Refractory CD19-Positive Leukemia|Recruiting||Phase 1|60|Anticipated|St. Jude Children's Research Hospital||2|||||||f|t|f|||t||||||||2023-09-04 01:26:27.677681|2023-09-04 01:26:27.677681|OTHER|||||
NCT04512716||2020-07-28|||2023-07-24|2020-08-10|2020-08-13|Actual|||||||2023-07-24|2023-07-25|Actual|February 2, 2021|Actual|2021-02-02|July 2023|2023-07-31|January 2025|Anticipated|2025-01-31|January 2025|Anticipated|2025-01-31||Interventional|||Iomab-ACT: A Pilot Study of 131-I Apamistamab Followed by CD19-Targeted CAR T-Cell Therapy for Patients With Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia or Diffuse Large B-Cell Lymphoma|Iomab-ACT: A Pilot Study of 131-I Apamistamab Followed by CD19-Targeted CAR T-Cell Therapy for Patients With Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia or Diffuse Large B-Cell Lymphoma|Recruiting||Early Phase 1|6|Anticipated|Memorial Sloan Kettering Cancer Center||1||||||||t|f|||||||||Yes|Memorial Sloan Kettering Cancer Center supports the international committee of medical journal editors (ICMJE) and the ethical obligation of responsible sharing of data from clinical trials. The protocol summary, a statistical summary, and informed consent form will be made available on clinicaltrials.gov when required as a condition of Federal awards, other agreements supporting the research and/or as otherwise required. Requests for deidentified individual participant data can be made beginning 12 months after publication and for up to 36 months post publication. Deidentified individual participant data reported in the manuscript will be shared under the terms of a Data Use Agreement and may only be used for approved proposals. Requests may be made to: crdatashare@mskcc.org.|2023-09-04 01:27:14.099604|2023-09-04 01:27:14.099604|OTHER|||||
NCT04146051||2019-10-29|||2023-07-21|2019-10-29|2019-10-31|Actual|||||||2023-07-21|2023-07-25|Actual|December 4, 2019|Actual|2019-12-04|July 2023|2023-07-31|December 1, 2023|Anticipated|2023-12-01|December 1, 2023|Anticipated|2023-12-01||Interventional|||Descartes-08 CAR-T Cells in Generalized Myasthenia Gravis (MG)|Autologous T-Cells Expressing A Chimeric Antigen Receptor Directed To B-Cell Maturation Antigen (BCMA) In Patients With Generalized Myasthenia Gravis (MG)|Recruiting||Phase 2|30|Anticipated|Cartesian Therapeutics||3|||f||||f|t|f|||||||||No||2023-09-04 01:27:49.856553|2023-09-04 01:27:49.856553|INDUSTRY|||||
NCT03938987||2019-04-30|||2023-07-21|2019-05-02|2019-05-06|Actual|||||||2023-07-21|2023-07-25|Actual|March 3, 2021|Actual|2021-03-03|July 2023|2023-07-31|December 2027|Anticipated|2027-12-31|December 2025|Anticipated|2025-12-31||Interventional|ACIT001/EXC002||Anti-CD19, Dual Co-stimulatory (4-1BB, CD3ζ) Chimeric Antigen Receptor T-cells in Patients With Relapsed/Refractory Aggressive Lymphoma or Acute Lymphoblastic Leukemia (ALL)|A Phase 1b/2 Multi-center, De-centralized, Dose Selection Study of Autologous CD19-directed Chimeric Antigen Receptor (CAR) T-cells in Patients With Relapsed/Refractory Aggressive Lymphoma or Acute Lymphoblastic Leukemia (ALL)|Recruiting||Phase 1/Phase 2|63|Anticipated|University of Alberta||1|||f||||t|f|f|||||||||No||2023-09-04 01:28:15.107794|2023-09-04 01:28:15.107794|OTHER|||||
NCT03980691||2019-06-07|||2021-07-19|2019-06-07|2019-06-10|Actual|||||||2021-07-19|2021-07-20|Actual|December 1, 2017|Actual|2017-12-01|July 2021|2021-07-31|May 31, 2020|Actual|2020-05-31|May 31, 2020|Actual|2020-05-31||Interventional|||Effect of Chidamide Combined With CAT-T or TCR-T Cell Therapy on HIV-1 Latent Reservoir|Effect of Chidamide Combined With CAT-T or TCR-T Cell Therapy on HIV-1 Latent Reservoir|Completed||Phase 1|4|Actual|Guangzhou 8th People's Hospital||2|||f||||f|f|f|||||||||||2023-09-03 07:23:06.839754|2023-09-03 07:23:06.839754|OTHER|||||
NCT02713984||2016-03-12|||2020-03-17|2016-03-18|2016-03-21|Estimate|||||||2020-03-17|2020-03-19|Actual|March 2016||2016-03-31|March 2020|2020-03-31|July 2019|Actual|2019-07-31|July 2019|Actual|2019-07-31||Interventional|||A Clinical Research of CAR T Cells Targeting HER2 Positive Cancer|A Clinical Research of CAR T Cells Targeting HER2 Positive Cancer|Withdrawn||Phase 1/Phase 2|0|Actual|Southwest Hospital, China||1||Reform CAR structure due to safety consideration|f||||f|||||||||||Undecided||2023-09-02 11:48:08.56707|2023-09-02 11:48:08.56707|OTHER|||||
NCT03232619||2017-07-20|||2020-09-20|2017-07-25|2017-07-28|Actual|||||||2020-09-20|2020-09-22|Actual|August 1, 2018|Actual|2018-08-01|September 2020|2020-09-30|September 15, 2020|Actual|2020-09-15|May 6, 2020|Actual|2020-05-06||Interventional|||CD19-CART Treatment for ALL|Safety and Efficacy Evaluation of CD19-CART Treatment for Refractory or Recurrent ALL|Completed||Phase 1/Phase 2|4|Actual|Bioray Laboratories||2|||f||||f|f|f|||f||||||No||2023-09-04 19:40:38.966951|2023-09-04 19:40:38.966951|INDUSTRY|||||
NCT04792593||2021-03-08|||2021-03-08|2021-03-08|2021-03-11|Actual|||||||2021-03-08|2021-03-11|Actual|December 3, 2020|Actual|2020-12-03|March 2021|2021-03-31|February 10, 2022|Anticipated|2022-02-10|December 10, 2021|Anticipated|2021-12-10||Interventional|||Senl-h19 CAR-T Cell Injection in the Treatment of Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia|Senl-h19 CAR-T Cell Injection in the Treatment of Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia|Unknown status|Recruiting|Not Applicable|15|Anticipated|Hebei Senlang Biotechnology Inc., Ltd.||1|||f|||||f|f|||||||||||2023-09-04 19:41:18.80655|2023-09-04 19:41:18.80655|INDUSTRY|||||
NCT05473221||2022-07-01|||2022-07-21|2022-07-21|2022-07-25|Actual|||||||2022-07-21|2022-07-25|Actual|August 2, 2022|Anticipated|2022-08-02|July 2022|2022-07-31|August 2, 2025|Anticipated|2025-08-02|August 2, 2024|Anticipated|2024-08-02||Interventional|||Evaluate the Safety and Efficacy of CD33 CAR-T in Patients With R/R AML|To Evaluate the Safety and Efficacy of CD33 CAR-T in Patients With Relapsed and Refractory Acute Myeloid Leukemia|Not yet recruiting||Phase 1|20|Anticipated|Zhejiang University||1|||f||||f|f|f|||||||||||2023-09-04 19:42:11.468495|2023-09-04 19:42:11.468495|OTHER|||||
NCT04390542||2020-05-12|||2021-07-14|2020-05-12|2020-05-15|Actual|||||||2021-07-14|2021-07-20|Actual|June 2021|Anticipated|2021-06-30|July 2021|2021-07-31|September 2021|Anticipated|2021-09-30|August 2021|Anticipated|2021-08-31||Interventional|||Intervention for Caregivers of Patients Undergoing HSCT or CAR T-cell Therapy|A Pilot Study Evaluating Feasibility, Acceptability, Usability, Satisfaction and Preliminary Efficacy of an Intervention for Caregivers of Patients Undergoing HSCT or CAR T-cell Therapy|Withdrawn||Not Applicable|0|Actual|Case Comprehensive Cancer Center||2||Funding unavailable|f||||f|f|f|||||||||No|Pilot study|2023-09-01 02:48:08.480594|2023-09-01 02:48:08.480594|OTHER|||||
NCT03674463||2018-09-12|||2018-12-13|2018-09-12|2018-09-17|Actual|||||||2018-12-13|2018-12-14|Actual|July 26, 2018|Actual|2018-07-26|September 2018|2018-09-30|December 31, 2020|Anticipated|2020-12-31|December 31, 2020|Anticipated|2020-12-31||Interventional|||LCAR-B4822M-02 Cells in Treating Relapsed/Refractory (R/R) Multiple Myeloma|LCAR-B4822M-02 Cells in Treating Relapsed/Refractory (R/R) Multiple Myeloma|Unknown status|Active, not recruiting|Phase 1|10|Anticipated|Second Affiliated Hospital of Xi'an Jiaotong University||1|||f||||f|f|f|||||||||Undecided||2023-09-04 01:51:52.373273|2023-09-04 01:51:52.373273|OTHER|||||
NCT04745559||2021-02-04|||2023-04-17|2021-02-04|2021-02-09|Actual|||||||2023-04-17|2023-04-19|Actual|February 18, 2021|Actual|2021-02-18|April 2023|2023-04-30|February 2025|Anticipated|2025-02-28|February 2024|Anticipated|2024-02-29||Interventional|||Optimizing Cellular and Humoral Immunity by Vaccinating With PCV13 Before and After CAR-T Therapy|Optimizing Cellular and Humoral Immunity to Pneumococcus by Vaccination With Pneumococcal 13-valent Conjugate Vaccine Before and After CD19-targeted CAR T-cell Immunotherapy|Recruiting||Phase 2|26|Anticipated|H. Lee Moffitt Cancer Center and Research Institute||1|||f||||t|t|f|||t||||||||2023-09-04 19:44:42.228457|2023-09-04 19:44:42.228457|OTHER|||||
NCT05554575||2022-09-13|||2022-09-22|2022-09-22|2022-09-26|Actual|||||||2022-09-22|2022-09-26|Actual|October 2022|Anticipated|2022-10-31|September 2022|2022-09-30|September 2024|Anticipated|2024-09-30|September 2024|Anticipated|2024-09-30||Interventional|||Chimeric Antigen Receptor T-Cell (CAR-T) Cells in Patients With R/R T-LBL|Safety and Efficacy of BT-007 CAR-T Cells in the Treatment of Patients With Relapsed/Refractory T Cell Lymphoblastic Lymphoma (R/R T-LBL)|Recruiting||Phase 1|15|Anticipated|Bioceltech Therapeutics, Ltd.||1|||f|||||f|f|||||||||Undecided||2023-09-04 19:45:18.635221|2023-09-04 19:45:18.635221|INDUSTRY|||||
NCT01318317||2011-03-16|2021-09-21||2023-06-19|2011-03-16|2011-03-18|Estimate|2021-11-22|2021-12-21|Actual||||2023-06-19|2023-06-23|Actual|September 19, 2011|Actual|2011-09-19|June 2023|2023-06-30|December 30, 2023|Anticipated|2023-12-30|October 3, 2013|Actual|2013-10-03||Interventional|||Genetically Engineered Lymphocyte Therapy After Peripheral Blood Stem Cell Transplant in Treating Patients With High-Risk, Intermediate-Grade, B-cell Non-Hodgkin Lymphoma|Phase I/II Study of Cellular Immunotherapy Using Central Memory-Enriched CD8+ T Cells Lentivirally Transduced to Express A CD19-Specific Chimeric Immunoreceptor Following Peripheral Blood Stem Cell Transplantation for Patients With High-Risk Intermediate Grade B-Lineage Non-Hodgkin Lymphoma|Active, not recruiting||Phase 1/Phase 2|8|Actual|City of Hope Medical Center||1|||f||||t|||||||||||||2023-09-04 19:45:20.283805|2023-09-04 19:45:20.283805|OTHER|||||
NCT04325841||2020-03-26|||2022-08-12|2020-03-26|2020-03-30|Actual|||||||2022-08-12|2022-08-15|Actual|May 1, 2020|Actual|2020-05-01|August 2022|2022-08-31|November 1, 2024|Anticipated|2024-11-01|May 1, 2024|Anticipated|2024-05-01||Interventional|||Phase II Study of Anti-CD19 CAR-T Cells Treating Leukemia Children|Phase II Study of Autologous Murine Anti-CD19 Chimeric Antigen Receptor T Cells Treating Refractory or Relapsed B Acute Lymphoblastic Leukemia Children|Recruiting||Phase 2|100|Anticipated|Beijing Boren Hospital||1|||f|||||f|f|||||||||No||2023-09-04 19:45:31.23358|2023-09-04 19:45:31.23358|OTHER|||||
NCT03559764||2018-05-08|||2018-06-14|2018-06-14|2018-06-18|Actual|||||||2018-06-14|2018-06-18|Actual|June 2018|Anticipated|2018-06-30|June 2018|2018-06-30|May 2020|Anticipated|2020-05-31|February 2020|Anticipated|2020-02-29||Interventional|||Study of BCMA CAR-T in Multiple Myeloma|Clinical Study on the Safety and Efficacy of Anti-BCMA CAR T Cells With Relapsed and Refractory Multiple Myeloma|Unknown status|Not yet recruiting|Early Phase 1|20|Anticipated|Allife Medical Science and Technology Co., Ltd.||1|||f|||||f|f|||f||||||||2023-09-04 02:00:59.910414|2023-09-04 02:00:59.910414|INDUSTRY|||||
NCT00881920||2009-04-14|||2023-02-17|2009-04-14|2009-04-15|Estimate|||||||2023-02-17|2023-02-21|Actual|July 2009|Actual|2009-07-31|February 2023|2023-02-28|July 2035|Anticipated|2035-07-31|January 2025|Anticipated|2025-01-31||Interventional|CHARKALL||Kappa-CD28 T Lymphocytes, Chronic Lymphocytic Leukemia, B-cell Lymphoma or Multiple Myeloma, CHARKALL|Phase I Study of Adoptive Transfer of Autologous T Lymphocytes Engrafted With a Chimeric Antigen Receptor Targeting the Kappa Light Chain of Immunoglobulin Expressed in Patients With CLL, B-Cell Lymphoma or Multiple Myeloma|Recruiting||Phase 1|54|Anticipated|Baylor College of Medicine||3|||f||||t|||||||||||||2023-09-04 02:04:56.023814|2023-09-04 02:04:56.023814|OTHER|||||
NCT05538195||2022-09-09|||2022-09-09|2022-09-09|2022-09-13|Actual|||||||2022-09-09|2022-09-13|Actual|June 7, 2022|Actual|2022-06-07|May 2022|2022-05-31|June 7, 2025|Anticipated|2025-06-07|December 30, 2024|Anticipated|2024-12-30||Interventional|||Safety and Efficacy of CEA-targeted CAR-T for CEA-positive Advanced Malignant Solid Tumors|Chimeric Antigen Receptor T Lymphocytes (CAR-T) Targeting CEA in the Treatment of CEA Positive Clinical Study of Advanced Malignant Solid Tumors|Recruiting||Phase 1/Phase 2|60|Anticipated|Chongqing Precision Biotech Co., Ltd||2|||f||||f|f|f|||||||||Undecided||2023-09-04 19:47:35.118633|2023-09-04 19:47:35.118633|INDUSTRY|||||
NCT04995003||2021-08-02|||2023-06-23|2021-08-02|2021-08-06|Actual|||||||2023-06-23|2023-06-27|Actual|December 7, 2021|Actual|2021-12-07|June 2023|2023-06-30|February 1, 2040|Anticipated|2040-02-01|February 1, 2025|Anticipated|2025-02-01||Interventional|||HER2 Chimeric Antigen Receptor (CAR) T Cells in Combination With Checkpoint Blockade in Patients With Advanced Sarcoma|Phase I Study of HER2 Chimeric Antigen Receptor (CAR) T Cells in Combination With Checkpoint Blockade in Patients With Advanced Sarcoma (HEROS 3.0)|Recruiting||Phase 1|25|Anticipated|Baylor College of Medicine||2|||f||||t|t|f|||||||||||2023-08-31 13:18:20.69674|2023-08-31 13:18:20.69674|OTHER|||||
NCT05626400||2022-11-15|||2022-11-22|2022-11-15|2022-11-23|Actual|||||||2022-11-22|2022-11-25|Actual|August 29, 2022|Actual|2022-08-29|August 2022|2022-08-31|December 30, 2027|Anticipated|2027-12-30|October 30, 2027|Anticipated|2027-10-30||Interventional|||Clinical Study of Senl-T7 CAR T Cells in the Treatment of Relapsed and Refractory CD7+ Acute T-ALL/T-LBL|Clinical Study of Senl-T7 CAR T Cells in the Treatment of Relapsed and Refractory CD7+ Acute T Lymphoblastic Leukemia and T Lymphoblastic Lymphoma|Recruiting||Not Applicable|100|Anticipated|Hebei Senlang Biotechnology Inc., Ltd.||1|||f|||||f|f|||||||||||2023-09-04 02:13:03.937375|2023-09-04 02:13:03.937375|INDUSTRY|||||
NCT05208853||2021-12-24|||2022-01-12|2022-01-12|2022-01-26|Actual|||||||2022-01-12|2022-01-26|Actual|February 10, 2022|Anticipated|2022-02-10|January 2022|2022-01-31|February 10, 2022|Anticipated|2022-02-10|February 10, 2022|Anticipated|2022-02-10||Interventional|||An Exploratory Clinical Study Evaluating the Safety and Efficacy of Anti CD30 CAR T Cells in Patients With CD30+ Relapsed/Refractory Lymphoma|An Exploratory Clinical Study Evaluating the Safety and Efficacy of Anti CD30 CAR T Cells Injection (Anti CD30 CAR T Cells) in Patients With CD30+ Relapsed/Refractory Lymphoma|Not yet recruiting||Early Phase 1|9|Anticipated|Zhejiang University||1|||f|||||f|f|||||||||||2023-09-04 02:18:20.735075|2023-09-04 02:18:20.735075|OTHER|||||
NCT05106946||2021-10-25|||2021-11-09|2021-10-25|2021-11-04|Actual|||||||2021-11-09|2021-11-11|Actual|October 25, 2021|Actual|2021-10-25|November 2021|2021-11-30|October 25, 2024|Anticipated|2024-10-25|October 25, 2023|Anticipated|2023-10-25||Interventional|||Safety and Clinical Activity of ThisCART22 in Patients With r/r Non-Hodgkin's B Cell Lymphoma|An Open and Single Dose-escalation Study to Evaluate the Safety and Clinical Activity of Allogeneic CAR-T Targeting CD22(ThisCART22) in Patients With Relapsed and/or Refractory Non-Hodgkin's B Cell Lymphoma (r/r B-NHL)|Recruiting||Phase 1|20|Anticipated|Fundamenta Therapeutics, Ltd.||1|||f|||||f|f|||||||||||2023-09-04 02:32:49.26923|2023-09-04 02:32:49.26923|INDUSTRY|||||
NCT05333302||2022-04-12|||2023-02-16|2022-04-12|2022-04-18|Actual|||||||2023-02-16|2023-02-17|Actual|October 26, 2020|Actual|2020-10-26|February 2023|2023-02-28|June 2023|Anticipated|2023-06-30|June 2023|Anticipated|2023-06-30||Interventional|||Pilot CAR-T Cells Therapy for Children/Young Adults With CD19+ R/R Leukemia/Lymphoma|Pilot Study of CD19 CAR-T Cells Therapy for Relapsed or Refractory Acute Lymphoblastic Leukemia/Lymphoma in Children/Young Adults|Recruiting||Phase 1|10|Anticipated|Belarusian Research Center for Pediatric Oncology, Hematology and Immunology||1|||f|||||f|f|||||||||||2023-09-02 11:54:31.65514|2023-09-02 11:54:31.65514|OTHER|||||
NCT05515185||2022-08-23|||2022-08-23|2022-08-23|2022-08-25|Actual|||||||2022-08-23|2022-08-25|Actual|September 9, 2022|Anticipated|2022-09-09|August 2022|2022-08-31|September 8, 2024|Anticipated|2024-09-08|September 8, 2024|Anticipated|2024-09-08||Interventional|||B7-H3 Targeting CAR-T Cells Therapy for B7-H3 Positive Solid Tumors|An Open, Single-arm Clinical Study of Autologous T Cells (CAR-T) Targeting B7-H3 Chimeric Antigen Receptor Gene in the Treatment of Patients With Advanced Gastrointestinal Tumors|Not yet recruiting||Early Phase 1|30|Anticipated|The First People's Hospital of Lianyungang||1|||f||||f|f|f|||||||||No||2023-09-04 19:59:48.20618|2023-09-04 19:59:48.20618|OTHER|||||
NCT05514327||2022-08-22|||2022-08-22|2022-08-22|2022-08-24|Actual|||||||2022-08-22|2022-08-24|Actual|September 1, 2022|Anticipated|2022-09-01|August 2022|2022-08-31|December 1, 2024|Anticipated|2024-12-01|September 1, 2024|Anticipated|2024-09-01||Interventional|||A Study of Ultra-fraction Radiotherapy Bridging CART in R/R DLBCL|the Safety and Efficacy of Ultra-fraction Radiotherapy Bridging CART Cell Therapy in Relapsed/Refractory Diffuse Large b Cell Lymphoma|Not yet recruiting||Not Applicable|20|Anticipated|Peking Union Medical College Hospital||1|||f|||||f|f||||||3 years after the closure of the study|upon email request||Yes|the study protocol, statistical analysis plan, informed consent form, clinical study report would be available upon email request in 3 years after the closure of the study|2023-09-04 20:00:10.285329|2023-09-04 20:00:10.285329|OTHER|||||
NCT03173417||2017-05-30|||2019-05-17|2017-05-30|2017-06-01|Actual|||||||2019-05-17|2019-05-20|Actual|May 23, 2017|Actual|2017-05-23|May 2019|2019-05-31|May 1, 2019|Actual|2019-05-01|May 1, 2019|Actual|2019-05-01||Interventional|||Safety and Efficacy Evaluation of IM19 CAR-T Cells (IM19CAR-T)|Safety and Efficacy Evaluation of IM19 CAR-T Cells On CD19+ Refractory or Relapsed B-ALL Patients|Completed||Phase 1/Phase 2|177|Actual|Beijing Immunochina Medical Science & Technology Co., Ltd.||1|||f||||f|f|f|||||||||Undecided||2023-09-04 20:01:27.630703|2023-09-04 20:01:27.630703|INDUSTRY|||||
NCT03980288||2019-06-02|||2023-01-27|2019-06-05|2019-06-10|Actual|||||||2023-01-27|2023-01-31|Actual|July 23, 2019|Actual|2019-07-23|January 2023|2023-01-31|December 30, 2020|Actual|2020-12-30|December 30, 2020|Actual|2020-12-30||Interventional|||4th Generation Chimeric Antigen Receptor T Cells Targeting Glypican-3|A Phase I Clinical Study of 4th Generation Chimeric Antigen Receptor T Cells Targeting Glypican-3 ( CAR-GPC3 T Cells) in Patients With Advanced Hepatocellular Carcinoma|Completed||Phase 1|6|Actual|Zhejiang University||1|||f||||t|f|f|||||||||No||2023-09-03 08:04:21.04592|2023-09-03 08:04:21.04592|OTHER|||||
NCT03525782||2018-04-26|||2018-05-03|2018-05-03|2018-05-16|Actual|||||||2018-05-03|2018-05-16|Actual|February 1, 2018|Actual|2018-02-01|May 2018|2018-05-31|January 31, 2022|Anticipated|2022-01-31|January 31, 2021|Anticipated|2021-01-31||Interventional|||Anti-MUC1 CAR T Cells and PD-1 Knockout Engineered T Cells for NSCLC|A Clinical Study of Anti-MUC1 CAR T Cells and PD-1 Knockout Engineered T Cells for Patients With Advanced Non-small Cell Lung Cancer|Unknown status|Recruiting|Phase 1/Phase 2|60|Anticipated|The First Affiliated Hospital of Guangdong Pharmaceutical University||5|||f||||f|f|f|||||||||No||2023-09-04 02:59:34.268862|2023-09-04 02:59:34.268862|OTHER|||||
NCT05429905||2021-12-16|||2023-03-07|2022-06-20|2022-06-23|Actual|||||||2023-03-07|2023-03-09|Actual|July 18, 2022|Actual|2022-07-18|March 2023|2023-03-31|December 2025|Anticipated|2025-12-31|December 2024|Anticipated|2024-12-31||Interventional|||Dual Anti-CD22/CD19 Chimeric Antigen Receptor-directed T Cells (CART2219.1) for Relapsed Refractory B-Lineage Leukaemia|Dual Anti-CD22/CD19 Chimeric Antigen Receptor-directed T Cells (CART2219.1) for Relapsed Refractory B-Lineage Leukaemia|Recruiting||Phase 1/Phase 2|48|Anticipated|KK Women's and Children's Hospital||3|||f||||t|f|f|||||||||Undecided||2023-09-04 03:02:40.0233|2023-09-04 03:02:40.0233|OTHER_GOV|||||
NCT04173988||2019-11-13|||2022-11-12|2019-11-20|2019-11-22|Actual|||||||2022-11-12|2022-11-15|Actual|January 9, 2020|Actual|2020-01-09|November 2022|2022-11-30|July 20, 2024|Anticipated|2024-07-20|October 20, 2023|Anticipated|2023-10-20||Interventional|||Study of alloCART-19 Cell Therapy in Pediatric Patients With Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia|A Single Center, Open Label, Single Arm Exploratory Clinical Study of CD19-Directed Allogeneic Chimeric Antigen Receptor CART-cell Immunotherapy Cell Therapy in Pediatric Patients With Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia|Recruiting||Early Phase 1|6|Anticipated|Children's Hospital of Fudan University||1|||f||||t|f|f|||||||||No||2023-09-04 03:03:10.147059|2023-09-04 03:03:10.147059|OTHER|||||
NCT04280133||2020-02-19|||2023-01-24|2020-02-19|2020-02-21|Actual|||||||2023-01-24|2023-01-26|Actual|May 25, 2020|Actual|2020-05-25|January 2023|2023-01-31|February 24, 2023|Anticipated|2023-02-24|October 26, 2022|Actual|2022-10-26||Interventional|||CAR T-CELL Therapy Educational Video Trial|A Randomized Controlled Trial of an Educational Video Tool for Patients Receiving CAR T-Cell Therapy|Active, not recruiting||Not Applicable|80|Actual|Massachusetts General Hospital||2|||f||||f|f|f||||||Data can be shared no earlier than 1 year following the date of publication|Contact the Partners Innovations team at http://www.partners.org/innovation||Yes|The Dana-Farber / Harvard Cancer Center encourages and supports the responsible and ethical sharing of data from clinical trials. De-identified participant data from the final research dataset used in the published manuscript may only be shared under the terms of a Data Use Agreement. Requests may be directed to Sponsor Investigator or designee. The protocol and statistical analysis plan will be made available on Clinicaltrials.gov only as required by federal regulation or as a condition of awards and agreements supporting the research.|2023-09-04 20:06:56.177921|2023-09-04 20:06:56.177921|OTHER|||||
NCT05422521||2022-05-31|||2022-08-30|2022-06-13|2022-06-16|Actual|||||||2022-08-30|2022-09-02|Actual|August 29, 2022|Actual|2022-08-29|August 2022|2022-08-31|August 29, 2024|Anticipated|2024-08-29|August 29, 2023|Anticipated|2023-08-29||Interventional|CART-Omic||Radiomics and Metabolomics in the Follow-up of CAR T-cells for Refractory or Relapsed Non-Hodgkin's Lymphoma|Radiomics and Metabolomics in the Follow-up of CAR T-cells for Refractory or Relapsed Non-Hodgkin's Lymphoma: Pilot Study|Recruiting||Not Applicable|20|Anticipated|Centre Hospitalier Universitaire de Nice||1|||f||||f|f|f|||||||||No||2023-09-04 20:13:51.959204|2023-09-04 20:13:51.959204|OTHER|||||
NCT02932956||2016-10-12|||2023-06-05|2016-10-12|2016-10-13|Estimate|||||||2023-06-05|2023-06-06|Actual|December 17, 2018|Actual|2018-12-17|June 2023|2023-06-30|February 2037|Anticipated|2037-02-28|September 27, 2021|Actual|2021-09-27||Interventional|GAP||Glypican 3-specific Chimeric Antigen Receptor Expressed in T Cells for Patients With Pediatric Solid Tumors (GAP)|Glypican 3-specific Chimeric Antigen Receptor Expressed in Autologous T Cells as Immunotherapy for Patients With Pediatric Solid Tumors|Active, not recruiting||Phase 1|10|Actual|Baylor College of Medicine||1|||f||||t|t|f|||||||||||2023-09-04 03:20:07.418409|2023-09-04 03:20:07.418409|OTHER|||||
NCT02290951||2014-11-07|||2023-06-05|2014-11-11|2014-11-14|Estimate|||||||2023-06-05|2023-06-06|Actual|January 9, 2015|Actual|2015-01-09|September 2022|2022-09-30|December 2, 2025|Anticipated|2025-12-02|December 2, 2025|Anticipated|2025-12-02||Interventional|ELM-1||Study to Investigate the Safety and Tolerability of Odronextamab in Patients With CD20+ B-Cell Malignancies|An Open-Label, Multi-Center Phase 1 Study to Investigate the Safety and Tolerability of REGN1979, an Anti-CD20 x Anti-CD3 Bispecific Monoclonal Antibody, in Patients With CD20+ B-Cell Malignancies Previously Treated With CD20-Directed Antibody Therapy (ELM-1)|Active, not recruiting||Phase 1|200|Actual|Regeneron Pharmaceuticals||3|||t||||f|t|f|||||||||||2023-09-04 03:20:38.141922|2023-09-04 03:20:38.141922|INDUSTRY||NCT05619367|Available||
NCT05059912||2021-09-17|||2021-09-17|2021-09-17|2021-09-28|Actual|||||||2021-09-17|2021-09-28|Actual|August 5, 2021|Actual|2021-08-05|August 2021|2021-08-31|August 3, 2024|Anticipated|2024-08-03|August 3, 2023|Anticipated|2023-08-03||Interventional|||CD7 CAR T-cell for R/R CD7+ T Cell Lymphoma|Humanized CD7 CAR T-cell Therapy for R/R CD7+ T Cell Lymphoma|Recruiting||Phase 2|20|Anticipated|The First Affiliated Hospital of Soochow University||1|||f|||||f|f|||||||||No||2023-09-04 03:25:58.719924|2023-09-04 03:25:58.719924|OTHER|||||
NCT04976218||2021-07-19|||2022-11-13|2021-07-19|2021-07-26|Actual|||||||2022-11-13|2022-11-16|Actual|March 15, 2022|Actual|2022-03-15|November 2022|2022-11-30|December 31, 2024|Anticipated|2024-12-31|December 20, 2023|Anticipated|2023-12-20||Interventional|||TGFβR-KO CAR-EGFR T Cells in Previously Treated Advanced EGFR-positive Solid Tumors|Phase Ⅰ Study of EGFR Targeted TGFβR-KO CAR T Cells in the Treatment of Previously Treated Advanced EGFR-positive Solid Tumors|Recruiting||Phase 1|30|Anticipated|Chinese PLA General Hospital||1|||f||||t|f|f|||||||||||2023-09-04 03:37:23.970866|2023-09-04 03:37:23.970866|OTHER|||||
NCT05038696||2021-05-26|||2021-09-07|2021-09-07|2021-09-09|Actual|||||||2021-09-07|2021-09-09|Actual|April 28, 2021|Actual|2021-04-28|April 2021|2021-04-30|August 1, 2026|Anticipated|2026-08-01|May 1, 2026|Anticipated|2026-05-01||Interventional|ALaCART||ALaCART-B: Acute Leukemia and Chimeric Antigen Receptor-T Cell Therapy for B-lymphoblastic Leukemia.|Chimeric-Antigen Receptor (CAR) T-Cell Therapy Using Multiple CARs and Cell Marker Profiling in High Risk and Relapsed/ Refractory B-Lineage Acute Lymphoblastic Leukaemia|Recruiting||Phase 1|40|Anticipated|National University Hospital, Singapore||1|||f||||t|f|f|||||||||No||2023-09-04 03:38:47.617087|2023-09-04 03:38:47.617087|OTHER|||||
NCT03191773||2017-06-15|||2017-06-17|2017-06-16|2017-06-19|Actual|||||||2017-06-17|2017-06-20|Actual|June 30, 2017|Anticipated|2017-06-30|June 2017|2017-06-30|December 31, 2020|Anticipated|2020-12-31|December 31, 2020|Anticipated|2020-12-31||Interventional|||A Study of Anti-CD19 CAR-T Cell Immunotherapy for Refractory /Relapsed B Cell Malignancies|A Prospective, Multicenter, Single-Arm Study of Anti-CD19 CAR-T Cell Immunotherapy for Refractory /Relapsed B Cell Malignancies|Unknown status|Recruiting|Phase 1/Phase 2|100|Anticipated|Second Affiliated Hospital of Guangzhou Medical University||1|||f|||||f|f|||f||||||No||2023-09-04 20:27:54.635923|2023-09-04 20:27:54.635923|OTHER|||||
NCT05371132||2022-03-24|||2022-11-18|2022-05-08|2022-05-12|Actual|||||||2022-11-18|2022-11-23|Actual|June 20, 2022|Actual|2022-06-20|November 2022|2022-11-30|August 16, 2023|Anticipated|2023-08-16|August 16, 2023|Anticipated|2023-08-16||Interventional|||Study to Evaluate CD8 PET Imaging as a Marker of Immune Response to Stereotactic Body Radiation Therapy (ELIXR)|Pilot Phase I Study to Evaluate CD8 PET Imaging as a Marker of Immune Response to Stereotactic Body Radiation Therapy (ELIXR)|Recruiting||Phase 1|10|Anticipated|City of Hope Medical Center||1|||||||t|t|f|||||||||||2023-09-03 08:27:28.07373|2023-09-03 08:27:28.07373|OTHER|||||
NCT05150522||2021-11-22|||2021-12-07|2021-12-07|2021-12-09|Actual|||||||2021-12-07|2021-12-09|Actual|July 1, 2021|Actual|2021-07-01|July 2021|2021-07-31|July 2024|Anticipated|2024-07-31|July 2024|Anticipated|2024-07-31||Interventional|||B Cell Maturation Antigen Targeted CAR-T Cells in Treatment With Relapsed and Refractory Multiple Myeloma|B Cell Maturation Antigen Targeted CAR-T Cells in Treatment With Relapsed and Refractory Multiple Myeloma|Recruiting||Phase 1/Phase 2|10|Anticipated|Shenzhen University General Hospital||1|||f|||||f|f|||||||||No||2023-09-04 03:47:11.440807|2023-09-04 03:47:11.440807|OTHER|||||
NCT03182803||2017-06-05|||2017-06-07|2017-06-07|2017-06-09|Actual|||||||2017-06-07|2017-06-09|Actual|June 7, 2017|Anticipated|2017-06-07|June 2017|2017-06-30|April 20, 2019|Anticipated|2019-04-20|January 20, 2019|Anticipated|2019-01-20||Interventional|||CTLA-4 and PD-1 Antibodies Expressing Mesothelin-CAR-T Cells for Mesothelin Positive Advanced Solid Tumor|A Clinical Study of CTL-A4 and PD-1 Antibodies Expressing Mesothelin-CAR-T Cells for Patients With Mesothelin Positive Advanced Solid Tumors|Unknown status|Recruiting|Phase 1/Phase 2|40|Anticipated|Shanghai Cell Therapy Research Institute||1|||f||||f|f|f|||||||||No||2023-09-04 20:30:21.366216|2023-09-04 20:30:21.366216|OTHER|||||
NCT03638167||2018-08-15|||2023-01-18|2018-08-15|2018-08-20|Actual|||||||2023-01-18|2023-01-20|Actual|March 19, 2019|Actual|2019-03-19|January 2023|2023-01-31|March 2040|Anticipated|2040-03-31|March 2025|Anticipated|2025-03-31||Interventional|||EGFR806-specific CAR T Cell Locoregional Immunotherapy for EGFR-positive Recurrent or Refractory Pediatric CNS Tumors|Phase 1 Study of EGFR806-specific CAR T Cell Locoregional Immunotherapy for EGFR-positive Recurrent or Refractory Pediatric Central Nervous System Tumors|Active, not recruiting||Phase 1|11|Actual|Seattle Children's Hospital||2|||f||||t|t|f|||||||||No||2023-09-04 03:51:51.76131|2023-09-04 03:51:51.76131|OTHER|||||
NCT03598179||2018-06-27|||2019-08-05|2018-07-14|2018-07-26|Actual|||||||2019-08-05|2019-08-07|Actual|June 1, 2018|Actual|2018-06-01|August 2019|2019-08-31|July 1, 2020|Anticipated|2020-07-01|December 30, 2019|Anticipated|2019-12-30||Interventional|||XLCART001 Treatment in Relapsed/Refractory/High-risk B-cell Malignancy Subjects|A Single-center, Open Study Evaluating Efficacy and Safety of XLCART001（CD-19） Treatment in Relapsed/Refractory/High-risk B-cell Malignancy Subjects|Unknown status|Active, not recruiting|Phase 2|10|Anticipated|The First Affiliated Hospital with Nanjing Medical University|||||f|||||f|f|||||||||||2023-09-04 03:52:05.548503|2023-09-04 03:52:05.548503|OTHER|||||
NCT05385263||2022-04-13|||2022-05-22|2022-05-17|2022-05-23|Actual|||||||2022-05-22|2022-05-26|Actual|May 11, 2022|Actual|2022-05-11|April 2022|2022-04-30|October 2024|Anticipated|2024-10-31|April 2024|Anticipated|2024-04-30||Interventional|||Addition of Nivolumab to Anti-CD-19 CAR-T Cells in Patients With Stable/Progressive DLBCL at Lymphodepletion|Addition of Nivolumab to Standard of Care With Anti-CD-19 CAR-T Cells in Patients With Stable/Progressive DLBCL at Lymphodepletion|Recruiting||Phase 2|20|Anticipated|Tel-Aviv Sourasky Medical Center||1|||f||||f|f|f|||||||||||2023-09-04 20:34:28.10706|2023-09-04 20:34:28.10706|OTHER_GOV|||||
NCT05085431||2021-10-11|||2021-10-11|2021-10-11|2021-10-20|Actual|||||||2021-10-11|2021-10-20|Actual|November 5, 2021|Anticipated|2021-11-05|October 2021|2021-10-31|November 5, 2024|Anticipated|2024-11-05|November 5, 2024|Anticipated|2024-11-05||Interventional|||A Study of CD19/BCMA Chimeric Antigen Receptor T Cells Therapy for Patients With Refractory Sjogren's Syndrome|A Study of CD19/BCMA Chimeric Antigen Receptor T Cells Therapy for Patients With Refractory Sjogren's Syndrome|Recruiting||Early Phase 1|9|Anticipated|Zhejiang University||1|||f||||t|f|f|||||||||||2023-09-04 20:35:26.575875|2023-09-04 20:35:26.575875|OTHER|||||
NCT03576807||2018-06-21|||2018-06-21|2018-06-21|2018-07-03|Actual|||||||2018-06-21|2018-07-03|Actual|April 4, 2018|Actual|2018-04-04|April 2018|2018-04-30|April 3, 2020|Anticipated|2020-04-03|April 3, 2019|Anticipated|2019-04-03||Interventional|||The Clinical Research of Anti-CD20 CAR-T Cells in Patients With Refractory or Relapsed B Lymphocyte Lymphoma|The Clinical Research of Anti-CD20 CAR-T Cells in Patients With Refractory or Relapsed B Lymphocyte Lymphoma|Unknown status|Recruiting|Phase 1|20|Anticipated|Shanghai Longyao Biotechnology Inc., Ltd.||1|||f||||f|f|f|||||||||Undecided||2023-09-04 03:58:29.110871|2023-09-04 03:58:29.110871|OTHER|||||
NCT03931720||2019-04-25|||2019-04-27|2019-04-27|2019-04-30|Actual|||||||2019-04-27|2019-04-30|Actual|May 2019|Anticipated|2019-05-31|April 2019|2019-04-30|May 2022|Anticipated|2022-05-31|May 2021|Anticipated|2021-05-31||Interventional|||Clinical Research of ROBO1 Specific BiCAR-NK/T Cells on Patients With Malignant Tumor|Clinical Research of ROBO1 Specific BiCAR-NK/T Cells on Patients With Malignant Tumor|Unknown status|Recruiting|Phase 1/Phase 2|20|Anticipated|Asclepius Technology Company Group (Suzhou) Co., Ltd.||1|||f|||||f|f|||||||||No||2023-09-03 08:33:29.253449|2023-09-03 08:33:29.253449|INDUSTRY|||||
NCT04846439||2021-04-13|||2021-10-19|2021-04-13|2021-04-15|Actual|||||||2021-10-19|2021-10-27|Actual|April 29, 2021|Actual|2021-04-29|April 2021|2021-04-30|March 31, 2024|Anticipated|2024-03-31|March 31, 2023|Anticipated|2023-03-31||Interventional|||Sequential Infusion of CD19 and BCMA CAR-T Cells to Improve PTR in Patients With AL|Sequential Infusion of CD19 and BCMA Chimeric Antigen Receptor T Cells to Improve Alloimmune-mediated Platelet Transfusion Refractoriness in Patients With Acute Leukemia in Complete Remission|Recruiting||Phase 1/Phase 2|20|Anticipated|The First Affiliated Hospital of Soochow University||1|||f|||||f|f|||||||||||2023-09-04 20:40:44.451631|2023-09-04 20:40:44.451631|OTHER|||||
NCT02194374||2014-07-16|||2017-06-09|2014-07-17|2014-07-18|Estimate|||||||2017-06-09|2017-06-12|Actual|January 2015|Actual|2015-01-31|June 2017|2017-06-30|June 2017|Actual|2017-06-30|June 2017|Actual|2017-06-30||Interventional|||Autologous ROR1R-CAR-T Cells for Chronic Lymphocytic Leukemia (CLL)|A Study to Infuse ROR1-Specific Autologous T Cells for Patients With Chronic Lymphocytic Leukemia (CLL) / Small Lymphocytic Lymphoma (SLL)|Withdrawn||Phase 1|0|Actual|M.D. Anderson Cancer Center||1||Study closed with no enrollment due to unavailability of reagent.|f||||f|||||||||||||2023-09-04 05:23:33.808723|2023-09-04 05:23:33.808723|OTHER|||||
NCT02659943||2016-01-20|2021-02-22||2023-03-24|2016-01-20|2016-01-21|Estimate|2021-04-14|2021-05-04|Actual||||2023-03-24|2023-04-19|Actual|January 21, 2016|Actual|2016-01-21|March 2023|2023-03-31|December 31, 2022|Actual|2022-12-31|June 12, 2018|Actual|2018-06-12||Interventional||Baseline data was collected and reported here for the participants enrolled but not treated.|T Cells Expressing a Fully-human AntiCD19 Chimeric Antigen Receptor for Treating B-cell Malignancies|T Cells Expressing a Fully-Human Anti-CD19 Chimeric Antigen Receptor for Treating B-cell Malignancies|Completed||Phase 1|27|Actual|National Institutes of Health Clinical Center (CC)||6|||f||||f|t|f|||||||||No||2023-09-04 20:41:36.345989|2023-09-04 20:41:36.345989|NIH|||||
NCT03919240||2019-04-15|||2020-06-29|2019-04-15|2019-04-18|Actual|||||||2020-06-29|2020-07-01|Actual|December 1, 2015|Actual|2015-12-01|April 2019|2019-04-30|December 31, 2023|Anticipated|2023-12-31|December 31, 2020|Anticipated|2020-12-31||Interventional|||CAR-T Cell Therapy Targeting to CD19 for R/R ALL|CD19-targeting Chimeric Antigen Receptor T-cell Therapy for Patients With Refractory and Relapsed B-cell Acute Lymphoblastic Leukemia|Recruiting||Phase 1/Phase 2|50|Anticipated|The First Affiliated Hospital of Soochow University||1|||f||||f|f|f|||||||||||2023-09-03 08:36:45.728789|2023-09-03 08:36:45.728789|OTHER|||||
NCT05017883||2021-08-17|||2021-11-03|2021-08-17|2021-08-24|Actual|||||||2021-11-03|2021-11-04|Actual|July 1, 2021|Actual|2021-07-01|August 2021|2021-08-31|October 2025|Anticipated|2025-10-31|October 2023|Anticipated|2023-10-31||Interventional|||TAA05 Cell Injection in the Treatment of Recurrent / Refractory Acute Myeloid Leukemia|TAA05 Cell Injection in the Treatment of Recurrent / Refractory Acute Myeloid Leukemia|Recruiting||Not Applicable|5|Anticipated|PersonGen BioTherapeutics (Suzhou) Co., Ltd.||1|||f|||||f|f|||||||||||2023-09-04 20:43:56.812841|2023-09-04 20:43:56.812841|INDUSTRY|||||
NCT03672253||2018-09-13|||2018-12-13|2018-09-13|2018-09-14|Actual|||||||2018-12-13|2018-12-14|Actual|July 26, 2018|Actual|2018-07-26|September 2018|2018-09-30|December 31, 2020|Anticipated|2020-12-31|December 31, 2020|Anticipated|2020-12-31||Interventional|||CAR-T Re-treatment for Refractory/Relapsed Multiple Myeloma|Study of CAR-T Cells Targeting BCMA for Previously CAR-T Treated Refractory/Relapsed Multiple Myeloma|Unknown status|Active, not recruiting|Phase 1|20|Anticipated|Second Affiliated Hospital of Xi'an Jiaotong University||1|||f||||f|f|f|||||||||Undecided||2023-09-04 05:32:20.831576|2023-09-04 05:32:20.831576|OTHER|||||
NCT02905188||2016-09-14|||2023-02-03|2016-09-14|2016-09-19|Estimate|||||||2023-02-03|2023-02-06|Actual|March 28, 2019|Actual|2019-03-28|February 2023|2023-02-28|January 6, 2023|Actual|2023-01-06|November 17, 2021|Actual|2021-11-17||Interventional|GLYCAR||Glypican 3-specific Chimeric Antigen Receptor Expressing T Cells for Hepatocellular Carcinoma (GLYCAR)|Glypican 3-specific Chimeric Antigen Receptor Expressing T Cells as Immunotherapy for Patients With Hepatocellular Carcinoma|Completed||Phase 1|9|Actual|Baylor College of Medicine||1|||||||t|t|f|||f||||||||2023-09-04 05:32:27.644757|2023-09-04 05:32:27.644757|OTHER|||||
NCT04952272||2021-06-27|||2023-02-26|2021-06-27|2021-07-07|Actual|||||||2023-02-26|2023-02-28|Actual|March 1, 2021|Actual|2021-03-01|February 2023|2023-02-28|June 30, 2036|Anticipated|2036-06-30|June 30, 2024|Anticipated|2024-06-30||Interventional|||Intratumor CpG-ODN Injection Boosters Immune Killing Against in Situ Tumor Antigen Release for Advanced Solid Tumors|Intratumor CpG-ODN Injection Boosters Immune Killing Against in Situ Tumor Antigen Released by Interventional Approaches for Advanced Solid Tumors|Recruiting||Phase 1|50|Anticipated|Second Affiliated Hospital of Guangzhou Medical University|||||f||||f|f|f|||||||||No||2023-09-04 05:34:03.3737|2023-09-04 05:34:03.3737|OTHER|||||
NCT05256641||2022-01-04|||2023-03-09|2022-02-15|2022-02-25|Actual|||||||2023-03-09|2023-03-13|Actual|January 23, 2023|Actual|2023-01-23|March 2023|2023-03-31|January 30, 2025|Anticipated|2025-01-30|January 30, 2024|Anticipated|2024-01-30||Interventional|||Acalabrutinib Maintenance for the Treatment of Patients With Large B-cell Lymphoma|Acalabrutinib Maintenance Following Cellular Therapy for Large B-Cell Lymphoma Patients at Very High Risk for Relapse|Recruiting||Phase 1/Phase 2|24|Anticipated|Jonsson Comprehensive Cancer Center||3|||||||t|t|f|||f||||||||2023-09-01 03:12:21.628193|2023-09-01 03:12:21.628193|OTHER|||||
NCT04735471||2021-01-26|||2023-03-10|2021-01-28|2021-02-03|Actual|||||||2023-03-10|2023-03-13|Actual|March 4, 2021|Actual|2021-03-04|March 2023|2023-03-31|March 31, 2024|Anticipated|2024-03-31|March 31, 2023|Anticipated|2023-03-31||Interventional|GLEAN-1||A Safety and Efficacy Study of ADI-001, an Anti-CD20 Allogeneic Gamma Delta CAR-T, in Subjects With B Cell Malignancies|A Phase 1 Safety and Efficacy Study of ADI-001 Anti-CD20 CAR-engineered Allogeneic Gamma Delta (γδ) T Cells in Adults With B Cell Malignancies|Recruiting||Phase 1|78|Anticipated|Adicet Bio, Inc||3|||f||||f|t|f|||||||||No||2023-09-01 03:13:18.447128|2023-09-01 03:13:18.447128|INDUSTRY|||||
NCT04661384||2020-09-16|||2023-03-10|2020-12-08|2020-12-10|Actual|||||||2023-03-10|2023-03-13|Actual|March 5, 2021|Actual|2021-03-05|March 2023|2023-03-31|November 17, 2025|Anticipated|2025-11-17|November 17, 2025|Anticipated|2025-11-17||Interventional|||Brain Tumor-Specific Immune Cells (IL13Ralpha2-CAR T Cells) for the Treatment of Leptomeningeal Glioblastoma, Ependymoma, or Medulloblastoma|A Phase 1 Study to Evaluate IL13Rα2-Targeted Chimeric Antigen Receptor (CAR) T Cells for Adult Patients With Leptomeningeal Glioblastoma, Ependymoma or Medulloblastoma|Recruiting||Phase 1|30|Anticipated|City of Hope Medical Center||1|||||||t|t|f|||f||||||||2023-09-01 03:13:24.844848|2023-09-01 03:13:24.844848|OTHER|||||
NCT05131763||2021-11-05|||2021-11-20|2021-11-20|2021-11-23|Actual|||||||2021-11-20|2021-11-23|Actual|March 1, 2021|Actual|2021-03-01|November 2021|2021-11-30|December 1, 2023|Anticipated|2023-12-01|December 1, 2022|Anticipated|2022-12-01||Interventional|||NKG2D-based CAR T-cells Immunotherapy for Patient With r/r NKG2DL+ Solid Tumors|A Phase I Clinical Trial of NKG2D-based CAR T-cells Injection for Subjects With Relapsed/Refractory NKG2DL+ Solid Tumors|Recruiting||Phase 1|3|Anticipated|Fudan University||1|||f|||||f|f|||||||||No||2023-09-04 20:55:51.527288|2023-09-04 20:55:51.527288|OTHER|||||
NCT05097443||2021-10-26|||2021-11-18|2021-10-26|2021-10-28|Actual|||||||2021-11-18|2021-11-19|Actual|April 15, 2021|Actual|2021-04-15|November 2021|2021-11-30|December 31, 2024|Anticipated|2024-12-31|December 31, 2023|Anticipated|2023-12-31||Interventional|||Orelabrutinib, Rituximab and Combination Chemotherapy in Newly-diagnosed Aggressive B-cell Non-Hodgkin Lymphoma|A Multi-center and Prospective Clinical Study of Orelabrutinib, Rituximab and Combination Chemotherapy in Patients With Newly-diagnosed Aggressive B-cell Non-Hodgkin Lymphoma|Recruiting||Phase 3|130|Anticipated|Shandong Provincial Hospital||1|||f|||||f|f|||||||||||2023-09-04 20:56:14.351029|2023-09-04 20:56:14.351029|OTHER_GOV|||||
NCT03090659||2017-03-07|||2023-06-08|2017-03-20|2017-03-27|Actual|||||||2023-06-08|2023-06-12|Actual|October 2, 2015|Actual|2015-10-02|June 2023|2023-06-30|December 31, 2023|Anticipated|2023-12-31|December 31, 2023|Anticipated|2023-12-31||Interventional|LEGEND-2||LCAR-B38M Cells in Treating Relapsed/Refractory (R/R) Multiple Myeloma|A Clinical Study of Legend Biotech BCMA-chimeric Antigen Receptor Technology in Treating Relapsed/Refractory (R/R) Multiple Myeloma Patients|Active, not recruiting||Phase 1/Phase 2|100|Anticipated|Nanjing Legend Biotech Co.||1|||f||||t|f|f|||||||||Undecided||2023-09-04 21:03:11.312566|2023-09-04 21:03:11.312566|INDUSTRY|||||
NCT05302037||2022-03-20|||2022-03-20|2022-03-20|2022-03-31|Actual|||||||2022-03-20|2022-03-31|Actual|April 2022|Anticipated|2022-04-30|January 2022|2022-01-31|December 2023|Anticipated|2023-12-31|March 2023|Anticipated|2023-03-31||Interventional|ANGELICA||Allogeneic NKG2DL-targeting CAR γδ T Cells (CTM-N2D) in Advanced Cancers|A Phase I Trial to Evaluate Allogeneic NKG2DL-targeting Chimeric Antigen Receptor-grafted γδ T Cells (CTM-N2D) in Subjects With Advanced Solid Tumours or Haematological Malignancies|Not yet recruiting||Phase 1|9|Anticipated|CytoMed Therapeutics Pte Ltd||2|||f||||t|f|f|||||||||No||2023-09-04 21:04:52.688635|2023-09-04 21:04:52.688635|INDUSTRY|||||
NCT04969354||2021-07-04|||2021-07-17|2021-07-17|2021-07-20|Actual|||||||2021-07-17|2021-07-20|Actual|October 1, 2021|Anticipated|2021-10-01|July 2021|2021-07-31|September 30, 2026|Anticipated|2026-09-30|September 30, 2025|Anticipated|2025-09-30||Interventional|||Clinical Study of CAIX-targeted CAR-T Cells in the Treatment of Advanced Renal Cell Carcinoma|Clinical Study of CAIX-targeted CAR-T Cells in the Treatment of Advanced Renal Cell Carcinoma|Recruiting||Phase 1|20|Anticipated|The Affiliated Hospital of Xuzhou Medical University||1|||f||||t|f|f|||||||||No||2023-09-04 05:51:56.061347|2023-09-04 05:51:56.061347|OTHER|||||
NCT05620680||2022-11-11|||2022-11-11|2022-11-11|2022-11-17|Actual|||||||2022-11-11|2022-11-17|Actual|October 1, 2022|Actual|2022-10-01|November 2022|2022-11-30|October 31, 2028|Anticipated|2028-10-31|October 31, 2026|Anticipated|2026-10-31||Interventional|||CD7 CAR-T Cells in T-cell Lymphoma/Leukemia|Study of CD7 CAR-T Cells in Adult Refractory and Recurrent T-cell Lymphoma/Leukemia|Recruiting||Not Applicable|20|Anticipated|Shenzhen University General Hospital||1|||f||||t|f|f|||||||||||2023-09-01 03:20:32.535447|2023-09-01 03:20:32.535447|OTHER|||||
NCT05633615||2022-11-21|||2023-08-11|2022-11-21|2022-12-01|Actual|||||||2023-08-11|2023-08-14|Actual|June 12, 2023|Actual|2023-06-12|August 2023|2023-08-31|December 4, 2029|Anticipated|2029-12-04|December 4, 2024|Anticipated|2024-12-04||Interventional|||Testing Drug Treatments After CAR T-cell Therapy in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma|A Randomized Phase II Trial of Consolidation Therapy Following CD19 CAR T-Cell Treatment for Relapsed/Refractory Diffuse Large B-Cell Lymphoma or Grade IIIB Follicular Lymphoma|Recruiting||Phase 2|396|Anticipated|SWOG Cancer Research Network||5|||f||||t|t|f|||||||||||2023-09-04 21:22:30.943579|2023-09-04 21:22:30.943579|NETWORK|||||
NCT05587543||2022-09-27|||2023-08-10|2022-10-19|2022-10-20|Actual|||||||2023-08-10|2023-08-14|Actual|December 28, 2022|Actual|2022-12-28|August 2023|2023-08-31|October 2030|Anticipated|2030-10-31|October 2027|Anticipated|2027-10-31||Interventional|||Clinical Study on the EBV CAR-T /TCR-T Cells in the Treatment of Nasopharyngeal Carcinoma|Clinical Study on the Safety and Efficacy of EBV CAR-T /TCR-T Cells in the Treatment of Recurrent / Refractory EBV Positive Nasopharyngeal Carcinoma|Recruiting||Early Phase 1|24|Anticipated|Fudan University||2|||f||||f|f|f|||||||||No||2023-09-04 21:22:38.279802|2023-09-04 21:22:38.279802|OTHER|||||
NCT02442297||2015-05-11|||2023-08-10|2015-05-11|2015-05-13|Estimate|||||||2023-08-10|2023-08-14|Actual|April 1, 2016|Actual|2016-04-01|August 2023|2023-08-31|April 2037|Anticipated|2037-04-30|April 27, 2022|Actual|2022-04-27||Interventional|iCAR||T Cells Expressing HER2-specific Chimeric Antigen Receptors(CAR) for Patients With HER2-Positive CNS Tumors|Phase I Study of Intracranial Injection of T Cells Expressing HER2-specific Chimeric Antigen Receptors (CAR) in Subjects With HER2-Positive Tumors of the Central Nervous System (iCAR)|Active, not recruiting||Phase 1|10|Actual|Baylor College of Medicine||2|||f||||t|||||||||||||2023-09-04 21:27:08.936659|2023-09-04 21:27:08.936659|OTHER|||||
NCT04732845||2021-01-27|||2023-08-28|2021-01-27|2021-02-01|Actual|||||||2023-08-28|2023-08-29|Actual|April 26, 2021|Actual|2021-04-26|August 2023|2023-08-31|December 1, 2024|Anticipated|2024-12-01|June 1, 2024|Anticipated|2024-06-01||Interventional|||Human AntiCD19 Chimeric Antigen Receptor T Cells for Relapsed or Refractory Lymphoid Malignancies|Phase I Clinical Trial of Human AntiCD19 Chimeric Antigen Receptor T Cells for Treatment of Relapsed or Refractory Lymphoid Malignancies (Non-Hodgkin Lymphoma, Acute Lymphoblastic Leukemia, Chronic Lymphocytic Leukemia)|Recruiting||Phase 1|36|Anticipated|Case Comprehensive Cancer Center||2|||f||||t|t|f||||||Beginning 3 months and ending 5 years following article publication|Link to be provided at time of article publication||Yes|Individual participant data that underlie or influence the results observed from the study|2023-09-04 06:00:56.083321|2023-09-04 06:00:56.083321|OTHER|||||
NCT03434769||2018-02-09|||2023-08-28|2018-02-09|2018-02-15|Actual|||||||2023-08-28|2023-08-29|Actual|July 9, 2018|Actual|2018-07-09|August 2023|2023-08-31|December 1, 2023|Anticipated|2023-12-01|October 1, 2023|Anticipated|2023-10-01||Interventional|||AntiCD19 Chimeric Antigen Receptor T Cells for Relapsed or Refractory Non Hodgkin Lymphoma|Phase I Clinical Trial of AntiCD19 Chimeric Antigen Receptor T Cells for Treatment of Relapsed or Refractory Non Hodgkin Lymphoma|Active, not recruiting||Phase 1|31|Actual|Case Comprehensive Cancer Center||1|||f||||t|t|f|||f||||||||2023-09-04 06:03:59.814881|2023-09-04 06:03:59.814881|OTHER|||||
NCT05623488||2022-11-11|||2023-06-20|2022-11-11|2022-11-21|Actual|||||||2023-06-20|2023-06-22|Actual|February 6, 2023|Actual|2023-02-06|February 2023|2023-02-28|February 2038|Anticipated|2038-02-28|February 2025|Anticipated|2025-02-28||Interventional|||CAR T Cells in Mesothelin-Expressing Breast Cancer|Phase 1, Adaptive-design Trial of Human Chimeric Antigen Receptor Modified T Cells in Patients With Mesothelin Expressing Breast Cancer|Recruiting||Phase 1|12|Anticipated|University of Pennsylvania||2|||f||||t|t|t|t||||||||No||2023-09-04 21:35:30.388107|2023-09-04 21:35:30.388107|OTHER|||||
NCT05457010||2022-07-08|||2023-06-21|2022-07-12|2022-07-13|Actual|||||||2023-06-21|2023-06-22|Actual|November 28, 2022|Actual|2022-11-28|June 2023|2023-06-30|November 17, 2025|Anticipated|2025-11-17|September 30, 2025|Anticipated|2025-09-30||Interventional|||Phase I Study of Cell Therapies for the Treatment of Patients With Relapsed or Refractory AML or High-risk MDS|Master Protocol for the Phase 1 Study of Cell Therapies for the Treatment of Patients With Relapsed or Refractory Acute Myeloid Leukemia or High-risk Myelodysplastic Syndrome, Including Long-term Safety Follow-up|Recruiting||Phase 1|24|Anticipated|Arcellx, Inc.||1|||f||||f|t|f|||||||||No||2023-09-04 21:36:32.695795|2023-09-04 21:36:32.695795|INDUSTRY|||||
NCT05454241||2022-07-04|||2023-06-18|2022-07-08|2022-07-12|Actual|||||||2023-06-18|2023-06-22|Actual|September 7, 2022|Actual|2022-09-07|June 2023|2023-06-30|September 7, 2025|Anticipated|2025-09-07|September 7, 2024|Anticipated|2024-09-07||Interventional|||CD7 CAR-T for Patients With r/r CD7+ Hematologic Malignancies|Efficacy, Safety and PK of CD7 CAR-T in Patients With Relapsed or Refractory CD7+ Hematological Malignancies|Recruiting||Phase 2|22|Anticipated|Institute of Hematology & Blood Diseases Hospital||1|||f||||f|f|f|||||||||No|When the research is completed, it will be shared in the form of a paper publication|2023-09-04 21:36:34.804987|2023-09-04 21:36:34.804987|OTHER|||||
NCT05442580||2022-06-28|||2023-06-20|2022-07-01|2022-07-05|Actual|||||||2023-06-20|2023-06-22|Actual|May 30, 2023|Actual|2023-05-30|June 2023|2023-06-30|May 2041|Anticipated|2041-05-31|May 2041|Anticipated|2041-05-31||Interventional|||CART-38 in Adult AML and MM Patients|Phase 1 Study of Lintivirally Transduced T Cells Engineered to Contain Anti-CD38 Linked to TCRζ and 4-1BB Signaling Domains in Subjects With Acute Myeloid Leukemia and Multiple Myeloma|Recruiting||Phase 1|36|Anticipated|University of Pennsylvania||8|||f||||t|t|f|||||||||||2023-09-04 21:36:40.917167|2023-09-04 21:36:40.917167|OTHER|||||
NCT05432635||2022-06-21|||2023-06-22|2022-06-21|2022-06-27|Actual|||||||2023-06-22|2023-06-23|Actual|September 7, 2022|Actual|2022-09-07|June 2023|2023-06-30|April 25, 2027|Anticipated|2027-04-25|April 25, 2026|Anticipated|2026-04-25||Interventional|||Genetically Modified T-cells (CMV-Specific CD19-CAR T-cells) Plus a Vaccine (CMV-MVA Triplex) Following Stem Cell Transplantation for the Treatment of Intermediate or High Grade B-cell Non-Hodgkin Lymphoma|Pilot/Feasibility Study of CMV-Specific CD19-CAR T Cells Plus CMV-MVA Triplex Following Autologous Hematopoietic Stem Cell Transplantation for Patients With Intermediate or High Grade B-Lineage Non-Hodgkin Lymphoma (B-NHL)|Recruiting||Phase 1|15|Anticipated|City of Hope Medical Center||1|||||||t|t|f|||f||||||||2023-09-04 21:36:45.613191|2023-09-04 21:36:45.613191|OTHER|||||
NCT04877613||2021-05-03|||2023-06-20|2021-05-03|2021-05-07|Actual|||||||2023-06-20|2023-06-22|Actual|August 19, 2021|Actual|2021-08-19|June 2023|2023-06-30|June 1, 2039|Anticipated|2039-06-01|June 1, 2039|Anticipated|2039-06-01||Interventional|||GFRα4 CAR T Cells in MTC Patients|Phase I Trial of GFRα4 CAR T Cells in Adult Patients With Recurrent or Metastatic Medullary Thyroid Cancer|Recruiting||Phase 1|18|Anticipated|University of Pennsylvania||4|||||||t|t|f|||||||||No||2023-09-04 21:39:53.998211|2023-09-04 21:39:53.998211|OTHER|||||
NCT04499339||2020-07-24|||2023-06-20|2020-07-31|2020-08-05|Actual|||||||2023-06-20|2023-06-22|Actual|July 22, 2020|Actual|2020-07-22|June 2023|2023-06-30|March 2024|Anticipated|2024-03-31|March 2024|Anticipated|2024-03-31||Interventional|||A Phase I/IIa Clinical Trial to Assess Feasibility, Safety and Antitumor Activity of Autologous SLAMF7 CAR-T Cells in Multiple Myeloma|A Phase I/IIa Clinical Trial to Assess Feasibility, Safety and Antitumor Activity of Autologous SLAMF7 CAR-T Cells in Multiple Myeloma|Active, not recruiting||Phase 1/Phase 2|38|Anticipated|Wuerzburg University Hospital||1|||f||||t|f|f|||||||||||2023-09-04 21:41:44.550415|2023-09-04 21:41:44.550415|OTHER|||||
NCT04484012||2020-07-07|||2023-06-19|2020-07-21|2020-07-23|Actual|||||||2023-06-19|2023-06-22|Actual|December 31, 2020|Actual|2020-12-31|June 2023|2023-06-30|September 2, 2024|Anticipated|2024-09-02|September 2, 2024|Anticipated|2024-09-02||Interventional|||Modified Immune Cells (CD19 CAR T Cells) and Acalabrutinib for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma|A Phase 2 Study to Evaluate CD19-Specific Chimeric Antigen Receptor (CAR)-T Cells Combined With Acalabrutinib for Patients With Relapsed or Refractory Mantle Cell Lymphoma (MCL)|Recruiting||Phase 2|36|Anticipated|City of Hope Medical Center||1|||||||t|t|f|||f||||||||2023-09-04 21:41:48.908818|2023-09-04 21:41:48.908818|OTHER|||||
NCT02685670||2016-02-14|||2017-03-14|2016-02-14|2016-02-19|Estimate|||||||2017-03-14|2017-03-16|Actual|February 2016||2016-02-29|March 2017|2017-03-31|December 2019|Anticipated|2019-12-31|December 2017|Anticipated|2017-12-31||Interventional|MatchCART||Competitive Transfer of αCD19-TCRz-CD28 and αCD19-TCRz-CD137 CAR-T Cells for B-cell Leukemia/Lymphoma|A Phase I/II Study of Competitive Transfer of αCD19-TCRz-CD28 and αCD19-TCRz-CD137 Chimeric Antigen Receptor T-Cells in Patients With Refractory CD19+ B-lineage Leukemia/Lymphoma|Unknown status|Recruiting|Phase 1/Phase 2|20|Anticipated|The Second Affiliated Hospital of Henan University of Traditional Chinese Medicine||1|||f||||t|||||||||||Undecided||2023-09-02 12:10:44.624421|2023-09-02 12:10:44.624421|OTHER|||||
NCT04430530||2020-06-09|||2020-06-10|2020-06-10|2020-06-12|Actual|||||||2020-06-10|2020-06-12|Actual|June 1, 2020|Anticipated|2020-06-01|June 2020|2020-06-30|December 31, 2023|Anticipated|2023-12-31|May 31, 2023|Anticipated|2023-05-31||Interventional|||4SCAR-T Therapy Post CD19-targeted Immunotherapy|4SCAR-T Therapy After Anti-CD19 Immunotherapy Targeting B Cell Acute Lymphoblastic Leukemia|Recruiting||Phase 1/Phase 2|100|Anticipated|Shenzhen Geno-Immune Medical Institute||1|||f||||f|f|f|||||||||No||2023-09-04 06:18:02.951713|2023-09-04 06:18:02.951713|OTHER|||||
NCT03585764||2018-07-02|||2023-06-21|2018-07-02|2018-07-13|Actual|||||||2023-06-21|2023-06-22|Actual|October 24, 2018|Actual|2018-10-24|June 2023|2023-06-30|October 2038|Anticipated|2038-10-31|October 2038|Anticipated|2038-10-31||Interventional|||MOv19-BBz CAR T Cells in aFR Expressing Recurrent High Grade Serous Ovarian, Fallopian Tube, or Primary Peritoneal Cancer|Phase I Clinical Trial of Adoptive Transfer of Autologous Folate Receptor - Alpha Redirected T Cells for Recurrent High Grade Serous Ovarian, Fallopian Tube, or Primary Peritoneal Cancer|Recruiting||Phase 1|18|Anticipated|University of Pennsylvania||4|||f||||f|t|t|t||||||||||2023-09-04 21:46:35.52215|2023-09-04 21:46:35.52215|OTHER|||||
NCT03549442||2018-04-27|||2023-06-20|2018-05-24|2018-06-08|Actual|||||||2023-06-20|2023-06-22|Actual|May 9, 2018|Actual|2018-05-09|June 2023|2023-06-30|March 2036|Anticipated|2036-03-31|March 2036|Anticipated|2036-03-31||Interventional|||Up-front CART-BCMA With or Without huCART19 in High-risk Multiple Myeloma|Phase 1 Study of CART-BCMA With or Without huCART19 as Consolidation of Standard First or Second-Line Therapy for High-Risk Multiple Myeloma|Active, not recruiting||Phase 1|40|Actual|University of Pennsylvania||4|||||||f|t|f|||||||||||2023-09-04 21:46:43.390389|2023-09-04 21:46:43.390389|OTHER|||||
NCT03288493||2017-09-13|2023-04-25||2023-05-26|2017-09-18|2017-09-20|Actual|2023-05-26|2023-06-22|Actual||||2023-05-26|2023-06-22|Actual|September 20, 2017|Actual|2017-09-20|April 2023|2023-04-30|April 27, 2022|Actual|2022-04-27|April 27, 2022|Actual|2022-04-27||Interventional|||P-BCMA-101 Tscm CAR-T Cells in the Treatment of Patients With Multiple Myeloma (MM)|Open-Label, Multicenter, Phase 1 Study to Assess the Safety of P BCMA-101 in Subjects With Relapsed / Refractory Multiple Myeloma (MM) Followed by a Phase 2 Assessment of Response and Safety (PRIME)|Terminated||Phase 1/Phase 2|105|Actual|Poseida Therapeutics, Inc.||8||Phase I portion of the study was completed. The phase II portion of the study was terminated early to focus on an Allogeneic BCMA CAR-T program.|f||||t|t|f|||||||||||2023-09-04 21:47:31.2063|2023-09-04 21:47:31.2063|INDUSTRY|||||
NCT03054298||2017-02-09|||2023-06-20|2017-02-10|2017-02-15|Actual|||||||2023-06-20|2023-06-22|Actual|April 6, 2017|Actual|2017-04-06|June 2023|2023-06-30|March 2025|Anticipated|2025-03-31|March 2025|Anticipated|2025-03-31||Interventional|||CAR T Cells in Mesothelin Expressing Cancers|Phase I Study of Human Chimeric Antigen Receptor Modified T Cells in Patients With Mesothelin Expressing Cancers|Recruiting||Phase 1|27|Anticipated|University of Pennsylvania||7|||f||||t|t|f|||||||||Undecided||2023-09-04 21:48:22.323841|2023-09-04 21:48:22.323841|OTHER|||||
NCT02935543||2016-10-12|2020-01-09||2023-06-20|2016-10-13|2016-10-17|Estimate|2020-01-27|2020-02-05|Actual||||2023-06-20|2023-06-22|Actual|October 2016|Actual|2016-10-31|January 2020|2020-01-31|December 12, 2018|Actual|2018-12-12|December 12, 2018|Actual|2018-12-12||Interventional|||CART19 in Adult Patients With Minimal Residual Disease During Upfront Treatment for ALL|Phase 2 Study of CD19-directed Chimeric Antigen Receptor-modified T Cells (CART19) for Adult Patients With Minimal Residual Disease During Upfront Treatment for Acute Lymphoblastic Leukemia|Terminated||Phase 2|1|Actual|University of Pennsylvania||1||Study is terminated because of administrative reasons.|f||||t|||||||||||||2023-09-04 21:48:31.525418|2023-09-04 21:48:31.525418|OTHER|||||
NCT02277522||2014-10-27|||2023-06-20|2014-10-27|2014-10-29|Estimate|||||||2023-06-20|2023-06-22|Actual|October 2014||2014-10-31|November 2017|2017-11-30|June 27, 2017|Actual|2017-06-27|November 2016|Actual|2016-11-30||Interventional|||CD19 Redirected Autologous T Cells for Hodgkin Lymphoma|Pilot Study of Redirected Autologous T Cells Engineered to Contain Anti-CD19 Linked to TCRζ and 4-1BB Signaling Domains in Patients With Chemotherapy Relapsed or Refractory Hodgkin Lymphoma|Terminated||Early Phase 1|4|Actual|University of Pennsylvania||1||unable to meet enrollment goal|f||||t|||||||||||||2023-09-04 21:49:53.020353|2023-09-04 21:49:53.020353|OTHER|||||
NCT02030847||2014-01-07|2019-04-05||2023-06-20|2014-01-07|2014-01-09|Estimate|2019-05-23|2019-05-24|Actual||||2023-06-20|2023-06-22|Actual|February 27, 2014|Actual|2014-02-27|August 2019|2019-08-31|April 26, 2018|Actual|2018-04-26|April 26, 2018|Actual|2018-04-26||Interventional||Out of 42 enrolled, only 30 patients were infused with CART-19 product. 30 infused patients were considered for baseline analysis.|Study of Redirected Autologous T Cells Engineered to Contain Anti-CD19 Attached to TCR and 4-1BB Signaling Domains in Patients With Chemotherapy Resistant or Refractory Acute Lymphoblastic Leukemia|Phase II Study of Redirected Autologous T Cells Engineered to Contain Anti-CD19 Attached to TCR and 4-1BB Signaling Domains in Patients With Chemotherapy Resistant or RefractoryAcute Lymphoblastic Leukemia|Completed||Phase 2|42|Actual|University of Pennsylvania||1|||f||||t|||||||||||||2023-09-04 21:50:00.757624|2023-09-04 21:50:00.757624|OTHER|||||
NCT01837602||2013-04-18|||2023-06-20|2013-04-22|2013-04-23|Estimate|||||||2023-06-20|2023-06-22|Actual|April 2013||2013-04-30|October 2018|2018-10-31|August 13, 2018|Actual|2018-08-13|August 13, 2018|Actual|2018-08-13||Interventional|||cMet CAR RNA T Cells Targeting Breast Cancer|Clinical Trial of Autologous cMet Redirected T Cells Administered Intratumorally in Patients With Breast Cancer|Completed||Phase 1|6|Actual|University of Pennsylvania||1|||f||||t|||||||||||||2023-09-04 21:50:16.76521|2023-09-04 21:50:16.76521|OTHER|||||
NCT04861480||2021-04-06|||2023-04-16|2021-04-25|2021-04-27|Actual|||||||2023-04-16|2023-04-18|Actual|June 16, 2021|Actual|2021-06-16|April 2023|2023-04-30|July 18, 2024|Anticipated|2024-07-18|December 31, 2023|Anticipated|2023-12-31||Interventional|||Dual-target CAR-T Cells (C-4-29) in the Treatment of Relapsed/Refractory Multiple Myeloma|Phase I Clinical Study of CAR-T Cells (C-4-29) in the Treatment of Patients With Relapsed/Refractory Multiple Myeloma|Enrolling by invitation||Phase 1|18|Anticipated|Chongqing Precision Biotech Co., Ltd||1|||f||||f|f|f|||||||||||2023-09-04 06:20:34.325641|2023-09-04 06:20:34.325641|INDUSTRY|||||
NCT04429438||2020-06-09|||2020-06-10|2020-06-10|2020-06-12|Actual|||||||2020-06-10|2020-06-12|Actual|June 1, 2020|Anticipated|2020-06-01|June 2020|2020-06-30|December 31, 2023|Anticipated|2023-12-31|July 31, 2023|Anticipated|2023-07-31||Interventional|||Multi-CAR-T Cells Targeting B Cell Lymphomas|Primary, Booster and Consolidation Multi-CAR-T Cell Therapy for the Treatment of Refractory B Cell Lymphomas|Recruiting||Phase 1/Phase 2|11|Anticipated|Shenzhen Geno-Immune Medical Institute||1|||f||||f|f|f|||||||||No||2023-09-04 06:21:39.479351|2023-09-04 06:21:39.479351|OTHER|||||
NCT04850560||2021-04-18|||2021-06-05|2021-04-18|2021-04-20|Actual|||||||2021-06-05|2021-06-09|Actual|May 18, 2021|Actual|2021-05-18|April 2021|2021-04-30|May 1, 2024|Anticipated|2024-05-01|May 1, 2022|Anticipated|2022-05-01||Interventional|||Sequential Low-dose Decitabine With PD-1/CD28 CD19 CAR-T in Relapsed or Refractory B-cell Lymphoma|Sequential Low-dose Decitabine Therapy With Novel CAR-T Carrying PD-1/CD28 Chimeric Switch Receptor in Relapsed or Refractory B-cell Lymphoma|Recruiting||Phase 1|30|Anticipated|Second Affiliated Hospital, School of Medicine, Zhejiang University||1|||f||||f|f|f|||||||||No||2023-09-04 06:24:54.849768|2023-09-04 06:24:54.849768|OTHER|||||
NCT05091541||2021-09-15|||2021-10-12|2021-10-12|2021-10-25|Actual|||||||2021-10-12|2021-10-25|Actual|October 20, 2021|Anticipated|2021-10-20|October 2021|2021-10-31|October 20, 2039|Anticipated|2039-10-20|October 20, 2024|Anticipated|2024-10-20||Interventional|||A Phase 1/2 Study of CT120 in Patient With Relapsed/Refractory B-cell Non-Hodgkin's Lymphoma|A Multicenter Phase I/II Clinical Study on Fully Human Anti-CD19/CD22 Dual Target Chimeric Antigen Receptor Autologous T Cell Injection (CT120) for the Treatment of Relapsed/Refractory B-cell Non-Hodgkin's Lymphoma|Not yet recruiting||Phase 1/Phase 2|125|Anticipated|Nanjing IASO Biotherapeutics Co.,Ltd||1|||f||||t|f|f|||||||||||2023-09-04 22:04:48.535269|2023-09-04 22:04:48.535269|INDUSTRY|||||
NCT04981691||2021-07-07|||2021-09-16|2021-07-26|2021-07-29|Actual|||||||2021-09-16|2021-09-17|Actual|October 1, 2021|Anticipated|2021-10-01|September 2021|2021-09-30|July 9, 2022|Anticipated|2022-07-09|January 9, 2022|Anticipated|2022-01-09||Interventional|Amaretto||Anti-mesothelin CAR-T Cells With Advanced Refractory Solid Tumors|An Open, Single-center, Exploratory Clinical Trial to Evaluate the Safety and Efficacy of mRNA CAR-mesothelin T Cells in Patients With Advanced Refractory Solid Tumors|Recruiting||Phase 1|12|Anticipated|Ruijin Hospital||1|||f||||f|f|f|||||||||No||2023-09-04 22:07:59.540562|2023-09-04 22:07:59.540562|OTHER|||||
NCT05106907||2021-10-25|||2021-10-25|2021-10-25|2021-11-04|Actual|||||||2021-10-25|2021-11-04|Actual|October 25, 2021|Actual|2021-10-25|October 2021|2021-10-31|October 24, 2024|Anticipated|2024-10-24|October 24, 2023|Anticipated|2023-10-24||Interventional|||Safety and Clinical Activity of ThisCART19 in Patients With r/r Non-Hodgkin's B Cell Lymphoma|An Open and Single Dose-escalation Study to Evaluate the Safety and Clinical Activity of Allogeneic CAR-T Targeting CD19(ThisCART19) in Patients With Relapsed and/or Refractory Non-Hodgkin's B Cell Lymphoma (r/r B-NHL)|Recruiting||Phase 1|20|Anticipated|Fundamenta Therapeutics, Ltd.||1|||f|||||f|f|||||||||||2023-09-04 22:10:15.504901|2023-09-04 22:10:15.504901|INDUSTRY|||||
NCT01475058||2011-11-10||2017-01-31|2017-02-14|2011-11-16|2011-11-21|Estimate||||2017-02-14|2017-02-15|Actual|2017-02-14|2017-02-15|Actual|April 2012||2012-04-30|February 2017|2017-02-28|July 2014|Actual|2014-07-31|April 2014|Actual|2014-04-30||Interventional|||CD19 CAR T Cells for B Cell Malignancies After Allogeneic Transplant|A Phase I/II Study of Cellular Immunotherapy With Donor Central Memory-derived Virus-specific CD8+ T-cells Engineered to Target CD19 for CD19+ Malignancies After Allogeneic Hematopoietic Stem Cell Transplant|Completed||Phase 1/Phase 2|1|Actual|Fred Hutchinson Cancer Center||1|||f||||t|||||||||||||2023-09-04 06:29:30.592069|2023-09-04 06:29:30.592069|OTHER|||||
NCT03463928||2018-03-07|||2018-03-12|2018-03-12|2018-03-13|Actual|||||||2018-03-12|2018-03-13|Actual|October 8, 2017|Actual|2017-10-08|March 2018|2018-03-31|December 2019|Anticipated|2019-12-31|June 2019|Anticipated|2019-06-30||Interventional|||A Feasibility and Safety Study of Concomitant Therapy With Allo-CAR-T Cells and Allo-HSCT in Patients With Relapse or Refractory Leukemia|Phase I Study to Evaluate Treatment of Relapsed or Refractory Leukemia With Donor-derived HSCT Following Donor-derived CD19/22 Bispecific CAR-T Cells or CD19-directed CAR-T Cells|Unknown status|Recruiting|Phase 1|10|Anticipated|Chinese PLA General Hospital|||||f|||||f|f|||||||||No||2023-09-04 06:32:44.395907|2023-09-04 06:32:44.395907|OTHER|||||
NCT04436029||2020-06-15|||2022-03-10|2020-06-15|2020-06-17|Actual|||||||2022-03-10|2022-03-11|Actual|June 12, 2020|Actual|2020-06-12|March 2022|2022-03-31|March 10, 2022|Actual|2022-03-10|March 10, 2022|Actual|2022-03-10||Interventional|||Descartes-11 Consolidation Treatment in Patients With High-Risk Multiple Myeloma Who Have Residual Disease After Induction Therapy|Descartes-11 Consolidation Treatment in Patients With High-Risk Multiple Myeloma Who Have Residual Disease After Induction Therapy|Completed||Phase 2|4|Actual|Cartesian Therapeutics||1|||f||||f|t|f|||||||||||2023-09-04 22:18:14.885547|2023-09-04 22:18:14.885547|INDUSTRY|||||
NCT05123209||2021-09-08|||2021-11-05|2021-11-05|2021-11-17|Actual|||||||2021-11-05|2021-11-17|Actual|August 24, 2021|Actual|2021-08-24|September 2021|2021-09-30|August 30, 2023|Anticipated|2023-08-30|August 30, 2023|Anticipated|2023-08-30||Interventional|||Safety and Efficacy Evaluation of IM83 CAR-T Cells for Patients With Advanced Liver Tumors|Safety and Efficacy Evaluation of IM83 CAR-T Cells for Patients Wirh Advanced Liver Tumors|Recruiting||Phase 1|12|Anticipated|Beijing Immunochina Medical Science & Technology Co., Ltd.||2|||f|||||f|f|||||||||No||2023-09-04 22:19:03.622848|2023-09-04 22:19:03.622848|INDUSTRY|||||
NCT03796390||2019-01-04|||2019-01-09|2019-01-04|2019-01-08|Actual|||||||2019-01-09|2019-01-11|Actual|December 26, 2018|Actual|2018-12-26|January 2019|2019-01-31|June 6, 2021|Anticipated|2021-06-06|November 6, 2020|Anticipated|2020-11-06||Interventional|||Study Evaluating Safety and Efficacy of CAR-T Cells Targeting CD123 in Patients With Acute Myelocytic Leukemia|Study Evaluating Safety and Efficacy of CAR-T Cells Targeting CD123 in Patients With Acute Myelocytic Leukemia|Unknown status|Recruiting|Phase 1|15|Anticipated|Hebei Senlang Biotechnology Inc., Ltd.||1|||f|||||f|f|||||||||||2023-09-03 09:10:57.000574|2023-09-03 09:10:57.000574|INDUSTRY|||||
NCT04697940||2020-12-20|||2022-11-21|2021-01-05|2021-01-06|Actual|||||||2022-11-21|2022-11-25|Actual|December 15, 2020|Actual|2020-12-15|November 2022|2022-11-30|December 30, 2025|Anticipated|2025-12-30|December 30, 2023|Anticipated|2023-12-30||Interventional|||Decitabine-primed Tandem CD19/CD20 CAR T Cells Treatment in r/r B-NHL|Decitabine-primed Tandem Targeting CD19 and CD20 Chimeric Antigen Receptor T Cells Treatment in Relapsed and/or Refractory Non-Hodgkin's Lymphoma Patients|Recruiting||Phase 1/Phase 2|33|Anticipated|Chinese PLA General Hospital||1|||f|||||f|f|||||||||No||2023-09-04 06:35:47.984344|2023-09-04 06:35:47.984344|OTHER|||||
NCT05620732||2022-11-11|||2022-11-17|2022-11-11|2022-11-17|Actual|||||||2022-11-17|2022-11-22|Actual|October 1, 2022|Actual|2022-10-01|November 2022|2022-11-30|October 31, 2028|Anticipated|2028-10-31|October 31, 2025|Anticipated|2025-10-31||Interventional|||Treatment of Advanced Malignant Solid Tumors With Claudin18.2CAR-T|Efficacy and Safety of Claudin18.2CAR-T in Advanced Pancreatic Cancer and Gastric Carcinoma|Recruiting||Not Applicable|20|Anticipated|Shenzhen University General Hospital||1|||f||||t|f|f|||||||||No||2023-09-03 09:12:15.403912|2023-09-03 09:12:15.403912|OTHER|||||
NCT03016377||2017-01-06|||2023-06-16|2017-01-06|2017-01-10|Estimate|||||||2023-06-16|2023-06-18|Actual|March 22, 2012|Actual|2012-03-22|June 2023|2023-06-30|April 22, 2041|Anticipated|2041-04-22|April 22, 2026|Anticipated|2026-04-22||Interventional|||Administration of Autologous CAR-T CD19 Antigen With Inducible Safety Switch in Patients With Relapsed/Refractory ALL|Administration of Autologous CAR-T Cells Targeting the CD19 Antigen and Containing the Inducible caspase9 Safety Switch in Patients With Relapsed/Refractory Acute Lymphoblastic Leukemia|Recruiting||Phase 1/Phase 2|54|Anticipated|UNC Lineberger Comprehensive Cancer Center||2|||f||||t|t|f|||||||||No||2023-08-31 13:23:36.763955|2023-08-31 13:23:36.763955|OTHER|||||
NCT05495464||2022-07-28|||2022-11-18|2022-08-08|2022-08-10|Actual|||||||2022-11-18|2022-11-22|Actual|November 18, 2022|Actual|2022-11-18|October 2022|2022-10-31|March 31, 2027|Anticipated|2027-03-31|March 31, 2027|Anticipated|2027-03-31||Interventional|||"A Pilot Window-3 Study of Acalabrutinib Plus Rituximab Followed by Brexucabtagene Autoleucel Therapy in Patients With Previously Untreated High-risk Mantle Cell Lymphoma"|"A Pilot Window-3 Study of Acalabrutinib Plus Rituximab Followed by Brexucabtagene Autoleucel Therapy in Patients With Previously Untreated High-risk Mantle Cell Lymphoma"|Recruiting||Early Phase 1|20|Anticipated|M.D. Anderson Cancer Center||2|||||||t|t|f|||||||||||2023-09-03 09:13:36.96513|2023-09-03 09:13:36.96513|OTHER|||||
NCT03710421||2018-10-05|||2022-11-22|2018-10-15|2018-10-18|Actual|||||||2022-11-22|2022-11-25|Actual|February 13, 2019|Actual|2019-02-13|November 2022|2022-11-30|December 10, 2023|Anticipated|2023-12-10|December 10, 2023|Anticipated|2023-12-10||Interventional|||CS1-CAR T Therapy Following Chemotherapy in Treating Patients With Relapsed or Refractory CS1 Positive Multiple Myeloma|Phase I Study to Evaluate Cellular Immunotherapy Using Memory-Enriched T Cells Lentivirally Transduced to Express a CS1-Targeting, Hinge-Optimized, 41BB-Costimulatory Chimeric Antigen Receptor and a Truncated EGFR Following Lymphodepleting Chemotherapy in Adult Patients With CS1+ Multiple Myeloma|Recruiting||Phase 1|30|Anticipated|City of Hope Medical Center||1|||||||t|t|f|||f||||||||2023-09-04 08:52:07.831792|2023-09-04 08:52:07.831792|OTHER|||||
NCT04429451||2020-06-09|||2020-06-10|2020-06-10|2020-06-12|Actual|||||||2020-06-10|2020-06-12|Actual|January 1, 2020|Actual|2020-01-01|June 2020|2020-06-30|December 31, 2024|Anticipated|2024-12-31|October 31, 2023|Anticipated|2023-10-31||Interventional|||PSMA-specific CAR-T Cell Therapy|Phase I/II Clinical Trial of 4SCAR-PSMA T Cell Therapy Targeting PSMA Positive Malignancies|Recruiting||Phase 1/Phase 2|100|Anticipated|Shenzhen Geno-Immune Medical Institute||1|||f|||||f|f|||||||||No||2023-09-04 22:34:20.897061|2023-09-04 22:34:20.897061|OTHER|||||
NCT04828174||2021-03-31|||2021-03-31|2021-03-31|2021-04-01|Actual|||||||2021-03-31|2021-04-01|Actual|March 31, 2021|Actual|2021-03-31|March 2021|2021-03-31|March 2024|Anticipated|2024-03-31|March 2023|Anticipated|2023-03-31||Interventional|||Anti-TRBC1 CAR-T Cell Therapy in Patients With TRBC1 Positive T Cell Malignancies|The Safety and Clinical Efficacy of Human TRBC1 CAR-T Cell Therapy for Patients With Relapsed/Refractory TRBC1 Positive T Cell Hematological Maliganacies|Recruiting||Phase 1|9|Anticipated|Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine||1|||f|||||f|f|||||||||No||2023-09-04 06:43:40.97377|2023-09-04 06:43:40.97377|OTHER|||||
NCT05043571||2021-06-13|||2021-09-07|2021-09-07|2021-09-14|Actual|||||||2021-09-07|2021-09-14|Actual|September 8, 2021|Anticipated|2021-09-08|June 2021|2021-06-30|November 1, 2026|Anticipated|2026-11-01|November 1, 2026|Anticipated|2026-11-01||Interventional|||CARTALL: Chimeric-Antigen Receptor (CAR) T-Cell Therapy for Relapsed/ Refractory T-Lineage Acute Lymphoblastic Leukaemia|Anti-CD7 Protein Expression Blocker (PEBL) Chimeric-Antigen Receptor (CAR) T-Cell Therapy for Relapsed/ Refractory T-Lineage Acute Lymphoblastic Leukaemia (CARTALL)|Recruiting||Phase 1|20|Anticipated|National University Hospital, Singapore||1|||f||||t|f|f|||||||||No||2023-09-04 22:37:29.921547|2023-09-04 22:37:29.921547|OTHER|||||
NCT05030779||2021-08-18|||2021-08-31|2021-08-31|2021-09-01|Actual|||||||2021-08-31|2021-09-01|Actual|September 10, 2021|Anticipated|2021-09-10|August 2021|2021-08-31|September 10, 2022|Anticipated|2022-09-10|March 10, 2022|Anticipated|2022-03-10||Interventional|||A Study of CD19/BCMA Chimeric Antigen Receptor T Cells Therapy for Patients With Refractory Systemic Lupus Erythematosus|Clinical Trial for the Safety and Efficacy of CD19/BCMA Chimeric Antigen Receptor T Cells Therapy for Patients With Refractory Systemic Lupus Erythematosus|Unknown status|Recruiting|Early Phase 1|9|Anticipated|Zhejiang University||1|||f||||t|f|f|||||||||||2023-09-04 22:39:42.206439|2023-09-04 22:39:42.206439|OTHER|||||
NCT05290155||2022-03-09|||2022-08-29|2022-03-18|2022-03-22|Actual|||||||2022-08-29|2022-08-30|Actual|May 4, 2022|Actual|2022-05-04|August 2022|2022-08-31|April 1, 2024|Anticipated|2024-04-01|April 1, 2023|Anticipated|2023-04-01||Interventional|||Anti-CD7 CAR-T Cell Therapy for Relapse and Refractory CD7 Positive T Cell Malignancies|The Safety and Clinical Efficacy of Human CD7 CAR-T Cell Therapy for Patients With Relapsed/Refractory CD7 Positive T Cell Hematological Maliganacies|Recruiting||Phase 1|4|Anticipated|Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine||1|||f||||f|f|f|||||||||No||2023-09-04 22:44:21.635407|2023-09-04 22:44:21.635407|OTHER|||||
NCT04169932||2019-11-08|||2019-11-18|2019-11-18|2019-11-20|Actual|||||||2019-11-18|2019-11-20|Actual|November 22, 2019|Anticipated|2019-11-22|November 2019|2019-11-30|November 22, 2022|Anticipated|2022-11-22|November 22, 2022|Anticipated|2022-11-22||Interventional|||The Clinical Study of CD20 CAR-T Cells in Patients With Relapsed and Refractory B Cell Non-Hodgkin Lymphoma|The Clinical Study of CD20 CAR-T Cells in Patients With Relapsed and Refractory B Cell Non-Hodgkin Lymphoma|Unknown status|Recruiting|Early Phase 1|20|Anticipated|Shanghai Longyao Biotechnology Inc., Ltd.||1|||f|||||f|f|||||||||||2023-09-02 12:18:46.062955|2023-09-02 12:18:46.062955|OTHER|||||
NCT03993743||2019-06-19|||2019-08-24|2019-06-19|2019-06-21|Actual|||||||2019-08-24|2019-08-28|Actual|May 27, 2019|Actual|2019-05-27|August 2019|2019-08-31|May 27, 2022|Anticipated|2022-05-27|October 27, 2020|Anticipated|2020-10-27||Interventional|||A Study of CD147-targeted CAR-T by Hepatic Artery Infusions for Very Advanced Hepatocellular Carcinoma|An Open-label, Dose Escalation Clinical Study to Access the Safety and Clinical Activity of CD147-targeted CART by Hepatic Artery Infusions for Very Advanced Hepatocellular Carcinoma|Unknown status|Recruiting|Phase 1|34|Anticipated|Xijing Hospital||1|||f|||||f|f|||||||||||2023-09-03 09:17:58.677704|2023-09-03 09:17:58.677704|OTHER|||||
NCT05281809||2022-03-08|||2022-08-10|2022-03-08|2022-03-16|Actual|||||||2022-08-10|2022-08-12|Actual|April 19, 2022|Actual|2022-04-19|August 2022|2022-08-31|December 1, 2037|Anticipated|2037-12-01|August 5, 2037|Anticipated|2037-08-05||Interventional|||Local Manufacture of CAR T-Cell Products for the Treatment of B-Cell Lymphoma and B-Acute Lymphoblastic Leukemia|A Feasibility Study Following a Phase 2a Design to Demonstrate Successful Local Manufacture of Chimeric Antigen Receptor (CAR) T-Cell Products for the Treatment of B-Cell Lymphoma and B-Acute Lymphoblastic Leukemia|Recruiting||Phase 2|30|Anticipated|Allegheny Singer Research Institute (also known as Allegheny Health Network Research Institute)||1|||f||||t|t|f|||||||||No||2023-09-04 22:47:27.730006|2023-09-04 22:47:27.730006|OTHER|||||
NCT02081937||2014-03-06|||2014-03-10|2014-03-06|2014-03-07|Estimate|||||||2014-03-10|2014-03-11|Estimate|March 2014||2014-03-31|March 2014|2014-03-31|December 2019|Anticipated|2019-12-31|December 2018|Anticipated|2018-12-31||Interventional|||CART-19 Immunotherapy in Mantle Cell Lymphoma|Anti-CD19 Chimeric Antigen Receptor Modified T Cells Infusion in Mantle Cell Lymphoma|Unknown status|Recruiting|Phase 1/Phase 2|2|Anticipated|Chinese PLA General Hospital||1|||f||||t|||||||||||||2023-09-04 06:51:27.763528|2023-09-04 06:51:27.763528|OTHER|||||
NCT04796441||2021-03-08|||2021-03-11|2021-03-11|2021-03-12|Actual|||||||2021-03-11|2021-03-12|Actual|December 16, 2020|Actual|2020-12-16|March 2021|2021-03-31|February 16, 2022|Anticipated|2022-02-16|December 16, 2021|Anticipated|2021-12-16||Interventional|||Clinical Study of Universal CAR-γδT Cell Injection in the Treatment of Patients With Relapsed AML After Transplantation|Clinical Study of Universal CAR-γδT Cell Injection in the Treatment of Patients With Relapsed AML After Transplantation|Unknown status|Recruiting|Not Applicable|20|Anticipated|Hebei Senlang Biotechnology Inc., Ltd.||1|||f|||||f|f|||||||||||2023-09-04 22:48:01.574098|2023-09-04 22:48:01.574098|INDUSTRY|||||
NCT04796675||2021-03-10|||2021-04-05|2021-03-11|2021-03-15|Actual|||||||2021-04-05|2021-04-08|Actual|April 10, 2021|Anticipated|2021-04-10|April 2021|2021-04-30|March 10, 2024|Anticipated|2024-03-10|March 10, 2023|Anticipated|2023-03-10||Interventional|||Cord Blood Derived Anti-CD19 CAR-Engineered NK Cells for B Lymphoid Malignancies|Safety and Efficacy of Cord Blood Derived Anti-CD19 CAR-Engineered NK Cells for Relapsed/Refractory B Lymphoid Malignancies: a Single-center, Open-label, Single-arm Clinical Study|Recruiting||Phase 1|27|Anticipated|Wuhan Union Hospital, China||1|||f|||||f|f|||||||||No||2023-09-04 22:48:06.556565|2023-09-04 22:48:06.556565|OTHER|||||
NCT04803929||2021-03-15|||2021-03-19|2021-03-15|2021-03-18|Actual|||||||2021-03-19|2021-03-23|Actual|March 3, 2021|Actual|2021-03-03|March 2021|2021-03-31|March 1, 2026|Anticipated|2026-03-01|March 1, 2024|Anticipated|2024-03-01||Interventional|||Clinical Study of Anti-ILT3 CAR-T Therapy for R/R AML(M4/M5)|Clinical Study of Autologous T Cells Modified With ILT3 Chimeric Antigen Receptor for Relapsed/Refractory Acute Myeloid Leukemia (M4/M5)|Recruiting||Early Phase 1|25|Anticipated|Carbiogene Therapeutics Co. Ltd.||1|||f||||t|f|f|||||||||||2023-09-04 22:48:10.275653|2023-09-04 22:48:10.275653|INDUSTRY|||||
NCT04785833||2021-03-03|||2021-03-03|2021-03-03|2021-03-08|Actual|||||||2021-03-03|2021-03-08|Actual|March 4, 2021|Anticipated|2021-03-04|March 2021|2021-03-31|February 4, 2024|Anticipated|2024-02-04|April 30, 2022|Anticipated|2022-04-30||Interventional|||CD7 CAR-T in the Treatment of CD7 Positive Refractory Relapsed Acute Leukemia|A Prospective, Open, Single-arm Clinical Study on the Efficacy and Safety of CD7 CAR-T in the Treatment of CD7-positive Refractory Relapsed Acute Leukemia|Recruiting||Not Applicable|20|Anticipated|PersonGen BioTherapeutics (Suzhou) Co., Ltd.||1|||f|||||f|f|||||||||||2023-09-04 22:48:28.379605|2023-09-04 22:48:28.379605|INDUSTRY|||||
NCT05199519||2021-11-28|||2023-05-22|2022-01-06|2022-01-20|Actual|||||||2023-05-22|2023-05-24|Actual|December 13, 2021|Actual|2021-12-13|May 2023|2023-05-31|January 19, 2023|Actual|2023-01-19|October 29, 2022|Actual|2022-10-29||Interventional|||Study to Evaluate the Safety, Tolerance, Pharmacokinetics and Preliminary Efficacy of IBI345|A Phase Ia Study to Evaluate the Safety, Tolerance, Pharmacokinetics and Preliminary Efficacy of IBI345 in Patients With CLDN18.2-positive Solid Tumors|Completed||Phase 1|7|Actual|Innovent Biologics (Suzhou) Co. Ltd.||1|||f||||f|f|f|||||||||No||2023-09-04 22:50:45.357737|2023-09-04 22:50:45.357737|INDUSTRY|||||
NCT04790747||2021-03-08|||2021-03-08|2021-03-08|2021-03-10|Actual|||||||2021-03-08|2021-03-10|Actual|March 2021|Anticipated|2021-03-31|March 2021|2021-03-31|March 2025|Anticipated|2025-03-31|March 2024|Anticipated|2024-03-31||Interventional|||Sequential Radiotherapy With CAR-T Cells in the Treatment of Relapsed and Refractory Hematological Malignancies With Extramedullary Lesions|Clinical Trial for the Safety and Efficacy of Sequential Radiotherapy With CAR-T Cells in the Treatment of Relapsed and Refractory Hematological Malignancies With Extramedullary Lesions|Recruiting||Phase 1/Phase 2|50|Anticipated|Zhejiang University||1|||f||||t|f|f|||||||||No||2023-09-04 22:51:07.787562|2023-09-04 22:51:07.787562|OTHER|||||
NCT05474885||2022-07-23|||2022-07-23|2022-07-23|2022-07-26|Actual|||||||2022-07-23|2022-07-26|Actual|April 1, 2022|Actual|2022-04-01|April 2022|2022-04-30|April 30, 2025|Anticipated|2025-04-30|April 30, 2025|Anticipated|2025-04-30||Interventional|||BCMA-CD19 cCAR T Cell Treatment of Relapsed/Refractory Systemic Lupus Erythematosus (SLE)|BCMA-CD19 cCAR T Cell Treatment of Relapsed/Refractory Systemic Lupus Erythematosus (SLE)|Recruiting||Phase 1|15|Anticipated|iCell Gene Therapeutics||1|||f|||||f|f|||||||||||2023-09-04 22:53:19.621377|2023-09-04 22:53:19.621377|INDUSTRY|||||
NCT04433221||2020-06-09|||2020-06-12|2020-06-12|2020-06-16|Actual|||||||2020-06-12|2020-06-16|Actual|July 1, 2020|Anticipated|2020-07-01|June 2020|2020-06-30|December 31, 2023|Anticipated|2023-12-31|May 31, 2023|Anticipated|2023-05-31||Interventional|||Combination Immunotherapy Targeting Sarcomas|Safety and Efficacy Evaluation of a Combination Immunotherapy Targeting Sarcomas|Recruiting||Phase 1/Phase 2|20|Anticipated|Shenzhen Geno-Immune Medical Institute||1|||f||||f|f|f|||||||||No||2023-09-04 22:54:55.896949|2023-09-04 22:54:55.896949|OTHER|||||
NCT05472610||2022-07-21|||2022-07-21|2022-07-21|2022-07-25|Actual|||||||2022-07-21|2022-07-25|Actual|June 4, 2021|Actual|2021-06-04|July 2022|2022-07-31|January 2023|Anticipated|2023-01-31|January 2023|Anticipated|2023-01-31||Interventional|||Study of Efficacy of BZ019 in Large B-cell Lymphoma|A Phase II Clinical Study of CD19-targeted Chimeric Antigen Receptor (CAR) T Cells Injection, for Relapsed and Refractory (R/R) Large B-cell Lymphoma|Recruiting||Phase 2|36|Anticipated|Shanghai Mengchao Cancer Hospital||1|||f||||f|f|f|||||||||||2023-09-04 06:55:59.819294|2023-09-04 06:55:59.819294|OTHER|||||
NCT05412329||2022-06-04|||2022-07-23|2022-06-06|2022-06-09|Actual|||||||2022-07-23|2022-07-26|Actual|June 13, 2022|Actual|2022-06-13|July 2022|2022-07-31|June 1, 2024|Anticipated|2024-06-01|June 1, 2024|Anticipated|2024-06-01||Interventional|||Study of Dual Targeted CD19/BCMA FASTCART GC012F in Relapsed/ Refractory Multiple Myeloma|Open- Label Phase I Study to Assess the RP2D of GC012F CAR-T in Subjects With Relapsed/Refractory Multiple Myeloma|Recruiting||Phase 1|9|Anticipated|Shanghai Changzheng Hospital||1|||f||||f|f|f|||||||||||2023-09-04 22:56:27.264472|2023-09-04 22:56:27.264472|OTHER|||||
NCT02652910||2015-11-18|||2019-02-25|2016-01-11|2016-01-12|Estimate|||||||2019-02-25|2019-02-27|Actual|December 2015||2015-12-31|April 2016|2016-04-30|December 2019|Anticipated|2019-12-31|June 2019|Anticipated|2019-06-30||Interventional|MeCAR||Memory-enriched CAR-T Cells Immunotherapy for B Cell Lymphoma|A Two-Arm, Single-Center, Open-Label Pilot Study of IL-2 Programmed or IL-7/IL-15 Programmed Anti-CD19:TCRz:CD28 T-cells in Patient With CD19-Positive Lymphoma That is Resistant or Refractory to Chemotherapy|Unknown status|Recruiting|Phase 1/Phase 2|20|Anticipated|Xinqiao Hospital of Chongqing||2|||f||||t|||||||||||||2023-09-02 12:22:09.382856|2023-09-02 12:22:09.382856|OTHER|||||
NCT04977193||2021-07-12|||2021-07-23|2021-07-23|2021-07-26|Actual|||||||2021-07-23|2021-07-26|Actual|November 1, 2021|Anticipated|2021-11-01|July 2021|2021-07-31|November 1, 2024|Anticipated|2024-11-01|May 1, 2023|Anticipated|2023-05-01||Interventional|||A Study to Evaluate the Safety and Efficacy of ly011 Cell Injection in the Treatment of Advanced Gastric Adenocarcinoma|to Evaluate the Safety and Efficacy of LY011 Cell Injection（Targeting CLDN 18.2 Chimeric Antigen Receptor T Cells） in the Treatment of Advanced Gastric Adenocarcinoma|Recruiting||Early Phase 1|18|Anticipated|Shanghai Longyao Biotechnology Inc., Ltd.||1|||f||||f|f|f|||||||||||2023-09-04 22:59:54.147175|2023-09-04 22:59:54.147175|OTHER|||||
NCT05243212||2021-10-11|||2023-04-17|2022-02-07|2022-02-16|Actual|||||||2023-04-17|2023-04-18|Actual|September 19, 2021|Actual|2021-09-19|April 2023|2023-04-30|September 1, 2028|Anticipated|2028-09-01|September 1, 2023|Anticipated|2023-09-01||Interventional|||Study of CAR-BCMA, a Chimeric Antigen Receptor T Cell (CAR-T) Therapy Directed Against BCMA in Subjects With Multiple Myeloma|A Phase 1/2, Open-Label, Dose Escalation and Confirmation Study of CAR-BCMA, a Chimeric Antigen Receptor T Cell (CAR-T) Therapy Directed Against BCMA in Subjects With Multiple Myeloma|Recruiting||Phase 1/Phase 2|75|Anticipated|Sheba Medical Center||2|||f||||t|f|f|||||||||||2023-09-04 07:00:29.54197|2023-09-04 07:00:29.54197|OTHER_GOV|||||
NCT05128786||2021-11-10|||2023-04-14|2021-11-10|2021-11-22|Actual|||||||2023-04-14|2023-04-18|Actual|December 30, 2021|Actual|2021-12-30|April 2023|2023-04-30|August 15, 2025|Anticipated|2025-08-15|August 15, 2024|Anticipated|2024-08-15||Interventional|||CCT301-38 CAR-T in Patients With Relapsed or Refractory AXL Positive Sarcomas|A Phase I Trial to Assess Safety, Tolerability and Anti-tumor Activity of Autologous T Cell Modified Chimeric Antigen Receptor (CAR) (CCT301-38) in Patients With Relapsed or Refractory AXL Positive Sarcomas|Recruiting||Phase 1|9|Anticipated|Shanghai PerHum Therapeutics Co., Ltd.||1|||f|||||f|f|||||||||||2023-09-04 07:00:48.32394|2023-09-04 07:00:48.32394|INDUSTRY|||||
NCT04782193||2021-02-26|||2023-04-16|2021-03-02|2021-03-04|Actual|||||||2023-04-16|2023-04-18|Actual|May 23, 2021|Actual|2021-05-23|April 2023|2023-04-30|July 1, 2024|Anticipated|2024-07-01|December 31, 2023|Anticipated|2023-12-31||Interventional|||a Clinical Research of CD19 and CD22 Targeted Prime CAR-T Cell in Relapsed/Refractory B Cell Lymphoma|Study Evaluating Safety and Efficacy of CD19 and CD22 Targeted Prime CAR-T Cell in Patients With Relapsed/Refractory B Cell Lymphoma|Recruiting||Phase 1/Phase 2|40|Anticipated|Chongqing Precision Biotech Co., Ltd||1|||f||||f|f|f|||||||||Undecided||2023-09-04 07:01:44.268035|2023-09-04 07:01:44.268035|INDUSTRY|||||
NCT04781634||2021-02-26|||2023-04-16|2021-03-02|2021-03-04|Actual|||||||2023-04-16|2023-04-18|Actual|March 7, 2021|Actual|2021-03-07|February 2023|2023-02-28|July 1, 2024|Anticipated|2024-07-01|December 31, 2023|Anticipated|2023-12-31||Interventional|||a Clinical Research of CD19 and CD22 Targeted Prime CAR-T Cell in Relapsed/Refractory B-ALL|Study Evaluating Safety and Efficacy of CD19 and CD22 Targeted Prime CAR-T Cell in Patients With Relapsed/Refractory B-ALL|Recruiting||Phase 1/Phase 2|40|Anticipated|Chongqing Precision Biotech Co., Ltd||1|||f||||f|f|f|||||||||Undecided||2023-09-04 07:01:44.872392|2023-09-04 07:01:44.872392|INDUSTRY|||||
NCT04776330||2021-02-26|||2023-04-16|2021-02-26|2021-03-01|Actual|||||||2023-04-16|2023-04-18|Actual|March 7, 2021|Actual|2021-03-07|April 2023|2023-04-30|July 1, 2024|Anticipated|2024-07-01|December 31, 2023|Anticipated|2023-12-31||Interventional|||a Clinical Research of BCMA-Targeted Prime CAR-T Cell Therapy in Relapsed/Refractory Multiple Myeloma|Study Evaluating Safety and Efficacy of BCMA-Targeted Prime CAR-T Cell in Patients With Relapsed/Refractory Multiple Myeloma|Recruiting||Phase 1/Phase 2|80|Anticipated|Chongqing Precision Biotech Co., Ltd||1|||f||||t|f|f|||||||||||2023-09-04 07:01:45.487763|2023-09-04 07:01:45.487763|INDUSTRY|||||
NCT04649983||2020-08-30|||2023-04-16|2020-11-29|2020-12-02|Actual|||||||2023-04-16|2023-04-18|Actual|September 1, 2019|Actual|2019-09-01|April 2023|2023-04-30|July 1, 2024|Anticipated|2024-07-01|December 31, 2023|Anticipated|2023-12-31||Interventional|||CD19 and CD22 Targeted CAR-T Cell Therapy for Relapsed/Refractory B Cell Leukemia and Lymphoma|Safety and Efficacy of CD19 and CD22 Targeted CAR-T Therapy for Relapsed/Refractory B Cell Leukemia and Lymphoma|Recruiting||Phase 1/Phase 2|40|Anticipated|Chongqing Precision Biotech Co., Ltd||1|||f||||f|f|f|||||||||Undecided||2023-09-04 07:02:06.266461|2023-09-04 07:02:06.266461|INDUSTRY|||||
NCT04648475||2020-08-30|||2023-04-16|2020-11-29|2020-12-01|Actual|||||||2023-04-16|2023-04-18|Actual|August 25, 2020|Actual|2020-08-25|March 2023|2023-03-31|July 1, 2024|Anticipated|2024-07-01|December 31, 2023|Anticipated|2023-12-31||Interventional|||Safety and Efficacy of CD19 and CD22 Targeted CAR-T Therapy for Relapsed/Refractory B Cell Leukemia and Lymphoma|CD19 and CD22 Targeted CAR-T Cell Therapy for Relapsed/Refractory B Cell Leukemia and Lymphoma|Recruiting||Phase 1/Phase 2|40|Anticipated|Chongqing Precision Biotech Co., Ltd||1|||f||||f|f|f|||||||||No||2023-09-04 07:02:06.868116|2023-09-04 07:02:06.868116|INDUSTRY|||||
NCT04511871||2020-08-10|||2023-04-14|2020-08-12|2020-08-13|Actual|||||||2023-04-14|2023-04-18|Actual|July 9, 2020|Actual|2020-07-09|April 2023|2023-04-30|March 29, 2025|Anticipated|2025-03-29|March 29, 2024|Anticipated|2024-03-29||Interventional|||A Phase I Trial of CCT303-406 in Patients With Relapsed or Refractory HER2 Positive Solid Tumors|A Phase I Trial to Assess Safety, Tolerability and Anti-tumor Activity of Autologous T Cell Modified Chimeric Antigen Receptor (CAR) (CCT303-406) in Patients With Relapsed or Refractory HER2 Positive Solid Tumors|Recruiting||Phase 1|15|Anticipated|Shanghai PerHum Therapeutics Co., Ltd.||1|||f|||||f|f|||||||||||2023-09-04 07:02:31.838195|2023-09-04 07:02:31.838195|INDUSTRY|||||
NCT04348643||2020-04-14|||2023-04-16|2020-04-14|2020-04-16|Actual|||||||2023-04-16|2023-04-18|Actual|February 20, 2020|Actual|2020-02-20|April 2022|2022-04-30|April 30, 2024|Anticipated|2024-04-30|December 31, 2023|Anticipated|2023-12-31||Interventional|||Safety and Efficacy of CEA-Targeted CAR-T Therapy for Relapsed/Refractory CEA+ Cancer|Clinical Study of CEA-Targeted CAR-T Therapy in Patients With Relapsed and Refractory CEA+ Cancer|Recruiting||Phase 1/Phase 2|40|Anticipated|Chongqing Precision Biotech Co., Ltd||1|||f||||t|f|f|||||||||||2023-09-04 07:02:49.714877|2023-09-04 07:02:49.714877|INDUSTRY|||||
NCT04272151||2020-02-13|||2023-04-16|2020-02-14|2020-02-17|Actual|||||||2023-04-16|2023-04-18|Actual|December 1, 2019|Actual|2019-12-01|March 2023|2023-03-31|July 1, 2024|Anticipated|2024-07-01|December 31, 2023|Anticipated|2023-12-31||Interventional|||Safety and Efficacy of BCMA-Targeted CAR-T Therapy for Relapsed/Refractory Multiple Myeloma|Safety and Efficacy of BCMA-Targeted CAR-T Therapy for Relapsed/Refractory Multiple Myeloma|Recruiting||Phase 1/Phase 2|40|Anticipated|Chongqing Precision Biotech Co., Ltd||1|||f||||t|f|f|||||||||||2023-09-04 07:02:58.188138|2023-09-04 07:02:58.188138|INDUSTRY|||||
NCT04272125||2020-02-13|||2023-04-16|2020-02-14|2020-02-17|Actual|||||||2023-04-16|2023-04-18|Actual|December 1, 2019|Actual|2019-12-01|April 2023|2023-04-30|July 1, 2024|Anticipated|2024-07-01|December 31, 2023|Anticipated|2023-12-31||Interventional|||Safety and Efficacy of CD123-Targeted CAR-T Therapy for Relapsed/Refractory Acute Myeloid Leukemia|Safety and Efficacy of CD123-Targeted CAR-T Therapy for Relapsed/Refractory Acute Myeloid Leukemia|Recruiting||Phase 1/Phase 2|40|Anticipated|Chongqing Precision Biotech Co., Ltd||1|||f||||t|f|f|||||||||||2023-09-04 07:02:58.876984|2023-09-04 07:02:58.876984|INDUSTRY|||||
NCT04271800||2020-02-13|||2023-04-16|2020-02-14|2020-02-17|Actual|||||||2023-04-16|2023-04-18|Actual|December 1, 2019|Actual|2019-12-01|April 2023|2023-04-30|July 1, 2024|Anticipated|2024-07-01|December 31, 2023|Anticipated|2023-12-31||Interventional|||Safety and Efficacy of CD19-Targeted CAR-T Therapy for Relapsed/Refractory CD19+ B Cell Leukemia and Lymphoma|Safety and Efficacy of CD19-Targeted CAR-T Therapy for Relapsed/Refractory CD19+ B Cell Leukemia and Lymphoma|Recruiting||Phase 1/Phase 2|40|Anticipated|Chongqing Precision Biotech Co., Ltd||1|||f||||t|f|f|||||||||||2023-09-04 07:02:59.742566|2023-09-04 07:02:59.742566|INDUSTRY|||||
NCT04271644||2020-02-13|||2023-04-16|2020-02-14|2020-02-17|Actual|||||||2023-04-16|2023-04-18|Actual|April 1, 2019|Actual|2019-04-01|March 2023|2023-03-31|July 1, 2024|Anticipated|2024-07-01|December 31, 2023|Anticipated|2023-12-31||Interventional|||BCMA-Targeted CAR-T Cell Therapy for Relapsed/Refractory Multiple Myeloma|BCMA-Targeted CAR-T Cell Therapy for Relapsed/Refractory Multiple Myeloma|Recruiting||Phase 1/Phase 2|80|Anticipated|Chongqing Precision Biotech Co., Ltd||1|||f||||t|f|f|||f||||||||2023-09-04 07:03:00.663186|2023-09-04 07:03:00.663186|INDUSTRY|||||
NCT04271410||2020-02-13|||2023-04-16|2020-02-14|2020-02-17|Actual|||||||2023-04-16|2023-04-18|Actual|June 1, 2019|Actual|2019-06-01|March 2023|2023-03-31|July 1, 2024|Anticipated|2024-07-01|December 31, 2023|Anticipated|2023-12-31||Interventional|||CD19+Targeted CAR-T Cell Therapy for Relapsed/Refractory CD19+ B Cell Leukemia and Lymphoma|CD19+Targeted CAR-T Cell Therapy for Relapsed/Refractory CD19+ B Cell Leukemia and Lymphoma|Recruiting||Phase 1/Phase 2|80|Anticipated|Chongqing Precision Biotech Co., Ltd||1|||f||||t|f|f|||f||||||||2023-09-04 07:03:01.737607|2023-09-04 07:03:01.737607|INDUSTRY|||||
NCT04265963||2020-01-31|||2023-04-16|2020-02-09|2020-02-12|Actual|||||||2023-04-16|2023-04-18|Actual|September 1, 2019|Actual|2019-09-01|March 2023|2023-03-31|July 1, 2024|Anticipated|2024-07-01|December 31, 2023|Anticipated|2023-12-31||Interventional|||CD123-Targeted CAR-T Cell Therapy for Relapsed/Refractory Acute Myeloid Leukemia|CD123-Targeted CAR-T Cell Therapy for Relapsed/Refractory Acute Myeloid Leukemia|Recruiting||Phase 1/Phase 2|45|Anticipated|Chongqing Precision Biotech Co., Ltd||1|||f|||||f|f|||||||||||2023-09-04 07:03:02.663892|2023-09-04 07:03:02.663892|INDUSTRY|||||
NCT04951141||2021-06-24|||2021-07-01|2021-07-01|2021-07-06|Actual|||||||2021-07-01|2021-07-06|Actual|January 1, 2019|Actual|2019-01-01|June 2021|2021-06-30|December 21, 2023|Anticipated|2023-12-21|September 30, 2023|Anticipated|2023-09-30||Interventional|||Clinical Study of Intratumoral Injection of CAR-T Cells in the Treatment of Advanced Liver Tumors|Beijing Immunochina Medical Science & Technology Co., Ltd.|Recruiting||Early Phase 1|10|Anticipated|Beijing Immunochina Medical Science & Technology Co., Ltd.||1|||f|||||f|f|||||||||||2023-09-04 23:04:46.272856|2023-09-04 23:04:46.272856|INDUSTRY|||||
NCT03060343||2017-02-12|||2017-02-18|2017-02-18|2017-02-23|Actual|||||||2017-02-18|2017-02-23|Actual|November 28, 2016|Actual|2016-11-28|February 2017|2017-02-28|November 28, 2019|Anticipated|2019-11-28|November 28, 2018|Anticipated|2018-11-28||Interventional|||Zeushield Cytotoxic T Lymphocytes (Z-CTLs) for Relapsed or Refractory Non Small Cell Lung Cancer (NSCLC)|Preliminary Clinical Study of Autologous T Cells Modified Chimeric Antigen Receptor (CAR) Targeting PD-L1 and CD80/CD86 (Zeushield Cytotoxic T Lymphocytes) for the Treatment of Recurrent or Refractory Non Small Cell Lung Cancer|Unknown status|Recruiting|Early Phase 1|10|Anticipated|Second Xiangya Hospital of Central South University||1|||f|||||f|f|||||||||Undecided||2023-09-04 23:06:07.792151|2023-09-04 23:06:07.792151|OTHER|||||
NCT04489862||2020-07-21|||2020-07-27|2020-07-27|2020-07-28|Actual|||||||2020-07-27|2020-07-28|Actual|May 13, 2020|Actual|2020-05-13|July 2020|2020-07-31|December 2022|Anticipated|2022-12-31|June 2022|Anticipated|2022-06-30||Interventional|||αPD1-MSLN-CAR T Cells for the Treatment of MSLN-positive Advanced Solid Tumors|An Exploratory Study of MSLN-CAR T Cells Secreting PD-1 Nanobodies for the Treatment of MSLN-positive Advanced Solid Tumors|Unknown status|Recruiting|Early Phase 1|10|Anticipated|Wuhan Union Hospital, China||1|||f||||f|f|f|||||||||No||2023-09-04 08:46:26.169111|2023-09-04 08:46:26.169111|OTHER|||||
NCT04788472||2021-03-05|||2021-03-05|2021-03-05|2021-03-09|Actual|||||||2021-03-05|2021-03-09|Actual|March 5, 2021|Anticipated|2021-03-05|March 2021|2021-03-31|March 5, 2025|Anticipated|2025-03-05|March 5, 2024|Anticipated|2024-03-05||Interventional|||Sequential CD19 and CD22 CAR-T Therapy for Newly Diagnosed Ph+ B-ALL|Clinical Trial for the Safety and Efficacy of Sequential CD19 and CD22 CAR-T Therapy for Adult Patients With Newly Diagnosed Ph Chromosome Positive B-cell Acute Lymphoblastic Leukemia|Recruiting||Phase 1/Phase 2|50|Anticipated|Zhejiang University||1|||f||||t|f|f|||||||||No||2023-09-04 07:07:11.552023|2023-09-04 07:07:11.552023|OTHER|||||
NCT04650451||2020-11-20|||2023-04-18|2020-12-01|2020-12-02|Actual|||||||2023-04-18|2023-04-20|Actual|December 7, 2020|Actual|2020-12-07|April 2023|2023-04-30|January 2, 2027|Anticipated|2027-01-02|December 31, 2025|Anticipated|2025-12-31||Interventional|||Safety and Activity Study of HER2-Targeted Dual Switch CAR-T Cells (BPX-603) in Subjects With HER2-Positive Solid Tumors|A Phase 1/2, Open-Label, Multicenter, Non-Randomized, Safety and Activity Study of HER2-Targeted Dual Switch CAR-T Cells (BPX-603) In Subjects With Previously Treated Advanced HER2-Positive Solid Tumors|Suspended||Phase 1|220|Anticipated|Bellicum Pharmaceuticals||1||Due to a Dose Limiting Toxicity in another sister trial with same technology.|f||||f|t|f|||||||||||2023-09-01 03:41:54.540151|2023-09-01 03:41:54.540151|INDUSTRY|||||
NCT04526834||2020-08-20|||2023-04-18|2020-08-25|2020-08-26|Actual|||||||2023-04-18|2023-04-20|Actual|September 8, 2021|Actual|2021-09-08|April 2023|2023-04-30|March 2036|Anticipated|2036-03-31|November 22, 2022|Actual|2022-11-22||Interventional|CERTAIN||Phase 1 Study of Autologous CD30.CAR-T in Relapsed or Refractory CD30 Positive Non-Hodgkin Lymphoma|Phase 1 Study of CD30-Directed Genetically Modified Autologous T-Cells (CD30.CAR-T) in Patients With Relapsed or Refractory CD30 Positive Non-Hodgkin Lymphoma|Active, not recruiting||Phase 1|21|Anticipated|Tessa Therapeutics||1||||||||t|f|||||||||No||2023-09-01 03:42:06.420507|2023-09-01 03:42:06.420507|INDUSTRY|||||
NCT04427449||2020-06-09|||2020-06-09|2020-06-09|2020-06-11|Actual|||||||2020-06-09|2020-06-11|Actual|June 1, 2020|Actual|2020-06-01|June 2020|2020-06-30|December 31, 2023|Anticipated|2023-12-31|May 31, 2023|Anticipated|2023-05-31||Interventional|||4SCAR-CD44v6 T Cell Therapy Targeting Cancer|Multi-center Phase I/II Clinical Trial of 4SCAR-CD44v6 T Cells for Treating Cancer|Recruiting||Phase 1/Phase 2|100|Anticipated|Shenzhen Geno-Immune Medical Institute||1|||f|||||f|f|||||||||||2023-09-04 23:25:36.028664|2023-09-04 23:25:36.028664|OTHER|||||
NCT04812691||2021-01-18|||2021-03-22|2021-03-22|2021-03-24|Actual|||||||2021-03-22|2021-03-24|Actual|July 10, 2020|Actual|2020-07-10|January 2021|2021-01-31|March 31, 2023|Anticipated|2023-03-31|June 30, 2021|Anticipated|2021-06-30||Interventional|||CD19-targeted CAR T Cells （JWCAR029） for Primary Refractory Diffuse Large B Cell Lymphoma|CD19-targeted CAR T Cells （JWCAR029） for Primary Refractory Diffuse Large B Cell Lymphoma, Phase Ⅰ,Open-label,Single-arm,Muticenter Study|Unknown status|Recruiting|Phase 1|12|Anticipated|Shanghai Ming Ju Biotechnology Co., Ltd.||1|||f|||||f|f|||||||||No||2023-09-04 23:25:39.370879|2023-09-04 23:25:39.370879|INDUSTRY|||||
NCT04787263||2021-03-02|||2021-03-24|2021-03-05|2021-03-08|Actual|||||||2021-03-24|2021-03-26|Actual|March 4, 2021|Actual|2021-03-04|February 2021|2021-02-28|March 3, 2038|Anticipated|2038-03-03|March 3, 2025|Anticipated|2025-03-03||Interventional|||CD19-CAR_Lenti T Cells in Pediatric Patients Affected by Relapsed/Refractory CD19+ ALL and DLBCL or PML|Phase I/II Study of Anti-CD19 Chimeric Antigen Receptor-Expressing T Cells in Pediatric Patients Affected by Relapsed/Refractory CD19+ Acute Lymphoblastic Leukemia and Diffuse Large B Cell Lymphoma (DLBCL) or Primary Mediastinal B Cell Lymphoma (PML)|Recruiting||Phase 1/Phase 2|32|Anticipated|Bambino Gesù Hospital and Research Institute||1|||f|||||f|f|||||||||||2023-09-04 23:26:46.881134|2023-09-04 23:26:46.881134|OTHER|||||
NCT04340167||2020-04-08|||2022-08-12|2020-04-08|2020-04-09|Actual|||||||2022-08-12|2022-08-15|Actual|May 1, 2020|Actual|2020-05-01|August 2022|2022-08-31|October 1, 2024|Anticipated|2024-10-01|May 1, 2024|Anticipated|2024-05-01||Interventional|||Study of Anti-CD22 CAR-T Cells Treating Leukemia Children|Phase II Study of Autologous Humanized Anti-CD22 Chimeric Antigen Receptor T Cells Treating Refractory or Relapsed B Acute Lymphoblastic Leukemia Children|Recruiting||Phase 2|100|Anticipated|Beijing Boren Hospital||1|||f|||||f|f|||||||||||2023-09-04 23:27:58.71039|2023-09-04 23:27:58.71039|OTHER|||||
NCT04134325||2019-09-13|||2023-02-21|2019-10-17|2019-10-22|Actual|||||||2023-02-21|2023-02-22|Actual|September 1, 2019|Actual|2019-09-01|February 2023|2023-02-28|July 7, 2037|Anticipated|2037-07-07|April 22, 2024|Anticipated|2024-04-22||Interventional|||Study of PD-1 Inhibitors After CD30.CAR T Cell Therapy in Relapsed/Refractory Hodgkin Lymphoma|A Prospective Pilot Study Assessing the Immunomodulatory Effect and Clinical Activity of Programmed Cell Death Protein 1 Inhibition Following CD30 Directed Chimeric Antigen Receptor T Cell Therapy in Relapsed/Refractory Classical Hodgkin Lymphoma|Recruiting||Early Phase 1|20|Anticipated|UNC Lineberger Comprehensive Cancer Center||2|||f||||t|t|f|||f||||||No||2023-09-04 23:28:31.936068|2023-09-04 23:28:31.936068|OTHER|||||
NCT05535673||2022-08-30|||2022-09-09|2022-09-09|2022-09-10|Actual|||||||2022-09-09|2022-09-10|Actual|September 2, 2022|Anticipated|2022-09-02|September 2022|2022-09-30|July 1, 2025|Anticipated|2025-07-01|July 1, 2025|Anticipated|2025-07-01||Interventional|||Safety, Efficacy and Pharmacokinetics of ThisCART19A in Patients With Refractory or Relapsed B Cell Lymphoma|A Single Dose-escalation Study to Evaluate the Safety, Efficacy and Pharmacokinetics of Allogeneic CAR-T Targeting CD19 in Patients With Refractory or Relapsed B Cell Lymphoma|Not yet recruiting||Phase 1|15|Anticipated|Zhengzhou University||1|||f||||f|f|f|||||||||No||2023-09-04 23:31:58.242908|2023-09-04 23:31:58.242908|OTHER|||||
NCT05464719||2022-07-11|||2023-08-29|2022-07-14|2022-07-19|Actual|||||||2023-08-29|2023-08-31|Estimate|September 23, 2022|Actual|2022-09-23|August 2023|2023-08-31|January 30, 2026|Anticipated|2026-01-30|January 30, 2026|Anticipated|2026-01-30||Interventional|||A Phase II Study of Loncastuximab Tesirine as Consolidation Strategy in Patients With LBCL in PR After CAR T-cell Therapy|A Phase II Study of Loncastuximab Tesirine as Consolidation Strategy in Patients With LBCL in PR After CAR T-cell Therapy|Recruiting||Phase 2|30|Anticipated|M.D. Anderson Cancer Center||1|||||||t|t|f|||||||||||2023-09-01 04:18:46.993|2023-09-01 04:18:46.993|OTHER|||||
NCT04257578||2020-01-28|||2023-04-18|2020-02-03|2020-02-06|Actual|||||||2023-04-18|2023-04-20|Actual|December 2, 2020|Actual|2020-12-02|April 2023|2023-04-30|March 1, 2029|Anticipated|2029-03-01|March 1, 2024|Anticipated|2024-03-01||Interventional|||Acalabrutinib and Anti-CD19 CAR T-cell Therapy for the Treatment of B-cell Lymphoma|Acalabrutinib in Combination With Anti-CD19 Chimeric Antigen Receptor T-Cells (CART) in B-Cell Lymphoma|Recruiting||Phase 1/Phase 2|50|Anticipated|University of Washington||1|||f||||t|t|f|||||||||No||2023-09-01 03:42:37.888374|2023-09-01 03:42:37.888374|OTHER|||||
NCT03721068||2018-10-24|||2023-06-16|2018-10-24|2018-10-26|Actual|||||||2023-06-16|2023-06-18|Actual|February 19, 2019|Actual|2019-02-19|June 2023|2023-06-30|June 19, 2039|Anticipated|2039-06-19|June 19, 2024|Anticipated|2024-06-19||Interventional|||Study of CAR T-Cells Targeting the GD2 With IL-15+iCaspase9 for Relapsed/Refractory Neuroblastoma or Relapsed/Refractory Osteosarcoma|A Phase I Study of Autologous Activated T-Cells Expressing a 2nd Generation GD2 Chimeric Antigen Receptor, IL-15, and iCaspase9 Safety Switch Administered To Patients With Relapsed/Refractory Neuroblastoma or Relapsed/Refractory Osteosarcoma|Recruiting||Phase 1|18|Anticipated|UNC Lineberger Comprehensive Cancer Center||1|||||||t|t|f|||||||||||2023-08-31 13:22:15.631414|2023-08-31 13:22:15.631414|OTHER|||||
NCT04892277||2021-05-12|||2023-05-18|2021-05-17|2021-05-19|Actual|||||||2023-05-18|2023-05-19|Actual|July 14, 2022|Actual|2022-07-14|May 2023|2023-05-31|December 15, 2025|Anticipated|2025-12-15|December 15, 2024|Anticipated|2024-12-15||Interventional|||CD19-Directed CAR-T Cell Therapy for the Treatment of Relapsed/Refractory B Cell Malignancies|Phase I Dose Escalation Trial of CD19 Directed Chimeric Antigen Receptor T Cell Therapy in the Treatment of Relapsed/Refractory B Cell Malignancies|Recruiting||Phase 1|25|Anticipated|Mayo Clinic||1|||f||||t|t|f|||||||||||2023-09-04 23:37:59.851085|2023-09-04 23:37:59.851085|OTHER|||||
NCT03672318||2018-09-13|||2023-08-14|2018-09-13|2018-09-14|Actual|||||||2023-08-14|2023-08-15|Actual|January 14, 2019|Actual|2019-01-14|August 2023|2023-08-31|June 2028|Anticipated|2028-06-30|July 2024|Anticipated|2024-07-31||Interventional|||Study of ATLCAR.CD138 Cells for Relapsed/Refractory Multiple Myeloma|Phase I Study of Autologous CAR T-Cells Targeting the CD138 Antigen for Relapsed or Refractory Multiple Myeloma|Recruiting||Phase 1|33|Anticipated|UNC Lineberger Comprehensive Cancer Center||1|||f||||t|t|f|||||||||||2023-08-31 13:22:23.782528|2023-08-31 13:22:23.782528|OTHER|||||
NCT05528887||2022-09-01|||2022-09-01|2022-09-01|2022-09-06|Actual|||||||2022-09-01|2022-09-06|Actual|September 16, 2021|Actual|2021-09-16|September 2022|2022-09-30|June 2026|Anticipated|2026-06-30|June 2024|Anticipated|2024-06-30||Interventional|||Study of CAR-T Cell Therapy in the Treatment of Relapsed/Refractory Hematological Malignancies|Safety and Efficacy Study of Chimeric Antigen Receptor T (CAR-T) Cells in the Treatment of Relapsed/Refractory Hematological Malignancies|Recruiting||Phase 1|10|Anticipated|The Affiliated People's Hospital of Ningbo University||1|||f||||f|f|f|||||||||||2023-09-04 23:41:10.864307|2023-09-04 23:41:10.864307|OTHER_GOV|||||
NCT05523661||2021-11-14|||2022-08-29|2022-08-29|2022-08-31|Actual|||||||2022-08-29|2022-08-31|Actual|March 1, 2021|Actual|2021-03-01|August 2022|2022-08-31|September 1, 2024|Anticipated|2024-09-01|March 1, 2024|Anticipated|2024-03-01||Interventional|||Dasatinib Plus Anti-CD19/CD22 Bispecific CAR-T Cell Therapy for Elderly Ph-positive ALL Patients|The Safety and Clinical Efficacy of Dasatinib Plus Human CD19/CD22 Bispecific CAR-T Cell Therapy for Elderly Subjects With Ph-positive Acute Lymphoblastic Leukemia|Recruiting||Phase 1|15|Anticipated|Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine||1|||f|||||f|f|||||||||No||2023-09-04 23:42:32.903106|2023-09-04 23:42:32.903106|OTHER|||||
NCT05478343||2022-07-26|||2022-07-26|2022-07-26|2022-07-28|Actual|||||||2022-07-26|2022-07-28|Actual|May 6, 2021|Actual|2021-05-06|July 2022|2022-07-31|August 1, 2023|Anticipated|2023-08-01|May 1, 2023|Anticipated|2023-05-01||Interventional|||Clinical Trial to Evaluate the Safety and Efficacy of IM21 CAR-T Cells in Patients With Relapsed and Refractory (R/R) Multiple Myeloma|Clinical Trial to Evaluate the Safety and Efficacy of IM21 CAR-T Cells in Patients With Relapsed and Refractory (R/R) Multiple Myeloma|Recruiting||Early Phase 1|10|Anticipated|Beijing Immunochina Medical Science & Technology Co., Ltd.||1|||f|||||f|f|||||||||||2023-09-04 23:50:06.607598|2023-09-04 23:50:06.607598|INDUSTRY|||||
NCT05480501||2022-07-27|||2022-07-27|2022-07-27|2022-07-29|Actual|||||||2022-07-27|2022-07-29|Actual|July 11, 2022|Actual|2022-07-11|July 2022|2022-07-31|October 1, 2024|Anticipated|2024-10-01|August 1, 2024|Anticipated|2024-08-01||Interventional|||Clinical Trial to Evaluate the Safety and Efficacy of IM19 CAR-T Cells in Patients With Relapsed and Refractory (R/R) B-cell Acute Lymphoblastic Leukemia|Clinical Trial to Evaluate the Safety and Efficacy of IM19 CAR-T Cells in Patients With Relapsed and Refractory (R/R) B-cell Acute Lymphoblastic Leukemia|Recruiting||Early Phase 1|9|Anticipated|Beijing Immunochina Medical Science & Technology Co., Ltd.||1|||f|||||f|f|||||||||||2023-09-04 23:55:34.70021|2023-09-04 23:55:34.70021|INDUSTRY|||||
NCT05472857||2022-07-20|||2022-09-22|2022-07-21|2022-07-25|Actual|||||||2022-09-22|2022-09-26|Actual|August 8, 2022|Actual|2022-08-08|September 2022|2022-09-30|December 2024|Anticipated|2024-12-31|December 2024|Anticipated|2024-12-31||Interventional|||Clinical Study of CLDN18.2-targeting CAR T Cells in Advanced Solid Tumors With Positive CLDN18.2 Expression|Clinical Study of CLDN18.2-targeting Chimeric Antigen Receptor-modified Autologous T Cells in Advanced Solid Tumors With Positive CLDN18.2 Expression|Recruiting||Phase 1|30|Anticipated|Suzhou Immunofoco Biotechnology Co., Ltd||1|||f||||t|f|f|||f||||||No||2023-09-04 23:56:19.558374|2023-09-04 23:56:19.558374|INDUSTRY|||||
NCT05477927||2022-05-07|||2022-09-15|2022-07-26|2022-07-28|Actual|||||||2022-09-15|2022-09-19|Actual|October 30, 2022|Anticipated|2022-10-30|September 2022|2022-09-30|December 31, 2024|Anticipated|2024-12-31|December 31, 2024|Anticipated|2024-12-31||Interventional|||Dual-targeting VEGFR1 and PD-L1 CAR-T for Cancers Patients With Pleural or Peritoneal Metastases|A Phase Ia/Ib, Open-label, Single-arm, Dose-escalation and Expansion Study of Specific Dual-targeting VEGFR1 and PD-L1 CAR-T in Cancer Patients With Pleural or Peritoneal Metastases|Recruiting||Phase 1|58|Anticipated|Sichuan University||1|||f|||||f|f|||||||||||2023-09-04 23:57:25.247479|2023-09-04 23:57:25.247479|OTHER|||||
NCT04973527||2021-07-07|||2022-08-12|2021-07-21|2021-07-22|Actual|||||||2022-08-12|2022-08-16|Actual|July 2, 2021|Actual|2021-07-02|August 2022|2022-08-31|July 20, 2022|Actual|2022-07-20|July 11, 2022|Actual|2022-07-11||Interventional|||LCAR-T2C CAR-T Cells in Relapsed or Refractory CD4+ T Lymphocyte Tumor|A Phase I, Multicenter Study to Evaluate the Safety, Tolerability, and Efficacy of LCAR-T2C CAR-T Cells in Relapsed or Refractory CD4+ T Lymphocyte Tumor Patients|Terminated||Phase 1|9|Actual|Beijing Boren Hospital||1||Both the sponsors and collaborator are considering terminating the study|f|||||f|f|||||||||||2023-09-05 00:10:45.963748|2023-09-05 00:10:45.963748|OTHER|||||
NCT02915445||2016-09-21|||2022-10-08|2016-09-23|2016-09-27|Estimate|||||||2022-10-08|2022-10-12|Actual|July 2016||2016-07-31|October 2022|2022-10-31|July 2023|Anticipated|2023-07-31|July 2023|Anticipated|2023-07-31||Interventional|||EpCAM CAR-T for Treatment of Advanced Solid Tumors|T Cells Armed With Chimeric Antigen Receptor Recognizing EpCAM for Patients With Advanced Solid Tumors|Recruiting||Phase 1|30|Anticipated|Sichuan University||1|||f||||t|f|f|||||||||No||2023-09-04 07:35:25.92196|2023-09-04 07:35:25.92196|OTHER|||||
NCT05421663||2022-06-10|||2022-12-09|2022-06-13|2022-06-16|Actual|||||||2022-12-09|2022-12-13|Actual|August 9, 2022|Actual|2022-08-09|December 2022|2022-12-31|July 2038|Anticipated|2038-07-31|May 2025|Anticipated|2025-05-31||Interventional|||A Study of C-CAR039 in Patients With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma|A Phase Ib Multicenter, Open-Label, Study of C-CAR039, an Autologous CD19/CD20 Bi-specific CAR-T Cell Therapy in Adult Patients With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma|Recruiting||Phase 1|15|Anticipated|Cellular Biomedicine Group, Inc.||1|||f|||||t|f|||||||||No||2023-09-05 00:18:28.687524|2023-09-05 00:18:28.687524|INDUSTRY|||||
NCT04840875||2021-04-08|||2022-08-12|2021-04-08|2021-04-12|Actual|||||||2022-08-12|2022-08-15|Actual|April 20, 2021|Actual|2021-04-20|August 2022|2022-08-31|April 20, 2025|Anticipated|2025-04-20|April 20, 2023|Anticipated|2023-04-20||Interventional|||Phase I Clinical Trial of Autologous CD7-CAR T Cells in the Treatment of High-risk Acute T-cell Leukemia / Lymphoma|Phase I Clinical Trial of Autologous CD7-CAR T Cells in the Treatment of High-risk Acute T-cell Leukemia / Lymphoma|Recruiting||Phase 1|20|Anticipated|Beijing Boren Hospital||1|||f|||||f|f|||||||||No||2023-09-05 00:19:34.113717|2023-09-05 00:19:34.113717|OTHER|||||
NCT04703686||2021-01-04|||2023-01-09|2021-01-08|2021-01-11|Actual|||||||2023-01-09|2023-01-10|Actual|March 30, 2021|Actual|2021-03-30|January 2023|2023-01-31|March 1, 2026|Anticipated|2026-03-01|September 24, 2023|Anticipated|2023-09-24||Interventional|||Treatment by a Bispecific CD3xCD20 Antibody for Relapse/Refractory Lymphomas After CAR T-cells Therapy|A Phase II Trial Evaluating Glofitamab, a Bispecific CD3xCD20 Antibody for Relapse/Refractory Lymphomas After CAR T-cells Therapy|Recruiting||Phase 2|78|Anticipated|The Lymphoma Academic Research Organisation||1|||f||||f|f|f|||||||||No||2023-09-04 07:39:48.748557|2023-09-04 07:39:48.748557|OTHER|||||
NCT03366350||2017-12-01|||2019-05-08|2017-12-07|2017-12-08|Actual|||||||2019-05-08|2019-05-10|Actual|April 15, 2016|Actual|2016-04-15|May 2019|2019-05-31|June 1, 2021|Anticipated|2021-06-01|January 1, 2021|Anticipated|2021-01-01||Interventional|||Anti-CD19 CAR-T Therapy Bridging to HSCT for CD19+ B-Cell Malignancies|A Phase 1/2 Study Evaluating the Safety and Efficacy of Anti-CD19 Chimeric Antigen Receptor-Modified T Cell (CAR-T) Therapy Bridging to Hematological Stem Cell Transplantation (HSCT) for Relapsed/Refractory CD19+ B-Cell Malignancies|Unknown status|Recruiting|Phase 1/Phase 2|50|Anticipated|Wuhan Sian Medical Technology Co., Ltd||1|||f||||f|f|f|||||||||Undecided||2023-09-04 07:44:56.308279|2023-09-04 07:44:56.308279|INDUSTRY|||||
NCT04219319||2019-11-20|||2022-08-12|2020-01-03|2020-01-07|Actual|||||||2022-08-12|2022-08-16|Actual|December 15, 2021|Actual|2021-12-15|August 2022|2022-08-31|July 20, 2022|Actual|2022-07-20|July 20, 2022|Actual|2022-07-20||Interventional|||LCAR-T2C CAR-T Cells in Relapsed or Refractory CD4+ T-cell Lymphoma|A Phase I, Multicenter Study to Evaluate the Safety, Tolerability, and Efficacy of LCAR-T2C CAR-T Cells in Relapsed or Refractory CD4+ T Lymphocyte Tumor Patiens|Terminated||Phase 1|4|Actual|The First Affiliated Hospital with Nanjing Medical University||1||Both the sponsors and collaborator are considering terminating the study|f|||||f|f|||||||||||2023-09-05 00:38:48.126588|2023-09-05 00:38:48.126588|OTHER|||||
NCT04503980||2020-08-05|||2020-08-05|2020-08-05|2020-08-07|Actual|||||||2020-08-05|2020-08-07|Actual|March 26, 2020|Actual|2020-03-26|August 2020|2020-08-31|June 2022|Anticipated|2022-06-30|March 2021|Anticipated|2021-03-31||Interventional|||αPD1-MSLN-CAR T Cells for the Treatment of MSLN-positive Advanced Solid Tumors|An Exploratory Study of αPD1-MSLN-CAR T Cells Secreting PD-1 Nanobodies for the Treatment of MSLN-positive Advanced Solid Tumors|Unknown status|Recruiting|Early Phase 1|10|Anticipated|Shanghai Cell Therapy Group Co.,Ltd||1|||f||||f|f|f|||||||||||2023-09-04 07:51:48.689121|2023-09-04 07:51:48.689121|INDUSTRY|||||
NCT04599556||2020-10-21|||2022-09-18|2020-10-21|2020-10-22|Actual|||||||2022-09-18|2022-09-21|Actual|November 20, 2021|Actual|2021-11-20|October 2021|2021-10-31|December 2023|Anticipated|2023-12-31|December 2022|Anticipated|2022-12-31||Interventional|||Clinical Trial for the Safety and Efficacy of Anti-CD7 CAR-T Cell Therapy for Patients With Relapsed or Refractory CD7 Positive Hematological Malignancy|Clinical Trial for the Safety and Efficacy of Anti-CD7 Chimeric Antigen Receptor Cell Therapy for Patients With Relapsed or Refractory CD7 Positive Hematological Malignancy|Recruiting||Phase 1/Phase 2|108|Anticipated|Zhejiang University||3|||f|||||f|f|||||||||No||2023-09-05 00:46:38.316583|2023-09-05 00:46:38.316583|OTHER|||||
NCT02348216||2015-01-22|2021-09-06||2022-10-17|2015-01-27|2015-01-28|Estimate|2021-10-26|2021-11-23|Actual||||2022-10-17|2022-10-19|Actual|April 21, 2015|Actual|2015-04-21|October 2022|2022-10-31|July 2023|Anticipated|2023-07-31|September 10, 2020|Actual|2020-09-10||Interventional|ZUMA-1|The Safety Analysis Set included all participants treated with any dose of axicabtagene ciloleucel.|Study Evaluating the Safety and Efficacy of KTE-C19 in Adult Participants With Refractory Aggressive Non-Hodgkin Lymphoma|A Phase 1/2 Multicenter Study Evaluating the Safety and Efficacy of KTE-C19 in Adults With Refractory Aggressive Non-Hodgkin Lymphoma|Active, not recruiting||Phase 1/Phase 2|307|Actual|Gilead Sciences||1|||f||||t|t|f||||||18 months after study completion|A secured external environment with username, password, and RSA code.|http://www.gilead.com/research/disclosure-and-transparency|Yes|Qualified external researchers may request IPD for this study after study completion. For more information, please visit our website at http://www.gilead.com/research/disclosure-and transparency|2023-09-05 01:04:55.186688|2023-09-05 01:04:55.186688|INDUSTRY|||||
NCT03488160||2018-03-26|||2018-04-07|2018-04-03|2018-04-04|Actual|||||||2018-04-07|2018-04-10|Actual|April 10, 2018|Anticipated|2018-04-10|April 2018|2018-04-30|April 20, 2019|Anticipated|2019-04-20|April 10, 2019|Anticipated|2019-04-10||Interventional|||CAR-T Treatment for Relapse / Refractory Type Safety and Effectiveness of Lymphoma|CAR-T Cell Therapy for Relapsed / Refractory CD19 Positive Clinical Study on the Safety and Effectiveness of Lymphoma|Unknown status|Recruiting|Not Applicable|6|Anticipated|Sinobioway Cell Therapy Co., Ltd.||1|||f||||t|f|f|||||||||No||2023-09-04 08:02:12.041928|2023-09-04 08:02:12.041928|INDUSTRY|||||
NCT03540303||2018-05-16|||2018-05-29|2018-05-29|2018-05-30|Actual|||||||2018-05-29|2018-05-30|Actual|April 12, 2018|Actual|2018-04-12|April 2018|2018-04-30|April 30, 2020|Anticipated|2020-04-30|April 30, 2020|Anticipated|2020-04-30||Interventional|||Cytoplasmic Activated PD-1 CAR T Cells in Refractory/Relapsed B Cell Lymphoma|Phase Ⅰ Study of CAR19 T Cells Carrying Cytoplasmic Activated PD-1 in the Treatment of Refractory/Relapsed B Cell Lymphoma|Unknown status|Recruiting|Phase 1|15|Anticipated|Henan Cancer Hospital||1|||f||||t|f|f|||||||||||2023-09-04 08:02:53.951004|2023-09-04 08:02:53.951004|OTHER_GOV|||||
NCT03994913||2019-06-12|||2023-04-13|2019-06-20|2019-06-21|Actual|||||||2023-04-13|2023-04-14|Actual|August 14, 2019|Actual|2019-08-14|April 2023|2023-04-30|May 27, 2021|Actual|2021-05-27|January 20, 2021|Actual|2021-01-20||Interventional|||Clinical Trial to Evaluate CD19 CAR T (CT032) in Patients With Relapsed and/or Refractory Non-Hodgkin's B Cell Lymphoma|An Open, Multi-center Phase Ⅰ/II Clinical Study to Evaluate the Safety and Efficacy of CT032 Humanized CD19 Autologous Car T Cell Injection in Patients With Relapsed and/or Refractory Non-Hodgkin's B Cell Lymphoma|Completed||Phase 1/Phase 2|20|Actual|CARsgen Therapeutics Co., Ltd.||1|||f||||t|f|f|||||||||No||2023-09-05 01:17:32.814716|2023-09-05 01:17:32.814716|INDUSTRY|||||
NCT04136275||2019-10-19|||2022-12-13|2019-10-21|2019-10-23|Actual|||||||2022-12-13|2022-12-15|Actual|June 19, 2020|Actual|2020-06-19|December 2022|2022-12-31|September 30, 2024|Anticipated|2024-09-30|September 30, 2023|Anticipated|2023-09-30||Interventional|||CAR-37 T Cells In Hematologic Malignancies|A Phase I Clinical Trial With CAR-37 T Cells for the Treatment of Patients With Relapsed or Refractory CD37+ Hematologic Malignancies|Recruiting||Phase 1|18|Anticipated|Massachusetts General Hospital||2|||f||||t|t|f||||||Data can be shared no earlier than 1 year following the date of publication|MGH - Contact the Partners Innovations team at http://www.partners.org/innovation||Yes|The Dana-Farber / Harvard Cancer Center encourages and supports the responsible and ethical sharing of data from clinical trials. De-identified participant data from the final research dataset used in the published manuscript may only be shared under the terms of a Data Use Agreement. Requests may be directed to the Sponsor Investigator or designee]. The protocol and statistical analysis plan will be made available on Clinicaltrials.gov only as required by federal regulation or as a condition of awards and agreements supporting the research|2023-09-05 01:19:51.259445|2023-09-05 01:19:51.259445|OTHER|||||
NCT05459870||2022-07-12|||2022-07-17|2022-07-12|2022-07-15|Actual|||||||2022-07-17|2022-07-19|Actual|July 31, 2022|Anticipated|2022-07-31|July 2022|2022-07-31|June 30, 2026|Anticipated|2026-06-30|July 31, 2025|Anticipated|2025-07-31||Interventional|||CAR-T Cells Targeting Autoimmune Diseases|CAR-T Cells Targeting B Cell Related Autoimmune Diseases|Recruiting||Phase 1/Phase 2|30|Anticipated|Shenzhen Geno-Immune Medical Institute||1|||f||||f|f|f|||||||||No||2023-09-04 08:14:59.65199|2023-09-04 08:14:59.65199|OTHER|||||
NCT05631912||2022-11-21|||2023-07-03|2022-11-21|2022-11-30|Actual|||||||2023-07-03|2023-07-06|Actual|June 30, 2023|Actual|2023-06-30|July 2023|2023-07-31|December 15, 2025|Anticipated|2025-12-15|December 15, 2024|Anticipated|2024-12-15||Interventional|||TRAC Locus-inserted CD19-targeting STAR-T Cell Therapy in r/r B-NHL|Autologous TRAC Locus-inserted CD19-targeting Synthetic T-cell Receptor Antigen Receptor T (STAR-T) Cells for Relapsed/Refractory B-cell Non-Hodgkin's Lymphoma|Recruiting||Phase 1/Phase 2|38|Anticipated|Chinese PLA General Hospital||1|||f||||t|f|f|||||||||No||2023-09-03 09:56:47.235085|2023-09-03 09:56:47.235085|OTHER|||||
NCT03651128||2018-08-16|||2022-12-13|2018-08-27|2018-08-29|Actual|||||||2022-12-13|2022-12-15|Actual|April 16, 2019|Actual|2019-04-16|December 2022|2022-12-31|April 8, 2027|Anticipated|2027-04-08|April 8, 2027|Anticipated|2027-04-08||Interventional|KarMMa-3||Efficacy and Safety Study of bb2121 Versus Standard Regimens in Subjects With Relapsed and Refractory Multiple Myeloma (RRMM)|A Phase 3, Multicenter, Randomized, Open-label Study to Compare the Efficacy and Safety of bb2121 Versus Standard Regimens in Subjects With Relapsed and Refractory Multiple Myeloma (RRMM) (KarMMa-3)|Active, not recruiting||Phase 3|381|Actual|Celgene||2|||f||||t|t|f|||||||||||2023-09-05 01:39:38.136896|2023-09-05 01:39:38.136896|INDUSTRY|||||
NCT05585996||2022-10-16|||2023-02-02|2022-10-16|2022-10-19|Actual|||||||2023-02-02|2023-02-06|Actual|August 1, 2022|Actual|2022-08-01|February 2023|2023-02-28|December 30, 2025|Anticipated|2025-12-30|November 1, 2025|Anticipated|2025-11-01||Interventional|||Exploratory Clinical Study of CD19-targeted CAR-T and CAR-DC in the Treatment of Relapsed and Refractory B-cell Lymphoma|Exploratory Clinical Study of CD19-targeted CAR-T and CAR-DC in the Treatment of Relapsed and Refractory B-cell Lymphoma|Recruiting||Phase 1|70|Anticipated|Second Affiliated Hospital, School of Medicine, Zhejiang University||1|||f|||||f|f|||||||||No||2023-09-04 08:16:43.244832|2023-09-04 08:16:43.244832|OTHER|||||
NCT05397184||2022-05-13|||2023-06-30|2022-05-25|2022-05-31|Actual|||||||2023-06-30|2023-07-05|Actual|April 19, 2022|Actual|2022-04-19|June 2023|2023-06-30|February 28, 2025|Anticipated|2025-02-28|April 1, 2024|Anticipated|2024-04-01||Interventional|TvT CAR7||Base Edited CAR7 T Cells to Treat T Cell Malignancies (TvT CAR7)|Phase 1 Study of Base Edited CAR7 T Cells to Treat T Cell Malignancies (TvT CAR7)|Recruiting||Phase 1|10|Anticipated|Great Ormond Street Hospital for Children NHS Foundation Trust||1|||f||||t|f|f|||||||||No||2023-09-03 09:58:18.337708|2023-09-03 09:58:18.337708|OTHER|||||
NCT04706936||2020-12-03|||2023-02-02|2021-01-11|2021-01-13|Actual|||||||2023-02-02|2023-02-06|Actual|April 1, 2021|Actual|2021-04-01|February 2023|2023-02-28|April 2024|Anticipated|2024-04-30|October 2023|Anticipated|2023-10-31||Interventional|||Novel BCMA-targeted CAR-T Cell Therapy for Multiple Myeloma|Novel BCMA-targeted CAR-T Cell Therapy for Multiple Myeloma|Recruiting||Phase 1|25|Anticipated|Second Affiliated Hospital, School of Medicine, Zhejiang University||1|||f||||f|f|f|||||||||No||2023-09-04 08:17:29.179026|2023-09-04 08:17:29.179026|OTHER|||||
NCT05169489||2021-12-11|||2023-07-05|2021-12-11|2021-12-27|Actual|||||||2023-07-05|2023-07-06|Actual|January 24, 2022|Actual|2022-01-24|July 2023|2023-07-31|August 2025|Anticipated|2025-08-31|December 2023|Anticipated|2023-12-31||Interventional|||A Study of bbT369 in Relapsed and/or Refractory B Cell Non-Hodgkin's Lymphoma (NHL)|A Phase 1/2 Study of bbT369, a Dual Targeting CAR T Cell Drug Product With a Gene Edit, in Relapsed and/or Refractory B Cell Non-Hodgkin's Lymphoma (NHL)|Recruiting||Phase 1/Phase 2|50|Anticipated|2seventy bio||1|||f||||f|t|f|||||||||Yes||2023-09-03 09:59:24.792667|2023-09-03 09:59:24.792667|INDUSTRY|||||
NCT04150913||2019-11-01|||2022-12-13|2019-11-01|2019-11-05|Actual|||||||2022-12-13|2022-12-15|Actual|October 5, 2020|Actual|2020-10-05|December 2022|2022-12-31|November 2024|Anticipated|2024-11-30|November 2023|Anticipated|2023-11-30||Interventional|||A Phase 2 Trial of Anakinra for the Prevention of CAR-T Cell Mediated Neurotoxicity|A Phase 2 Trial of Anakinra for the Prevention of CAR-T Cell Mediated Neurotoxicity|Active, not recruiting||Phase 2|15|Actual|Massachusetts General Hospital||1|||f||||t|t|f||||||Data can be shared no earlier than 1 year following the date of publication|MGH - Contact the Partners Innovations team at http://www.partners.org/innovation||Yes|The Dana-Farber / Harvard Cancer Center encourages and supports the responsible and ethical sharing of data from clinical trials. De-identified participant data from the final research dataset used in the published manuscript may only be shared under the terms of a Data Use Agreement. Requests may be directed to Sponsor Investigator or designee. The protocol and statistical analysis plan will be made available on Clinicaltrials.gov only as required by federal regulation or as a condition of awards and agreements supporting the research.|2023-09-05 01:58:55.425471|2023-09-05 01:58:55.425471|OTHER|||||
NCT01454596||2011-10-06|2019-07-08||2019-08-16|2011-10-15|2011-10-19|Estimate|2019-08-16|2019-08-21|Actual||||2019-08-16|2019-08-21|Actual|May 16, 2012|Actual|2012-05-16|August 2019|2019-08-31|January 17, 2019|Actual|2019-01-17|November 1, 2018|Actual|2018-11-01||Interventional|||CAR T Cell Receptor Immunotherapy Targeting EGFRvIII for Patients With Malignant Gliomas Expressing EGFRvIII|A Phase I/II Study of the Safety and Feasibility of Administering T Cells Expressing Anti-EGFRvIII Chimeric Antigen Receptor to Patients With Malignant Gliomas Expressing EGFRvIII|Completed||Phase 1/Phase 2|18|Actual|National Institutes of Health Clinical Center (CC)||2|||f||||f|t|f|||||||||No||2023-09-05 02:04:42.787774|2023-09-05 02:04:42.787774|NIH|||||
NCT02215967||2014-08-12|2019-08-26||2019-09-20|2014-08-12|2014-08-13|Estimate|2019-09-20|2019-10-08|Actual||||2019-09-20|2019-10-08|Actual|August 12, 2014|Actual|2014-08-12|September 2019|2019-09-30|August 15, 2019|Actual|2019-08-15|April 25, 2019|Actual|2019-04-25||Interventional|||Study of T Cells Targeting B-Cell Maturation Antigen for Previously Treated Multiple Myeloma|A Phase I Clinical Trial of T-Cells Targeting B-Cell Maturation Antigen for Previously Treated Multiple Myeloma|Completed||Phase 1|30|Actual|National Institutes of Health Clinical Center (CC)||1|||f||||f|t|f|||||||||No||2023-09-05 02:05:47.875179|2023-09-05 02:05:47.875179|NIH|||||
NCT03937544||2019-04-22|||2019-05-02|2019-05-01|2019-05-03|Actual|||||||2019-05-02|2019-05-06|Actual|March 19, 2019|Actual|2019-03-19|May 2019|2019-05-31|March 18, 2024|Anticipated|2024-03-18|March 18, 2024|Anticipated|2024-03-18||Interventional|||Intravenous Autologous CD19 CAR-T Cells for R/R B-ALL|A Phase II/III Prospective, Open Label Study to Evaluate Safety and Efficacy of Intravenous Autologous CD19 CAR-T Cells for Relapsed/ Refractory B-Acute Lymphoblastic Leukaemia|Recruiting||Phase 2/Phase 3|10|Anticipated|National University of Malaysia||1|||f||||t|f|f|||||||||Undecided||2023-09-03 10:38:08.752746|2023-09-03 10:38:08.752746|OTHER|||||
NCT04539366||2020-09-04|||2023-07-04|2020-09-04|2020-09-07|Actual|||||||2023-07-04|2023-07-06|Actual|January 25, 2022|Actual|2022-01-25|June 2023|2023-06-30|August 1, 2024|Anticipated|2024-08-01|August 1, 2024|Anticipated|2024-08-01||Interventional|||Testing a New Immune Cell Therapy, GD2-Targeted Modified T-cells (GD2CART), in Children, Adolescents, and Young Adults With Relapsed/Refractory Osteosarcoma and Neuroblastoma, The GD2-CAR PERSIST Trial|GD2-CAR PERSIST: Production and Engineering of GD2-Targeted, Receptor Modified T Cells (GD2CART) for Osteosarcoma or Neuroblastoma to Increase Systemic Tumor Exposure|Suspended||Phase 1|67|Anticipated|National Cancer Institute (NCI)||1||Per CS0150968|||||t|t|f||||||||https://grants.nih.gov/policy/sharing.htm|Yes|NCI is committed to sharing data in accordance with NIH policy. For more details on how clinical trial data is shared, access the link to the NIH data sharing policy page.|2023-09-03 10:02:15.091463|2023-09-03 10:02:15.091463|NIH|||||
NCT05393804||2022-05-23|||2023-05-08|2022-05-23|2022-05-26|Actual|||||||2023-05-08|2023-05-09|Actual|May 20, 2022|Actual|2022-05-20|May 2023|2023-05-31|May 2025|Anticipated|2025-05-31|May 2025|Anticipated|2025-05-31||Interventional|||A Study of Whether Ide-cel (bb2121) Can Be Made From People With Multiple Myeloma Who Have Had a Hematopoietic Cell Transplant|Feasibility Trial of Autologous Anti-B Cell Maturation Antigen Chimeric Antigen Receptor T Cell Therapy Using Ide-Cel for Multiple Myeloma Patients Status Post Hematopoietic Cell Transplantation|Recruiting||Phase 2|32|Anticipated|Memorial Sloan Kettering Cancer Center||2|||f|||||t|f|||f||||||Yes|Memorial Sloan Kettering Cancer Center supports the international committee of medical journal editors (ICMJE) and the ethical obligation of responsible sharing of data from clinical trials. The protocol summary, a statistical summary, and informed consent form will be made available on clinicaltrials.gov when required as a condition of Federal awards, other agreements supporting the research and/or as otherwise required. Requests for deidentified individual participant data can be made beginning 12 months after publication and for up to 36 months post publication. Deidentified individual participant data reported in the manuscript will be shared under the terms of a Data Use Agreement and may only be used for approved proposals. Requests may be made to: crdatashare@mskcc.org.|2023-09-04 08:27:00.449547|2023-09-04 08:27:00.449547|OTHER|||||
NCT04404595||2020-05-19|||2023-07-03|2020-05-26|2020-05-27|Actual|||||||2023-07-03|2023-07-05|Actual|October 23, 2020|Actual|2020-10-23|July 2023|2023-07-31|September 1, 2035|Anticipated|2035-09-01|June 1, 2025|Anticipated|2025-06-01||Interventional|||Claudin18.2 CAR-T (CT041) in Patients With Gastric, Pancreatic Cancer, or Other Specified Digestive Cancers|Open-label, Multicenter, Phase 1b/2 Clinical Trial to Evaluate the Safety and Efficacy of Autologous Anti-claudin 18.2 Chimeric Antigen Receptor T-cell Therapy in Subjects With Advanced Gastric, Pancreatic, or Other Specified Digestive System Cancers|Recruiting||Phase 1/Phase 2|110|Anticipated|CARsgen Therapeutics Co., Ltd.||1|||f||||t|t|f|||||||||No||2023-09-03 10:02:39.590093|2023-09-03 10:02:39.590093|INDUSTRY|||||
NCT05315778||2022-03-31|||2022-03-31|2022-03-31|2022-04-07|Actual|||||||2022-03-31|2022-04-07|Actual|January 1, 2022|Actual|2022-01-01|March 2022|2022-03-31|June 30, 2023|Anticipated|2023-06-30|December 31, 2022|Anticipated|2022-12-31||Interventional|||Anti-BCMA CAR T-Cell Therapy for R/R ITP|Anti-BCMA CAR T-Cell Therapy for Relapsed/Refractory Immune Thrombocytopenia|Recruiting||Phase 2|5|Anticipated|The First Affiliated Hospital of Soochow University||1|||f||||f|f|f|||||||||Undecided||2023-09-01 03:59:17.390038|2023-09-01 03:59:17.390038|OTHER|||||
NCT04231747||2020-01-14|||2023-07-05|2020-01-14|2020-01-18|Actual|||||||2023-07-05|2023-07-06|Actual|May 21, 2020|Actual|2020-05-21|July 2023|2023-07-31|June 21, 2024|Anticipated|2024-06-21|June 21, 2024|Anticipated|2024-06-21||Interventional|||A Study of CC-97540, CD19-targeted NEX-T Chimeric Antigen Receptor (CAR) T Cells, in Subjects With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma|A Phase 1, Multicenter, Open-label Study of CC-97540, CD19-targeted NEX-T Chimeric Antigen Receptor (CAR) T Cells, in Subjects With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma|Active, not recruiting||Phase 1|80|Anticipated|Juno Therapeutics, a Subsidiary of Celgene||1|||f||||t|t|f||||||See Plan Description|See Plan Description|https://www.celgene.com/research-development/clinical-trials/clinical-trials-data-sharing/|Yes|"Information relating to our policy on data sharing and the process for requesting data can be found at the following link:~https://www.celgene.com/research-development/clinical-trials/clinical-trials-data-sharing/"|2023-09-03 10:03:19.475751|2023-09-03 10:03:19.475751|INDUSTRY|||||
NCT04952584||2021-06-28|||2023-03-22|2021-06-28|2021-07-07|Actual|||||||2023-03-22|2023-03-24|Actual|March 2024|Anticipated|2024-03-31|March 2023|2023-03-31|June 2040|Anticipated|2040-06-30|June 2025|Anticipated|2025-06-30||Interventional|||Allogeneic CD30 Chimeric Antigen Receptor Epstein-Barr Virus-Specific T Lymphocytes in Relapsed or Refractory CD30-Positive Lymphomas|A Phase 1 Study Evaluating the Safety and Activity of Allogeneic CD30 Chimeric Antigen Receptor Epstein-Barr Virus-Specific T Lymphocytes (CD30.CAR-EBVSTs) in Patients With Relapsed or Refractory CD30-Positive Lymphomas|Not yet recruiting||Phase 1|18|Anticipated|Baylor College of Medicine||1|||f||||t|t|f|||||||||||2023-09-04 08:28:11.919845|2023-09-04 08:28:11.919845|OTHER|||||
NCT03943472||2019-05-07|||2021-08-29|2019-05-07|2019-05-09|Actual|||||||2021-08-29|2021-08-31|Actual|July 8, 2019|Actual|2019-07-08|August 2021|2021-08-31|May 2022|Anticipated|2022-05-31|November 2021|Anticipated|2021-11-30||Interventional|||BCMA Chimeric Antigen Receptor Expressing T Cells Therapy for Relapsed/Refractory Multiple Myeloma|A Phase I Clinical Trial of T-Cells Targeting B-Cell Maturation Antigen for Subjects With Relapsed/Refractory Multiple Myeloma|Unknown status|Recruiting|Early Phase 1|10|Anticipated|Hrain Biotechnology Co., Ltd.||2|||f||||t|f|f|||||||||No||2023-09-03 10:33:56.115577|2023-09-03 10:33:56.115577|INDUSTRY|||||
NCT04684459||2020-12-21|||2022-09-12|2020-12-23|2020-12-24|Actual|||||||2022-09-12|2022-09-13|Actual|March 12, 2021|Actual|2021-03-12|September 2022|2022-09-30|January 1, 2024|Anticipated|2024-01-01|January 1, 2023|Anticipated|2023-01-01||Interventional|||Dual-targeting HER2 and PD-L1 CAR-T for Cancers With Pleural or Peritoneal Metastasis|Phase I Study of Specific CAR-T Dual-targeting HER2 and PD-L1 in Patients With Pleural or Peritoneal Metastasis of HER2 Positive Cancer|Recruiting||Early Phase 1|18|Anticipated|Sichuan University||1|||f|||||f|f|||||||||||2023-09-05 02:25:50.203989|2023-09-05 02:25:50.203989|OTHER|||||
NCT04684472||2020-12-21|||2022-09-22|2020-12-21|2020-12-24|Actual|||||||2022-09-22|2022-09-26|Actual|March 17, 2021|Actual|2021-03-17|September 2022|2022-09-30|January 1, 2024|Anticipated|2024-01-01|January 1, 2023|Anticipated|2023-01-01||Interventional|||Modified CD19 CAR-T in Patients With Relapsed or Refractory CD19+ B-cell Malignancies|Phase I, Open Label, Study of CXCR4 Modified CD19 CAR-T Therapy in Patients With Relapsed or Refractory CD19+ B-cell Malignancies|Recruiting||Phase 1|18|Anticipated|Sichuan University||1|||f|||||f|f|||||||||No||2023-09-05 02:31:10.587666|2023-09-05 02:31:10.587666|OTHER|||||
NCT02601313||2015-11-06|2020-08-21|2020-07-17|2023-03-22|2015-11-06|2015-11-10|Estimate|2020-08-21|2020-09-10|Actual|2020-07-17|2020-07-21|Actual|2023-03-22|2023-03-24|Actual|November 9, 2015|Actual|2015-11-09|March 2023|2023-03-31|June 2025|Anticipated|2025-06-30|July 24, 2019|Actual|2019-07-24||Interventional|ZUMA-2|The Safety Analysis Set included all participants treated with any dose of anti-CD19 CAR T cells.|Study of Brexucabtagene Autoleucel (KTE-X19) in Participants With Relapsed/Refractory Mantle Cell Lymphoma (Cohort 1 and Cohort 2)|A Phase 2 Multicenter Study Evaluating the Efficacy of KTE-X19 in Subjects With Relapsed/Refractory Mantle Cell Lymphoma|Active, not recruiting||Phase 2|105|Actual|Gilead Sciences||1|||f||||t|t|f|||||||||||2023-09-04 08:31:18.966437|2023-09-04 08:31:18.966437|INDUSTRY|||||
NCT04689659||2020-12-28|||2022-07-31|2020-12-29|2020-12-30|Actual|||||||2022-07-31|2022-08-02|Actual|February 1, 2021|Actual|2021-02-01|July 2022|2022-07-31|February 1, 2023|Anticipated|2023-02-01|February 1, 2023|Anticipated|2023-02-01||Interventional|||Multi-centers, Open-Label, Phase 2 Study to Evaluate the Efficacy and Safety of Donor-Derived CD7 CAR T Cells in Subjects With Relapsed or Refractory T-cell Leukemia/Lymphoma|Multi-centers, Open-Label, Phase 2 Study to Evaluate the Efficacy and Safety of Donor-Derived CD7 CAR T Cells in Subjects With Relapsed or Refractory T-cell Leukemia/Lymphoma|Recruiting||Phase 2|70|Anticipated|Beijing Boren Hospital||1|||f|||||f|f|||||||||No||2023-09-05 02:33:58.561561|2023-09-05 02:33:58.561561|OTHER|||||
NCT02414269||2015-04-02|||2023-07-03|2015-04-09|2015-04-10|Estimate|||||||2023-07-03|2023-07-05|Actual|May 2015|Actual|2015-05-31|July 2023|2023-07-31|April 30, 2024|Anticipated|2024-04-30|April 30, 2024|Anticipated|2024-04-30||Interventional|||Malignant Pleural Disease Treated With Autologous T Cells Genetically Engineered to Target the Cancer-Cell Surface Antigen Mesothelin|A Phase I/II Clinical Trial of Malignant Pleural Disease Treated With Autologous T Cells Genetically Engineered to Target the Cancer-Cell Surface Antigen Mesothelin|Active, not recruiting||Phase 1/Phase 2|113|Actual|Memorial Sloan Kettering Cancer Center||3|||f|||||||||||||||||2023-09-03 10:06:35.035888|2023-09-03 10:06:35.035888|OTHER|||||
NCT02208362||2014-08-01|||2023-07-03|2014-08-01|2014-08-05|Estimate|||||||2023-07-03|2023-07-05|Actual|May 18, 2015|Actual|2015-05-18|July 2023|2023-07-31|December 18, 2023|Anticipated|2023-12-18|December 18, 2023|Anticipated|2023-12-18||Interventional|||Genetically Modified T-cells in Treating Patients With Recurrent or Refractory Malignant Glioma|Phase I Study of Cellular ImmunoTx Using Memory Enriched T Cells Lentivirally Transduced to Express an IL13Rα2-Specific, Hinge-Optimized, 41BB-Costimulatory Chimeric Receptor and a Truncated CD19 for Pts With Rec/Ref MaligGlioma|Active, not recruiting||Phase 1|82|Actual|City of Hope Medical Center||5|||f||||t|||||||||||||2023-09-03 10:06:48.320395|2023-09-03 10:06:48.320395|OTHER|||||
NCT04034446||2019-07-24|||2022-08-02|2019-07-25|2019-07-26|Actual|||||||2022-08-02|2022-08-03|Actual|September 30, 2019|Actual|2019-09-30|August 2022|2022-08-31|December 2023|Anticipated|2023-12-31|December 2023|Anticipated|2023-12-31||Interventional|||CD19-CD22 Chimeric Antigen Receptor T (CAR-T) Cell for Treatment of B Cell Acute Lymphoblastic Leukemia (B-ALL)|a Feasibility and Safety Study of Bispecific CD19-CD22 CAR-T Cell in the Treatment of Relapsed or Refractory B-ALL|Active, not recruiting||Early Phase 1|2|Actual|Institute of Hematology & Blood Diseases Hospital||1|||f|||||f|f|||||||||||2023-09-05 02:42:52.246521|2023-09-05 02:42:52.246521|OTHER|||||
NCT03870945||2019-02-25|||2023-03-22|2019-03-08|2019-03-12|Actual|||||||2023-03-22|2023-03-23|Actual|February 25, 2019|Actual|2019-02-25|March 2023|2023-03-31|December 31, 2025|Anticipated|2025-12-31|December 17, 2020|Actual|2020-12-17||Interventional|||Safety of MB-CART2019.1 in Lymphoma Patients (MB-CART2019.1 Lymphoma / DALY 1)|A Phase I/II Safety, Dose Finding and Feasibility Trial of MB-CART2019.1 in Patients With Relapsed or Resistant CD20 and CD19 Positive B-NHL|Active, not recruiting||Phase 1/Phase 2|12|Actual|Miltenyi Biomedicine GmbH||2|||f||||t|f|f|||||||||No||2023-09-03 10:08:47.23057|2023-09-03 10:08:47.23057|INDUSTRY|||||
NCT04026100||2019-07-17|||2019-10-29|2019-07-17|2019-07-19|Actual|||||||2019-10-29|2019-10-31|Actual|December 1, 2019|Anticipated|2019-12-01|October 2019|2019-10-31|December 31, 2022|Anticipated|2022-12-31|August 31, 2022|Anticipated|2022-08-31||Interventional|||CTA101 in the Treatment of Relapsed or Refractory Diffuse Large B-cell Lymphoma|A Phase I Clinical Trial of CTA101 UCART Cells Injection in the Treatment of Relapsed or Refractory Diffuse Large B-cell Lymphoma|Unknown status|Not yet recruiting|Phase 1|9|Anticipated|The First Affiliated Hospital with Nanjing Medical University||1|||f|||||f|f|||||||||||2023-09-05 03:03:12.3728|2023-09-05 03:03:12.3728|OTHER|||||
NCT03473496||2018-03-15|||2021-09-17|2018-03-21|2018-03-22|Actual|||||||2021-09-17|2021-09-24|Actual|March 1, 2018|Actual|2018-03-01|September 2021|2021-09-30|January 31, 2020|Actual|2020-01-31|January 31, 2020|Actual|2020-01-31||Interventional|MM||CAR-T Cells Therapy in Relapsed/Refractory Multiple Myeloma|The Prospective, Multi-center And Single-arm Clinical Study of Chimeric Antigen Receptor T(CAR-T) Cells Therapy in Relapsed/Refractory Multiple Myeloma|Terminated||Not Applicable|2|Actual|Zhujiang Hospital||1||After CAR-T treatment, the benefit is not significant, and it is difficult to enroll.|f||||t|f|f|||||||||Undecided||2023-09-04 08:35:21.918058|2023-09-04 08:35:21.918058|OTHER|||||
NCT05398614||2022-05-20|||2022-05-29|2022-05-29|2022-06-01|Actual|||||||2022-05-29|2022-06-01|Actual|May 1, 2022|Actual|2022-05-01|April 2022|2022-04-30|June 30, 2024|Anticipated|2024-06-30|December 30, 2023|Anticipated|2023-12-30||Interventional|||SENL101 Autologous T Cell Injection in Adults With Relapsed or Refractory CD7+ Hematolymphoid Malignancies|Early Clinical Study of SENL101 Autologous T Cell Injection in the Treatment of Adult Patients With Relapsed or Refractory CD7+ Hematolymphoid Malignancies|Recruiting||Phase 1|18|Anticipated|Hebei Senlang Biotechnology Inc., Ltd.||1|||f|||||f|f|||||||||||2023-09-04 08:48:45.238867|2023-09-04 08:48:45.238867|INDUSTRY|||||
NCT03720496||2018-10-24|||2019-12-06|2018-10-24|2018-10-25|Actual|||||||2019-12-06|2019-12-09|Actual|November 1, 2018|Actual|2018-11-01|December 2019|2019-12-31|December 1, 2021|Anticipated|2021-12-01|June 1, 2021|Anticipated|2021-06-01||Interventional|||Treatment of Refractory/Relapsed Non-Hodgkin Lymphoma With CD19-TriCART Cell Therapy|Adoptive Immunotherapy for Refractory/Relapsed Non-Hodgkin Lymphoma With CD19-TriCART Cells|Unknown status|Recruiting|Phase 1|6|Anticipated|Timmune Biotech Inc.||1|||f||||t|f|f|||||||||No||2023-09-03 10:12:39.438143|2023-09-03 10:12:39.438143|INDUSTRY|||||
NCT03240328||2017-05-21|||2022-09-13|2017-08-02|2017-08-07|Actual|||||||2022-09-13|2022-09-14|Actual|October 4, 2017|Actual|2017-10-04|September 2022|2022-09-30|December 31, 2030|Anticipated|2030-12-31|December 31, 2023|Anticipated|2023-12-31||Interventional|||The Effect of Chimeric Antigen Receptor (CAR)-T Cell Therapy on the Reconstitution of HIV-specific Immune Function|The Effect of CAR-T Cell Therapy on the Reconstitution of HIV-specific Immune Function|Recruiting||Phase 1|40|Anticipated|Guangzhou 8th People's Hospital||1|||f||||f|f|f|||||||||No||2023-09-05 03:20:55.306363|2023-09-05 03:20:55.306363|OTHER|||||
NCT05240950||2021-12-26|||2022-03-09|2022-02-13|2022-02-15|Actual|||||||2022-03-09|2022-03-11|Actual|August 25, 2022|Anticipated|2022-08-25|March 2022|2022-03-31|December 25, 2026|Anticipated|2026-12-25|December 25, 2023|Anticipated|2023-12-25||Interventional|||Anti-CEA CAR-T Cells to Treat Colorectal Liver Metastases|A Clinical Study to Evaluate the Safety and Efficacy of Anti-CEA CAR-T Cells in the Treatment of Postoperative Minimal Residual Lesions in Colorectal Cancer Patients With Liver Metastases|Recruiting||Phase 1|18|Anticipated|Changhai Hospital||1|||f|||||f|f|||||||||||2023-09-05 03:24:53.486657|2023-09-05 03:24:53.486657|OTHER|||||
NCT04690192||2020-12-26|||2023-06-30|2020-12-26|2020-12-30|Actual|||||||2023-06-30|2023-07-03|Actual|January 1, 2021|Actual|2021-01-01|June 2023|2023-06-30|December 30, 2024|Anticipated|2024-12-30|December 30, 2023|Anticipated|2023-12-30||Interventional|||CNCT19 Following ASCT in Patients With Relapsed or Refractory B-cell Lymphoma|CNCT19 Following Autologous Stem Cell Transplantation in Patients With Relapsed or Refractory Aggressive B-cell Lymphoma|Recruiting||Phase 1/Phase 2|20|Anticipated|Institute of Hematology & Blood Diseases Hospital||1|||f||||f|f|f|||||||||No||2023-09-05 03:28:49.259347|2023-09-05 03:28:49.259347|OTHER|||||
NCT04049513||2019-07-29|||2023-06-29|2019-08-06|2019-08-08|Actual|||||||2023-06-29|2023-07-03|Actual|October 11, 2019|Actual|2019-10-11|June 2023|2023-06-30|February 2029|Anticipated|2029-02-28|May 2024|Anticipated|2024-05-31||Interventional|ENABLE||ENABLE (Engaging Toll-like Receptor Signalling for B-cell Lymphoma Chimeric Antigen Receptor Therapy)|A Phase I Dose Escalation Trial of Autologous Third-generation Anti-CD19 Chimeric Antigen Receptor T-cells (WZTL-002) for Relapsed and Refractory B-cell Lymphomas|Recruiting||Phase 1|30|Anticipated|Malaghan Institute of Medical Research||1|||f||||t|f|f|||||||||Yes|All IPD that underlie results in a publication|2023-09-05 03:29:35.94946|2023-09-05 03:29:35.94946|OTHER|||||
NCT03103971||2017-03-27|||2023-06-29|2017-03-31|2017-04-07|Actual|||||||2023-06-29|2023-07-03|Actual|November 3, 2017|Actual|2017-11-03|June 2023|2023-06-30|March 23, 2024|Anticipated|2024-03-23|March 23, 2023|Actual|2023-03-23||Interventional|||huJCAR014 CAR-T Cells in Treating Adult Patients With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma or Acute Lymphoblastic Leukemia|A Two-Stage Phase 1 Open-Label Study of huJCAR014, CD19-Targeted Chimeric Antigen Receptor (CAR)-Modified T Cells Bearing a Human Binding Domain, in Adult Patients With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma and Acute Lymphocytic Leukemia|Active, not recruiting||Phase 1|55|Actual|Fred Hutchinson Cancer Center||1|||f||||t|t|f|||||||||No||2023-09-05 03:31:00.044913|2023-09-05 03:31:00.044913|OTHER|||||
NCT05099237||2021-08-26|||2023-05-02|2021-10-18|2021-10-29|Actual|||||||2023-05-02|2023-05-03|Actual|December 1, 2021|Actual|2021-12-01|May 2023|2023-05-31|December 31, 2023|Anticipated|2023-12-31|December 31, 2023|Anticipated|2023-12-31||Interventional|EMBRaCE-GM||Enhanced Monitoring for Better Recovery and Cancer Experience in Greater Manchester|A Multi-cohort Trial to Investigate the Feasibility and Acceptability of Wearable Vital Signs Monitors in Patients Undergoing Cancer Treatment in Greater Manchester.|Recruiting||Not Applicable|80|Anticipated|Manchester University NHS Foundation Trust||3|||f||||t|f|f|||||||||No||2023-09-03 10:22:44.398614|2023-09-03 10:22:44.398614|OTHER_GOV|||||
NCT05483491||2022-07-20|||2023-04-17|2022-07-30|2022-08-02|Actual|||||||2023-04-17|2023-04-19|Actual|September 26, 2022|Actual|2022-09-26|April 2023|2023-04-30|December 31, 2028|Anticipated|2028-12-31|September 1, 2023|Anticipated|2023-09-01||Interventional|||KK-LC-1 TCR-T Cell Therapy for Gastric, Breast, Cervical, and Lung Cancer|T Cell Receptor Gene Therapy Targeting KK-LC-1 for Gastric, Breast, Cervical, Lung, and Other KK-LC-1 Positive Cancers|Recruiting||Phase 1|42|Anticipated|Rutgers, The State University of New Jersey||1|||||||t|t|f|||||||||No||2023-09-05 03:56:55.363387|2023-09-05 03:56:55.363387|OTHER|||||
NCT05274451||2022-02-18|||2023-08-30|2022-03-09|2022-03-10|Actual|||||||2023-08-30|2023-08-31|Estimate|March 29, 2022|Actual|2022-03-29|August 2023|2023-08-31|September 2026|Anticipated|2026-09-30|March 2025|Anticipated|2025-03-31||Interventional|||A Study to Investigate LYL797 in Adults With Solid Tumors|A Phase 1 Study to Assess the Safety and Efficacy of LYL797, ROR1-Targeting CAR T Cells, in Adults With Relapsed and/or Refractory Solid-Tumor Malignancies|Recruiting||Phase 1|54|Anticipated|Lyell Immunopharma, Inc.||1|||f|||||t|f|||||||||No||2023-09-01 04:20:00.435569|2023-09-01 04:20:00.435569|INDUSTRY|||||
NCT04410900||2020-05-28|||2023-04-18|2020-05-28|2020-06-01|Actual|||||||2023-04-18|2023-04-19|Actual|August 3, 2020|Actual|2020-08-03|April 2023|2023-04-30|February 1, 2025|Anticipated|2025-02-01|August 1, 2024|Anticipated|2024-08-01||Interventional|||Vaccine Responsiveness After CAR-T Cell Therapy|Rabies Vaccination to Assess Vaccine Responsiveness After B Cell Targeted CAR-T Cell Therapies|Recruiting||Phase 1|41|Anticipated|Fred Hutchinson Cancer Center||2|||f||||t|t|f||||||Data will be shared beginning 3 months and ending 5 years following article publication.|Data will be shared with researchers who provide a methodologically sound proposal. Data will be shared to achieve aims in the approved proposal. Proposals should be directed to Joshua A. Hill. To gain access, data requestors will need to sign a data access agreement.||Yes|Individual participant data that underlie the results reported in a future article will be shared, after deidentification (text, tables, figures, and appendices).|2023-08-31 03:57:59.318162|2023-08-31 03:57:59.318162|OTHER|||||
NCT04025216||2019-07-12|||2023-04-17|2019-07-16|2019-07-18|Actual|||||||2023-04-17|2023-04-19|Actual|October 10, 2019|Actual|2019-10-10|April 2023|2023-04-30|December 2, 2022|Actual|2022-12-02|December 2, 2022|Actual|2022-12-02||Interventional|||A Study of CART-TnMUC1 in Patients With TnMUC1-Positive Advanced Cancers|A Phase 1 Open-Label, Multi-Center First in Human Study of TnMUC1-Targeted Genetically-Modified Chimeric Antigen Receptor T Cells in Patients With Advanced TnMUC1-Positive Solid Tumors and Multiple Myeloma|Terminated||Phase 1|16|Actual|Tmunity Therapeutics||2||The sponsor finds the risk/benefit analysis unfavorable and has terminated the study.|f||||t|t|f|||||||||No||2023-08-31 03:58:48.503171|2023-08-31 03:58:48.503171|INDUSTRY|||||
NCT03919526||2019-04-07|||2022-07-15|2019-04-15|2019-04-18|Actual|||||||2022-07-15|2022-07-19|Actual|August 11, 2019|Actual|2019-08-11|July 2022|2022-07-31|August 1, 2022|Anticipated|2022-08-01|August 1, 2022|Anticipated|2022-08-01||Interventional|||Anti-CD19/CD22 Bispecific CAR-T Cell Therapy for MRD Positive ALL|The Safety and Clinical Efficacy of Human CD19/CD22 Bispecific CAR-T Cell Therapy for Subjects With MRD-positive B Cell Acute Lymphoblastic Leukemia|Recruiting||Phase 1|18|Anticipated|Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine||1|||f||||t|f|f|||||||||No||2023-09-04 08:57:44.251031|2023-09-04 08:57:44.251031|OTHER|||||
NCT05488132||2022-08-02|||2022-08-02|2022-08-02|2022-08-04|Actual|||||||2022-08-02|2022-08-04|Actual|April 1, 2022|Actual|2022-04-01|March 2022|2022-03-31|March 31, 2025|Anticipated|2025-03-31|March 31, 2024|Anticipated|2024-03-31||Interventional|||Administration of Anti-siglec-6 CAR-T Cell Therapy in Relapsed and Refractory Acute Myeloid Leukemia (rr/AML)|Application of Anti-siglec-6 CAR-T Cell Therapy in Relapsed and Refractory Acute Myeloid Leukemia (rr/AML)|Recruiting||Phase 1/Phase 2|20|Anticipated|Xuzhou Medical University||1|||f||||f|f|f|||||||||No||2023-09-04 08:57:46.384206|2023-09-04 08:57:46.384206|OTHER|||||
NCT05650749||2022-12-06|||2023-08-28|2022-12-06|2022-12-14|Actual|||||||2023-08-28|2023-08-30|Estimate|May 23, 2023|Actual|2023-05-23|August 2023|2023-08-31|January 30, 2026|Anticipated|2026-01-30|January 30, 2025|Anticipated|2025-01-30||Interventional|GPC2||GPC2 CAR T Cells for Relapsed or Refractory Neuroblastoma|Phase 1 Trial of GPC2-Directed Chimeric Antigen Receptor Autologous T Cells (GPC2 CAR T) for Relapsed or Refractory Neuroblastoma|Recruiting||Phase 1|30|Anticipated|Children's Hospital of Philadelphia||2|||f||||t|t|f|||||||||No||2023-08-31 04:18:03.754476|2023-08-31 04:18:03.754476|OTHER|||||
NCT05480449||2022-07-27|||2023-08-28|2022-07-27|2022-07-29|Actual|||||||2023-08-28|2023-08-30|Estimate|September 20, 2022|Actual|2022-09-20|August 2023|2023-08-31|September 20, 2027|Anticipated|2027-09-20|September 20, 2023|Anticipated|2023-09-20||Interventional|||Autologous HuCART19 T Cells Manufactured Using the CliniMACS Prodigy Platform for Pediatric B-ALL (huCART19 Prodigy)|Phase 1/2b Trial of Autologous Humanized CD19-Directed Chimeric Antigen Receptor T-Cells Manufactured Using the CliniMACS Prodigy Platform for the Treatment of Pediatric B Cell Acute Lymphoblastic Leukemia (B-ALL)|Active, not recruiting||Phase 1/Phase 2|89|Anticipated|Children's Hospital of Philadelphia||2|||f||||t|t|f|||||||||||2023-08-31 04:19:19.270957|2023-08-31 04:19:19.270957|OTHER|||||
NCT03265106||2017-08-25|||2021-02-03|2017-08-25|2017-08-29|Actual|||||||2021-02-03|2021-02-04|Actual|November 1, 2016|Actual|2016-11-01|February 2021|2021-02-28|December 30, 2021|Anticipated|2021-12-30|May 30, 2021|Anticipated|2021-05-30||Interventional|||A Clinical Study Evaluating the Safety and Efficacy of BinD19 Treatment in Childhood R/R ALL and Lymphoma Subjects|A Clinical Study Evaluating the Safety and Efficacy of BinD19 Treatment in Relapse or Refractory Childhood Acute Lymphoblastic Leukemia and Lymphoma Subjects|Unknown status|Active, not recruiting|Phase 1/Phase 2|20|Anticipated|Shenzhen BinDeBio Ltd.||1|||f||||t|f|f|||||||||No||2023-09-04 08:58:17.966308|2023-09-04 08:58:17.966308|INDUSTRY|||||
NCT04789408||2021-03-05|||2023-08-28|2021-03-05|2021-03-09|Actual|||||||2023-08-28|2023-08-30|Estimate|July 19, 2021|Actual|2021-07-19|August 2023|2023-08-31|January 2039|Anticipated|2039-01-31|January 2024|Anticipated|2024-01-31||Interventional|||Study of KITE-222 in Participants With Relapsed/Refractory Acute Myeloid Leukemia|A Phase 1 Open-label, Multicenter Study Evaluating the Safety of KITE-222, an Autologous Anti-CLL-1 CAR T-cell Therapy, in Subjects With Relapsed/Refractory Acute Myeloid Leukemia|Recruiting||Phase 1|40|Anticipated|Gilead Sciences||1|||f||||f|t|f|||||||||No||2023-08-31 04:22:21.943332|2023-08-31 04:22:21.943332|INDUSTRY|||||
NCT04318678||2020-03-20|||2023-08-28|2020-03-20|2020-03-24|Actual|||||||2023-08-28|2023-08-30|Estimate|July 29, 2020|Actual|2020-07-29|August 2023|2023-08-31|July 1, 2025|Anticipated|2025-07-01|July 1, 2024|Anticipated|2024-07-01||Interventional|||CD123-Directed Autologous T-Cell Therapy for Acute Myelogenous Leukemia (CATCHAML)|CD123-Directed Autologous T-Cell Therapy for Acute Myelogenous Leukemia (CATCHAML)|Active, not recruiting||Phase 1|32|Anticipated|St. Jude Children's Research Hospital||1|||f||||f|t|f|||t|||Data will be made available at the time of article publication.|Data will be provided to researchers following a formal request with the following information: full name of requestor, affiliation, data set requested, and timing of when data is needed. As an informational point, the lead statistician and study principal investigator will be informed that primary results datasets have been requested.||Yes|Individual participant de-identified datasets containing the variables analyzed in the published article will be made available (related to the study primary or secondary objectives contained in the publication). Supporting documents such as the protocol, statistical analyses plan, and informed consent are available through the CTG website for the specific study. Data used to generate the published article will be made available at the time of article publication. Investigators who seek access to individual level de-identified data will contact the computing team in the Department of Biostatistics (ClinTrialDataRequest@stjude.org) who will respond to the data request.|2023-08-31 04:23:49.32496|2023-08-31 04:23:49.32496|OTHER|||||
NCT03829540||2018-12-19|||2023-08-28|2019-02-01|2019-02-04|Actual|||||||2023-08-28|2023-08-30|Estimate|June 18, 2019|Actual|2019-06-18|August 2023|2023-08-31|December 2037|Anticipated|2037-12-31|December 2025|Anticipated|2025-12-31||Interventional|||CD4CAR for CD4+ Leukemia and Lymphoma|A Phase I, Multicenter Study of CD4- Directed Chimeric Antigen Receptor Engineered T-cells (CD4CAR) in Patients With Relapsed or Refractory CD4+ Hematological Malignancies|Recruiting||Phase 1|20|Anticipated|Indiana University||1|||f||||t|t|f|||||||||No||2023-08-31 04:25:35.843778|2023-08-31 04:25:35.843778|OTHER|||||
NCT03262298||2017-08-14|||2021-02-06|2017-08-22|2017-08-25|Actual|||||||2021-02-06|2021-02-09|Actual|August 20, 2017|Actual|2017-08-20|February 2021|2021-02-28|August 20, 2022|Anticipated|2022-08-20|August 20, 2021|Anticipated|2021-08-20||Interventional|||Anti-CD22 CAR-T Cell Therapy Targeting B Cell Malignancies|Anti-CD22 Chimeric Antigen Receptor (CAR)-Modified T Cell Therapy Targeting CD22 in Treating Patients With B Cell Malignancies|Unknown status|Recruiting|Phase 1/Phase 2|20|Anticipated|Affiliated Hospital to Academy of Military Medical Sciences||1|||f||||t|f|f|||||||||Undecided||2023-09-04 08:58:47.499794|2023-09-04 08:58:47.499794|OTHER|||||
NCT01460901||2011-10-25|2018-07-16||2019-07-22|2011-10-26|2011-10-27|Estimate|2019-07-22|2019-07-23|Actual||||2019-07-22|2019-07-23|Actual|October 2012||2012-10-31|July 2019|2019-07-31|January 2015|Actual|2015-01-31|January 2015|Actual|2015-01-31||Interventional|STALLONe||Study of Donor Derived, Multi-virus-specific, Cytotoxic T-Lymphocytes for Relapsed/Refractory Neuroblastoma|Phase I Study of Donor Derived,Gene Modified, Multi-virus-specific, Cytotoxic T-Lymphocytes Redirected to GD2 for Relapsed/Refractory Neuroblastoma Post-allo Stem Cell Transplantation With Submyeloblative Conditioning|Completed||Phase 1|5|Actual|Children's Mercy Hospital Kansas City||1|||f||||t|||||||||||||2023-08-31 05:36:18.273817|2023-08-31 05:36:18.273817|OTHER|||||
NCT04888468||2021-05-12|||2022-03-16|2021-05-12|2021-05-17|Actual|||||||2022-03-16|2022-03-18|Actual|November 5, 2019|Actual|2019-11-05|May 2021|2021-05-31|September 1, 2021|Actual|2021-09-01|June 29, 2021|Actual|2021-06-29||Interventional|||Phase I Study of pCAR-19B in the Treatment of CD19-positive Relapsed/Refractory B-ALL in Children and Adolescents|A Phase I Clinical Study of Anti-CD19 CAR-T Therapy (pCAR-19B) in the Treatment of CD19-positive Relapsed/Refractory B-ALL|Completed||Phase 1|9|Actual|Chongqing Precision Biotech Co., Ltd||1|||f||||f|f|f|||||||||||2023-08-31 05:36:39.428114|2023-08-31 05:36:39.428114|INDUSTRY|||||
NCT04556266||2020-09-15|||2022-03-04|2020-09-15|2020-09-21|Actual|||||||2022-03-04|2022-03-18|Actual|July 1, 2021|Actual|2021-07-01|March 2022|2022-03-31|March 1, 2022|Actual|2022-03-01|March 1, 2022|Actual|2022-03-01||Interventional|||A Phase I Trial of Donor- Derived 19-28z CAR T Cells Following Allogeneic Transplant for the Treatment of CD19 Malignancies|A Phase I Trial Evaluating the Safety of Consolidative Infusions of CD19-Specific Chimeric Antigen Receptor (CAR) T Cells Following T-cell Depleted Allogeneic Transplantation for High Risk B-cell Malignancies|Withdrawn||Phase 1|0|Actual|Memorial Sloan Kettering Cancer Center||4||No patients were enrolled to this study since being open to enrollment. Due to changes in available therapies, there aren't enough people who will be eligible for the study. Therefore, the study was closed.||||||t|f|||||||||Yes|Memorial Sloan Kettering Cancer Center supports the international committee of medical journal editors (ICMJE) and the ethical obligation of responsible sharing of data from clinical trials. The protocol summary, a statistical summary, and informed consent form will be made available on clinicaltrials.gov when required as a condition of Federal awards, other agreements supporting the research and/or as otherwise required. Requests for deidentified individual participant data can be made beginning 12 months after publication and for up to 36 months post publication. Deidentified individual participant data reported in the manuscript will be shared under the terms of a Data Use Agreement and may only be used for approved proposals. Requests may be made to: crdatashare@mskcc.org.|2023-08-31 05:37:00.169266|2023-08-31 05:37:00.169266|OTHER|||||
NCT04432506||2020-06-11|||2023-08-29|2020-06-12|2020-06-16|Actual|||||||2023-08-29|2023-08-31|Estimate|July 27, 2020|Actual|2020-07-27|August 2023|2023-08-31|January 31, 2025|Anticipated|2025-01-31|January 31, 2025|Anticipated|2025-01-31||Interventional|||Anakinra for the Reduction of CAR-T Toxicity in Patients With Relapsed or Refractory Large B-cell Lymphoma|Pilot Study of Anakinra to Mitigate CAR-T Toxicity in Subjects With Relapsed or Refractory Large B-Cell Lymphoma|Active, not recruiting||Phase 2|20|Anticipated|M.D. Anderson Cancer Center||1|||||||f|t|f|||||||||||2023-09-01 04:24:21.707429|2023-09-01 04:24:21.707429|OTHER|||||
NCT04196205||2019-12-09|||2019-12-11|2019-12-11|2019-12-12|Actual|||||||2019-12-11|2019-12-12|Actual|December 1, 2019|Anticipated|2019-12-01|December 2019|2019-12-31|August 1, 2021|Anticipated|2021-08-01|August 1, 2020|Anticipated|2020-08-01||Interventional|||Anti-CD19 CAR-T Cells for Relapsed or Refractory Acute Lymphoblastic Leukemia and Lymphomas|Study Evaluating the Safety and Efficacy With Anti-CD19 CAR-T Cells for Relapsed or Refractory Acute Lymphoblastic Leukemia and Lymphomas|Unknown status|Recruiting|Phase 1/Phase 2|20|Anticipated|The First Affiliated Hospital of Nanchang University||1|||f||||t|f|f|||||||||||2023-08-31 05:50:24.272803|2023-08-31 05:50:24.272803|OTHER|||||
NCT02992834||2016-12-12|||2016-12-12|2016-12-12|2016-12-14|Estimate|||||||2016-12-12|2016-12-14|Estimate|December 2016||2016-12-31|December 2016|2016-12-31|January 2022|Anticipated|2022-01-31|August 2020|Anticipated|2020-08-31||Interventional|||Anti-CD19:TCRζ Chimeric Antigen Receptor-T Cells in the Treatment for CD19+ B Cell Lymphoma|Anti-CD19:TCRζ Chimeric Antigen Receptor-T Cells in the Treatment for Chemotherapy-resistant or Refractory CD19+B Cell Lymphoma:a Double-arm, Single Center, Open-label Clinical Trial|Unknown status|Not yet recruiting|Phase 4|10|Anticipated|The First People's Hospital of Changzhou||2|||f||||t|||||||||||No||2023-08-31 06:01:18.457774|2023-08-31 06:01:18.457774|OTHER|||||
NCT04071366||2019-08-26|||2023-08-29|2019-08-26|2019-08-28|Actual|||||||2023-08-29|2023-08-31|Estimate|February 7, 2020|Actual|2020-02-07|August 2023|2023-08-31|August 22, 2023|Actual|2023-08-22|February 23, 2023|Actual|2023-02-23||Interventional|||A Study of Itacitinib for the Prevention of Cytokine Release Syndrome Induced by Immune Effector Cell Therapy|A Phase 2 Study of Itacitinib, for the Prevention of Cytokine Release Syndrome Induced by Immune Effector Cell Therapy|Completed||Phase 2|112|Actual|Incyte Corporation||2|||f||||f|t|f|||||||||No||2023-09-01 04:26:03.282106|2023-09-01 04:26:03.282106|INDUSTRY|||||
NCT03159819||2017-05-11|||2018-03-08|2017-05-17|2017-05-19|Actual|||||||2018-03-08|2018-03-12|Actual|April 1, 2017|Actual|2017-04-01|March 2018|2018-03-31|December 31, 2021|Anticipated|2021-12-31|December 31, 2019|Anticipated|2019-12-31||Interventional|||Clinical Study of CAR-CLD18 T Cells in Patients With Advanced Gastric Adenocarcinoma and Pancreatic Adenocarcinoma|Clinical Study of Redirected Autologous T Cells With a Claudin18.2-targeted Chimeric Antigen Receptor in Patients With Advanced Gastric Adenocarcinoma and Pancreatic Adenocarcinoma|Unknown status|Recruiting|Not Applicable|24|Anticipated|Changhai Hospital||1|||f||||t|f|f|||||||||Undecided||2023-08-31 06:06:43.234944|2023-08-31 06:06:43.234944|OTHER|||||
NCT03696784||2018-10-03|||2023-06-16|2018-10-03|2018-10-05|Actual|||||||2023-06-16|2023-06-18|Actual|March 12, 2019|Actual|2019-03-12|June 2023|2023-06-30|March 22, 2043|Anticipated|2043-03-22|March 22, 2027|Anticipated|2027-03-22||Interventional|||Anti-CD19 CAR-T Cells With Inducible Caspase 9 Safety Switch for B-cell Lymphoma|A Phase I Study of Autologous Activated T-cells Targeting the CD19 Antigen and Containing the Inducible Caspase 9 Safety Switch in Subjects With Relapsed/Refractory B-cell Lymphoma|Recruiting||Phase 1|30|Anticipated|UNC Lineberger Comprehensive Cancer Center||2|||f||||t|t|f|||||||||No||2023-08-31 06:19:14.579527|2023-08-31 06:19:14.579527|OTHER|||||
NCT03890198||2019-03-17|||2020-06-30|2019-03-24|2019-03-26|Actual|||||||2020-06-30|2020-07-02|Actual|April 22, 2019|Actual|2019-04-22|June 2020|2020-06-30|March 6, 2020|Actual|2020-03-06|March 6, 2020|Actual|2020-03-06||Interventional|||A Phase 1 Study of LCAR-C182A Cells in the Treatment of Advanced Gastric Cancer and Pancreatic Ductal Adenocarcinoma|A Phase 1, Open-Label Study Evaluating the Safety, Tolerability and Efficacy of LCAR-C182A, an Anti-Claudin18.2 CAR-T Cell Therapy in Patients With Advanced Gastric Cancer and Pancreatic Ductal Adenocarcinoma|Terminated||Early Phase 1|2|Actual|First Affiliated Hospital Xi'an Jiaotong University||1||the Preliminary data, progress of this study and the adjustment of the pipeline and strategy .|f||||f|f|f|||||||||||2023-09-03 10:59:37.153221|2023-09-03 10:59:37.153221|OTHER|||||
NCT03881774||2019-03-16|||2019-03-19|2019-03-16|2019-03-19|Actual|||||||2019-03-19|2019-03-21|Actual|February 27, 2019|Actual|2019-02-27|March 2019|2019-03-31|January 31, 2022|Anticipated|2022-01-31|January 31, 2021|Anticipated|2021-01-31||Interventional|||Cord Blood Derived CAR-T Cells in Refractory/Relapsed B Cell Malignancies|Clinical Study of Cord Blood Derived CAR-T Cells in Patients With Refractory/Relapsed B Cell Leukemia/Lymphoma Who Are Failed for Autologous CAR-T Cells or Autologous CAR-T Can Not be Prepared|Unknown status|Recruiting|Phase 1|20|Anticipated|Henan Cancer Hospital||1|||f||||t|f|f|||||||||No||2023-09-03 10:59:54.557868|2023-09-03 10:59:54.557868|OTHER_GOV|||||
NCT05312476||2022-03-21|||2022-04-03|2022-04-03|2022-04-05|Actual|||||||2022-04-03|2022-04-05|Actual|February 10, 2022|Actual|2022-02-10|March 2022|2022-03-31|February 10, 2025|Anticipated|2025-02-10|February 10, 2025|Anticipated|2025-02-10||Interventional|||Clinical Study on CAR-T Targeting Igβ Targets in Refractory Relapsed Non-Hodgkin's Lymphoma|Clinical Study of the Safety, Tolerability and Preliminary Efficacy of Chimeric Antigen Receptor T Cells (CAR-T) Targeting Igβ Targets in Patients With Igβ-positive Refractory Relapsed Non-Hodgkin's Lymphoma|Recruiting||Phase 2|12|Anticipated|The First Affiliated Hospital of Soochow University||1|||f||||f|f|f|||||||||||2023-08-31 06:22:19.960715|2023-08-31 06:22:19.960715|OTHER|||||
NCT04088890||2019-09-11|||2023-02-22|2019-09-11|2019-09-13|Actual|||||||2023-02-22|2023-02-24|Actual|September 12, 2019|Actual|2019-09-12|February 2023|2023-02-28|September 2034|Anticipated|2034-09-30|April 2023|Anticipated|2023-04-30||Interventional|||Autologous CD22 CAR T Cells in Adults w/ Recurrent or Refractory B Cell Malignancies|Phase I/Ib Clinical Trial of Autologous CD22 Chimeric Antigen Receptor (CAR) T Cells in Adults With Recurrent or Refractory B Cell Malignancies|Recruiting||Phase 1|92|Anticipated|Stanford University||2|||f||||t|t|f|||f||||||No||2023-08-31 06:23:47.369914|2023-08-31 06:23:47.369914|OTHER|||||
NCT03435796||2018-01-09|||2023-08-30|2018-02-15|2018-02-19|Actual|||||||2023-08-30|2023-08-31|Estimate|June 19, 2018|Actual|2018-06-19|August 2023|2023-08-31|November 30, 2036|Anticipated|2036-11-30|November 30, 2036|Anticipated|2036-11-30||Interventional|||Long-Term Follow-up Protocol for Participants Treated With Gene-Modified T Cells|Long-Term Follow-up Protocol for Subjects Treated With Gene-Modified T Cells|Recruiting||Phase 2/Phase 3|317|Anticipated|Celgene||1|||f||||f|t|f|||||||||||2023-09-01 04:27:53.256739|2023-09-01 04:27:53.256739|INDUSTRY|||||
NCT05381181||2022-05-11|||2023-01-25|2022-05-15|2022-05-19|Actual|||||||2023-01-25|2023-01-27|Actual|December 20, 2023|Anticipated|2023-12-20|May 2022|2022-05-31|May 3, 2026|Anticipated|2026-05-03|May 30, 2024|Anticipated|2024-05-30||Interventional|||Safety and Efficacy Evaluation of Next-generation CD19-UCART|Clinical Study of the Safety and Efficacy of Next-generation Universal CD19 Chimeric Antigen Receptor T Cells in the Treatment of Relapsed or Refractory B Cell Malignancies|Not yet recruiting||Phase 1|20|Anticipated|Bioray Laboratories||1|||f||||f|f|f|||||||||No||2023-08-31 06:27:35.611144|2023-08-31 06:27:35.611144|INDUSTRY|||||
NCT05211557||2022-01-13|||2022-01-25|2022-01-25|2022-01-27|Actual|||||||2022-01-25|2022-01-27|Actual|November 16, 2021|Actual|2021-11-16|January 2022|2022-01-31|August 31, 2026|Anticipated|2026-08-31|August 31, 2023|Anticipated|2023-08-31||Interventional|||Study of Fully Human B7H3 CAR-T in Treating Recurrent Malignant Ovarian Cancer|A Single-Arm, Open-Label Study to Evaluate Safety and Efficacy of Fully Human B7H3 CAR-T in Treating Patients With Recurrent Malignant Ovarian Cancer|Recruiting||Phase 1/Phase 2|15|Anticipated|The Affiliated Hospital of Xuzhou Medical University||1|||f||||f|f|f|||||||||No||2023-09-04 09:04:20.67933|2023-09-04 09:04:20.67933|OTHER|||||
NCT05477446||2022-07-18|||2022-07-25|2022-07-25|2022-07-28|Actual|||||||2022-07-25|2022-07-28|Actual|October 1, 2022|Anticipated|2022-10-01|July 2022|2022-07-31|August 1, 2025|Anticipated|2025-08-01|June 1, 2025|Anticipated|2025-06-01||Interventional|||Safety and Efficacy of CD207 Targeted CAR-T Cell Therapy in Patients With R/R Langerhans Cell Histiocytosis|Safety and Efficacy of CD207 Targeted CAR-T Cell Therapy in Patients With Relapsed and Refractory (R/R) Langerhans Cell Histiocytosis|Not yet recruiting||Phase 1|12|Anticipated|Beijing Friendship Hospital||1|||f||||f|f|f|||||||||No||2023-09-04 09:04:35.567286|2023-09-04 09:04:35.567286|OTHER|||||
NCT04762485||2021-02-08|||2021-06-01|2021-02-17|2021-02-21|Actual|||||||2021-06-01|2021-06-02|Actual|June 1, 2021|Actual|2021-06-01|January 2021|2021-01-31|February 28, 2024|Anticipated|2024-02-28|February 28, 2023|Anticipated|2023-02-28||Interventional|||Humanized CD7 CAR T-cell Therapy for r/r CD7+ Acute Leukemia|Humanized Chimeric Antigen Receptor T Cells Against CD7 for Refractory/Relapsed CD7+ Acute Leukemia|Recruiting||Phase 1/Phase 2|20|Anticipated|The First Affiliated Hospital of Soochow University||1|||f|||||f|f|||||||||||2023-08-31 06:39:33.713453|2023-08-31 06:39:33.713453|OTHER|||||
NCT03030976||2017-01-22|||2017-02-04|2017-01-22|2017-01-25|Estimate|||||||2017-02-04|2017-02-07|Estimate|March 2017|Anticipated|2017-03-31|January 2017|2017-01-31|March 2018|Anticipated|2018-03-31|January 2018|Anticipated|2018-01-31||Interventional|||A Study of CD19 Redirected Autologous T Cells for CD19 Positive Systemic Lupus Erythematosus (SLE)|An Open-labeled, Uncontrolled, Single-arm Pilot Study to Evaluate Cellular Immunotherapy Using CD19-targeted Chimeric Antigen Receptor Engineered T Cells in Patients With CD19+ B Cell Systemic Lupus Erythematosus (SLE)|Unknown status|Recruiting|Phase 1|5|Anticipated|Shanghai GeneChem Co., Ltd.||2|||f||||f|f|f|||||||||Undecided||2023-08-31 06:42:03.426049|2023-08-31 06:42:03.426049|INDUSTRY|||||
NCT01087294||2010-03-13|||2023-08-30|2010-03-13|2010-03-16|Estimate|||||||2023-08-30|2023-08-31|Estimate|August 4, 2010|Actual|2010-08-04|January 18, 2023|2023-01-18|March 1, 2024|Anticipated|2024-03-01|March 1, 2024|Anticipated|2024-03-01||Interventional|||Administration of Anti-CD19-chimeric-antigen-receptor-transduced T Cells From the Original Transplant Donor to Patients With Recurrent or Persistent B-cell Malignancies After Allogeneic Stem Cell Transplantation|Administration of Anti-CD19-Chimeric-Antigen-Receptor-Transduced T Cells From the Original Transplant Donor to Patients With Recurrent or Persistent B-Cell Malignancies After Allogeneic Stem Cell Transplantation|Active, not recruiting||Phase 1|85|Actual|National Institutes of Health Clinical Center (CC)||3|||f|||||t|f||||||Clinical data will be available during the study and indefinitely.@@@@@@Genomic data will be available once genomic data are uploaded per protocol GDS plan for as long as database is active.|Clinical data will be made available via subscription to BTRIS and with the permission of the study PI.@@@@@@Genomic data will be made available via dbGaP through requests to the data custodians.||Yes|.All IPD recorded in the medical record will be shared with intramural investigators upon request.@@@@@@All collected IPD will be shared with collaborators under the terms of collaborative agreements.|2023-09-01 04:31:07.9218|2023-09-01 04:31:07.9218|NIH|||||
NCT03602157||2018-07-17|||2022-11-11|2018-07-25|2018-07-26|Actual|||||||2022-11-11|2022-11-14|Actual|December 12, 2018|Actual|2018-12-12|November 2022|2022-11-30|September 30, 2041|Anticipated|2041-09-30|September 30, 2026|Anticipated|2026-09-30||Interventional|||Study of CAR-T Cells Expressing CD30 and CCR4 for r/r CD30+ HL and CTCL|Phase I Study of the Administration of T Lymphocytes Co-Expressing the CD30 Chimeric Antigen Receptor (CAR) and CCR4 for Relapsed/Refractory CD30+ Hodgkin Lymphoma and Cutaneous T-Cell Lymphoma|Recruiting||Phase 1|59|Anticipated|UNC Lineberger Comprehensive Cancer Center||1|||f||||t|t|f|||||||||No||2023-08-31 06:54:20.609104|2023-08-31 06:54:20.609104|OTHER|||||
NCT03049449||2017-02-09|2022-04-28||2022-12-21|2017-02-09|2017-02-10|Actual|2022-04-28|2022-05-25|Actual||||2022-12-21|2023-01-18|Actual|March 17, 2017|Actual|2017-03-17|December 2022|2022-12-31|January 26, 2022|Actual|2022-01-26|January 26, 2022|Actual|2022-01-26||Interventional||2 participants who had baseline data collected and were enrolled but not treated, is reported here.|T Cells Expressing a Fully-Human Anti-CD30 Chimeric Antigen Receptor for Treating CD30-Expressing Lymphomas|Anti-CD30 CAR T Cells With Fully-human Binding Domains for Treating CD30-expressing Lymphomas Including Anaplastic Large Cell Lymphomas|Completed||Phase 1|26|Actual|National Institutes of Health Clinical Center (CC)||1|||f||||f|t|f||||||Data will be shared before publication. And at the time of publication or shortly thereafter.|An National Institutes of Health (NIH)-funded or approved public repository - Clinical Trials.gov, Biomedical Translational Research Information System (BTRIS), and publication and/or presentations.||Yes|We will share coded, linked data in an National Institutes of Health (NIH)-funded or approved public repository. Coded, linked data in Biomedical Translational Research Information System (BTRIS).|2023-08-31 06:54:53.005235|2023-08-31 06:54:53.005235|NIH|||||
NCT03222674||2017-07-14|||2018-10-15|2017-07-17|2017-07-19|Actual|||||||2018-10-15|2018-10-17|Actual|July 15, 2017|Actual|2017-07-15|October 2018|2018-10-31|December 31, 2020|Anticipated|2020-12-31|December 31, 2019|Anticipated|2019-12-31||Interventional|||Multi-CAR T Cell Therapy for Acute Myeloid Leukemia|Multi-center Phase I/II Clinical Trial of Multi-CAR T Cell Therapy for Acute Myeloid Leukemia|Unknown status|Recruiting|Phase 1/Phase 2|10|Anticipated|Shenzhen Geno-Immune Medical Institute||1|||f||||f|f|f|||||||||No||2023-09-04 09:07:31.031416|2023-09-04 09:07:31.031416|OTHER|||||
NCT05164770||2021-12-07|||2021-12-07|2021-12-07|2021-12-21|Actual|||||||2021-12-07|2021-12-21|Actual|March 1, 2021|Actual|2021-03-01|December 2021|2021-12-31|December 31, 2024|Anticipated|2024-12-31|December 31, 2023|Anticipated|2023-12-31||Interventional|||Study of Zanubrutinib, Rituximab and Combination Chemotherapy in Newly-diagnosed Aggressive B-cell Non-Hodgkin Lymphoma|A Multi-center, Prospective Clinical Study of Zanubrutinib, Rituximab and Combination Chemotherapy in Patients With Newly-diagnosed Aggressive B-cell Non-Hodgkin Lymphoma|Recruiting||Phase 3|160|Anticipated|Shandong Provincial Hospital||2|||f|||||f|f|||||||||||2023-08-31 06:59:30.11302|2023-08-31 06:59:30.11302|OTHER_GOV|||||
NCT03448978||2018-01-24|||2022-03-10|2018-02-27|2018-02-28|Actual|||||||2022-03-10|2022-03-11|Actual|February 26, 2018|Actual|2018-02-26|March 2022|2022-03-31|December 31, 2021|Actual|2021-12-31|December 26, 2021|Actual|2021-12-26||Interventional|||Autologous CD8+ T-cells Expressing an Anti-BCMA CAR in Patients With Myeloma|Combined Phase I-Phase II Study of Autologous CD8+ T-cells Transiently Expressing a Chimeric Antigen Receptor Directed to B-Cell Maturation Antigen in Patients With Multiple Myeloma|Completed||Phase 1/Phase 2|38|Actual|Cartesian Therapeutics||1|||f||||f|t|f|||||||||No||2023-09-03 11:11:22.590372|2023-09-03 11:11:22.590372|INDUSTRY|||||
NCT03126864||2017-04-20|||2019-11-01|2017-04-20|2017-04-24|Actual|||||||2019-11-01|2019-11-04|Actual|August 4, 2017|Actual|2017-08-04|November 2019|2019-11-30|October 10, 2019|Actual|2019-10-10|October 10, 2019|Actual|2019-10-10||Interventional|||Study of Adoptive Cellular Therapy Using Autologous T Cells Transduced With Lentivirus to Express a CD33 Specific Chimeric Antigen Receptor in Patients With Relapsed or Refractory CD33-Positive Acute Myeloid Leukemia|A Phase 1 Safety Study of Adoptive Cellular Therapy Using Autologous T Cells Transduced With Lentivirus to Express a CD33 Specific Chimeric Antigen Receptor in Patients With Relapsed or Refractory CD33-Positive Acute Myeloid Leukemia|Terminated||Phase 1|11|Actual|M.D. Anderson Cancer Center||2||Terminated per the PI's request.|f||||f|t|f|||||||||||2023-08-31 07:22:28.955164|2023-08-31 07:22:28.955164|OTHER|||||
NCT03383952||2017-12-06|||2017-12-19|2017-12-19|2017-12-27|Actual|||||||2017-12-19|2017-12-27|Actual|March 1, 2017|Actual|2017-03-01|December 2017|2017-12-31|December 31, 2025|Anticipated|2025-12-31|December 31, 2020|Anticipated|2020-12-31||Interventional|||A Clinical Study of CD19 Targeted CAR-T for Patients With CD19+ Lymphoma and Leukemia|A Phase I Trial of CD19 Targeted ICAR19 T Cells in Patients With CD19+ Leukemia and Lymphoma.|Recruiting||Phase 1|20|Anticipated|Immune Cell, Inc.||1|||f|||||f|f|||||||||||2023-08-31 07:27:19.16488|2023-08-31 07:27:19.16488|INDUSTRY|||||
NCT01583686||2012-04-20|2019-08-29||2019-10-10|2012-04-20|2012-04-24|Estimate|2019-09-19|2019-10-09|Actual||||2019-10-10|2019-10-14|Actual|May 4, 2012|Actual|2012-05-04|October 2019|2019-10-31|December 17, 2018|Actual|2018-12-17|December 17, 2018|Actual|2018-12-17||Interventional|||CAR T Cell Receptor Immunotherapy Targeting Mesothelin for Patients With Metastatic Cancer|Phase I/II Study of Metastatic Cancer Using Lymphodepleting Conditioning Followed by Infusion of Anti-mesothelin Gene Engineered Lymphocytes|Terminated||Phase 1/Phase 2|15|Actual|National Institutes of Health Clinical Center (CC)||2||Study terminated due to slow/insufficient accrual.|f||||f|t|f|||||||||No||2023-08-31 07:30:01.262067|2023-08-31 07:30:01.262067|NIH|||||
NCT03366324||2017-12-01|||2018-11-18|2017-12-07|2017-12-08|Actual|||||||2018-11-18|2018-11-20|Actual|May 1, 2016|Actual|2016-05-01|November 2018|2018-11-30|June 1, 2021|Anticipated|2021-06-01|January 1, 2021|Anticipated|2021-01-01||Interventional|||Anti-CD19 CAR-T Therapy Combine With HSCT to Treat MRD+ B-cell Malignancies|A Phase 1/2 Study Evaluating the Safety and Efficacy of the Combination of Anti-CD19 Chimeric Antigen Receptor-Modified T Cell (CAR-T) Therapy and Hematological Stem Cell Transplantation (HSCT) for MRD+ B-cell Malignancies|Unknown status|Recruiting|Phase 1/Phase 2|20|Anticipated|Wuhan Sian Medical Technology Co., Ltd||1|||f|||||f|f|||||||||Undecided||2023-08-31 07:35:29.937979|2023-08-31 07:35:29.937979|INDUSTRY|||||
NCT03882840||2019-03-18|||2023-02-26|2019-03-18|2019-03-20|Actual|||||||2023-02-26|2023-02-28|Actual|January 1, 2019|Actual|2019-01-01|February 2023|2023-02-28|January 1, 2029|Anticipated|2029-01-01|January 1, 2026|Anticipated|2026-01-01||Interventional|||Induced-T Cell Like NK Cellular Immunotherapy for Cancer Lack of MHC-I|Induced-T Cell Like NK Cellular Immunotherapy for Cancers That Are Lack of MHC-I Expression|Recruiting||Phase 1/Phase 2|30|Anticipated|Second Affiliated Hospital of Guangzhou Medical University||1|||f|||||f|f|||||||||||2023-09-01 05:37:33.587033|2023-09-01 05:37:33.587033|OTHER|||||
NCT03198546||2017-06-21|||2023-02-26|2017-06-23|2017-06-26|Actual|||||||2023-02-26|2023-02-28|Actual|July 1, 2017|Actual|2017-07-01|February 2023|2023-02-28|August 1, 2029|Anticipated|2029-08-01|August 1, 2025|Anticipated|2025-08-01||Interventional|||GPC3-CAR-T Cells for Immunotherapy of Cancer With GPC3 Expression|CAR-T Cell Targeting GPC3 for Immunotherapy of Hepatocellular Carcinoma: Phase I Clinical Trial|Recruiting||Phase 1|30|Anticipated|Second Affiliated Hospital of Guangzhou Medical University||1|||f||||f|f|f|||||||||No||2023-09-01 05:37:42.452912|2023-09-01 05:37:42.452912|OTHER|||||
NCT03590574||2018-07-07|||2023-02-16|2018-07-07|2018-07-18|Actual|||||||2023-02-16|2023-02-21|Actual|August 30, 2018|Actual|2018-08-30|February 2023|2023-02-28|July 2025|Anticipated|2025-07-31|July 2023|Anticipated|2023-07-31||Interventional|||Phase I/II Study Evaluating AUTO4 in Patients With TRBC1 Positive T Cell Lymphoma|A Single Arm, Open Label, Multi-centre, Phase I/II Study Evaluating the Safety and Clinical Activity of AUTO4, a CAR T-cell Treatment Targeting TRBC1, in Patients With Relapsed or Refractory TRBC1 Positive Selected T Cell Non-Hodgkin Lymphoma|Recruiting||Phase 1/Phase 2|200|Anticipated|Autolus Limited||1|||f||||t|f|f|||||||||No||2023-09-01 05:40:31.468451|2023-09-01 05:40:31.468451|INDUSTRY|||||
